assay_id,doc_id,confidence_score,assay_strain,cell_id,assay_category,curated_by,tissue_id,assay_cell_type,assay_tissue,assay_tax_id,description,assay_type,assay_test_type,assay_organism,assay_subcellular_fraction,tid
1,11087,8,,,,Autocuration,,,,,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 30 uM,B,,,,12052
2,684,0,,,,Autocuration,,,,,Compound was evaluated for its ability to mobilize calcium in 1321NI cells,F,,,,22226
3,15453,0,,,,Autocuration,,,,,,B,,,,22226
4,17841,4,,,,Autocuration,,,,9913.0,Binding affinity against A2 adenosine receptor in bovine striatal membranes using [3H]CGS-21680,B,,Bos taurus,,104729
5,17430,1,,163.0,,Intermediate,,143B,,9606.0,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),F,,Homo sapiens,,80001
6,17430,1,,163.0,,Intermediate,,143B,,9606.0,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),F,,Homo sapiens,,80001
7,13799,1,,163.0,,Intermediate,,143B,,10090.0,Cytotoxic Activity was evaluated against 143B (TK-) tumor cells,F,,Mus musculus,,80001
8,17774,1,,163.0,,Expert,,143B,,9606.0,In vitro cell cytotoxicity was determined against 143B cell line,F,,Homo sapiens,,80001
9,3801,1,,163.0,,Intermediate,,143B,,9606.0,Inhibitory activity against tumor osteosarcoma cell line 143B after 72 hr continuous exposure to compound,F,,Homo sapiens,,80001
10,17430,1,,163.0,,Intermediate,,143B,,9606.0,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,F,,Homo sapiens,,80001
11,17430,1,,163.0,,Intermediate,,143B,,9606.0,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,F,,Homo sapiens,,80001
12,17774,1,,163.0,,Expert,,143B,,9606.0,In vitro cell cytotoxicity was determined against 143B-LTK cell line,F,,Homo sapiens,,80001
13,11324,1,,,,Intermediate,,,,1280.0,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",F,,Staphylococcus aureus,,50185
14,11324,1,,,,Intermediate,,,,1280.0,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",F,,Staphylococcus aureus,,50185
15,11324,1,,,,Intermediate,,,,1280.0,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",F,,Staphylococcus aureus,,50185
16,11324,1,,,,Intermediate,,,,1280.0,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",F,,Staphylococcus aureus,,50185
17,11347,9,,,,Expert,,,,10116.0,Inhibition of cytochrome P450 progesterone 15-alpha hydroxylase,A,,Rattus norvegicus,,100122
18,16474,8,,,,Autocuration,,,,,Concentration that cause 50% activation of human reticulocyte 15-lipoxygenase (15-HLO),B,,,,12054
19,10091,8,,,,Autocuration,,,,,Inhibition of partially purified 15-lipoxygenase from human leukocytes,B,,,,12054
20,16474,8,,,,Autocuration,,,,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),B,,,,12054
21,16474,8,,,,Autocuration,,,,,Compound was evaluated for the percent increase in activation concentration of human reticulocyte 15-lipoxygenase (15-HLO),B,,,,12054
22,16474,8,,,,Autocuration,,,,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),B,,,,12054
23,16474,8,,,,Autocuration,,,,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,B,,,,12054
24,16474,8,,,,Autocuration,,,,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,B,,,,12054
25,14352,0,,,,Autocuration,,,,,"Inhibitory concentration against 15-lipoxygenase, by inhibiting 15-HETE production by human umbilical vein endothelial cells (HUVEC) stimulated by calcium ionophore A 23187 at concentration of 10e-5 M.",B,,,,22226
26,5646,8,,,,Autocuration,,,,9986.0,In vitro inhibitory activity of compound on rabbit reticulocyte 15-lipoxygenase,B,,Oryctolagus cuniculus,,12054
27,5646,8,,,,Autocuration,,,,9986.0,Inhibition of rabbit reticulocyte 15-lipoxygenase by compound (30 uM),B,,Oryctolagus cuniculus,,12054
28,10997,8,,,,Autocuration,,,,,Inhibitory activity against 15-lipoxygenase in rat polymorphonuclear leukocytes,B,,,,12426
29,6309,8,,,,Autocuration,,,,3847.0,Inhibitory activity against 15-lipoxygenase was determined obtained from soya bean,B,,soya bean,,12054
30,167,8,,,,Autocuration,,,,3847.0,Inhibitory activity against soybean 15-lipoxygenase was evaluated,B,,Glycine max,,12054
31,167,8,,,,Autocuration,,,,3847.0,Inhibitory activity against soybean 15-lipoxygenase was evaluated at 100 uM,B,,Glycine max,,12054
32,11087,8,,,,Autocuration,,,,3847.0,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 10 uM,B,,Glycine max,,12054
33,11087,8,,,,Autocuration,,,,3847.0,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 100 uM,B,,Glycine max,,12054
34,13622,8,,,,Autocuration,,,,3847.0,Compound was tested in vitro for inhibition of 15-lipoxygenase soybean,B,,Glycine max,,12054
35,13622,8,,,,Autocuration,,,,3847.0,Compound at 100 uM was tested in vitro for inhibition of 15-lipoxygenase soybean,B,,Glycine max,,12054
36,11347,0,,,,Autocuration,,,,10116.0,Inhibition of cytochrome P450 progesterone 16-alpha hydroxylase,A,,Rattus norvegicus,,22226
37,5926,0,,,,Autocuration,,,,562.0,Binding affinity against bacterial 16S rRNA using mass spectrometry based assay,B,,Escherichia coli,,22226
38,4567,0,,,,Autocuration,,,,,Dissociation constant with dimeric 16S rRNA RNA construct B,B,,,,22226
39,3782,3,,,,Intermediate,,,,,Dissociation constant towards 16S rRNA construct A,B,,,,22222
40,3782,3,,,,Intermediate,,,,,Dissociation constant towards 16S rRNA construct B,B,,,,22222
41,4466,3,,,,Expert,,,,562.0,Binding affinity of aminoglycoside to 16S ribosomal RNA A-site in Escherichia coli,B,,Escherichia coli,,100263
42,6592,3,,,,Expert,,,,562.0,Binding affinity for the 16S ribosomal RNA A-site of Escherichia coli,B,,Escherichia coli,,100263
43,898,8,,,,Autocuration,,,,,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),B,,,,13053
44,898,8,,,,Autocuration,,,,,Inhibitory constant against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),B,,,,13053
45,13163,8,,,,Autocuration,,,,9606.0,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,B,,Homo sapiens,,20001
46,13163,8,,,,Autocuration,,,,9606.0,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,B,,Homo sapiens,,20001
47,10691,9,,,,Expert,,,,10116.0,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",B,,Rattus norvegicus,,12971
48,10691,9,,,,Expert,,,,10116.0,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",B,,Rattus norvegicus,,12971
49,10691,9,,,,Expert,,,,10116.0,"Percent inhibition of 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",B,,Rattus norvegicus,,12971
50,10691,9,,,,Expert,,,,10116.0,"Percent inhibition of Steroid 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",B,,Rattus norvegicus,,12971
51,898,8,,,,Autocuration,,,,,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),B,,,,13053
52,912,8,,,,Autocuration,,,,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1),B,,,,11512
53,912,8,,,,Autocuration,,,,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 1 uM concentration,B,,,,11512
54,912,8,,,,Autocuration,,,,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 10 uM concentration,B,,,,11512
55,15103,5,,,,Autocuration,,,,10116.0,Selectivity ratio of binding affinity towards mu to delta receptors of rat brain membranes,B,,Rattus norvegicus,Membranes,104740
56,5116,1,,506.0,,Intermediate,,1A9,,9606.0,Cytotoxicity against ovarian cancer cell line (1A-9) of humans was determined,F,,Homo sapiens,,80002
57,14578,7,,,,Autocuration,,Oocytes,,10116.0,Functional antagonism by electrical assays in Xenopus oocytes expressing 1A/2A NMDA receptor subtype,F,,Rattus norvegicus,,104835
58,14578,7,,,,Autocuration,,Oocytes,,10116.0,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2B NMDA receptor,F,,Rattus norvegicus,,104821
59,14578,7,,,,Autocuration,,Oocytes,,10116.0,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2C NMDA receptor,F,,Rattus norvegicus,,104848
60,4787,1,,506.0,,Expert,,1A9,,9606.0,In vitro effective concentration required to reduce the number of human ovarian cancer (1A9) after 3-day incubation,F,,Homo sapiens,,80002
61,4787,1,,506.0,,Intermediate,,1A9,,9606.0,In vitro effective concentration required to reduce the number of human ovarian cancer cells (1A9) after 3-day incubation,F,,Homo sapiens,,80002
62,3547,1,,506.0,,Intermediate,,1A9,,9606.0,Cytotoxic activity against human ovarian cancer (1A9) cell line,F,,Homo sapiens,,80002
63,3547,1,,506.0,,Intermediate,,1A9,,9606.0,Cytotoxic activity against human ovarian cancer (1A9) cell line; ND=Not determined,F,,Homo sapiens,,80002
64,6726,1,,506.0,,Intermediate,,1A9,,9606.0,Effective dose of compound against replication of 1A9 cell line was evaluated,F,,Homo sapiens,,80002
65,3455,1,,506.0,,Expert,,1A9,,9606.0,In vitro cytotoxic activity was determined against ovarian cancer (1A9) cell line,F,,Homo sapiens,,80002
66,5726,1,,506.0,,Intermediate,,1A9,,9606.0,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line),F,,Homo sapiens,,80002
67,5726,1,,506.0,,Intermediate,,1A9,,9606.0,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line); NA is not active,F,,Homo sapiens,,80002
68,5726,1,,506.0,,Intermediate,,1A9,,9606.0,In vitro percent inhibition evaluated against human ovarian cancer (1A9 cell line) at >20 ug/mL,F,,Homo sapiens,,80002
69,3395,1,,506.0,,Intermediate,,1A9,,9606.0,Inhibitory activity against Taxol resistant 1A9 cell lines,F,,Homo sapiens,,80002
70,3415,1,,506.0,,Expert,,1A9,,9606.0,Cytotoxicity against human ovarian cancer (1A9) cell lines.,F,,Homo sapiens,,80002
71,3415,1,,506.0,,Expert,,1A9,,9606.0,Percentage inhibition of human ovarian cancer (1A9) cell lines.,F,,Homo sapiens,,80002
72,17099,1,,506.0,,Expert,,1A9,,9606.0,Effective dose required for inhibitory activity against 1A9 human tumor cell line.,F,,Homo sapiens,,80002
73,17099,1,,506.0,,Intermediate,,1A9,,9606.0,Percent inhibition against 1A9 human tumor cell line at 0.10 ug/mL,F,,Homo sapiens,,80002
74,17099,1,,506.0,,Intermediate,,1A9,,9606.0,Percent inhibition against 1A9 human tumor cell line at <0.00008 ug/mL,F,,Homo sapiens,,80002
75,17099,1,,506.0,,Intermediate,,1A9,,9606.0,Percent inhibition against 1A9 human tumor cell line at >10 ug/mL,F,,Homo sapiens,,80002
76,17721,1,,503.0,,Intermediate,,Jurkat,,9606.0,Inhibitory concentration against Jurkat cells,F,,Homo sapiens,,81072
77,1229,0,,,,Intermediate,,,,,In vitro anticancer activity against 2 NCI SCLC cell lines; inactive,F,,,,22226
78,11347,9,,,,Expert,,,,10116.0,Inhibition of cytochrome P450 progesterone 2-alpha-hydroxylase,A,,Rattus norvegicus,,100121
79,17117,8,,,,Expert,,,,,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",B,,,,11231
80,17117,8,,,,Expert,,,,,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",B,,,,11231
81,17117,8,,,,Expert,,,,,"In vitro inhibition of human 2,3-oxidosqualene cyclase at 100 nM.",B,,,,11231
82,11375,8,,,,Autocuration,,,,5476.0,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Candida albicans microsomes",B,,Candida albicans,Microsomes,11231
83,11375,8,,,,Autocuration,,,,5476.0,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Candida albicans microsomes",B,,Candida albicans,Microsomes,11231
84,11375,8,,,,Autocuration,,,,4932.0,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Saccharomyces cerevisiae microsomes",B,,Saccharomyces cerevisiae,Microsomes,11231
85,11375,8,,,,Autocuration,,,,4932.0,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Saccharomyces cerevisiae microsomes",B,,Saccharomyces cerevisiae,Microsomes,11231
86,11375,8,,,,Autocuration,2107.0,,Liver,9823.0,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in pig liver microsomes",B,,Sus scrofa,Microsomes,12083
87,791,8,,,,Autocuration,,,,10116.0,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase",B,,Rattus norvegicus,,11231
88,791,8,,,,Autocuration,,,,10116.0,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase (OSC)",B,,Rattus norvegicus,,11231
89,791,8,,,,Autocuration,,,,10116.0,"Evaluated for its activity to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase, activity expressed as Ki",B,,Rattus norvegicus,,11231
90,11375,9,,,,Autocuration,2107.0,,Liver,10116.0,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in rat liver microsomes",B,,Rattus norvegicus,Microsomes,12083
91,11375,9,,,,Autocuration,2107.0,,Liver,10116.0,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",B,,Rattus norvegicus,Microsomes,12083
92,153,9,,,,Autocuration,2107.0,,Liver,10116.0,"Compound was evaluated for inhibitory activity against 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",B,,Rattus norvegicus,Microsomes,12083
93,8269,8,,,,Expert,,,,,Molar concentration needed to give 50% prevention of 2-5A (Adenosine dependent endoribonuclease),B,,,,11377
94,8269,8,,,,Expert,,,,,Molar concentration required to displace 50% of the radiolabeled probe from 2-5A (Adenosine dependent endoribonuclease) in endonuclease-nitrocellulose complex,B,,,,11377
95,17653,1,,726.0,,Expert,,HepG2,,9606.0,In vitro cytotoxic concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,F,,Homo sapiens,,81020
96,14277,1,,726.0,,Intermediate,,HepG2,,9606.0,50% Effective concentration of compound required for inhibiting intracellular viral replicative intermediate DNA in HBV-transfected 2.2.15 cell line.,F,,Homo sapiens,,81020
97,1717,1,,726.0,,Intermediate,,HepG2,,9606.0,Antiviral activity against Hepatitis B virus in 2.2.15 cell line,F,,Homo sapiens,,81020
98,14091,1,,726.0,,Intermediate,,HepG2,,9606.0,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells,F,,Homo sapiens,,81020
99,14091,1,,726.0,,Intermediate,,HepG2,,9606.0,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells; Not determined,F,,Homo sapiens,,81020
100,17653,1,,,,Expert,,,,10407.0,In vitro effective concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,F,,Hepatitis B virus,,50606
101,13105,1,,726.0,,Intermediate,,HepG2,,9606.0,Ability to inhibit the episomal HBV-DNA in 2.2.15 cells.,F,,Homo sapiens,,81020
102,1717,1,,726.0,,Intermediate,,HepG2,,9606.0,Concentration required to inhibit 50% of 2.2.15 cell line,F,,Homo sapiens,,81020
103,13105,1,,726.0,,Intermediate,,HepG2,,9606.0,Anti viral activity against 2.2.15 cells (concentration required to reduce the log phase cell growth by 50%).,A,,Homo sapiens,,81020
104,13600,1,,,,Intermediate,,2.2.15,,9606.0,Cytotoxic activity of compound against uninfected 2.2.15 cells.,F,,Homo sapiens,,50587
105,13467,1,,,,Intermediate,,2.2.15,,9606.0,Anti hepatitis-B virus activity was evaluated in 2.2.15 cells.,F,,Homo sapiens,,50587
106,17477,1,,,,Expert,,2.2.15,,10407.0,"Inhibition of the replication of HBV in 2.2.15 cells, by DNA hybridization assay",F,,Hepatitis B virus,,50606
107,1593,1,,,,Intermediate,,2.2.15,,9606.0,In vitro anti-HBV activity in 2.2.15 cells,F,,Homo sapiens,,50587
108,1593,1,,,,Intermediate,,2.2.15,,9606.0,In vitro anti-HBV activity in 2.2.15 cells; Not determined,F,,Homo sapiens,,50587
109,15089,1,,,,Intermediate,,2.2.15,,9606.0,The compound was tested in vitro for the anti-HBV activity against 2.2.15 cells,F,,Homo sapiens,,50587
110,15089,1,,,,Intermediate,,2.2.15,,9606.0,The compound was tested in vitro for the anti-HBV activity in 2.2.15 cells,F,,Homo sapiens,,50587
111,1593,1,,,,Intermediate,,2.2.15,,9606.0,Cytotoxicity in 2.2.15 cells,F,,Homo sapiens,,50587
112,1593,1,,,,Intermediate,,2.2.15,,9606.0,Cytotoxicity in 2.2.15 cells; Not determined,F,,Homo sapiens,,50587
113,13600,1,,,,Intermediate,,2.2.15,,9606.0,Inhibitory activity of compound against hepatitis B virus (HBV) in growing cultures of 2.2.15 cells,F,,Homo sapiens,,50587
114,13467,1,,,,Intermediate,,2.2.15,,9606.0,The growth inhibition activity for the compound was evaluated in 2.2.15 cells.,F,,Homo sapiens,,50587
115,13467,1,,,,Intermediate,,2.2.15,,9606.0,Selectivity index was determined from the ratio of IC50 to the EC50 values evaluated in 2.2.15 cells.,F,,Homo sapiens,,50587
116,14764,1,,726.0,,Intermediate,,HepG2,,9606.0,Antiviral activity against HBV was determined in 2.215 cell line,F,,Homo sapiens,,81020
117,6531,0,,,,Autocuration,,,,9606.0,Inhibition of 20-HETE synthesis in human renal microsomes,B,,Homo sapiens,Microsomes,22226
118,17322,0,,,,Autocuration,,,,,Inhibitory activity against 20-HETE production from arachidonic acid using human renal microsome 20-HETE synthase.,B,,,,22226
119,17072,1,,388.0,,Intermediate,,2008,,9606.0,Inhibitory concentration against 2008 (ovarian) cells,F,,Homo sapiens,,80612
120,16936,1,,388.0,,Intermediate,,2008,,9606.0,50% Growth inhibitory concentration( GI 50 ) by using 2008 human ovarian carcinoma cell lines.,F,,Homo sapiens,,80612
121,16936,1,,388.0,,Intermediate,,2008,,9606.0,Compound was tested for 50% growth inhibitory concentration by using human ovarian carcinoma cell lines (2008),F,,Homo sapiens,,80612
122,17146,1,,388.0,,Intermediate,,2008,,9606.0,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells,F,,Homo sapiens,,80612
123,17146,1,,388.0,,Intermediate,,2008,,9606.0,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells; not detected,F,,Homo sapiens,,80612
124,10797,1,,561.0,,Intermediate,,2008/R,,9606.0,In vitro inhibition of 2008/R ovarian cancer cell line,F,,Homo sapiens,,80613
125,10797,1,,561.0,,Intermediate,,2008/R,,9606.0,In vitro inhibition of 2008/R ovarian cancer cell line; NA= Not achievable,F,,Homo sapiens,,80613
126,10797,1,,389.0,,Intermediate,,2008/S,,9606.0,In vitro inhibition of 2008/S ovarian cancer cell line,F,,Homo sapiens,,80614
127,10797,1,,389.0,,Intermediate,,2008/S,,9606.0,In vitro inhibition of 2008/S ovarian cancer cell line; NA= Not achievable,F,,Homo sapiens,,80614
128,4823,2,,,,Expert,,,,9606.0,Tested in vitro for inhibition of chymotrypsin like activity of purified human 20S proteasome,B,,Homo sapiens,,100256
129,12912,2,,,,Intermediate,,,,9606.0,Compound was evaluated for inhibitory activity against 20S proteasome from human liver and brain,B,,Homo sapiens,,100256
130,2957,2,,,,Expert,,,,,Inhibition of chymotrypsin-like activity of 20S proteasome,B,,,,100256
131,2957,2,,,,Expert,,,,,Inhibition of chymotrypsin-like activity of 20S proteasome; value ranges from 10-20 uM,B,,,,100256
132,3260,2,,,,Intermediate,,,,,Inhibitory activity against 20S proteosome,B,,,,100256
133,3451,0,,,,Autocuration,,,,9606.0,Compound was tested for inhibitory activity against tryptase,B,,Homo sapiens,,22226
134,13885,1,,726.0,,Intermediate,,HepG2,,9606.0,Concentration required to inhibit 50% of extracellular circular replication of HBV DNA using 2215 cell line,F,,Homo sapiens,,81020
135,13885,1,,726.0,,Intermediate,,HepG2,,9606.0,Concentration required to inhibit 50% of intracellular circular replication of HBV DNA using 2215 cell line,F,,Homo sapiens,,81020
136,3676,0,,,,Autocuration,,,,,Compound was tested for the inhibition of Alpha-glucosidase,B,,,,22226
137,6043,8,,,,Autocuration,,,,,Inhibitory concentration against human neutrophil elastase (HNE),B,,,,235
138,11140,0,,,,Autocuration,948.0,,Heart,10116.0,Change in heart rate was expressed in percent at at a dose 0.002 mg/kg iv in anesthetized rat,F,,Rattus norvegicus,,22226
139,10543,8,,,,Autocuration,,,,,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,F,,,,19640
140,10543,8,,,,Expert,,,,,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,F,,,,19640
141,10543,8,,,,Autocuration,,,,,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,B,,,,19640
142,10543,8,,,,Expert,,,,,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,F,,,,19640
143,11365,1,,524.0,,Intermediate,,P338,,10090.0,In Vitro evaluation for the growth inhibition of Subline (P388/AMSA) Leukemia cell lines,F,,Mus musculus,,80360
144,11365,1,,524.0,,Intermediate,,P338,,10090.0,In Vitro evaluation for the growth inhibition of Subline (P388/CP) Leukemia cell lines,F,,Mus musculus,,80360
145,11803,1,,554.0,,Intermediate,,PBL,,9606.0,Compound was evaluated for the inhibition of cell replication human peripheral blood lymphocytes (PBL's).,F,,Homo sapiens,,80384
146,11803,0,,,,Autocuration,,,,9940.0,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells,F,,Ovis aries,,22226
147,11803,0,,,,Autocuration,,,,9940.0,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells.,F,,Ovis aries,,22226
148,12278,8,,,,Autocuration,,,,,Compound is evaluated in vitro for the inhibition single mutant of HIV-1 RT (Y181C),B,,,,191
149,8249,0,,,,Autocuration,,,,9606.0,Compound was evaluated for its inhibitory effect on thymidine [3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-5,F,,Homo sapiens,,22226
150,8249,0,,,,Autocuration,,,,9606.0,Compound was evaluated for its inhibitory effect on thymidine [3H]-dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-6,F,,Homo sapiens,,22226
151,8249,0,,635.0,,Autocuration,,CCRF-CEM,,9606.0,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in at conc. 10e-7,F,,Homo sapiens,,22226
152,8249,0,,635.0,,Autocuration,,CCRF-CEM,,9606.0,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM cells in culture at conc. 10e-4,F,,Homo sapiens,,22226
153,8249,0,,635.0,,Autocuration,,CCRF-CEM,,9606.0,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-5,F,,Homo sapiens,,22226
154,8249,0,,635.0,,Autocuration,,CCRF-CEM,,9606.0,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-6,F,,Homo sapiens,,22226
155,8249,0,,,,Autocuration,,,,9606.0,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM/MTX cells in at conc. 10e-7.,F,,Homo sapiens,,22226
156,8249,0,,,,Autocuration,,,,9606.0,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-4,F,,Homo sapiens,,22226
157,16992,6,,,,Autocuration,,,,,In vitro binding affinity towards (alpha-4)2(beta-2)3 neuronal nicotinic acetylcholine receptor in P2 membrane fractions of rat forebrain,B,,,,104290
158,10543,1,,,,Intermediate,,,,1314.0,Minimum inhibitory concentration of compound against Streptococcus pyogenus septicemia in the mouse,F,,Streptococcus pyogenes,,50264
159,17833,1,,,,Intermediate,,,,10335.0,Antiviral activity against 07/1 strain of thymidine kinase negative (TK-) Varicella-Zoster Virus (VZV),F,,Human herpesvirus 3,,50527
160,17290,1,,468.0,,Expert,,HEL,,10335.0,Antiviral activity against 07/1 strain of VZV in HEL (human erythroleukemia) cells.,F,,vericilla zoster virus,,50527
161,17290,1,,,,Intermediate,,,,10335.0,Antiviral activity against 07/1 strain of VZV; ND: No data,F,,vericilla zoster virus,,50527
162,17290,1,,,,Intermediate,,,,10335.0,Antiviral activity against 07/1 strain of VZV; ND=No data,F,,vericilla zoster virus,,50527
163,10932,1,,,,Intermediate,,,,561.0,"Antibacterial activity was determined against gram negative organism, Enterobacter cloacae (MA2646)",F,,escherichia cloac,,50145
164,9707,0,,,,Autocuration,,,,,Ratio of Ki at A2 to Ki at A1 receptors,B,,,,22226
165,2346,8,,,,Expert,,,,5476.0,"In vitro inhibition of 1,3-beta-glucan synthase in Candida albicans membrane assay.",B,,Candida albicans,,11143
166,2205,8,,,,Expert,,,,284593.0,"Inhibition of 1,3-beta-glucan synthase",B,,Candida glabrata CBS 138,,18077
167,11900,1,,832.0,,Intermediate,,1-87 tumor cell line,,9606.0,Inhibition of growth of 1-87 human tumor cell line,F,,Homo sapiens,,80609
168,14864,9,,,,Expert,,,,10116.0,Inhibition of 1-lipoxygenase (LOX)in RBL cells,B,,Rattus norvegicus,,12166
169,16474,9,,,,Autocuration,,,,3847.0,Inhibitory activity against soybean 1-lipoxygenase (SLO),B,,Glycine max,,100171
170,16474,9,,,,Autocuration,,,,3847.0,Inhibitory activity against soybean 1-lipoxygenase (SLO); no effect,B,,Glycine max,,100171
171,16474,9,,,,Autocuration,,,,3847.0,% inhibition against soybean 1-lipoxygenase (SLO),B,,Glycine max,,100171
172,16474,9,,,,Autocuration,,,,3847.0,percent inhibition against soybean 1-lipoxygenase (SLO);NI is no inhibition,B,,Glycine max,,100171
173,3094,9,,,,Autocuration,,,,3847.0,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 10:90,B,,Glycine max,,100171
174,3094,9,,,,Autocuration,,,,3847.0,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 1:99,B,,Glycine max,,100171
175,3094,9,,,,Autocuration,,,,3847.0,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 25:75,B,,Glycine max,,100171
176,3094,9,,,,Autocuration,,,,3847.0,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 35:65,B,,Glycine max,,100171
177,3094,9,,,,Autocuration,,,,3847.0,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 50:50,B,,Glycine max,,100171
178,3094,9,,,,Autocuration,,,,3847.0,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 76:24,B,,Glycine max,,100171
179,3094,9,,,,Autocuration,,,,3847.0,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 87:13,B,,Glycine max,,100171
180,3094,9,,,,Autocuration,,,,3847.0,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 89:11,B,,Glycine max,,100171
181,3094,9,,,,Autocuration,,,,3847.0,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 95:5,B,,Glycine max,,100171
182,3094,9,,,,Autocuration,,,,3847.0,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 97:3,B,,Glycine max,,100171
183,3094,9,,,,Autocuration,,,,3847.0,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 99:1,B,,Glycine max,,100171
184,10413,0,,,,Autocuration,,,,10090.0,Evaluated for inhibitory activity on 10-formyltetrahydrofolate synthetase(L cell) at folate substrate concentration of 100 uM,B,,Mus musculus,,22226
185,16929,1,,294.0,,Intermediate,,C3H 10T1/2,,10090.0,Cells were harvested and were assayed for luciferase and -galactosidase activities (Transcriptional activity),F,,Mus musculus,,80049
186,1229,0,,,,Intermediate,,,,,In vitro anticancer activity against 11 NCI NSCLC cell lines; inactive,F,,,,22226
187,16587,8,,,,Autocuration,,,,,In vitro inhibitory activity against human 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),B,,,,11489
188,16587,8,,,,Autocuration,,,,,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),B,,,,11862
189,16587,8,,,,Autocuration,,,,,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA).,B,,,,11862
190,16587,8,,,,Autocuration,,,,,Ability to convert [3H]cortisol to the tritium labeled cortisone in the presence of human 11 beta hydroxysteroid dehydrogenase type 2,B,,,,11489
191,16587,8,,,,Autocuration,,,,,Inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 2 at a concentration of 0.2 mM; NI means no inhibition,B,,,,11862
192,8058,9,,,,Expert,,,,9913.0,Evaluated for inhibition of bovine adrenal cortical mitochondrial 11 beta-hydroxylase,F,,Bos taurus,,12347
193,9065,9,,,,Expert,,,,10116.0,Effect on adrenal 11-beta-hydroxylase activity at 10e-4 M; No significant effect,B,,Rattus norvegicus,,100120
194,8865,9,,,,Expert,2369.0,,Adrenal gland,10116.0,Inhibition of 11 beta-hydroxylase from rat adrenal gland,B,,Rattus norvegicus,,100120
195,9066,9,,,,Expert,,,,10116.0,Inhibition of rat adrenal 11-beta-hydroxylase,B,,Rattus norvegicus,,100120
196,8394,9,,,,Expert,,,,10116.0,Inhibition of rat adrenal 11-beta-hydroxylase,B,,Rattus norvegicus,,100120
197,8394,9,,,,Expert,,,,10116.0,Inhibition of rat adrenal 11-beta-hydroxylase at 10e-5 M,B,,Rattus norvegicus,,100120
198,6431,8,,,,Autocuration,,,,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 1 of wistar rat liver cytosol at 10 uM was determined using [3H]cortisone,B,,,,10328
199,6431,8,,,,Autocuration,,,,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,B,,,,11490
200,6431,8,,,,Autocuration,,,,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,B,,,,11490
201,9295,8,,,,Autocuration,,,,,Compound was tested for the percent of inhibition against 12-LO at 10 uM,F,,,,11134
202,10193,8,,,,Autocuration,,,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,B,,,,12052
203,13622,8,,,,Autocuration,,,,,Compound was tested in vitro for inhibition of 12-LO human platelet,B,,,,11134
204,12079,8,,,,Autocuration,,,,,Inhibitory concentration against human platelet 12-lipoxygenase,F,,,,11134
205,13622,8,,,,Autocuration,,,,,Compound at 100 uM was tested in vitro for inhibition of 12-LO human platelet,B,,,,11134
206,12079,9,,,,Autocuration,,,,9606.0,Inhibitory concentration against human platelet 12-lipoxygenase,F,,Homo sapiens,,11134
207,13500,8,,,,Expert,,,,,Tested for inhibition of 12-LO (12-lipoxygenase) as an inhibitor of 12(S)-HETE biosynthesis in mouse epidermal homogenates,B,,,,11835
208,13723,8,,,,Expert,,,,,Inhibitory activity against conversion of [1-14C]arachidonic acid to 12-HPETE and its reduction product 12-HETE by porcine leukocyte type 12-lipoxygenase,B,,,,11601
209,16474,8,,,,Autocuration,,,,,Inhibitory activity against human platelet 12-lipoxygenase (12-HLO),B,,,,11134
210,1630,8,,,,Autocuration,,,,,Inhibitory activity against human platelet 12-lipoxygenase,B,,,,11134
211,167,8,,,,Autocuration,,,,,Inhibitory activity against human platelet 12-lipoxygenase was evaluated,B,,,,11134
212,16474,8,,,,Autocuration,,,,,% inhibition against human platelet 12-lipoxygenase (12-HLO),B,,,,11134
213,167,8,,,,Autocuration,,,,,Inhibitory activity against human platelet 12-lipoxygenase was evaluated at 100 uM,B,,,,11134
214,16474,8,,,,Autocuration,,,,,percent inhibition against human platelet 12-lipoxygenase (12-HLO); NI is no inhibition,B,,,,11134
215,10091,8,,,,Autocuration,,,,,Inhibitory activity towards porcine 12-lipoxygenase,B,,,,11601
216,11966,8,,,,Autocuration,,,,,Tested for inhibition against porcine 12-LO,B,,,,11601
217,951,8,,,,Autocuration,,,,,Inhibition of 12-lipoxygenase was evaluated in rat platelets stimulated by thrombin up to a concentration of 10 uM; NE means No effect,B,,,,12052
218,10997,8,,,,Autocuration,,,,,Inhibitory activity against 12-lipoxygenase in rat platelet rich plasma,B,,,,12052
219,10193,8,,,,Expert,,,,,In vitro inhibition of rat platelet 12-lipoxygenase,B,,,,12052
220,10193,8,,,,Autocuration,,,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,B,,,,12052
221,10193,8,,,,Autocuration,,,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 100 uM,B,,,,12052
222,10193,8,,,,Autocuration,,,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 30 uM,B,,,,12052
223,10193,8,,,,Autocuration,,,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,B,,,,12052
224,10193,8,,,,Autocuration,,,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase,B,,,,12052
225,11087,8,,,,Autocuration,,,,,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 100 uM,B,,,,12052
226,15569,1,,621.0,,Intermediate,,41M,,9606.0,Cytotoxic activity in a panel of Human ovarian tumor 41M cell line after 96h of drug exposure,F,,Homo sapiens,,80007
227,12989,1,,621.0,,Expert,,41M,,9606.0,In vitro antitumor activity against 41M cell line.,F,,Homo sapiens,,80007
228,16745,1,,621.0,,Intermediate,,41M,,9606.0,cytotoxicity against 41M cells incubated for 24 hr in MTT assay.,F,,Homo sapiens,,80007
229,15569,1,,621.0,,Intermediate,,41M,,9606.0,Cytotoxic activity in a panel of Human ovarian tumor 41M/CDDP cell line after 96h of drug exposure,F,,Homo sapiens,,80007
230,12989,1,,621.0,,Expert,,41M,,9606.0,In vitro antitumor activity against 41McisR cell line.,F,,Homo sapiens,,80007
231,12989,1,,621.0,,Expert,,41M,,9606.0,Resistant factor was determined between IC50 of cisplatin-resistant human tumor cell lines to that of 41McisR cell line,F,,Homo sapiens,,80007
232,16745,1,,621.0,,Intermediate,,41M,,9606.0,cytotoxicity against 41McisR cells incubated for 24 hr in MTT assay,F,,Homo sapiens,,80007
233,6210,9,,,,Expert,,,,9606.0,Inhibition of 5'-inosine monophosphate dehydrogenase type I (IMPDH I),B,,Homo sapiens,,84
234,6210,9,,,,Expert,,,,9606.0,Inhibition of 5'-inosine monophosphate dehydrogenase type II (IMPDH II),B,,Homo sapiens,,68
235,6226,8,,,,Expert,,,,,Inhibitory activity against inosine 5'-inosine monophosphate dehydrogenase type II (IMPDH II),B,,,,68
236,17855,8,,,,Expert,,,,,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase,B,,,,10201
237,17855,8,,,,Expert,,,,,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase; nd = Not determined,B,,,,10201
238,17855,8,,,,Expert,,,,,Initial dissociation constant towards human 5'-methylthioadenosine phosphorylase,B,,,,10201
239,10413,8,,,,Autocuration,,,,,"Evaluated for inhibitory activity on 5,10-Methenyl Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",B,,,,12220
240,10413,8,,,,Autocuration,,,,562.0,"Inhibitory activity against 5,10-methylenetetrahydrofolate dehydrogenase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",B,,Escherichia coli,,11303
241,10413,8,,,,Autocuration,,,,562.0,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",B,,Escherichia coli,,11303
242,10413,8,,,,Autocuration,,,,562.0,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM;NT=Not tested",B,,Escherichia coli,,11303
243,10413,8,,,,Autocuration,,,,,"Evaluated for inhibitory activity on 5,10-Methylene Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",B,,,,12220
244,10413,8,,,,Autocuration,,,,,"Evaluated for inhibitory activity on 5,10-methylenetetrahydrofolate dehydrogenase(L cell) at folate substrate concentration of 100 uM",B,,,,12220
245,7587,8,,,,Autocuration,,,,9823.0,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",B,,Sus scrofa,,11303
246,7587,8,,,,Autocuration,,,,9823.0,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (A,porcine liver) enzyme.",B,,Sus scrofa,,11303
247,7587,8,,,,Autocuration,,,,9823.0,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-4 M inhibitory concentration",B,,Sus scrofa,,11303
248,7587,8,,,,Autocuration,,,,9823.0,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-5 M inhibitory concentration",B,,Sus scrofa,,11303
249,7587,8,,,,Autocuration,,,,9823.0,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",B,,Sus scrofa,,11303
250,7587,8,,,,Autocuration,,,,9823.0,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",B,,Sus scrofa,,11303
251,7587,8,,,,Autocuration,,,,9823.0,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-5 M inhibitory concentration",B,,Sus scrofa,,11303
252,7587,8,,,,Autocuration,,,,9823.0,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-6 M inhibitory concentration",B,,Sus scrofa,,11303
253,7587,8,,,,Autocuration,,,,9823.0,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-7 M inhibitory concentration",B,,Sus scrofa,,11303
254,7587,8,,,,Autocuration,,,,9823.0,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme.",B,,Sus scrofa,,11303
255,7587,8,,,,Autocuration,,,,9823.0,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",B,,Sus scrofa,,11303
256,7587,8,,,,Autocuration,,,,9823.0,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",B,,Sus scrofa,,11303
257,7323,8,,,,Autocuration,,,,,"Compound was tested for in vitro inhibition of 5,10-Methylene Tetrahydrofolate Cyclohydrolase, competitive against (+)-L-5,10-methenyltetrahydrofolate",B,,,,11303
258,7587,0,,,,Autocuration,,,,9823.0,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme at 10E-4 M inhibitory concentration",B,,Sus scrofa,,22226
259,7587,0,,,,Autocuration,,,,9823.0,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme.",B,,Sus scrofa,,22226
260,13750,8,,,,Expert,,,,4932.0,Inhibition of 5-Desaturase involved in ergosterol biosynthesis,B,,Saccharomyces cerevisiae,,100249
261,7662,0,,,,Autocuration,,,,10116.0,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,B,,Rattus norvegicus,,22226
262,7662,0,,,,Autocuration,,,,10116.0,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,B,,Rattus norvegicus,,22226
263,7662,0,,,,Autocuration,,,,10116.0,"Irreversible inhibition of Walker 256 FUDR phosphorylase; expressed as Vo/Vi, velocity without inhibitor to that of velocity with inhibitor",B,,Rattus norvegicus,,22226
264,12211,6,,,,Autocuration,,,,,"Tested for 5-HT 3 receptor antagonist potency by ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",F,,,,104698
265,12211,6,,,,Autocuration,,,,,"Compound was tested for its 5-HT 3 receptor antagonist potency by their ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",F,,,,104698
266,12211,9,,,,Intermediate,2116.0,,Ileum,10141.0,Relative ability to increase cholinergically mediated contractions in isolated ileum of guinea pig,F,,Cavia porcellus,,20033
267,12211,8,,,,Expert,,,,,Stimulatory activity of intragastric pressure was tested in the rat,F,,,,10623
268,15453,8,,,,Autocuration,,,,,% Decrease of 5-HT carrier-receptor -bound radioactivity using paroxetine as a radioligand.,B,,,,121
269,11884,0,,,,Autocuration,,,,10116.0,Dose to reduce neuronal firing against 5-HT cells in rats (iv),F,,Rattus norvegicus,,22226
270,7185,8,,,,Autocuration,,,,,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,F,,,,12688
271,6876,9,,,,Expert,,,,9606.0,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine,B,,Homo sapiens,,121
272,6876,9,,,,Expert,,,,9606.0,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine; No data,B,,Homo sapiens,,121
273,11863,8,,,,Autocuration,,,,,Inhibition of high affinity 5-HT uptake at concentration of 1 uM,F,,,,12198
274,11863,8,,,,Autocuration,,,,,Inhibition constant of high-affinity 5-HT uptake,B,,,,12198
275,11863,8,,,,Autocuration,,,,,Michaelis-Menten constant was reported for high affinity transport of 5-HT,F,,,,12198
276,11863,8,,,,Autocuration,,,,,Maximum rate was determined for high affinity transport of 5-HT,F,,,,12198
277,4639,4,,,,Autocuration,,,,,Compound was tested for agonistic activity against 5-HT uptake,F,,,,104714
278,15796,8,,,,Expert,,,,,Inhibition affinity against 5-HT-1B receptor in rat frontal cortex using radio binding assay,B,,,,10577
279,15796,8,,,,Expert,,,,9913.0,Inhibition affinity against 5-HT-1D receptor in bovine caudate nucleus using radio binding assay,B,,Bos taurus,,105
280,12801,5,,,,Autocuration,,,,10116.0,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,B,,Rattus norvegicus,,104744
281,12801,4,,,,Autocuration,,,,,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1 using [3H]5-HT as radioligand,B,,,,104744
282,12120,4,,,,Autocuration,,,,,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M,B,,,Membranes,104744
283,12120,4,,,,Autocuration,,,,,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M.,B,,,Membranes,104744
284,11963,4,,,,Autocuration,,,,,Displacement of binding of [3H]-5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,B,,,,104744
285,11701,8,,,,Autocuration,,,,,Dose required to reduce neuronal firing of 5-HT1A cells by 50%,F,,,,51
286,9995,8,,,,Autocuration,10000000.0,,Hippocampus,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,,,,51
287,9995,8,,,,Autocuration,10000000.0,,Hippocampus,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,B,,,,51
288,9995,8,,,,Autocuration,10000000.0,,Hippocampus,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,,,,51
289,16394,8,,,,Autocuration,,,,,Antagonistic activity at postsynaptic 5-HT1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (.26-3.52),F,In vivo,,,10576
290,11574,9,,,,Intermediate,,,,10141.0,Effect on forskolin stimulated adenylate cyclase activity at 5-HT1D receptor of guinea pig substantia nigra.,F,,Cavia porcellus,,105570
291,15779,8,,449.0,,Autocuration,,CHO,,,Binding affinity towards 5-HT1F (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,B,,,,279
292,15363,8,,,,Autocuration,,,,,Compound was tested for the displacement of [125I]DOI from clone human 5-hydroxytryptamine 2A receptor,B,,,,107
293,15363,9,,,,Expert,,,,10116.0,Efficacy against 5-hydroxytryptamine 2A receptor,F,,Rattus norvegicus,,12687
294,15329,8,,,,Expert,,,,,Intrinsic activity towards 5-HT2A receptor of rat tail artery,F,,,,12687
295,15329,8,,,,Expert,,,,,Relative potency towards 5-HT2A receptor of rat tail artery,F,,,,12687
296,15329,8,,,,Expert,,,,,Blocking 5-HT2A receptor-mediated contractions of rat tail artery,F,,,,12687
297,15329,8,,,,Expert,,,,,Partial agonism at 5-HT2A receptor was evaluated in presence of ketanserin (3-10 nM) in isolated rat tail artery,F,,,,12687
298,15329,8,,,,Autocuration,,,,,Compound was tested for the intrinsic activity against 5-HT2A receptors of rat tail artery.,F,,,,12687
299,15329,8,,,,Expert,,,,,Effectiveness in blocking 5-HT2A receptor-mediated contractions of rat tail artery,F,,,,12687
300,273,9,,,,Intermediate,2116.0,,Ileum,10141.0,Evaluated for the agonistic activity against 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,F,,Cavia porcellus,,20033
301,273,9,,,,Intermediate,2116.0,,Ileum,10141.0,Agonistic activity against Serotonin 5-HT4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI),F,,Cavia porcellus,,20033
302,273,9,,,,Intermediate,2116.0,,Ileum,10141.0,Evaluated for the agonistic activity against Serotonin 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,F,,Cavia porcellus,,20033
303,12092,8,,,,Autocuration,,,,,The binding affinity was measured on 5-hydroxytryptamine 4 receptor using [3H]- GR-113808 as radioligand.,B,,,,10623
304,1317,9,,,,Expert,,,,10116.0,Antagonist activity against 5-HT4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,F,,Rattus norvegicus,,10623
305,12409,8,,,,Expert,,,,,Binding affinity against 5-hydroxytryptamine 4 receptor,B,,,,168
306,11126,0,,,,Autocuration,,,,9031.0,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of chick intestine,B,,Gallus gallus,,22226
307,11126,0,,,,Autocuration,,,,9606.0,Inhibitory effect (10e-6 M) on the 25-OH-D3-1-hydroxylase activity,F,,Homo sapiens,,22226
308,11126,0,,,,Autocuration,,,,9606.0,25-OH-D3-1-hydroxylase activity (10e-6 M) was measured as %control,F,,Homo sapiens,,22226
309,11126,1,,649.0,,Autocuration,,HL-60,,9606.0,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of human HL-60 cells,B,,Homo sapiens,,80156
310,11126,0,,,,Autocuration,,,,9606.0,Inhibitory effect (10e-6 M) on the 25-hydroxyvitamin D3-1-hydroxylase activity,B,,Homo sapiens,,22226
311,11126,0,,,,Autocuration,,,,9606.0,25-hydroxyvitamin D3-1-hydroxylase activity (10e-6 M) was measured as %control,B,,Homo sapiens,,22226
312,17807,7,,,,Autocuration,,Oocytes,,9606.0,Displacement of [3H]-Ro- 15-1788 from human GABA-A alpha-1-beta-3-gamma-2 receptor subunits expressed in Xenopus oocytes,B,,Homo sapiens,,104703
313,16575,2,,,,Intermediate,,,,,Chymotryptic inhibitory activity against 26S proteasome,F,,,,100256
314,15407,2,,,,Intermediate,,,,,Inhibitory activity against 26S proteasome degradation of IkB,B,,,,100256
315,10797,1,,478.0,,Intermediate,,A2780,,9606.0,In vitro inhibition of 2780/DOX ovarian cancer cell line,F,,Homo sapiens,,81034
316,10797,1,,478.0,,Intermediate,,A2780,,9606.0,In vitro inhibition of 2780/S ovarian cancer cell line,F,,Homo sapiens,,81034
317,3469,0,,,,Autocuration,,,,9606.0,Relative activity on the cellular accumulation of vincristine in multidrug-resistant (MDR) human ovarian cancer 2780AD cells,F,,Homo sapiens,,22226
318,16037,3,,,,Intermediate,,,,,Association constant for binding to AATT 28-mer AATT hairpin,B,,,,22222
319,16037,3,,,,Intermediate,,,,,Kinetically Defined Association Constant for 28-mer AATT hairpin.,B,,,,22222
320,16037,3,,,,Intermediate,,,,,Reaction Rate Parameter for 28-mer AATT hairpin,B,,,,22222
321,16037,3,,,,Intermediate,,,,,Reaction Rate Parameter for 28-mer AATT hairpin,B,,,,22222
322,16524,0,,,,Autocuration,,,,9606.0,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 1),F,,Homo sapiens,,22226
323,16524,0,,,,Autocuration,,,,9606.0,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 2),F,,Homo sapiens,,22226
324,16524,0,,,,Autocuration,,,,9606.0,Inhibitory concentration by single cycle replication assay using envelope deficient HIV-1,F,,Homo sapiens,,22226
325,16758,0,,,,Autocuration,,,,10029.0,Cytotoxicity against cell line 2SC/20 determined by MTT test,F,,Cricetulus griseus,,22226
326,16758,0,,,,Autocuration,,,,10029.0,Cytotoxicity against cell line 2SC/20 of hamster determined by MTT test,F,,Cricetulus griseus,,22226
327,16758,0,,,,Autocuration,,,,10029.0,Inhibitory concentration against the growth of 2SC/20 cell line after 72 hr of drug exposure by MTT test,F,,Cricetulus griseus,,22226
328,14360,8,,,,Autocuration,,,,,Binding affinity on 3 beta-hydroxysteroid dehydrogenase,B,,,,241
329,14360,9,,,,Expert,,,,9606.0,Binding affinity for 3-beta-hydroxysteroid dehydrogenase,B,,Homo sapiens,,241
330,9964,0,,,,Autocuration,,,,10116.0,Selectivity ratio of ID50 in liver and heart,B,,Rattus norvegicus,,22226
331,9964,8,,,,Autocuration,,,,,"Selectivity, ratio of relative ID50 in liver and heart",B,,,,12132
332,9964,8,,,,Autocuration,,,,,Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to T3,B,,,,12132
333,9964,8,,,,Autocuration,,,,,"Binding affinity to the receptor was determined in nuclei of heart In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",B,,,,12132
334,9964,8,,,,Autocuration,,,,,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",B,,,,12132
335,9964,8,,,,Autocuration,,,,,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",B,In vivo,,,12132
336,9964,8,,,,Autocuration,,,,,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",F,In vivo,,,12132
337,9964,0,,,,Autocuration,,,,,"Binding affinity to the thyroid hormone receptor was determined in vitro in isolated nuclei of rat liver relative to 3,5,3' triiodothyronine",B,,,,22226
338,9964,8,,,,Autocuration,,,,,Binding affinity to the receptor was determined in vitro in isolated nuclei of rat liver relative to T3,B,,,,12132
339,9964,0,,,,Autocuration,,,,9606.0,"Binding affinity to thyroid hormone receptor beta, relative to 3,5,3' triiodothyronine receptor, in isolated nuclei of heart",B,,Homo sapiens,,22226
340,9964,8,,,,Autocuration,,,,,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,B,,,,12132
341,9964,8,,,,Autocuration,,,,,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,F,,,,12132
342,9964,8,,,,Autocuration,,,,,"Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to 3,5,3' triiodothyronine receptor",B,,,,12132
343,9964,0,,,,Autocuration,,,,10116.0,"In vivo binding affinity for 3,5,3'' triiodothyronine receptor of heart nuclei 1 hr after intravenous administration",B,,Rattus norvegicus,,22226
344,9964,8,,,,Autocuration,,,,,Binding affinity to the receptor was determined in nuclei of heart in vivo 1 hour after intravenous administration relative to T3,B,In vivo,,,12132
345,9964,8,,,,Autocuration,,,,,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",B,,,,12132
346,9964,0,,,,Autocuration,,,,10116.0,"In vivo binding affinity for 3,5,3' triiodothyronine receptor of liver nuclei 1 hour after intravenous administration",B,,Rattus norvegicus,,22226
347,9964,8,,,,Autocuration,,,,,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",B,,,,12132
348,9964,8,,,,Autocuration,,,,,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",F,,,,12132
349,3796,0,,,,Autocuration,,,,10116.0,"Inhibition of [125I]L-T3 binding to rat hepatic 3,5,3''-triiodo-L-thyronine receptor",B,,Rattus norvegicus,,22226
350,4251,8,,,,Autocuration,,,,562.0,Inhibition constant for binding to Co2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,B,,Escherichia coli,,19690
351,4251,8,,,,Autocuration,,,,562.0,Inhibition constant for binding to Zn2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,B,,Escherichia coli,,19690
352,4251,8,,,,Autocuration,,,,562.0,Kinetics expressed as Michaelis-Menten constant against Co2+ form of 3-dehydroquinate synthase purified from Escherichia coli,B,,Escherichia coli,,19690
353,4251,8,,,,Autocuration,,,,562.0,Kinetics expressed as Michaelis-Menten constant against Zn2+ form of 3-dehydroquinate synthase purified from Escherichia coli,B,,Escherichia coli,,19690
354,166,8,,,,Autocuration,,,,,Type of inhibition of 3-dehydroquinate synthase was determined; R - Slowly reversible,B,,,,19690
355,17861,8,,,,Autocuration,,,,,Compound was evaluated for its inhibitory constant against 3-dehydroquinate synthase,B,,,,19690
356,166,8,,,,Autocuration,,,,,Inhibition constant against 3-dehydroquinate synthase,B,,,,19690
357,166,8,,,,Autocuration,,,,,Association rate constant against 3-dehydroquinate synthase,B,,,,19690
358,166,8,,,,Autocuration,,,,,Rate constant against 3-dehydroquinate synthase,B,,,,19690
359,3548,0,,,,Autocuration,,,,,Inhibitory activity against fuc-TVII,B,,,,22226
360,9877,9,,,,Autocuration,2107.0,,Liver,10116.0,Ability of compound (2.5 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,B,,Rattus norvegicus,Microsomes,12236
361,9877,9,,,,Autocuration,2107.0,,Liver,10116.0,Ability of compound (2500 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,B,,Rattus norvegicus,Microsomes,12236
362,9877,9,,,,Autocuration,2107.0,,Liver,10116.0,Ability of compound (250 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,B,,Rattus norvegicus,Microsomes,12236
363,9877,9,,,,Autocuration,2107.0,,Liver,10116.0,Ability of compound (25 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,B,,Rattus norvegicus,Microsomes,12236
364,9877,9,,,,Autocuration,2107.0,,Liver,10116.0,Ability of compound at 0 uM to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,B,,Rattus norvegicus,Microsomes,12236
365,9877,9,,,,Autocuration,2107.0,,Liver,10116.0,Ability of compound to inhibit the activity of 3-hydroxy-3-methylglutarylcoenzyme A(HMGR) reductase in rat liver microsomes,B,,Rattus norvegicus,Microsomes,12236
366,9877,9,,,,Autocuration,2107.0,,Liver,10116.0,Percentage inhibition of 3-hydroxy-3-methyl glutaryl coenzyme A reductase in rat liver microsomes at 250 uM,B,,Rattus norvegicus,Microsomes,12236
367,9877,9,,,,Autocuration,2107.0,,Liver,10116.0,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 0 uM,B,,Rattus norvegicus,Microsomes,12236
368,9877,9,,,,Autocuration,2107.0,,Liver,10116.0,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2.5 uM,B,,Rattus norvegicus,Microsomes,12236
369,9877,9,,,,Autocuration,2107.0,,Liver,10116.0,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2500 uM,B,,Rattus norvegicus,Microsomes,12236
370,9877,9,,,,Autocuration,2107.0,,Liver,10116.0,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 25 uM,B,,Rattus norvegicus,Microsomes,12236
371,3003,4,,,,Autocuration,,,,,Inhibitory activity against 3-phosphoglycerate kinase.,B,,,,104832
372,3003,4,,,,Autocuration,,,,,Binding affinity was evaluated towards 3-phosphoglycerate kinase at 37 degrees Celsius in 0.1 m NaCl pH 7.1,B,,,,104832
373,3003,4,,,,Autocuration,,,,,"Michaelis-Menten constant with 1,3-bisphosphoglyceric acid (1,3-BPG) against 3-phosphoglycerate kinase",B,,,,104832
374,17185,9,,,,Expert,,,,9606.0,Inhibition of human 3-phosphoinositide-dependent protein kinase 1 at 10 uM,B,,Homo sapiens,,10612
375,6072,1,,844.0,,Intermediate,,3677 melanoma cell line,,9606.0,Cytotoxicity on 3677 melanoma cells,F,,Homo sapiens,,80616
376,6072,1,,844.0,,Intermediate,,3677 melanoma cell line,,9606.0,Cytotoxicity on 3677 melanoma cells in combination with L-49-sFv-bL,F,,Homo sapiens,,80616
377,5018,1,,700.0,,Intermediate,,MC-38,,10090.0,Antitumor activity against Mouse colon 38 at 500 ug/disk in disk diffusion assay,F,,Mus musculus,,80617
378,2852,0,,,,Intermediate,,,,9606.0,Compound was evaluated for inhibition of tumor cell growth using sulforhodamine-B assay in 38 human cell lines,F,,Homo sapiens,,22226
379,8663,0,,798.0,,Autocuration,,B16,,,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; NT= Not tested,F,,,,22226
380,8663,0,,798.0,,Autocuration,,B16,,,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; reproducible significant activity.,F,,,,22226
381,3245,9,,,,Expert,,,,12131.0,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease,F,,Human rhinovirus 14,,12464
382,3245,1,,,,Intermediate,,,,169066.0,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease; NI means No inhibition to 50 uM,F,,Human rhinovirus sp.,,50085
383,3877,1,,,,Intermediate,,,,169066.0,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as KI,F,,human rhinovirus type 14,,50679
384,3877,1,,,,Intermediate,,,,169066.0,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as kinact,F,,human rhinovirus type 14,,50679
385,5861,9,,,,Expert,,,,12131.0,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,F,,Human rhinovirus 14,,12464
386,5861,9,,,,Expert,,,,12131.0,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,F,,Human rhinovirus 14,,12464
387,5861,9,,,,Expert,,,,12131.0,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,F,,Human rhinovirus 14,,12464
388,5861,9,,,,Expert,,,,12131.0,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay; inactive,F,,Human rhinovirus 14,,12464
389,13748,1,,,,Intermediate,,,,12059.0,Compound was tested for the inhibitory activity of compound towards human rhinovirus 3C protease,F,,Enterovirus,,50665
390,13748,1,,,,Intermediate,,,,12059.0,Compound was tested for the inhibitory activity of compound towards human rhinovirus-16 3C protease,F,,Enterovirus,,50665
391,13748,1,,,,Intermediate,,,,12059.0,Compound was tested for the inhibitory activity of compound towards human rhinovirus-2 3C protease,F,,Enterovirus,,50665
392,13748,1,,,,Intermediate,,,,12059.0,Compound was tested for the inhibitory activity of compound towards human rhinovirus-89 3C protease,F,,Enterovirus,,50665
393,13748,8,,,,Expert,,,,147712.0,Inhibition of human rhinovirus 3C protease,B,,Human rhinovirus B,,12464
394,17699,0,,,,Autocuration,,,,9606.0,Compound was tested for inhibition of a proteinase 3CL pro of human coronavirus; Inhibited,B,,Homo sapiens,,22226
395,7145,1,,833.0,,Intermediate,,3EM 37,,10090.0,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 100 mg/kg (Dose range 200-12.5),F,,Mus musculus,,80619
396,7145,1,,833.0,,Intermediate,,3EM 37,,10090.0,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 128 mg/kg (Dose range 256-16),F,,Mus musculus,,80619
397,7145,1,,833.0,,Intermediate,,3EM 37,,10090.0,Compound tested for toxicity against 3EM 37 Mouse Ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (10/10),F,,Mus musculus,,80619
398,7145,1,,833.0,,Intermediate,,3EM 37,,10090.0,Compound tested for toxicity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (6/6),F,,Mus musculus,,80619
399,7145,1,,833.0,,Intermediate,,3EM 37,,10090.0,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as animal weight difference of the treated and the control (T-C) at OD of 100 mg/kg,F,,Mus musculus,,80619
400,7145,1,,833.0,,Intermediate,,3EM 37,,10090.0,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as percentage of cured animals at OD of 100 mg/kg,F,,Mus musculus,,80619
401,5325,1,,847.0,,Intermediate,,3LL cell line,,10090.0,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing 15 mg/kg b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,F,,Mus musculus,,80620
402,5325,1,,847.0,,Intermediate,,3LL cell line,,10090.0,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,F,,Mus musculus,,80620
403,5325,1,,847.0,,Expert,,3LL cell line,,10090.0,In vivo anti-tumor and anti-metastatic activity following p.o. administration b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor; Not tested.,F,,Mus musculus,,80620
404,16169,1,,847.0,,Intermediate,,3LL cell line,,10090.0,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 1 uM dose,F,,Mus musculus,,80620
405,16169,1,,847.0,,Intermediate,,3LL cell line,,10090.0,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 10 uM dose,F,,Mus musculus,,80620
406,16169,1,,847.0,,Intermediate,,3LL cell line,,10090.0,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 250 uM dose,F,,Mus musculus,,80620
407,16169,1,,847.0,,Intermediate,,3LL cell line,,10090.0,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 50 uM dose,F,,Mus musculus,,80620
408,16169,1,,847.0,,Intermediate,,3LL cell line,,10090.0,accumulation of compound in 3LL cells was measured with DFMO by ICP-AES at 50 uM dose,F,,Mus musculus,,80620
409,16169,1,,847.0,,Intermediate,,3LL cell line,,10090.0,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 1 uM dose,F,,Mus musculus,,80620
410,16169,1,,847.0,,Intermediate,,3LL cell line,,10090.0,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 10 uM dose,F,,Mus musculus,,80620
411,16169,1,,847.0,,Intermediate,,3LL cell line,,10090.0,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 250 uM dose,F,,Mus musculus,,80620
412,16169,1,,847.0,,Intermediate,,3LL cell line,,10090.0,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,F,,Mus musculus,,80620
413,16169,1,,847.0,,Intermediate,,3LL cell line,,10090.0,accumulation of compound in 3LL cells was measured without DFMO by ICP-AES at 50 uM dose,F,,Mus musculus,,80620
414,16169,1,,847.0,,Intermediate,,3LL cell line,,10090.0,Effect on the growth of 3LL cells by DFMO pretreatment at 48 hr incubation,F,,Mus musculus,,80620
415,16169,1,,847.0,,Intermediate,,3LL cell line,,10090.0,Effect on the growth of 3LL cells was evaluated using an MTT assay at 48 hour incubation,F,,Mus musculus,,80620
416,16169,1,,847.0,,Intermediate,,3LL cell line,,10090.0,Effect on the growth of 3LL cells was evaluated using an MTT assay at 72 hour incubation,F,,Mus musculus,,80620
417,16169,1,,847.0,,Intermediate,,3LL cell line,,10090.0,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,F,,Mus musculus,,80620
418,16169,1,,847.0,,Intermediate,,3LL cell line,,10090.0,putrescine levels in 3LL cells after the treatment of 1 uM of Compound,F,,Mus musculus,,80620
419,16169,1,,847.0,,Intermediate,,3LL cell line,,10090.0,putrescine levels in 3LL cells after the treatment of 10 uM of Compound,F,,Mus musculus,,80620
420,16169,1,,847.0,,Intermediate,,3LL cell line,,10090.0,putrescine levels in 3LL cells after the treatment of 250 uM of Compound,F,,Mus musculus,,80620
421,16169,1,,847.0,,Intermediate,,3LL cell line,,10090.0,putrescine levels in 3LL cells after the treatment of 50 uM of Compound,F,,Mus musculus,,80620
422,16169,1,,847.0,,Intermediate,,3LL cell line,,10090.0,spermidine levels in 3LL cells after the treatment of 1 uM of Compound,F,,Mus musculus,,80620
423,16169,1,,847.0,,Intermediate,,3LL cell line,,10090.0,spermidine levels in 3LL cells after the treatment of 10 uM of Compound,F,,Mus musculus,,80620
424,16169,1,,847.0,,Intermediate,,3LL cell line,,10090.0,spermidine levels in 3LL cells after the treatment of 250 uM of Compound,F,,Mus musculus,,80620
425,16169,1,,847.0,,Intermediate,,3LL cell line,,10090.0,spermidine levels in 3LL cells after the treatment of 50 uM of Compound,F,,Mus musculus,,80620
426,16169,1,,847.0,,Intermediate,,3LL cell line,,10090.0,spermine levels in 3LL cells after the treatment of 1 uM of Compound,F,,Mus musculus,,80620
427,16169,1,,847.0,,Intermediate,,3LL cell line,,10090.0,spermine levels in 3LL cells after the treatment of 10 uM of Compound,F,,Mus musculus,,80620
428,16169,1,,847.0,,Intermediate,,3LL cell line,,10090.0,spermine levels in 3LL cells after the treatment of 250 uM of Compound,F,,Mus musculus,,80620
429,16169,1,,847.0,,Intermediate,,3LL cell line,,10090.0,spermine levels in 3LL cells after the treatment of 50 uM of Compound,F,,Mus musculus,,80620
430,15547,1,,971.0,,Intermediate,,3LLD122,,9606.0,Concentration required to inhibit the colony formation of lung carcinoma (3LLD122) cell lines by 50%,F,,Homo sapiens,,80621
431,8663,0,,,,Autocuration,,,,,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible minimal activity,F,,,,22226
432,8663,0,,,,Autocuration,,,,,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible significant activity.,F,,,,22226
433,8663,0,,,,Autocuration,,,,,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; NT= Not tested,F,,,,22226
434,8663,0,,,,Autocuration,,,,,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; reproducible significant activity.,F,,,,22226
435,4504,1,,723.0,,Intermediate,,NIH3T3,,10090.0,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,F,,Mus musculus,,80951
436,4504,1,,723.0,,Intermediate,,NIH3T3,,10090.0,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,F,,Mus musculus,,80951
437,12695,8,,723.0,,Expert,,NIH3T3,,,Inhibition of 6 nM bombesin induced [3H]thymidine incorporation measured in swiss 3T3 cells using a mitogenicity assay,F,,,,11169
438,12695,1,,723.0,,Intermediate,,NIH3T3,,10090.0,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; na=Not active,F,,Mus musculus,,80951
439,12695,1,,723.0,,Intermediate,,NIH3T3,,10090.0,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; nt=Not tested,F,,Mus musculus,,80951
440,17642,1,,723.0,,Expert,,NIH3T3,,10090.0,Effective dose against murine 3T3 fibroblasts cells,F,,Mus musculus,,80951
441,17642,1,,723.0,,Expert,,NIH3T3,,10090.0,Dose required against murine 3T3 fibroblasts cells; 1-10 uM,F,,Mus musculus,,80951
442,12340,1,,723.0,,Expert,,NIH3T3,,10090.0,Cytotoxic effect on 3T3 cells,F,,Mus musculus,,80951
443,12340,1,,723.0,,Expert,,NIH3T3,,10090.0,Cytotoxic effect on 3T3 cells,F,,Mus musculus,,80951
444,12716,1,,723.0,,Intermediate,,NIH3T3,,10090.0,Compound was tested for the concentration necessary to inhibit swiss 3T3 Mouse Fibroblast cell growth rate by 50%.,F,,Mus musculus,,80951
445,6277,1,,723.0,,Intermediate,,NIH3T3,,10090.0,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,F,,Mus musculus,,80951
446,6277,1,,723.0,,Intermediate,,NIH3T3,,10090.0,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration; nd=No data,F,,Mus musculus,,80951
447,6277,1,,723.0,,Expert,,NIH3T3,,10090.0,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration,F,,Mus musculus,,80951
448,6277,1,,723.0,,Expert,,NIH3T3,,10090.0,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.d.=no data,F,,Mus musculus,,80951
449,6277,1,,723.0,,Intermediate,,NIH3T3,,10090.0,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.t.=not tested,F,,Mus musculus,,80951
450,6277,1,,723.0,,Expert,,NIH3T3,,10090.0,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration,F,,Mus musculus,,80951
451,6277,1,,723.0,,Expert,,NIH3T3,,10090.0,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.d.=no data,F,,Mus musculus,,80951
452,6277,1,,723.0,,Intermediate,,NIH3T3,,10090.0,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.t.=not tested,F,,Mus musculus,,80951
453,17780,1,,723.0,,Expert,,NIH3T3,,10090.0,In vivo inhibition of H-ras-transformed 3T3 fibroblasts in nude mouse tumor models,F,,Mus musculus,,80951
454,12751,7,,,,Autocuration,,,,10090.0,Inhibition of PDGF-dependent autophosphorylation of PDGF-R in mouse BALB/c3T3 cells,F,,Mus musculus,,104860
455,12380,1,,723.0,,Expert,,NIH3T3,,10090.0,Inhibition of Swiss 3T3 Mouse fibroblast proliferation,F,,Mus musculus,,80951
456,14892,1,,723.0,,Intermediate,,NIH3T3,,10090.0,Inhibitory activity against 3T3 cell line,F,,Mus musculus,,80951
457,12695,1,,723.0,,Intermediate,,NIH3T3,,10090.0,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured,F,,Mus musculus,,80951
458,12695,8,,,,Expert,,,,,Ability of peptide to inhibit binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane.,F,,,,11169
459,12695,1,,723.0,,Intermediate,,NIH3T3,,10090.0,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured; nt=Not tested,F,,Mus musculus,,80951
460,12695,1,,723.0,,Intermediate,,NIH3T3,,10090.0,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells was measured,F,,Mus musculus,,80951
461,12695,8,,,,Expert,,,,,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells,F,,,,11169
462,12695,8,,,,Expert,,,,,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells; nt=Not tested,F,,,,11169
463,6277,1,,723.0,,Intermediate,,NIH3T3,,10090.0,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,F,,Mus musculus,,80951
464,6277,1,,723.0,,Expert,,NIH3T3,,10090.0,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line was determined using NR coloration; n.d.=no data,F,,Mus musculus,,80951
465,4959,9,,723.0,,Expert,,NIH3T3,,9606.0,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells,F,,Homo sapiens,,9
466,4959,9,,723.0,,Expert,,NIH3T3,,9606.0,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells (Not tested),F,,Homo sapiens,,9
467,4959,9,,723.0,,Expert,,NIH3T3,,9606.0,Inhibition of ligand induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells,F,,Homo sapiens,,188
468,4959,9,,723.0,,Expert,,NIH3T3,,9606.0,Inhibition of ligand-induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells (Not tested),F,,Homo sapiens,,188
469,12082,1,,723.0,,Intermediate,,NIH3T3,,10090.0,Inhibitory concentration of compound rwas calculated on 3T3 cells by [3H]Thd incorporation,F,,Mus musculus,,80951
470,12082,1,,723.0,,Intermediate,,NIH3T3,,10090.0,Inhibitory concentration of compound was calculated on 3T3 cells by [14C]Leu incorporation,F,,Mus musculus,,80951
471,12082,1,,723.0,,Intermediate,,NIH3T3,,10090.0,Inhibitory concentration of compound was calculated on 3T3 cells by using clonal assay,F,,Mus musculus,,80951
472,12082,1,,723.0,,Intermediate,,NIH3T3,,10090.0,Inhibitory concentration was calculated on 3T3 cells by using growth assay,F,,Mus musculus,,80951
473,2643,1,,723.0,,Intermediate,,NIH3T3,,10090.0,In vitro cytotoxicity was evaluated in mouse embryo BALB/c 3T3 cells,F,,Mus musculus,,80951
474,11926,1,,723.0,,Expert,,NIH3T3,,10090.0,Inhibition of Swiss 3T3 mouse fibroblast proliferation,F,,Mus musculus,,80951
475,15204,1,,723.0,,Intermediate,,NIH3T3,,10090.0,The compound was tested for cytotoxicity against 3T3 fibroblast murine cell line.,A,,Mus musculus,,80951
476,15992,1,,723.0,,Expert,,NIH3T3,,10090.0,Effective concentration required to inhibit the growth of murine 3T3 fibroblasts,F,,Mus musculus,,80951
477,16279,1,,723.0,,Intermediate,,NIH3T3,,10090.0,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014); Not tested,F,,Mus musculus,,80951
478,16279,1,,723.0,,Intermediate,,NIH3T3,,10090.0,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),F,,Mus musculus,,80951
479,16279,1,,723.0,,Intermediate,,NIH3T3,,10090.0,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),F,,Mus musculus,,80951
480,16279,1,,723.0,,Intermediate,,NIH3T3,,10090.0,cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),F,,Mus musculus,,80951
481,16279,1,,723.0,,Intermediate,,NIH3T3,,10090.0,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),F,,Mus musculus,,80951
482,16279,1,,723.0,,Intermediate,,NIH3T3,,10090.0,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),F,,Mus musculus,,80951
483,12831,1,,723.0,,Expert,,NIH3T3,,10090.0,Inhibition of swiss 3T3 mouse fibroblast proliferation,F,,Mus musculus,,80951
484,13497,1,,723.0,,Intermediate,,NIH3T3,,10090.0,Compound was tested for sublethal concentrations in 3T3 mouse fibroblast lysis.,F,,Mus musculus,,80951
485,13715,1,,620.0,,Intermediate,,3T3-L1,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,F,,,,80006
486,13618,1,,620.0,,Intermediate,,3T3-L1,,10090.0,Concentration required to stimulate glucose uptake in 3T3-L1 adipocytes after 48 hr incubation,F,,Mus musculus,,80006
487,11902,1,,620.0,,Intermediate,,3T3-L1,,10090.0,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 0.3 uM,F,,Mus musculus,,80006
488,11902,1,,620.0,,Intermediate,,3T3-L1,,10090.0,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 3 uM,F,,Mus musculus,,80006
489,11902,1,,620.0,,Intermediate,,3T3-L1,,10090.0,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 30 uM,F,,Mus musculus,,80006
490,14840,1,,620.0,,Intermediate,,3T3-L1,,10090.0,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 24 hr",F,,Mus musculus,,80006
491,14840,1,,620.0,,Intermediate,,3T3-L1,,10090.0,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 3 hr",F,,Mus musculus,,80006
492,13715,1,,620.0,,Intermediate,,3T3-L1,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes,F,,,,80006
493,13715,1,,620.0,,Intermediate,,3T3-L1,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,F,,,,80006
494,13715,1,,620.0,,Intermediate,,3T3-L1,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,F,,,,80006
495,13715,1,,620.0,,Intermediate,,3T3-L1,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,F,,,,80006
496,13715,1,,620.0,,Intermediate,,3T3-L1,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,F,,,,80006
497,13715,1,,620.0,,Intermediate,,3T3-L1,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.3 uM dose.,F,,,,80006
498,13715,1,,620.0,,Intermediate,,3T3-L1,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.5 uM dose.,F,,,,80006
499,13715,1,,620.0,,Intermediate,,3T3-L1,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,F,,,,80006
500,13715,1,,620.0,,Intermediate,,3T3-L1,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,F,,,,80006
501,13715,1,,620.0,,Expert,,3T3-L1,,,In vitro measurements 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,F,,,,80006
502,13715,1,,620.0,,Expert,,3T3-L1,,,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,F,,,,80006
503,13715,1,,620.0,,Intermediate,,3T3-L1,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,F,,,,80006
504,13715,1,,620.0,,Intermediate,,3T3-L1,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,F,,,,80006
505,13715,1,,620.0,,Intermediate,,3T3-L1,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 300 uM dose.,F,,,,80006
506,13715,1,,620.0,,Expert,,3T3-L1,,,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,F,,,,80006
507,13715,1,,620.0,,Expert,,3T3-L1,,,In vitro by measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,F,,,,80006
508,13715,1,,620.0,,Expert,,3T3-L1,,,In vitro measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,F,,,,80006
509,13715,1,,620.0,,Intermediate,,3T3-L1,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,F,,,,80006
510,13715,1,,620.0,,Intermediate,,3T3-L1,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,F,,,,80006
511,13715,1,,620.0,,Intermediate,,3T3-L1,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,F,,,,80006
512,13715,1,,620.0,,Intermediate,,3T3-L1,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,F,,,,80006
513,13715,1,,620.0,,Intermediate,,3T3-L1,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,F,,,,80006
514,13715,1,,620.0,,Intermediate,,3T3-L1,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,F,,,,80006
515,13715,1,,620.0,,Intermediate,,3T3-L1,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,F,,,,80006
516,13715,1,,620.0,,Intermediate,,3T3-L1,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,F,,,,80006
517,6411,8,,620.0,,Expert,,3T3-L1,,,Inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells,F,,,,11214
518,6411,1,,620.0,,Intermediate,,3T3-L1,,10090.0,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; ND = No data,F,,Mus musculus,,80006
519,6411,8,,620.0,,Expert,,3T3-L1,,,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; Na = Not active,F,,,,11214
520,3966,1,,620.0,,Expert,,3T3-L1,,10090.0,Insulin-sensitizing activity; triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 1 uM expressed as percent activity of pioglitazone,F,,Mus musculus,,80006
521,3966,1,,620.0,,Intermediate,,3T3-L1,,10090.0,Compound was tested for insulin-sensitizing activity by measuring triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 10 uM expressed as percent activity of pioglitazone,F,,Mus musculus,,80006
522,15556,1,,620.0,,Expert,,3T3-L1,,10090.0,Stimulation of adipogenesis in 3T3-L1 cells is expressed as concentration equivalent to the [ 1-14C] uptake counts after treatment with 0.2 ug/mL troglitazone,F,,Mus musculus,,80006
523,5845,1,,620.0,,Expert,,3T3-L1,,10090.0,Effective concentration for enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,F,,Mus musculus,,80006
524,14422,1,,620.0,,Expert,,3T3-L1,,10090.0,Effective concentration for 50% enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,F,,Mus musculus,,80006
525,5845,1,,620.0,,Expert,,3T3-L1,,10090.0,Percentage of rosiglitazone response for insulin-sensitizing activity at 1 uM concentration in 3T3-L1 cells,F,,Mus musculus,,80006
526,14508,1,,620.0,,Expert,,3T3-L1,,10090.0,In vitro glucose transport activity in 3T3-LI adipocytes at 10 uM concentration.,F,,Mus musculus,,80006
527,14508,1,,620.0,,Expert,,3T3-L1,,10090.0,In vitro glucose transport activity in 3T3-LI adipocytes at 3 uM concentration.,F,,Mus musculus,,80006
528,14508,1,,620.0,,Expert,,3T3-L1,,10090.0,In vitro glucose transport activity in 3T3-LI adipocytes at 30 uM concentration.,F,,Mus musculus,,80006
529,6349,1,,1118.0,,Intermediate,,3Y1 cell line,,10116.0,Inhibitory activity against rat fibroblast (3Y1) cell line,F,,Rattus norvegicus,,80622
530,15899,1,,1118.0,,Expert,,3Y1 cell line,,10116.0,Mean concentration causing inhibition of cell growth in 3Y1 cells.,F,,Rattus norvegicus,,80622
531,15899,1,,1118.0,,Expert,,3Y1 cell line,,10116.0,Cytotoxicity in 3Y1 cells.,F,,Rattus norvegicus,,80622
532,15899,1,,1118.0,,Expert,,3Y1 cell line,,10116.0,Cytostatic effect in 3Y1 cells.,F,,Rattus norvegicus,,80622
533,15899,1,,1118.0,,Intermediate,,3Y1 cell line,,10116.0,"Mean averaged concentration for total growth inhibition, which signifies cytostatic effect",F,,Rattus norvegicus,,80622
534,17038,1,,1118.0,,Expert,,3Y1 cell line,,10116.0,Concentration to inhibit growth of normal rat fibroblast cells (3Y1-B cells) after 72 h exposure,F,,Rattus norvegicus,,80622
535,12421,0,,,,Autocuration,,,,,In vitro inhibitory activity against human adrenal 3-beta hydroxy-delta 5-teroid isomerase,B,,,,22226
536,12947,0,,,,Autocuration,,,,,Inhibition of recombinant human adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,B,,,,22226
537,12947,0,,,,Autocuration,,,,,Inhibition of recombinant rat adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,B,,,,22226
538,4896,9,,,,Expert,,,,9823.0,In vitro inhibition against of 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) from pig liver by the enol borate method,B,,Sus scrofa,,11607
539,6148,8,,,,Autocuration,,,,,In vitro inhibitory concentration required against 4-hydroxyphenylpyruvate dioxygenase (4-HPPD) taken from pig liver,B,,,,11607
540,16432,8,,,,Autocuration,,,,,Inhibition of pig liver 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) enzyme,B,,,,11607
541,4978,8,,,,Expert,,,,,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver,B,,,,11607
542,4978,8,,,,Expert,,,,,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver; (observed value),B,,,,11607
543,3723,8,,,,Autocuration,,,,,In vitro inhibitory activity against HPPD(4-hydroxyphenylpyruvate Dioxygenase) from pig liver using enol borate assay method,B,,,,11607
544,3518,8,,,,Autocuration,,,,,Compound was evaluated for complete competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD),B,,,,11607
545,4164,8,,,,Autocuration,,,,,In vitro inhibition of 4-hydroxyphenylpyruvate dioxygenase obtained from purified pig liver by enol-borate method,B,,,,11607
546,3518,8,,,,Autocuration,,,,,Inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated,B,,,,11607
547,4164,9,,,,Expert,,,,9823.0,Inhibition of 4-hydroxyphenylpyruvate dioxygenase of purified pig liver by enol-borate method,B,,Sus scrofa,,11607
548,3518,8,,,,Autocuration,,,,,The inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated.,B,,,,11607
549,3518,8,,,,Autocuration,,,,,Compound was evaluated for competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD) (complete inhibition was observed at a concentration of 0.5-1.0 mM),B,,,,11607
550,4978,8,,,,Autocuration,,,,,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver,B,,,,11607
551,4978,8,,,,Autocuration,,,,,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver; (observed value),B,,,,11607
552,6455,4,,,,Autocuration,,,,,Binding affinity against melatonin (MT1) receptor (pC1),B,,,,104733
553,2222,0,,,,Autocuration,,,,,Compound was tested for inhibitory activity against 5-hydroxytryptamine 1 receptor,B,,,,22226
554,13020,0,,,,Autocuration,,,,,Inhibition of [3H]- 5-HT binding to 5-hydroxytryptamine 1 receptor at 10e-5 M,B,,,,22226
555,13021,0,,,,Autocuration,,,,,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1 receptor of central nervous system,B,,,,22226
556,14532,8,,,,Autocuration,,,,,Inhibitory activity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand at 10e-5 M concentration,B,,,,10619
557,14118,8,,,,Autocuration,,,,,Binding affinity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,B,,,,10619
558,11884,8,,,,Autocuration,10000000.0,,Hippocampus,,Binding affinity at 5-hydroxytryptamine 1A receptor in bovine hippocampal preparation using [3H]8-OH-DPAT,B,,,,51
559,13969,8,,,,Expert,,,,,Binding affinity against 5-hydroxytryptamine 1A receptor was measured using [3H]8-OH-DPAT as radioligand,B,,,,51
560,13392,8,,,,Expert,,,,,Binding affinity for 5-hydroxytryptamine 1A receptor,B,,,,51
561,14430,8,,,,Expert,,,,,Affinity towards 5-hydroxytryptamine 1A receptor in membranes from bovine hippocampus using [3H]OH-DPAT,B,,,,51
562,12248,8,,,,Autocuration,10000000.0,,Hippocampus,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,B,,,,51
563,12249,8,,,,Autocuration,10000000.0,,Hippocampus,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,B,,,,51
564,9995,8,,,,Autocuration,10000000.0,,Hippocampus,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,B,,,,51
565,9995,8,,,,Autocuration,10000000.0,,Hippocampus,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,,,,51
566,9995,8,,,,Autocuration,10000000.0,,Hippocampus,,In vitro inhibition of azido-[125I]-IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,B,,,,51
567,9995,8,,,,Autocuration,10000000.0,,Hippocampus,,In vitro inhibition of [125I]IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,B,,,,51
568,9995,8,,,,Autocuration,10000000.0,,Hippocampus,,In vitro inhibition of [125I]IPAPP (2.5 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,,,,51
569,12249,8,,,,Autocuration,10000000.0,,Hippocampus,,Inhibitory concentration against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,B,,,,51
570,11799,8,,,,Autocuration,10000000.0,,Hippocampus,,"Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",B,,,,51
571,14331,9,,,,Expert,,,,10116.0,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampal membranes,B,,Rattus norvegicus,Membranes,10576
572,11884,8,,,,Expert,10000000.0,,Hippocampus,9913.0,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of bovine hippocampus.,B,,Bos taurus,,51
573,14331,8,,,,Autocuration,10000000.0,,Hippocampus,,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (0.5 nM) ligand in hippocampus + frontal bovine was determined,B,,,,51
574,11701,8,,,,Autocuration,10000000.0,,Hippocampus,,Compound was evaluated for its ability to displace [3H]DPAT from 5-HT1A receptor in homogenates of bovine hippocampus,B,,,,51
575,11701,8,,,,Expert,10000000.0,,Hippocampus,,Ability to displace [3H]-DPAT from 5-hydroxytryptamine 1A receptor in homogenates of bovine hippocampus.,B,,,,51
576,12248,8,,,,Autocuration,10000000.0,,Hippocampus,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in bovine hippocampus,B,,,,51
577,12248,8,,449.0,,Autocuration,,CHO,,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in CHO cells,B,,,,51
578,12248,8,,,,Expert,10000000.0,,Hippocampus,,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,B,,,,51
579,12249,8,,,,Expert,10000000.0,,Hippocampus,,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,B,,,,51
580,12248,8,,449.0,,Autocuration,,CHO,,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,B,,,,51
581,11799,8,,,,Expert,10000000.0,,Hippocampus,,"Binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",B,,,,51
582,634,8,,,,Autocuration,,,,,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,B,,,,51
583,9995,8,,,,Autocuration,10000000.0,,Hippocampus,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,B,,,,51
584,9995,8,,,,Autocuration,10000000.0,,Hippocampus,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,,,,51
585,9995,8,,,,Autocuration,10000000.0,,Hippocampus,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,B,,,,51
586,9995,8,,,,Autocuration,10000000.0,,Hippocampus,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,,,,51
587,9995,8,,,,Autocuration,10000000.0,,Hippocampus,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,B,,,,51
588,12210,8,,,,Expert,10000000.0,,Hippocampus,,In vivo binding affinity towards [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus.,B,,,,51
589,13311,8,,,,Expert,10000000.0,,Hippocampus,,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,,,,51
590,2331,9,,449.0,,Expert,,CHO,,9606.0,"Tested in vitro for the inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor, expressed in cloned CHO cells.",B,,Homo sapiens,,51
591,1375,8,,,,Autocuration,,,,10141.0,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig,F,,Cavia porcellus,,51
592,1375,8,,,,Autocuration,,,,10141.0,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig; NT means not tested,F,,Cavia porcellus,,51
593,11574,8,,,,Autocuration,10000000.0,,Hippocampus,10141.0,Effect on forskolin stimulated adenylate cyclase activity at 5-hydroxytryptamine 1A receptor of guinea pig hippocampus.,F,,Cavia porcellus,,51
594,12867,8,,,,Autocuration,2116.0,,Ileum,10141.0,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,B,,Cavia porcellus,,51
595,12867,8,,,,Autocuration,2116.0,,Ileum,10141.0,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,B,,Cavia porcellus,,51
596,12867,8,,,,Autocuration,2116.0,,Ileum,10141.0,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,B,,Cavia porcellus,,51
597,12867,8,,,,Autocuration,2116.0,,Ileum,10141.0,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,B,,Cavia porcellus,,51
598,12867,8,,,,Autocuration,2116.0,,Ileum,10141.0,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,B,,Cavia porcellus,,51
599,12867,8,,,,Autocuration,2116.0,,Ileum,10141.0,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor; Inactive at dose level of 1.0 uM,B,,Cavia porcellus,,51
600,11574,8,,,,Autocuration,,,,10141.0,Binding affinity against 5-hydroxytryptamine 1A receptor,B,,Cavia porcellus,,51
601,13114,8,,,,Autocuration,,,,10141.0,Compound is evaluated for in vitro receptor binding affinity against 5-hydroxytryptamine 1A receptor,B,,Cavia porcellus,,51
602,13181,8,,,,Autocuration,,,,10141.0,Binding affinity was determined against 5-hydroxytryptamine 1A receptor,B,,Cavia porcellus,,51
603,10639,8,,,,Autocuration,10000000.0,,Hippocampus,10141.0,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,B,,Cavia porcellus,,106
604,10639,8,,,,Autocuration,10000000.0,,Hippocampus,10141.0,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,F,,Cavia porcellus,,106
605,11883,8,,449.0,,Autocuration,,CHO,,10029.0,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),B,,Cricetulus griseus,,11863
606,17785,8,,,,Autocuration,,,,,Fraction involved in salt bridge interactions with Asp3:11 part of the 5-hydroxytryptamine 1A receptor,B,,,,51
607,1558,8,,308.0,,Autocuration,,HeLa,,,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-HT 1A receptor in HeLa cells; value ranges from 85-370,F,,,,51
608,1558,8,,308.0,,Autocuration,,HeLa,,,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1A receptor in HeLa cells; value ranges from 95-320,F,,,,51
609,15740,8,,,,Autocuration,,,,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,F,,,,51
610,17624,8,,449.0,,Autocuration,,CHO,,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,F,,,,51
611,17624,8,,449.0,,Expert,,CHO,,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,F,,,,51
612,17624,8,,449.0,,Autocuration,,CHO,,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=Not determined,F,,,,51
613,17624,8,,449.0,,Autocuration,,CHO,,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=not determined,F,,,,51
614,17624,8,,449.0,,Expert,,CHO,,,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,B,,,,51
615,17624,8,,449.0,,Expert,,CHO,,,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,B,,,,51
616,17624,8,,449.0,,Autocuration,,CHO,,,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells; nd=not determined,B,,,,51
617,14256,8,,,,Autocuration,,,,,In vitro potency at human 5-hydroxytryptamine 1A receptor in inhibiting forskolin-stimulated accumulation of intracellular cAMP,F,,,,51
618,3445,9,,308.0,,Expert,,HeLa,,9606.0,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,B,,Homo sapiens,,51
619,3445,9,,308.0,,Expert,,HeLa,,9606.0,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells; Inverse,B,,Homo sapiens,,51
620,17200,9,,449.0,,Expert,,CHO,,9606.0,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor,B,,Homo sapiens,,51
621,17200,9,,449.0,,Expert,,CHO,,9606.0,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor; Not determined,B,,Homo sapiens,,51
622,15180,8,,,,Autocuration,,,,,Eudisimic ratio(ER) is the antilog of the defference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,F,,,,51
623,15180,8,,,,Autocuration,,,,,Eudisimic ratio(ER) is the antilog of the difference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,F,,,,51
624,16026,8,,,,Autocuration,,,,,"Percent of maximum effect on binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",F,,,,51
625,2759,8,,449.0,,Autocuration,,CHO,,,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,F,,,,51
626,2759,9,,449.0,,Expert,,CHO,,9606.0,Agonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),F,,Homo sapiens,,51
627,2759,8,,449.0,,Autocuration,,CHO,,,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),F,,,,51
628,2759,9,,449.0,,Expert,,CHO,,9606.0,Agonistic efficacy in adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),F,,Homo sapiens,,51
629,2759,8,,449.0,,Autocuration,,CHO,,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,F,,,,51
630,2759,8,,449.0,,Autocuration,,CHO,,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 1),F,,,,51
631,2759,9,,449.0,,Expert,,CHO,,9606.0,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),F,,Homo sapiens,,51
632,2759,8,,449.0,,Autocuration,,CHO,,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),F,,,,51
633,2759,9,,449.0,,Expert,,CHO,,9606.0,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),F,,Homo sapiens,,51
634,3445,9,,,,Expert,,,,9606.0,Percent efficacy against cloned human 5-hydroxytryptamine 1A receptor normalized to the maximal 5-HT response,F,,Homo sapiens,,51
635,5272,9,,,,Expert,,,,9606.0,"Agonist activity at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",F,,Homo sapiens,,51
636,5272,9,,,,Expert,,,,9606.0,"Agonist activity at the 5-hydroxytryptamine 1A receptor in vitro using a [35S]GTP-gamma-S, No data",F,,Homo sapiens,,51
637,5272,9,,,,Expert,,,,9606.0,"Agonist activity at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S,",F,,Homo sapiens,,51
638,17624,8,,449.0,,Autocuration,,CHO,,,Agonistic effect against 5-HT1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,F,,,,51
639,17624,8,,449.0,,Autocuration,,CHO,,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,F,,,,51
640,17624,8,,449.0,,Autocuration,,CHO,,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,F,,,,51
641,17624,8,,449.0,,Expert,,CHO,,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,F,,,,51
642,17624,8,,449.0,,Autocuration,,CHO,,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,F,,,,51
643,17624,8,,449.0,,Autocuration,,CHO,,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=not determined,F,,,,51
644,17624,8,,449.0,,Autocuration,,CHO,,,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,F,,,,51
645,17624,8,,449.0,,Autocuration,,CHO,,,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=Not determined,F,,,,51
646,17624,8,,449.0,,Expert,,CHO,,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,F,,,,51
647,17624,8,,449.0,,Autocuration,,CHO,,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=not determined,F,,,,51
648,17624,8,,449.0,,Autocuration,,CHO,,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,F,,,,51
649,17624,8,,449.0,,Autocuration,,CHO,,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35]GTPgammaS as radioligand in CHO cells relative to 5-HT; nd=Not determined,F,,,,51
650,6563,8,,,,Autocuration,,,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",F,,,,51
651,6563,8,,,,Autocuration,,,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",F,,,,51
652,6563,8,,,,Autocuration,,,,,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,F,,,,51
653,17296,8,,722.0,,Autocuration,,HEK293,,,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,F,,,,51
654,6876,9,,,,Expert,,,,9606.0,"Evaluated for stimulation at 1 uM concentration expressed as percent of the maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine",F,,Homo sapiens,,51
655,6876,8,,,,Expert,,,,,"Stimulation of percent maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine at 1 uM; nd = not determined",F,,,,51
656,5272,9,,,,Expert,,,,9606.0,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor,F,,Homo sapiens,,51
657,5272,9,,,,Expert,,,,9606.0,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor; No data,F,,Homo sapiens,,51
658,5548,8,,,,Autocuration,,,,,"Maximal response as a result of 5-HT1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",F,,,,51
659,5548,8,,,,Expert,,,,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding",F,,,,51
660,5548,8,,,,Autocuration,,,,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",F,,,,51
661,5548,8,,,,Autocuration,,,,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",F,,,,51
662,5929,8,,,,Expert,,,,,"Maximal stimulation of expressed human 5-hydroxytryptamine 1A receptor assayed by [35S]GTP-gamma-S, binding",F,,,,51
663,5929,9,,,,Expert,,,,9606.0,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND means not determined",F,,Homo sapiens,,51
664,5929,9,,,,Expert,,,,9606.0,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND=Not determined",F,,Homo sapiens,,51
665,16245,8,,,,Autocuration,,,,,"Maximal stimulation was expressed as percentage of the maximal 5-HT response in the [35S]GTP-gamma-S, binding assay on 5-hydroxytryptamine 1A receptor",F,,,,51
666,5640,8,,,,Expert,,,,,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",F,,,,51
667,5640,8,,,,Autocuration,,,,,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Emin (%): not determined",F,,,,51
668,14509,8,,449.0,,Autocuration,,CHO,,,Antagonist activity was measured against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay,F,,,,51
669,14509,8,,449.0,,Expert,,CHO,,,Antagonist activity against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay.,F,,,,51
670,15331,8,,,,Autocuration,,,,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,B,,,,51
671,15331,8,,,,Autocuration,,,,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,B,,,,51
672,6563,8,,,,Autocuration,,,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",F,,,,51
673,6563,8,,,,Autocuration,,,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay; NA indicates not available",F,,,,51
674,6563,8,,,,Autocuration,,,,,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,F,,,,51
675,6563,9,,,,Expert,,,,9606.0,Forskolin stimulated cAMP assessment of agonist activity for 5-hydroxytryptamine 1A receptor,F,,Homo sapiens,,51
676,6563,8,,,,Autocuration,,,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",F,,,,51
677,5272,9,,,,Expert,,,,9606.0,Antagonism of 5-hydroxytryptamine 1A receptor determined in vitro,F,,Homo sapiens,,51
678,5272,9,,,,Expert,,,,9606.0,"Antagonism of 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",F,,Homo sapiens,,51
679,5272,9,,,,Expert,,,,9606.0,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",F,,Homo sapiens,,51
680,5272,9,,,,Expert,,,,9606.0,Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro; No data,F,,Homo sapiens,,51
681,5272,9,,,,Expert,,,,9606.0,Antagonism at the 5-hydroxytryptamine 1A receptor in vitro,F,,Homo sapiens,,51
682,5272,9,,,,Expert,,,,9606.0,"Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",F,,Homo sapiens,,51
683,5272,9,,,,Expert,,,,9606.0,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",F,,Homo sapiens,,51
684,5272,9,,,,Expert,,,,9606.0,Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro; No data,F,,Homo sapiens,,51
685,16146,9,,,,Expert,,,,9606.0,Inhibition of human 5-hydroxytryptamine 1A receptor,B,,Homo sapiens,,51
686,17624,8,,449.0,,Autocuration,,CHO,,,Binding affinity against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,B,,,,51
687,13706,9,,722.0,,Expert,,HEK293,,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor alpha expressed in HEK 293 cells,B,,,,105
688,15250,8,,449.0,,Autocuration,,CHO,,,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1A receptor stably expressed in CHO cells,B,,,,51
689,17624,8,,449.0,,Autocuration,,CHO,,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,F,,,,51
690,6861,8,,,,Expert,,,,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in human CYP3A4 assay,B,,,,51
691,17200,9,,,,Expert,,,,9606.0,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,B,,Homo sapiens,,51
692,17624,8,,449.0,,Autocuration,,CHO,,,Inhibition concentration against 5-HT 1A receptor using cAMP as radioligand in CHO cells,B,,,,51
693,17624,8,,449.0,,Autocuration,,CHO,,,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,B,,,,51
694,12058,0,,,,Autocuration,,,,10116.0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,F,In vivo,Rattus norvegicus,,22226
695,12058,0,,,,Autocuration,,,,10116.0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration; Inactive,F,In vivo,Rattus norvegicus,,22226
696,12058,0,,,,Autocuration,,,,10116.0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration,F,In vivo,Rattus norvegicus,,22226
697,12058,0,,,,Autocuration,,,,10116.0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,F,In vivo,Rattus norvegicus,,22226
698,12058,0,,,,Autocuration,,,,10116.0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Partial response at the highest dose tested,F,In vivo,Rattus norvegicus,,22226
699,12058,0,,,,Autocuration,,,,10116.0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,F,In vivo,Rattus norvegicus,,22226
700,12058,0,,,,Autocuration,,,,10116.0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration,F,In vivo,Rattus norvegicus,,22226
701,12058,0,,,,Autocuration,,,,10116.0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration; Inactive,F,In vivo,Rattus norvegicus,,22226
702,12058,0,,,,Autocuration,,,,10116.0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration,F,In vivo,Rattus norvegicus,,22226
703,12058,0,,,,Autocuration,,,,10116.0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; Inactive,F,In vivo,Rattus norvegicus,,22226
704,12058,0,,,,Autocuration,,,,10116.0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; partial response at the highest dose tested,F,In vivo,Rattus norvegicus,,22226
705,12058,0,,,,Autocuration,,,,10116.0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration,F,In vivo,Rattus norvegicus,,22226
706,12058,0,,,,Autocuration,,,,10116.0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Inactive,F,In vivo,Rattus norvegicus,,22226
707,12058,0,,,,Autocuration,,,,10116.0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Partial response at the highest dose tested,F,In vivo,Rattus norvegicus,,22226
708,12058,0,,,,Autocuration,,,,10116.0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration,F,In vivo,Rattus norvegicus,,22226
709,12058,0,,,,Autocuration,,,,10116.0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Inactive,F,In vivo,Rattus norvegicus,,22226
710,12058,0,,,,Autocuration,,,,10116.0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Partial response at the highest dose tested,F,In vivo,Rattus norvegicus,,22226
711,12058,0,,,,Autocuration,,,,10116.0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; partial response at the highest dose tested,F,In vivo,Rattus norvegicus,,22226
712,12058,0,,,,Autocuration,,,,10116.0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,F,In vivo,Rattus norvegicus,,22226
713,11440,4,,,,Autocuration,,,,,Affinity in displacing [125I](R)-DOI from rat cortical homogenate 5-HT2 receptor.,B,,,,105093
714,6238,8,,,,Autocuration,1898.0,,Hypothalamus,,Binding affinity towards 5-HT 7 receptor in rat hypothalamus membranes using [3H]5-CT as radioligand,B,,,,11923
715,10046,8,,,,Autocuration,,,,,Inhibitory activity against 5-HT1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data,B,,,,10577
716,10046,8,,,,Autocuration,,,,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data.,B,,,,10577
717,10046,8,,,,Expert,,,,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,B,,,,10577
718,167,8,,,,Autocuration,,,,,"Inhibitory activity against human whole blood, LTB4 5-lipoxygenase was evaluated",B,,,,55
719,167,8,,,,Autocuration,,,,,"Inhibitory activity against intact human PMNL, LTB4 5-lipoxygenase was evaluated",B,,,,55
720,11520,8,,,,Autocuration,,,,,Compound was evaluated for the inhibition of 5-LO (lipoxygenase),F,,,,12166
721,11520,8,,,,Autocuration,,,,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,F,,,,12166
722,11520,8,,,,Autocuration,,,,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,F,,,,12166
723,11520,8,,,,Autocuration,,,,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,F,,,,12166
724,135,8,,,,Autocuration,,,,10141.0,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN,F,,Cavia porcellus,,55
725,135,8,,,,Autocuration,,,,10141.0,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN; not active at the highest concentration (3 ug/mL) tested; No activity,F,,Cavia porcellus,,55
726,11311,8,,,,Autocuration,,,,10141.0,The compound was tested for inhibitory activity against 5-Lipoxygenase in guinea pig polymorphonuclear leukocytes,B,,Cavia porcellus,,55
727,10193,8,,,,Autocuration,,,,10141.0,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,B,,Cavia porcellus,,55
728,12281,9,,,,Expert,,,,9606.0,Inhibitory concentration against 5-lipoxygenase from human whole blood,B,,Homo sapiens,,55
729,11311,8,,,,Autocuration,,,,,The compound was tested for inhibitory activity against 5-Lipoxygenase in human polymorphonuclear leukocytes[PMNS],B,,,,55
730,12576,8,,,,Autocuration,,,,,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,F,,,,17087
731,12281,8,,,,Autocuration,,,,,Inhibitory concentration against 5-lipoxygenase from mouse macrophage,B,,,,17087
732,12576,8,,,,Autocuration,,,,,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,F,,,,17087
733,11089,8,,,,Expert,,,,9823.0,Inhibition of arachidonate 5-lipoxygenase purified from porcine leukocytes.,B,,Sus scrofa,,55
734,11006,8,,,,Expert,,,,,In vitro inhibition of rat 5-Lipoxygenase,B,,,,12166
735,11481,9,,,,Expert,,,,10116.0,Inhibitory activity against 5-Lipoxygenase,B,,Rattus norvegicus,,12166
736,10864,8,,702.0,,Expert,,RBL-1,,,Inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells,B,,,,12166
737,3595,8,,702.0,,Autocuration,,RBL-1,,,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),B,,,,12166
738,11311,8,,702.0,,Autocuration,,RBL-1,,,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat RBL-1,B,,,,12166
739,11311,8,,,,Autocuration,,,,,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat blood,B,,,,12166
740,11311,8,,,,Autocuration,,,,,The compound was tested for inhibitory activity against 5-Lipoxygenase receptor in rat polymorphonuclear leukocytes[PMNS],B,,,,12166
741,11006,8,,,,Autocuration,,,,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,B,,,,12166
742,3595,8,,702.0,,Autocuration,,RBL-1,,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,B,,,,12166
743,11311,8,,,,Autocuration,,,,,The compound was tested for inhibition of isolated 5-Lipoxygenase,B,,,,12166
744,11481,0,,,,Autocuration,,,,10116.0,Ratio of IC50 against 5-LO and COX,B,,Rattus norvegicus,,22226
745,11006,8,,,,Autocuration,,,,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,B,,,,12166
746,11006,8,,,,Autocuration,,,,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM; range is 20-35%,B,,,,12166
747,11311,8,,,,Autocuration,,,,,The compound was tested for inhibition against 5-Lipoxygenase in rat polymorphonuclear leukocytes at 10 uM concentration,B,,,,12166
748,11006,8,,,,Autocuration,,,,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) ex vivo,F,,,,12166
749,4288,8,,,,Autocuration,2367.0,,Prostate gland,,Compound was tested for the inhibition of type 2 5-alpha-reductase of human prostates,B,,,,120
750,7587,0,,,,Autocuration,,,,8932.0,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-4 M inhibitory concentration,B,,Columba livia,,22226
751,7587,0,,,,Autocuration,,,,8932.0,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-5 M inhibitory concentration,B,,Columba livia,,22226
752,7587,0,,,,Autocuration,,,,8932.0,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme.,B,,Columba livia,,22226
753,11249,8,,,,Autocuration,,,,,Compound was evaluated for the inhibition of 5-aminoimidazole-4-carboxamide ribonucleotide transformylase obtained from human at 100 uM,B,,,,10732
754,8003,9,,,,Expert,,,,10116.0,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT); NT = Not Tested,F,,Rattus norvegicus,,12198
755,8003,9,,,,Expert,,,,10116.0,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),F,,Rattus norvegicus,,12198
756,8003,9,,,,Expert,,,,10116.0,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),F,,Rattus norvegicus,,12198
757,12416,8,,,,Expert,10000000.0,,Hippocampus,,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,B,,,,10576
758,16293,8,,,,Autocuration,,,,,Binding affinity towards human 5-hydroxytryptamine 1 receptor,B,,,,51
759,13047,0,,,,Autocuration,,,,9986.0,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,B,,Oryctolagus cuniculus,,22226
760,13047,0,,,,Autocuration,,,,9986.0,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,B,,Oryctolagus cuniculus,,22226
761,13047,0,,,,Autocuration,,,,9986.0,Binding affinity against 5-hydroxytryptamine 1D receptor using rabbit saphenous vein assay.,B,,Oryctolagus cuniculus,,22226
762,13047,0,,,,Autocuration,,,,9986.0,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,B,,Oryctolagus cuniculus,,22226
763,10085,4,,,,Autocuration,10000000.0,,Hippocampus,,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,B,,,,104744
764,10085,4,,,,Autocuration,10000000.0,,Hippocampus,,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,B,,,,104744
765,10085,4,,,,Autocuration,10000000.0,,Hippocampus,,Ability to bind at serotonin 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,B,,,,104744
766,9841,4,,,,Autocuration,,,,,Ability to inhibit binding of titreated serotonin to the 5-hydroxytryptamine 1 receptor in rat brain frontal cortex membranes,B,,,Membranes,104744
767,8822,5,,,,Autocuration,,,,10116.0,Binding affinity towards 5-hydroxytryptamine 1 receptor in brain cortical membranes of rat,B,,Rattus norvegicus,,104744
768,9806,5,,,,Autocuration,,,,10116.0,Binding affinity towards 5-hydroxytryptamine 1 receptor in rat frontal cortex homogenates using [3H]5-HT as a radioligand,B,,Rattus norvegicus,,104744
769,9806,5,,,,Autocuration,,,,10116.0,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as a radioligand from rat frontal cortex homogenates,B,,Rattus norvegicus,,104744
770,8868,4,,,,Autocuration,,,,,Binding affinity towards 5-hydroxytryptamine 1 receptor was measured using radioligand ([3H]5-HT) binding assay,B,,,,104744
771,9036,4,,,,Autocuration,10000000.0,,Hippocampus,,Binding affinity towards hippocampus 5-hydroxytryptamine 1 receptor was measured using radioligand [3H]5-HT,B,,,,104744
772,11374,4,,,,Autocuration,10000000.0,,Hippocampus,,Compound was evaluated for the inhibition of [3H]5-HT (concentration of 12 nM) specific binding to rat hippocampus,B,,,,104744
773,10881,4,,,,Autocuration,,,,,Inhibitory activity against 5-hydroxytryptamine 1 receptor by 3H ligand binding experiments.,B,,,,104744
774,8822,4,,,,Autocuration,,,,,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat,B,,,,104744
775,9806,5,,,,Autocuration,,,,10116.0,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat cortical membrane homogenates using radioligand ([3H]5-HT) binding assay.,B,,Rattus norvegicus,,104744
776,15463,4,,,,Autocuration,,,,,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,B,,,,104744
777,15463,4,,,,Autocuration,,,,,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,B,,,,104744
778,14542,4,,,,Autocuration,955.0,,Brain,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,B,,,,104744
779,14542,4,,,,Autocuration,955.0,,Brain,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,B,,,,104744
780,8569,4,,,,Autocuration,,,,,Percent inhibition of 5-hydroxytryptamine 1 receptor from rat cortex membrane using [3H]- serotonin as radioligand at 33 uM,B,,,,104744
781,10062,5,,,,Autocuration,,,,10116.0,Inhibition of [3H]5-HT radioligand binding against 5-hydroxytryptamine 1 receptor,B,,Rattus norvegicus,,104744
782,4771,4,,,,Autocuration,,,,,Ancillary Binding affinity towards rat 5-hydroxytryptamine 1 receptor,B,,,,104744
783,10062,4,,,,Autocuration,,,,,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,B,,,,104744
784,10062,4,,,,Autocuration,,,,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,B,,,,104744
785,10062,4,,,,Autocuration,,,,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,B,,,,104744
786,15463,4,,,,Autocuration,,,,,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,B,,,,104744
787,15463,4,,,,Autocuration,,,,,Binding affinity towards central 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,B,,,,104744
788,9098,4,,,,Autocuration,,,,,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined,B,,,,104744
789,3070,0,,,,Autocuration,,,,10116.0,Affinity for 5-hydroxytryptamine 1 receptor,B,,Rattus norvegicus,,22226
790,14542,4,,,,Autocuration,955.0,,Brain,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex,B,,,,104744
791,14542,4,,,,Autocuration,955.0,,Brain,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,B,,,,104744
792,6398,4,,,,Autocuration,,,,,Compound was evaluated for 5-hydroxytryptamine 1 receptor binding,B,,,,104744
793,1344,4,,,,Autocuration,955.0,,Brain,,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 1 receptor in rat brain using [3H]HT radioligand assay,B,,,,104744
794,11963,4,,,,Autocuration,,,,,Displacement of binding of [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,B,,,,104744
795,8908,0,,,,Autocuration,,,,10116.0,Displacement of [3H]spiperone from 5-hydroxytryptamine 1 receptor of rat cortex,B,,Rattus norvegicus,,22226
796,9098,4,,,,Autocuration,,,,,Evaluated for binding affinity towards rat cortical membranes at 5-hydroxytryptamine 1 receptor binding site by using [3H]-5-HT as a radioligand.,B,,,,104744
797,8841,5,,,,Autocuration,,,,10116.0,Binding affinity for 5-hydroxytryptamine 1 receptor of rat prefrontal cortex,B,,Rattus norvegicus,,104744
798,8814,0,,,,Autocuration,,,,10116.0,Displacement of [3H]5-HT from 5-hydroxytryptamine 1 receptor of rat cortical membrane homogenates,B,,Rattus norvegicus,,22226
799,11752,4,,,,Autocuration,,,,,The ability to inhibit [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cortex,B,,,,104744
800,11642,4,,,,Autocuration,955.0,,Brain,,The binding affinity was measured on serotonin 5-hydroxytryptamine 1 receptor in rat brain tissue,B,,,,104744
801,11642,4,,,,Autocuration,,,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1 receptor by displacing [3H]5-HT radioligand in rat cerebral cortex,B,,,,104744
802,9231,4,,,,Autocuration,955.0,,Brain,,Tested for 5-hydroxytryptamine 1 receptor binding ability by displacement of [3H]5-HT from rat brain synaptosomes,B,,,,104744
803,11351,4,,,,Autocuration,955.0,,Brain,,Inhibition constant (1 uM) was measured on 5-hydroxytryptamine 1 receptor/uptake using [3H]- serotonin as radioligand in rat brain cortex.,B,,,,104744
804,4639,0,,,,Autocuration,,,,,Compound was tested for binding affinity against 5-HT1 receptor,B,,,,22226
805,1205,0,,,,Autocuration,,,,,Inhibitory concentration against 5-hydroxytryptamine 1 receptor,B,,,,22226
806,10025,8,,,,Expert,,,,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,B,,,,10576
807,13241,8,,,,Autocuration,,,,,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",F,,,,10576
808,16245,8,,,,Autocuration,,,,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,F,In vivo,,,10576
809,16245,8,,,,Autocuration,,,,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,F,In vivo,,,10576
810,12438,8,,,,Autocuration,,,,,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor,F,,,,10576
811,16245,8,,,,Autocuration,,,,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,F,In vivo,,,10576
812,16245,8,,,,Autocuration,,,,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,F,In vivo,,,10576
813,15740,8,,,,Autocuration,,,,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats,F,,,,10576
814,15535,8,,,,Autocuration,,,,,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 10 uM concentration,F,,,,10576
815,15535,8,,,,Expert,,,,,Percent inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation in GH4ZD10 cells expressing 5-HT1A receptor at 50 uM relative to 5-HT,F,,,,51
816,15535,8,,,,Autocuration,,,,,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 50 uM concentration; No effect,F,,,,10576
817,9888,8,,,,Expert,,,,,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes expressed as Hill values,B,,,,10576
818,10085,8,,,,Autocuration,10000000.0,,Hippocampus,,Ability to bind at 5-hydroxytryptamine 1A receptor of rat hippocampus by displacing [3H]8-OH-DPAT,B,,,,10576
819,10085,8,,,,Autocuration,10000000.0,,Hippocampus,,Ability to bind at serotonin 5-hydroxytryptamine 1A receptors of rat hippocampus by displacing [3H]8-OH-DPAT,B,,,,10576
820,17331,8,,,,Expert,,,,,Binding affinity against 5-hydroxytryptamine 1A receptor (5-HT1A) by displacement of [3H]8-OH-DPAT from rat hippocampus membranes,B,,,Membranes,10576
821,10845,9,,,,Expert,10000000.0,,Hippocampus,10116.0,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]8-OH-DPAT,B,,Rattus norvegicus,,10576
822,10845,9,,,,Expert,10000000.0,,Hippocampus,10116.0,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,B,,Rattus norvegicus,,10576
823,10845,8,,,,Expert,10000000.0,,Hippocampus,,Binding affinity against 5-hydroxytryptamine 1A receptor using in rat hippocampal tissue using [3H]8-OH-DPAT as radioligand,B,,,,10576
824,10845,9,,,,Expert,10000000.0,,Hippocampus,10116.0,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor; IA-Inactive,B,,Rattus norvegicus,,10576
825,10845,9,,,,Expert,10000000.0,,Hippocampus,10116.0,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,B,,Rattus norvegicus,,10576
826,13730,8,,,,Expert,,,,,Binding affinity towards rat 5-hydroxytryptamine 1A receptor was evaluated using [3H]8-OH-DPAT as radioligand,B,,,,10576
827,13508,8,,,,Expert,,,,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using [3H]8-OH-DPAT as radioligand,B,,,,10576
828,13508,8,,,,Expert,10000000.0,,Hippocampus,,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus membrane using [3H]8-OH-DPAT as radioligand,B,,,,10576
829,12073,8,,,,Expert,10000000.0,,Hippocampus,,Binding affinity by measuring displacement of [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,,,10576
830,4671,8,,,,Autocuration,10000000.0,,Hippocampus,,Binding affinity to 5-hydroxytryptamine 1A receptor of rat hippocampus with [3H]8-OH-DPAT as radioligand,B,,,,10576
831,13631,8,,,,Expert,10000000.0,,Hippocampus,,Binding affinity towards serotonin 5-HT1A receptor was determined in rat hippocampus using [3H]8-OH-DPAT as ligand,B,,,,10576
832,12438,8,,,,Autocuration,,,,,Binding affinity was measured against serotonin 5-hydroxytryptamine 1A receptor,B,,,,10576
833,10483,8,,,,Autocuration,,,,,Binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH- DPAT as radioligand,B,,,,10576
834,10483,8,,,,Autocuration,10000000.0,,Hippocampus,,Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]-8-OH- DPAT as radioligand,B,,,,10576
835,12352,8,,,,Intermediate,,,,,Binding affinity against 5-hydroxytryptamine 1A (5-HT1A) receptor in rat hippocampus membranes,B,,,,10576
836,14732,8,,,,Autocuration,10000000.0,,Hippocampus,,Binding affinity was measured at the serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampal membrane.,B,,,,10576
837,11049,9,,,,Expert,,,,10116.0,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand.,B,,Rattus norvegicus,,10576
838,11049,9,,,,Expert,,,,10116.0,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand; ND-Not determined,B,,Rattus norvegicus,,10576
839,13657,8,,,,Expert,,,,,"Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding (NSB)",B,,,,10576
840,11473,8,,,,Autocuration,,,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH-DPAT as radioligand,B,,,,10576
841,2014,8,,,,Autocuration,,,,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonin 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,B,,,,10576
842,3086,8,,,,Expert,10000000.0,,Hippocampus,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,,,10576
843,15854,8,,,,Expert,,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,B,,,,10576
844,10922,8,,,,Expert,10000000.0,,Hippocampus,,Affinity for 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,B,,,,10576
845,13346,8,,,,Expert,10000000.0,,Hippocampus,,Inhibition of [3H]8-OH-DPAT binding at serotonin 5-hydroxytryptamine 1A receptor from rat hippocampus tissue.,B,,,,10576
846,15311,8,,,,Expert,,,,,In vitro inhibition of [3H]8-OH-DPAT binding to rat 5-HT 1a receptors.,B,,,,10576
847,10922,8,,,,Autocuration,10000000.0,,Hippocampus,,Compound was measured for affinity at 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,B,,,,10576
848,10025,8,,,,Autocuration,,,,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor<br>at 1 uM,B,,,,10576
849,10025,8,,,,Expert,,,,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,B,,,,10576
850,9742,8,,,,Autocuration,,,,,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,B,,,,10576
851,9742,8,,,,Autocuration,,,,,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,F,,,,10576
852,12304,8,,,,Expert,,,,,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,B,,,,10576
853,15789,8,,,,Autocuration,10000000.0,,Hippocampus,,In vitro affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT in rat hippocampus,B,,,,10576
854,9912,8,,,,Autocuration,,,,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]-8-OH-DPAT as the radioligand",B,,,,10576
855,9912,8,,,,Autocuration,,,,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand.",B,,,,10576
856,9912,8,,,,Autocuration,,,,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand",B,,,,10576
857,16693,8,,,,Expert,,,,,In vitro binding affinity for serotonin 5-hydroxytryptamine 1A receptor fof rat cerebral cortex using [3H]8-OH-DPAT as radioligand,B,,,,10576
858,13276,8,,,,Expert,,,,,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,B,,,,10576
859,12678,8,,,,Autocuration,10000000.0,,Hippocampus,,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,B,,,,10576
860,11825,8,,,,Autocuration,,,,,In vitro binding affinity towards the 5-hydroxytryptamine 1A receptor was evaluated,B,,,,10576
861,12443,8,,,,Expert,,,,,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 1A receptor by displacement of [3H]- tetralin,B,,,,10576
862,13830,8,,,,Expert,,,,,In vitro inhibitory activity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,B,,,,10576
863,14286,8,,,,Expert,10000000.0,,Hippocampus,,In vitro inhibitory concentration against radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane.,B,,,,10576
864,14356,9,,,,Expert,10000000.0,,Hippocampus,10116.0,In vitro radioligand binding assay on 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,B,,Rattus norvegicus,,10576
865,15306,8,,,,Autocuration,,,,,Inhibition concentration against 5-hydroxytryptamine 1A receptor,B,,,,10576
866,15306,8,,,,Expert,,,,,Inhibitory concentration against 5-hydroxytryptamine 1A receptor (Inactive at >1000 nM concentration),B,,,,10576
867,16616,9,,,,Expert,,,,10116.0,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",F,,Rattus norvegicus,,10576
868,3651,8,,,,Autocuration,10000000.0,,Hippocampus,,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Residual radioligand binding higher than 50%",B,,,,10576
869,14331,8,,,,Autocuration,10000000.0,,Hippocampus,,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,F,,,,10576
870,14331,8,,,,Autocuration,10000000.0,,Hippocampus,,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,F,,,,10576
871,14178,9,,,,Expert,,,,10116.0,Inhibition of radiolabeled [3H]-8-OH-DPAT ligand binding to 5-hydroxytryptamine 1A receptor,B,,Rattus norvegicus,,10576
872,10639,9,,,,Expert,,,,10116.0,Displacement of [3H]8-OH-DPAT from rat cortex 5-hydroxytryptamine 1A receptor,B,,Rattus norvegicus,,10576
873,12306,8,,,,Autocuration,10000000.0,,Hippocampus,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,B,,,,10576
874,1348,9,,,,Expert,,,,10116.0,Inhibitory activity against 5-hydroxytryptamine 1A receptor subtype,B,,Rattus norvegicus,,10576
875,13605,8,,,,Autocuration,10000000.0,,Hippocampus,,Inhibitory activity against [3H]DPAT binding to 5-HT1A receptor in rat hippocampus,B,,,,10576
876,17624,8,,449.0,,Autocuration,,CHO,,,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,B,,,,51
877,17624,8,,449.0,,Autocuration,,CHO,,,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,F,,,,51
878,17624,8,,449.0,,Autocuration,,CHO,,,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,F,,,,51
879,15267,8,,,,Autocuration,,,,,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,B,,,,51
880,16532,8,,,,Autocuration,,,,,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT; Not tested,B,,,,51
881,6563,8,,,,Autocuration,,,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",F,,,,51
882,4751,8,,449.0,,Autocuration,,CHO,,,Ability to displace [3H]-8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor at a concentration of 1 uM,B,,,,51
883,15463,8,,,,Autocuration,,,,,Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor,B,,,,51
884,3805,8,,,,Autocuration,,,,,In vitro binding affinity against human 5-hydroxytryptamine 1A receptor at a concentration of 100 (nM),B,,,,51
885,5640,8,,,,Autocuration,,,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,51
886,6563,8,,,,Autocuration,,,,,Inhibition of [3H]8-OH-DPAT binding to human 5-hydroxytryptamine 1A receptor at 1000 nM compound concentration,B,,,,51
887,5548,8,,,,Autocuration,,,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand at 100 nM concentration,B,,,,51
888,6347,8,,,,Autocuration,,,,,Percent binding affinity against 5-hydroxytryptamine 1A receptor,B,,,,51
889,17296,8,,722.0,,Autocuration,,HEK293,,,Intrinsic activity for human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,F,,,,51
890,13047,8,,,,Autocuration,,,,,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the absence of endothelium,B,,,,51
891,15740,8,,,,Autocuration,,,,,Dissociation constant against human 5-hydroxytryptamine 1A receptor receptor,B,,,,51
892,5640,8,,,,Expert,,,,,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",F,,,,51
893,5640,8,,,,Autocuration,,,,,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Ki (nM): not determined",F,,,,51
894,17211,8,,308.0,,Expert,,HeLa,,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor,B,,,,51
895,4751,8,,449.0,,Autocuration,,CHO,,,Ability to displace [3H]8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor,B,,,,51
896,6491,9,,,,Expert,,,,9606.0,Affinity towards human 5-hydroxytryptamine 1A serotonin receptor,B,,Homo sapiens,,51
897,4707,8,,,,Autocuration,,,,,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT-as radioligand,B,,,,51
898,13910,9,,,,Expert,,,,9606.0,Binding affinity against 5-hydroxytryptamine 1A receptor,B,,Homo sapiens,,51
899,16190,8,,308.0,,Autocuration,,HeLa,,,Binding affinity against 5-hydroxytryptamine 1A receptor in HeLa cells was determined using [3H]5-HT,B,,,,51
900,16633,8,,,,Autocuration,,,,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,51
901,11898,8,,449.0,,Autocuration,,CHO,,,Binding affinity against [3H]- -8-OH-DPAT -labeled 5-hydroxytryptamine 1A sites in cloned CHO cells,B,,,,51
902,11898,8,,449.0,,Autocuration,,CHO,,,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,B,,,,51
903,14331,8,,,,Autocuration,,,,,Binding affinity against human 5-hydroxytryptamine 1A receptor,B,,,,51
904,17624,8,,449.0,,Expert,,CHO,,,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand,B,,,,51
905,17624,8,,449.0,,Autocuration,,CHO,,,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand; nd=not determined,B,,,,51
906,3307,8,,,,Autocuration,,,,,Binding affinity of compound to human 5-hydroxytryptamine 1A receptor,B,,,,51
907,6563,9,,449.0,,Expert,,CHO,,9606.0,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,B,,Homo sapiens,,51
908,14165,8,,,,Autocuration,,,,,Binding affinity for 5-hydroxytryptamine 1A receptor in HeLa transfected cell type using [3H]8-OH-DPAT as radioligand,B,,,,51
909,5732,8,,,,Autocuration,,,,,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,B,,,,51
910,13366,8,,,,Expert,,,,,In vitro affinity at human cloned 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,B,,,,51
911,17626,8,,,,Autocuration,,,,,Binding affinity towards human 5-hydroxytryptamine 1A receptor,B,,,,51
912,6588,8,,308.0,,Expert,,HeLa,,,Binding affinity towards human 5-hydroxytryptamine 1A receptor by the displacement of [3H]5-HT radioligand from the cloned receptor expressed in HeLa cells,B,,,,51
913,16209,8,,,,Autocuration,,,,,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]-5-HT as radioligand,B,,,,51
914,15463,8,,,,Autocuration,,,,,Binding affinity towards recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,B,,,,51
915,15463,8,,,,Autocuration,,,,,Binding affinity towards recombinant human Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,B,,,,51
916,14770,8,,,,Autocuration,,,,,Binding affinity for recombinant human 5-hydroxytryptamine 1A receptor using [3H]5-HT as radioligand.,B,,,,51
917,16245,8,,1167.0,,Autocuration,,Cell line,,,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines (He La),B,,,,51
918,16245,8,,,,Autocuration,,,,,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines(He La),B,,,,51
919,5548,8,,,,Autocuration,,,,,Binding affinity towards 5-HT1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,51
920,5548,8,,,,Expert,,,,,Binding affinity was determined towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,51
921,5548,8,,,,Autocuration,,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,51
922,6876,8,,,,Expert,,,,,Binding affinity was evaluated at 5-hydroxytryptamine 1A receptor labeled with [3H]-8-OH-DPAT,B,,,,51
923,2598,8,,,,Autocuration,,,,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,51
924,17785,8,,,,Expert,,,,,Binding affinity to human 5-hydroxytryptamine 1A receptor was measured using [3H]-8-hydroxy-2-(di-n-propylamine) tetraline [3H]8-OH-DPAT) as radioligand,B,,,,51
925,6013,8,,,,Autocuration,,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,B,,,,51
926,5929,8,,,,Expert,,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,B,,,,51
927,16633,8,,,,Autocuration,,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,51
928,1558,8,,,,Autocuration,,,,,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,B,,,,51
929,16026,8,,,,Expert,,,,,Binding affinity towards human cloned 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,51
930,12469,8,,,,Autocuration,,,,,Binding affinity was measured on 5-hydroxytryptamine 1A receptor in AK cells transfected with human 5-HT1A gene labeled with [3H]-8-OH-DPAT,B,,,,51
931,15874,9,,,,Expert,,,,9606.0,Binding affinity was measured on cloned Human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,B,,Homo sapiens,,51
932,15874,8,,,,Autocuration,,,,,Binding affinity was measured on cloned human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,B,,,,51
933,3935,8,,,,Autocuration,,,,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1A receptor,B,,,,51
934,15818,8,,,,Autocuration,,,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1A receptor,B,,,,51
935,13706,8,,485.0,,Autocuration,,CHO-K1,,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells.,B,,,,51
936,13729,8,,485.0,,Expert,,CHO-K1,,,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1A receptor in CHO-K1 cells,F,,,,51
937,15413,8,,,,Autocuration,,,,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor,B,,,,51
938,15413,8,,,,Autocuration,,,,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 1),B,,,,51
939,15413,8,,,,Autocuration,,,,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 2),B,,,,51
940,15413,8,,,,Autocuration,,,,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor by Panlabs assay,B,,,,51
941,3445,9,,308.0,,Expert,,HeLa,,9606.0,Displacement of specific [3H]- 5-HT binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,B,,Homo sapiens,,51
942,15740,8,,,,Autocuration,,,,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,B,,,,51
943,15740,8,,,,Autocuration,,,,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor receptor,B,,,,51
944,17626,8,,,,Autocuration,,,,,In vitro binding affinity tested on human 5-hydroxytryptamine 1A receptor,B,,,,51
945,4234,9,,,,Expert,,,,9606.0,In vitro binding affinity to human 5-hydroxytryptamine 1A receptor,B,,Homo sapiens,,51
946,5640,8,,,,Expert,,,,,In vitro binding affinity at 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,B,,,,51
947,5272,8,,,,Expert,,,,10116.0,In vitro binding affinity towards Human 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT,B,,Rattus norvegicus,,51
948,4622,8,,449.0,,Autocuration,,CHO,,,In vitro binding affinity towards cloned human 5-hydroxytryptamine 1A receptor expressed in Chinese hamster ovary (CHO) cells using [3H]8-OH-DPAT as radioligand,B,,,,51
949,17085,8,,,,Expert,,,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor,B,,,,51
950,3025,8,,,,Autocuration,,,,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,B,,,,51
951,15315,8,,,,Expert,,,,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor,B,,,,51
952,15267,8,,,,Autocuration,,,,,Inhibition of [3H]- OH-DPAT binding against 5-hydroxytryptamine 1A receptor from human recombinant,B,,,,51
953,17158,8,,308.0,,Autocuration,,HeLa,,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor serotonergic receptor in human HeLa cells,B,,,,51
954,14214,9,,308.0,,Expert,,HeLa,,9606.0,Receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor in HeLa cells,B,,Homo sapiens,,51
955,17133,8,,,,Autocuration,,,,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,51
956,16532,8,,,,Autocuration,,,,,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT,B,,,,51
957,2391,9,,,,Expert,,,,9606.0,Affinity for 5-hydroxytryptamine 1A receptor subtype,B,,Homo sapiens,,51
958,14447,8,,,,Autocuration,,,,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes,B,,,,51
959,14447,8,,,,Autocuration,,,,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes.,B,,,,51
960,15086,8,,,,Autocuration,,,,,The compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor receptor,B,,,,51
961,13051,9,,,,Expert,,,,9606.0,Binding affinity for cloned human 5-hydroxytryptamine 1A receptor,B,,Homo sapiens,,51
962,16026,8,,,,Autocuration,,,,,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor; Not active",F,,,,51
963,17085,8,,,,Expert,,,,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor; ND means not determined,B,,,,51
964,17133,8,,,,Autocuration,,,,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,51
965,17133,8,,,,Autocuration,,,,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; ND means Not determined,B,,,,51
966,17211,8,,308.0,,Autocuration,,HeLa,,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,B,,,,51
967,17211,8,,308.0,,Autocuration,,HeLa,,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT=not tested,B,,,,51
968,17211,8,,308.0,,Autocuration,,HeLa,,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,B,,,,51
969,17211,8,,308.0,,Autocuration,,HeLa,,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,B,,,,51
970,16394,8,,,,Autocuration,,,,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",F,,,,51
971,16394,8,,,,Autocuration,,,,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",F,,,,51
972,16394,8,,,,Autocuration,,,,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",F,,,,51
973,16394,8,,,,Autocuration,,,,,Antagonist induction of hypothermia by 8-OH-DPAT in 5-hydroxytryptamine 1A receptor after subcutaneous administration; NT is not tested,F,In vivo,,,51
974,16394,8,,,,Autocuration,,,,,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]-8-OH-DPAT binding in Chinese hamster ovary cell line; NT is not tested,B,,,,51
975,15740,8,,,,Autocuration,,,,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor receptor; Not tested,F,,,,51
976,15740,8,,,,Autocuration,,,,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor; Not tested,F,,,,51
977,15740,8,,,,Autocuration,,,,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,B,,,,51
978,17296,8,,722.0,,Autocuration,,HEK293,,,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,F,,,,51
979,5640,8,,,,Expert,,,,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at 1 uM.",F,,,,51
980,5640,8,,,,Autocuration,,,,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means Not determined",F,,,,51
981,5640,8,,,,Autocuration,,,,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means not determined",F,,,,51
982,5640,8,,,,Autocuration,,,,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; Not determined",F,,,,51
983,2759,8,,449.0,,Autocuration,,CHO,,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,F,,,,51
984,16394,8,,,,Autocuration,,,,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT",F,,,,51
985,16394,9,,,,Expert,,,,9606.0,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared to 5-HT",F,,Homo sapiens,,51
986,3445,9,,,,Expert,,,,9606.0,Percent efficacy against human 5-hydroxytryptamine 1A receptor relative to maximal 5-HT response,F,,Homo sapiens,,51
987,4316,8,,449.0,,Expert,,CHO,,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by incubating human 5-hydroxytryptamine 1A receptor transfected CHO cells with [3H]8-OH-DPAT,B,,,,51
988,4316,8,,,,Expert,,,,,In vitro inhibition of [3H]8-OH-DPAT binding to human cloned 5-hydroxytryptamine 1A receptor on CHO cell membranes.,B,,,,51
989,15180,9,,,,Expert,,,,9606.0,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,F,,Homo sapiens,,51
990,15180,9,,,,Expert,,,,9606.0,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,F,,Homo sapiens,,51
991,15042,8,,,,Autocuration,,,,,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,F,,,,51
992,15042,8,,,,Autocuration,,,,,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,F,,,,51
993,15042,8,,,,Autocuration,,,,,Maximum binding affinity was evaluated as ([35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,F,,,,51
994,15042,8,,,,Autocuration,,,,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,F,,,,51
995,15042,8,,,,Autocuration,,,,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,F,,,,51
996,15042,8,,,,Autocuration,,,,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,F,,,,51
997,15042,8,,,,Autocuration,,,,,Agonist efficacy was evaluated as [35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,F,,,,51
998,15180,9,,308.0,,Expert,,HeLa,,9606.0,Concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,F,,Homo sapiens,,51
999,15180,9,,308.0,,Expert,,HeLa,,9606.0,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,F,,Homo sapiens,,51
1000,15180,9,,308.0,,Expert,,HeLa,,9606.0,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,F,,Homo sapiens,,51
1001,16245,8,,,,Autocuration,,,,,"Potency (pD2) for the stimulation of [35S]GTP-gamma-S, binding on 5-hydroxytryptamine 1A receptor",F,,,,51
1002,16026,8,,,,Autocuration,,,,,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",F,,,,51
1003,17296,8,,722.0,,Autocuration,,HEK293,,,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,F,,,,51
1004,2759,8,,449.0,,Autocuration,,CHO,,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),F,,,,51
1005,2759,8,,449.0,,Autocuration,,CHO,,,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells,F,,,,51
1006,2759,9,,449.0,,Expert,,CHO,,9606.0,Potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 1),F,,Homo sapiens,,51
1007,2759,8,,449.0,,Autocuration,,CHO,,,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),F,,,,51
1008,15419,8,,,,Expert,,,,,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor,F,,,,51
1009,15419,8,,,,Autocuration,,,,,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor; Not tested,F,,,,51
1010,16026,8,,,,Autocuration,,,,,"ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",F,,,,51
1011,1414,8,,,,Expert,,,,,Ability to bind to 5-hydroxytryptamine 1A receptor from cloned human expressed in Ha7 cells,B,In vitro,,,51
1012,1414,8,,,,Expert,,,,,Ability to bind to 5-hydroxytryptamine 1A receptor subtype from cloned human expressed in Ha7 cells,B,In vitro,,,51
1013,12861,8,,,,Autocuration,,,,,Binding activity radioligand.,B,,,,51
1014,12861,8,,,,Autocuration,,,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,B,,,,51
1015,5104,8,,,,Autocuration,,,,,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,B,,,,51
1016,5105,8,,,,Autocuration,,,,,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,B,,,,51
1017,16312,8,,,,Autocuration,,,,,binding affinity towards human recombinant 5-hydroxytryptamine 1A receptor,B,,,,51
1018,15180,9,,,,Expert,,,,9606.0,Displacement of [3H]8-hydroxy-2-(di-n-propylamino)tetralin from human 5-hydroxytryptamine 1A receptor,B,,Homo sapiens,,51
1019,5033,8,,,,Autocuration,,,,,Ability to displace the radioligand [3H]-8-OH-DPAT from human 5-hydroxytryptamine 1A receptor,B,,,,51
1020,16909,9,,449.0,,Expert,,CHO,,9606.0,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,B,,Homo sapiens,,51
1021,2590,8,,,,Autocuration,,,,,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor,F,,,,51
1022,2590,8,,,,Autocuration,,,,,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor; Not determined,F,,,,51
1023,16394,8,,,,Expert,,,,,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding in Chinese hamster ovary cell line,B,,,,51
1024,4540,9,,722.0,,Expert,,HEK293,,9606.0,Binding affinity to human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]-8-OH- DPAT as radioligand,B,,Homo sapiens,,51
1025,17296,8,,722.0,,Autocuration,,HEK293,,,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells,B,,,,51
1026,17296,8,,722.0,,Autocuration,,HEK293,,,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells using [3H]8-OH-DPAT as radioligand,B,,,,51
1027,15779,8,,722.0,,Autocuration,,HEK293,,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,B,,,,51
1028,15779,8,,722.0,,Autocuration,,HEK293,,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand; ND means no data,B,,,,51
1029,15779,8,,722.0,,Autocuration,,HEK293,,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;ND means no data.,B,,,,51
1030,6166,8,,,,Autocuration,,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,B,,,,51
1031,15779,8,,722.0,,Autocuration,,HEK293,,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,B,,,,51
1032,4199,8,,722.0,,Autocuration,,HEK293,,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT as the radioligand,B,,,,51
1033,15316,8,,,,Autocuration,,,,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT binding from human 5-hydroxytryptamine 1A receptor in mammalian cells,B,,,,51
1034,14875,8,,,,Autocuration,,,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1A receptor,B,,,,51
1035,14727,8,,308.0,,Expert,,HeLa,,,Binding affinity at human cloned 5-hydroxytryptamine 1A receptor expressed in HeLa cells by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,B,,,,51
1036,14727,8,,,,Expert,,,,,Binding affinity at native 5-hydroxytryptamine 1A receptor in rat by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,B,,,,51
1037,15146,8,,722.0,,Autocuration,,HEK293,,,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor in human cloned receptors in HEK 293 cells using [3H]8-OH-DPAT,B,,,,51
1038,5213,8,,722.0,,Autocuration,,HEK293,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1A receptor in HEK 293 using [3H]5-CT as a radioligand,B,,,,51
1039,16429,8,,,,Autocuration,,,,,In vitro binding affinity at human recombinant 5-hydroxytryptamine 1A receptor in mammalian cells using 3[H]8-OH-DPAT as the radioligand,B,,,,51
1040,15042,9,,308.0,,Expert,,HeLa,,9606.0,The binding affinity was evaluated on cloned human 5-hydroxytryptamine 1A receptor expressed in HeLa cells by using DPAT as radioligand.,B,,Homo sapiens,,51
1041,14818,8,,722.0,,Autocuration,,HEK293,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT.,B,,,,51
1042,4829,8,,722.0,,Autocuration,,HEK293,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1A receptor in HEK293 cells, using [3H]8-OH-DPAT as radioligand",B,,,,51
1043,17200,9,,,,Expert,,,,,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,B,,,,51
1044,13051,9,,,,Autocuration,,,,9606.0,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor,B,,Homo sapiens,,51
1045,5486,8,,,,Autocuration,,,,,Binding affinity towards 5-HT1B receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,B,,,,106
1046,5254,8,,,,Autocuration,,,,,Binding affinity against 5-HT1D receptor,B,,,,105
1047,5254,8,,,,Autocuration,,,,,Binding affinity against 5-hydroxytryptamine 1A receptor,B,,,,105
1048,15331,8,,,,Autocuration,,,,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,B,,,,107
1049,13506,8,,,,Autocuration,,,,9606.0,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,B,,Homo sapiens,,10576
1050,15267,8,,,,Autocuration,,,,,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,B,,,,51
1051,16616,8,,,,Autocuration,,,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 15 min after administration of the compound,F,In vivo,,,11863
1052,16616,8,,,,Autocuration,,,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 30 min after administration of the compound,F,In vivo,,,11863
1053,16616,8,,,,Autocuration,,,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 60 min after administration of the compound,F,In vivo,,,11863
1054,16616,9,,,,Expert,,,,10090.0,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 15 min,F,,Mus musculus,,11863
1055,16616,9,,,,Expert,,,,10090.0,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 30 min,F,,Mus musculus,,11863
1056,16616,9,,,,Expert,,,,10090.0,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 60 min,F,,Mus musculus,,11863
1057,16616,9,,,,Expert,,,,10090.0,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 15 min,F,,Mus musculus,,11863
1058,16616,9,,,,Expert,,,,10090.0,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 30 min,F,,Mus musculus,,11863
1059,16616,9,,,,Expert,,,,10090.0,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 60 min,F,,Mus musculus,,11863
1060,10297,8,,,,Autocuration,10000000.0,,Hippocampus,,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,B,,,,11863
1061,13704,8,,,,Expert,,,,,Inhibitory activity against serotonin 5-hydroxytryptamine 1A receptor from mice.,B,,,,11863
1062,10297,9,,,,Expert,10000000.0,,Hippocampus,10090.0,Inhibitory activity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,B,,Mus musculus,,11863
1063,10297,8,,,,Autocuration,10000000.0,,Hippocampus,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,B,,,,11863
1064,10297,9,,,,Expert,10000000.0,,Hippocampus,10090.0,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,B,,Mus musculus,,11863
1065,10297,8,,,,Autocuration,10000000.0,,Hippocampus,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,B,,,,11863
1066,217,8,,,,Autocuration,,,,,Compound was tested for binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as a radioligand,B,,,,11863
1067,10297,9,,,,Expert,10000000.0,,Hippocampus,10090.0,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,B,,Mus musculus,,11863
1068,4921,8,,,,Autocuration,,,,9823.0,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor,B,,Sus scrofa,,51
1069,4921,8,,,,Autocuration,,,,9823.0,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor; ND denotes not determined,B,,Sus scrofa,,51
1070,4996,8,,,,Autocuration,,,,9823.0,Binding affinity of compound measured for 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT-labeled porcine brain homogenates,B,,Sus scrofa,,51
1071,12918,8,,,,Autocuration,,,,9823.0,Compound was evaluated for the binding affinity at 5- HT1A receptor,B,,Sus scrofa,,51
1072,5333,8,,,,Autocuration,,,,9823.0,Compound was tested in vitro for its ability to compete with [3H]8-OH-DPAT at 5-hydroxytryptamine 1A receptor in porcine brain homogenate,B,,Sus scrofa,,51
1073,4437,8,,,,Autocuration,,,,9823.0,In vitro for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in porcine brain homogenate,B,,Sus scrofa,,51
1074,1742,8,,,,Autocuration,,,,9823.0,Compound was tested for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in pig cortex,B,,Sus scrofa,,51
1075,16688,8,,,,Expert,,,,9823.0,Displacement of [3H]- 8-OH-DPAT from porcine 5-hydroxytryptamine 1A receptor,B,,Sus scrofa,,51
1076,12861,8,,,,Autocuration,,,,9823.0,Binding activity radioligand.,B,,Sus scrofa,,51
1077,12861,8,,,,Expert,,,,9823.0,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,B,,Sus scrofa,,51
1078,12861,8,,,,Autocuration,,,,9823.0,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,B,,Sus scrofa,,51
1079,12490,8,,,,Expert,,,,,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor from pig cortex,B,,,,10624
1080,11828,8,,,,Expert,,,,9823.0,Displacement of [3H]8-OH-DPAT from pig cortex 5-hydroxytryptamine 1A receptor,B,,Sus scrofa,,51
1081,11866,8,,,,Autocuration,10000000.0,,Hippocampus,9823.0,Binding affinity for 5-hydroxytryptamine 1A receptor in piglet hippocampus using [3H]8-OH-DPAT,B,,Sus scrofa,,51
1082,12827,8,,,,Autocuration,,,,9823.0,Binding affinity towards 5-hydroxytryptamine 1A receptor in pig frontal cortex membranes using [8H]-OH-DPAT,B,,Sus scrofa,,51
1083,12918,8,,,,Autocuration,,,,9823.0,Binding affinity was evaluated by 5-hydroxytryptamine 1A receptor agonism in the pig cortex by displacing 8-OH-DPAT,B,,Sus scrofa,,51
1084,12919,8,,,,Expert,,,,9823.0,Agonistic activity against 5-hydroxytryptamine 1A receptor in pig cortex using [3H]8-OH-DPAT,F,,Sus scrofa,,51
1085,13047,8,,,,Autocuration,,,,9986.0,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the presence of endothelium,B,,Oryctolagus cuniculus,,51
1086,15796,9,,,,Expert,,,,10116.0,Inhibition activity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using radio binding assays,B,,Rattus norvegicus,,10576
1087,3651,9,,,,Expert,10000000.0,,Hippocampus,10116.0,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Less active",B,,Rattus norvegicus,,10576
1088,188,8,,,,Autocuration,,,,,Tested for the effect on binding at 5-hydroxytryptamine 1A receptor; No activity,B,,,,10576
1089,16616,9,,,,Expert,,,,10116.0,"Antagonist activity to stimulate binding of [35S]GTP-gamma-S, to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",F,,Rattus norvegicus,Membranes,10576
1090,16616,9,,,,Expert,10000000.0,,Hippocampus,10116.0,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",F,,Rattus norvegicus,Membranes,10576
1091,12306,8,,,,Autocuration,10000000.0,,Hippocampus,,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,B,,,,10576
1092,17167,9,,,,Expert,10000000.0,,Hippocampus,10116.0,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding,B,,Rattus norvegicus,,10576
1093,14776,8,,,,Autocuration,,,,,Binding affinity measured at the 5-hydroxytryptamine 1A receptor by the inhibition of [3H]8-OH-DPAT binding to rat cortex using unlabeled buspirone for nonspecific binding.,B,,,,10576
1094,12158,8,,,,Expert,,,,,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand.,B,,,,10576
1095,13481,8,,,,Autocuration,,,,,Binding affinity of [3H]- -8-OH-DPAT labelled towards Rat Hippocampal 5-hydroxytryptamine 1A receptor using radioligand binding assay,B,,,,10576
1096,13427,8,,,,Autocuration,,,,,Binding affinity of [3H]-8-OH-DPAT towards 5-hydroxytryptamine 1A receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,B,In vitro,,,10576
1097,10210,8,,,,Autocuration,,,,,Binding affinity of compound against 5-hydroxytryptamine 1A receptor binding site using radioligand [3H]8-OH-DPAT,B,,,,10576
1098,10205,8,,,,Autocuration,,,,,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,B,,,Membranes,10576
1099,10205,8,,,,Autocuration,,,,,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,B,,,Membranes,10576
1100,10205,8,,,,Expert,,,,,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor in rat striatal membranes by [3H]OH-DPAT displacement.,B,,,Membranes,10576
1101,12280,9,,,,Expert,,,,10116.0,Binding affinity for 5-hydroxytryptamine 1A receptor with [3H]5-HT,B,,Rattus norvegicus,,10576
1102,17386,8,,,,Expert,,,,,Binding affinity to the rat 5-hydroxytryptamine 1A receptor,B,,,,10576
1103,13654,8,,,,Expert,,,,,Binding affinity was tested on 5-hydroxytryptamine 1A receptor using radioligand [3H]5-HT binding assay.,B,,,,10576
1104,14423,8,,,,Autocuration,10000000.0,,Hippocampus,,Binding affinity against 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as the radioligand.,B,,,,10576
1105,15412,8,,,,Autocuration,10000000.0,,Hippocampus,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus tissue.,B,,,,10576
1106,12073,8,,,,Autocuration,10000000.0,,Hippocampus,,Binding affinity by measuring displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,,,10576
1107,4101,9,,,,Expert,,,,10116.0,Displacement of [3H]8-OH-DPAT from rat striata 5-hydroxytryptamine 1A receptor,B,,Rattus norvegicus,,10576
1108,10062,8,,,,Autocuration,,,,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1A receptor,B,,,,10576
1109,6238,8,,,,Autocuration,,,,,Binding affinity towards 5-HT 1A receptor in rat cerebral cortex membranes using [3H]8-OH-DPAT as radioligand,B,,,,10576
1110,16273,8,,,,Autocuration,,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,B,,,,10576
1111,11139,8,,,,Autocuration,,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in competitive binding assay,B,,,,10576
1112,16796,8,,,,Expert,,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,B,,,,10576
1113,9548,9,,,,Expert,955.0,,Brain,10116.0,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,B,,Rattus norvegicus,,10576
1114,10381,8,,,,Autocuration,955.0,,Brain,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,B,,,,10576
1115,13408,8,,,,Autocuration,,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hypocampus membrane using [3H]8-OH-DPAT as radioligand,B,,,,10576
1116,13825,9,,,,Expert,10000000.0,,Hippocampus,10116.0,Binding affinity towards 5-hydroxytryptamine 1A receptor in the rat brain (hippocampus) using [3H]8-OH-DPAT,B,,Rattus norvegicus,,10576
1117,11147,8,,,,Expert,10000000.0,,Hippocampus,,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]-8-hydroxy-2-(di-n-propylamine) tetralin (8-OH-DPAT) as a radioligand,B,,,,10576
1118,10552,8,,,,Autocuration,,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor sites in cortical membranes using [3H]8-OH-DPAT as radioligand,B,,,,10576
1119,10552,8,,,,Autocuration,2435.0,,Striatum,,"Binding affinity towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",B,,,,10576
1120,17136,9,,,,Expert,,,,10116.0,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cortex membranes,B,,Rattus norvegicus,Membranes,10576
1121,5778,9,,,,Expert,,,,10116.0,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cerebral cortex membranes,B,,Rattus norvegicus,Membranes,10576
1122,13481,8,,,,Autocuration,10000000.0,,Hippocampus,,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,10576
1123,13481,8,,,,Autocuration,10000000.0,,Hippocampus,,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; Not tested,B,,,,10576
1124,13630,8,,,,Intermediate,10000000.0,,Hippocampus,,Binding affinity against rat hippocampal 5-hydroxytryptamine 1A (5-HT1A) receptor determined using [3H]8-OH-DPAT as radioligand,B,,,,10576
1125,16245,8,,,,Expert,,,,,Binding was determined on 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,B,,,,10576
1126,14509,8,,,,Autocuration,10000000.0,,Hippocampus,,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand,B,,,,10576
1127,14509,8,,,,Expert,10000000.0,,Hippocampus,,Binding affinity against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.,B,,,,10576
1128,14509,8,,,,Autocuration,10000000.0,,Hippocampus,,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.; ND = Not determined,B,,,,10576
1129,14509,8,,,,Autocuration,10000000.0,,Hippocampus,,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand; ND = Not determined,B,,,,10576
1130,14256,8,,,,Expert,,,,,Binding affinity was evaluated by determining in vitro displacement of [3H]8-OH-DPAT from the central 5-hydroxytryptamine 1A receptor recognition site in rat frontal cortex homogenate.,B,,,,10576
1131,11139,8,,,,Autocuration,,,,,Binding affinity was evaluated by using [3H]8-OH-DPAT radioligand by using competitive binding assay on 5-hydroxytryptamine 1A receptor,B,,,,10576
1132,11047,9,,,,Expert,,,,10116.0,Binding affinity for 5-HT1A measured by displacing [3H]8-OH-DPAT from rat cortical membranes; Not determined,B,,Rattus norvegicus,,10576
1133,11047,9,,,,Expert,,,,10116.0,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes,B,,Rattus norvegicus,,10576
1134,11047,9,,,,Expert,,,,10116.0,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes;ND-Not determined,B,,Rattus norvegicus,,10576
1135,2395,9,,485.0,,Expert,,CHO-K1,,10116.0,Binding affinity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,B,,Rattus norvegicus,,10576
1136,9699,8,,,,Autocuration,,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,B,,,,10576
1137,12028,9,,,,Expert,10000000.0,,Hippocampus,10116.0,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [125I]trans-8-OH-PIPAT in membrane homogenates of hippocampal tissue of rat brain,B,,Rattus norvegicus,,10576
1138,12028,8,,,,Autocuration,10000000.0,,Hippocampus,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in membrane homogenates of hippocampal tissue of rat brain,B,,,,10576
1139,5815,8,,,,Autocuration,,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex,B,,,,10576
1140,16616,8,,,,Expert,,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates,B,,,,10576
1141,5815,8,,,,Autocuration,,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT,B,,,,10576
1142,2761,8,,,,Autocuration,10000000.0,,Hippocampus,,"Binding affinity towards 5-hydroxytryptamine 1A receptor using 0.1 nM [3H]-8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tet-ralin), from rat hippocampal homogenate",B,,,,10576
1143,13133,8,,,,Expert,,,,,Binding affinity was determined against 5-hydroxytryptamine 1A receptor using [3H]WB-4101,B,,,,10576
1144,10444,8,,,,Autocuration,,,,,Binding affinity was determined against 5-hydroxytryptamine 1A receptor was determined in male Sprague-Dawley rat brain.,B,,,,10576
1145,13278,9,,,,Expert,,,,10116.0,Binding affinity was measured against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT by lysergic acid amides,B,,Rattus norvegicus,,10576
1146,15874,8,,,,Autocuration,,,,,Binding affinity was measured on cloned rat 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,B,,,,10576
1147,10552,8,,,,Autocuration,2435.0,,Striatum,,"Binding affinity of the compound towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",B,,,Membranes,10576
1148,11130,8,,,,Autocuration,,,,,Binding constant against 5-hydroxytryptamine 1A receptor (in vitro),B,,,,10576
1149,11130,8,,,,Autocuration,,,,,Binding constant against 5-hydroxytryptamine 1A receptor (in vivo),B,In vivo,,,10576
1150,14542,8,,,,Autocuration,955.0,,Brain,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex,B,,,,10576
1151,13670,9,,,,Expert,,,,10116.0,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,B,,Rattus norvegicus,,10576
1152,9888,8,,,,Expert,,,,,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes,B,,,,10576
1153,3678,9,,,,Expert,,,,10116.0,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus membranes,B,,Rattus norvegicus,Membranes,10576
1154,11332,8,,,,Autocuration,10000000.0,,Hippocampus,,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,B,,,,10576
1155,11332,8,,,,Autocuration,10000000.0,,Hippocampus,,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 1A receptor receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,B,,,,10576
1156,1185,8,,,,Expert,,,,,Ability to displace [3H]-8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,B,,,,10576
1157,2014,8,,,,Expert,,,,,Binding affinity at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes by [3H]8-OH-DPAT displacement.,B,,,,10576
1158,1185,8,,,,Autocuration,,,,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,B,,,,10576
1159,14429,8,,,,Expert,,,,,Compound was evaluated for its binding affinity against 5-hydroxytryptamine 1A receptor from rat cerebral cortex,B,,,,10576
1160,16288,8,,,,Expert,,,,,"Binding affinity to 5-hydroxytryptamine 1A receptor (5-HT 1A receptor, serotonin receptor) from rat cortex using [3H]8-OH-DPAT as radioligand",B,,,,10576
1161,5432,9,,,,Expert,,,,10116.0,Displacement of [3H]prazosin from rat cortex membrane 5-hydroxytryptamine 1A receptor,B,,Rattus norvegicus,,10576
1162,14429,8,,,,Autocuration,,,,,Compound was evaluated for its binding affinity with 5-hydroxytryptamine 1A receptor using membranes prepared from rat cerebral cortex,B,,,,10576
1163,13672,8,,,,Expert,,,,,Binding affinity towards rat 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand.,B,,,,10576
1164,11296,8,,,,Expert,10000000.0,,Hippocampus,,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,B,,,,10576
1165,11296,8,,,,Autocuration,,,,,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site.,B,,,,10576
1166,14749,8,,449.0,,Expert,,CHO,,,Binding affinity against rat 5-hydroxytryptamine 1A receptor in CHO cells.,B,,,,10576
1167,15086,8,,,,Expert,,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat brain using [3H]-8-OH-DPAT as radioligand,B,,,,10576
1168,13462,8,,,,Autocuration,10000000.0,,Hippocampus,,Compound was tested for the Binding affinity against rat hippocampal 5-hydroxytryptamine 1A receptor by Radio ligand [3H]8-OH-DPAT binding assay.,B,,,,10576
1169,15363,8,,,,Autocuration,,,,,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,B,,,,10576
1170,15363,8,,,,Autocuration,,,,,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,B,,,,10576
1171,10796,8,,,,Autocuration,,,,,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1A receptor,B,,,,10576
1172,12816,8,,,,Expert,955.0,,Brain,,Binding affinity for 5-hydroxytryptamine 1A receptor in rat brain tissue using [3H]8-OH-DPAT as radioligand,B,,,,10576
1173,13542,8,,,,Expert,10000000.0,,Hippocampus,,In vitro displacement of [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,B,,,,10576
1174,13308,8,,,,Expert,,,,,In vitro ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor sites of rat brain cortex.,B,,,,10576
1175,13541,8,,,,Expert,10000000.0,,Hippocampus,,In vitro affinity at 5-hydroxytryptamine 1A receptor of rat hippocampus by [3H]8-OH-DPAT displacement.,B,,,,10576
1176,10058,8,,,,Autocuration,10000000.0,,Hippocampus,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-HT1A receptor of rat hippocampus and the value ranges from 9 - 12,B,,,,10576
1177,10058,8,,,,Autocuration,10000000.0,,Hippocampus,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,B,,,,10576
1178,10058,8,,,,Autocuration,10000000.0,,Hippocampus,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 12 to 17,B,,,,10576
1179,10058,8,,,,Autocuration,10000000.0,,Hippocampus,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 391-841,B,,,,10576
1180,10058,8,,,,Autocuration,10000000.0,,Hippocampus,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 17.,B,,,,10576
1181,10058,8,,,,Autocuration,10000000.0,,Hippocampus,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 20.,B,,,,10576
1182,10058,8,,,,Autocuration,10000000.0,,Hippocampus,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 245 to 736,B,,,,10576
1183,10058,8,,,,Autocuration,10000000.0,,Hippocampus,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 25 - 84,B,,,,10576
1184,10058,8,,,,Autocuration,10000000.0,,Hippocampus,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 48 to 59,B,,,,10576
1185,10058,8,,,,Autocuration,10000000.0,,Hippocampus,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 3 -5,B,,,,10576
1186,10058,8,,,,Autocuration,10000000.0,,Hippocampus,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 15 - 31,B,,,,10576
1187,10058,8,,,,Autocuration,10000000.0,,Hippocampus,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 27 - 42,B,,,,10576
1188,10058,8,,,,Autocuration,10000000.0,,Hippocampus,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 6 - 13,B,,,,10576
1189,10058,9,,,,Expert,10000000.0,,Hippocampus,10116.0,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,B,,Rattus norvegicus,,10576
1190,10058,8,,,,Autocuration,10000000.0,,Hippocampus,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.; ND is No Data.,B,,,,10576
1191,10058,8,,,,Autocuration,10000000.0,,Hippocampus,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus. and the value ranges from 16 - 27,B,,,,10576
1192,12879,8,,,,Expert,,,,,Displacement of [3H]2-(di-N-propylamino)-8-hydroxytetralin from central 5-hydroxytryptamine 1A receptor recognition sites in rat frontal cortex homogenates.,B,,,,10576
1193,11964,8,,,,Expert,,,,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate,B,,,,10576
1194,11964,8,,,,Autocuration,,,,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 1),B,,,,10576
1195,11964,8,,,,Autocuration,,,,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 2),B,,,,10576
1196,9548,8,,,,Expert,955.0,,Brain,,Evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,B,,,,10576
1197,9098,8,,,,Expert,,,,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand.,B,,,,10576
1198,9098,8,,,,Autocuration,,,,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand; ND is no data.,B,,,,10576
1199,9098,8,,,,Autocuration,,,,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand;ND means no data,B,,,,10576
1200,13248,8,,449.0,,Expert,,CHO,,,In vitro displacement of radioactively labeled ligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor site in CHO cells,B,,,,10576
1201,3147,8,,,,Expert,,,,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat cortical membranes,B,,,,10576
1202,13949,8,,,,Expert,,,,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor of rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,B,,,,10576
1203,11883,8,,449.0,,Autocuration,,CHO,,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),B,,,,10576
1204,11883,8,,,,Autocuration,,,,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (agonist) as radioligand (sc),B,,,,10576
1205,11883,9,,,,Expert,,,,10116.0,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT,B,,Rattus norvegicus,,10576
1206,15535,8,,,,Expert,,,,,In vitro binding affinity at 5-HT1A receptors assayed by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,B,,,Membranes,10576
1207,15535,8,,,,Autocuration,,,,,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes + cortex,B,,,,10576
1208,15535,8,,,,Autocuration,,,,,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes+cortex,B,,,,10576
1209,16372,9,,449.0,,Expert,,CHO,,9606.0,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,B,,Homo sapiens,,51
1210,14608,8,,,,Expert,,,,,In vitro binding affinity for 5-hydroxytryptamine 1A receptor in rat hippocampal membranes by [125I]-labeled agonist displacement.,B,,,,10576
1211,4795,9,,,,Expert,10000000.0,,Hippocampus,10116.0,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus,B,,Rattus norvegicus,,10576
1212,13863,8,,,,Autocuration,,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,B,,,,10576
1213,13863,8,,,,Autocuration,,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=100-230,B,,,,10576
1214,13863,8,,,,Autocuration,,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=12-14,B,,,,10576
1215,13863,8,,,,Autocuration,,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=16-20,B,,,,10576
1216,13863,8,,,,Autocuration,,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=160-430,B,,,,10576
1217,13863,8,,,,Autocuration,,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=174-224,B,,,,10576
1218,13863,8,,,,Autocuration,,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=184-503,B,,,,10576
1219,13863,8,,,,Autocuration,,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=19-23,B,,,,10576
1220,13863,8,,,,Autocuration,,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=2.2-3.2,B,,,,10576
1221,13863,8,,,,Autocuration,,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=2.7-3.6,B,,,,10576
1222,13863,8,,,,Autocuration,,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=20-23,B,,,,10576
1223,13863,8,,,,Autocuration,,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=21-28,B,,,,10576
1224,13863,8,,,,Autocuration,,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=240-760,B,,,,10576
1225,13863,8,,,,Autocuration,,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=39-87,B,,,,10576
1226,13863,8,,,,Autocuration,,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=4.6-5.2,B,,,,10576
1227,9742,8,,,,Autocuration,,,,,Inhibitory activity tested in vitro at 5-hydroxytryptamine 1A receptor binding site in rat,B,,,,10576
1228,12073,8,,,,Autocuration,,,,,Inhibitory concentration against 5-hydroxytryptamine 1A receptor,B,,,,10576
1229,4101,8,,,,Autocuration,,,,,Inhibitory concentration against binding of 5-hydroxytryptamine 1A receptor from striata of male Wistar rats by displacement of [3H]8-OH-DPAT,B,,,,10576
1230,15360,8,,,,Autocuration,,,,,Inhibitory concentration against radioligand [3H]hydroxy-2-(di-n-propylamino)-tetralin binding to 5-hydroxytryptamine 1A receptor in rat,B,,,,10576
1231,11576,8,,,,Autocuration,10000000.0,,Hippocampus,,Inhibitory concentration against radioligand [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,B,,,,10576
1232,5834,8,,,,Expert,,,,,Inhibition of the 5-hydroxytryptamine 1A receptor in rat dorsal raphe,B,,,,10576
1233,2395,9,,485.0,,Expert,,CHO-K1,,10116.0,Inhibitory concentration against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,B,,Rattus norvegicus,,10576
1234,1375,8,,,,Autocuration,,,,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand,B,,,,10576
1235,1375,8,,,,Autocuration,,,,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand; NT means not tested,B,,,,10576
1236,3967,8,,,,Autocuration,,,,,The compound was evaluated for the ability to displace [3H]- 8-OH -DPAT from 5-hydroxytryptamine 1A receptor ( striata of male wistar rats),B,,,,10576
1237,12884,8,,,,Expert,,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor binding site using [3H]8-OH-DPAT. ,B,,,,10576
1238,2343,8,,,,Expert,,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor using receptor binding assay,B,,,,10576
1239,11511,8,,,,Autocuration,,,,,"The compound was tested in vitro for inhibitory activity against 5-HT1A receptor in rats, using [3H]8-OH-DPAT as radioligand",B,,,,10576
1240,11511,9,,,,Expert,,,,10116.0,"Inhibitory activity against 5-hydroxytryptamine 1A receptor in rats, using [3H]8-OH-DPAT as radioligand",B,,Rattus norvegicus,,10576
1241,16394,8,,,,Autocuration,,,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat,F,In vivo,,,10576
1242,16394,8,,,,Autocuration,,,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.10-6.20),F,In vivo,,,10576
1243,16394,8,,,,Autocuration,,,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.60),F,In vivo,,,10576
1244,16394,8,,,,Autocuration,,,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.80),F,In vivo,,,10576
1245,16394,8,,,,Autocuration,,,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.37-4.27),F,In vivo,,,10576
1246,16394,8,,,,Autocuration,,,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-2.70),F,In vivo,,,10576
1247,16394,8,,,,Autocuration,,,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-4),F,In vivo,,,10576
1248,16394,8,,,,Autocuration,,,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.45-4.51),F,In vivo,,,10576
1249,16394,8,,,,Autocuration,,,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.50-5.30),F,In vivo,,,10576
1250,16394,8,,,,Autocuration,,,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.60-1.60),F,In vivo,,,10576
1251,16394,8,,,,Autocuration,,,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.72-2.87),F,In vivo,,,10576
1252,16394,8,,,,Autocuration,,,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.80-5.80),F,In vivo,,,10576
1253,16394,8,,,,Autocuration,,,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (1.50-16.5),F,In vivo,,,10576
1254,16394,8,,,,Autocuration,,,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (2.20-30.5),F,In vivo,,,10576
1255,16394,8,,,,Autocuration,,,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges is not computable,F,In vivo,,,10576
1256,16616,9,,,,Expert,,,,10116.0,"Percent increase of R(+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",F,,Rattus norvegicus,Membranes,10576
1257,16796,8,,,,Autocuration,,,,,% inhibition towards 5-HT1A receptor from rat hippocampal membranes,B,,,,10576
1258,16796,8,,,,Autocuration,,,,,% inhibition towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,B,,,,10576
1259,15629,8,,,,Autocuration,,,,,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor.,B,,,,10576
1260,13241,8,,,,Autocuration,,,,,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",F,,,,10576
1261,12073,8,,,,Expert,10000000.0,,Hippocampus,,Measurement of binding affinity by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,,,10576
1262,14286,8,,,,Autocuration,10000000.0,,Hippocampus,,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane,B,,,,10576
1263,14542,8,,,,Autocuration,955.0,,Brain,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex at 10 uM,B,,,,10576
1264,13630,8,,,,Autocuration,,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,F,,,,10576
1265,13630,8,,,,Autocuration,,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0+ 1 uM 5-HT.,F,,,,10576
1266,13630,8,,,,Autocuration,,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.01 uM+ 1 uM 5-HT.,F,,,,10576
1267,13630,8,,,,Autocuration,,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,F,,,,10576
1268,13630,8,,,,Expert,,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,F,,,,10576
1269,13630,8,,,,Autocuration,,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM+ 1 uM 5-HT.,F,,,,10576
1270,13630,9,,,,Expert,,,,10116.0,Effect against 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at 0.1 uM dose,F,,Rattus norvegicus,,10576
1271,13630,8,,,,Autocuration,,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,F,,,,10576
1272,13630,8,,,,Expert,,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 1 uM 5-HT.,F,,,,10576
1273,13630,8,,,,Autocuration,,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 0.1 uM 5-HT.,F,,,,10576
1274,13630,8,,,,Expert,,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM,F,,,,10576
1275,13630,8,,,,Autocuration,,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM+ 10 uM 5-HT.,F,,,,10576
1276,13630,8,,,,Expert,,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,F,,,,10576
1277,13630,8,,,,Autocuration,,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 0.1 uM 5-HT.,F,,,,10576
1278,13630,8,,,,Autocuration,,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,F,,,,10576
1279,13630,8,,,,Autocuration,,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 1 uM 5-HT.,F,,,,10576
1280,13630,8,,,,Expert,,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 3 uM 5-HT.,F,,,,10576
1281,13630,8,,,,Expert,,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,F,,,,10576
1282,13630,8,,,,Autocuration,,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 30 uM,F,,,,10576
1283,13630,8,,,,Expert,,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM,F,,,,10576
1284,13630,8,,,,Autocuration,,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM+ 50 uM 5-HT.,F,,,,10576
1285,13630,8,,,,Autocuration,,,,,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM,F,,,,10576
1286,13630,8,,,,Autocuration,,,,,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,F,,,,10576
1287,13630,8,,,,Autocuration,,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,F,,,,10576
1288,9783,8,,,,Autocuration,10000000.0,,Hippocampus,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue,B,,,,10576
1289,9783,8,,,,Expert,10000000.0,,Hippocampus,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue at 1 uM,B,,,,10576
1290,14331,9,,,,Expert,,,,10116.0,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membranes at 10e-7 M,B,,Rattus norvegicus,Membranes,10576
1291,15260,8,,,,Expert,10000000.0,,Hippocampus,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue at 1 uM,B,,,,10576
1292,15260,8,,,,Autocuration,10000000.0,,Hippocampus,,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 0.1 uM concentration,B,,,,10576
1293,15260,8,,,,Autocuration,10000000.0,,Hippocampus,,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 1 uM concentration,B,,,,10576
1294,16616,9,,,,Expert,,,,10116.0,"Percent inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",F,,Rattus norvegicus,,10576
1295,15629,8,,,,Autocuration,,,,,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor,B,,,,10576
1296,15086,8,,,,Autocuration,,,,,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,B,,,,10576
1297,5717,8,,,,Expert,,,,,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,F,,,,10576
1298,12652,8,,,,Autocuration,,,,,Binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,B,,,,10576
1299,14608,8,,,,Autocuration,10000000.0,,Hippocampus,,In vitro binding affinity for 5-hydroxytryptamine 1A receptor was determined by measuring specific inhibition of [125I]-binding to rat hippocampal membrane preparations,B,,,,10576
1300,12306,8,,,,Autocuration,10000000.0,,Hippocampus,,Inhibition of binding of [125I]-8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,B,,,,10576
1301,12306,8,,,,Autocuration,10000000.0,,Hippocampus,,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,B,,,,10576
1302,15247,9,,,,Expert,,,,10116.0,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,B,,Rattus norvegicus,,10576
1303,17529,8,,,,Expert,10000000.0,,Hippocampus,,Ability to bind to central serotonin 5-hydroxytryptamine 1A receptor in vitro in hippocampus of the rat brain using [3H]8-OH-DPAT radioligand,B,,,,10576
1304,14826,8,,,,Autocuration,10000000.0,,Hippocampus,,Ability to displace [3H]- -OH-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,,,10576
1305,14826,8,,,,Autocuration,10000000.0,,Hippocampus,,Ability to displace [3H]- -(OH)-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,,,10576
1306,13241,8,,,,Autocuration,10000000.0,,Hippocampus,,Ability to displace [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,B,,,,10576
1307,14093,8,,,,Autocuration,10000000.0,,Hippocampus,,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor,B,,,,10576
1308,14093,8,,,,Autocuration,10000000.0,,Hippocampus,,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor; Not tested,B,,,,10576
1309,14442,8,,,,Autocuration,955.0,,Brain,,Affinity at [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in rat brain homogenate was determined,B,,,,10576
1310,9919,8,,,,Autocuration,,,,,Affinity for 5-hydroxytryptamine 1A receptor site,B,,,,10576
1311,9919,8,,,,Autocuration,,,,,Affinity for 5-hydroxytryptamine 1A receptor site,B,,,,10576
1312,11440,8,,,,Autocuration,10000000.0,,Hippocampus,,Affinity in displacing [3H]8-OH-DPAT from rat hippocampal 5-HT1A receptor.,B,,,,10576
1313,11257,8,,,,Autocuration,,,,,Affinity on 5-hydroxytryptamine 1A receptor labeled by [3H]8-OH-DPAT,B,,,,10576
1314,10330,8,,,,Expert,,,,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand,B,,,,10576
1315,17331,9,,,,Expert,10000000.0,,Hippocampus,10116.0,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus mambranes,B,,Rattus norvegicus,,10576
1316,16567,8,,,,Expert,,,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane,B,,,,10576
1317,12058,9,,,,Expert,,,,10116.0,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",B,,Rattus norvegicus,,10576
1318,9699,8,,,,Autocuration,10000000.0,,Hippocampus,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal tissue,B,,,,10576
1319,9547,8,,,,Autocuration,,,,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat was determined using [3H]8-OH-DPAT in binding assay,B,,,,10576
1320,10330,8,,,,Autocuration,,,,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]DOB as radioligand,B,,,,10576
1321,14331,8,,,,Autocuration,,,,,Binding affinity against rat 5-hydroxytryptamine 1A receptor,B,,,,10576
1322,14060,9,,,,Expert,,,,10116.0,Binding affinity against rat brain 5-hydroxytryptamine 1A receptor,B,,Rattus norvegicus,,10576
1323,14744,8,,,,Autocuration,10000000.0,,Hippocampus,,Binding affinity against the 5-hydroxytryptamine 1A receptor labelled with [3H]8-OH-DPAT in rat hippocampal homogenates,B,,,,10576
1324,13506,8,,,,Autocuration,,,,,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,B,,,,10576
1325,10862,8,,,,Expert,955.0,,Brain,,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,B,,,,10576
1326,10862,8,,,,Expert,955.0,,Brain,,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,B,,,,10576
1327,10062,8,,,,Expert,,,,,Binding affinity at rat 5-hydroxytryptamine 1A receptor by [3H]WB-4101 displacement.,B,,,,10576
1328,12073,8,,,,Autocuration,,,,,Binding affinity for 5-hydroxytryptamine 1A receptor by use of [3H]8-OH-DPAT in male rat,B,,,,10576
1329,14875,8,,,,Autocuration,,,,,GTPgammaS radioligand binding assay,B,,,,106
1330,2391,8,,,,Autocuration,,,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,B,,,,106
1331,2391,8,,,,Autocuration,,,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Partial agonist,F,,,,106
1332,2391,8,,,,Autocuration,,,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Slient antagonist,F,,,,106
1333,2391,8,,,,Autocuration,,,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,B,,,,106
1334,2391,8,,,,Autocuration,,,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,B,,,,106
1335,2391,8,,,,Autocuration,,,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; silent antagonist,F,,,,106
1336,17211,8,,308.0,,Expert,,HeLa,,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor,B,,,,106
1337,17211,8,,308.0,,Autocuration,,HeLa,,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor receptor,B,,,,106
1338,6491,9,,,,Expert,,,,9606.0,Affinity towards human 5-hydroxytryptamine 1B serotonin receptor,B,,Homo sapiens,,106
1339,16190,8,,449.0,,Autocuration,,CHO,,,Binding affinity against 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,B,,,,106
1340,14165,8,,,,Autocuration,,,,,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]5-CT as radioligand,B,,,,106
1341,14165,8,,,,Autocuration,,,,,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]GR-125743 as radioligand,B,,,,106
1342,4234,9,,,,Expert,,,,9606.0,Binding affinity to cloned human 5-hydroxytryptamine 1B receptor,B,,Homo sapiens,,106
1343,6328,8,,,,Expert,,,,,Binding affinity towards human 5-hydroxytryptamine 1B receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,B,,,,106
1344,14770,8,,,,Autocuration,,,,,Binding affinity for recombinant human 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,B,,,,106
1345,2598,8,,,,Autocuration,,,,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1B receptor using [3H]5-CT as radioligand,B,,,,106
1346,6897,8,,,,Expert,,,,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,B,,,,106
1347,6897,8,,,,Autocuration,,,,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,B,,,,106
1348,6013,8,,,,Autocuration,,,,,Binding affinity towards 5-hydroxytryptamine 1B receptor,B,,,,106
1349,5843,8,,,,Expert,,,,,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,B,,,,106
1350,14454,8,,,,Expert,,,,,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT trifluoroacetate as radioligand,B,,,,106
1351,16209,8,,,,Autocuration,,,,,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT radioligand,B,,,,106
1352,3935,8,,,,Autocuration,,,,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1B receptor,B,,,,106
1353,13729,8,,485.0,,Expert,,CHO-K1,,,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1B receptor in CHO-K1 cells,F,,,,106
1354,14251,8,,,,Expert,,,,,Agonist activity to the human recombinant 5-hydroxytryptamine 1B receptor,F,,,,106
1355,17085,8,,,,Expert,,,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor,B,,,,106
1356,3025,8,,,,Autocuration,,,,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,B,,,,106
1357,15315,8,,,,Expert,,,,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor,B,,,,106
1358,14214,9,,,,Expert,,,,9606.0,Receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor in Cos-7 cells,B,,Homo sapiens,,106
1359,3804,9,,,,Expert,,,,9606.0,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,B,,Homo sapiens,,106
1360,2391,9,,,,Expert,,,,9606.0,Affinity for 5-hydroxytryptamine 1B receptor subtype,B,,Homo sapiens,,106
1361,4175,9,,,,Expert,,,,9606.0,Binding affinity for human 5-hydroxytryptamine 1B receptor,B,,Homo sapiens,,106
1362,17296,8,,449.0,,Autocuration,,CHO,,,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand; Not determined,B,,,,106
1363,17085,8,,,,Expert,,,,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor; ND means not determined,B,,,,106
1364,17211,8,,308.0,,Autocuration,,HeLa,,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,B,,,,106
1365,17211,8,,308.0,,Autocuration,,HeLa,,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT=not tested,B,,,,106
1366,17211,8,,308.0,,Autocuration,,HeLa,,,Ability to displace [3H]-5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,B,,,,106
1367,15926,9,,,,Expert,,,,9606.0,Binding activity against human 5-hydroxytryptamine 1B receptor; NT means not tested,B,,Homo sapiens,,106
1368,16312,8,,485.0,,Autocuration,,CHO-K1,,,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor; not tested,B,,,,106
1369,5843,8,,,,Expert,,,,,Selectivity ratio against cloned human 5-HT1B receptor to that of h5-HT1D receptor,B,,,,106
1370,5843,8,,,,Autocuration,,,,,Selectivity ratio against cloned human 5-hydroxytryptamine 1B receptor to that of human 5-hydroxytryptamine 1D receptor,B,,,,106
1371,16312,8,,485.0,,Expert,,CHO-K1,,,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor,B,,,,106
1372,15926,9,,,,Expert,,,,9606.0,Binding activity against human 5-hydroxytryptamine 1B receptor,B,,Homo sapiens,,106
1373,15926,9,,,,Expert,,,,9606.0,Binding activity against human 5-hydroxytryptamine 1B receptor,B,,Homo sapiens,,106
1374,4540,9,,449.0,,Expert,,CHO,,9606.0,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,B,,Homo sapiens,,106
1375,6166,8,,,,Autocuration,,,,,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor was determined,B,,,,106
1376,17296,8,,449.0,,Autocuration,,CHO,,,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand,B,,,,106
1377,17296,8,,449.0,,Autocuration,,CHO,,,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells,B,,,,106
1378,17296,8,,449.0,,Autocuration,,CHO,,,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells using [3H]5-CT as radioligand,B,,,,106
1379,15779,8,,449.0,,Autocuration,,CHO,,,Binding affinity towards 5-hydroxytryptamine 1B (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,B,,,,106
1380,15779,8,,449.0,,Autocuration,,CHO,,,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,B,,,,106
1381,15779,8,,449.0,,Autocuration,,CHO,,,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand;ND means no data.,B,,,,106
1382,4199,8,,449.0,,Autocuration,,CHO,,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as the radioligand,B,,,,106
1383,14875,9,,,,Expert,,,,9606.0,Binding affinity for human 5-hydroxytryptamine 1B receptor,B,,Homo sapiens,,106
1384,15146,8,,449.0,,Autocuration,,CHO,,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,B,,,,106
1385,5213,8,,,,Autocuration,,,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1B receptor in CHO using [3H]5-HT as a radioligand,B,,,,106
1386,14818,8,,449.0,,Autocuration,,CHO,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,B,,,,106
1387,4829,8,,449.0,,Autocuration,,CHO,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1B receptor in CHO cells, using [3H]5-HT as radioligand",B,,,,106
1388,14454,8,,,,Expert,,,,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 1 uM,F,,,,106
1389,14454,8,,,,Expert,,,,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 10 uM,F,,,,106
1390,14875,8,,449.0,,Autocuration,,CHO,,,"Effect of compound on [35S]GTP-gamma-S, radioligand binding CHO cells expressing human 5-hydroxytryptamine 1B receptor",F,,,,106
1391,14875,8,,449.0,,Autocuration,,CHO,,,"Effect of compound on [35S]GTP-gamma-S, radioligand binding in CHO cells expressing human 5-hydroxytryptamine 1B receptor",F,,,,106
1392,15250,8,,,,Autocuration,,,,,"Compound was tested for maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-HT.",F,,,,105
1393,15250,8,,449.0,,Autocuration,,CHO,,,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells.,B,,,,105
1394,15086,8,,,,Autocuration,,,,,The compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,B,,,,17105
1395,3025,8,,,,Autocuration,,,,9986.0,5-hydroxytryptamine 1B receptor agonist potency determined in rabbit saphenous vein contraction model,F,,Oryctolagus cuniculus,,106
1396,14998,8,,,,Autocuration,,,,9986.0,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein (RbSV).,B,,Oryctolagus cuniculus,,106
1397,14998,8,,,,Intermediate,,,,9986.0,"Binding affinity against vascular 5-hydroxytryptamine 1B receptor, measured using ring preparations of rabbit saphenous vein (RbSV)",B,,Oryctolagus cuniculus,,106
1398,14998,8,,,,Autocuration,,,,9986.0,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein(RbSV).,B,,Oryctolagus cuniculus,,106
1399,13969,8,,,,Expert,,,,,Binding affinity towards 5-hydroxytryptamine 1B receptor was measured using [3H]5-HT as radioligand,B,,,,10577
1400,13392,9,,,,Intermediate,,,,,Binding affinity for 5-hydroxytryptamine 1B receptor,B,,,,10577
1401,3651,9,,,,Expert,2435.0,,Striatum,10116.0,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Less active,B,,Rattus norvegicus,,10577
1402,10025,8,,,,Expert,,,,,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,B,,,,10577
1403,13863,8,,,,Autocuration,,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=48-77,B,,,,10576
1404,13863,8,,,,Autocuration,,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=63-95,B,,,,10576
1405,13863,8,,,,Autocuration,,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=710-980,B,,,,10576
1406,13863,8,,,,Autocuration,,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=78-140,B,,,,10576
1407,13863,8,,,,Autocuration,,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=85-130,B,,,,10576
1408,13863,8,,,,Autocuration,,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=89-280,B,,,,10576
1409,4622,8,,,,Autocuration,10000000.0,,Hippocampus,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampus membrane.,B,,,,10576
1410,14911,8,,,,Intermediate,,,,,Binding affinity at 5-hydroxytryptamine 1A (5-HT1A) receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand,B,,,,10576
1411,12678,8,,,,Autocuration,10000000.0,,Hippocampus,,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,B,,,,10576
1412,12678,8,,,,Expert,10000000.0,,Hippocampus,,In vitro binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampal homogenate by [125I](R)-(+)-trans-8-OH-PIPAT displacement.,B,,,,10576
1413,14235,8,,,,Expert,10000000.0,,Hippocampus,,In vitro binding affinity to rat hippocampal 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,B,,,,10576
1414,14949,8,,,,Expert,10000000.0,,Hippocampus,,In vitro binding affinity towards 5-hydroxytryptamine 1A r receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,B,,,,10576
1415,14949,8,,,,Expert,10000000.0,,Hippocampus,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,B,,,,10576
1416,14949,8,,,,Expert,10000000.0,,Hippocampus,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; ND=not determined,B,,,,10576
1417,14949,8,,,,Expert,10000000.0,,Hippocampus,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; Not determined,B,,,,10576
1418,14949,8,,,,Expert,10000000.0,,Hippocampus,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; not determined,B,,,,10576
1419,16118,8,,,,Expert,,,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,B,,,,10576
1420,3268,8,,,,Autocuration,,,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes,B,,,,10576
1421,3268,8,,,,Autocuration,,,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes; Inactive,B,,,,10576
1422,16117,8,,,,Expert,,,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using radioligand [3H]-8-OH-DPAT,B,,,,10576
1423,9783,8,,,,Expert,10000000.0,,Hippocampus,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue.,B,,,,10576
1424,9783,8,,,,Autocuration,10000000.0,,Hippocampus,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue; NT=Not tested,B,,,,10576
1425,14356,9,,,,Expert,10000000.0,,Hippocampus,10116.0,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,B,,Rattus norvegicus,,10576
1426,15740,8,,,,Autocuration,,,,,Inhibition constant of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,F,,,,10576
1427,12306,8,,,,Autocuration,10000000.0,,Hippocampus,,Inhibition of binding of [125I]8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,B,,,,10576
1428,13348,9,,,,Expert,10000000.0,,Hippocampus,10116.0,Displacement of [3H]5-HT from rat hippocampal 5-hydroxytryptamine 1A receptor with 10e-6 M ketanserin,B,,Rattus norvegicus,,10576
1429,10394,8,,,,Autocuration,,,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor in rat cortical membranes using [3H]8-OH-DPAT as a radioligand,B,,,,10576
1430,15260,8,,,,Autocuration,10000000.0,,Hippocampus,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue,B,,,,10576
1431,10046,8,,,,Expert,10000000.0,,Hippocampus,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,B,,,,10576
1432,15260,8,,,,Intermediate,10000000.0,,Hippocampus,,Antagonist activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor,F,,,,10576
1433,12851,8,,,,Autocuration,,,,,Inhibitory affinity constant against 5-hydroxytryptamine 1A receptor,B,,,,10576
1434,2148,9,,,,Expert,10000000.0,,Hippocampus,10116.0,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat brain hippocampus,B,,Rattus norvegicus,,10576
1435,13134,8,,,,Expert,,,,,Affinity against the 5-hydroxytryptamine receptor 1A using [3H]WB-4101.,B,,,,10576
1436,12462,8,,,,Autocuration,,,,,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain,B,,,,10576
1437,12462,8,,,,Expert,,,,,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain tissue,B,,,,10576
1438,12462,8,,449.0,,Autocuration,,CHO,,,Tested for affinity against 5-hydroxytryptamine 1A receptors using [3H]8-OH-DPAT in homogenized rat cloned CHO cells,B,,,,10576
1439,11933,8,,,,Expert,,,,,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand,B,,,,10576
1440,11933,8,,,,Autocuration,,,,,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand; ND is Not Determined,B,,,,10576
1441,403,9,,,,Expert,10000000.0,,Hippocampus,10116.0,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,B,,Rattus norvegicus,,10576
1442,15538,8,,,,Autocuration,10000000.0,,Hippocampus,,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,,,10576
1443,15538,8,,,,Autocuration,10000000.0,,Hippocampus,,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; NA means Not Active,B,,,,10576
1444,15538,8,,,,Autocuration,10000000.0,,Hippocampus,,Tested for binding affinity by measuring displacement of [3H]-8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; ND means Not Determined,B,,,,10576
1445,12464,8,,,,Intermediate,,,,,Binding affinity to displace [3H]2-(di-N-propylamino)-8-hydroxy-tetralin from 5-hydroxytryptamine 1A (5-HT1A) receptor in rat frontal cortex homogenates,B,,,,10576
1446,1455,8,,,,Expert,,,,,Binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand assay.,B,,,,10576
1447,12652,8,,,,Autocuration,,,,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,B,,,,10576
1448,12639,8,,,,Autocuration,10000000.0,,Hippocampus,,Tested for the inhibitory activity against 5-hydroxytryptamine 1A receptor in rat hippocampal,B,,,,10576
1449,13949,8,,,,Expert,,,,,Tested in vitro for binding affinity by measuring its ability to inhibit [3H]8-OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes.,B,,,,10576
1450,12463,9,,,,Expert,,,,10116.0,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT,B,,Rattus norvegicus,,10576
1451,14829,8,,,,Expert,10000000.0,,Hippocampus,,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation,B,,,,10576
1452,14829,8,,,,Autocuration,10000000.0,,Hippocampus,,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation; ND=not determined,B,,,,10576
1453,12092,8,,,,Autocuration,,,,,The binding affinity was measured on 5-hydroxytryptamine 1A receptor using [3H]- 8-OH-DPAT as radioligand.,B,,,,10576
1454,403,8,,,,Autocuration,,,,,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 1 mM of MnCl2,B,,,,10576
1455,403,8,,,,Autocuration,,,,,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 3*10e-5 M GTP gamma S,B,,,,10576
1456,3967,8,,,,Expert,,,,,Binding affinity at 5-hydroxytryptamine 1A receptor from striata of wistar rats by [3H]- 8-OH -DPAT displacement.,B,,,,10576
1457,12771,9,,,,Expert,,,,10116.0,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat brain synaptosomal preparations,B,,Rattus norvegicus,,10576
1458,15086,8,,,,Autocuration,,,,,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,B,,,,10576
1459,14909,8,,,,Autocuration,10000000.0,,Hippocampus,,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,,,10576
1460,14949,8,,,,Expert,10000000.0,,Hippocampus,,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,,,10576
1461,2309,9,,,,Expert,10000000.0,,Hippocampus,10116.0,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]8-OH-DPAT,B,,Rattus norvegicus,,10576
1462,4170,8,,,,Expert,,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,B,,,,10576
1463,11642,9,,,,Expert,10000000.0,,Hippocampus,10116.0,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 from rat hippocampus,B,,Rattus norvegicus,,10576
1464,11642,8,,,,Autocuration,10000000.0,,Hippocampus,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 radioligand in rat hippocampus,B,,,,10576
1465,12953,8,,,,Autocuration,10000000.0,,Hippocampus,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]-8-OH-DPAT as radioligand,B,,,,10576
1466,12953,8,,,,Autocuration,10000000.0,,Hippocampus,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand.,B,,,,10576
1467,12953,8,,,,Expert,10000000.0,,Hippocampus,,Binding affinity for 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand,B,,,,10576
1468,12903,8,,449.0,,Expert,,CHO,,,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1A receptor expressed in CHO cells, by using [3H]8-OH-DPAT as radioligand.",B,,,,10576
1469,12536,8,,,,Expert,,,,,Displacement of the radioligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,B,,,,10576
1470,10058,8,,,,Autocuration,,,,,The inhibition activity of 5-HT1A at 1 uM,B,,,,10576
1471,12902,8,,485.0,,Expert,,CHO-K1,,,"Binding affinity against 5-hydroxytryptamine 1A receptor from CHO-K1 cells, using [3H]8-OH-DPAT as the radioligand.",B,,,,10576
1472,14057,8,,,,Expert,,,,,Binding affinities against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membrane,B,,,,10576
1473,11296,8,,,,Autocuration,,,,,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-HT 1A receptor site.,B,,,,10576
1474,11296,8,,,,Autocuration,10000000.0,,Hippocampus,,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,B,,,,10576
1475,11296,8,,,,Expert,10000000.0,,Hippocampus,,Ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,B,,,,10576
1476,16616,9,,,,Expert,,,,10116.0,Antagonist activity to stimulate binding of [35S]-GTP-gamma S binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes,F,,Rattus norvegicus,Membranes,10576
1477,16616,9,,,,Expert,10000000.0,,Hippocampus,10116.0,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",F,,Rattus norvegicus,Membranes,10576
1478,16567,8,,,,Autocuration,,,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not -determined.,B,,,,10576
1479,16567,8,,,,Autocuration,,,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not defined.,B,,,,10576
1480,16567,8,,,,Autocuration,,,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not determined.,B,,,,10576
1481,16567,8,,,,Autocuration,,,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND means not determined.,B,,,,10576
1482,17136,8,,,,Autocuration,,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; No data,B,,,,10576
1483,17136,8,,,,Autocuration,,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; Not determined,B,,,,10576
1484,16616,9,,,,Expert,,,,10116.0,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates; ND means No data,B,,Rattus norvegicus,,10576
1485,17331,8,,,,Autocuration,10000000.0,,Hippocampus,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes,B,,,,10576
1486,17331,8,,,,Autocuration,10000000.0,,Hippocampus,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes; Not tested,B,,,,10576
1487,17167,9,,,,Expert,10000000.0,,Hippocampus,10116.0,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding; Not tested,B,,Rattus norvegicus,,10576
1488,15740,8,,,,Autocuration,,,,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,F,,,,10576
1489,15740,8,,,,Autocuration,,,,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; not tested,F,,,,10576
1490,4671,8,,,,Autocuration,,,,,Ratio of binding affinity to 5-HT 1A and D2 receptor,B,,,,10576
1491,10058,8,,,,Autocuration,10000000.0,,Hippocampus,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,B,,,,10576
1492,10058,8,,,,Autocuration,10000000.0,,Hippocampus,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,B,,,,10576
1493,10058,8,,,,Autocuration,10000000.0,,Hippocampus,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.,B,,,,10576
1494,12073,8,,,,Autocuration,,,,,Percentage inhibition against 5-hydroxytryptamine 1A receptor,B,,,,10576
1495,2759,8,,,,Autocuration,,,,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),B,,,,10576
1496,2759,8,,,,Autocuration,,,,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),F,,,,10576
1497,2759,8,,,,Autocuration,,,,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),B,,,,10576
1498,2759,8,,,,Autocuration,,,,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),F,,,,10576
1499,2759,8,,,,Autocuration,,,,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,F,,,,10576
1500,9737,8,,,,Autocuration,955.0,,Brain,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,B,,,,10576
1501,9737,8,,,,Autocuration,,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [3H]8-OH-DPAT as a radioligand,B,,,,10576
1502,5717,8,,,,Expert,,,,,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT as radioligand.,F,,,,10576
1503,12253,8,,,,Autocuration,10000000.0,,Hippocampus,,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,B,,,,10576
1504,14025,8,,,,Autocuration,,,,,Affinity pKi for 5-hydroxytryptamine 1A receptor was measured in rat cortex homogenates.,B,,,,10576
1505,10425,8,,,,Expert,,,,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cerebral cortical membrane using [3H]-8-OH-DPAT as radioligand.,B,,,,10576
1506,14998,8,,,,Autocuration,,,,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cortex homogenates.,B,,,,10576
1507,13694,8,,,,Autocuration,10000000.0,,Hippocampus,,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]- 8-hydri\oxy-2-(di-n-propylamino)tetraline) binding assay,B,,,,10576
1508,13694,8,,,,Autocuration,10000000.0,,Hippocampus,,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]8-hydroxy-2-(di-n-propylamino)-tetraline) binding assay,B,,,,10576
1509,4342,8,,,,Autocuration,,,,,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined,B,,,,10576
1510,12936,9,,,,Expert,,,,10116.0,Binding affinity against rat 5-hydroxytryptamine 1A receptor,B,,Rattus norvegicus,,10576
1511,13144,9,,,,Expert,,,,10116.0,Inhibition of [3H]2-(di-N-propylamino)-8-hydroxytetralin binding to 5-HT1A receptor of rat frontal cortex homogenates,B,,Rattus norvegicus,,10576
1512,13343,8,,,,Expert,,,,,Binding affinity of a compound to rat brain 5-hydroxytryptamine 1A (serotonin) receptor assayed by radiolabeled [3H]-8-OH-DPAT ligand displacement,B,,,,10576
1513,12132,8,,,,Expert,,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,B,,,,10576
1514,15419,8,,,,Expert,,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]8-OH-DPAT as a radioligand,B,,,,10576
1515,1479,8,,,,Autocuration,10000000.0,,Hippocampus,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,B,,,,10576
1516,14287,8,,,,Expert,,,,,In vitro by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor on rat cortical membrane,B,,,,10576
1517,13116,8,,,,Expert,,,,,Binding affinity at 5-hydroxytryptamine 1A receptor,B,,,,10576
1518,2759,9,,,,Expert,,,,10116.0,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat frontal cortex membranes,B,,Rattus norvegicus,Membranes,10576
1519,2759,8,,,,Autocuration,,,,,Compound was tested for inhibition constant against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,B,,,,10576
1520,14748,8,,,,Expert,,,,,"Binding affinity for rat cortex 5-hydroxytryptamine 1A receptor, by displacement of 0.2 nM [3H]8-OH-DPAT radioligand",B,,,,10576
1521,12304,8,,,,Autocuration,,,,,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,B,,,,10576
1522,12409,9,,,,Expert,10000000.0,,Hippocampus,10116.0,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT,B,,Rattus norvegicus,,10576
1523,12409,9,,,,Expert,10000000.0,,Hippocampus,10116.0,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus with [3H]8-OH-DPAT,B,,Rattus norvegicus,,10576
1524,13267,8,,,,Autocuration,10000000.0,,Hippocampus,,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]-SB 207710 as radioligand,B,,,,10576
1525,15194,8,,,,Autocuration,,,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,B,,,,10576
1526,14256,8,,,,Expert,,,,,pKi value against rat 5-hydroxytryptamine 1A receptor.,B,,,,10576
1527,16567,8,,,,Autocuration,,,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is define as non-determined.,B,,,,10576
1528,15740,8,,,,Autocuration,,,,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,F,,,,10576
1529,13278,9,,,,Expert,,,,10116.0,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,B,,Rattus norvegicus,,12687
1530,1970,8,,,,Expert,,,,,Inhibition of specific [3H]OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,B,,,Membranes,10626
1531,10034,8,,,,Autocuration,955.0,,Brain,,Concentration of compound required to inhibit cortical 5-hydroxytryptamine 1A receptor binding sites in rat brain was evaluated,B,,,,10576
1532,13348,8,,,,Autocuration,,,,10116.0,Inhibitory activity against 5-hydroxytryptamine 1A receptor isolated from rat hippocampus membranes membrane using [3H]5-HT as radioligand in the presence of 10e-6 M ketanserin as 5-HT2 blocker,B,,Rattus norvegicus,,51
1533,13630,8,,,,Autocuration,,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,F,,,,10576
1534,10862,8,,,,Autocuration,955.0,,Brain,,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,B,,,,10576
1535,12058,8,,,,Autocuration,,,,,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",B,,,,10576
1536,4639,8,,,,Autocuration,,,,,Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor,B,,,,51
1537,15453,8,,,,Expert,,,,,Percent decrease in 5-hydroxytryptamine 1A receptor binding using 8-OH-DPAT,B,,,,51
1538,4820,8,,,,Expert,,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,B,,,,51
1539,1089,8,,,,Autocuration,,,,,Tested for binding affinity for 5-hydroxytryptamine 1A receptor,B,,,,51
1540,386,8,,,,Autocuration,,,,,The compound was evaluated for its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in cellular brain membranes,B,,,Brain membranes,51
1541,6011,8,,,,Autocuration,,,,,Inhibition of binding towards 5-hydroxytryptamine 1A receptor at 100 nM concentration,B,,,,51
1542,5014,8,,,,Autocuration,,,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1A receptor,B,,,,51
1543,4402,8,,,,Expert,,,,,Binding affinity for 5-hydroxytryptamine 1A receptor determined using [3H]8-OH-DPAT as radioligand,B,,,,51
1544,17066,8,,,,Expert,,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,B,,,,51
1545,17515,8,,,,Autocuration,,,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1A receptor; inactive at 10 uM,B,,,,51
1546,2474,8,,,,Autocuration,,,,,Binding affinity against 5-hydroxytryptamine 1A receptor,B,,,,51
1547,4775,8,,,,Autocuration,,,,,Binding affinity to 5-hydroxytryptamine 1A receptor was determined,B,,,,51
1548,14294,9,,,,Expert,,,,9606.0,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H]-(+)-8-OH-DPAT.,B,,Homo sapiens,,51
1549,14294,9,,,,Expert,,,,9606.0,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H](+)-8-OH-DPAT; inactive,B,,Homo sapiens,,51
1550,12249,8,,449.0,,Autocuration,,CHO,,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,B,,,,51
1551,11376,8,,,,Expert,,,,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor expressed in CHO cell membranes,B,,,,51
1552,2474,8,,,,Autocuration,,,,,Compound was measured in vivo for its binding affinity at 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,In vivo,,,51
1553,13311,8,,,,Autocuration,10000000.0,,Hippocampus,,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,,,,51
1554,4373,8,,,,Autocuration,,,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1A receptor was determined,B,,,,51
1555,1633,8,,,,Expert,,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT.,B,,,,51
1556,11866,8,,,,Autocuration,,,,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,B,,,,51
1557,4373,8,,,,Autocuration,,,,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,B,,,,51
1558,4687,8,,,,Autocuration,,,,,Evaluated for the binding affinity to 5-hydroxytryptamine 1A receptor,B,,,,51
1559,16946,8,,,,Autocuration,,,,,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,B,,,,11863
1560,13291,8,,,,Autocuration,,,,,Binding affinity against 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT radioligand,B,,,,11863
1561,14159,8,,,,Autocuration,,,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1A receptor,B,,,,11863
1562,10812,8,,,,Autocuration,,,,,Compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor by using [3H]DPAT as radioligand,B,,,,11863
1563,3032,9,,449.0,,Expert,,CHO,,10090.0,In vitro binding affinity against 5-hydroxytryptamine 1A receptor in CHO cells,B,,Mus musculus,,11863
1564,16655,8,,,,Autocuration,,,,,Inhibition of 5-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,B,,,,11863
1565,14532,8,,,,Autocuration,,,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand at 10e-5 M concentration,B,,,,11863
1566,13944,8,,,,Autocuration,,,,,Binding affinity against 5-hydroxytryptamine 1A receptor,B,,,,11863
1567,13033,8,,,,Autocuration,,,,,Binding affinity against serotonergic 5-HT1a receptor,B,,,,11863
1568,10321,8,,,,Autocuration,,,,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by using [3H]8-OH-DPAT as radioligand,B,,,,11863
1569,2968,9,,,,Expert,,,,10090.0,Binding affinity for 5-hydroxytryptamine 1A receptor,B,,Mus musculus,,11863
1570,13964,8,,,,Autocuration,,,,,Binding affinity at 5-hydroxytryptamine 1A receptor,B,,,,11863
1571,15527,8,,,,Autocuration,,,,,"Binding affinity towards 5-hydroxytryptamine 1A receptor receptor, using [3H]5-HT as radioligand.",B,,,,11863
1572,12248,8,,449.0,,Autocuration,,CHO,,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,B,,,,11863
1573,12249,8,,449.0,,Autocuration,,CHO,,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,B,,,,11863
1574,15120,8,,,,Autocuration,,,,,Compound was tested for binding affinity using [3H]8-OH-DPAT against 5-hydroxytryptamine 1A receptor,B,,,,11863
1575,13313,8,,,,Autocuration,,,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by using [3H]-8-OH-DPAT as radioligand,B,,,,11863
1576,2613,8,,,,Autocuration,,,,,In vivo binding affinity was evaluated against 5-hydroxytryptamine 1A receptor,B,,,,11863
1577,16700,8,,,,Autocuration,,,,,The binding affinity towards 5-hydroxytryptamine 1A receptor; No affinity,B,,,,11863
1578,2201,8,,,,Autocuration,,,,,Ability to displace [125I]iodosulpiride from 5-hydroxytryptamine 1A receptor,B,,,,11863
1579,1274,9,,,,Expert,,,,10090.0,Binding affinity against 5-hydroxytryptamine 1A receptor,B,,Mus musculus,,11863
1580,1317,8,,,,Autocuration,,,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor using radioligand binding assay,B,,,,11863
1581,12146,8,,,,Autocuration,,,,,Tested against 5-hydroxytryptamine 1A receptor,B,,,,11863
1582,14059,8,,,,Autocuration,,,,,The compound's binding affinity against 5-hydroxytryptamine 1A receptor,B,,,,11863
1583,14025,8,,,,Expert,,,,9986.0,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein,B,,Oryctolagus cuniculus,,106
1584,14025,8,,,,Autocuration,,,,9986.0,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein(RbSV); NS=non surmountable,B,,Oryctolagus cuniculus,,106
1585,14447,9,,722.0,,Intermediate,,HEK293,,9593.0,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1B receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,B,,Gorilla gorilla,,105571
1586,3025,8,,,,Autocuration,,,,10141.0,5-HT1B agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,F,In vivo,Cavia porcellus,,106
1587,3025,8,,,,Autocuration,,,,10141.0,5-hydroxytryptamine 1B receptor agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,F,In vivo,Cavia porcellus,,106
1588,15329,8,,,,Autocuration,,,,10141.0,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery,F,,Cavia porcellus,,106
1589,15329,8,,,,Autocuration,,,,10141.0,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery; n.d. indicates Not determined,F,,Cavia porcellus,,106
1590,15847,8,,,,Autocuration,,,,10141.0,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig,F,,Cavia porcellus,,106
1591,15847,8,,,,Autocuration,,,,10141.0,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig; ND means not done,F,,Cavia porcellus,,106
1592,14165,8,,,,Autocuration,,,,,Intrinsic activity for Antagonism of 5-hydroxytryptamine 1B receptor-mediated stimulation of [35S]GTP gamma S binding,F,,,,106
1593,14214,8,,,,Autocuration,,,,,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine (5-CT),F,,,,106
1594,14214,8,,,,Autocuration,,,,,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine(5-CT),F,,,,106
1595,14214,9,,,,Expert,,,,9606.0,Agonist activity at 5-hydroxytryptamine 1B receptor by measuring the inhibition of forskolin-stimulated cAMP formation,F,,Homo sapiens,,106
1596,13729,9,,485.0,,Expert,,CHO-K1,,9606.0,Inhibition of forskolin-stimulated c-AMP formation by human 5-hydroxytryptamine 1B receptor expressed in CHO-K1 cells,F,,Homo sapiens,,106
1597,3025,8,,449.0,,Autocuration,,CHO,,,Effective concentration determined by measuring inhibition of forskolin-stimulated c-AMP formation at 5-hydroxytryptamine 1B receptor stably transfected in CHO cell lines,F,,,,106
1598,2391,8,,,,Autocuration,,,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,B,,,,106
1599,2391,8,,,,Autocuration,,,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; full agonist,F,,,,106
1600,14956,8,,449.0,,Expert,,CHO,,,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1B receptor",F,,,,106
1601,2598,8,,449.0,,Autocuration,,CHO,,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line,F,,,,106
1602,2598,8,,449.0,,Autocuration,,CHO,,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Antagonist,F,,,,106
1603,2598,8,,449.0,,Autocuration,,CHO,,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Full Agonist,F,,,,106
1604,2598,8,,449.0,,Autocuration,,CHO,,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Partial Agonist,F,,,,106
1605,14956,8,,,,Expert,,,,,"Efficacy was evaluated relative to human 5-HT1B receptor using [35S]GTP-gamma-S, as radioligand",F,,,,106
1606,14956,8,,,,Autocuration,,,,,"Efficacy of compound was evaluated relative to human 5-hydroxytryptamine 1B receptor using [35S]GTP-gamma-S, as radioligand",F,,,,106
1607,14214,9,,,,Expert,,,,9606.0,Percentage Maximal inhibition obtained with 1 uM 5-HT against 5-hydroxytryptamine 1B receptor,B,,Homo sapiens,,106
1608,3463,8,,449.0,,Expert,,CHO,,,Ability to displace [3H]5-HT from recombinant human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells determined in vitro,B,,,,106
1609,15331,8,,,,Autocuration,,,,,Affinity of compound towards 5-hydroxytryptamine 1B receptor was evaluated using radioligand binding technique,B,,,,106
1610,16146,9,,,,Expert,,,,9606.0,Binding affinity against 5-hydroxytryptamine 1B receptor,B,,Homo sapiens,,106
1611,14159,9,,449.0,,Expert,,CHO,,9606.0,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1B receptor expressed in CHO cells,B,,Homo sapiens,,106
1612,14158,8,,449.0,,Expert,,CHO,,,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells by [3H]5-HT binding displacement.,B,,,,106
1613,14159,8,,,,Autocuration,,,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1B receptor,B,,,,106
1614,15250,8,,449.0,,Expert,,CHO,,,Displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,B,,,,106
1615,15250,8,,449.0,,Expert,,CHO,,,Binding affinity at cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells by [3H]5-HT displacement.,B,,,,106
1616,15331,8,,449.0,,Expert,,CHO,,,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,B,,,,106
1617,15332,8,,449.0,,Expert,,CHO,,,Displacement of [3H]5-HT binding from cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells.,B,,,,106
1618,14956,8,,449.0,,Expert,,CHO,,,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1B receptor expressed in CHO cells,B,,,,106
1619,3805,8,,,,Autocuration,,,,,In vitro binding affinity against human 5-hydroxytryptamine 1B receptor at a concentration of 100 (nM),B,,,,106
1620,14875,8,,,,Autocuration,,,,,Intrinsic activity for each compound is calculated as a percentage of the 5-hydroxytryptamine 1B receptor response,B,,,,106
1621,14454,8,,,,Autocuration,,,,9986.0,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),F,,Oryctolagus cuniculus,,105
1622,14454,8,,,,Expert,,,,9986.0,Tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),F,,Oryctolagus cuniculus,,105
1623,16288,8,,,,Autocuration,,,,,Affinity at 5-hydroxytryptamine 1D receptor (For sumatriptan = Ki (nM)-12+/-1.9),B,,,,105
1624,16288,8,,,,Autocuration,,,,,Affinity at 5-hydroxytryptamine 1D receptor from calf caudate using [3H]5-HT as radioligand (For sumatriptan = Ki(nM)-12+/-1.9),B,,,,105
1625,16312,8,,,,Autocuration,,,,,Binding affinity against calf caudate 5-hydroxytryptamine 1D receptor,B,,,,105
1626,1348,8,,,,Expert,,,,9913.0,Inhibitory activity against 5-hydroxytryptamine 1D receptor subtype,B,,Bos taurus,,105
1627,5834,8,,,,Autocuration,,,,9913.0,Inhibitory concentration required against 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT,B,,Bos taurus,,105
1628,13366,8,,,,Autocuration,2435.0,,Striatum,9913.0,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,B,,Bos taurus,,105
1629,1414,8,,,,Expert,,,,9913.0,Ability to bind to 5-hydroxytryptamine 1D receptor of calf substantia nigra,B,,Bos taurus,,105
1630,14998,8,,,,Autocuration,,,,9913.0,Binding affinity against 5-hydroxytryptamine 1D receptor in calf caudate homogenates.,B,,Bos taurus,,105
1631,11473,8,,,,Autocuration,,,,9913.0,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,B,,Bos taurus,,105
1632,11473,8,,,,Autocuration,,,,9913.0,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,B,,Bos taurus,,105
1633,10639,8,,,,Autocuration,,,,9913.0,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,B,,Bos taurus,,105
1634,10639,8,,,,Autocuration,,,,9913.0,Inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,B,,Bos taurus,,105
1635,1375,8,,,,Autocuration,,,,9913.0,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand,B,,Bos taurus,,105
1636,1375,8,,,,Autocuration,,,,9913.0,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand; NT means not tested,B,,Bos taurus,,105
1637,16532,8,,,,Autocuration,,,,9913.0,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,B,,Bos taurus,,105
1638,11147,8,,,,Autocuration,,,,9913.0,Binding affinity towards 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand,B,,Bos taurus,,105
1639,13366,8,,,,Autocuration,2435.0,,Striatum,9913.0,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,B,,Bos taurus,,105
1640,10444,8,,,,Autocuration,,,,9913.0,Binding affinity was determined against 5-hydroxytryptamine 1D receptor in bovine caudate homogenate,B,,Bos taurus,,105
1641,16532,8,,,,Autocuration,,,,9913.0,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT,B,,Bos taurus,,105
1642,16532,8,,,,Autocuration,,,,9913.0,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,B,,Bos taurus,,105
1643,12827,8,,,,Autocuration,,,,9913.0,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP,B,,Bos taurus,,105
1644,12827,8,,,,Autocuration,,,,9913.0,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP; Not determined,B,,Bos taurus,,105
1645,12919,8,,,,Expert,,,,9913.0,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,F,,Bos taurus,,105
1646,14025,8,,,,Autocuration,,,,9913.0,Affinity pKi for 5-hydroxytryptamine 1D receptor was measured in calf caudate homogenate,B,,Bos taurus,,105
1647,12919,8,,,,Expert,,,,9913.0,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,F,,Bos taurus,,105
1648,12919,8,,,,Expert,,,,9913.0,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,F,,Bos taurus,,105
1649,12919,8,,,,Expert,,,,9913.0,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,F,,Bos taurus,,105
1650,14447,8,,722.0,,Autocuration,,HEK293,,9593.0,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1D receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,B,,Gorilla gorilla,,105
1651,1375,9,,,,Intermediate,,,,10141.0,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra,B,,Cavia porcellus,,105570
1652,1375,9,,,,Intermediate,,,,10141.0,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra; NT means not tested,B,,Cavia porcellus,,105570
1653,12409,9,,,,Intermediate,,,,10141.0,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptor by the agonist GR-46611,F,,Cavia porcellus,,105570
1654,12409,9,,,,Intermediate,,,,10141.0,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,F,,Cavia porcellus,,105570
1655,12409,9,,,,Intermediate,,,,10141.0,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611; range is 2-9,F,,Cavia porcellus,,105570
1656,12409,9,,,,Intermediate,,,,10141.0,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-0.4,F,,Cavia porcellus,,105570
1657,12409,9,,,,Intermediate,,,,10141.0,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-1.2,F,,Cavia porcellus,,105570
1658,11574,9,,,,Intermediate,,,,10141.0,Binding affinity against 5-hydroxytryptamine 1D receptor,B,,Cavia porcellus,,105570
1659,1558,9,,,,Intermediate,,,,10141.0,Binding affinity towards guinea pig 5-hydroxytryptamine 1D receptor was determined,B,,Cavia porcellus,,105570
1660,12409,9,,,,Intermediate,,,,10141.0,Compound at 3 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,F,,Cavia porcellus,,105570
1661,12409,9,,,,Intermediate,,,,10141.0,Compound at 45 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,F,,Cavia porcellus,,105570
1662,12409,9,,,,Intermediate,,,,10141.0,Compound at 50 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,F,,Cavia porcellus,,105570
1663,12409,9,,,,Intermediate,,,,10141.0,Compound at oral dose of 45 mg/kg was tested for percent inhibition against 5-hydroxytryptamine 1D receptor causes hypothermia in guinea pig,F,,Cavia porcellus,,105570
1664,12253,9,,,,Intermediate,,,,10141.0,Binding affinity of 5-hydroxytryptamine 1D receptor using [3H]-8-HT in guinea pig cortex,B,,Cavia porcellus,,105570
1665,12936,9,,,,Intermediate,,,,10141.0,Binding affinity against guinea pig 5-hydroxytryptamine 1D receptor,B,,Cavia porcellus,,105570
1666,13181,8,,,,Autocuration,,,,10141.0,Binding affinity was determined against 5-hydroxytryptamine 4 receptor using [125I]SB 207710 as radioligand from piglet hippocampal membranes,B,,Cavia porcellus,,105
1667,12409,9,,,,Intermediate,2435.0,,Striatum,10141.0,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor in guinea-pig striatum in presence of BMY-7378 and mesulergine,B,,Cavia porcellus,,105570
1668,10639,9,,,,Intermediate,,,,10141.0,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of guinea pig substantia nigra,B,,Cavia porcellus,,105570
1669,5254,8,,,,Autocuration,,,,,Binding affinity against 5-hydroxytryptamine 1D receptor,B,,,,51
1670,13051,8,,,,Autocuration,,,,,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta,B,,,,106
1671,3463,8,,,,Expert,,,,,Maximum stimulation of [35S]GTP gamma-S binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor,F,,,,105
1672,15315,8,,,,Autocuration,,,,,Ability to inhibit forskolin-stimulated adenylate cyclase in a cell line expressing human 5-hydroxytryptamine 1D receptor,F,,,,105
1673,6011,8,,,,Autocuration,,,,,Ability to inhibit forskolin-stimulated adenylate cyclase activity in Chinese hamster ovary (CHO) stable cell lines expressing human 5-hydroxytryptamine 1D receptor,F,,,,105
1674,14159,9,,449.0,,Expert,,CHO,,9606.0,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing 5-hydroxytryptamine 1D receptor",F,,Homo sapiens,,105
1675,14159,8,,449.0,,Autocuration,,CHO,,,"Compound was evaluated for the stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor.",F,,,,105
1676,15250,8,,449.0,,Expert,,CHO,,,Agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,B,,,,105
1677,15250,8,,449.0,,Autocuration,,CHO,,,Compound was tested for measuring agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor,B,,,,105
1678,15331,8,,449.0,,Expert,,CHO,,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",F,,,,105
1679,15332,9,,449.0,,Expert,,CHO,,9606.0,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",F,,Homo sapiens,,105
1680,15332,8,,449.0,,Expert,,CHO,,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the human 5-hydroxytryptamine 1D receptor.",F,,,,105
1681,3294,8,,449.0,,Autocuration,,CHO,,,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor",F,,,,105
1682,14158,8,,449.0,,Expert,,CHO,,,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor.",F,,,,105
1683,14956,8,,449.0,,Expert,,CHO,,,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor",F,,,,105
1684,12469,8,,,,Autocuration,,,,,Compound was evaluated for its agonistic activity on 5-hydroxytryptamine 1D receptor,F,,,,105
1685,3463,8,,449.0,,Expert,,CHO,,,Measurement of agonist-induced [35S]-GTP gamma-S binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,F,,,,105
1686,15250,9,,449.0,,Expert,,CHO,,9606.0,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",F,,Homo sapiens,,105
1687,15250,9,,449.0,,Expert,,CHO,,9606.0,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",F,,Homo sapiens,,105
1688,14956,8,,,,Expert,,,,,"Efficacy was evaluated relative to human 5-hydroxytryptamine 1D receptor using [35S]GTP-gamma-S, as radioligand",F,,,,105
1689,14159,8,,,,Autocuration,,,,,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor.",F,,,,105
1690,14159,9,,,,Expert,,,,9606.0,"Maximum stimulation of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1D receptor relative to 5-HT",F,,Homo sapiens,,105
1691,14499,9,,449.0,,Expert,,CHO,,9606.0,Percent efficacy relative to 5-HT treatment of CHO cells expressing 5-HT 1d receptor,F,,Homo sapiens,,105
1692,15315,8,,,,Autocuration,,,,,Intrinsic activity for 5-hydroxytryptamine 1D receptor,F,,,,105
1693,3294,8,,,,Autocuration,,,,,Ability to displace [3H]- -5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in chinese hamster cells (CHO cells),B,In vitro,,,105
1694,3463,8,,449.0,,Expert,,CHO,,,Ability to displace [3H]-5-HT from recombinant human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells determined in vitro,B,,,,105
1695,15331,8,,,,Autocuration,,,,,Affinity of compound towards 5-hydroxytryptamine 1D receptor was evaluated using radioligand binding technique,B,,,,105
1696,14159,9,,449.0,,Expert,,CHO,,9606.0,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,B,,Homo sapiens,,105
1697,14158,8,,449.0,,Expert,,CHO,,,Binding affinity by displacement to human cloned 5-hydroxytryptamine 1D receptor in CHO cells by [3H]5-HT displacement.,B,,,,105
1698,14159,8,,,,Autocuration,,,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1D receptor,B,,,,105
1699,15250,8,,449.0,,Expert,,CHO,,,Binding affinity at human cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells by [3H]5-HT displacement.,B,,,,105
1700,15250,8,,449.0,,Expert,,CHO,,,Displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,B,,,,105
1701,15331,8,,449.0,,Expert,,CHO,,,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,B,,,,105
1702,15332,9,,449.0,,Expert,,CHO,,9606.0,Displacement of [3H]5-HT binding from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,B,,Homo sapiens,,105
1703,14499,9,,449.0,,Expert,,CHO,,9606.0,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,B,,Homo sapiens,,105
1704,15332,8,,449.0,,Expert,,CHO,,,Displacement of [3H]5-HT binding to the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,B,,,,105
1705,14956,8,,449.0,,Expert,,CHO,,,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor expressed in CHO cells,B,,,,105
1706,3805,8,,,,Autocuration,,,,,In vitro binding affinity against human 5-hydroxytryptamine 1D receptor at a concentration of 100 (nM),B,,,,105
1707,6011,9,,449.0,,Expert,,CHO,,9606.0,Inhibition of [3H]5-HT binding to human 5-hydroxytryptamine 1D receptor expressed in CHO cells at 1 uM,B,,Homo sapiens,,105
1708,16190,8,,449.0,,Autocuration,,CHO,,,Binding affinity against 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,B,,,,105
1709,14165,8,,,,Autocuration,,,,,Binding affinity for 5-hydroxytryptamine 1D receptor in Cos-7 transfected cell type using [3H]5-CT as radioligand,B,,,,105
1710,4234,9,,,,Expert,,,,9606.0,Binding affinity to cloned human 5-hydroxytryptamine 1D receptor,B,,Homo sapiens,,105
1711,15527,8,,,,Autocuration,,,,,"Binding affinity towards 5-HT1D receptor, using [3H]5-HT as radioligand.",B,,,,105
1712,6328,8,,,,Expert,,,,,Binding affinity towards human 5-hydroxytryptamine 1D receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,B,,,,105
1713,16209,8,,,,Autocuration,,,,,Binding affinity towards human 5-hydroxytryptamine 1D receptor was determined using [3H]5-HT as radioligand,B,,,,105
1714,14770,8,,,,Autocuration,,,,,Binding affinity for recombinant human 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand.,B,,,,105
1715,2598,8,,,,Autocuration,,,,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1D receptor using [3H]-5-CT as radioligand,B,,,,105
1716,6897,8,,,,Expert,,,,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1D receptor,B,,,,105
1717,6013,8,,,,Autocuration,,,,,Binding affinity towards 5-hydroxytryptamine 1D receptor,B,,,,105
1718,5843,8,,,,Expert,,,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,B,,,,105
1719,14454,8,,,,Expert,,,,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand,B,,,,105
1720,14454,8,,,,Autocuration,,,,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; Not determined,B,,,,105
1721,14454,8,,,,Autocuration,,,,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; not determined,B,,,,105
1722,15818,8,,,,Autocuration,,,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1D receptor,B,,,,105
1723,13729,8,,485.0,,Expert,,CHO-K1,,,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1D receptor in CHO-K1 cells,F,,,,105
1724,6011,9,,,,Expert,,,,9606.0,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in Chinese hamster ovary cells (CHO cells),B,In vitro,Homo sapiens,,105
1725,4234,9,,,,Expert,,,,9606.0,In vitro binding affinity to human 5-hydroxytryptamine 1D receptor,B,,Homo sapiens,,105
1726,17085,8,,,,Expert,,,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,B,,,,105
1727,3025,8,,,,Autocuration,,,,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,B,,,,105
1728,15315,8,,,,Expert,,,,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor,B,,,,105
1729,14214,9,,,,Expert,,,,9606.0,Receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor in Cos-7 cells,B,,Homo sapiens,,105
1730,3804,9,,,,Expert,,,,9606.0,Binding affinity for human 5-hydroxytryptamine 1D receptor,B,,Homo sapiens,,105
1731,16700,8,,,,Autocuration,,,,,The binding affinity towards the 5-hydroxytryptamine 1D receptor; No affinity,B,,,,105
1732,2391,9,,,,Expert,,,,9606.0,Affinity for 5-hydroxytryptamine 1D receptor subtype,B,,Homo sapiens,,105
1733,4175,9,,,,Expert,,,,9606.0,Binding affinity for human 5-hydroxytryptamine 1D receptor,B,,Homo sapiens,,105
1734,17085,8,,,,Autocuration,,,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,B,,,,105
1735,17085,8,,,,Expert,,,,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor; ND means not determined,B,,,,105
1736,15926,9,,,,Expert,,,,9606.0,Binding activity against human 5-hydroxytryptamine 1D receptor; NT means not tested,B,,Homo sapiens,,105
1737,16312,8,,485.0,,Autocuration,,CHO-K1,,,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; Not tested,B,,,,105
1738,16312,8,,485.0,,Autocuration,,CHO-K1,,,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; not tested,B,,,,105
1739,14956,4,,449.0,,Autocuration,,CHO,,,Selectivity towards 5-HT1D and to that of 5-HT1B in CHO cells,B,,,,104802
1740,3294,8,,,,Autocuration,,,,,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by the 5-HT",F,,,,105
1741,12861,8,,,,Autocuration,,,,,Binding activity radioligand.,B,,,,105
1742,12861,8,,,,Autocuration,,,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,B,,,,105
1743,16312,8,,485.0,,Expert,,CHO-K1,,,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor,B,,,,105
1744,5104,8,,,,Autocuration,,,,,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,B,,,,105
1745,5105,8,,,,Autocuration,,,,,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,B,,,,105
1746,14499,8,,,,Autocuration,,,,,Measured as -log Ka on 5-hydroxytryptamine 1D receptor,B,,,,105
1747,15926,9,,,,Expert,,,,9606.0,Binding activity against human 5-hydroxytryptamine 1D receptor,B,,Homo sapiens,,105
1748,4540,9,,449.0,,Expert,,CHO,,9606.0,Binding affinity to human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,B,,Homo sapiens,,105
1749,15779,8,,449.0,,Autocuration,,CHO,,,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]-5-HT as radioligand.,B,,,,105
1750,15779,8,,449.0,,Autocuration,,CHO,,,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,B,,,,105
1751,6166,8,,,,Autocuration,,,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,B,,,,105
1752,15779,8,,449.0,,Autocuration,,CHO,,,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand.,B,,,,105
1753,15779,8,,449.0,,Autocuration,,CHO,,,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]-5-HT as radioligand.;ND means no data.,B,,,,105
1754,17451,8,,722.0,,Autocuration,,HEK293,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,B,,,,105
1755,17451,8,,722.0,,Autocuration,,HEK293,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,B,,,,105
1756,17451,8,,722.0,,Autocuration,,HEK293,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand; Not determined,B,,,,105
1757,4199,8,,449.0,,Autocuration,,CHO,,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as the radioligand,B,,,,105
1758,14875,9,,,,Expert,,,,9606.0,Binding affinity for human 5-hydroxytryptamine 1D receptor,B,,Homo sapiens,,105
1759,15146,8,,449.0,,Autocuration,,CHO,,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT,B,,,,105
1760,5213,8,,,,Autocuration,,,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1D receptor in CHO using [3H]5-HT as a radioligand,B,,,,105
1761,14818,8,,449.0,,Autocuration,,CHO,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT.,B,,,,105
1762,4829,8,,449.0,,Autocuration,,CHO,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells, using [3H]5-HT as radioligand",B,,,,105
1763,14454,8,,,,Expert,,,,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 1 uM,F,,,,105
1764,14454,8,,,,Expert,,,,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 10 uM,F,,,,105
1765,5254,8,,,,Autocuration,,,,,Binding affinity against 5-HT2C receptor,B,,,,108
1766,5254,8,,,,Autocuration,,,,,Binding affinity against 5-hydroxytryptamine 1D receptor,B,,,,108
1767,10639,8,,,,Autocuration,,,,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,B,,,,10577
1768,10639,8,,,,Autocuration,,,,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,F,,,,10577
1769,12352,8,,,,Expert,,,,,"Binding affinity for 5-hydroxytryptamine 1B receptor in rat cortex, striatum and globus pallidus",B,,,,10577
1770,9098,8,,,,Autocuration,,,,,Binding affinity towards 5-HT1B was determined,B,,,,10577
1771,14430,8,,,,Expert,,,,,Affinity towards 5-hydroxytryptamine 1B receptor in membranes from rat frontal cortex using [3H]5-HT,B,,,,10577
1772,13657,8,,,,Expert,,,,,"Binding affinity to 5-HT1B receptors using rat cortex+striatum + globus pallidus,[3H]-5-OH-tryptamine, and serotonin for NSB",B,,,,10577
1773,13657,8,,,,Autocuration,,,,,"Compound was evaluated for binding affinity on 5-HT1B receptors using rat cortex+striatum+ globus pallidus,[ 3H]-5-OH-tryptamine, and serotonin for NSB.",B,,,,10577
1774,15854,8,,,,Expert,,,,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,B,,,,10577
1775,10639,9,,,,Expert,,,,10116.0,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT,B,,Rattus norvegicus,,10577
1776,10025,8,,,,Autocuration,,,,,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,B,,,,10577
1777,10025,8,,,,Autocuration,,,,,"Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol, binds to 5-hydroxytryptamine 1B receptor at 1 uM",B,,,,10577
1778,14286,8,,,,Autocuration,,,,,In vitro inhibitory concentration against radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,B,,,,10577
1779,3651,8,,,,Autocuration,2435.0,,Striatum,,Inhibition of [3H]-5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Residual radioligand binding higher than 50%,B,,,,10577
1780,14178,9,,,,Expert,,,,10116.0,Inhibition of radiolabeled [3H]-5-HT ligand binding to 5-hydroxytryptamine 1B receptor,B,,Rattus norvegicus,,10577
1781,10639,8,,,,Autocuration,,,,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT as the radioligand.,B,,,,10577
1782,13605,8,,,,Autocuration,2435.0,,Striatum,,Inhibitory activity against [3H]5-HT binding to 5-HT1B receptor in rat striatum,B,,,,10577
1783,5834,8,,,,Autocuration,2435.0,,Striatum,,Inhibitory concentration required against 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT,B,,,,10577
1784,10922,8,,,,Autocuration,2435.0,,Striatum,,compound was measured for affinity against 5-hydroxytryptamine 1B receptor labelled with [3H]5-HT radioligand in striatum tissue,B,,,,10577
1785,14286,8,,,,Autocuration,,,,,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,B,,,,10577
1786,11825,8,,,,Autocuration,,,,,In vitro binding affinity towards the 5-hydroxytryptamine 1B receptor at 10 e-6 M,B,,,,10577
1787,14826,8,,,,Autocuration,2435.0,,Striatum,,Ability to displace [3H]5-HT bound to 5-hydroxytryptamine 1B receptor in rat striatum,B,,,,10577
1788,9699,8,,,,Autocuration,2435.0,,Striatum,,Binding affinity against 5-HT1B serotonin receptor in rat striatum,B,,,,10577
1789,14423,8,,,,Autocuration,,,,,Binding affinity against 5-hydroxytryptamine 1B receptor in membranes of Rat cerebral cortex,B,,,,10577
1790,10062,8,,,,Expert,,,,,Binding affinity at rat 5-hydroxytryptamine 1B receptor by [3H]5-HT displacement.,B,,,,10577
1791,10062,8,,,,Autocuration,,,,,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,B,,,,10577
1792,12280,9,,,,Expert,,,,10116.0,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor,B,,Rattus norvegicus,,10577
1793,15412,8,,,,Autocuration,2435.0,,Striatum,,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum,B,,,,10577
1794,15412,8,,,,Autocuration,2435.0,,Striatum,,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum.,B,,,,10577
1795,10062,8,,,,Autocuration,,,,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,B,,,,10577
1796,11147,8,,,,Autocuration,,,,,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,B,,,,10577
1797,9547,8,,,,Autocuration,,,,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat was determined using 50 uL of [125I]ICYP in binding assay,B,,,,10577
1798,10444,8,,,,Autocuration,,,,,Binding affinity was determined against 5-hydroxytryptamine 1B receptor was determined in male Sprague-Dawley rat brain.,B,,,,10577
1799,12469,8,,,,Autocuration,2435.0,,Striatum,,Binding affinity was measured on 5-hydroxytryptamine 1B receptor in rat striatum labeled with [3H]5-HT,B,,,,10577
1800,9098,8,,,,Expert,,,,,Binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand.,B,,,,10577
1801,9098,8,,,,Autocuration,,,,,Compound was evaluated for the binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand; ND is no data.,B,,,,10577
1802,9699,8,,,,Autocuration,,,,,Evaluated for binding affinity towards 5-hydroxytryptamine 1B receptor,B,,,,10577
1803,10394,8,,,,Autocuration,,,,,Inhibitory activity against 5-hydroxytryptamine 1B receptor in rat cortical membranes using [3H]5-HT as a radioligand,B,,,,10577
1804,12092,8,,,,Autocuration,,,,,The binding affinity was measured on 5-hydroxytryptamine 1B receptor using [3H]- serotonin as radioligand.,B,,,,10577
1805,16700,8,,,,Autocuration,,,,,The binding affinity towards the receptor rat 5-hydroxytryptamine 1B receptor; No affinity,B,,,,10577
1806,403,9,,,,Expert,,,,10116.0,Binding affinity against 5-hydroxytryptamine 1B receptor in rat striatal membranes using [3H]5-HT as radioligand,B,,Rattus norvegicus,,10577
1807,12771,9,,,,Expert,,,,10116.0,Binding affinity towards 5-hydroxytryptamine 1B receptor,B,,Rattus norvegicus,,10577
1808,11642,8,,,,Autocuration,,,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1B receptor by displacing [3H]serotonin radioligand in rat cerebral cortex,B,,,,10577
1809,12953,8,,,,Autocuration,,,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand,B,,,,10577
1810,12953,8,,,,Autocuration,,,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand.,B,,,,10577
1811,12953,8,,,,Expert,2435.0,,Striatum,,Binding affinity for 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT as radioligand,B,,,,10577
1812,12953,8,,,,Autocuration,,,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand; Nonactive at 10 uM,B,,,,10577
1813,9737,8,,,,Autocuration,955.0,,Brain,,Binding affinity against 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,B,,,,10577
1814,9737,8,,,,Autocuration,,,,,Binding affinity against 5-HT1B receptor in rat frontal cortex using [3H]-5-HT in presence of 0.1 uM [3H]-8-OH-DPAT as a radioligand,B,,,,10577
1815,9737,8,,,,Autocuration,955.0,,Brain,,Binding affinity towards 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,B,,,,10577
1816,12827,8,,,,Autocuration,,,,,Binding affinity towards 5-hydroxytryptamine 2C receptor of porcine choroid plexus using [3H]mesulergine,B,,,,10577
1817,5033,8,,,,Autocuration,,,,,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-hydroxytryptamine 1B receptor,B,,,,10577
1818,9786,9,,,,Expert,,,,10116.0,Displacement of [3H]5-HT from 5-HT1B receptor of rat frontal cortex homogenate,B,,Rattus norvegicus,,10577
1819,13116,8,,,,Expert,,,,,Binding affinity at 5-hydroxytryptamine 1B receptor,B,,,,10577
1820,16429,8,,,,Autocuration,,,,,In vitro binding affinity at 5-hydroxytryptamine 1B receptor in rat striatal muscles using [125I](-)-iodocyanopindolol as the radioligand,B,,,,10577
1821,12409,9,,,,Expert,,,,10116.0,In vitro binding affinity towards 5-hydroxytryptamine 1B receptor in rat striatal membrane with [125I]- iodocyanopindolol,B,,Rattus norvegicus,,10577
1822,15194,8,,,,Autocuration,,,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,B,,,,10577
1823,15194,8,,,,Autocuration,,,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,B,,,,10577
1824,5486,4,,,,Autocuration,,,,,Binding affinity towards 5-HT2 receptor by the displacement of [3H]-ketanserin] in rat cerebral cortex,B,,,,104686
1825,4639,8,,,,Autocuration,,,,,Compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,B,,,,106
1826,386,8,,,,Autocuration,,,,,The compound was evaluated for its ability to displace [3H]5-HT from 5-hydroxytryptamine 1B receptor in cellular brain membranes,B,,,Brain membranes,106
1827,2474,8,,,,Autocuration,,,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1B receptor at a concentration of 100 nM using [125I]CYP as radioligand,B,,,,106
1828,6011,8,,,,Autocuration,,,,,Inhibition of binding towards 5-hydroxytryptamine 1B receptor at 100 nM concentration,B,,,,106
1829,5014,8,,,,Autocuration,,,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1B receptor,B,,,,106
1830,17515,8,,,,Autocuration,,,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1B receptor; inactive at 10 uM,B,,,,106
1831,4373,8,,,,Autocuration,,,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1B receptor was determined,B,,,,106
1832,1633,8,,,,Expert,,,,,Binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]5-HT.,B,,,,106
1833,1633,8,,,,Autocuration,,,,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]ketanserin.,B,,,,106
1834,4373,8,,,,Autocuration,,,,,Binding affinity for 5-hydroxytryptamine 1B receptor was determined,B,,,,106
1835,4687,8,,,,Autocuration,,,,,Evaluated for the binding affinity to 5-hydroxytryptamine 1B receptor,B,,,,106
1836,11574,8,,,,Autocuration,,,,,Binding affinity against 5-hydroxytryptamine 1B receptor,B,,,,106
1837,10321,8,,,,Autocuration,,,,,Binding affinity for 5-hydroxytryptamine 1B receptor was determined by using [3H]5-HT as radioligand,B,,,,106
1838,15527,8,,,,Autocuration,,,,,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,B,,,,106
1839,17200,8,,,,Autocuration,,,,,Inhibitory constant against 5-hydroxytryptamine 1B receptor using with [125I]- cyanopindolol radioligand,B,,,,106
1840,14423,4,,,,Autocuration,,,,,Binding affinity against 5-hydroxytryptamine 1B receptor - 5-hydroxytryptamine 1D receptor using [3H]5-HT as the radioligand.,B,,,,104802
1841,5834,8,,,,Autocuration,,,,9913.0,Inhibitory concentration required against 5-hydroxytryptamine 1C receptor in bovine choroid plexus using [3H]mesulergine,B,,Bos taurus,,108
1842,11473,8,,,,Autocuration,,,,9823.0,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,B,,Sus scrofa,,108
1843,11473,8,,,,Autocuration,,,,9823.0,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1C receptor in pig choroid plexus using [3H]mesulergine as radioligand,B,,Sus scrofa,,108
1844,10639,8,,,,Autocuration,,,,9823.0,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,B,,Sus scrofa,,108
1845,10639,8,,,,Autocuration,,,,9823.0,inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,B,,Sus scrofa,,108
1846,14331,8,,,,Autocuration,,,,9823.0,Binding affinity of compound towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine (1.2 nM) ligand in choroid Plexus pig was determined,B,,Sus scrofa,,108
1847,10796,8,,,,Autocuration,,,,9823.0,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1C receptor,B,,Sus scrofa,,108
1848,9098,8,,,,Expert,,,,9823.0,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 2C receptor binding site by using [3H]-MES as a radioligand.,B,,Sus scrofa,,108
1849,14331,8,,,,Expert,,,,9823.0,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 1C receptor of pig choroid Plexus,B,,Sus scrofa,,108
1850,11828,8,,,,Expert,,,,9823.0,Displacement of [3H]mesulergine from pig cortex 5-hydroxytryptamine 1C receptor,B,,Sus scrofa,,108
1851,11866,8,,,,Autocuration,,,,9823.0,Binding affinity for 5-hydroxytryptamine 1C receptor in piglet choroid plexus using [3H]5-HT,B,,Sus scrofa,,108
1852,13047,8,,,,Autocuration,,,,9986.0,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,B,,Oryctolagus cuniculus,,108
1853,188,9,,,,Autocuration,,,,10116.0,Tested for the effect on binding at 5-hydroxytryptamine 1C receptor; No activity,B,,Rattus norvegicus,,12689
1854,11825,9,,,,Autocuration,,,,10116.0,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,B,,Rattus norvegicus,,12689
1855,11825,9,,,,Autocuration,,,,10116.0,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,B,,Rattus norvegicus,,12689
1856,11624,9,,,,Expert,,,,10116.0,Binding affinity against 5-hydroxytryptamine 1C receptor in rat using [3H]mesulergine as radioligand,B,,Rattus norvegicus,,12689
1857,11139,9,,,,Autocuration,,,,10116.0,Binding affinity towards 5-hydroxytryptamine 1C receptor using [125 I]-SCH23982 as radioligand in competitive binding assay,B,,Rattus norvegicus,,12689
1858,11147,9,,,,Autocuration,,,,10116.0,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,B,,Rattus norvegicus,,12689
1859,10444,9,,,,Autocuration,,,,10116.0,Binding affinity was determined against 5-hydroxytryptamine 1C receptor was determined in male Sprague-Dawley rat brain.,B,,Rattus norvegicus,,12689
1860,11624,9,,,,Expert,,,,10116.0,Binding affinity against 5-hydroxytryptamine 1C receptor,B,,Rattus norvegicus,,12689
1861,11662,9,,,,Autocuration,,,,10116.0,"Compound was tested for binding affinity towards 5-HT1C (5-HT1C) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",B,,Rattus norvegicus,,12689
1862,11662,9,,,,Autocuration,,,,10116.0,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",B,,Rattus norvegicus,,12689
1863,11662,9,,,,Expert,,,,10116.0,"Binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",B,,Rattus norvegicus,,12689
1864,11662,9,,,,Autocuration,,,,10116.0,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",B,,Rattus norvegicus,,12689
1865,9098,9,,,,Autocuration,,,,10116.0,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 1C receptor binding site by using [3H]- MES as a radioligand.,B,,Rattus norvegicus,,12689
1866,10394,9,,,,Autocuration,,,,10116.0,Inhibitory activity against 5-hydroxytryptamine 1C receptor in rat cortical membranes using [3H]mesulergine as a radioligand,B,,Rattus norvegicus,,12689
1867,11933,8,,,,Expert,,,,,Tested for binding affinity against 5-hydroxytryptamine 1C receptor from rat frontal cortical regions using [3H]mesulergine as radioligand,B,,,,12689
1868,12092,9,,,,Autocuration,,,,10116.0,The binding affinity was measured on 5-hydroxytryptamine 1C receptor using [3H]- serotonin as radioligand.,B,,Rattus norvegicus,,12689
1869,12253,9,,,,Autocuration,,,,10116.0,Binding affinity of 5-hydroxytryptamine 1C receptor using [3H]- ketanserin in rat frontal cortex,B,,Rattus norvegicus,,12689
1870,12253,9,,722.0,,Autocuration,,HEK293,,10116.0,Binding affinity towards rat 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand expressed in 293 cells,B,,Rattus norvegicus,,12689
1871,1558,8,,,,Autocuration,,,,,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,B,,,,108
1872,2474,8,,,,Autocuration,,,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,B,,,,108
1873,2474,8,,,,Autocuration,,,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,B,,,,108
1874,11574,8,,,,Autocuration,,,,,Binding affinity against 5-hydroxytryptamine 1C receptor,B,,,,12689
1875,1558,8,,,,Autocuration,,,,,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,B,,,,12689
1876,13944,8,,,,Autocuration,,,,,Binding affinity against 5-hydroxytryptamine 1C receptor,B,,,,12689
1877,13033,8,,,,Autocuration,,,,,Binding affinity against serotonergic 5-HT1c receptor,B,,,,12689
1878,10321,8,,,,Autocuration,,,,,Binding affinity for 5-hydroxytryptamine 1C receptor was determined by using [3H]- mesulergine as radioligand,B,,,,12689
1879,11866,8,,,,Autocuration,,,,,Binding affinity for 5-hydroxytryptamine 1C receptor was determined,B,,,,12689
1880,14454,8,,,,Autocuration,,,,9986.0,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),B,,Oryctolagus cuniculus,,105
1881,11574,4,,,,Autocuration,,,,,Binding affinity against 5-hydroxytryptamine 2 receptor using [125I]DOI as radioligand.,B,,,,104686
1882,11574,4,,,,Autocuration,,,,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ket as radioligand.,B,,,,104686
1883,13631,4,,,,Autocuration,,,,,Binding affinity towards serotonin 5-HT2 receptor was determined in rat cortex using [3H]spiperone as ligand,B,,,,104686
1884,9630,5,,,,Autocuration,,,,10116.0,Binding affinity towards 5-hydroxytryptamine 2 receptor as antagonism of serotonin-induced contractions in rat jugular vein,B,,Rattus norvegicus,,104686
1885,8822,5,,,,Autocuration,,,,10116.0,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain cortical membranes,B,,Rattus norvegicus,,104686
1886,9064,5,,,,Autocuration,955.0,,Brain,10116.0,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain using [3H]spiroperidol,B,,Rattus norvegicus,,104686
1887,8868,4,,,,Autocuration,,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor measured using radioligand ([3H]spiperone) binding assay,B,,,,104686
1888,9064,4,,,,Autocuration,,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- spiroperidol,B,,,,104686
1889,9806,4,,,,Autocuration,,,,,Binding affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenates by [3H]-spiperone displacement.,B,,,,104686
1890,9098,4,,,,Autocuration,,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,B,,,,104686
1891,8868,4,,,,Autocuration,,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor was measured using radioligand ([3H]spiperone) binding assay,B,,,,104686
1892,12765,4,,,,Autocuration,,,,,Binding affinity at serotonin 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,B,,,,104686
1893,11049,4,,,,Autocuration,,,,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,B,,,,104686
1894,11049,4,,,,Autocuration,,,,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,B,,,,104686
1895,11049,4,,,,Autocuration,,,,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]-Ketanserin as radioligand; not determined,B,,,,104686
1896,11049,4,,,,Autocuration,,,,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand; ND-Not determined,B,,,,104686
1897,11049,4,,,,Autocuration,,,,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,B,,,,104686
1898,11473,4,,,,Autocuration,,,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [125I]DOI as radioligand,B,,,,104686
1899,11473,4,,,,Autocuration,,,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [3H]ketanserin as radioligand,B,,,,104686
1900,3086,4,,,,Autocuration,,,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat pre frontal cortex,B,,,,104686
1901,11049,4,,,,Autocuration,,,,,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,B,,,,104686
1902,11049,4,,,,Autocuration,,,,,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,B,,,,104686
1903,10639,4,,,,Autocuration,,,,,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 2 receptor of rat anterior cortex using [3H]ketanserin as the radioligand,B,,,,104686
1904,10922,4,,,,Autocuration,,,,,Compound was measured for affinity at 5-hydroxytryptamine 2 receptor in rat cortical by [3H]spiroperidol displacement.,B,,,,104686
1905,9064,5,,,,Autocuration,955.0,,Brain,10116.0,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,B,,Rattus norvegicus,,104686
1906,10748,4,,,,Autocuration,955.0,,Brain,,Compound was tested for its inhibitory effect on the binding profile in 5-hydroxytryptamine 2 receptor using [3H]spiroperidol in rat brain.,B,,,,104686
1907,11614,4,,,,Autocuration,,,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor from rat cortical membranes.,B,,,Membranes,104686
1908,11615,4,,,,Autocuration,,,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,B,,,Membranes,104686
1909,11615,4,,,,Autocuration,,,,,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor,B,,,,104686
1910,11614,4,,,,Autocuration,,,,,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor from rat cortical membranes.,B,,,Membranes,104686
1911,11702,4,,,,Autocuration,,,,,Inhibition of [3H]ketanserin binding to rat 5-hydroxytryptamine 2 receptors.,B,,,,104686
1912,11702,4,,,,Autocuration,,,,,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor; NT=Not tested,B,,,,104686
1913,11702,5,,,,Autocuration,,,,10116.0,Inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor,B,,Rattus norvegicus,,104686
1914,11702,4,,,,Autocuration,,,,,Compound was tested for the inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor; NT=Not tested,B,,,,104686
1915,13346,4,,,,Autocuration,,,,,Inhibition of [3H]ketanserin binding at 5-hydroxytryptamine 2 receptor from rat frontal cortex.,B,,,,104686
1916,10025,4,,,,Autocuration,,,,,Concentration necessary to achieve half maximal inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor,B,,,,104686
1917,10025,4,,,,Autocuration,,,,,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,B,,,,104686
1918,10025,4,,,,Autocuration,,,,,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",B,,,,104686
1919,9036,4,,,,Autocuration,,,,,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]-spiperone,B,,,,104686
1920,9036,4,,,,Autocuration,,,,,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]spiperone; IA=Inactive,B,,,,104686
1921,9161,4,,,,Autocuration,,,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.,B,,,,104686
1922,12304,4,,,,Autocuration,,,,,Inhibition of binding of radioligand [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cerebral cortex,B,,,,104686
1923,13276,4,,,,Autocuration,,,,,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand.,B,,,,104686
1924,11825,4,,,,Autocuration,,,,,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,B,,,,104686
1925,12443,4,,,,Autocuration,,,,,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 2 receptor by displacement of [3H]- ketanserin,B,,,,104686
1926,13830,4,,,,Autocuration,,,,,In vitro inhibitory activity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor,B,,,,104686
1927,9592,4,,,,Autocuration,,,,,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes,B,,,Membranes,104686
1928,9592,4,,,,Autocuration,,,,,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes; Not tested,B,,,Membranes,104686
1929,10881,4,,,,Autocuration,,,,,Inhibitory activity against 5-hydroxytryptamine 2 receptor by 3H ligand binding experiments.,B,,,,104686
1930,13605,4,,,,Autocuration,,,,,Inhibitory activity against [3H]spiroperidol binding to 5-HT2 receptor in rat cortex,B,,,,104686
1931,11624,5,,,,Autocuration,,,,10116.0,Inhibitory activity against 5-hydroxytryptamine 2 receptor,B,,Rattus norvegicus,,104686
1932,4101,4,,,,Autocuration,,,,,Inhibitory concentration against 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,B,,,,104686
1933,4101,4,,,,Autocuration,,,,,Inhibitory concentration against binding of 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,B,,,,104686
1934,15360,4,,,,Autocuration,,,,,Inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat,B,,,,104686
1935,11576,4,,,,Autocuration,,,,,Inhibitory concentration against radioligand [3H]spiperone binding to 5-hydroxytryptamine 2 receptor in rat cortex,B,,,,104686
1936,5834,4,,,,Autocuration,,,,,Inhibitory concentration required against 5-hydroxytryptamine 2 receptor in rat cortex using [3H]spiperone,B,,,,104686
1937,2395,5,,485.0,,Autocuration,,CHO-K1,,10116.0,Inhibitory concentration against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,B,,Rattus norvegicus,,104686
1938,11965,4,,,,Autocuration,,,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,B,,,Membranes,104686
1939,3967,4,,,,Autocuration,,,,,The compound was evaluated for the ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor ( striata of male wistar rats),B,,,,104686
1940,11130,4,,,,Autocuration,,,,,The concentration required to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat brain membranes (in vitro),B,,,Brain membranes,104686
1941,13427,4,,,,Autocuration,,,,,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,B,In vitro,,,104686
1942,9443,4,,,,Autocuration,,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor,B,,,,104686
1943,9443,4,,,,Autocuration,,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,B,,,,104686
1944,11825,4,,,,Autocuration,,,,,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,B,,,,104686
1945,12120,4,,,,Autocuration,,,,,Percent inhibition of binding of 1.0 nM [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e -5 M,B,,,Membranes,104686
1946,12120,4,,,,Autocuration,,,,,Percent inhibition of binding of 1.0 nM [3H]-ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e-5 M.,B,,,Membranes,104686
1947,11963,4,,,,Autocuration,1515.0,,Thoracic aorta,,Tested for antagonistic activity against 5-hydroxytryptamine 2 receptor from rat thoracic aorta,F,,,,104686
1948,9069,4,,,,Autocuration,,,,,Binding affinity for membrane-bound 5-hydroxytryptamine 2 receptor,B,,,,104686
1949,8868,4,,,,Autocuration,,,,,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,B,,,,104686
1950,17200,8,,,,Autocuration,,,,,Inhibitory constant against human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,B,,,,10624
1951,17200,8,,,,Autocuration,,,,,Inhibitory constant against human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,B,,,,10624
1952,13969,8,,,,Expert,,,,,Binding affinity against 5-hydroxytryptamine 1D receptor was measured using [3H]5-HT as radioligand,B,,,,17106
1953,13392,9,,,,Expert,,,,,Binding affinity for 5-hydroxytryptamine 1D receptor,B,,,,17106
1954,1742,8,,,,Autocuration,,,,,Compound was tested for its ability to displace [125I]GTI binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,B,,,,17106
1955,1742,8,,,,Autocuration,,,,,Compound was tested for its ability to displace [3H]-5-HT binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,B,,,,17106
1956,14331,8,,,,Autocuration,2435.0,,Striatum,,Binding affinity against 5-hydroxytryptamine 1D receptor using [3H]5-HT in pig striatum + frontalCortex,B,,,,17106
1957,12861,8,,,,Autocuration,,,,,Relative agonist efficacy against 1 uM 5-hydroxytryptamine 1D receptor,F,,,,17106
1958,12861,8,,,,Expert,,,,,Binding activity against 5-hydroxytryptamine 1D receptor from pig caudate membrane using [3H]5-HT as radioligand,B,,,,17106
1959,12861,8,,,,Autocuration,,,,,Binding activity radioligand.,B,,,,17106
1960,12861,8,,,,Autocuration,,,,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,B,,,,17106
1961,12861,8,,,,Expert,,,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,B,,,,17106
1962,12861,8,,,,Autocuration,,,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,B,,,,17106
1963,675,8,,,,Autocuration,,,,,Compound was tested for the displacement of [3H]-5-HT to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,B,,,,17106
1964,12490,8,,,,Expert,,,,,Displacement of [3H]5-HT binding to 5-hydroxytryptamine 1D receptor from pig caudate membrane,B,,,,17106
1965,11828,8,,,,Expert,,,,,Displacement of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1D receptor in pig caudate membrane,B,,,,17106
1966,11866,8,,,,Autocuration,,,,,Binding affinity for 5-hydroxytryptamine 1D receptor in piglet caudate using [3H]5-HT,B,,,,17106
1967,773,8,,,,Autocuration,,,,9823.0,In Vitro Binding affinity againist 5-hydroxytryptamine 1D receptor by displacing [125I]GTI from pig caudate,B,,Sus scrofa,,105
1968,13047,8,,,,Expert,,,,9986.0,The compound was tested for intrinsic activity against 5-HT1D receptor,B,,Oryctolagus cuniculus,,105
1969,13047,8,,,,Autocuration,,,,9986.0,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,B,,Oryctolagus cuniculus,,105
1970,13047,8,,,,Expert,,,,9986.0,The compound was tested for binding affinity against 5-HT1D receptor,B,,Oryctolagus cuniculus,,105
1971,188,8,,,,Autocuration,,,,,Tested for the effect on binding at 5-hydroxytryptamine 1D receptor; No activity,B,,,,10578
1972,10639,8,,,,Autocuration,,,,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of rat substantia nigra,F,,,,10578
1973,12438,8,,,,Autocuration,,,,,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor,F,,,,10578
1974,12438,8,,,,Autocuration,,,,,Binding affinity was measured against serotonin 5-hydroxytryptamine 1D receptor,B,,,,10578
1975,15854,8,,,,Expert,,,,,Binding affinity towards 5-hydroxytryptamine 1D receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,B,,,,10578
1976,10394,8,,,,Autocuration,,,,,Inhibitory activity against 5-hydroxytryptamine 1D receptor in rat cortical membranes using [3H]5-HT as a radioligand,B,,,,10578
1977,12092,8,,,,Autocuration,,,,,The binding affinity was measured on 5-hydroxytryptamine 1D receptor using [3H]- serotonin as radioligand.,B,,,,10578
1978,3389,8,,,,Expert,,,,,Binding affinity to 5-hydroxytryptamine 1D receptor in the rat forebrain by [3H]- SB-204269 displacement.,B,,,,10578
1979,6011,8,,,,Autocuration,,,,,Inhibition of binding towards 5-hydroxytryptamine 1D receptor at 100 nM concentration,B,,,,105
1980,4639,8,,,,Autocuration,,,,,Compound was tested for binding affinity against 5-hydroxytryptamine 1D receptor,B,,,,105
1981,2474,8,,,,Autocuration,,,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1D receptor at a concentration of 10 uM using [3H]5-HT as radioligand,B,,,,105
1982,5014,8,,,,Autocuration,,,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1D receptor,B,,,,105
1983,17515,8,,,,Autocuration,,,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1D receptor; inactive at 10 uM,B,,,,105
1984,11866,8,,,,Autocuration,,,,,Binding affinity for 5-hydroxytryptamine 1D receptor was determined,B,,,,105
1985,4687,8,,,,Autocuration,,,,,Evaluated for the binding affinity against 5-hydroxytryptamine 1D receptor,B,,,,105
1986,12146,8,,,,Autocuration,,,,,Tested against 5-hydroxytryptamine 1D receptor,B,,,,105
1987,10321,8,,,,Autocuration,,,,,Binding affinity for 5-hydroxytryptamine 1D receptor was determined by using [3H]5-HT as radioligand,B,,,,105
1988,13267,8,,722.0,,Autocuration,,HEK293,,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,B,,,,105
1989,1274,9,,,,Expert,,,,9606.0,Binding affinity against 5-Hydroxytryptamine 1D receptor,B,,Homo sapiens,,105
1990,15250,8,,,,Autocuration,,,,,,B,,,,105
1991,13706,8,,485.0,,Autocuration,,CHO-K1,,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,B,,,,106
1992,13706,8,,485.0,,Autocuration,,CHO-K1,,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,B,,,,105
1993,13706,8,,722.0,,Autocuration,,HEK293,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line.,B,,,,105
1994,13706,8,,722.0,,Autocuration,,HEK293,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,B,,,,105
1995,13047,8,,,,Autocuration,,,,,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,B,,,,105
1996,13366,8,,,,Autocuration,,,,,Binding affinity of compound against 5-HT1Dalpha Binding affinity of compound against 5-HT1D alpha receptors in human,B,,,,105
1997,13366,8,,,,Expert,,,,,In vitro affinity human cloned 5-hydroxytryptamine 1D receptor alpha by [3H]5-HT displacement.,B,,,,105
1998,1558,8,,,,Autocuration,,,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor alpha was determined,B,,,,105
1999,12902,8,,485.0,,Expert,,CHO-K1,,,"Binding affinity against 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells, using [3H]-5-HT as the radioligand.",B,,,,105
2000,13706,8,,485.0,,Autocuration,,CHO-K1,,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,B,,,,105
2001,13706,8,,,,Autocuration,,,,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor alpha measured as the reduction of forskolin-stimulated cAMP.,F,,,,105
2002,13706,8,,,,Autocuration,,,,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,F,,,,105
2003,14251,8,,,,Autocuration,,,,,Compound was tested for its agonist activity against human 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,F,,,,105
2004,14251,8,,,,Autocuration,,,,,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,F,,,,105
2005,14251,8,,,,Autocuration,,,,,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,F,,,,105
2006,13313,8,,,,Autocuration,,,,,In vitro binding affinity towards 5-HT1D alpha receptor by using [3H]5-HT as radioligand,B,,,,105
2007,13313,8,,,,Autocuration,,,,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]5-HT as radioligand,B,,,,105
2008,13366,8,,,,Autocuration,,,,,Selectivity towards 5-hydroxytryptamine 1D receptor beta to that of 5-hydroxytryptamine 1D receptor alpha,B,,,,105
2009,13051,8,,,,Expert,,,,,Binding affinity to recombinant human 5-hydroxytryptamine 1D receptor alpha,B,,,,105
2010,12903,8,,449.0,,Expert,,CHO,,,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor alpha expressed in CHO cells, by using [3H]5-HT as radioligand",B,,,,105
2011,12469,9,,,,Autocuration,,,,9606.0,Binding affinity was measured on 5-hydroxytryptamine 1D receptor alpha in COS cells transfected with human 5-HT1D alpha gene labeled with [3H]5-HT,B,,Homo sapiens,,105
2012,5619,8,,,,Autocuration,,,,,Binding affinity (in vitro) against 5-hydroxytryptamine 1D receptor alpha using radio-ligand binding assay,B,,,,17106
2013,13047,8,,,,Autocuration,,,,9986.0,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,B,,Oryctolagus cuniculus,,105
2014,16633,8,,,,Autocuration,,,,,Binding affinities against 5-hydroxytryptamine 1D receptor alpha,B,,,,105
2015,16633,8,,,,Autocuration,,,,,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,B,,,,105
2016,16633,8,,,,Autocuration,,,,,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,B,,,,105
2017,16633,8,,,,Autocuration,,,,,Binding affinity towards 5-hydroxytryptamine 1D receptor alpha using [3H]8-OH-DPAT as radioligand,B,,,,105
2018,3269,8,,,,Autocuration,,,,,Affinity against 5-hydroxytryptamine 1D receptor alpha,B,,,,105
2019,12409,8,,,,Expert,,,,,Binding affinity against 5-hydroxytryptamine 1D receptor alpha,B,,,,105
2020,13706,8,,,,Autocuration,,,,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,F,,,,106
2021,13706,8,,722.0,,Autocuration,,HEK293,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line.,B,,,,106
2022,13706,8,,722.0,,Autocuration,,HEK293,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,B,,,,106
2023,12903,8,,449.0,,Autocuration,,CHO,,,"The compound was tested in vitro for binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",B,,,,106
2024,13047,8,,,,Autocuration,,,,,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,B,,,,106
2025,13366,9,,,,Expert,,,,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,B,,,,106
2026,13366,9,,,,Expert,,,,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,B,,,,106
2027,13366,9,,,,Expert,,,,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,B,,,,106
2028,13366,8,,,,Autocuration,,,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined using [3H]8-OH-DPAT as radioligand,B,,,,106
2029,13366,8,,,,Autocuration,,,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor was determined using [3H]8-OH-DPAT as radioligand,B,,,,106
2030,12469,8,,449.0,,Autocuration,,CHO,,,Binding affinity was measured on 5-hydroxytryptamine 1D receptor beta in CHO cells transfected with human 5-HT1D beta gene labeled with [3H]5-HT,B,,,,106
2031,13706,8,,485.0,,Autocuration,,CHO-K1,,,Compound was tested for binding affinity against cloned human 5-HT1D beta receptor expressed in CHO-K1 cells.,B,,,,106
2032,13706,8,,485.0,,Autocuration,,CHO-K1,,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells.,B,,,,106
2033,13706,8,,,,Autocuration,,,,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,F,,,,106
2034,12902,8,,485.0,,Expert,,CHO-K1,,,"Binding affinity against 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells, using [3H]5-HT as the radioligand.",B,,,,106
2035,13051,8,,,,Expert,,,,,Binding affinity for cloned human 5-hydroxytryptamine 1D receptor beta,B,,,,105
2036,12903,8,,449.0,,Expert,,CHO,,,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",B,,,,106
2037,1558,8,,485.0,,Autocuration,,CHO-K1,,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.24-0.55,F,,,,105
2038,1558,8,,485.0,,Autocuration,,CHO-K1,,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.6-2.0,F,,,,105
2039,1558,8,,485.0,,Autocuration,,CHO-K1,,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 2.8-6.5,F,,,,105
2040,1558,8,,485.0,,Autocuration,,CHO-K1,,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 30-70,F,,,,105
2041,1558,8,,,,Autocuration,,,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined,B,,,,105
2042,13047,8,,,,Autocuration,,,,9986.0,Binding affinity against 5-hydroxytryptamine 3 receptor using rabbit saphenous vein assay.,B,,Oryctolagus cuniculus,,106
2043,13313,8,,,,Autocuration,,,,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]-5-HT as radioligand,B,,,,105
2044,13313,8,,,,Autocuration,,,,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor beta by using [3H]5-HT as radioligand,B,,,,105
2045,12409,8,,,,Expert,,,,,Binding affinity against 5-hydroxytryptamine 1D receptor beta,B,,,,105
2046,15250,8,,449.0,,Autocuration,,CHO,,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1E receptor stably expressed in CHO cells,B,,,,10618
2047,1348,9,,,,Expert,,,,9606.0,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype,B,,Homo sapiens,,10618
2048,1348,8,,,,Autocuration,,,,,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype; NA denotes data not available,B,,,,10618
2049,4234,9,,,,Expert,,,,9606.0,Binding affinity to cloned human 5-hydroxytryptamine 1E receptor,B,,Homo sapiens,,10618
2050,16209,8,,,,Autocuration,,,,,Binding affinity towards human 5-hydroxytryptamine 1E receptor was determined using [3H]5-HT as radioligand,B,,,,10618
2051,10444,8,,,,Autocuration,,,,,Binding affinity was determined against 5-hydroxytryptamine 1E receptor in human cortical homogenate,B,,,,10618
2052,3935,8,,,,Autocuration,,,,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1E receptor,B,,,,10618
2053,15818,8,,,,Autocuration,,,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1E receptor,B,,,,10618
2054,17085,8,,,,Autocuration,,,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1E receptor,B,,,,10618
2055,12936,9,,449.0,,Expert,,CHO,,9606.0,Binding affinity against human 5-hydroxytryptamine 1E receptor expressed in CHO cells,B,,Homo sapiens,,10618
2056,6166,8,,,,Autocuration,,,,,Binding affinity towards cloned human 5-hydroxytryptamine 1E receptor was determined,B,,,,10618
2057,15779,8,,449.0,,Autocuration,,CHO,,,Binding affinity towards 5-hydroxytryptamine 1E receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,B,,,,10618
2058,15779,8,,449.0,,Autocuration,,CHO,,,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand.,B,,,,10618
2059,15779,8,,449.0,,Autocuration,,CHO,,,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand;ND means no data.,B,,,,10618
2060,13181,8,,,,Autocuration,,,,,Binding affinity was determined against 5-hydroxytryptamine 1D receptor,B,,,,10618
2061,4199,8,,449.0,,Autocuration,,CHO,,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as the radioligand,B,,,,10618
2062,14875,8,,,,Autocuration,,,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1E receptor,B,,,,10618
2063,15146,8,,449.0,,Autocuration,,CHO,,,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]-5-HT,B,,,,10618
2064,5213,8,,,,Autocuration,,,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1E receptor in CHO using [3H]5-HT as a radioligand,B,,,,10618
2065,12146,8,,,,Autocuration,,,,,Tested for binding affinity towards cloned human 5-hydroxytryptamine 1E receptor using [3H]5-HT as radioligand,B,,,,10618
2066,13267,8,,449.0,,Autocuration,,CHO,,,The binding affinity (pKi) measured against 5-hydroxytryptamine 1E receptor (cloned human receptors in CHO cells) using [3H]5-HT1E as radioligand,B,,,,10618
2067,14818,8,,449.0,,Autocuration,,CHO,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT.,B,,,,10618
2068,4829,8,,449.0,,Autocuration,,CHO,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells, using [3H]5-HT as radioligand",B,,,,10618
2069,4373,8,,,,Autocuration,,,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1E receptor was determined,B,,,,10618
2070,4373,8,,,,Autocuration,,,,,Binding affinity for 5-hydroxytryptamine 1E receptor was determined,B,,,,10618
2071,14159,8,,,,Autocuration,,,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1E receptor,B,,,,10618
2072,16633,8,,,,Autocuration,,,,,Binding affinity towards 5-hydroxytryptamine 1E receptor,B,,,,10618
2073,17085,8,,,,Autocuration,,,,,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-HT1F receptor",F,,,,279
2074,17085,8,,,,Expert,,,,,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-hydroxytryptamine 1F receptor",F,,,,279
2075,16209,8,,,,Autocuration,,,,,In vitro effective concentration for inhibition of skolin-stimulated adenylate cyclase in cell line expressing human 5-hydroxytryptamine 1F receptor,F,,,,279
2076,16209,8,,,,Autocuration,,,,,In vitro agonist potency against human 5-hydroxytryptamine 1F receptor,F,,,,279
2077,17085,8,,,,Expert,,,,,"Maximum stimulation of of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine 1F receptor",F,,,,279
2078,14159,8,,,,Autocuration,,,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1F receptor,B,,,,279
2079,15250,8,,449.0,,Autocuration,,CHO,,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1F receptor stably expressed in CHO cells,B,,,,279
2080,3805,8,,,,Autocuration,,,,,In vitro binding affinity against human 5-hydroxytryptamine 1F receptor at a concentration of 100 (nM),B,,,,279
2081,16190,8,,449.0,,Autocuration,,CHO,,,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT radioligand,B,,,,279
2082,16190,8,,,,Autocuration,,,,,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT radioligand,B,,,,279
2083,16209,8,,,,Autocuration,,,,,Binding affinity towards human 5-hydroxytryptamine 1F receptor,B,,,,279
2084,16209,8,,,,Autocuration,,,,,Binding affinity towards human 5-hydroxytryptamine 1F receptor was determined,B,,,,279
2085,16209,8,,,,Autocuration,,,,,Binding affinity towards human 5-hydroxytryptamine 1F receptor using [3H]-5-HT radioligand,B,,,,279
2086,6866,8,,,,Autocuration,,,,,In vitro binding affinity for human 5-hydroxytryptamine 1F receptor,B,,,,279
2087,17085,8,,,,Expert,,,,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1F receptor,B,,,,279
2088,16312,8,,,,Autocuration,,,,,Binding affinity towards human recombinant 5-hydroxytryptamine 1F receptor,B,,,,279
2089,6166,8,,,,Autocuration,,,,,Binding affinity towards cloned human 5-hydroxytryptamine 1F receptor was determined,B,,,,279
2090,15779,8,,449.0,,Autocuration,,CHO,,,Binding affinity towards 5-hydroxytryptamine 1F receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,B,,,,279
2091,4199,8,,449.0,,Autocuration,,CHO,,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1F receptor in CHO cells using [3H]-5-HT as the radioligand,B,,,,279
2092,14875,8,,,,Autocuration,,,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1F receptor,B,,,,279
2093,15146,8,,449.0,,Autocuration,,CHO,,,Compound was tested for its binding affinity against 5-hydroxytryptamine 1F receptor in human cloned receptors in CHO cells using [3H]5-HT,B,,,,279
2094,5213,8,,,,Autocuration,,,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT as a radioligand,B,,,,279
2095,14818,8,,449.0,,Autocuration,,CHO,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT.,B,,,,279
2096,4829,8,,449.0,,Autocuration,,CHO,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",B,,,,279
2097,4829,8,,449.0,,Autocuration,,CHO,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",B,,,,279
2098,4373,8,,,,Autocuration,,,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1F receptor was determined,B,,,,279
2099,4373,8,,,,Autocuration,,,,,Binding affinity for 5-hydroxytryptamine 1F receptor was determined,B,,,,279
2100,5014,8,,,,Autocuration,,,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1F receptor,B,,,,279
2101,11662,4,,,,Autocuration,,,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]-ketanserin as radioligand",B,,,,104686
2102,11662,4,,,,Autocuration,,,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",B,,,,104686
2103,11662,4,,,,Autocuration,,,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",B,,,,104686
2104,14093,8,,,,Autocuration,,,,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,B,,,,12687
2105,11200,4,,,,Autocuration,,,,,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-HT2 receptor 1 hr after oral administration",F,In vivo,,,104686
2106,11200,4,,,,Autocuration,,,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,F,,,,104686
2107,12352,8,,,,Intermediate,,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor in calf frontal cortex,B,,,,17005
2108,13657,0,,,,Autocuration,,,,9913.0,"Binding affinity to 5-hydroxytryptamine 2 receptor using calf frontal cortex, [3H]- ketanserin, and spiperone for NSB",B,,Bos taurus,,22226
2109,14331,0,,,,Autocuration,,,,9913.0,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex at 10e-7 M,B,,Bos taurus,,22226
2110,14331,0,,,,Autocuration,,,,9913.0,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex,B,,Bos taurus,,22226
2111,14331,0,,,,Autocuration,,,,,Binding affinity of compound towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin (0.8 nM) ligand in frontal cortex bovine was determined,B,,,,22226
2112,12685,4,,,,Autocuration,,,,10141.0,Binding affinity for serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin in guinea pig frontal cortex,B,,Cavia porcellus,,104784
2113,14389,4,,,,Autocuration,,,,10141.0,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of guinea pig frontal cortex membranes,B,,Cavia porcellus,,104784
2114,14386,4,,,,Autocuration,,,,10141.0,Compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin from guinea pig frontal cortex,B,,Cavia porcellus,,104784
2115,5732,4,,,,Autocuration,,,,,Binding affinity towards cloned human 5-hydroxytryptamine 2 receptor was determined,B,,,,104784
2116,16293,4,,,,Autocuration,,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,B,,,,104784
2117,2078,4,,,,Autocuration,,,,,In vitro binding affinity of compound against neuronal 5-hydroxytryptamine 2 receptor,B,,,,104784
2118,5486,8,,,,Autocuration,,,,,Binding affinity towards 5-HT7 receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,B,,,,10209
2119,11820,4,,,,Autocuration,,,,,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,B,In vivo,,,104826
2120,10297,4,,,,Autocuration,,,,,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,B,,,,104826
2121,13704,4,,,,Autocuration,,,,,Inhibitory activity against serotonin 5-hydroxytryptamine 2 receptor from mice.,B,,,,104826
2122,10297,5,,,,Autocuration,,,,10090.0,Inhibitory activity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in mouse cerebral cortex,B,,Mus musculus,,104826
2123,11820,4,,,,Autocuration,,,,,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,B,In vivo,,,104826
2124,10297,5,,,,Autocuration,,,,10090.0,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]-ketanserin in mouse cerebral cortex,B,,Mus musculus,,104826
2125,11555,4,,,,Autocuration,,,,,The compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2 receptor,B,,,,104826
2126,11555,4,,,,Autocuration,,,,,In vitro binding affinity for serotonin 5-hydroxytryptamine (5-HT) 2 receptors,B,,,,104826
2127,11555,4,,,,Autocuration,,,,,The compound was tested in vitro for its binding affinity towards serotonin 5-hydroxytryptamine 2 receptor; nd = no data,B,,,,104826
2128,10297,5,,,,Autocuration,,,,10090.0,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,B,,Mus musculus,,104826
2129,16688,4,,,,Autocuration,,,,9823.0,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin,B,,Sus scrofa,,104784
2130,16688,4,,,,Autocuration,,,,9823.0,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin with 10 uM prazosin,B,,Sus scrofa,,104784
2131,5333,0,,,,Autocuration,,,,,Compound was tested in vitro for its ability to compete with [3H]-ketanserin at 5-hydroxytryptamine 2 receptor in porcine brain homogenate,B,,,,22226
2132,4437,0,,,,Autocuration,,,,,In vitro for its ability to displace [3H]- ketanserin from 5-hydroxytryptamine 2 receptor in porcine brain homogenate,B,,,,22226
2133,5033,8,,,,Autocuration,,,,9823.0,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2 receptor,B,,Sus scrofa,,17005
2134,15267,4,,,,Autocuration,,,,,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,B,,,,104686
2135,15267,4,,,,Autocuration,,,,,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,B,,,,104686
2136,11820,4,,,,Autocuration,,,,,Binding affinity against 5-hydroxytryptamine 2 receptor from rat cortical synaptosomal membrane using radioligand [3H]ketanserin.,B,,,,104826
2137,9069,4,,,,Autocuration,,,,,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,B,,,,104686
2138,9162,5,,,,Autocuration,,,,10116.0,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; ND means no data,B,,Rattus norvegicus,,104686
2139,9162,4,,,,Autocuration,,,,,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein.,B,,,,104686
2140,9162,4,,,,Autocuration,,,,,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; no appreciable 5-HT2 receptor affinity,B,,,,104686
2141,10428,4,,,,Autocuration,,,,,Antagonistic activity against (5-hydroxytryptamine 2 receptor) serotonin-induced contractions in the rat jugular vein,F,,,,104686
2142,9628,4,,,,Autocuration,,,,,Binding affinity to the 5-hydroxytryptamine 2 receptor assayed by antagonism of serotonin-induced contractions in the rat jugular vein,B,,,,104686
2143,12704,4,,,,Autocuration,,,,,Binding affinity against serotonin 5-hydroxytryptamine 2 receptor,B,,,,104686
2144,15453,5,,,,Autocuration,,,,10116.0,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,B,,Rattus norvegicus,,104686
2145,188,4,,,,Autocuration,,,,,Tested for the effect on binding at 5-hydroxytryptamine 2 receptor; No activity,B,,,,104686
2146,10349,4,,,,Autocuration,,,,,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.4 nM dose of [3H]- spiperone as a radioligand.,B,,,,104686
2147,10349,4,,,,Autocuration,,,,,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.6 nM dose of [3H]- spiperone as a radioligand.,B,,,,104686
2148,8868,4,,,,Autocuration,,,,,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,B,,,,104686
2149,10025,4,,,,Autocuration,,,,,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,B,,,,104686
2150,10025,4,,,,Autocuration,,,,,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",B,,,,104686
2151,11702,4,,,,Autocuration,,,,,Compound was tested for the inhibition of quipazine binding at 5-HT2 receptor,B,,,,104686
2152,11702,4,,,,Autocuration,,,,,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor,B,,,,104686
2153,11702,4,,,,Autocuration,,,,,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor; NT=Not tested,B,,,,104686
2154,11702,4,,,,Autocuration,,,,,Compound was tested for the inhibition of quipazine induced head twitches in rats,F,,,,104686
2155,11702,4,,,,Autocuration,,,,,Compound was tested for the inhibition of quipazine induced head twitches in rats; NT=Not tested,F,,,,104686
2156,10085,4,,,,Autocuration,10000000.0,,Hippocampus,,Ability to bind at 5-hydroxytryptamine 2 receptor of rat hippocampus by displacing [3H]spiperone,B,,,,104686
2157,10085,4,,,,Autocuration,10000000.0,,Hippocampus,,Ability to bind at serotonin 5-hydroxytryptamine 2 receptors of rat hippocampus by displacing [3H]spiperone,B,,,,104686
2158,9630,5,,,,Autocuration,955.0,,Brain,10116.0,Displacement of [3H]spiroperidol from 5-hydroxytryptamine 2 receptor in rat brain,B,,Rattus norvegicus,,104686
2159,11070,4,,,,Autocuration,,,,,Ability to inhibit binding of [3H]KET to 5-hydroxytryptamine 2 receptor in rat cortex,B,,,,104686
2160,9841,4,,,,Autocuration,,,,,Ability to inhibit binding of titreated spiperone to 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,B,,,Membranes,104686
2161,9841,4,,,,Autocuration,,,,,Ability to inhibit binding of titreated spiperone to the 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,B,,,Membranes,104686
2162,13291,4,,,,Autocuration,,,,,Affinity for 5-hydroxytryptamine 2 receptor binding sites by its ability to displace [3H]spiperone from rat frontal cortex.,B,,,,104686
2163,10590,4,,,,Autocuration,,,,,Antagonistic activity against 5-hydroxytryptamine 2 receptor on rat frontal cortex membrane.,F,,,,104686
2164,9064,5,,,,Autocuration,955.0,,Brain,10116.0,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,B,,Rattus norvegicus,,104686
2165,12268,5,,,,Autocuration,,,,10116.0,Binding affinity at 5-hydroxytryptamine 2 receptor by the inhibition of binding to [3H]ketanserin in rat cortical membranes,B,,Rattus norvegicus,Membranes,104686
2166,13508,4,,,,Autocuration,955.0,,Brain,,Binding affinity against 5-hydroxytryptamine 2 receptor in rat brain using [3H]ketanserin as radioligand,B,,,,104686
2167,11279,4,,,,Autocuration,,,,,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,F,,,,104686
2168,11200,4,,,,Autocuration,,,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-HT2 receptor in rat thoracic aortic strips,F,,,,104686
2169,11200,4,,,,Autocuration,,,,,In vitro antagonistic activity tested against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,F,,,,104686
2170,11200,4,,,,Autocuration,,,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,F,,,,104686
2171,11200,4,,,,Autocuration,,,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,F,,,,104686
2172,11200,4,,,,Autocuration,,,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,F,,,,104686
2173,9231,4,,,,Autocuration,955.0,,Brain,,Tested for 5-hydroxytryptamine 2 receptor binding ability by displacement of [3H]spiperone from rat brain frontal cortex synaptosomes,B,,,,104686
2174,9737,4,,,,Autocuration,,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,B,,,,104686
2175,9737,4,,,,Autocuration,955.0,,Brain,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,B,,,,104686
2176,9737,4,,,,Autocuration,,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex,B,,,,104686
2177,9737,4,,,,Autocuration,,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,B,,,,104686
2178,11828,5,,,,Autocuration,,,,10116.0,isplacement of [3H]DOB from rat cortex homogenate 5-hydroxytryptamine 2 receptor,B,,Rattus norvegicus,,104686
2179,12253,4,,,,Autocuration,,,,,Binding affinity of 5-hydroxytryptamine 2 receptor using [3H]- ketanserin in rat frontal cortex,B,,,,104686
2180,12253,4,,,,Autocuration,,,,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat frontal cortex,B,,,,104686
2181,11279,4,,,,Autocuration,,,,,"5-hydroxytryptamine 2 receptor antagonistic activity at concentrations of<br>3,10 and 30 uM on the rat tail artery.",F,,,,104686
2182,11866,4,,,,Autocuration,,,,,Binding affinity for 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- ketanserin,B,,,,104686
2183,14424,5,,,,Autocuration,,,,10116.0,Binding affinity against 5-hydroxytryptamine 2 receptor in serotonin-induced contraction of the rat aorta,B,,Rattus norvegicus,,104686
2184,15180,5,,,,Autocuration,,,,10116.0,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,B,,Rattus norvegicus,,104686
2185,15180,5,,,,Autocuration,,,,10116.0,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,B,,Rattus norvegicus,,104686
2186,9786,5,,,,Autocuration,,,,10116.0,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat frontal cortex homogenate,B,,Rattus norvegicus,,104686
2187,12132,4,,,,Autocuration,,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand.,B,,,,104686
2188,5486,4,,,,Autocuration,,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in rat cerebral cortex membrane,B,,,,104686
2189,15316,4,,,,Autocuration,,,,,Compound was evaluated for its ability to displace [3H]ketanserin binding from cloned rat cerebral cortex membranes 5-hydroxytryptamine 2 receptor,B,,,,104686
2190,16429,4,,,,Autocuration,,,,,In vitro binding affinity to 5-hydroxytryptamine 2 receptor of rat cerebral cortex membranes using [3H]ketanserin as the radioligand,B,,,,104686
2191,14617,4,,,,Autocuration,,,,,pKi value for 5-hydroxytryptamine 2 receptor binding site,B,,,,104686
2192,11351,4,,,,Autocuration,955.0,,Brain,,Inhibitory constant (1 uM) was measured on 5-hydroxytryptamine 2 receptor/uptake using [3H]- ketanserin as radioligand in rat brain cortex.,B,,,,104686
2193,11279,4,,,,Autocuration,,,,,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,F,,,,104686
2194,9523,4,,,,Autocuration,,,,,Binding affinity at 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,B,,,,105075
2195,9523,4,,,,Autocuration,,,,,Binding affinity at 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,B,,,,105075
2196,9523,4,,,,Autocuration,,,,,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,B,,,,105075
2197,9523,4,,,,Autocuration,,,,,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,B,,,,105075
2198,9523,4,,,,Autocuration,,,,,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,B,,,,105075
2199,9523,4,,,,Autocuration,,,,,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,B,,,,105075
2200,9523,4,,,,Autocuration,,,,,Hill coefficient of compound was determined,B,,,,105075
2201,4771,0,,,,Autocuration,,,,,Ancillary Binding affinity towards rat 5-hydroxytryptamine 2 receptor,B,,,,22226
2202,5033,5,,,,Autocuration,,,,10116.0,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-ketanserin) from 5-hydroxytryptamine 2 receptor of rat cerebral cortex membrane,B,,Rattus norvegicus,,104686
2203,10845,8,,,,Expert,,,,,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand,B,,,,12687
2204,10845,8,,,,Expert,,,,,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand; IA-Inactive,B,,,,12687
2205,16288,8,,,,Autocuration,,,,,Affinity at 5-hydroxytryptamine 2 receptor (For ketanserin = Ki(nM)= 0.7+/-0.09),B,,,,12687
2206,16288,8,,,,Autocuration,,,,,Affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex using [3H]ketanserin as radioligand (For ketanserin = Ki(nM)=0.7+/-0.09),B,,,,12687
2207,16190,8,,,,Autocuration,,,,,Binding affinity for 5-hydroxytryptamine 2 receptor of rat cortical membrane using [3H]DOB radioligand,B,,,,12687
2208,12463,5,,,,Autocuration,,,,10116.0,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 2 receptor using radioligand [3H]ketanserin,B,,Rattus norvegicus,,104686
2209,9699,4,,,,Autocuration,,,,,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand",B,,,,104686
2210,9699,4,,,,Autocuration,,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand,B,,,,104686
2211,11662,4,,,,Autocuration,,,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",B,,,,104686
2212,1205,4,,,,Autocuration,,,,,Inhibitory concentration against 5-hydroxytryptamine 2 receptor,B,,,,104784
2213,11376,0,,,,Autocuration,,,,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2 receptor from mammalian clones expressed in CHO cell membranes using [3H]-ketanserin as radioligand,B,,,,22226
2214,11376,4,,,,Autocuration,,,,,"Binding affinity towards 5-hydroxytryptamine 2 receptor expressed in CHO cell membranes using [3H]ketanserin (60 Ci/mmol, 1 nM)",B,,,,104784
2215,4639,4,,,,Autocuration,,,,,Compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor,B,,,,104784
2216,2222,4,,,,Autocuration,,,,,Compound was tested for inhibitory activity against 5-hydroxytryptamine 2 receptor,B,,,,104784
2217,1558,4,,,,Autocuration,,,,,Compound was tested for its affinity towards 5-hydroxytryptamine 2 receptor,B,,,,104784
2218,1089,4,,,,Autocuration,,,,,Tested for binding affinity for 5-hydroxytryptamine 2 receptor,B,,,,104784
2219,386,4,,,,Autocuration,,,,,The compound was evaluated for its ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor in cellular brain membranes,B,,,Brain membranes,104784
2220,2474,4,,,,Autocuration,,,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 2 receptor at a concentration of 10 uM using [3H]ketanserin as radioligand,B,,,,104784
2221,17066,4,,,,Autocuration,,,,,Binding affinity towards 5-HT2 receptor,B,,,,104784
2222,959,4,,,,Autocuration,,,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,B,,,,104784
2223,6398,4,,,,Autocuration,,,,,Compound was evaluated for 5-hydroxytryptamine 2 receptor binding,B,,,,104784
2224,11889,4,,,,Autocuration,,,,,In vitro binding affinity against rat 5-hydroxytryptamine 2 receptor.,B,,,,104686
2225,4221,4,,,,Autocuration,,,,,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,B,,,,104784
2226,11026,4,,,,Autocuration,,,,,The compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor using ketanserin as radioligand,B,,,,104784
2227,11866,4,,,,Autocuration,,,,,Binding affinity for 5-hydroxytryptamine 2 receptor was determined,B,,,,104784
2228,4221,4,,,,Autocuration,,,,,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,B,,,,104784
2229,13950,0,,,,Autocuration,,,,,In Vitro binding affinity for 5-hydroxytryptamine 2 receptor,B,,,,22226
2230,1263,4,,,,Autocuration,,,,,5-hydroxytryptamine 2 receptor binding affinity,B,,,,104784
2231,13291,8,,,,Autocuration,,,,,Binding affinity against 5-hydroxytryptamine 2 receptor was determined using [ [3H]spiperone radioligand,B,,,,17005
2232,10812,8,,,,Autocuration,,,,,Compound was tested for the binding affinity against 5-hydroxytryptamine 2 receptor by using [3H]ketanserin as radioligand,B,,,,17005
2233,13020,4,,,,Autocuration,,,,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,B,,,,104784
2234,13021,4,,,,Autocuration,,,,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of central nervous system,B,,,,104784
2235,13020,4,,,,Autocuration,,,,,Ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,B,,,,104784
2236,14532,8,,,,Autocuration,,,,,Inhibitory activity against 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand at 10e-5 M concentration,B,,,,17005
2237,13944,8,,,,Autocuration,,,,,Binding affinity against 5-hydroxytryptamine 2 receptor,B,,,,17005
2238,14331,8,,,,Autocuration,,,,,Binding affinity against 5-hydroxytryptamine 2 receptor,B,,,,17005
2239,14118,8,,,,Autocuration,,,,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,B,,,,17005
2240,13033,8,,,,Autocuration,,,,,Binding affinity against serotonergic 5-HT2 receptor,B,,,,17005
2241,10321,8,,,,Autocuration,,,,,Binding affinity for 5-hydroxytryptamine 2 receptor was determined by using [3H]ketanserin as radioligand,B,,,,17005
2242,12918,8,,,,Autocuration,,,,,Compound was evaluated for the binding affinity at 5- HT2 receptor,B,,,,17005
2243,15120,8,,,,Autocuration,,,,,Compound was tested for binding affinity using [3H]ketanserin against 5-hydroxytryptamine 2 receptor,B,,,,17005
2244,2613,8,,,,Autocuration,,,,,In vivo binding affinity was evaluated against 5-hydroxytryptamine 2 receptor,B,,,,17005
2245,13378,5,,,,Autocuration,,,,9606.0,Inhibitory activity against cloned human 5-HT2 receptor,B,,Homo sapiens,,104784
2246,2331,5,,449.0,,Autocuration,,CHO,,9606.0,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells",B,,Homo sapiens,,104784
2247,2331,5,,449.0,,Autocuration,,CHO,,9606.0,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells.",B,,Homo sapiens,,104784
2248,2331,5,,449.0,,Autocuration,,CHO,,9606.0,"Tested in vitro for the inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; Inactive",B,,Homo sapiens,,104784
2249,2331,5,,449.0,,Autocuration,,CHO,,9606.0,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; not tested",B,,Homo sapiens,,104784
2250,4170,4,,,,Autocuration,,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor,B,,,,104784
2251,15453,4,,,,Autocuration,,,,,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,B,,,,104784
2252,1479,8,,,,Autocuration,,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor,B,,,,17005
2253,11139,4,,,,Autocuration,,,,,Binding affinity towards 5-hydroxytryptamine 2- receptor using [3H]ketanserin as radioligand in competitive binding assay,B,,,,104686
2254,13969,8,,,,Expert,,,,,Binding affinity against 5-hydroxytryptamine 2A receptor was measured using [3H]ketanserin as radioligand,B,,,,17005
2255,13392,8,,,,Expert,,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor,B,,,,17005
2256,14430,8,,,,Expert,,,,,Affinity towards 5-hydroxytryptamine 2A receptor in membranes from bovine frontal cortex using [3H]ketanserin,B,,,,17005
2257,13181,8,,,,Autocuration,,,,10141.0,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,B,,Cavia porcellus,,107
2258,17200,8,,,,Autocuration,,,,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,B,,,,51
2259,17200,8,,,,Autocuration,,,,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,B,,,,107
2260,17200,8,,,,Autocuration,,,,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,B,,,,51
2261,13463,8,,,,Autocuration,,,,,Binding affinity analysed on 5-HT 2A human clone using [3H]ketanserin as radioligand,B,,,,107
2262,6347,8,,449.0,,Autocuration,,CHO,,,Effective concentration against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,B,,,,107
2263,6857,9,,449.0,,Expert,,CHO,,9606.0,Functional activity against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader,F,,Homo sapiens,,107
2264,4176,8,,,,Autocuration,,,,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,F,,,,107
2265,4176,8,,,,Autocuration,,,,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line; no data,F,,,,107
2266,4176,8,,,,Autocuration,,,,,Functional antagonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,F,,,,107
2267,6347,8,,449.0,,Autocuration,,CHO,,,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand, expressed as Emax",B,,,,107
2268,6347,8,,449.0,,Autocuration,,CHO,,,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells, expressed as Emax",B,,,,107
2269,15331,8,,,,Autocuration,,,,,Affinity of compound towards human 5-hydroxytryptamine 2A receptor was evaluated using radioligand binding technique,B,,,,107
2270,16146,9,,,,Expert,,,,9606.0,Inhibition of human 5-hydroxytryptamine 2A receptor,B,,Homo sapiens,,107
2271,15250,8,,449.0,,Autocuration,,CHO,,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,B,,,,107
2272,13631,8,,,,Expert,,,,,Inhibitory concentration against human 5-HT2A receptor in BEK cells,B,,,,107
2273,3805,8,,,,Autocuration,,,,,In vitro binding affinity against human 5-hydroxytryptamine 2A receptor at a concentration of 100 (nM),B,,,,107
2274,4011,8,,449.0,,Autocuration,,CHO,,,Ability to displace [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor was determined,B,,,,107
2275,4012,8,,449.0,,Expert,,CHO,,,Displacement of [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor.,B,,,,107
2276,6366,8,,307.0,,Expert,,L929,,,Ability to displace [125I]R91150 from human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells,B,,,,107
2277,15949,8,,449.0,,Expert,,CHO,,,Ability to displace [3H]ketanserin binding to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,B,,,,107
2278,14093,8,,,,Autocuration,,,,,Agonist activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand,F,,,,107
2279,13481,8,,,,Autocuration,,,,,Agonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,F,,,,107
2280,6347,8,,449.0,,Autocuration,,CHO,,,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,B,,,,107
2281,6347,8,,449.0,,Autocuration,,CHO,,,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand; Nd means not done,B,,,,107
2282,14093,8,,,,Autocuration,,,,,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]-Ketanserin radioligand,F,,,,107
2283,14093,8,,,,Autocuration,,,,,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand; Not tested,F,,,,107
2284,13481,8,,,,Autocuration,,,,,Antagonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,F,,,,107
2285,14442,8,,,,Autocuration,,,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [125 I]DOI as radioligand,B,,,,107
2286,14442,8,,,,Autocuration,,,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,B,,,,107
2287,14755,8,,,,Autocuration,,,,,Binding activity against cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand.,B,,,,107
2288,16441,8,,,,Autocuration,,,,,Binding affinity against 5-hydroxytryptamine 2A receptor in humans,B,,,,107
2289,14744,8,,,,Autocuration,,,,,Binding affinity against the cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand,B,,,,107
2290,16659,8,,449.0,,Expert,,CHO,,,Binding affinity for displacement of [3H]ketanserin to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,B,,,,107
2291,3307,8,,,,Autocuration,,,,,Binding affinity of compound to human 5-hydroxytryptamine 2A receptor,B,,,,107
2292,6857,9,,,,Expert,,,,9606.0,Affinity for human 5-hydroxytryptamine 2A receptor expressed in mammalian cell line,B,,Homo sapiens,,107
2293,5635,8,,,,Expert,,,,,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand.,B,,,,107
2294,4234,9,,,,Expert,,,,9606.0,Binding affinity to cloned human 5-hydroxytryptamine 2A receptor,B,,Homo sapiens,,107
2295,15527,8,,,,Autocuration,,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,B,,,,107
2296,6588,8,,449.0,,Expert,,CHO,,,Binding affinity towards human 5-hydroxytryptamine 2A receptor by the displacement of [3H]ketanserin radioligand from the cloned receptor expressed in CHO cells,B,,,,107
2297,13631,8,,,,Expert,,,,,Binding affinity towards human 5-HT2A receptor in BEK cells,B,,,,107
2298,17723,8,,,,Autocuration,,,,,Binding affinity towards human serotonin 5-hydroxytryptamine 2A receptor,B,,,,107
2299,14770,8,,,,Autocuration,,,,,Binding affinity for recombinant human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,B,,,,107
2300,16293,9,,,,Expert,,,,9606.0,Binding affinity for human 5-hydroxytryptamine 2A receptor,B,,Homo sapiens,,107
2301,16209,8,,,,Autocuration,,,,,Binding affinity towards human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,B,,,,107
2302,12469,8,,,,Autocuration,,,,,Binding affinity was measured on 5-hydroxytryptamine 2A receptor in GF6 cells transfected with human 5-HT2A gene labeled with [3H]ketanserin,B,,,,107
2303,15363,8,,,,Autocuration,,,,,Compound was tested for the displacement of [125I]-DOI from clone human 5-hydroxytryptamine 2A receptor,B,,,,107
2304,15363,8,,,,Autocuration,,,,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2A receptor,B,,,,107
2305,16441,8,,,,Expert,,,,,"Tested on genetically transfected COS7 cell membranes selectively expressing human 5-hydroxytryptamine 2A receptor, using [3H]ketanserin as radioligand",B,,,,107
2306,8,8,,,,Autocuration,,,,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in human using [3H]ketanserin as radioligand,B,,,,107
2307,4176,8,,722.0,,Autocuration,,HEK293,,,In vitro binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells was determined using [3H]ketanserin as radioligand,B,,,,107
2308,17085,8,,,,Autocuration,,,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2A receptor,B,,,,107
2309,17200,8,,,,Autocuration,,,,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,B,,,,107
2310,17200,9,,,,Expert,,,,9606.0,Inhibitory constant determined against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,B,,Homo sapiens,,107
2311,4013,9,,449.0,,Expert,,CHO,,9606.0,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in CHO cells,B,,Homo sapiens,,107
2312,5088,8,,,,Autocuration,,,,,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor,B,,,,107
2313,5088,9,,,,Expert,,,,9606.0,Displacement of [3H]DOB from human 5-hydroxytryptamine 2A receptor,B,,Homo sapiens,,107
2314,5088,8,,,,Autocuration,,,,,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]DOB as labeled ligand; binding data not obtained,B,,,,107
2315,5088,9,,,,Expert,,,,9606.0,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor,B,,Homo sapiens,,107
2316,5088,8,,,,Autocuration,,,,,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand,B,,,,107
2317,5088,8,,,,Autocuration,,,,,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,B,,,,107
2318,9786,4,,,,Autocuration,,,,,Ability to displace 0.75 nM [3H]ketanserin in 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenate,B,,,,104686
2319,9205,5,,,,Autocuration,,,,10116.0,Ability to inhibit [3H]spiperone binding to 5-hydroxytryptamine 2 receptor determined in rat,B,,Rattus norvegicus,,104686
2320,11257,4,,,,Autocuration,,,,,Affinity on 5-hydroxytryptamine 2 receptor labeled by [125I]DOI,B,,,,104686
2321,9362,4,,,,Autocuration,,,,,Affinity towards [3H]- DOB -labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,B,,,,104686
2322,9362,4,,,,Autocuration,,,,,Affinity towards [3H]- ketanserin-labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,B,,,,104686
2323,10590,4,,,,Autocuration,,,,,Inhibition of 5-hydroxytryptamine 2 induced vasoconstriction of rat caudal artery.,B,,,,104686
2324,10468,4,,,,Autocuration,,,,,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,B,,,,104686
2325,13050,4,,,,Autocuration,,,,,Binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortex using [125]-(R)-DOI as radioligand,B,,,,104686
2326,11624,4,,,,Autocuration,,,,,Binding affinity against 5-hydroxytryptamine 2 receptor in rat using [3H]ketanserin as radioligand,B,,,,104686
2327,10468,4,,,,Autocuration,,,,,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,B,,,,104686
2328,10330,4,,,,Autocuration,,,,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,B,,,,104686
2329,10062,4,,,,Autocuration,,,,,Binding affinity at rat 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,B,,,,104686
2330,11642,4,,,,Autocuration,,,,,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,B,,,,104686
2331,10062,4,,,,Autocuration,,,,,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,B,,,,104686
2332,13427,4,,,,Autocuration,,,,,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,B,In vitro,,,104686
2333,12280,5,,,,Autocuration,,,,10116.0,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,B,,Rattus norvegicus,,104686
2334,4101,5,,,,Autocuration,,,,10116.0,Binding affinity for 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]ketanserin,B,,Rattus norvegicus,,104686
2335,10062,4,,,,Autocuration,,,,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 2 receptor,B,,,,104686
2336,11147,4,,,,Autocuration,,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]DOB as,B,,,,104686
2337,2395,5,,485.0,,Autocuration,,CHO-K1,,10116.0,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,B,,Rattus norvegicus,,104686
2338,2395,5,,485.0,,Autocuration,,CHO-K1,,10116.0,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,B,,Rattus norvegicus,,104686
2339,9098,5,,,,Autocuration,,,,10116.0,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand,B,,Rattus norvegicus,,104686
2340,9098,4,,,,Autocuration,,,,,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand.,B,,,,104686
2341,9098,5,,,,Autocuration,,,,10116.0,Binding affinity to 5-hydroxytryptamine 2 receptor of rat cortical membranes using [3H]- DOB; ND means no data.,B,,Rattus norvegicus,,104686
2342,9443,4,,,,Autocuration,,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor,B,,,,104686
2343,9443,4,,,,Autocuration,,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,B,,,,104686
2344,9699,4,,,,Autocuration,,,,,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand in rat frontal cortex",B,,,,104686
2345,9699,4,,,,Autocuration,,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand in rat frontal cortex,B,,,,104686
2346,9098,4,,,,Autocuration,,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,B,,,,104686
2347,3070,5,,,,Autocuration,,,,10116.0,Affinity for 5-hydroxytryptamine 2 receptor,B,,Rattus norvegicus,,104686
2348,9547,4,,,,Autocuration,,,,,Binding affinity towards serotonin 5-hydroxytryptamine 2 receptor of rat determined using 0.5 nM of [3H]ketanserin in binding assay,B,,,,104686
2349,10444,4,,,,Autocuration,,,,,Binding affinity was determined against 5-hydroxytryptamine 2 receptor from male Sprague-Dawley rat brain.,B,,,,104686
2350,14617,4,,,,Autocuration,,,,,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor from rat tissue homogenate,B,,,,104686
2351,14617,4,,,,Autocuration,,,,,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor rat tissue homogenate,B,,,,104686
2352,11130,4,,,,Autocuration,,,,,Binding constant against 5-hydroxytryptamine 2 receptor (in vitro),B,,,,104686
2353,11130,4,,,,Autocuration,,,,,Binding constant against 5-hydroxytryptamine 2 receptor (in vivo),B,In vivo,,,104686
2354,14542,4,,,,Autocuration,955.0,,Brain,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat brain,B,,,,104686
2355,2797,4,,,,Autocuration,,,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2 receptor from rat,B,,,,104686
2356,11332,4,,,,Autocuration,,,,,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,B,,,,104686
2357,11332,4,,,,Autocuration,,,,,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,B,,,,104686
2358,10752,4,,,,Autocuration,1870.0,,Frontal cortex,,Compound was evaluated for its ability to displace 0.25 nM [125I](R)-DOI from binding sites in rat frontal cortex.,B,,,,104686
2359,1185,4,,,,Autocuration,,,,,Ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,B,,,,104686
2360,1185,4,,,,Autocuration,,,,,Compound was evaluated for its ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,B,,,,104686
2361,11624,5,,,,Autocuration,,,,10116.0,Binding affinity against 5-Hydroxy tryptamine 2 (5-hydroxytryptamine 2)receptor,B,,Rattus norvegicus,,104686
2362,1344,4,,,,Autocuration,,,,,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 2 receptor in rat cortex using [3H]ketanserin radioligand assay,B,,,,104686
2363,15453,5,,,,Autocuration,2435.0,,Striatum,10116.0,Binding affinity against 5-hydroxytryptamine 2 receptor in rat striatum using [3H]-RP62203,B,,Rattus norvegicus,,104686
2364,11662,4,,,,Autocuration,,,,,"Binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",B,,,,104686
2365,11662,4,,,,Autocuration,,,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",B,,,,104686
2366,10796,4,,,,Autocuration,,,,,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 2 receptor,B,,,,104686
2367,9069,4,,,,Autocuration,,,,,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,B,,,,104686
2368,8814,5,,,,Autocuration,,,,10116.0,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortical membrane homogenates,B,,Rattus norvegicus,,104686
2369,8908,5,,,,Autocuration,,,,10116.0,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortex,B,,Rattus norvegicus,,104686
2370,9098,4,,,,Autocuration,,,,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,B,,,,104686
2371,9098,4,,,,Autocuration,,,,,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 (5-HT2) receptor using [3H]KET as a radioligand,B,,,,104686
2372,9098,4,,,,Autocuration,,,,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,B,,,,104686
2373,9098,4,,,,Autocuration,,,,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.,B,,,,104686
2374,9098,4,,,,Autocuration,,,,,Binding affinity to 5-hydroxytryptamine 2 receptor in rat frontal cortical membranes by [3H]- KET displacement.,B,,,,104686
2375,9098,4,,,,Autocuration,,,,,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.;ND is not determined,B,,,,104686
2376,9098,4,,,,Autocuration,,,,,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand;ND means no data,B,,,,104686
2377,9161,4,,,,Autocuration,,,,,In vitro binding affinity at 5-hydroxytryptamine 2 receptor in rat cortical tissue by [3H]spiperone displacement; No data.,B,,,,104686
2378,9161,4,,,,Autocuration,,,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 165 to 263,B,,,,104686
2379,9161,4,,,,Autocuration,,,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 2.4 to 5.3,B,,,,104686
2380,9161,4,,,,Autocuration,,,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue.,B,,,,104686
2381,9161,4,,,,Autocuration,,,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 140 to 980,B,,,,104686
2382,9161,4,,,,Autocuration,,,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 76 to 299,B,,,,104686
2383,9161,4,,,,Autocuration,,,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue; value may range from 12 to 66,B,,,,104686
2384,9161,4,,,,Autocuration,,,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 136 to 220,B,,,,104686
2385,9161,4,,,,Autocuration,,,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 197 to 341,B,,,,104686
2386,9161,4,,,,Autocuration,,,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 23 to 187,B,,,,104686
2387,9161,4,,,,Autocuration,,,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 29 to 132,B,,,,104686
2388,9161,4,,,,Autocuration,,,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 6 to 75,B,,,,104686
2389,12094,4,,,,Autocuration,,,,,In vitro binding affinity on 5-hydroxytryptamine 2 receptor is inhibition of binding of [125I]- I-LSD to P11 cells,B,,,,104686
2390,12018,4,,,,Autocuration,,,,,In vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat striatal membranes by [3H]ketanserin displacement.,B,,,,104686
2391,10394,4,,,,Autocuration,,,,,Inhibitory activity against 5-hydroxytryptamine 2 receptor in rat cortical membranes using [3H]ketanserin as a radioligand,B,,,,104686
2392,15260,4,,,,Autocuration,,,,,Inhibitory activity against rat cortical 5-hydroxytryptamine 2 receptor,B,,,,104686
2393,11624,5,,,,Autocuration,,,,10116.0,Inhibitory constant against 5-hydroxytryptamine 2 receptor,B,,Rattus norvegicus,,104686
2394,13654,4,,,,Autocuration,,,,,Percentage specific displacement of radioligand [3H]-ketanserin from 5-hydroxytryptamine 2 receptor,B,,,,104686
2395,9541,4,,,,Autocuration,,,,,Potency to displace [3H]- Spiperone from 5-hydroxytryptamine 2 receptor in rat striatum,B,,,,104686
2396,11933,4,,,,Autocuration,,,,,Tested for binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortical regions using [3H]ketanserin as radioligand,B,,,,104686
2397,15538,4,,,,Autocuration,,,,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex,B,,,,104686
2398,15538,4,,,,Autocuration,,,,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; NA means Not Active,B,,,,104686
2399,15538,4,,,,Autocuration,,,,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; not determined,B,,,,104686
2400,8841,5,,,,Autocuration,,,,,Displacement of [3H]ketanserin from rat prefrontal cortex 5-hydroxytryptamine 2 receptor,B,,,,104686
2401,1455,4,,,,Autocuration,,,,,Binding affinity to 5-hydroxytryptamine 2 receptor using [3H]ketanserin radioligand assay.,B,,,,104686
2402,1455,4,,,,Autocuration,,,,,Tested for its binding affinity to Tested for its binding affinity to 5-hydroxytryptamine 2 receptor using [3H]-ketanserin radioligand assay using [3H]-ketanserin radioligand assay,B,,,,104686
2403,11752,4,,,,Autocuration,,,,,The ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat whole brain,B,,,,104686
2404,11642,4,,,,Autocuration,955.0,,Brain,,The binding affinity was measured on 5-hydroxytryptamine 2 receptor in rat brain tissue,B,,,,104686
2405,12092,4,,,,Autocuration,,,,,The binding affinity was measured on 5-hydroxytryptamine 2 receptor using [3H]- spiperone as radioligand.,B,,,,104686
2406,3967,4,,,,Autocuration,,,,,Binding affinity at 5-hydroxytryptamine 2 receptor from striata wistar rats by [3H]ketanserin displacement.,B,,,,104686
2407,12771,5,,,,Autocuration,,,,10116.0,Binding affinity towards 5-hydroxytryptamine 2 receptor,B,,Rattus norvegicus,,104686
2408,11642,4,,,,Autocuration,,,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [3H]ketanserin radioligand in rat cerebral cortex,B,,,,104686
2409,11628,4,,,,Autocuration,,,,,The compound was tested in vitro for binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [125]I-LSD radioligand,B,,,,104686
2410,13654,4,,,,Autocuration,,,,,Percentage specific displacement of radioligand [3H]ketanserin from 5-hydroxytryptamine 2 receptor,B,,,,104686
2411,11200,4,,,,Autocuration,,,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,F,,,,104686
2412,11200,4,,,,Autocuration,,,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,F,,,,104686
2413,11200,4,,,,Autocuration,,,,,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",F,In vivo,,,104686
2414,11200,4,,,,Autocuration,,,,,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",F,In vivo,,,104686
2415,11200,4,,,,Autocuration,,,,,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",F,In vivo,,,104686
2416,11200,4,,,,Autocuration,,,,,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",F,In vivo,,,104686
2417,15436,8,,,,Expert,955.0,,Brain,,Affinity for 5-hydroxytryptamine 2A receptor in rat brain cortex by ability to displace [3H]ketanserin,B,,,,12687
2418,15436,9,,,,Expert,,,,10116.0,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,B,,Rattus norvegicus,,12687
2419,14025,8,,,,Autocuration,,,,,Affinity pKi for 5-hydroxytryptamine 2A receptor was measured in rat cortex homogenates,B,,,,12687
2420,4342,8,,,,Autocuration,,,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor was determined,B,,,,12687
2421,13735,9,,,,Expert,,,,10116.0,Displacement of [3H]ketanserin from 5-HT2A receptor of rat frontal cortex,B,,Rattus norvegicus,,12687
2422,5816,9,,,,Expert,,,,10116.0,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,B,,Rattus norvegicus,,12687
2423,14287,8,,,,Expert,,,,,Binding affinity was evaluated in vitro by displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor on rat cortical membrane,B,,,,12687
2424,15738,8,,,,Autocuration,,,,,In vitro affinity against serotonin ( 5-hydroxytryptamine 2A receptor ) receptor,B,,,,12687
2425,15738,9,,,,Expert,,,,10116.0,In vitro affinity against serotonin 5-hydroxytryptamine 2A receptor,B,,Rattus norvegicus,,12687
2426,15026,8,,,,Autocuration,,,,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]-ketanserin as radioligand,B,,,,12687
2427,16647,8,,,,Expert,,,,,Half-maximal inhibition of [3H]- Ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,B,,,,12687
2428,16647,8,,,,Autocuration,,,,,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat tissue homogenate,B,,,,12687
2429,13345,9,,,,Expert,,,,10116.0,Displacement of [3H]-ketanserin from rat brain 5-hydroxytryptamine 2A receptor,B,,Rattus norvegicus,,12687
2430,1543,8,,,,Autocuration,,,,,Inhibition constant for in vitro inhibition of [3H]ketanserin binding to rat frontal cortex membranes 5-hydroxytryptamine 2A receptor,B,,,Membranes,12687
2431,12444,8,,,,Autocuration,,,,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor rat frontal cortex membrane,B,,,,12687
2432,16404,8,,,,Expert,,,,,Inhibitory constant on 5-hydroxytryptamine 2A receptor of Rat frontal cortex,B,,,,12687
2433,16404,8,,449.0,,Autocuration,,CHO,,,Inhibitory constant on human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,B,,,,12687
2434,15577,8,,,,Expert,,,,,Kinetic inhibition constant evaluated by measuring serotonergic activity,B,,,,12687
2435,15577,8,,,,Autocuration,,,,,Serotonergic activity of the compound.,B,,,,12687
2436,2495,8,,,,Autocuration,,,,,Tested in vitro for its ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat frontal cortex membranes,B,,,,12687
2437,15042,9,,,,Expert,,,,10116.0,The binding affinity was evaluated on 5-hydroxytryptamine 2A receptor expressed in rat cortex by using [3H]ketanserin as radioligand.,B,,Rattus norvegicus,,12687
2438,15026,8,,,,Expert,,,,,In vitro ability to displace [3H]ketanserin binding from 5-hydroxytryptamine 2A receptor in rat striatal membrane.,B,,,,12687
2439,12919,9,,,,Expert,,,,10116.0,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,F,,Rattus norvegicus,,12687
2440,12919,9,,,,Expert,,,,10116.0,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,F,,Rattus norvegicus,,12687
2441,12919,9,,,,Expert,,,,10116.0,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,F,,Rattus norvegicus,,12687
2442,15194,8,,,,Autocuration,,,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,B,,,,12687
2443,15194,8,,,,Autocuration,,,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand.,B,,,,12687
2444,4820,8,,,,Expert,,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor,B,,,,107
2445,6736,8,,,,Autocuration,,,,,Binding affinity against serotonin 5-hydroxytryptamine 2A receptor was determined using human [125I]-eotaxin,B,,,,107
2446,5163,8,,,,Autocuration,,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.000001 mol/L,B,,,,107
2447,5163,8,,,,Autocuration,,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.00001 mol/L,B,,,,107
2448,6011,8,,,,Autocuration,,,,,Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration,B,,,,107
2449,14294,9,,,,Expert,,,,9606.0,Percent inhibition against 5-hydroxytryptamine 2A receptor using [3H]ketanserin at 1 uM,B,,Homo sapiens,,107
2450,5014,8,,,,Autocuration,,,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2A receptor,B,,,,107
2451,17066,8,,,,Expert,,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor,B,,,,107
2452,17515,8,,,,Autocuration,,,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor; inactive at 10 uM,B,,,,107
2453,6736,8,,,,Expert,,,,,Inhibition of [125I]-eotaxin binding to serotonin 5-hydroxytryptamine 2A receptor,B,,,,107
2454,5163,8,,,,Expert,,,,,Affinity for 5-hydroxytryptamine 2A receptor,B,,,,107
2455,16911,8,,723.0,,Expert,,NIH3T3,,,Binding affinity was performed using [3H]ketanserin as the radioligand and stably transfected NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor (GF-62 cells).,B,,,,107
2456,6841,8,,,,Expert,,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,B,,,,107
2457,6119,8,,,,Expert,,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand.,B,,,,107
2458,3962,8,,,,Autocuration,,,,,Compound was evaluated for its binding against 5-hydroxytryptamine 2A receptor,B,,,,107
2459,4373,8,,,,Autocuration,,,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2A receptor was determined,B,,,,107
2460,4373,8,,,,Autocuration,,,,,Binding affinity relative to indolopiperidine (compound 1)for 5-hydroxytryptamine 2A receptor was determined,B,,,,107
2461,3962,8,,,,Autocuration,,,,,Compound was evaluated for its inverse agonist activity against 5-hydroxytryptamine 2A receptor,F,,,,107
2462,1633,8,,,,Expert,,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin,B,,,,107
2463,4373,8,,,,Autocuration,,,,,Binding affinity for 5-hydroxytryptamine 2A receptor was determined,B,,,,107
2464,6576,8,,,,Expert,,,,,Binding affinity towards serotonin 5-hydroxytryptamine 2A receptor,B,,,,107
2465,4687,8,,,,Autocuration,,,,,Evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor,B,,,,107
2466,16946,8,,,,Autocuration,,,,,Ability to displace [3H]-ketanserin from 5-hydroxytryptamine 2A receptor,B,,,,107
2467,14159,8,,,,Autocuration,,,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 2A receptor,B,,,,107
2468,3032,8,,449.0,,Expert,,CHO,,10090.0,In vitro binding affinity against 5-hydroxytryptamine 2A receptor in CHO cells,B,,Mus musculus,,107
2469,16655,8,,,,Autocuration,,,,,Inhibition of ketanserin binding to 5-hydroxytryptamine 2A receptor,B,,,,107
2470,13964,8,,,,Autocuration,,,,,Binding affinity at 5-hydroxytryptamine 2A receptor,B,,,,107
2471,16989,8,,,,Expert,,,,,Binding affinity towards Serotonin 5-hydroxytryptamine 2A receptor,B,,,,107
2472,16117,8,,,,Autocuration,,,,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor was determined,B,,,,107
2473,16700,8,,,,Autocuration,,,,,The binding affinity towards 5-hydroxytryptamine 2A receptor; No affinity,B,,,,107
2474,3269,8,,,,Autocuration,,,,,Affinity against 5-hydroxytryptamine 2A receptor,B,,,,107
2475,1274,9,,,,Expert,,,,9606.0,Binding affinity against 5-Hydroxytryptamine 2A receptor,B,,Homo sapiens,,107
2476,1317,8,,,,Autocuration,,,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using radioligand binding assay,B,,,,107
2477,12146,8,,,,Autocuration,,,,,Tested against 5-hydroxytryptamine 2A receptor,B,,,,107
2478,12652,4,,,,Autocuration,,,,,Binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,B,,,,105075
2479,12652,4,,,,Autocuration,,,,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H] ketanserin,B,,,,105075
2480,12652,4,,,,Autocuration,,,,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor agonist [125I]- - (+/-)DOI,B,,,,105075
2481,12652,4,,,,Autocuration,,,,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,B,,,,105075
2482,16647,8,,,,Autocuration,,,,,Selectivity ratio towards 5-hydroxytryptamine 2A receptor to Dopamine receptor D2 (5-HT2A/D2 ),B,,,,107
2483,15851,9,,722.0,,Expert,,HEK293,,9606.0,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND means no data,B,,Homo sapiens,,227
2484,6857,9,,449.0,,Expert,,CHO,,9606.0,Functional activity against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader,F,,Homo sapiens,,227
2485,3805,8,,,,Autocuration,,,,,In vitro binding affinity against human 5-HT2B receptor at a concentration of 100 (nM),B,,,,227
2486,6491,9,,,,Expert,,,,9606.0,Affinity towards human 5-hydroxytryptamine 2B serotonin receptor,B,,Homo sapiens,,227
2487,14093,8,,,,Autocuration,,,,,Agonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT radioligand,F,,,,227
2488,13481,8,,,,Autocuration,,,,,Agonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]-5-HT as radioligand,F,,,,227
2489,14093,8,,,,Autocuration,,,,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand,F,,,,227
2490,14093,8,,,,Autocuration,,,,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand; Not tested,F,,,,227
2491,14093,8,,,,Autocuration,,,,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine radioligand,F,,,,227
2492,13481,8,,,,Autocuration,,,,,Antagonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,F,,,,227
2493,14442,8,,,,Autocuration,,,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine as radioligand,B,,,,227
2494,14442,8,,,,Autocuration,,,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT 2B as radioligand,B,,,,227
2495,14442,8,,,,Autocuration,,,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,B,,,,227
2496,12369,8,,,,Autocuration,,,,,The compound evaluated for its affinity against 5-hydroxytryptamine 2A receptor,B,,,,107
2497,12369,8,,,,Expert,,,,,Affinity against 5-hydroxytryptamine 2A receptor (D) labeled with [125I]DOI.,B,,,,107
2498,12369,8,,,,Expert,,,,,Affinity against 5-hydroxytryptamine 2A receptor (K) labeled with [3H]ketanserin.,B,,,,107
2499,14447,8,,,,Autocuration,,,,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes,B,,,,107
2500,14447,8,,,,Autocuration,,,,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes.,B,,,,107
2501,17451,8,,723.0,,Autocuration,,NIH3T3,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,B,,,,107
2502,6857,8,,449.0,,Autocuration,,CHO,,,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,F,,,,107
2503,6857,9,,449.0,,Expert,,CHO,,9606.0,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,F,,Homo sapiens,,107
2504,5635,4,,,,Autocuration,,,,,Selectivity ratio of binding affinity of 5-hydroxytryptamine 2A receptor to that of 5-hydroxytryptamine 2C receptor.,B,,,,104817
2505,12861,8,,,,Autocuration,,,,,Binding activity radioligand.,B,,,,107
2506,12861,8,,,,Autocuration,,,,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,B,,,,107
2507,5105,8,,307.0,,Autocuration,,L929,,,Binding affinity for human cloned 5-HT2A receptor expressed in L929 cells using [125I]R91150 as radioligand,B,,,,107
2508,5104,8,,307.0,,Expert,,L929,,,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand,B,,,,107
2509,5105,8,,307.0,,Expert,,L929,,,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells by [125I]R91150 displacement.,B,,,,107
2510,5105,8,,307.0,,Autocuration,,L929,,,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand; Not tested,B,,,,107
2511,5254,8,,,,Autocuration,,,,,Binding affinity against 5-HT2A receptor,B,,,,107
2512,5254,8,,,,Autocuration,,,,,Binding affinity against 5-hydroxytryptamine 2A receptor,B,,,,107
2513,13267,8,,722.0,,Autocuration,,HEK293,,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,B,,,,107
2514,13267,8,,722.0,,Autocuration,,HEK293,,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,B,,,,107
2515,14157,9,,722.0,,Expert,,HEK293,,9606.0,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells,B,,Homo sapiens,,107
2516,12936,9,,722.0,,Expert,,HEK293,,9606.0,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,B,,Homo sapiens,,107
2517,14068,8,,,,Expert,,,,,Binding affinity against human 5-hydroxytryptamine 2A receptor using displacement of [3H]5-HT,B,,,,107
2518,12936,9,,722.0,,Expert,,HEK293,,9606.0,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,B,,Homo sapiens,,107
2519,12936,9,,722.0,,Expert,,HEK293,,9606.0,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,B,,Homo sapiens,,107
2520,4540,9,,722.0,,Expert,,HEK293,,9606.0,Binding affinity to human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]- ketanserin as radioligand,B,,Homo sapiens,,107
2521,6166,8,,,,Expert,,,,,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor.,B,,,,107
2522,17296,8,,722.0,,Autocuration,,HEK293,,,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,B,,,,107
2523,17296,8,,722.0,,Autocuration,,HEK293,,,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,B,,,,107
2524,17296,8,,722.0,,Autocuration,,HEK293,,,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]ketanserin as radioligand,B,,,,107
2525,15779,9,,722.0,,Expert,,HEK293,,9606.0,Binding affinity towards 5-hydroxytryptamine 2A receptor (human cloned receptor) in HEK 293 cells using [3H]ketanserin as radioligand.,B,,Homo sapiens,,107
2526,14391,8,,722.0,,Expert,,HEK293,,,Binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells using [3H]ketanserin as radioligand,B,,,,107
2527,15851,8,,722.0,,Expert,,HEK293,,,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2A in HEK293 cells, using [3H]ketanserin as radioligand.",B,,,,107
2528,15851,9,,722.0,,Expert,,HEK293,,9606.0,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells; compound is insoluble,B,,Homo sapiens,,107
2529,3832,8,,722.0,,Expert,,HEK293,,,Binding affinity towards human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by displacement of [3H]ketanserin,B,,,,107
2530,3833,8,,722.0,,Expert,,HEK293,,,In vitro binding affinity at human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by [3H]ketanserin displacement.,B,,,,107
2531,12936,9,,722.0,,Expert,,HEK293,,9606.0,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,B,,Homo sapiens,,107
2532,17451,8,,723.0,,Autocuration,,NIH3T3,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand,B,,,,107
2533,17451,8,,723.0,,Autocuration,,NIH3T3,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,B,,,,107
2534,17451,8,,723.0,,Autocuration,,NIH3T3,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,B,,,,107
2535,4199,8,,722.0,,Autocuration,,HEK293,,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]ketanserin as the radioligand,B,,,,107
2536,1883,8,,485.0,,Autocuration,,CHO-K1,,,Compound was evaluated for displacement of [3H]ketanserin from human cloned 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells,B,,,,107
2537,1883,8,,485.0,,Expert,,CHO-K1,,,Displacement of [3H]-ketanserin from human cloned 5-hydroxytryptamine 2A receptor expressed in CHO-K1 cells.,B,,,,107
2538,14875,9,,,,Expert,,,,9606.0,Binding affinity for human 5-hydroxytryptamine 2A receptor,B,,Homo sapiens,,107
2539,15146,8,,722.0,,Autocuration,,HEK293,,,Compound was tested for its binding affinity against 5-hydroxytryptamine 2A receptor in human cloned receptors in HEK 293 cells using [3H]ketanserin,B,,,,107
2540,5213,8,,722.0,,Autocuration,,HEK293,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2A receptor in HEK 293 using [3H]ketanserin as a radioligand,B,,,,107
2541,16404,9,,449.0,,Expert,,CHO,,9606.0,Inhibitory constant for human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,B,,Homo sapiens,,107
2542,14818,8,,722.0,,Autocuration,,HEK293,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2A receptor in HEK293 cells using [3H]-ketanserin.,B,,,,107
2543,4829,8,,722.0,,Autocuration,,HEK293,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2A receptor in HEK293 cells, using [3H]ketanserin as radioligand",B,,,,107
2544,12652,8,,723.0,,Autocuration,,NIH3T3,,,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2A receptor in 3T3 cells,F,,,,10620
2545,4682,8,,723.0,,Expert,,NIH3T3,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells,B,,,,107
2546,12652,8,,,,Autocuration,,,,,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2A receptor,F,,,,10620
2547,4921,8,,,,Autocuration,,,,,Ability to displace [3H]-Ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor,B,,,,10621
2548,4921,8,,,,Autocuration,,,,,Ability to displace [3H]ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor; ND denotes not determined,B,,,,10621
2549,16312,8,,,,Autocuration,,,,9986.0,Binding affinity against rabbit aorta 5-HT2A receptor,B,,Oryctolagus cuniculus,,107
2550,14998,8,,,,Expert,,,,9986.0,Binding affinity for 5-hydroxytryptamine 2A receptor of rabbit aorta ring preparations,B,,Oryctolagus cuniculus,,107
2551,14025,8,,,,Expert,,,,9986.0,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 2A receptor in the rabbit saphenous aorta,B,,Oryctolagus cuniculus,,107
2552,13047,8,,,,Autocuration,,,,9986.0,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,B,,Oryctolagus cuniculus,,107
2553,13047,8,,,,Expert,,,,9986.0,The compound was tested for binding affinity against 5-HT2A receptor,B,,Oryctolagus cuniculus,,107
2554,1883,8,,485.0,,Autocuration,,CHO-K1,,,Compound was evaluated for displacement of [3H]ketanserin from cloned rat 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells.,B,,,,10576
2555,13463,8,,,,Autocuration,,,,,Binding affinity analysed towards 5-HT 2A in rat jugular vein,B,,,,12687
2556,13463,8,,,,Autocuration,,,,,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,B,,,,12687
2557,13463,8,,,,Autocuration,945.0,,Stomach,,Binding affinity analysed on 5-HT 2A in rat stomach fundus.,B,,,,12687
2558,13463,9,,,,Expert,945.0,,Stomach,10116.0,Binding affinity for 5-HT 2A in rat stomach fundus,B,,Rattus norvegicus,,12687
2559,13463,8,,,,Autocuration,,,,,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,B,,,,12687
2560,16326,8,,723.0,,Expert,,NIH3T3,,,Ability to stimulate phosphoinositide hydrolysis in NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor,B,,,,12687
2561,14093,8,,,,Autocuration,,,,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2A receptor,F,,,,12687
2562,14093,8,,,,Autocuration,,,,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast expressing 5-hydroxytryptamine 2A receptor,F,,,,12687
2563,15740,8,,,,Autocuration,,,,,Evaluated for the effective concentration at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,B,,,,12687
2564,16633,8,,,,Autocuration,,,,,Functional potency at the rat 5-hydroxytryptamine 2A receptor as effective concentration EC50 for stimulating Phosphoinositide accumulation,B,,,,12687
2565,17200,9,,,,Expert,,,,10116.0,In vitro relative agonist activity against 5-hydroxytryptamine 2A using PI assay in rat vascular smooth muscle cells,F,,Rattus norvegicus,,12687
2566,17133,8,,,,Autocuration,,,,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,B,,,,12687
2567,17133,8,,,,Autocuration,,,,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,B,,,,12687
2568,17133,8,,,,Autocuration,,,,,Tested for its ability to activate phospholipase c by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,B,,,,12687
2569,17200,8,,,,Autocuration,,,,,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,F,,,,12687
2570,15363,8,,,,Autocuration,,,,,Efficacy at 5-hydroxytryptamine 2A receptor,F,,,,12687
2571,17200,8,,,,Autocuration,,,,,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),B,,,,12687
2572,17200,9,,,,Expert,,,,10116.0,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),B,,Rattus norvegicus,,12687
2573,17200,9,,,,Expert,,,,10116.0,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor determined by using PI assay (Emax),B,,Rattus norvegicus,,12687
2574,17200,9,,,,Expert,,,,10116.0,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,F,,Rattus norvegicus,,12687
2575,17200,8,,,,Autocuration,,,,,The receptor (5-hydroxytryptamine 2A) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,F,,,,12687
2576,17211,8,,,,Autocuration,,,,,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor,B,,,,12687
2577,17331,8,,,,Expert,,,,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes,B,,,,12687
2578,13565,8,,,,Expert,,,,,Binding affinity to serotonin 5-hydroxytryptamine 2A receptors using a radioligand [3H]ketanserin binding assay in rat cortical membranes,B,,,,12687
2579,13730,8,,,,Expert,,,,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was evaluated using [3H]- ketanserin as radioligand,B,,,,12687
2580,12416,8,,,,Expert,,,,,In vitro affinity towards 5-hydroxytryptamine 2A receptor using [3H]spiroperidol as radioligand in cortex,B,,,,12687
2581,15295,8,,,,Autocuration,,,,,Compound was tested for it's binding affinity towards 5-hydroxytryptamine 2A receptor,B,,,,12687
2582,1742,8,,,,Autocuration,,,,,Compound was tested for its ability to displace [3H]DOB from 5-hydroxytryptamine 2A receptor in rat cortex homogenates,B,,,,12687
2583,15295,8,,,,Autocuration,,,,,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor,B,,,,12687
2584,14970,8,,,,Expert,,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]ketanserin as radioligand,B,,,,12687
2585,16693,8,,,,Expert,,,,,In vitro binding affinity for serotonin 5-hydroxytryptamine 2A receptor of rat cerebral cortex using [3H]ketanserin as radioligand,B,,,,12687
2586,14776,9,,,,Expert,,,,10116.0,Inhibition of [3H]ketanserin binding to rat frontal cortex membrane 5-hydroxytryptamine 2A receptor,B,,Rattus norvegicus,,12687
2587,14286,8,,,,Autocuration,,,,,In vitro inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cortical membrane,B,,,,12687
2588,17200,9,,,,Expert,,,,10116.0,In vitro inhibition of [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,B,,Rattus norvegicus,,12687
2589,15306,8,,,,Expert,,,,,Inhibitory concentration against 5-hydroxytryptamine 2A receptor (Inactive at >1000 nM concentration),B,,,,12687
2590,14178,9,,,,Expert,,,,10116.0,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2A receptor,B,,Rattus norvegicus,,12687
2591,14229,9,,,,Expert,,,,10116.0,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor from rat brain,B,,Rattus norvegicus,,12687
2592,12884,8,,,,Expert,,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor binding site using [3H]ketanserin. ,B,,,,12687
2593,13149,8,,,,Expert,,,,,"Binding affinity for 5-hydroxytryptamine 2A receptor, activity is expressed as IC50 values.",B,,,,12687
2594,15295,9,,,,Expert,,,,10116.0,Displacement of [3H]ketanserin from rat cortical membrane 5-hydroxytryptamine 2A receptor at 10e-7 M,B,,Rattus norvegicus,,12687
2595,15740,8,,,,Autocuration,,,,,Intrinsic activity was determined at 5-hydroxytryptamine 2A receptor which is percentage response given compared with the response produced by 10 uM serotonin.,B,,,,12687
2596,15185,8,,,,Autocuration,,,,,"Compound was tested for binding affinity at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate using [125I]-2,5-Dimethoxy -4-iodoamphetamine (DOI).",B,,,,12687
2597,15185,8,,,,Autocuration,,,,,"Compound was tested for binding affinity using [3H]MDL-100,907 at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate.",B,,,,12687
2598,17529,8,,,,Expert,,,,,Ability to bind to central serotonin 5-hydroxytryptamine 2A receptor in vitro in cortex of the rat brain using [3H]ketanserin radioligand,B,,,,12687
2599,14826,8,,,,Autocuration,,,,,Ability to displace [3H]- ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,B,,,,12687
2600,17211,8,,,,Expert,,,,,Displacement of [3H]ketanserin (0.5 nM) from rat cerebral cortex 5-hydroxytryptamine 2A receptors,B,,,,12687
2601,14826,8,,,,Autocuration,,,,,Ability to displace [3H]ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,B,,,,12687
2602,14093,8,,,,Autocuration,,,,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,B,,,,12687
2603,14093,8,,,,Autocuration,,,,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor; Not tested,B,,,,12687
2604,13246,8,,723.0,,Expert,,NIH3T3,,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor in NIH3T3 cell line membranes,B,,,,12687
2605,13246,8,,,,Expert,,,,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor.,B,,,,12687
2606,15436,9,,,,Expert,,,,10116.0,Affinity 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,B,,Rattus norvegicus,,12687
2607,15436,9,,,,Expert,,,,10116.0,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,B,,Rattus norvegicus,,12687
2608,14442,8,,,,Autocuration,955.0,,Brain,,Affinity at [3H]ketanserin-labeled 5-hydroxytryptamine 2A receptor in rat brain homogenate was determined,B,,,,12687
2609,12457,8,,,,Expert,,,,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2A receptor,B,,,,12687
2610,12457,8,,723.0,,Expert,,NIH3T3,,,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2A receptor,B,,,,12687
2611,14755,8,,,,Autocuration,,,,,"Antagonistic activity measured for 5-hydroxytryptamine 2A receptor using [3H]-MDL- 100,907 as radioligand in rat cortical homogenates.",F,,,,12687
2612,4707,8,,,,Autocuration,,,,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was determined using [125I]- DOI as radioligand,B,,,,12687
2613,13297,8,,,,Expert,,,,,Binding affinity against 5-hydroxytryptamine 2A receptor,B,,,,12687
2614,17331,8,,,,Expert,,,,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat prefrontal cerebral cortex mambranes,B,,,,12687
2615,4664,8,,,,Autocuration,,,,,Binding affinity against 5-hydroxytryptamine 2A receptor from rat forebrain using [3H]ketanserin as radioligand,B,,,,12687
2616,16633,8,,,,Autocuration,,,,,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,B,,,,12687
2617,4664,9,,723.0,,Expert,,NIH3T3,,10116.0,Binding affinity against 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells using [3H]ketanserin,B,,Rattus norvegicus,,12687
2618,16133,8,,,,Expert,,,,,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,B,,,,12687
2619,16133,8,,,,Expert,,,,,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,B,,,,12687
2620,14060,9,,,,Expert,,,,10116.0,Binding affinity against rat brain 5-hydroxytryptamine 2A receptor,B,,Rattus norvegicus,,12687
2621,16326,8,,,,Expert,,,,,Binding affinity at cloned rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,B,,,,12687
2622,16659,8,,449.0,,Expert,,CHO,,,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,B,,,,12687
2623,14776,8,,,,Autocuration,,,,,Binding affinity measured at the 5-hydroxytryptamine 2A receptor by the inhibition of [3H]ketanserin binding to rat cortex using unlabeled mianserin for nonspecific binding.,B,,,,12687
2624,13481,8,,,,Autocuration,,,,,Binding affinity of [3H]- ketanserin labelled towards Rat cortical 5-hydroxytryptamine 2A receptor using radioligand binding assay,B,,,,12687
2625,17386,8,,,,Autocuration,,,,,Binding affinity of compound was tested for 5-hydroxytryptamine 2A receptor,B,,,,12687
2626,6611,9,,,,Expert,,,,10116.0,Binding affinity for 5-hydroxytryptamine 2A receptor,B,,Rattus norvegicus,,12687
2627,14423,8,,,,Autocuration,,,,,Binding affinity against 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as the radioligand.,B,,,,12687
2628,15412,8,,,,Autocuration,,,,,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex,B,,,,12687
2629,15412,8,,,,Autocuration,,,,,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex.,B,,,,12687
2630,6238,8,,,,Autocuration,,,,,Binding affinity towards 5-HT 2A receptor in rat cerebral frontal cortex membranes using [3H]ketanserin as radioligand,B,,,,12687
2631,6648,8,,,,Expert,,,,,Binding affinity at 5-hydroxytryptamine 2A receptor of rat.,B,,,,12687
2632,5667,8,,,,Expert,,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor sites by using [3H]ketanserin as radioligand,B,,,,12687
2633,6611,9,,,,Expert,,,,10116.0,Binding affinity for 5-hydroxytryptamine 2A serotonin receptor,B,,Rattus norvegicus,,12687
2634,13481,8,,,,Autocuration,,,,,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,B,,,,12687
2635,13481,8,,,,Autocuration,,,,,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand; Not tested,B,,,,12687
2636,15558,8,,723.0,,Expert,,NIH3T3,,,Displacement of [3H]ketanserin from NIH3T3 cells stably expressing rat 5-hydroxytryptamine 2A receptor,B,,,,12687
2637,6013,8,,,,Autocuration,,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor,B,,,,12687
2638,16633,8,,,,Autocuration,,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,B,,,,12687
2639,6013,8,,,,Autocuration,,,,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor from fundus tissue was determined using [3H]mesulergine as radioligand,B,,,,12687
2640,6013,9,,,,Expert,,,,10116.0,Binding affinity for rat 5-hydroxytryptamine 2A receptor using [3H]DOB,B,,Rattus norvegicus,,12687
2641,6013,8,,,,Autocuration,,,,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor was determined using [3H]DOB as radioligand; ND=No data,B,,,,12687
2642,6013,8,,,,Expert,,,,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor by [3H]ketanserin displacement.,B,,,,12687
2643,6013,8,,,,Autocuration,,,,,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]DOB as radioligand,B,,,,12687
2644,6013,8,,,,Autocuration,,,,,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]ketanserin as radioligand,B,,,,12687
2645,16293,8,,,,Autocuration,,,,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor,B,,,,12687
2646,17175,8,,723.0,,Expert,,NIH3T3,,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor expressed in NIH3T3 cells using [3H]ketanserin as radioligand,B,,,,12687
2647,13278,9,,,,Expert,,,,10116.0,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,B,,Rattus norvegicus,,12687
2648,3682,8,,,,Autocuration,5383.0,,Caudate-putamen,,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2A receptor in homogenate of caudate putamen tissue from rat brain,B,,,,12687
2649,2014,8,,,,Autocuration,,,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand,B,,,,12687
2650,2014,8,,,,Autocuration,,,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand; Not determined,B,,,,12687
2651,4932,8,,,,Autocuration,,,,,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2A receptor in cloned rat cell culture,B,,,,12687
2652,4932,8,,,,Autocuration,,,,,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2A receptor in cloned rat prefrontal cortex homogenate,B,,,,12687
2653,3935,8,,,,Autocuration,,,,,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2A receptor,B,,,,12687
2654,5432,9,,,,Expert,10000000.0,,Hippocampus,10116.0,Displacement of [3H]8-OH-DPAT from rat hippocampus membrane 5-hydroxytryptamine 2A receptor,B,,Rattus norvegicus,,12687
2655,15818,8,,,,Autocuration,,,,,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2A receptor,B,,,,12687
2656,13672,8,,,,Autocuration,,,,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand.,B,,,,12687
2657,13672,8,,,,Autocuration,,,,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]-ketanserin radioligand.,B,,,,12687
2658,14749,8,,723.0,,Expert,,NIH3T3,,,Binding affinity against rat 5-hydroxytryptamine 2A receptor in NIH3T3 cells.,B,,,,12687
2659,13462,8,,,,Autocuration,,,,,Compound was tested for the Binding affinity against rat frontal cortex 5-hydroxytryptamine 2A receptor by Radio ligand [3H]ketanserin binding assay.,B,,,,12687
2660,15740,8,,,,Autocuration,,,,,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,B,,,,12687
2661,16647,8,,,,Expert,,,,,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,B,,,,12687
2662,13345,8,,,,Autocuration,955.0,,Brain,,In vitro ability to displace [3H]ketanserin from 5-hydroxytryptamine 2A receptor in rat brain.,B,,,,12687
2663,16740,8,,,,Autocuration,,,,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,B,,,,12687
2664,16740,8,,,,Autocuration,,,,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,B,,,,12687
2665,15535,9,,,,Expert,,,,10116.0,In vitro binding affinity at 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat cortex,B,,Rattus norvegicus,,12687
2666,16740,8,,,,Expert,,,,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,B,,,,12687
2667,16740,8,,,,Autocuration,,,,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,B,,,,12687
2668,16740,8,,,,Autocuration,,,,,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane,B,,,,12687
2669,4795,9,,,,Expert,,,,10116.0,Displacement of [3H]- Ketanserin from rat cortex 5-hydroxytryptamine 2A receptor,B,,Rattus norvegicus,,12687
2670,8,8,,,,Expert,,,,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand,B,,,,12687
2671,8,8,,,,Autocuration,,,,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand; Not active at 10-5 M,B,,,,12687
2672,17200,9,,,,Expert,,,,10116.0,In vitro inhibitory constant against [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,B,,Rattus norvegicus,,12687
2673,2148,9,,,,Expert,,,,10116.0,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor of rat brain cortex,B,,Rattus norvegicus,,12687
2674,13345,5,,,,Expert,,,,10116.0,"Relative binding affinity for D2 receptor and 5-hydroxytryptamine 2A receptor, ratio of Ki",B,,Rattus norvegicus,,105102
2675,5088,8,,,,Autocuration,,,,,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,B,,,,12687
2676,5088,8,,,,Autocuration,,,,,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,B,,,,12687
2677,17133,8,,,,Autocuration,,,,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2A receptor using [125 I]-DOI as radioligand,B,,,,12687
2678,17133,9,,,,Expert,,,,10116.0,In vitro binding to 5-hydroxytryptamine 2A receptor using [125 I]-DOI,B,,Rattus norvegicus,,12687
2679,16532,8,,,,Autocuration,,,,,The binding affinity at 5-hydroxytryptamine 2A receptor was determined using [3H]ketanserin,B,,,,12687
2680,15086,8,,,,Autocuration,,,,,The compound was tested for binding affinity against 5-hydroxytryptamine 2A receptor,B,,,,12687
2681,2309,9,,,,Expert,,,,10116.0,Binding affinity for 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,B,,Rattus norvegicus,,12687
2682,12953,8,,,,Expert,,,,,Binding affinity to 5-hydroxytryptamine 2A receptor from rat cortex assayed using [3H]ketanserin as radioligand.,B,,,,12687
2683,12953,8,,,,Autocuration,,,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as radioligand.; Nonactive at 10 uM,B,,,,12687
2684,12953,8,,,,Autocuration,,,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]-ketanserin as radioligand; Nonactive at 10 uM,B,,,,12687
2685,16659,8,,449.0,,Autocuration,,CHO,,,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells; ND is No Data,B,,,,12687
2686,16740,8,,,,Autocuration,,,,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,B,,,,12687
2687,16740,8,,,,Autocuration,,,,,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,B,,,,12687
2688,17133,8,,,,Autocuration,,,,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor; Not determined,B,,,,12687
2689,17211,8,,,,Autocuration,,,,,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor; NT=not tested,B,,,,12687
2690,17331,8,,,,Autocuration,,,,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes; Not tested,B,,,,12687
2691,16633,8,,,,Autocuration,,,,,Compound was evaluated for effective dose measured in nmol/kg following a dose of 0.04 mg/kg and 0.093 uM/kg (95%CI); range 32-63,B,,,,12687
2692,16633,8,,,,Autocuration,,,,,Compound was evaluated for the percentage of rats disrupted following a dose of 0.04 mg/kg and 0.097 uM/kg,B,,,,12687
2693,16633,8,,,,Autocuration,,,,,Compound was evaluated for the percentage of rats disrupted following a dose of 0.08 mg/kg and 0.194 uM/kg,B,,,,12687
2694,15026,8,,,,Expert,,,,,Ratio of pKi of 5-HT2A to that of 5-HT2C receptor,B,,,,12687
2695,15026,8,,,,Expert,,,,,Ratio of pKi of 5-HT2A to that of D2 receptor,B,,,,12687
2696,16404,4,,,,Expert,,,,,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,B,,,,105093
2697,16404,4,,,,Expert,,,,,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,B,,,,105093
2698,16404,4,,,,Expert,,,,,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor,B,,,,105075
2699,16404,8,,,,Autocuration,,,,,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor; ND is no data,B,,,,12687
2700,16326,8,,,,Expert,,,,,Percent maximal 5-HT stimulation at cloned rat 5-hydroxytryptamine 2A receptor (phosphoinositide hydrolysis study) at a conc of 100 uM,B,,,,12687
2701,15847,8,,,,Autocuration,,,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat,F,,,,12687
2702,15847,8,,,,Autocuration,,,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat; ND means not done,F,,,,12687
2703,15329,8,,,,Autocuration,,,,,Effectiveness of compound in blocking 5-hydroxytryptamine 2A receptor-mediated contractions of rat tail artery,F,,,,12687
2704,16404,8,,,,Expert,1515.0,,Thoracic aorta,,Negative log concentration of antagonist on 5-hydroxytryptamine 2A receptor in rat thoracic aorta,F,,,,12687
2705,16404,8,,,,Expert,1515.0,,Thoracic aorta,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta,F,,,,12687
2706,16404,8,,,,Autocuration,1515.0,,Thoracic aorta,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta; ND is not determined.,F,,,,12687
2707,12861,8,,,,Autocuration,,,,,Binding activity radioligand.,B,,,,12687
2708,12861,8,,,,Expert,,,,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,B,,,,12687
2709,12861,8,,,,Autocuration,,,,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,B,,,,12687
2710,12490,8,,,,Expert,,,,,Displacement of [3H]DOB binding to 5-hydroxytryptamine 2A receptor from rat cortex homogenate,B,,,,12687
2711,12827,8,,339.0,,Autocuration,,N1E-115,,,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930,B,,,,12687
2712,12827,8,,339.0,,Autocuration,,N1E-115,,,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930; Not determined,B,,,,12687
2713,12918,8,,,,Autocuration,,,,,Binding affinity was evaluated by 5-hydroxytryptamine 2A receptor agonism in the rat cortex by displacing ketanserin,B,,,,12687
2714,12919,9,,,,Expert,,,,10116.0,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]-ketanserin,F,,Rattus norvegicus,,12687
2715,17723,8,,,,Autocuration,,,,,Binding affinity towards human serotonin 5-hydroxytryptamine 2C receptor,B,,,,108
2716,6013,8,,,,Autocuration,,,,,Binding affinity towards 5-hydroxytryptamine 2C receptor,B,,,,108
2717,16293,8,,,,Autocuration,,,,,Binding affinity towards human 5-hydroxytryptamine 2C receptor,B,,,,108
2718,3857,8,,,,Expert,,,,,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,B,,,,108
2719,3857,8,,,,Expert,,,,,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor; Not determined,B,,,,108
2720,3857,8,,,,Expert,,,,,Binding affinity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,B,,,,108
2721,15363,8,,,,Autocuration,,,,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,B,,,,108
2722,15363,8,,,,Autocuration,,,,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,B,,,,108
2723,16441,8,,,,Expert,,,,,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]mesulergine,B,,,,108
2724,16441,8,,,,Expert,,,,,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]-mesulergine; ND is No Data.,B,,,,108
2725,4176,8,,722.0,,Autocuration,,HEK293,,,In vitro binding affinity towards human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells was determined using [3H]mesulergine as radioligand,B,,,,108
2726,17085,8,,,,Autocuration,,,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2C receptor,B,,,,108
2727,17200,9,,,,Expert,,,,9606.0,Inhibitory constant against cloned human 5-hydroxytryptamine 2C receptor using with [125I]- DOI radioligand,B,,Homo sapiens,,108
2728,5088,8,,,,Expert,,,,,Binding affinity towards human 5-hydroxytryptamine 2C receptor.,B,,,,108
2729,5088,8,,,,Autocuration,,,,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]DOB as radioligand,B,,,,108
2730,5088,8,,,,Autocuration,,,,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,B,,,,108
2731,5088,8,,,,Autocuration,,,,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,B,,,,108
2732,16659,8,,449.0,,Autocuration,,CHO,,,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,B,,,,108
2733,16659,8,,449.0,,Autocuration,,CHO,,,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells; ND is no data,B,,,,108
2734,17451,8,,723.0,,Autocuration,,NIH3T3,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,B,,,,108
2735,6857,9,,449.0,,Expert,,CHO,,9606.0,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,F,,Homo sapiens,,108
2736,3857,8,,,,Expert,,,,,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,B,,,,108
2737,12861,8,,,,Autocuration,,,,,Binding activity radioligand.,B,,,,108
2738,12861,8,,,,Autocuration,,,,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,B,,,,108
2739,5104,8,,449.0,,Expert,,CHO,,,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand,B,,,,108
2740,5105,8,,449.0,,Expert,,CHO,,,Binding affinity at human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells by [3H]mesulergine displacement.,B,,,,108
2741,5105,8,,449.0,,Autocuration,,CHO,,,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand; NT means not tested,B,,,,108
2742,5254,8,,,,Autocuration,,,,,Binding affinity against 5-HT2C receptor,B,,,,108
2743,13267,8,,722.0,,Autocuration,,HEK293,,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,B,,,,108
2744,14157,9,,722.0,,Expert,,HEK293,,9606.0,Displacement of [3H]mesulergine from 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells,B,,Homo sapiens,,108
2745,12936,9,,722.0,,Expert,,HEK293,,9606.0,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,B,,Homo sapiens,,108
2746,14068,8,,,,Expert,,,,,Binding affinity against human 5-hydroxytryptamine 2C receptor using displacement of [3H]DOB,B,,,,108
2747,12936,9,,722.0,,Expert,,HEK293,,9606.0,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,B,,Homo sapiens,,108
2748,4540,9,,722.0,,Expert,,HEK293,,9606.0,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand,B,,Homo sapiens,,108
2749,4540,9,,722.0,,Expert,,HEK293,,9606.0,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand; Nd means not determined,B,,Homo sapiens,,108
2750,6166,8,,,,Autocuration,,,,,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor was determined,B,,,,108
2751,17296,8,,722.0,,Autocuration,,HEK293,,,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptors in HEK 293 cells using [3H]mesulergine as radioligand,B,,,,108
2752,17296,8,,722.0,,Autocuration,,HEK293,,,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]mesulergine as radioligand,B,,,,108
2753,15779,8,,722.0,,Autocuration,,HEK293,,,Binding affinity towards 5-HT2C (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,B,,,,108
2754,15779,8,,722.0,,Autocuration,,HEK293,,,Binding affinity towards 5-hydroxytryptamine 2C receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,B,,,,108
2755,14391,8,,722.0,,Expert,,HEK293,,,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells using [3H]mesulergine as radioligand,B,,,,108
2756,15779,8,,722.0,,Autocuration,,HEK293,,,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand",B,,,,108
2757,15851,8,,722.0,,Expert,,HEK293,,,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2C in HEK293 cells, using [3H]mesulergine as radioligand.",B,,,,108
2758,15851,9,,722.0,,Expert,,HEK293,,9606.0,Displacement of [3H]mesulergine from human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells; compound insoluble,B,,Homo sapiens,,108
2759,15779,8,,722.0,,Autocuration,,HEK293,,,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand; no data",B,,,,108
2760,3832,8,,722.0,,Expert,,HEK293,,,Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by displacement of [3H]mesulergine,B,,,,108
2761,3833,8,,722.0,,Expert,,HEK293,,,In vitro binding affinity at human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by [3H]mesulergine displacement.,B,,,,108
2762,17451,8,,723.0,,Autocuration,,NIH3T3,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand,B,,,,108
2763,4199,8,,722.0,,Autocuration,,HEK293,,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine as the radioligand,B,,,,108
2764,1883,8,,485.0,,Expert,,CHO-K1,,,Displacement of [3H]mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO-K1 cells,B,,,,108
2765,4321,9,,,,Expert,,,,9606.0,Binding affinity against 5-hydroxytryptamine 2C receptor,B,,Homo sapiens,,108
2766,14875,8,,,,Autocuration,,,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 2C receptor,B,,,,108
2767,15146,8,,722.0,,Autocuration,,HEK293,,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine,B,,,,108
2768,5213,8,,722.0,,Autocuration,,HEK293,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2C receptor in HEK 293 using [3H]mesulergine as a radioligand,B,,,,108
2769,16404,8,,308.0,,Autocuration,,HeLa,,,Inhibitory constant on human 5-hydroxytryptamine 2C receptor transfected in to HeLa cells,B,,,,108
2770,13267,8,,,,Autocuration,,,,,Selectivity as the ratio of Ki value towards 5-hydroxytryptamine 2C receptor to that of pA2 value towards 5-hydroxytryptamine 2B receptor,F,,,,108
2771,13267,8,,,,Autocuration,10000000.0,,Hippocampus,,The binding affinity (pKi) measured against 5-hydroxytryptamine 3 receptor of rat hippocampus and entorhinal cortex using [3H]granisetron as radioligand,F,,,,108
2772,14818,8,,722.0,,Autocuration,,HEK293,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2C receptor in HEK293 cells using [3H]mesulergine.,B,,,,108
2773,4829,8,,722.0,,Autocuration,,HEK293,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]5-mesulergine as radioligand",B,,,,108
2774,13463,8,,,,Autocuration,,,,,Binding affinity analysed on 5-HT 2C in human clone using [3H]mesulergine as radioligand,B,,,,11864
2775,13463,8,,,,Autocuration,945.0,,Stomach,,Binding affinity analysed on 5-HT 2C in rat stomach fundus,B,,,,11864
2776,13463,8,,,,Autocuration,945.0,,Stomach,,Binding affinity analysed towards 5-HT 2C in rat stomach fundus,B,,,,11864
2777,12652,8,,625.0,,Autocuration,,A9,,,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2C receptor in A9 cells,F,,,,11864
2778,4682,8,,723.0,,Autocuration,,NIH3T3,,,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,B,,,,11864
2779,4682,8,,723.0,,Autocuration,,NIH3T3,,,Binding affinity to 5-hydroxytryptamine 2C receptor measured using radioligand [3H]Mesulergine in stably transfected NIH3T3 cells,B,,,,11864
2780,4682,8,,723.0,,Autocuration,,NIH3T3,,,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,B,,,,11864
2781,12652,8,,,,Autocuration,,,,,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2C receptor,F,,,,11864
2782,13463,8,,,,Autocuration,945.0,,Stomach,10090.0,Binding affinity analysed on 5-HT 2C in rat stomach fundus.,B,,Mus musculus,,12689
2783,13463,9,,,,Expert,945.0,,Stomach,10116.0,Binding affinity towards 5-HT 2C receptor in rat stomach fundus,B,,Rattus norvegicus,,12689
2784,13969,8,,,,Expert,,,,,Binding affinity against 5-Hydroxytryptamine 2C Receptor was measured using [3H]N-methyl-mesulergine as radioligand,B,,,,108
2785,13392,8,,,,Expert,,,,9823.0,Binding affinity for 5-hydroxytryptamine 2C receptor,B,,Sus scrofa,,108
2786,13392,8,,,,Expert,,,,,Binding affinity towards 5-hydroxytryptamine 2C receptor,B,,,,108
2787,14430,8,,,,Expert,,,,,Affinity towards 5-hydroxytryptamine 2C receptor in membranes from pig choroid plexus using [3H]N-methyl-mesulergine,B,,,,108
2788,1742,8,,,,Autocuration,,,,,Compound was tested for its ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor in pig cortex,B,,,,108
2789,14286,8,,,,Autocuration,,,,,In vitro inhibitory concentration against radioligand [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in pig cortical membrane,B,,,,108
2790,5619,8,,,,Autocuration,,,,,Binding affinity towards pig 5-hydroxytryptamine 2C receptor,B,,,,108
2791,15086,8,,,,Autocuration,,,,,The compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,B,,,,108
2792,12861,8,,,,Autocuration,,,,,Binding activity radioligand.,B,,,,108
2793,12861,8,,,,Expert,,,,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,B,,,,108
2794,12861,8,,,,Autocuration,,,,,Binding activity against 5-hydroxytryptamine 3 receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,B,,,,108
2795,12827,8,,,,Autocuration,,,,,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT,B,,,,108
2796,12827,8,,,,Autocuration,,,,,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT; Not determined,B,,,,108
2797,12919,8,,,,Expert,,,,9823.0,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,F,,Sus scrofa,,108
2798,12919,8,,,,Expert,,,,9823.0,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,F,,Sus scrofa,,108
2799,16429,8,,,,Autocuration,,,,9823.0,In vitro binding affinity at 5-hydroxytryptamine 2C receptor in pig choroid plexus using 3[H]mesulergine as the radioligand,B,,Sus scrofa,,108
2800,773,8,,,,Autocuration,,,,9823.0,In Vitro Binding affinity againist 5-hydroxytryptamine 2C receptor by displacing [3H]mesulergine from pig cortex,B,,Sus scrofa,,108
2801,5033,8,,,,Autocuration,,,,9823.0,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2C receptor,B,,Sus scrofa,,108
2802,12861,8,,,,Autocuration,,,,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,B,,,,12687
2803,14093,8,,,,Autocuration,,,,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2C receptor,F,,,,12689
2804,14970,8,,,,Expert,,,,,Binding affinity towards 5-HT2C receptor from rat using [3H]mesulergine as radioligand,B,,,,12689
2805,14970,8,,,,Autocuration,,,,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand,B,,,,12689
2806,14970,8,,,,Autocuration,,,,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand; Not tested,B,,,,12689
2807,14178,9,,,,Expert,,,,10116.0,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2C receptor,B,,Rattus norvegicus,,12689
2808,14178,9,,,,Expert,,,,10116.0,Inhibition of radiolabeled [3H]mesulergine ligand binding to 5-hydroxytryptamine 2C receptor,B,,Rattus norvegicus,,12689
2809,14229,9,,,,Expert,,,,10116.0,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in rat brain membranes,B,,Rattus norvegicus,Brain membranes,12689
2810,16532,8,,,,Autocuration,,,,,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine; Not tested,B,,,,12689
2811,14826,8,,,,Autocuration,,,,,Ability to displace [3H]mesulergine bound to 5-hydroxytryptamine 2C receptor in rat cortex,B,,,,12689
2812,17211,8,,,,Autocuration,,,,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-HT2C receptor,B,,,,12689
2813,17211,8,,,,Expert,,,,,Displacement of [3H]mesulergine (0.5 nM) from rat 5-hydroxytryptamine 2C receptor expressed in SR-3T3 cells,B,In vitro,,,12689
2814,13246,8,,723.0,,Expert,,NIH3T3,,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor in NIH3T3 cell line membranes,B,,,,12689
2815,13246,8,,,,Expert,,,,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor.,B,,,,12689
2816,12457,8,,,,Expert,,,,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2C receptor,B,,,,12689
2817,12457,8,,723.0,,Expert,,NIH3T3,,,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2C receptor,B,,,,12689
2818,4707,8,,,,Autocuration,,,,,Binding affinity towards rat 5-hydroxytryptamine 2C receptor was determined using [125I]- DOI as radioligand,B,,,,12689
2819,13297,8,,,,Expert,,,,,Binding affinity against 5-hydroxytryptamine 2C receptor,B,,,,12689
2820,16633,8,,,,Autocuration,,,,,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,B,,,,12689
2821,16133,8,,,,Expert,,,,,Binding affinity against rat 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,B,,,,12689
2822,16326,8,,,,Expert,,,,,Binding affinity at cloned rat 5-hydroxytryptamine 2C receptor using [3H]DOI as radioligand,B,,,,12689
2823,14423,8,,,,Autocuration,,,,,Binding affinity against 5-hydroxytryptamine 2C receptor from rat cortex using [3H]mesulergine as the radioligand.,B,,,,12689
2824,15412,8,,,,Autocuration,,,,,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex,B,,,,12689
2825,15412,8,,,,Autocuration,,,,,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex.,B,,,,12689
2826,15558,8,,625.0,,Expert,,A9,,,Displacement of [3H]mesulergine from A9 cells stably expressing rat 5-hydroxytryptamine 2C receptor,B,,,,12689
2827,16633,8,,,,Autocuration,,,,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,B,,,,12689
2828,6013,8,,,,Expert,,,,,Binding affinity towards cloned rat 5-hydroxytryptamine 2C receptor from fundus tissue by [3H]mesulergine displacement.,B,,,,12689
2829,17175,8,,,,Expert,,,,,Binding affinity towards rat 5-hydroxytryptamine 2C receptor expressed in A-9 cells using [3H]mesulergine as radioligand,B,In vitro,,,12689
2830,12469,8,,,,Autocuration,,,,,Binding affinity was measured on 5-hydroxytryptamine 2C receptor in J1 cells transfected with rat 5-HT2C gene labeled with [3H]mesulergine,B,,,,12689
2831,3682,8,,,,Autocuration,5383.0,,Caudate-putamen,,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2C receptor in homogenate of caudate putamen tissue from rat brain,B,,,,12689
2832,4932,8,,,,Autocuration,,,,,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2C receptor in cloned rat cell culture,B,,,,12689
2833,4932,8,,,,Autocuration,,,,,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2C receptor in cloned rat prefrontal cortex homogenate; ND denotes no data,B,,,,12689
2834,3935,8,,,,Autocuration,,,,,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2C receptor,B,,,,12689
2835,15818,8,,,,Autocuration,,,,,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2C receptor,B,,,,12689
2836,15818,8,,,,Autocuration,,,,,Compound was evaluated for its binding affinity towards rat r5-hydroxytryptamine 2C receptor,B,,,,12689
2837,14749,8,,,,Expert,,,,,Binding affinity against rat 5-hydroxytryptamine 2C receptor in A-9 cells.,B,,,,12689
2838,15740,8,,,,Autocuration,,,,,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2C receptor,B,,,,12689
2839,17133,9,,,,Expert,,,,10116.0,In vitro binding to 5-hydroxytryptamine 2C receptor using [125 I]-DOI,B,,Rattus norvegicus,,12689
2840,16532,8,,,,Autocuration,,,,,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine,B,,,,12689
2841,12369,8,,,,Autocuration,,,,,The compound evaluated for its affinity against 5-hydroxytryptamine 2C receptor,B,,,,12689
2842,12369,8,,,,Expert,,,,,Affinity against 5-hydroxytryptamine 2C receptor in J1 cells transfected with the rat 5-HT2C gene labeled with [3H]mesulergine.,B,,,,12689
2843,2309,9,,,,Expert,,,,10116.0,Binding affinity against 5-hydroxytryptamine 2C receptor in rat choroid plexus using [3H]N-methyl-mesulergine,B,,Rattus norvegicus,,12689
2844,12953,8,,,,Autocuration,,,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor,B,,,,12689
2845,12953,8,,,,Autocuration,,,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor from rat cortex using [3H]-citalopram as radioligand; Nonactive at 10 uM,B,,,,12689
2846,12953,8,,,,Autocuration,,,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand; Nonactive at 10 uM,B,,,,12689
2847,12953,8,,,,Expert,,,,,Binding affinity for 5-hydroxytryptamine 2C receptor,B,,,,12689
2848,17133,8,,,,Autocuration,,,,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2C receptor using [125 I]-DOI as radioligand; Not determined,B,,,,12689
2849,17211,8,,,,Autocuration,,,,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT denotes not tested,B,,,,12689
2850,17211,8,,,,Autocuration,,,,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT=not tested,B,,,,12689
2851,14025,8,,,,Autocuration,,,,,Affinity pKi for 5-hydroxytryptamine 2C receptor was measured in rat cortex homogenates.,B,,,,12689
2852,14998,8,,,,Autocuration,,,,,Binding affinity against 5-hydroxytryptamine 2C receptor in rat cortex homogenates.,B,,,,12689
2853,4342,8,,,,Autocuration,,,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2C receptor was determined,B,,,,12689
2854,13735,9,,,,Expert,,,,10116.0,Displacement of [3H]mesulergine from rat 5-HT2C receptor expressed in HEK293,B,,Rattus norvegicus,,12689
2855,13181,8,,,,Autocuration,,,,,Binding affinity was determined against cloned human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,B,,,,12689
2856,1883,8,,485.0,,Autocuration,,CHO-K1,,,Compound was evaluated for displacement of [3H]mesulergine from cloned rat 5-hydroxytryptamine 2C receptor in transfected CHO-K1 cells.,B,,,,12689
2857,15194,8,,,,Autocuration,,,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,B,,,,12689
2858,15194,8,,,,Autocuration,,,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand.,B,,,,12689
2859,14579,8,,,,Autocuration,,,,,Compound tested for relative response using 0.1 uM 5-HT as agonist against 5-hydroxytryptamine 2C receptor,F,,,,12689
2860,4639,8,,,,Autocuration,,,,,Compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,B,,,,108
2861,4820,8,,,,Expert,,,,,Binding affinity towards 5-hydroxytryptamine 2C receptor,B,,,,108
2862,14442,8,,,,Autocuration,,,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand; Not Tested,B,,,,227
2863,14755,8,,,,Autocuration,,,,,Binding activity against cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand.,B,,,,227
2864,14744,8,,,,Autocuration,,,,,Binding affinity against the cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand,B,,,,227
2865,6857,9,,,,Expert,,,,9606.0,Affinity for human 5-hydroxytryptamine 2B receptor expressed in mammalian cell line,B,,Homo sapiens,,227
2866,16209,8,,,,Autocuration,,,,,Binding affinity towards human 5-hydroxytryptamine 2B receptor using [3H]5-HT as radioligand,B,,,,227
2867,15363,8,,,,Autocuration,,,,,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,B,,,,227
2868,15363,8,,,,Autocuration,,,,,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,B,,,,227
2869,15363,8,,,,Autocuration,,,,,Compound was tested for the displacement of [3H]5-HT from cloned human 5-hydroxytryptamine 2B receptor,B,,,,227
2870,17085,8,,,,Autocuration,,,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2B receptor,B,,,,227
2871,17200,9,,,,Expert,,,,9606.0,Inhibitory constant against cloned human 5-hydroxytryptamine 2B receptor using with [125I]- DOI radioligand,B,,Homo sapiens,,227
2872,15851,9,,722.0,,Expert,,HEK293,,9606.0,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,B,,Homo sapiens,,227
2873,15851,9,,722.0,,Expert,,HEK293,,9606.0,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,B,,Homo sapiens,,227
2874,6857,9,,449.0,,Expert,,CHO,,9606.0,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,F,,Homo sapiens,,227
2875,6857,9,,449.0,,Expert,,CHO,,9606.0,Rleative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,F,,Homo sapiens,,227
2876,15779,8,,722.0,,Autocuration,,HEK293,,,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",B,,,,227
2877,15851,8,,722.0,,Expert,,HEK293,,,Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells using [3H]5-HT as radioligand.,B,,,,227
2878,15779,8,,722.0,,Autocuration,,HEK293,,,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand; no data",B,,,,227
2879,14157,9,,722.0,,Expert,,HEK293,,9606.0,Displacement of [3H]5-HT from 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells,B,,Homo sapiens,,227
2880,4540,9,,722.0,,Expert,,HEK293,,9606.0,Binding affinity to human cloned 5-HT2B receptor in HEK 293 cells using [3H]- -5-HT as radioligand,B,,Homo sapiens,,227
2881,6166,8,,,,Autocuration,,,,,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor was determined,B,,,,227
2882,15779,8,,722.0,,Autocuration,,HEK293,,,Binding affinity towards 5-hydroxytryptamine 2B receptor (human cloned receptor) in HEK 293 cells using [3H]5-HT as radioligand.,B,,,,227
2883,14391,8,,722.0,,Expert,,HEK293,,,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells using [3H]5-HT as radioligand,B,,,,227
2884,3832,8,,722.0,,Expert,,HEK293,,,Binding affinity towards human cloned 5-HT2B receptor of HEK293 cells by displacement of [3H]5-HT,B,,,,227
2885,3833,8,,722.0,,Expert,,HEK293,,,In vitro binding affinity at human cloned 5-hydroxytryptamine 2B receptor of HEK293 cells by [3H]5-HT displacement.,B,,,,227
2886,15851,9,,722.0,,Expert,,HEK293,,9606.0,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells,B,,Homo sapiens,,227
2887,15851,9,,722.0,,Expert,,HEK293,,9606.0,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; compound is insoluble,B,,Homo sapiens,,227
2888,4199,8,,722.0,,Autocuration,,HEK293,,,Compound was evaluated for binding affinity against human cloned 5-HT2B receptor in HEK 293 cells using [3H]5-HT as the radioligand,B,,,,227
2889,1883,8,,485.0,,Expert,,CHO-K1,,,Displacement of [3H]-5-5HT from human cloned 5-hydroxytryptamine 2B receptor expressed in CHO-K1 cells,B,,,,227
2890,4321,8,,,,Expert,,,,,Binding affinity against 5-hydroxytryptamine 2B receptor,B,,,,227
2891,15146,8,,722.0,,Autocuration,,HEK293,,,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 2B receptor in HEK 293 cells using [3H]5-HT,B,,,,227
2892,5213,8,,722.0,,Autocuration,,HEK293,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2B receptor in HEK 293 using [3H]ketanserin as a radioligand,B,,,,227
2893,14818,8,,722.0,,Autocuration,,HEK293,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2B receptors in HEK293 cells using [3H]5-HT.,B,,,,227
2894,4829,8,,722.0,,Autocuration,,HEK293,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",B,,,,227
2895,4829,8,,722.0,,Autocuration,,HEK293,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",B,,,,227
2896,14025,8,,,,Autocuration,,,,9986.0,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 2B receptor in the endothelium intact rabbit jugular vein.,B,,Oryctolagus cuniculus,,227
2897,13463,8,,,,Expert,945.0,,Stomach,,Binding affinity analysed for 5-HT 2B receptor in rat stomach fundus,B,,,,12688
2898,7259,8,,,,Expert,945.0,,Stomach,,Affinity against 5-hydroxytryptamine 2B receptor in the isolated rat stomach fundus,B,,,,12688
2899,7259,8,,,,Autocuration,945.0,,Stomach,,Affinity against serotonergic receptor in the isolated rat stomach fundus,B,,,,12688
2900,7185,9,,,,Expert,945.0,,Stomach,10116.0,Antagonistic activity against 5-hydroxytryptamine 2B receptor obtained from rat stomach fundus preparation,F,,Rattus norvegicus,,12688
2901,7185,9,,,,Expert,,,,10116.0,Antagonistic against 5-hydroxytryptamine 2B receptor,F,,Rattus norvegicus,,12688
2902,13267,8,,,,Autocuration,945.0,,Stomach,,Antagonistic affinity measured as pA2 value on 5-hydroxytryptamine 2B receptor of the rat stomach fundus,F,,,,12688
2903,13735,9,,,,Expert,945.0,,Stomach,10116.0,Inhibition of 5-HT binding to 5-HT2B receptor of Rat stomach fundus,B,,Rattus norvegicus,,12688
2904,15738,8,,,,Autocuration,,,,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor,F,,,,12688
2905,15738,8,,,,Autocuration,,,,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor; No data,F,,,,12688
2906,15738,8,,,,Autocuration,,,,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B) receptor,F,,,,12688
2907,12936,9,,,,Expert,945.0,,Stomach,10116.0,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,B,,Rattus norvegicus,,12688
2908,12936,9,,,,Expert,945.0,,Stomach,10116.0,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,B,,Rattus norvegicus,,12688
2909,12936,9,,,,Expert,945.0,,Stomach,10116.0,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,B,,Rattus norvegicus,,12688
2910,12936,9,,,,Expert,945.0,,Stomach,10116.0,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,B,,Rattus norvegicus,,12688
2911,16404,8,,,,Autocuration,945.0,,Stomach,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,F,,,,12688
2912,16404,8,,,,Expert,945.0,,Stomach,,Negative log concentration of antagonist was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,F,,,,12688
2913,16404,8,,,,Autocuration,945.0,,Stomach,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is No Data.,F,,,,12688
2914,16404,8,,,,Autocuration,945.0,,Stomach,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is not determined.,F,,,,12688
2915,16404,9,,,,Expert,945.0,,Stomach,10116.0,Antagonistic activity on 5-hydroxytryptamine 2B receptor of Rat stomach fundus;ND is not determined,F,,Rattus norvegicus,,12688
2916,16404,8,,,,Autocuration,1515.0,,Thoracic aorta,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat thoracic aorta; ND is not determined,F,,,,12688
2917,7483,8,,,,Autocuration,,,,,The binding affinity of compound to 5-HT receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,B,,,,12688
2918,7483,8,,,,Expert,,,,,The binding affinity to 5-hydroxytryptamine 2B receptor of rat fundus,B,,,,12688
2919,7483,8,,,,Autocuration,,,,,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,B,,,,12688
2920,7483,8,,,,Autocuration,,,,,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus; Unable to determine valid PA2 value due to slope of Schild plot,B,,,,12688
2922,16404,9,,,,Autocuration,945.0,,Stomach,10116.0,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,F,,Rattus norvegicus,,12688
2923,6347,8,,,,Autocuration,,,,,Binding affinity against 5-hydroxytryptamine 1A receptor,B,,,,227
2924,4373,8,,,,Autocuration,,,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2B receptor was determined,B,,,,227
2925,4373,8,,,,Autocuration,,,,,Binding affinity for 5-hydroxytryptamine 2B receptor was determined,B,,,,227
2926,4687,8,,,,Autocuration,,,,,Evaluated for the binding affinity to 5-HT 2B receptor,B,,,,227
2927,16946,8,,,,Autocuration,,,,,Ability to displace [3H]5-HT from 5-hydroxytryptamine 2B receptor,B,,,,227
2928,16633,8,,,,Autocuration,,,,,Binding affinities against 5-hydroxytryptamine 2B receptor,B,,,,227
2929,16633,8,,,,Autocuration,,,,,Binding affinities towards 5-hydroxytryptamine 2B receptor,B,,,,227
2930,16633,8,,,,Autocuration,,,,,Binding affinity towards 5-hydroxytryptamine 2B receptor using [125I]DOI as radioligand,B,,,,227
2931,15026,8,,,,Expert,,,,,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,B,,,,108
2932,15738,8,,,,Autocuration,,,,9913.0,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,B,,Bos taurus,,108
2933,15738,8,,,,Autocuration,,,,9913.0,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10E-6 M,B,,Bos taurus,,108
2934,15738,8,,,,Autocuration,,,,9913.0,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10e-6 M,B,,Bos taurus,,108
2935,15738,8,,,,Autocuration,,,,9913.0,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at concentration of 10e-6 M,B,,Bos taurus,,108
2936,16404,8,,,,Expert,,,,9913.0,Inhibitory constant was determined on 5-hydroxytryptamine 2C receptor of Bovine choroid plexus,B,,Bos taurus,,108
2937,15026,8,,,,Expert,,,,9913.0,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,B,,Bos taurus,,108
2938,15738,8,,,,Autocuration,,,,9913.0,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,B,,Bos taurus,,108
2939,16312,8,,,,Autocuration,,,,10141.0,Binding affinity against guinea pig cortex 5-HT2C receptor in the presence of [3H]mesulergine,B,,Cavia porcellus,,108
2940,5486,9,,,,Intermediate,2435.0,,Striatum,10141.0,Binding affinity towards 5-HT4 receptor by the displacement of [3H]GR-113808 in guinea-pig striatum,B,,Cavia porcellus,,20033
2941,5254,8,,,,Autocuration,,,,,Binding affinity against 5-HT1A receptor,B,,,,51
2942,3857,8,,449.0,,Expert,,CHO,,,Agonistic activity for 5-HT2c (5-HT2C) by measuring [3H]inositol monophosphate fromation in CHO cells in which the human 5-HT2C receptor subtype was stably expressed,F,,,,108
2943,6857,9,,449.0,,Expert,,CHO,,9606.0,Functional activity against human 5-hydroxytryptamine 2C receptor expressed in CHO cells using fluorometric imaging plate reader,F,,Homo sapiens,,108
2944,4176,8,,,,Autocuration,,,,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2c receptor cell line,F,,,,108
2945,6347,8,,449.0,,Autocuration,,CHO,,,Agonistic binding efficacy against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand,B,,,,108
2946,6347,8,,449.0,,Autocuration,,CHO,,,"Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand, expressed as Emax",B,,,,108
2947,16146,9,,,,Expert,,,,9606.0,Inhibition of human 5-hydroxytryptamine 2C receptor,B,,Homo sapiens,,108
2948,3805,8,,,,Autocuration,,,,,In vitro binding affinity against human 5-hydroxytryptamine 2C receptor at a concentration of 100 (nM),B,,,,108
2949,3857,8,,,,Autocuration,,,,,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,B,,,,108
2950,5635,8,,,,Autocuration,,,,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor,B,,,,108
2951,5635,8,,,,Autocuration,,,,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,B,,,,108
2952,5635,8,,,,Autocuration,,,,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,B,,,,108
2953,4012,8,,449.0,,Expert,,CHO,,,Displacement of [H]-mesulergine from CHO cells expressing human 5-hydroxytryptamine 2C receptor.,B,,,,108
2954,6366,8,,449.0,,Expert,,CHO,,,Ability to displace [3H]- mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells,B,,,,108
2955,15949,8,,449.0,,Expert,,CHO,,,Ability to displace [3H]mesulergine binding to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,B,,,,108
2956,17211,8,,449.0,,Autocuration,,CHO,,,Ability to displace [3H]mesulergine (0.5 nM) from CHO cells of human 5-hydroxytryptamine 2C receptor,B,,,,108
2957,6491,9,,,,Expert,,,,9606.0,Affinity towards human 5-hydroxytryptamine 2C serotonin receptor,B,,Homo sapiens,,108
2958,14093,8,,,,Autocuration,,,,,Agonist activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand,F,,,,108
2959,13481,8,,,,Autocuration,,,,,Agonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,F,,,,108
2960,6347,8,,449.0,,Expert,,CHO,,10116.0,Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI ,B,,Rattus norvegicus,,108
2961,14093,8,,,,Autocuration,,,,,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand,F,,,,108
2962,14093,8,,,,Autocuration,,,,,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand; Not tested,F,,,,108
2963,13481,8,,,,Autocuration,,,,,Antagonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,F,,,,108
2964,14442,8,,,,Autocuration,,,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [125 I]DOI as radioligand,B,,,,108
2965,14442,8,,,,Autocuration,,,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand,B,,,,108
2966,14442,8,,,,Autocuration,,,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand;not tested,B,,,,108
2967,14755,8,,,,Autocuration,,,,,Binding activity against cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand.,B,,,,108
2968,14744,8,,,,Autocuration,,,,,Binding affinity against the cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand,B,,,,108
2969,16659,8,,449.0,,Expert,,CHO,,,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,B,,,,108
2970,6857,9,,,,Expert,,,,9606.0,Affinity for human 5-hydroxytryptamine 2C receptor expressed in mammalian cell line,B,,Homo sapiens,,108
2971,5635,8,,,,Expert,,,,,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand.,B,,,,108
2972,4234,9,,,,Expert,,,,9606.0,Binding affinity to cloned human 5-hydroxytryptamine 2C receptor,B,,Homo sapiens,,108
2973,16209,8,,,,Autocuration,,,,,Binding affinity towards human 5-HT2C receptor was determined using [125I]- DOI as radioligand,B,,,,108
2974,5778,7,,,,Autocuration,,,,10116.0,Binding affinity for 5-HT3 receptor by displacement of [3H]-LY 278584 in rat cerebral cortex membranes,B,,Rattus norvegicus,Membranes,104698
2975,5094,6,,,,Autocuration,,,,,Binding affinity towards rat 5-hydroxytryptamine 3 receptor was evaluated,B,,,,104698
2976,809,7,,,,Autocuration,,,,10116.0,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 in rat posterior cortex,B,,Rattus norvegicus,,104698
2977,1578,6,,,,Autocuration,,,,,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex,B,,,,104698
2978,809,6,,,,Autocuration,,,,,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex; Not tested,B,,,,104698
2979,12469,6,,,,Autocuration,,,,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor in NG-108 cells labeled with [3H]GR-65630,B,,,,104698
2980,14290,6,,,,Autocuration,,,,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex,B,,,,104698
2981,14290,6,,,,Autocuration,,,,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex.,B,,,,104698
2982,10609,6,,,,Autocuration,,,,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-5-HT,B,,,,104698
2983,10609,6,,,,Autocuration,,,,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]GR-65630,B,,,,104698
2984,10609,6,,,,Autocuration,,,,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-ketanserin,B,,,,104698
2985,15253,6,,,,Autocuration,,,,,"Compound was evaluated for its in vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",B,,,,104698
2986,15253,6,,,,Autocuration,,,,,"In vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",B,,,,104698
2987,11683,6,,,,Autocuration,,,,,Displacement of the 5-hydroxytryptamine 3 receptor ligand [3H]GR-65630 from rat brain cortical membranes.,B,,,Membranes,104698
2988,12092,6,,,,Autocuration,,,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor,B,,,,104698
2989,1946,6,,,,Autocuration,,,,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,B,,,,104698
2990,11623,6,,,,Autocuration,,,,,Ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15.,B,,,,104698
2991,11623,6,,,,Autocuration,,,,,Compound was evaluated for its ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15. ,B,,,,104698
2992,14788,6,,,,Autocuration,,,,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex,B,,,,104698
2993,5432,7,,,,Autocuration,,,,10116.0,Displacement of [3H]ketanserin from rat cortex 5-HT3 receptor,B,,Rattus norvegicus,,104698
2994,14826,6,,,,Autocuration,,,,,Ability to displace [3H]granisetron specifically bound to 5-hydroxytryptamine 3 receptor in rat cortical membrane,B,,,,104698
2995,2222,6,,,,Autocuration,,,,,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,B,,,,104698
2996,11963,6,,,,Autocuration,,,,,Displacement of binding of [3H]-BRL 43694 to 5-hydroxytryptamine 3 receptor in rat cerebral cortex,B,,,,104698
2997,14145,6,,,,Autocuration,,,,,In vitro affinity for 5-hydroxytryptamine 3 (5-HT3) receptor by displacement of [3H]BRL-43694 from rat entorhinal cortex,B,,,,104698
2998,17819,6,,,,Autocuration,,,,,In vitro binding affinity at serotonin 5-hydroxytryptamine 3 receptor in rat cortex by [3H]granisetron displacement.,B,,,,104698
2999,10394,6,,,,Autocuration,,,,,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]- 1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,B,,,,104698
3000,10394,6,,,,Autocuration,,,,,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]-1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,B,,,,104698
3001,15034,6,,,,Autocuration,,,,,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,B,,,,104698
3002,691,6,,,,Autocuration,,,,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,B,,,,104698
3003,12092,6,,,,Autocuration,,,,,Displacement of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortical membranes,B,,,Membranes,104698
3004,11752,7,,,,Autocuration,,,,10116.0,Inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor,B,,Rattus norvegicus,,104698
3005,11752,6,,,,Autocuration,955.0,,Brain,,The ability to inhibit [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortices,B,,,,104698
3006,301,6,,,,Autocuration,,,,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat posterior cortex by [3H]-BRL 43694 displacement.,B,,,,104698
3007,16532,6,,,,Autocuration,,,,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584,B,,,,104698
3008,16532,6,,,,Autocuration,,,,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,B,,,,104698
3009,12092,6,,,,Autocuration,,,,,The binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand.,B,,,,104698
3010,11684,6,,,,Autocuration,,,,,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630,B,,,,104698
3011,11684,6,,,,Autocuration,,,,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630.,B,,,,104698
3012,12953,6,,,,Autocuration,,,,,Binding affinity for 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand,B,,,,104698
3013,12953,6,,,,Autocuration,,,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand; NA means Not active,B,,,,104698
3014,12953,6,,,,Autocuration,,,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 3 receptor; Nonactive at 10 uM,B,,,,104698
3015,12861,6,,,,Autocuration,,,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,B,,,,104698
3016,11454,6,,,,Autocuration,,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 0.5 hours in urethane-anesthetized rats,F,In vivo,,,104698
3017,11454,6,,,,Autocuration,,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 1 hour in urethane-anesthetized rats,F,In vivo,,,104698
3018,11454,6,,,,Autocuration,,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 3 hours in urethane-anesthetized rats,F,In vivo,,,104698
3019,11454,6,,,,Autocuration,,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 6 hours in urethane-anesthetized rats,F,In vivo,,,104698
3020,11454,6,,,,Autocuration,,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 0.5 hours in urethane-anesthetized rats,F,In vivo,,,104698
3021,11454,6,,,,Autocuration,,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 1 hour in urethane-anesthetized rats,F,In vivo,,,104698
3022,11454,6,,,,Autocuration,,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 16 hours in urethane-anesthetized rats,F,In vivo,,,104698
3023,11454,6,,,,Autocuration,,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 3 hours in urethane-anesthetized rats,F,In vivo,,,104698
3024,11454,6,,,,Autocuration,,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 6 hours in urethane-anesthetized rats,F,In vivo,,,104698
3025,11454,6,,,,Autocuration,,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 0.5 hours in urethane-anesthetized rats,F,In vivo,,,104698
3026,11454,6,,,,Autocuration,,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 1 hour in urethane-anesthetized rats,F,In vivo,,,104698
3027,11454,6,,,,Autocuration,,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 3 hours in urethane-anesthetized rats,F,In vivo,,,104698
3028,11454,6,,,,Autocuration,,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 6 hours in urethane-anesthetized rats,F,In vivo,,,104698
3029,11454,6,,,,Autocuration,,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 0.5 hours in urethane-anesthetized rats,F,In vivo,,,104698
3030,11454,6,,,,Autocuration,,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 3 hours in urethane-anesthetized rats,F,In vivo,,,104698
3031,11454,6,,,,Autocuration,,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 1 hour in urethane-anesthetized rats,F,In vivo,,,104698
3032,11454,6,,,,Autocuration,,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 3 hours in urethane-anesthetized rats,F,In vivo,,,104698
3033,11454,6,,,,Autocuration,,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 1 hour in urethane-anesthetized rats,F,In vivo,,,104698
3034,10609,6,,,,Autocuration,,,,,5-hydroxytryptamine 3 receptor antagonist activity was confirmed by its ability to antagonize 5-HT evoked tachycardia of rabbit isolated heart,F,,,,104698
3035,12861,6,,,,Autocuration,,,,,Binding activity against 5-hydroxytryptamine 2A receptor from rat cortex homogenates using [3H]DOB as radioligand.,B,,,,104698
3036,12861,7,,,,Autocuration,,,,10116.0,Inhibition of [3H]-Q-ICS 205-930 binding to rat cortex homogenate 5-hydroxytryptamine 3 receptor,B,,Rattus norvegicus,,104698
3037,12861,6,,,,Autocuration,,,,,Binding activity radioligand.,B,,,,104698
3038,10728,6,,,,Autocuration,,,,,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor in rat brain membranes,B,,,Brain membranes,104698
3039,10728,6,,,,Autocuration,,,,,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes.,B,,,Brain membranes,104698
3040,5163,8,,,,Autocuration,,,,,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.000001 mol/L,B,,,,108
3041,5163,8,,,,Autocuration,,,,,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.00001 mol/L,B,,,,108
3042,6011,8,,,,Autocuration,,,,,Inhibition of binding towards 5-hydroxytryptamine 2C receptor at 100 nM concentration,B,,,,108
3043,5014,8,,,,Autocuration,,,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2C receptor,B,,,,108
3044,5635,8,,,,Autocuration,,,,,Binding affinity of compound towards 5-hydroxytryptamine 2C receptor,B,,,,108
3045,5163,8,,,,Expert,,,,,Affinity for 5-hydroxytryptamine 2C receptor,B,,,,108
3046,6841,8,,,,Autocuration,,,,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,B,,,,108
3047,6119,8,,,,Expert,,,,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand.,B,,,,108
3048,4373,8,,,,Autocuration,,,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2C receptor was determined,B,,,,108
3049,1633,8,,,,Autocuration,,,,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]-Ketanserin,B,,,,108
3050,1633,8,,,,Expert,,,,,Binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]N-methyl-mesulergine,B,,,,108
3051,4373,8,,,,Autocuration,,,,,Binding affinity for 5-hydroxytryptamine 2C receptor was determined,B,,,,108
3052,6576,8,,,,Expert,,,,,Binding affinity towards serotonin 5-hydroxytryptamine 2C receptor,B,,,,108
3053,4687,8,,,,Autocuration,,,,,Evaluated for the binding affinity to 5-hydroxytryptamine 2C receptor,B,,,,108
3054,12146,8,,,,Autocuration,,,,,Tested agains t5-hydroxytryptamine 2C receptor in experiment 1,B,,,,108
3055,12146,8,,,,Autocuration,,,,,Tested against 5-hydroxytryptamine 2C receptor in experiment 2,B,,,,108
3056,16946,8,,,,Autocuration,,,,,Ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor,B,,,,108
3057,14159,8,,,,Autocuration,,,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 2C receptor,B,,,,108
3058,16700,8,,,,Autocuration,,,,,The binding affinity towards 5-hydroxytryptamine 2C receptor; No affinity,B,,,,108
3059,3269,8,,,,Autocuration,,,,,Affinity against 5-hydroxytryptamine 2C receptor,B,,,,108
3060,1274,9,,,,Expert,,,,9606.0,Binding affinity against 5-hydroxytryptamine 2C receptor,B,,Homo sapiens,,108
3061,1317,8,,,,Autocuration,,,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2C receptor using radioligand binding assay,B,,,,108
3062,5834,8,,,,Autocuration,,,,9913.0,Inhibitory concentration required against 5-HT3 receptor in bovine area postrema using [3H]GR-65630,B,,Bos taurus,,144
3063,11147,8,,,,Autocuration,,,,9913.0,Binding affinity towards 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand,B,,Bos taurus,,144
3064,14145,4,,,,Expert,,,,10141.0,Antagonistic potency against serotonin 5-hydroxytryptamine 3 receptor in GPI assay,F,,Cavia porcellus,,104714
3065,10561,4,,,,Autocuration,2116.0,,Ileum,10141.0,Binding affinity to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,B,,Cavia porcellus,,104714
3066,15847,4,,,,Autocuration,,,,10141.0,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig,F,,Cavia porcellus,,104714
3067,15847,4,,,,Autocuration,,,,10141.0,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig; ND means not done,F,,Cavia porcellus,,104714
3068,10561,4,,,,Autocuration,2116.0,,Ileum,10141.0,Potency to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,B,,Cavia porcellus,,104714
3069,11454,4,,,,Autocuration,2116.0,,Ileum,10141.0,In vitro binding affinity was measured for 5-hydroxytryptamine 3 receptor in the guinea pig ileum.,B,,Cavia porcellus,,104714
3070,4639,4,,,,Autocuration,,,,10141.0,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea colon at a concentration 0.01 uM,F,,Cavia porcellus,,104714
3071,4639,4,,,,Autocuration,,,,10141.0,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.1 uM,F,,Cavia porcellus,,104714
3072,4639,4,,,,Autocuration,,,,10141.0,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM,F,,Cavia porcellus,,104714
3073,4639,4,,,,Autocuration,,,,10141.0,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM in the presence of 30 uM MDL 72222,F,,Cavia porcellus,,104714
3074,4639,4,,,,Autocuration,,,,10141.0,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 0.01 uM,F,,Cavia porcellus,,104714
3075,4639,4,,,,Autocuration,,,,10141.0,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 1 uM,F,,Cavia porcellus,,104714
3076,15253,4,,,,Autocuration,2116.0,,Ileum,10141.0,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum",F,,Cavia porcellus,,104714
3077,15253,4,,,,Autocuration,2116.0,,Ileum,10141.0,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum.",F,,Cavia porcellus,,104714
3078,11963,4,,,,Autocuration,2116.0,,Ileum,10141.0,Tested for the antagonistic activity against 5-hydroxytryptamine 3 receptor from guinea pig ileum,F,,Cavia porcellus,,104714
3079,1946,4,,,,Autocuration,2116.0,,Ileum,10141.0,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum,B,,Cavia porcellus,,104714
3080,1946,4,,,,Autocuration,2116.0,,Ileum,10141.0,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum; Not tested,B,,Cavia porcellus,,104714
3081,12045,4,,,,Autocuration,,,,10141.0,Binding affinity towards [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in HG108-15,B,,Cavia porcellus,,104714
3082,1559,4,,,,Autocuration,2116.0,,Ileum,10141.0,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,B,,Cavia porcellus,,104714
3083,273,4,,,,Autocuration,2116.0,,Ileum,10141.0,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),F,,Cavia porcellus,,104714
3084,273,4,,,,Autocuration,2116.0,,Ileum,10141.0,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor of isolated guinea pig ileum (GPI),F,,Cavia porcellus,,104714
3085,188,4,,,,Autocuration,2116.0,,Ileum,10141.0,Tested for antagonistic activity on 5-hydroxytryptamine 3 receptor mediated effects of 5-HT in guinea pig isolated ileum,F,,Cavia porcellus,,104714
3086,12919,4,,,,Autocuration,2116.0,,Ileum,10141.0,Agonistic activity against 5-hydroxytryptamine 3 receptor in guinea pig ileum assay,F,,Cavia porcellus,,104714
3087,12918,4,,,,Autocuration,2116.0,,Ileum,10141.0,5-hydroxytryptamine 3 receptor agonism in the guinea pig ileum by functional 5-HT3 receptor assay,F,,Cavia porcellus,,104714
3088,1559,4,,,,Autocuration,2116.0,,Ileum,10141.0,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,B,,Cavia porcellus,,104714
3089,273,4,,,,Autocuration,2116.0,,Ileum,10141.0,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),F,,Cavia porcellus,,104714
3090,1559,4,,,,Autocuration,2116.0,,Ileum,10141.0,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,B,,Cavia porcellus,,104714
3091,1559,4,,,,Autocuration,2116.0,,Ileum,10141.0,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum; Not determined,B,,Cavia porcellus,,104714
3092,1559,4,,,,Autocuration,2116.0,,Ileum,10141.0,Binding affinity towards 5-hydroxytryptamine 3 receptor of guinea pig ileum; not determined,B,,Cavia porcellus,,104714
3093,14424,4,,,,Autocuration,2116.0,,Ileum,10141.0,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor in guinea pig ileum.,B,,Cavia porcellus,,104714
3094,13181,0,,,,Autocuration,,,,10141.0,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,B,,Cavia porcellus,,22226
3095,5486,8,,,,Autocuration,,,,,Binding affinity towards 5-HT1A receptor by the displacement of [3H]-8-OH-DPAT] in human recombinant receptors in mammalian cell,B,,,,51
3096,6491,5,,,,Expert,,,,9606.0,Affinity towards human 5-hydroxytryptamine 3 serotonin receptor,B,,Homo sapiens,,104714
3097,6013,4,,,,Autocuration,,,,,Binding affinity towards 5-HT3 receptor,B,,,,104714
3098,12861,4,,,,Autocuration,,,,,Binding activity radioligand.,B,,,,104714
3099,12861,4,,,,Autocuration,,,,,Binding activity against 5-hydroxytryptamine 1A receptor from human brain cortex using [3H]8-OH-DPAT-HT as radioligand.,B,,,,104714
3100,5104,4,,,,Autocuration,,,,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,B,,,,104714
3101,5105,4,,,,Autocuration,,,,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,B,,,,104714
3102,5104,4,,,,Autocuration,,,,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor; NT means Not tested,B,,,,104714
3103,3935,0,,,,Autocuration,,,,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 3 receptor,B,,,,22226
3104,13657,4,,433.0,,Expert,,NG108-15,,,Displacement of [3H]-BRC 36694 from 5-hydroxytryptamine 3 receptor in NG108-15 cells,B,,,,105030
3105,10369,4,,,,Autocuration,,,,,"Percent inhibition of [3H]5 binding to 5-hydroxytryptamine 3 receptor was evaluated by injection of compound (75 microCi/kg, 1.32 ug/kg) into the tail vein of mice (in vivo)",B,In vivo,,,105030
3106,10369,4,,,,Autocuration,,,,,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),B,,,,105030
3107,12918,4,,,,Autocuration,,,,,Compound was evaluated for the binding affinity at 5- HT3 receptor subtype,B,,,,105030
3108,12918,4,,,,Autocuration,,,,,Compound was evaluated for the binding affinity at 5- HT3 receptor,B,,,,105030
3109,10369,4,,,,Autocuration,,,,,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),B,,,,105030
3110,773,4,,,,Autocuration,,,,,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,B,,,,105030
3111,12918,4,,,,Autocuration,,,,,5-hydroxytryptamine 3 receptor agonism in mouse,F,,,,105030
3112,10561,4,,,,Autocuration,,,,,Binding affinity towards 5-hydroxytryptamine 3 receptor was determined by using [3H]-ICS 205-930 as radioligand in mouse N1E 115 cells,B,,,,105030
3113,12827,4,,,,Autocuration,,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,B,,,,105030
3114,12827,4,,,,Autocuration,,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,B,,,,105030
3115,12918,4,,,,Autocuration,,,,,Binding affinity was evaluated by 5-hydroxytryptamine 3 receptor agonism in the mouse NIE-115 by displacing tropisetron,B,,,,105030
3116,273,4,,,,Autocuration,,,,,Compound was evaluated for binding to 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,B,,,,105030
3117,273,4,,,,Autocuration,,,,,Compound was evaluated for binding to Serotonin 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,B,,,,105030
3118,10561,4,,,,Autocuration,,,,,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,B,,,,105030
3119,5033,4,,,,Autocuration,,,,,Ability to displace the radioligand [3H]GR-65630 from 5-hydroxytryptamine 3 receptor expressed in NIE-115 cells,B,In vitro,,,105030
3120,16429,4,,339.0,,Autocuration,,N1E-115,,,In vitro binding affinity at 5-hydroxytryptamine 3 receptor in N1E-115 cells using 3[H]GR-65630 as the radioligand,B,,,,105030
3121,10322,8,,,,Autocuration,,,,,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,B,,,,11765
3122,14331,8,,,,Autocuration,,,,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in NG cells 108-15,B,,,,11765
3123,13462,9,,,,Autocuration,,,,10090.0,Compound was tested for the Binding affinity against N1e-115 neuroblastoma 5-hydroxytryptamine 3 receptor by Radio ligand [3H]GR-65630 binding assay.,B,,Mus musculus,,10630
3124,12861,8,,,,Autocuration,,,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,B,,,,17106
3125,15086,8,,,,Autocuration,,,,9823.0,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor,B,,Sus scrofa,,144
3126,12861,8,,,,Autocuration,,,,9823.0,Binding activity radioligand.,B,,Sus scrofa,,144
3127,10561,4,,,,Autocuration,,,,9986.0,Binding affinity to 5-hydroxytryptamine 3 receptor of neuronal in the afferent rabbit vagus,B,,Oryctolagus cuniculus,,104714
3128,10561,4,,,,Autocuration,,,,9986.0,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,B,,Oryctolagus cuniculus,,104714
3129,10561,4,,,,Autocuration,,,,9986.0,Potency at neuronal 5-hydroxytryptamine 3 receptors in the rabbit heart,B,,Oryctolagus cuniculus,,104714
3130,10561,4,,,,Autocuration,,,,9986.0,Potency to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,B,,Oryctolagus cuniculus,,104714
3131,273,4,,,,Autocuration,,,,9986.0,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),F,,Oryctolagus cuniculus,,104714
3132,273,4,,,,Autocuration,,,,9986.0,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),F,,Oryctolagus cuniculus,,104714
3133,273,4,,,,Autocuration,2116.0,,Ileum,9986.0,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),F,,Oryctolagus cuniculus,,104714
3134,273,4,,,,Autocuration,,,,9986.0,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),F,,Oryctolagus cuniculus,,104714
3135,273,4,,,,Autocuration,,,,9986.0,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),F,,Oryctolagus cuniculus,,104714
3136,273,4,,,,Autocuration,,,,9986.0,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),F,,Oryctolagus cuniculus,,104714
3137,273,4,,,,Autocuration,,,,9986.0,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),F,,Oryctolagus cuniculus,,104714
3138,13047,4,,449.0,,Autocuration,,CHO,,9986.0,Binding affinity against 5-hydroxytryptamine 3 receptor in CHO cells using [3H]5-HT as radioligand,B,,Oryctolagus cuniculus,,104714
3139,1650,7,,,,Autocuration,,,,10116.0,In vitro displacement of [3H]-LY 278584 from rat cerebral cortex 5-hydroxytryptamine 3 receptor,B,,Rattus norvegicus,,104698
3140,16288,8,,,,Autocuration,,,,,Affinity at 5-hydroxytryptamine 3 receptor from rat frontal cortex using [3H]granisetron as radioligand (For granisetron = Ki(nM)=0.3+/-0.01),B,,,,12020
3141,16288,8,,,,Autocuration,,,,,Affinity at 5-hydroxytryptamine 3 receptor (For granisetron = Ki (nM)=0.3+/-0.01),B,,,,12020
3142,10254,7,,,,Autocuration,,,,10116.0,In vitro displacement of [3H]ICS-205-930 from 5-hydroxytryptamine 3 receptor in cultured NG-108-15 rat glioma cells,B,,Rattus norvegicus,,104698
3143,14532,6,,,,Autocuration,,,,,"Binding affinity for 5-hydroxytryptamine 3 receptor in rat cerebral cortex, determined by displacement of [3H]GR-65630",B,,,,104698
3144,13392,6,,,,Autocuration,948.0,,Heart,,"5-Hydroxy tryptamine 3 receptor showing agonist activity (in vivo) in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",F,In vivo,,,104698
3145,13392,6,,,,Autocuration,948.0,,Heart,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",F,,,,104698
3146,13392,6,,,,Autocuration,948.0,,Heart,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",F,,,,104698
3147,13392,6,,,,Autocuration,948.0,,Heart,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as change in heart rate",F,,,,104698
3148,13392,6,,,,Autocuration,948.0,,Heart,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptorr in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",F,,,,104698
3149,13392,6,,,,Autocuration,,,,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100(ug/kg), evaluated as percent inhibition of bradycardia",F,,,,104698
3150,13392,6,,,,Autocuration,,,,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",F,,,,104698
3151,13392,6,,,,Autocuration,,,,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",F,,,,104698
3152,13392,6,,,,Autocuration,,,,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60(ug/kg), evaluated as percent inhibition of bradycardia",F,,,,104698
3153,1089,7,,,,Autocuration,,,,10116.0,Antagonism of 5-HT-induced Von Bezold-Jarisch reflex in rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor antagonism),F,In vivo,Rattus norvegicus,,104698
3154,1089,6,,,,Autocuration,,,,,Ability to antagonise the 5-HT- induced Von Bezold-Jarisch reflex in the rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor),F,In vivo,,,104698
3155,11454,7,,,,Autocuration,,,,10116.0,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,F,In vivo,Rattus norvegicus,,104698
3156,11454,7,,,,Autocuration,,,,10116.0,Inhibition of 5-HT-induced bradycardia by 5-hydroxytryptamine 3+,F,,Rattus norvegicus,,104698
3157,12205,7,,,,Autocuration,,,,10116.0,In vivo inhibitory concentration after 5 minutes against 5-hydroxytryptamine 3 receptor induced bradycardia [bezold-jarisch (B-J) reflex test] in rat by intravenous administration,F,In vivo,Rattus norvegicus,,104698
3158,1089,7,,,,Autocuration,,,,10116.0,Inhibition of 5-HT (1 ug/mL) induced depolarization in rat vagus nerve (5-hydroxytryptamine 3 receptor antagonism),F,,Rattus norvegicus,,104698
3159,5094,6,,,,Autocuration,,,,,Binding affinity towards 5-HT3 receptor in rat was evaluated,B,,,,104698
3160,2622,7,,,,Autocuration,,,,10116.0,Inhibition of [3H]GR-65630 binding to rat cortical membrane 5-hydroxytryptamine 3 receptor,B,,Rattus norvegicus,,104698
3161,245,6,,,,Autocuration,,,,,Binding affinity was evaluated in vitro by displacement of [3H]zacopride radioligand from 5-hydroxytryptamine 3 receptor,B,,,,104698
3162,14788,6,,,,Autocuration,,,,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex.,B,,,,104698
3163,14788,6,,,,Autocuration,,,,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement of [3H]granisetron from rat cerebral cortex,B,,,,104698
3164,3020,6,,,,Autocuration,,,,,Binding affinity against 5-hydroxytryptamine 3 receptor in rat cortical membrane using [3H]GR-65630 as radioligand,B,,,,104698
3165,1742,6,,,,Autocuration,,,,,Compound was tested for its ability to displace [3H]-Q-ICS 205-930 from 5-hydroxytryptamine 3 receptor in rat cortex homogenates,B,,,,104698
3166,17394,6,,,,Autocuration,955.0,,Brain,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to 5-hydroxytryptamine 3 receptor in rat brain cortical membrane,B,,,,104698
3167,17394,6,,,,Autocuration,955.0,,Brain,,Concentration required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine-3 receptor (5-HT 3 receptor)in rat brain cortical membrane,B,,,,104698
3168,17394,6,,,,Autocuration,,,,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine 3 receptor in rat cortical membrane,B,,,,104698
3169,14286,6,,,,Autocuration,,,,,In vitro inhibitory concentration against radioligand [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in rat cortical membrane,B,,,,104698
3170,14178,6,,,,Autocuration,,,,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate.,B,,,,104698
3171,14178,7,,,,Autocuration,,,,10116.0,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; Not active at 10000 nm,B,,Rattus norvegicus,,104698
3172,14178,7,,,,Autocuration,,,,10116.0,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; not active at 10000 nM,B,,Rattus norvegicus,,104698
3173,14178,7,,,,Autocuration,,,,10116.0,Inhibition of radiolabeled [3H]-Zacopride ligand binding to 5-hydroxytryptamine 3 receptor,B,,Rattus norvegicus,,104698
3174,15034,6,,,,Autocuration,,,,,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,B,,,,104698
3175,1089,6,,,,Autocuration,,,,,"Tested for inhibition of binding of [3H]GR-65630 to rat cortical membranes, expressed as IC50",B,,,Membranes,104698
3176,1089,7,,,,Autocuration,,,,10116.0,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 3 receptor,B,,Rattus norvegicus,,104698
3177,16532,6,,,,Autocuration,,,,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,B,,,,104698
3178,12801,7,,,,Autocuration,,,,10116.0,Inhibition of [3H]BRL-43694 binding to rat 5-hydroxytryptamine 3 receptor,B,,Rattus norvegicus,,104698
3179,15194,6,,433.0,,Autocuration,,NG108-15,,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells (using [3H]zacopride as radioligand),B,,,,104698
3180,15194,6,,433.0,,Autocuration,,NG108-15,,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells using [3H]zacopride as radioligand,B,,,,104698
3181,15194,6,,,,Autocuration,,,,,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor from rat cortical homogenate using [3H]zacopride as radioligand,B,,,,104698
3182,15194,6,,,,Autocuration,,,,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA= Not active,B,,,,104698
3183,15194,6,,,,Autocuration,,,,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA=Not active,B,,,,104698
3184,15194,6,,,,Autocuration,,,,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; not active,B,,,,104698
3185,10610,6,,,,Autocuration,,,,,Antagonist potency to 5-hydroxytryptamine 3 receptor was assayed by antagonism of the 5-HT-evoked reflex bradycardia [Bezold-Jarisch(BJ) reflex] in rats,F,,,,104698
3186,10355,7,,,,Autocuration,,,,10116.0,Antagonistic activity against 5-hydroxytryptamine 3 receptor as inhibition of 5-HT-induced bradycardia (von Bezold-jarisch reflex) in anesthetized rat,F,,Rattus norvegicus,,104698
3187,691,6,,,,Autocuration,,,,,"Compound was tested as a 5-hydroxytryptamine 3 receptor antagonist in the rat by assessment of the inhibition of the Bezold-Jarisch effect, when administered intravenously",F,,,,104698
3188,10611,6,,,,Autocuration,,,,,In vivo 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) antagonistic activity expressed as ability to inhibit Bezold-Jarich reflex evoked by 5-HT in rats,F,,,,104698
3189,12801,6,,,,Autocuration,,,,,Inhibition dose for 50 percent antagonism for 5-hydroxytryptamine 3 receptor in vivo in rats,F,In vivo,,,104698
3190,10609,6,,,,Autocuration,,,,,Inhibition of 5-HT evoked reflex bradycardia in rat.,F,,,,104698
3191,11454,6,,,,Autocuration,,,,,5-HT3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,104698
3192,11454,6,,,,Autocuration,,,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,104698
3193,11454,6,,,,Autocuration,,,,,5-hydroxytryptamine 3 receptor antagonistic activity measured by inhibition of 5-HT-induced bradycardia (iv administration 10 ug/kg dose in urethane-anesthetized rats),F,In vivo,,,104698
3194,11454,7,,,,Autocuration,,,,10116.0,5-hydroxytryptamine 3 receptor antagonistic activity as inhibition of 5-HT-induced bradycardia after iv administration of 100 ug/kg dose in urethane-anesthetized rats,F,In vivo,Rattus norvegicus,,104698
3195,11454,6,,,,Autocuration,,,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,104698
3196,11454,6,,,,Autocuration,,,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kgetized rats,F,In vivo,,,104698
3197,11454,6,,,,Autocuration,,,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 3 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,104698
3198,11454,6,,,,Autocuration,,,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 10 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,104698
3199,11454,6,,,,Autocuration,,,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 100 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,104698
3200,11454,6,,,,Autocuration,,,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 1000 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,104698
3201,11454,6,,,,Autocuration,,,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 30 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,104698
3202,11454,6,,,,Autocuration,,,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 300 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,104698
3203,11454,6,,,,Autocuration,,,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 3ug/kg dose in urethane-anesthetized rats,F,In vivo,,,104698
3204,11454,6,,,,Autocuration,,,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,104698
3205,11454,6,,,,Autocuration,,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 0.3 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,104698
3206,11454,6,,,,Autocuration,,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 1 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,104698
3207,11454,6,,,,Autocuration,,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 30 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,104698
3208,11454,6,,,,Autocuration,,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 0.05 hour,F,In vivo,,,104698
3209,11454,6,,,,Autocuration,,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 1 hour,F,In vivo,,,104698
3210,11454,6,,,,Autocuration,,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 16 hour,F,In vivo,,,104698
3211,11454,6,,,,Autocuration,,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 3 hour,F,In vivo,,,104698
3212,11454,6,,,,Autocuration,,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 6 hour,F,In vivo,,,104698
3213,11454,6,,,,Autocuration,,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,104698
3214,11454,6,,,,Autocuration,,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 100 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,104698
3215,11454,6,,,,Autocuration,,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,104698
3216,11454,6,,,,Autocuration,,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,104698
3217,11454,6,,,,Autocuration,,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 3 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,104698
3218,11454,6,,,,Autocuration,,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 30 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,104698
3219,11454,6,,,,Autocuration,,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 300 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,104698
3220,670,6,,,,Autocuration,,,,,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.)",F,,,,104698
3221,670,6,,,,Autocuration,,,,,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.); Not tested",F,,,,104698
3222,10321,6,,,,Autocuration,,,,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 10 ug/Kg,F,In vivo,,,104698
3223,10321,6,,,,Autocuration,,,,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 100 ug/Kg,F,In vivo,,,104698
3224,10321,6,,,,Autocuration,,,,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 2 ug/Kg,F,In vivo,,,104698
3225,10321,6,,,,Autocuration,,,,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 20 ug/Kg,F,In vivo,,,104698
3226,10321,6,,,,Autocuration,,,,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 5 ug/Kg,F,In vivo,,,104698
3227,10322,6,,,,Autocuration,,,,,Tested for inhibition of Bezold-Jarisch (B-J) reflex mediated by 5-hydroxytryptamine 3 receptor in rats after intravenous administration (2.0 ug/kg),F,In vivo,,,104698
3228,15412,6,,,,Autocuration,,,,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,F,,,,104698
3229,15412,6,,,,Autocuration,,,,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,F,,,,104698
3230,15412,7,,,,Autocuration,,,,10116.0,Intrinsic efficacy for rat 5-hydroxytryptamine 3 receptor,B,,Rattus norvegicus,,104698
3231,15412,6,,,,Autocuration,,,,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; PA means partial agonist,F,,,,104698
3232,15412,7,,,,Intermediate,10000000.0,,Hippocampus,,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) of rat cortex and hippocampus tissue,B,,,,104698
3233,15412,7,,,,Autocuration,,,,10116.0,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor of rat cortical membrane,B,,Rattus norvegicus,,104698
3234,17394,7,,,,Autocuration,,,,10116.0,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 5-hydroxytryptamine 3 receptor,B,,Rattus norvegicus,,104698
3235,12457,6,,,,Autocuration,,,,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 3 receptor,B,,,,104698
3236,12457,6,,,,Autocuration,,,,,Affinity was evaluated by inhibition of [3H]GR-65630 binding to NG108-15 cell transfected with cloned rat 5-hydroxytryptamine 3 receptor,B,,,,104698
3237,12205,6,,,,Autocuration,,,,,Binding affinity against radioligand [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in neuroblastoma-glioma (NG108-15) cells.,B,,,,104698
3238,14532,6,,,,Autocuration,,,,,Binding affinity for 5-hydroxytryptamine 3 receptor was determined by measuring displacement of [3H]GR-65630 from rat brain cortices,B,,,,104698
3239,1122,6,,,,Autocuration,,,,,Binding affinity to 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-BRL 43694 as radioligand,B,,,,104698
3240,5094,6,,,,Autocuration,,,,,Binding affinity towards 5-HT3 receptor in rat was evaluated,B,,,,104698
3241,809,9,,,,Intermediate,2116.0,,Ileum,10141.0,5-hydroxytryptamine 4 receptor agonist activity as increased response to electrical stimulation in guinea pig ileum,F,,Cavia porcellus,,20033
3242,809,9,,,,Intermediate,2116.0,,Ileum,10141.0,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum; Not tested,F,,Cavia porcellus,,20033
3243,14290,9,,,,Intermediate,2116.0,,Ileum,10141.0,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum",F,,Cavia porcellus,,20033
3244,14290,9,,,,Intermediate,2116.0,,Ileum,10141.0,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Inactive up to 10E-5 M",F,,Cavia porcellus,,20033
3245,14290,9,,,,Intermediate,2116.0,,Ileum,10141.0,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",F,,Cavia porcellus,,20033
3246,14290,9,,,,Intermediate,2116.0,,Ileum,10141.0,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",F,,Cavia porcellus,,20033
3247,14290,9,,,,Intermediate,2116.0,,Ileum,10141.0,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not capable of evaluation",F,,Cavia porcellus,,20033
3248,13961,9,,,,Intermediate,2116.0,,Ileum,10141.0,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum.,F,,Cavia porcellus,,20033
3249,13961,9,,,,Intermediate,2116.0,,Ileum,10141.0,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum. Activity expressed as percent of the maximum 5-HT response given in brackets.,F,,Cavia porcellus,,20033
3250,809,9,,,,Intermediate,2116.0,,Ileum,10141.0,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum,F,,Cavia porcellus,,20033
3251,809,9,,,,Intermediate,2116.0,,Ileum,10141.0,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not evaluable,F,,Cavia porcellus,,20033
3252,809,9,,,,Intermediate,2116.0,,Ileum,10141.0,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not tested,F,,Cavia porcellus,,20033
3253,14290,9,,,,Intermediate,2116.0,,Ileum,10141.0,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum",F,,Cavia porcellus,,20033
3254,14290,9,,,,Intermediate,2116.0,,Ileum,10141.0,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10-5 M",F,,Cavia porcellus,,20033
3255,14290,9,,,,Intermediate,2116.0,,Ileum,10141.0,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10E-5 M",F,,Cavia porcellus,,20033
3256,14290,9,,,,Intermediate,2116.0,,Ileum,10141.0,5-hydroxytryptamine 4 receptor antagonist activity as inhibition of 5-HT-induced contractions in guinea pig ileum; Not capable of evaluation.,F,,Cavia porcellus,,20033
3257,14290,9,,,,Intermediate,2116.0,,Ileum,10141.0,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",F,,Cavia porcellus,,20033
3258,14290,9,,,,Intermediate,2116.0,,Ileum,10141.0,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",F,,Cavia porcellus,,20033
3259,15034,9,,,,Intermediate,,,,10141.0,Displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor in guinea pig striatum,B,,Cavia porcellus,,20033
3260,5094,9,,,,Intermediate,2435.0,,Striatum,10141.0,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,B,,Cavia porcellus,,20033
3261,5094,9,,,,Intermediate,2435.0,,Striatum,10141.0,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,B,,Cavia porcellus,,20033
3262,5399,9,,,,Intermediate,2435.0,,Striatum,10141.0,Inhibitory activity against 5-hydroxytryptamine 4 receptor of guinea pig striatum using [3H]GR-113808 as radioligand,B,,Cavia porcellus,,20033
3263,17394,9,,,,Intermediate,2435.0,,Striatum,10141.0,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea pig striatum,B,,Cavia porcellus,,20033
3264,17394,9,,,,Intermediate,2435.0,,Striatum,10141.0,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea-pig striatum,B,,Cavia porcellus,,20033
3265,17394,9,,,,Intermediate,2435.0,,Striatum,10141.0,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to serotonin 5-hydroxytryptamine 4 receptor in guinea-pig striatum,B,,Cavia porcellus,,20033
3266,13961,9,,,,Intermediate,2116.0,,Ileum,10141.0,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum.,F,,Cavia porcellus,,20033
3267,13961,9,,,,Intermediate,2116.0,,Ileum,10141.0,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum. 95% confidence limits are in brackets.,F,,Cavia porcellus,,20033
3268,13961,9,,,,Intermediate,2116.0,,Ileum,10141.0,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,F,,Cavia porcellus,,20033
3269,16946,9,,,,Intermediate,,,,10141.0,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-6 M in guinea pig,B,,Cavia porcellus,,20033
3270,16946,9,,,,Intermediate,,,,10141.0,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-8 M in guinea pig,B,,Cavia porcellus,,20033
3271,15034,9,,,,Intermediate,,,,10141.0,Agonistic activity against 5-hydroxytryptamine 4 receptor,F,,Cavia porcellus,,20033
3272,15034,9,,,,Intermediate,,,,10141.0,Agonistic activity against 5-hydroxytryptamine 4 receptor; not tested,F,,Cavia porcellus,,20033
3273,12918,9,,,,Intermediate,,,,10141.0,Compound was evaluated for the relative potency with respect to serotonin against 5-hydroxytryptamine 4 receptor,F,,Cavia porcellus,,20033
3274,16946,9,,,,Intermediate,,,,10141.0,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor,B,,Cavia porcellus,,20033
3275,17394,9,,,,Intermediate,2435.0,,Striatum,10141.0,Inhibition of [3H]GR-113808 binding to guinea pig striatum 5-hydroxytryptamine 4 receptor,B,,Cavia porcellus,,20033
3276,15034,9,,,,Intermediate,2435.0,,Striatum,10141.0,Binding affinity against 5-hydroxytryptamine 4 receptor in guinea pig striatum using [3H]GR-113808 as radioligand,B,,Cavia porcellus,,20033
3277,5094,9,,,,Intermediate,2435.0,,Striatum,10141.0,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,B,,Cavia porcellus,,20033
3278,5094,9,,,,Intermediate,2435.0,,Striatum,10141.0,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,B,,Cavia porcellus,,20033
3279,17358,9,,,,Intermediate,2116.0,,Ileum,10141.0,Tested for affinity against 5-hydroxytryptamine 4 receptor in the myenteric plexus of the guinea pig ileum.,B,,Cavia porcellus,,20033
3280,12953,9,,,,Expert,,,,10141.0,Displacement of [3H]-GR113808 from 5-HT4 receptor of guinea pig striatum,B,,Cavia porcellus,,20033
3281,12953,9,,,,Intermediate,,,,10141.0,The compound was tested for their binding affinity towards 5-HT4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,B,,Cavia porcellus,,20033
3282,12953,9,,,,Intermediate,,,,10141.0,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand.,B,,Cavia porcellus,,20033
3283,12953,9,,,,Intermediate,,,,10141.0,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,B,,Cavia porcellus,,20033
3284,273,9,,,,Intermediate,2116.0,,Ileum,10141.0,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,F,,Cavia porcellus,,20033
3285,12918,9,,,,Intermediate,2116.0,,Ileum,10141.0,5-hydroxytryptamine 4 receptor agonist activity in the guinea pig ileum assay,F,,Cavia porcellus,,20033
3286,12919,9,,,,Intermediate,2116.0,,Ileum,10141.0,5-hydroxytryptamine 4 receptor agonistic activity was measured by twitch response enhancing activity in electrically stimulated guinea pig ileum preparation,F,,Cavia porcellus,,20033
3287,273,9,,,,Intermediate,2116.0,,Ileum,10141.0,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI).,F,,Cavia porcellus,,20033
3288,273,9,,,,Intermediate,2116.0,,Ileum,10141.0,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,F,,Cavia porcellus,,20033
3289,13181,9,,,,Intermediate,,,,10141.0,Ability to antagonize 5-HT-evoked contractions mediated through 5-hydroxytryptamine 4 receptor activation in the guinea pig distal colon LMMP,B,,Cavia porcellus,,20033
3290,13181,8,,,,Autocuration,,,,10141.0,Binding affinity was determined against 5-hydroxytryptamine 3 receptor,B,,Cavia porcellus,,168
3291,15034,9,,,,Intermediate,,,,10141.0,Antagonistic activity against 5-hydroxytryptamine 4 receptor,F,,Cavia porcellus,,20033
3292,5033,9,,,,Intermediate,,,,10141.0,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-hydroxytryptamine 4 receptor,B,,Cavia porcellus,,20033
3293,1980,9,,,,Intermediate,,,,10141.0,Binding affinity for 5-hydroxytryptamine 4 receptor by displacement of [3H]GR-113808 from guinea pig brain striatum.,B,,Cavia porcellus,,20033
3294,13181,8,,722.0,,Autocuration,,HEK293,,10141.0,Binding affinity was determined against 5-hydroxytryptamine 2C receptor using cloned rat receptors expressed in 293 cells radiolabeled with [3H]mesulergine,B,,Cavia porcellus,,168
3295,14287,9,,,,Intermediate,,,,10141.0,In vitro by displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor on guinea pig striatal membrane,B,,Cavia porcellus,,20033
3296,1317,9,,,,Intermediate,,,,10141.0,Compound was evaluated for binding affinity against 5-hydroxytryptamine 4 receptor using radioligand binding assay using [3H]GR as radioligand,B,,Cavia porcellus,,20033
3297,15316,9,,,,Intermediate,,,,10141.0,Compound was evaluated for its ability to displace [3H]GR-113808 binding from 5-hydroxytryptamine 4 receptor in guinea pig striatum.,B,,Cavia porcellus,,20033
3298,16429,9,,,,Intermediate,2435.0,,Striatum,10141.0,In vitro binding affinity at 5-hydroxytryptamine 4 receptor in guinea pig striatum using 3[H]GR-113808 as the radioligand,B,,Cavia porcellus,,20033
3299,14818,9,,,,Intermediate,10000000.0,,Hippocampus,10141.0,The compound was tested for its binding affinity towards 5-hydroxytryptamine 4 receptor in guinea pig hippocampus using [125I]SB-207710.,B,,Cavia porcellus,,20033
3300,15194,9,,,,Intermediate,,,,10141.0,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand,B,,Cavia porcellus,,20033
3301,15194,9,,,,Intermediate,,,,10141.0,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand.,B,,Cavia porcellus,,20033
3302,13961,9,,,,Intermediate,2116.0,,Ileum,10141.0,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,F,,Cavia porcellus,,20033
3303,5486,8,,,,Autocuration,,,,,Binding affinity towards 5-HT2C receptor by the displacement of [3H]mesulergine] in human recombinant receptors in mammalian cell,B,,,,108
3304,16209,8,,,,Autocuration,,,,,Binding affinity towards human 5-hydroxytryptamine 4 receptor using [3H]5-HT as radioligand,B,,,,168
3305,17085,8,,,,Autocuration,,,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 4 receptor,B,,,,168
3306,4199,8,,308.0,,Autocuration,,HeLa,,,Compound was evaluated for the binding affinity against human cloned 5-hydroxytryptamine 4 receptor in HeLa cells using [3H]-LSD as the radioligand,B,,,,168
3307,15146,8,,,,Autocuration,,,,,Compound was tested for its binding affinity against 5-hydroxytryptamine 4 receptor,B,,,,168
3308,5213,8,,,,Autocuration,,,,,Compound was tested for its binding affinity for 5-hydroxytryptamine 4 receptor,B,,,,168
3309,4829,8,,308.0,,Autocuration,,HeLa,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 4 receptor in HeLa cells, using [3H]LSD as radioligand",B,,,,168
3310,17358,8,,,,Autocuration,,,,,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons,B,,,,10622
3311,17358,8,,,,Autocuration,,,,,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons; IA means inactive,B,,,,10622
3312,16946,8,,,,Autocuration,,,,,Ability to displace [3H]GR-113808 from mouse 5-hydroxytryptamine 4 receptor in COS7 cells,B,,,,10622
3313,17358,8,,,,Autocuration,,,,,Tested for ability to stimulate 5-hydroxytryptamine 4 receptors in mouse Coliculi neurons,B,,,,10622
3314,268,8,,,,Autocuration,2081.0,,Cardiac atrium,,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model,F,,,,11249
3315,268,8,,,,Autocuration,2081.0,,Cardiac atrium,,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model; compound found inactive at 1 uM,F,,,,11249
3316,15086,8,,,,Autocuration,,,,,The compound was tested for binding affinity against 5-hydroxytryptamine 4 receptor,B,,,,11249
3317,14875,8,,,,Autocuration,10000000.0,,Hippocampus,,Compound was tested for binding affinity against piglet hippocampus 5-hydroxytryptamine 4 receptor,B,,,,11249
3318,13267,8,,,,Autocuration,10000000.0,,Hippocampus,9823.0,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]SB 207710 as radioligand,B,,Sus scrofa,,168
3319,13047,8,,,,Autocuration,,,,9986.0,Binding affinity against 5-hydroxytryptamine 2A receptor using rabbit saphenous vein assay.,B,,Oryctolagus cuniculus,,168
3320,1650,9,,,,Expert,,,,10116.0,Displacement of [3H]GR-113808 from rat striatum 5-hydroxytryptamine 4 receptor,B,,Rattus norvegicus,,10623
3321,567,8,,,,Autocuration,,,,,Tested for its agonist potency against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,F,,,,10623
3322,17358,8,,,,Autocuration,,,,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in relaxation of rat oesophagus,B,,,,10623
3323,188,8,,,,Autocuration,,,,,Tested for the effect on binding at 5-hydroxytryptamine 4 receptor; No activity,B,,,,10623
3324,670,8,,,,Autocuration,,,,,lntrinsic activity relative to 5-HT receptor,F,,,,10623
3325,204,8,,,,Autocuration,,,,,Compound was evaluated for the agonistic activity towards 5-hydroxytryptamine 4 receptor using the rat tunica muscularis mucosae (TMM) esophagus strip assay,F,,,,10623
3326,1946,8,,,,Expert,,,,,In vitro relaxation of carbachol pre-contracted rat oesophageal TMM.,F,,,,10623
3327,6398,8,,,,Autocuration,,,,,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay,F,,,,10623
3328,6398,8,,,,Autocuration,,,,,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay; IN = Inactive,F,,,,10623
3329,17358,8,,,,Autocuration,,,,,Efficient 5-hydroxytryptamine 4 agonist in the rat tunica muscularis mucosae,F,,,,10623
3330,6398,8,,,,Autocuration,,,,,Tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay of racemate mixture,F,,,,10623
3331,11752,8,,,,Expert,,,,,Relaxation of carbachol induced contractions of rat tunica muscularis mucosae,B,,,,10623
3332,809,8,,,,Autocuration,,,,,5-hydroxytryptamine 4 receptor agonist activity was determined by the relaxation of the carbachol-contracted rat esophageal tunica muscularis mucosae,F,,,,10623
3333,14178,9,,,,Expert,,,,10116.0,Inhibition of radiolabeled [3H]GR-113808 ligand binding to 5-hydroxytryptamine 4 receptor,B,,Rattus norvegicus,,10623
3334,567,8,,,,Autocuration,,,,,Tested for its efficacy against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,B,,,,10623
3335,1946,8,,,,Autocuration,,,,,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae.,B,,,,10623
3336,1946,8,,,,Autocuration,,,,,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae; No activity up to 104M concentration,B,,,,10623
3337,13961,9,,,,Expert,,,,10116.0,Binding affinity (Ki+/-SEM) against 5-hydroxytryptamine 4 receptor from cheng Prusoff equation by using [3H]GR-113808 in rat striatum,B,,Rattus norvegicus,,10623
3338,6238,8,,,,Autocuration,2435.0,,Striatum,,Binding affinity towards 5-HT 4 receptor in rat striatum membranes using [3H]GR-113808 as radioligand,B,,,,10623
3339,14290,8,,,,Autocuration,,,,,Binding affinity towards 5-HT4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand; Not tested,B,,,,10623
3340,14290,8,,,,Expert,,,,,Binding affinity towards 5-hydroxytryptamine 4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand,B,,,,10623
3341,809,9,,,,Expert,2435.0,,Striatum,10116.0,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,B,,Rattus norvegicus,,10623
3342,1578,8,,,,Autocuration,2435.0,,Striatum,,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,B,,,,10623
3343,16709,8,,,,Expert,2435.0,,Striatum,,Binding affinity to 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum membrane,B,,,,10623
3344,1946,8,,,,Expert,2435.0,,Striatum,,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatum by [3H]GR-113808 displacement.,B,,,,10623
3345,15253,8,,,,Expert,2435.0,,Striatum,,In vitro affinity at serotonergic 5-hydroxytryptamine 4 receptor by radioligand binding assay using [3H]GR-113808 in rat striatum membranes.,B,,,,10623
3346,4535,8,,,,Expert,2435.0,,Striatum,,In vitro binding affinity to 5-hydroxytryptamine 4 receptor in rat striatum membrane,B,,,,10623
3347,13961,8,,,,Expert,,,,,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatal membranes by [3H]GR-113808 displacement.,B,,,,10623
3348,17358,8,,,,Autocuration,955.0,,Brain,,Tested for potency against 5-hydroxytryptamine 4 receptor agonist in rat brain,F,,,,10623
3349,15847,8,,,,Autocuration,,,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat,F,,,,10623
3350,15847,8,,,,Autocuration,,,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat; ND means not done,F,,,,10623
3351,670,8,,,,Autocuration,,,,,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae,F,,,,10623
3352,670,8,,,,Autocuration,,,,,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae; Not tested,F,,,,10623
3353,1317,8,,,,Autocuration,,,,,Antagonist activity against 5-hydroxytryptamine 4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,F,,,,10623
3354,12936,9,,,,Expert,,,,10116.0,Binding affinity against rat 5-hydroxytryptamine 4 receptor,B,,Rattus norvegicus,,10623
3355,4535,8,,,,Expert,2435.0,,Striatum,,pKi against 5-hydroxytryptamine 4 receptor in rat striatum membrane,B,,,,10623
3356,14424,9,,,,Expert,,,,10116.0,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-5 M.,F,,Rattus norvegicus,,10623
3357,14424,8,,,,Expert,,,,,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-6 M.,F,,,,10623
3358,14424,8,,,,Expert,,,,,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,F,,,,10623
3359,14424,9,,,,Expert,,,,10116.0,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-8 M.,F,,Rattus norvegicus,,10623
3360,14424,8,,,,Autocuration,,,,,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-7 M.,F,,,,10623
3361,14424,8,,,,Expert,,,,,Antagonistic activity evaluated by ability to block serotonin induced relaxation (via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-8 M.,F,,,,10623
3362,14424,8,,,,Expert,,,,,Antagonistic activity evaluated by ability to block serotonin induced relaxation via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 0.1 mg/kg (p.o.),F,,,,10623
3363,14424,8,,,,Autocuration,,,,,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,F,,,,10623
3364,1980,8,,,,Autocuration,,,,10116.0,Estimate from relaxation of carbachol-contracted rat esophageal muscularis mucosae,F,,Rattus norvegicus,,168
3365,4639,8,,,,Autocuration,,,,,Compound was tested for agonistic activity against 5-hydroxytryptamine 4 receptor on guinea colon at a concentration 0.1 uM,F,,,,168
3366,17358,8,,,,Autocuration,,,,,Tested for affinity towards 5-hydroxytryptamine 4 receptor,B,,,,168
3367,17358,8,,,,Autocuration,,,,,Tested for affinity towards 5-hydroxytryptamine 4 receptor.,B,,,,168
3368,17358,8,,,,Autocuration,,,,,Compound was tested for 5-hydroxytryptamine 4 binding affinity,B,,,,168
3369,1558,8,,,,Autocuration,,,,,Compound was tested for its affinity towards 5-hydroxytryptamine 4 receptor,B,,,,168
3370,17358,8,,,,Autocuration,,,,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,F,,,,168
3371,16117,8,,,,Autocuration,,,,,In vitro binding affinity towards 5-HT4 receptor was determined,B,,,,168
3372,17358,8,,,,Autocuration,,,,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,F,,,,168
3373,17358,8,,,,Autocuration,,,,,Tested for agonist activity against 5-hydroxytryptamine 4 receptor,F,,,,168
3374,17358,8,,,,Autocuration,,,,,Tested for selectivity for 5-hydroxytryptamine 4 receptor,B,,,,168
3375,17358,8,,,,Autocuration,,,,,Tested for 5-hydroxytryptamine 4 binding affinity against cisapride,B,,,,168
3376,17358,8,,,,Autocuration,,,,,Tested for 5-hydroxytryptamine 4 binding affinity against renzapride,B,,,,168
3377,17358,8,,,,Autocuration,,,,,Tested for 5-hydroxytryptamine 4 binding affinity against zacopride,B,,,,168
3378,1274,8,,,,Expert,,,,,Binding affinity against 5-Hydroxytryptamine 4 receptor,B,,,,168
3379,10728,6,,,,Autocuration,,,,,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 recognition sites in rat brain membranes,B,,,Brain membranes,104698
3380,11695,6,,,,Autocuration,,,,,Compound was evaluated for the displacement of [3H]Q-ICS-205-930 from 5-HT3 recognition sites in rat brain membranes,B,,,Brain membranes,104698
3381,11695,6,,,,Autocuration,,,,,Displacement of [3H]Q-ICS-205-930 from 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes,B,,,Brain membranes,104698
3382,12490,6,,,,Autocuration,,,,,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor from rat cortex homogenate,B,,,,104698
3383,11828,7,,,,Autocuration,,,,10116.0,Displacement of [3H]-Q-ICS 205-930 from rat cortex homogenate 5-hydroxytryptamine 3 receptor,B,,Rattus norvegicus,,104698
3384,12253,6,,,,Autocuration,10000000.0,,Hippocampus,,Binding affinity of 5-hydroxytryptamine 3 receptor using [3H]granisetron in rat hippocampus and entorhinal cortex,B,,,,104698
3385,10561,6,,,,Autocuration,,,,,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,B,,,,104698
3386,10561,6,,,,Autocuration,,,,,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]quipazine as radioligand in rat cortex,B,,,,104698
3387,14432,6,,,,Autocuration,,,,,Rat 5-hydroxytryptamine 3 receptor (5-HT3) antagonist,F,,,,104698
3388,12936,7,,,,Autocuration,,,,10116.0,Binding affinity against rat 5-hydroxytryptamine 3 receptor,B,,Rattus norvegicus,,104698
3389,1274,7,,,,Autocuration,,,,10116.0,Binding affinity against 5-Hydroxytryptamine 3 receptor,B,,Rattus norvegicus,,104698
3390,1980,6,,,,Autocuration,,,,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of racemic [3H]zacopride from rat cortex,B,,,,104698
3391,670,6,,,,Autocuration,,,,,Binding affinity to 5-hydroxytryptamine 3 receptor was determined in rat cerebro cortical membranes using [3H]quipazine.,B,,,,104698
3392,968,7,,,,Autocuration,,,,10116.0,Displacement of [3H]granisetron from 5-hydroxytryptamine 3 receptor of rat cortex,B,,Rattus norvegicus,,104698
3393,14287,6,,,,Autocuration,,,,,In vitro by displacement of [3H]LY-278584 from 5-hydroxytryptamine 3 receptor on rat entorhinal cortex,B,,,,104698
3394,567,6,,,,Autocuration,,,,,Tested for its binding affinity by measuring its ability to displace [3H]granisetron from 5-hydroxytryptamine 3 receptor in rat cortex,B,,,,104698
3395,13267,6,,,,Autocuration,,,,,The binding affinity (pKi) measured against 5-hydroxytryptamine 1A receptor of rat cortex using [3H]8-OH-DPAT as radioligand,B,,,,104698
3396,14826,6,,,,Autocuration,,,,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat cortical membrane by [3H]graniestron displacement.,B,,,,104698
3397,15194,6,,,,Autocuration,,,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand,B,,,,104698
3398,15194,6,,,,Autocuration,,,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand.,B,,,,104698
3399,10394,7,,,,Autocuration,,,,10116.0,pKi value for inhibition of [3H]LY-278584 binding to 5-hydroxytryptamine 3 receptor,B,,Rattus norvegicus,,104698
3400,13657,9,,,,Expert,,,,,"Compound was evaluated for binding affinity on 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding",B,,,,10576
3401,1879,8,,,,Autocuration,955.0,,Brain,,Compound was tested for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat brain using [3H]zacopride as the radioligand.,F,,,,12020
3402,1879,8,,,,Autocuration,,,,,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor,F,,,,12020
3403,1879,8,,,,Autocuration,,,,,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat CNS.,F,,,,12020
3404,204,8,,,,Autocuration,,,,,Compound was evaluated in vivo for the antagonistic activity towards 5-hydroxytryptamine 3 receptor,F,In vivo,,,12020
3405,1879,8,,,,Autocuration,,,,,Compound was tested for its binding affinity towards 5-HT-3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,B,,,,12020
3406,1879,8,,,,Autocuration,,,,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,,12020
3407,1879,8,,,,Autocuration,,,,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,B,,,,12020
3408,1879,8,,,,Autocuration,,,,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using [125I]DAIZAC as the radioligand.,B,,,,12020
3409,10641,6,,,,Autocuration,,,,,"Concentration that inhibits the binding of radioligand, [3H]-ICS 205930, to 5-hydroxytryptamine 3 receptor from rat cortex",B,,,,104698
3410,773,8,,,,Autocuration,,,,,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,B,,,,12020
3411,11952,6,,,,Autocuration,,,,,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor in rat brain cortical membranes using radioligand [3H]quipazine,B,,,,104698
3412,14145,9,,,,Autocuration,,,,10116.0,Antagonist activity (100 ug/kg) for the Bezold Jarisch reflex evoked by 30 (ug/Kg) of 5-hydroxytryptamine 3 receptor in ethylurethane anesthetized rats i.v.,F,,Rattus norvegicus,,12020
3413,17066,8,,,,Expert,,,,,Binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,,144
3414,6398,4,,,,Autocuration,,,,,Compound was evaluated for 5-hydroxytryptamine 3 receptor binding,B,,,,104714
3415,10321,0,,,,Autocuration,,,,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,B,,,,22226
3416,511,4,,,,Autocuration,,,,,Tested for 5-hydroxytryptamine 3 receptor antagonist activity by inhibiting the 5-HT evoked Bezold-Jarisch reflex,F,,,,104714
3417,4639,4,,,,Autocuration,,,,,Compound was tested for binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,,104714
3418,4639,4,,,,Autocuration,,,,,Binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,,104714
3419,4639,4,,,,Autocuration,,,,10141.0,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 0.3 uM,F,,Cavia porcellus,,104714
3420,4639,4,,,,Autocuration,,,,10141.0,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,F,,Cavia porcellus,,104714
3421,4639,4,,,,Autocuration,,,,10141.0,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 30 uM,F,,Cavia porcellus,,104714
3422,1558,4,,,,Autocuration,,,,,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,B,,,,104714
3423,268,4,,,,Autocuration,,,,,Evaluated for the 5-hydroxytryptamine 3 receptor antagonistic activity in Bezold-Jarisch model expressed as inhibition of the reflex bradycardia induced by an intravenous injection,F,,,,104714
3424,2474,4,,,,Autocuration,,,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 3 receptor at a concentration of 10 uM using [3H]BRL-43694 as radioligand,B,,,,104714
3425,5067,4,,,,Autocuration,,,,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); A: agonist,F,,,,104714
3426,5067,4,,,,Autocuration,,,,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: agonist,F,,,,104714
3427,5067,4,,,,Autocuration,,,,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: antagonist,F,,,,104714
3428,5067,4,,,,Autocuration,,,,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); NA means data not available,B,,,,104714
3429,5067,4,,,,Autocuration,,,,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); PA: Partial agonist,F,,,,104714
3430,5067,4,,,,Autocuration,,,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; A: agonist,F,,,,104714
3431,5067,4,,,,Autocuration,,,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; ANT: Antagonist,F,,,,104714
3432,5067,4,,,,Autocuration,,,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA: not active,B,,,,104714
3433,5067,4,,,,Autocuration,,,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA means data not available,B,,,,104714
3434,5067,4,,,,Autocuration,,,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; PA: Partial agonist,F,,,,104714
3435,5067,4,,,,Autocuration,,,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; na means data not available,B,,,,104714
3436,5067,4,,,,Autocuration,,,,,Binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,,104714
3437,14331,4,,,,Autocuration,,,,,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor using [3H]-BRL-43694 (1 nM) ligand in NG cells 108-15 was determined,B,,,,104714
3438,5067,4,,,,Autocuration,,,,,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor; NA: not active,B,,,,104714
3439,6179,4,,433.0,,Autocuration,,NG108-15,,,Binding affinity for 5-HT3 receptor of NG108-15 cells using [3H]GR-65630,B,,,,104714
3440,4265,4,,,,Autocuration,,,,,Binding affinity to 5-HT3 serotonin receptor in NG 108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand.,B,,,,104714
3441,4265,4,,433.0,,Autocuration,,NG108-15,,,Binding affinity to 5-HT3 serotonin receptor in NG108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand,B,,,,104714
3442,17358,4,,,,Autocuration,,,,,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,B,,,,104714
3443,17358,4,,,,Autocuration,,,,,Compound was tested for selectivity against 5-hydroxytryptamine 3 receptor binding affinity,B,,,,104714
3444,13628,4,,,,Autocuration,,,,,Compound was tested for the inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor expressed in NG 108-15 cells,B,In vitro,,,104714
3445,4612,4,,,,Autocuration,,,,,In vitro Binding affinity towards 5-hydroxytryptamine 3 receptor was determined,B,,,,104714
3446,17358,4,,,,Autocuration,,,,,Tested for 5-hydroxytryptamine 3 receptor antagonist activity,F,,,,104714
3447,4639,4,,,,Autocuration,,,,10141.0,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 1 uM,F,,Cavia porcellus,,104714
3448,4639,4,,,,Autocuration,,,,10141.0,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM,F,,Cavia porcellus,,104714
3449,4639,4,,,,Autocuration,,,,10141.0,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM in the presence of 30 uM MDL 72222,F,,Cavia porcellus,,104714
3450,4639,4,,,,Autocuration,,,,10141.0,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,F,,Cavia porcellus,,104714
3451,511,4,,,,Autocuration,,,,,Binding affinity for the 5-hydroxytryptamine 3 receptor was evaluated in vitro by examining its ability to displace [3H]-BRL 43694.,B,,,,104714
3452,1479,4,,,,Autocuration,,,,,Binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,,104714
3453,1317,4,,,,Autocuration,,,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor using radioligand binding assay,B,,,,104714
3454,12146,4,,,,Autocuration,,,,,Tested against 5-hydroxytryptamine 3 receptor in experiment 1,B,,,,104714
3455,12146,4,,,,Autocuration,,,,,Tested against 5-hydroxytryptamine 3 receptor in experiment 2,B,,,,104714
3456,13969,4,,,,Autocuration,,,,,Binding affinity against 5-hydroxytryptamine 3 receptor was measured using [3H]granisetron as radioligand,B,,,,104714
3457,13392,8,,,,Expert,,,,,Binding affinity for 5-hydroxytryptamine 2C receptor,B,,,,108
3458,13392,6,,,,Autocuration,,,,,Binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,,104698
3459,14159,8,,,,Autocuration,,,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 3 receptor,B,,,,144
3460,1558,8,,,,Autocuration,,,,,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,B,,,,144
3461,16655,8,,,,Autocuration,,,,,Inhibition of GR-65630 binding to 5-hydroxytryptamine 3 receptor,B,,,,144
3462,13020,4,,,,Autocuration,,,,,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,B,,,,104714
3463,13021,4,,,,Autocuration,,,,,Inhibition of [3H]-BRL 43 694 binding to 5-hydroxytryptamine 3 receptor of central nervous system,B,,,,104714
3464,13020,4,,,,Autocuration,,,,,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,B,,,,104714
3465,10321,8,,,,Autocuration,,,,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,B,,,,144
3466,15818,8,,,,Autocuration,,,,,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,,144
3467,15818,8,,,,Autocuration,,,,,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,,144
3468,17358,8,,,,Autocuration,,,,,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,B,,,,144
3469,2222,8,,,,Autocuration,,,,,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,B,,,,144
3470,10322,8,,,,Autocuration,,,,,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,B,,,,144
3471,16117,8,,,,Autocuration,,,,,In vitro binding affinity towards 5-hydroxytryptamine 3 receptor was determined,B,,,,144
3472,17200,8,,,,Autocuration,,,,,Inhibitory constant against 5-hydroxytryptamine 3 receptor using [3H]GR-65630 radioligand,B,,,,144
3473,17358,8,,,,Autocuration,,,,,Tested for 5-hydroxytryptamine 3 receptor agonist activity,F,,,,144
3474,16700,8,,,,Autocuration,,,,,The binding affinity towards 5-hydroxytryptamine 3 receptor; No affinity,B,,,,144
3475,1980,8,,,,Autocuration,,,,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H](R)-zacopride from ondansetron-treated NG-108-15 cell membranes,B,,,,144
3476,1980,8,,,,Autocuration,,,,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H]-BRL 43694 from NG-108-15 cell membranes,B,,,,144
3477,12409,4,,,,Autocuration,,,,,Binding affinity against the 5-hydroxytryptamine 3 receptor,B,,,,104714
3478,4365,8,,,,Autocuration,,,,,Binding affinity against human 5-hydroxytryptamine 3A receptor,B,,,,144
3479,4365,8,,,,Autocuration,,,,,Percent efficacy against 5-hydroxytryptamine 3A receptor,F,,,,144
3480,4365,8,,,,Autocuration,,,,,Binding affinity against human 5-hydroxytryptamine 3A receptor,B,,,,144
3481,6769,9,,,,Expert,,Oocytes,,10116.0,Response at rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes,F,,Rattus norvegicus,,12020
3482,6769,9,,,,Expert,,Oocytes,,10116.0,Ability to block serotonin (30 uM)-evoked responses at rat 5HT3-alpha receptor expressed in xenopus oocytes,F,,Rattus norvegicus,,12020
3483,6769,9,,,,Expert,,Oocytes,,10116.0,Effect on rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes at concentration up to 100 uM,F,,Rattus norvegicus,,12020
3484,809,9,,,,Intermediate,2116.0,,Ileum,10141.0,5-hydroxytryptamine 4 receptor agonist activity as percent maximum 5-HT effect in response to electrical stimulation in male guinea pig ileum,F,,Cavia porcellus,,20033
3485,809,9,,,,Intermediate,2116.0,,Ileum,10141.0,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum,F,,Cavia porcellus,,20033
3486,14290,9,,,,Intermediate,,,,10141.0,5-hydroxytryptamine 4 receptor agonist activity is expressed as percent of the maximum 5-HT response,F,,Cavia porcellus,,20033
3487,17358,9,,,,Intermediate,2116.0,,Ileum,10141.0,Tested for affinity towards 5-hydroxytryptamine 4 receptor in electrically stimulated longitudinal muscle preparation of guinea pig ileum,B,,Cavia porcellus,,20033
3488,17358,9,,,,Intermediate,,,,10141.0,Tested for affinity towards 5-hydroxytryptamine 4 receptor in guinea pig distal colon preparation,B,,Cavia porcellus,,20033
3489,17358,9,,,,Intermediate,2116.0,,Ileum,10141.0,Tested for affinity towards 5-hydroxytryptamine 4 receptor in isolated guinea pig ileum longitudinal muscle preparation,B,,Cavia porcellus,,20033
3490,17386,8,,,,Autocuration,2116.0,,Ileum,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,B,,,,10209
3491,3269,8,,,,Autocuration,,,,,Affinity against 5-hydroxytryptamine 7 receptor,B,,,,10209
3492,7721,4,,,,Autocuration,,,,10141.0,Ability to displace [3H]5-HT binding from 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,B,,Cavia porcellus,,104841
3493,7721,4,,,,Autocuration,,,,10141.0,Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,B,,Cavia porcellus,,104841
3494,9117,4,,,,Autocuration,2116.0,,Ileum,10141.0,Evaluated for inhibition of 5-hydroxytryptamine receptor on guinea pig ileum at 10 uM; No effect,B,,Cavia porcellus,,104841
3495,7721,4,,,,Autocuration,,,,10141.0,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand, activity is expressed as Kd.",B,,Cavia porcellus,,104841
3496,7721,4,,,,Autocuration,,,,10141.0,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor using 1 uM LSD as masking ligand, activity is expressed as Kd.",B,,Cavia porcellus,,104841
3497,15796,4,,,,Autocuration,,,,10141.0,5-HT level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,F,,Cavia porcellus,,104841
3498,15796,4,,,,Autocuration,,,,10141.0,5-hydroxytryptamine level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,F,,Cavia porcellus,,104841
3499,15650,9,,,,Expert,2081.0,,Cardiac atrium,9606.0,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor in the presence of 10 nM compound in isolated human atrial myocytes,B,,Homo sapiens,,168
3500,15650,9,,,,Expert,2081.0,,Cardiac atrium,9606.0,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes,B,,Homo sapiens,,168
3501,6866,5,,,,Autocuration,,,,9606.0,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine",F,,Homo sapiens,,104841
3502,15650,9,,,,Expert,2081.0,,Cardiac atrium,9606.0,",Antagonism of stimulation of 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes",F,,Homo sapiens,,168
3503,10063,0,,,,Autocuration,,,,10090.0,Ability (10 ug/kg) to inhibit binding of [125I]iododexetimide to 5-hydroxytryptamine receptor in mice,B,,Mus musculus,,22226
3504,12665,0,,,,Autocuration,,,,10090.0,Percent inhibition of radioligand [3H]-LSD binding to 5-HT receptor at 10 uM concentration,B,,Mus musculus,,22226
3505,7504,4,,,,Autocuration,,,,,5-hydroxytryptamine receptor binding affinity was determined in rats,B,,,,104705
3506,7504,4,,,,Autocuration,,,,,Binding affinity at rat 5-hydroxytryptamine receptor.,B,,,,104705
3507,7038,4,,,,Autocuration,,,,,Affinity against 5-hydroxytryptamine receptors in rat fundus model,B,,,,104705
3508,7626,4,,,,Autocuration,,,,,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation,B,,,,104705
3509,7626,4,,,,Autocuration,,,,,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation; Not determined,B,,,,104705
3510,7185,4,,,,Autocuration,945.0,,Stomach,,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation,F,,,,104705
3511,7185,4,,,,Autocuration,945.0,,Stomach,,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation (resulted in discoloration in the oxygenated muscle bath to give varying results).,F,,,,104705
3512,7185,4,,,,Autocuration,,,,,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,F,,,,104705
3513,6960,4,,,,Autocuration,,,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2,B,,,,104705
3514,6960,4,,,,Autocuration,,,,,"Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2; Valid pA2, can not be determined because of slope of Schild plot.",B,,,,104705
3515,12416,8,,,,Autocuration,10000000.0,,Hippocampus,,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,B,,,,10576
3516,15753,8,,,,Expert,,,,,Binding affinity for rat 5-hydroxytryptamine transporter.,B,,,,12198
3517,8062,4,,,,Autocuration,,,,,Evaluated for inhibition of specific [3H]5-HT receptor binding in rat cortex.,B,,,,104705
3518,9036,5,,,,Autocuration,,,,10116.0,Binding affinity at serotonin 5-HT1-type site receptor in rat cortex by displacing [3H]5-HT,B,,Rattus norvegicus,,104705
3519,15067,5,,,,Autocuration,,,,10116.0,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,B,,Rattus norvegicus,,104705
3520,15753,9,,,,Expert,955.0,,Brain,10116.0,Inhibitory activity against [3H]- 5-hydroxytryptamine reuptake in whole rat brain minus cerebellum,F,,Rattus norvegicus,,12198
3521,15753,9,,,,Expert,2037.0,,Cerebellum,10116.0,Inhibition of [3H]5-HT reuptake in whole rat brain (minus cerebellum) homogenate.,F,,Rattus norvegicus,,12198
3522,15295,5,,,,Autocuration,,,,10116.0,Displacement of [3H]-citalopram from rat forebrain membrane 5-hydroxytryptamine receptor at 10e-7 M,B,,Rattus norvegicus,,104705
3523,6347,5,,,,Autocuration,,,,10116.0,Percent binding affinity against 5-hydroxytryptamine receptor,B,,Rattus norvegicus,,104705
3524,6763,0,,,,Autocuration,,,,,Ability to displace 0.4 nM [3H]paroxetine binding to 5-hydroxytryptamine receptor in rat frontal cortex,B,,,,22226
3525,12092,5,,,,Autocuration,,,,10116.0,The binding affinity was measured on 5-hydroxytryptamine receptor uptake receptor using [3H]- paroxetine as radioligand.,B,,Rattus norvegicus,,104705
3526,1579,5,,,,Autocuration,,,,10116.0,Affinity against 5-hydroxytryptamine receptor was determined,B,,Rattus norvegicus,,104705
3527,1579,5,,,,Autocuration,945.0,,Stomach,10116.0,Affinity against 5-hydroxytryptamine receptor was determined in rat stomach fundus strip,B,,Rattus norvegicus,,104705
3528,5963,9,,,,Expert,,,,9606.0,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,B,In vitro,Homo sapiens,,121
3529,5963,9,,,,Expert,,,,9606.0,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,B,In vitro,Homo sapiens,,121
3530,5030,8,,,,Autocuration,,,,,Ability to compete with radioactive ligands specific to the Serotonergic 5-HT receptor at 10 uM; NA means compound failed to compete,B,,,,18065
3531,15796,8,,,,Expert,,,,,Inhibition of 5-hydroxytryptamine reuptake,B,,,,121
3532,15413,8,,,,Autocuration,,,,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding",F,,,,18065
3533,15413,8,,,,Autocuration,,,,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 1)",F,,,,18065
3534,15413,8,,,,Autocuration,,,,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 2)",F,,,,18065
3535,12409,8,,,,Autocuration,,,,,Tested for 5-hydroxytryptamine receptor uptake,F,,,,18065
3536,16909,9,,449.0,,Expert,,CHO,,9606.0,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,B,,Homo sapiens,,51
3537,16909,9,,,,Expert,,,,9606.0,Antagonistic affinity tested against isolated human cloned alpha-1d adrenoceptor subtype,F,,Homo sapiens,,51
3538,15629,8,,,,Autocuration,,,,9606.0,In vitro binding affinity towards 5-hydroxytryptamine receptor 1A receptor by using [3H]8-OH-DPAT in rat hippocampal membranes.,B,,Homo sapiens,,10576
3539,15629,8,,,,Autocuration,,,,,Tested in vitro for % inhibition against 5-hydroxytryptamine receptor 1A,B,,,,10576
3540,15629,8,,,,Expert,,,,,In vitro binding affinity at 5-hydroxytryptamine receptor 1A receptor in rat hippocampal membranes by [3H]8-OH-DPAT displacement.,B,,,,10576
3541,10034,8,,,,Autocuration,2435.0,,Striatum,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 0.10 umol/kg,F,,,,10825
3542,10034,8,,,,Autocuration,2435.0,,Striatum,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 10 umol/kg,F,,,,10825
3543,10034,8,,,,Autocuration,2435.0,,Striatum,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 0.32 umol/kg,F,,,,10825
3544,10034,8,,,,Autocuration,2435.0,,Striatum,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 3.2 umol/kg,F,,,,10825
3545,10034,8,,,,Autocuration,2435.0,,Striatum,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 32 umol/kg,F,,,,10825
3546,10034,8,,,,Autocuration,2435.0,,Striatum,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 0.032 umol/kg,F,,,,10825
3547,10034,8,,,,Autocuration,2435.0,,Striatum,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 1.0 umol/kg,F,,,,10825
3548,10034,8,,,,Autocuration,2435.0,,Striatum,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 10 umol/kg,F,,,,10825
3549,10034,8,,,,Autocuration,2435.0,,Striatum,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 100 umol/kg,F,,,,10825
3550,10034,8,,,,Autocuration,2435.0,,Striatum,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 3.2 umol/kg,F,,,,10825
3551,10034,8,,,,Autocuration,2435.0,,Striatum,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 32 umol/kg,F,,,,10825
3552,10034,8,,,,Autocuration,349.0,,Limbic system,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.032 umol/kg,F,,,,10825
3553,10034,8,,,,Autocuration,349.0,,Limbic system,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,F,,,,10825
3554,10034,8,,,,Autocuration,349.0,,Limbic system,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.32 umol/kg,F,,,,10825
3555,10034,8,,,,Autocuration,349.0,,Limbic system,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 1.0 umol/kg,F,,,,10825
3556,10034,8,,,,Autocuration,349.0,,Limbic system,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 10 umol/kg,F,,,,10825
3557,10034,8,,,,Autocuration,349.0,,Limbic system,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 100 umol/kg,F,,,,10825
3558,10034,8,,,,Autocuration,349.0,,Limbic system,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 3.2 umol/kg,F,,,,10825
3559,1274,8,,,,Expert,,,,,Binding affinity against 5-hydroxytryptamine 4 receptor,B,,,,168
3560,17358,8,,,,Autocuration,,,,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,F,,,,168
3561,14532,8,,,,Autocuration,,,,,Inhibitory activity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand at 10e-5 M concentration,B,,,,168
3562,16989,8,,,,Expert,,,,,Binding affinity towards Serotonin 5-hydroxytryptamine 4 receptor,B,,,,168
3563,17200,8,,,,Autocuration,,,,,Inhibitory constant against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 radioligand,B,,,,168
3564,15779,8,,,,Autocuration,,,,,Binding affinity towards 5-hydroxytryptamine 4 receptor,B,,,,168
3565,15779,8,,,,Autocuration,,,,,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,B,,,,168
3566,15779,8,,,,Autocuration,,,,,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,B,,,,168
3567,15650,8,,643.0,,Autocuration,,COS-7,,,Binding affinity was determined against cloned 5-hydroxytryptamine 4A receptor isoform expressed in COS-7 cells,B,,,,168
3568,15650,8,,643.0,,Autocuration,,COS-7,,,Binding affinity was determined against cloned 5-hydroxytryptamine 4B receptor isoform expressed in COS-7 cells,B,,,,168
3569,15650,8,,643.0,,Autocuration,,COS-7,,,Binding affinity was determined against cloned 5-hydroxytryptamine 4C receptor isoform expressed in COS-7 cells,B,,,,168
3570,15650,8,,643.0,,Autocuration,,COS-7,,,Binding affinity was determined against cloned 5-hydroxytryptamine 4D receptor isoform expressed in COS-7 cells,B,,,,168
3571,17046,8,,673.0,,Autocuration,,C6,,,Binding affinity of compound towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,B,,,,168
3572,17046,8,,673.0,,Expert,,C6,,,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,B,,,,168
3573,15650,8,,673.0,,Expert,,C6,,,Binding affinity was determined against cloned 5-hydroxytryptamine 4E receptor isoform expressed in C6 glial cells incubated with 0.2 nM [3H]GR-113808,B,,,,168
3574,17046,8,,673.0,,Expert,,C6,,,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand; Not determined,B,,,,168
3575,17066,8,,,,Expert,,,,,Binding affinity towards 5-hydroxytryptamine 5 receptor,B,,,,10624
3576,17200,8,,,,Autocuration,,,,,Inhibitory constant against human 5-hydroxytryptamine 5A receptor using [3H]LSD radioligand,B,,,,105
3577,16146,9,,,,Expert,,,,9606.0,Binding affinity against 5-hydroxytryptamine 5A receptor,B,,Homo sapiens,,10624
3578,15250,8,,449.0,,Autocuration,,CHO,,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 5A receptor stably expressed in CHO cells,B,,,,10624
3579,6491,9,,,,Expert,,,,9606.0,Affinity towards human 5-hydroxytryptamine 5A serotonin receptor,B,,Homo sapiens,,10624
3580,17066,9,,,,Expert,,,,9606.0,Binding affinity towards human 5-hydroxytryptamine 5A receptor,B,,Homo sapiens,,10624
3581,17066,9,,,,Expert,,,,9606.0,Binding affinity towards human 5-hydroxytryptamine 5A receptor was evaluated using [3H]-5-CT as radioligand,B,,Homo sapiens,,10624
3582,4234,9,,,,Expert,,,,9606.0,Binding affinity to cloned human 5-hydroxytryptamine 5A receptor,B,,Homo sapiens,,10624
3583,6013,8,,,,Autocuration,,,,,Binding affinity towards 5-HT5A receptor,B,,,,10624
3584,17175,8,,,,Expert,,,,,Binding affinity towards human 5-hydroxytryptamine 5A receptor using LSD as radioligand,B,,,,10624
3585,15818,8,,,,Autocuration,,,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 5A receptor,B,,,,10624
3586,6166,8,,,,Autocuration,,,,,Binding affinity towards cloned human 5-HT5A receptor was determined,B,,,,10624
3587,15779,8,,722.0,,Autocuration,,HEK293,,,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,B,,,,10624
3588,15779,8,,722.0,,Autocuration,,HEK293,,,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,B,,,,10624
3589,5213,8,,722.0,,Autocuration,,HEK293,,,Compound was tested for its binding affinity in 5-hydroxytryptamine 5A receptor (using human cloned receptors in HEK 293 and [3H]5-CTas a radioligand ),B,,,,10624
3590,17066,9,,,,Expert,,,,10090.0,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor,B,,Mus musculus,,10625
3591,17066,9,,,,Expert,,,,10090.0,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [125I]-2-iodo LSD as radioligand,B,,Mus musculus,,10625
3592,17066,9,,,,Expert,,,,10090.0,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]- LSD as radioligand,B,,Mus musculus,,10625
3593,17066,9,,,,Expert,,,,10090.0,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]LSD as radioligand,B,,Mus musculus,,10625
3594,17066,9,,,,Expert,,,,10090.0,Binding affinity towards murine 5-hydroxytryptamine 5A receptor,B,,Mus musculus,,10625
3595,17175,8,,,,Expert,,,,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor using LSD as radioligand,B,,,,10625
3596,16190,8,,722.0,,Autocuration,,HEK293,,,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,B,,,,10576
3597,16190,8,,722.0,,Autocuration,,HEK293,,,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,B,,,,10626
3598,4820,8,,,,Expert,,,,,Binding affinity towards 5-HT5a receptor,B,,,,10624
3599,17066,9,,,,Expert,,,,9606.0,Binding affinity towards 5-hydroxytryptamine 5A receptor,B,,Homo sapiens,,10624
3600,17066,8,,,,Expert,,,,,Binding affinity for rodent 5-hydroxytryptamine 5A receptor,B,,,,10624
3601,17175,8,,,,Expert,,,,,Binding affinity towards 5-hydroxytryptamine 5A receptor using lysergic acid diethylamide (LSD) as radioligand,B,,,,10624
3602,16633,8,,,,Autocuration,,,,,Binding affinities against 5-hydroxytryptamine 5A receptor,B,,,,10624
3603,16633,8,,,,Autocuration,,,,,Binding affinities towards 5-hydroxytryptamine 5A receptor,B,,,,10624
3604,16700,8,,,,Autocuration,,,,,The binding affinity towards 5-hydroxytryptamine 5A receptor; No affinity,B,,,,10624
3605,4639,4,,,,Autocuration,,,,10141.0,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.01 uM,F,,Cavia porcellus,,104714
3606,5486,4,,,,Autocuration,,,,,Binding affinity towards 5-HT3 receptor by the displacement of [3H]GR-65630] in human recombinant receptors in mammalian cell,B,,,,104714
3607,16146,9,,,,Expert,,,,9606.0,Inhibition of human 5-hydroxytryptamine 6 receptor,B,,Homo sapiens,,10627
3608,17273,9,,,,Expert,,,,9606.0,Binding affinity towards 5-hydroxytryptamine 6 receptor using [3H]- LSD as radioligand,B,,Homo sapiens,,10627
3609,17687,8,,,,Autocuration,,,,,Inhibition against human 5-hydroxytryptamine 6 receptor,B,,,,10627
3610,6491,9,,,,Expert,,,,9606.0,Affinity towards human 5-hydroxytryptamine 6 serotonin receptor,B,,Homo sapiens,,10627
3611,16190,8,,308.0,,Expert,,HeLa,,,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells.,B,,,,10627
3612,17066,9,,,,Expert,,,,9606.0,Binding affinity towards [3H]LSD-labeled human 5-hydroxytryptamine 6 receptor,B,,Homo sapiens,,10627
3613,17066,9,,,,Expert,,,,9606.0,Binding affinity towards human 5-hydroxytryptamine 6 receptor,B,,Homo sapiens,,10627
3614,17066,9,,,,Expert,,,,9606.0,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [125I]-2-iodo LSD as radioligand,B,,Homo sapiens,,10627
3615,17066,9,,,,Expert,,,,9606.0,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [3H]-LSD as radioligand,B,,Homo sapiens,,10627
3616,3555,9,,,,Expert,,,,9606.0,Binding affinity against 5-hydroxytryptamine 6 receptor,B,,Homo sapiens,,10627
3617,5808,8,,,,Expert,,,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,B,,,,10627
3618,6013,8,,,,Autocuration,,,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,B,,,,10627
3619,15818,8,,722.0,,Expert,,HEK293,,,"Binding affinity for human 5-hydroxytryptamine 6 receptor expressed in HEK 293 human embryonic kidney cells, [3H]-lysergic acid diethylamide as radioligand",B,,,,10627
3620,16209,8,,,,Autocuration,,,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor using [3H]LSD as radioligand,B,,,,10627
3621,3935,8,,722.0,,Expert,,HEK293,,,Binding affinity against human 5-hydroxytryptamine 6 receptor stably transfected to HEK 293 human embryonic kidney cells using [3H]-lysergic acid diethylamide as radioligand,B,,,,10627
3622,15818,8,,,,Autocuration,,,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 6 receptor,B,,,,10627
3623,3805,9,,722.0,,Expert,,HEK293,,9606.0,Displacement of [3H]LSD from human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,B,,Homo sapiens,,10627
3624,16441,8,,,,Expert,,,,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD,B,,,,10627
3625,16441,8,,,,Expert,,,,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD; ND is No Data.,B,,,,10627
3626,6786,8,,643.0,,Expert,,COS-7,,,Ability to displace [3H]LSD from human 5-hydroxytryptamine 6 receptor transiently expressed in COS-7 cells,B,,,,10627
3627,4234,9,,,,Expert,,,,9606.0,In vitro binding affinity to human 5-hydroxytryptamine 6 receptor,B,,Homo sapiens,,10627
3628,17085,8,,,,Autocuration,,,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 6 receptor,B,,,,10627
3629,17200,8,,,,Autocuration,,,,,Inhibitory constant against human 5-hydroxytryptamine 6 receptor using [3H]LSD radioligand,B,,,,10627
3630,17451,8,,722.0,,Autocuration,,HEK293,,,Antagonism assessed in a functional cAMP binding assay using 5-CT to stimulate human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,B,,,,10627
3631,3935,8,,,,Autocuration,,,,,The compound was tested for antagonist activity by inhibition of human 5-HT6 stimulated adenylate cyclase,F,,,,10627
3632,5033,8,,,,Autocuration,,,,,Ability to displace the radioligand [3H]LSD from human 5-hydroxytryptamine 6 receptor,B,,,,10627
3633,4540,8,,,,Expert,,,,,Binding affinity against human 5-hydroxytryptamine 6 receptor,B,,,,10627
3634,4540,9,,308.0,,Expert,,HeLa,,9606.0,Binding affinity to human cloned 5-HT6 receptor in HeLa cells using [3H]- LSD as radioligand,B,,Homo sapiens,,10627
3635,4540,9,,308.0,,Expert,,HeLa,,9606.0,Binding affinity to human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]- LSD as radioligand,B,,Homo sapiens,,10627
3636,17296,8,,308.0,,Autocuration,,HeLa,,,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells,B,,,,10627
3637,17296,8,,308.0,,Autocuration,,HeLa,,,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,B,,,,10627
3638,17296,8,,308.0,,Autocuration,,HeLa,,,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,B,,,,10627
3639,15779,8,,449.0,,Autocuration,,CHO,,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,B,,,,10627
3640,15779,8,,722.0,,Autocuration,,HEK293,,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,B,,,,10627
3641,15779,8,,722.0,,Autocuration,,HEK293,,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand; ND means no data.,B,,,,10627
3642,15779,8,,722.0,,Autocuration,,HEK293,,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,B,,,,10627
3643,15779,8,,308.0,,Autocuration,,HeLa,,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HeLa cells using [3H]LSD as radioligand;ND means no data.,B,,,,10627
3644,6166,8,,,,Autocuration,,,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,B,,,,10627
3645,17451,8,,308.0,,Autocuration,,HeLa,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 6 receptor expressed in HeLa cells using [3H]LSD as radioligand,B,,,,10627
3646,15316,8,,,,Autocuration,,,,,Compound was evaluated for its ability to displace [3H]LSD binding from human recombinant 5-hydroxytryptamine 6 receptor,B,,,,10627
3647,4199,8,,,,Expert,,,,,Binding affinity against human 5-hydroxytryptamine 6 receptor,B,,,,10627
3648,15146,8,,308.0,,Expert,,HeLa,,,Binding affinity against human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]LSD,B,,,,10627
3649,5213,8,,,,Autocuration,,,,,Compound was tested for its binding affinity in 5-hydroxytryptamine 6 receptor (using human cloned receptors in HeLa and [3H]LSD as a radioligand ),B,,,,10627
3650,16429,8,,,,Autocuration,,,,,In vitro binding affinity at human recombinant 5-hydroxytryptamine 6 receptor in mammalian cells using 3[H]LSD as the radioligand,B,,,,10627
3651,14818,8,,308.0,,Autocuration,,HeLa,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]5-LSD.,B,,,,10627
3652,4829,8,,308.0,,Autocuration,,HeLa,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=3",B,,,,10627
3653,4829,8,,308.0,,Autocuration,,HeLa,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=9",B,,,,10627
3654,4829,8,,308.0,,Autocuration,,HeLa,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]LSD as radioligand; n=3",B,,,,10627
3655,15250,8,,449.0,,Autocuration,,CHO,,,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 6 receptor stably expressed in CHO cells,B,,,,10628
3656,14423,8,,,,Autocuration,,,,,Binding affinity against 5-hydroxytryptamine 6 receptor from CHO cell membranes using [3H]5-HT as the radioligand.,B,,,,10628
3657,15086,8,,,,Autocuration,,,,,The compound was tested for binding affinity against 5-hydroxytryptamine 6 receptor,B,,,,10628
3658,4342,8,,,,Autocuration,,,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor was determined,B,,,,10628
3659,16190,9,,308.0,,Autocuration,,HeLa,,9606.0,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells,B,,Homo sapiens,,10627
3660,4820,8,,,,Expert,,,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,B,,,,10627
3661,4639,8,,,,Autocuration,,,,,Percentage of displacement at 5-hydroxytryptamine 6 receptor at 10e-8 M,B,,,,10627
3662,17066,9,,,,Expert,,,,9606.0,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,F,,Homo sapiens,,10627
3663,6011,8,,,,Autocuration,,,,,Inhibition of binding towards 5-hydroxytryptamine 6 receptor at 100 nM concentration,B,,,,10627
3664,17066,8,,,,Expert,,,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,B,,,,10627
3665,17515,8,,,,Autocuration,,,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor; inactive at 10 uM,B,,,,10627
3666,5014,8,,,,Autocuration,,,,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 6 receptor,B,,,,10627
3667,4373,8,,,,Autocuration,,,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 6 receptor was determined,B,,,,10627
3668,17066,8,,,,Expert,,,,,Antagonistic activity towards 5-hydroxytryptamine 6 receptor,F,,,,10627
3669,17066,8,,,,Expert,,,,,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,F,,,,10627
3670,4373,8,,,,Autocuration,,,,,Binding affinity for 5-hydroxytryptamine 6 receptor was determined,B,,,,10627
3671,4687,8,,,,Autocuration,,,,,Evaluated for the binding affinity towards 5-hydroxytryptamine 6 receptor,B,,,,10627
3672,16946,8,,,,Autocuration,,,,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-6 M,B,,,,10627
3673,16946,8,,,,Autocuration,,,,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-8 M,B,,,,10627
3674,16633,8,,,,Autocuration,,,,,Binding affinities against 5-hydroxytryptamine 6 receptor,B,,,,10627
3675,16633,8,,,,Autocuration,,,,,Binding affinities towards 5-hydroxytryptamine 6 receptor,B,,,,10627
3676,17066,9,,,,Expert,,,,9606.0,Binding affinity towards 5-hydroxytryptamine 6 receptor,B,,Homo sapiens,,10627
3677,16700,8,,,,Autocuration,,,,,The binding affinity towards 5-hydroxytryptamine 6 receptor; No affinity,B,,,,10627
3678,3269,8,,,,Autocuration,,,,,Affinity against 5-hydroxytryptamine 6 receptor,B,,,,10627
3679,5486,8,,,,Autocuration,,,,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-CT],B,,,,10627
3680,16146,9,,,,Expert,,,,9606.0,Inhibition of human 5-hydroxytryptamine 7 receptor,B,,Homo sapiens,,10209
3681,5014,8,,722.0,,Autocuration,,HEK293,,,Compound was tested for its binding affinity towards human 5-hydroxytryptamine 7 receptor from HEK293 cells using radioligand [3H]LSD,B,,,,10209
3682,15463,8,,,,Autocuration,,,,,Compound at 1 uM was tested for the inhibition of radioligand [3H]LSD binding to recombinant human 5-hydroxytryptamine 7 receptor,B,,,,10209
3683,3805,8,,,,Autocuration,,,,,In vitro binding affinity against human 5-hydroxytryptamine 7 receptor at a concentration of 100 (nM),B,,,,10209
3684,5014,8,,722.0,,Expert,,HEK293,,,Inhibition (at 1 uM) of radioligand [3H]LSD binding to human 5-hydroxytryptamine 7 receptor on HEK293 cells,B,,,,10209
3685,6491,9,,,,Expert,,,,9606.0,Affinity towards human 5-hydroxytryptamine 7 serotonin receptor,B,,Homo sapiens,,10209
3686,16190,8,,449.0,,Autocuration,,CHO,,,Binding affinity for 5-hydroxytryptamine 7 receptor human cloned receptors in CHO cells using [3H]5-HT,B,,,,10209
3687,17066,9,,,,Expert,,,,9606.0,Binding affinity towards human 5-hydroxytryptamine 7 receptor,B,,Homo sapiens,,10209
3688,17066,9,,,,Expert,,,,9606.0,Displacement of [3H]5-HT from human 5-hydroxytryptamine 7 receptor,B,,Homo sapiens,,10209
3689,3555,9,,,,Expert,,,,9606.0,Binding affinity against 5-hydroxytryptamine 7 receptor,B,,Homo sapiens,,10209
3690,6588,8,,449.0,,Expert,,CHO,,,Binding affinity towards human 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-HT radioligand from the cloned receptor expressed in CHO cells,B,,,,10209
3691,15463,8,,,,Autocuration,,,,,Binding affinity towards recombinant human 5-hydroxytryptamine 7 receptor was determined using [3H]LSD as radioligand,B,,,,10209
3692,6013,8,,,,Autocuration,,,,,Binding affinity towards 5-hydroxytryptamine 7 receptor,B,,,,10209
3693,16209,8,,,,Autocuration,,,,,Binding affinity towards human 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,B,,,,10209
3694,3935,8,,,,Autocuration,,,,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 7 receptor,B,,,,10209
3695,15818,8,,,,Autocuration,,,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 7 receptor,B,,,,10209
3696,5014,8,,722.0,,Expert,,HEK293,,,Binding affinity towards human 5-hydroxytryptamine 7 receptor on HEK293 cells using radioligand [3H]LSD,B,,,,10209
3697,16441,8,,,,Expert,,,,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD,B,,,,10209
3698,16441,8,,,,Expert,,,,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD; ND is No Data.,B,,,,10209
3699,4234,9,,,,Expert,,,,9606.0,In vitro binding affinity to human 5-hydroxytryptamine 7 receptor,B,,Homo sapiens,,10209
3700,17085,8,,,,Autocuration,,,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor,B,,,,10209
3701,17200,8,,,,Autocuration,,,,,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]LSD radioligand,B,,,,10209
3702,17451,8,,449.0,,Autocuration,,CHO,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]-LSD as radioligand; Not determined,B,,,,10209
3703,17085,8,,,,Autocuration,,,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor; ND means not determined,B,,,,10209
3704,5104,8,,,,Autocuration,,,,,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor,B,,,,10209
3705,5104,8,,,,Autocuration,,,,,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor; Not tested,B,,,,10209
3706,5033,9,,643.0,,Expert,,COS-7,,9606.0,Ability to displace the radioligand [3H]5-carboxyamidotryptamine ([3H]5-CT) from human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,B,,Homo sapiens,,10209
3707,5486,8,,643.0,,Autocuration,,COS-7,,,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-5-CT) from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,B,,,,10209
3708,4540,9,,722.0,,Expert,,HEK293,,9606.0,Binding affinity to human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]-5-CT as radioligand,B,,Homo sapiens,,10209
3709,6166,8,,,,Expert,,,,,Binding affinity at human cloned 5-hydroxytryptamine 7 receptor.,B,,,,10209
3710,17342,8,,722.0,,Expert,,HEK293,,,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor was determined in HEK293 cells using [3H]5-CT as radioligand,B,,,,10209
3711,17342,8,,,,Expert,,,,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor was determined using [3H]5-CT as radioligand,B,,,,10209
3712,17296,8,,,,Autocuration,,,,,Binding affinity against 5-hydroxytryptamine 7 human receptors,B,,,,10209
3713,16429,8,,,,Expert,,,,,Binding affinity to human recombinant 5-hydroxytryptamine 7 receptor in mammalian cells using [3H]5-CT as radioligand,B,,,,10209
3714,15779,8,,722.0,,Autocuration,,HEK293,,,Binding affinity toward 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]-5-CT as radioligand.,B,,,,10209
3715,15779,8,,722.0,,Autocuration,,HEK293,,,Binding affinity towards 5-hydroxytryptamine 7 receptor (a) (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,B,,,,10209
3716,15779,8,,722.0,,Autocuration,,HEK293,,,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,B,,,,10209
3717,15779,8,,722.0,,Autocuration,,HEK293,,,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,B,,,,10209
3718,15779,8,,722.0,,Autocuration,,HEK293,,,Binding affinity towards 5-hydroxytryptamine 7 receptor 7(a) (human cloned receptor in HEK 293 cells using [3H]5-CT as radioligand.,B,,,,10209
3719,17451,8,,449.0,,Autocuration,,CHO,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]LSD as radioligand,B,,,,10209
3720,4199,8,,722.0,,Autocuration,,HEK293,,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand (n=3),B,,,,10209
3721,4199,9,,722.0,,Expert,,HEK293,,,Displacement of [3H]-5-CT from human 5-hydroxytryptamine 7 receptor expressed in HEK-293 cells,B,,,,10209
3722,4199,8,,722.0,,Autocuration,,HEK293,,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand(n=6),B,,,,10209
3723,3680,9,,722.0,,Intermediate,,HEK293,,,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells,B,,,,10209
3724,3680,9,,,,Intermediate,,,,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor using [3H]5-CT as radioligand,B,,,,10209
3725,15316,8,,643.0,,Autocuration,,COS-7,,,Compound was evaluated for its ability to displace [3H]5-CT binding from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells.,B,,,,10209
3726,15146,8,,722.0,,Autocuration,,HEK293,,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT,B,,,,10209
3727,5213,8,,722.0,,Expert,,HEK293,,,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor in HEK 293 using [3H]5-CT as a radioligand,B,,,,10209
3728,5213,8,,722.0,,Autocuration,,HEK293,,,Compound was tested for its binding affinity in 5-hydroxytryptamine 7 receptor (using human cloned receptors in HEK 293 and [3H]5-CT as a radioligand ),B,,,,10209
3729,14818,9,,722.0,,Expert,,HEK293,,9606.0,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT,B,,Homo sapiens,,10209
3730,14818,8,,722.0,,Autocuration,,HEK293,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT. ,B,,,,10209
3731,14818,8,,722.0,,Autocuration,,HEK293,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT.,B,,,,10209
3732,4829,8,,722.0,,Autocuration,,HEK293,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 7 receptor in HEK293 cells, using [3H]5-CT as radioligand",B,,,,10209
3733,17200,9,,,,Autocuration,,,,9606.0,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]-LSD radioligand; Not determined,B,,Homo sapiens,,10209
3734,17066,9,,,,Expert,,,,10090.0,Binding affinity towards mouse 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,B,,Mus musculus,,10022
3735,14025,8,,,,Autocuration,,,,9986.0,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 7 receptor in the endothelium denuded rabbit jugular vein.,B,,Oryctolagus cuniculus,,10209
3736,15250,8,,449.0,,Autocuration,,CHO,,,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 7 receptor stably expressed in CHO cells,B,,,,11923
3737,16372,8,,449.0,,Autocuration,,CHO,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 10000 nM,B,,,,11923
3738,16372,8,,449.0,,Autocuration,,CHO,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 100 nM,B,,,,11923
3739,16372,8,,449.0,,Autocuration,,CHO,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 1 nM,B,,,,11923
3740,16372,8,,449.0,,Autocuration,,CHO,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 10000 nM 5-HT.,B,,,,11923
3741,16372,8,,449.0,,Autocuration,,CHO,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 100 nM 5-HT.,B,,,,11923
3742,16372,8,,449.0,,Autocuration,,CHO,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 1 nM 5-HT,B,,,,11923
3743,16372,8,,449.0,,Autocuration,,CHO,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 10000 nM,B,,,,11923
3744,16372,8,,449.0,,Autocuration,,CHO,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 100 nM,B,,,,11923
3745,16372,8,,449.0,,Autocuration,,CHO,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM,B,,,,11923
3746,16372,8,,449.0,,Autocuration,,CHO,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 10000 nM 5-HT.,B,,,,11923
3747,16372,8,,449.0,,Autocuration,,CHO,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 100 nM 5-HT.,B,,,,11923
3748,16372,8,,449.0,,Autocuration,,CHO,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT.,B,,,,11923
3749,17066,8,,,,Expert,,,,,Binding affinity towards rat 5-hydroxytryptamine 7 receptor,B,,,,11923
3750,17066,9,,,,Expert,,,,10116.0,Binding affinity towards rat 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,B,,Rattus norvegicus,,11923
3751,17386,8,,,,Expert,,,,,Binding affinity to the rat 5-hydroxytryptamine 7 receptor,B,,,,11923
3752,14423,8,,,,Autocuration,,,,,Binding affinity against 5-hydroxytryptamine 7 receptor using from CHO cell membranes [3H]5-HT as the radioligand.,B,,,,11923
3753,15874,9,,,,Expert,,,,10116.0,Binding affinity against Rat 5-hydroxytryptamine 7 receptor using [3H]5-HT,B,,Rattus norvegicus,,11923
3754,15874,9,,,,Expert,,,,10116.0,Displacement of [3H]5-HT from over-expressed rat 5-hydroxytryptamine 7 receptor,B,,Rattus norvegicus,,11923
3755,16372,9,,449.0,,Expert,,CHO,,10116.0,Displacement of [3H]5-HT from rat 5-hydroxytryptamine 7 receptor expressed in CHO cells,B,,Rattus norvegicus,,11923
3756,4622,8,,,,Autocuration,,,,,In vitro binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,B,,,,11923
3757,15086,8,,,,Autocuration,,,,,The compound was tested for binding affinity against 5-hydroxytryptamine 7 receptor,B,,,,11923
3758,16372,8,,449.0,,Autocuration,,CHO,,,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; Not tested",B,,,,11923
3759,16372,8,,449.0,,Autocuration,,CHO,,,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; not tested",B,,,,11923
3760,16372,8,,449.0,,Autocuration,,CHO,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM; not tested,B,,,,11923
3761,16372,8,,449.0,,Autocuration,,CHO,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT; Not tested,B,,,,11923
3762,17386,8,,,,Autocuration,2116.0,,Ileum,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,F,,,,11923
3763,17386,8,,,,Autocuration,2116.0,,Ileum,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,F,,,,11923
3764,17386,8,,,,Autocuration,2116.0,,Ileum,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine receptor desensitization,F,,,,11923
3765,5831,9,,,,Expert,,,,10116.0,Inhibition of [3H]-5-CT binding to 5-hydroxytryptamine 7 receptor of rat cortical membranes,B,,Rattus norvegicus,Membranes,11923
3766,4342,8,,,,Autocuration,,,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor was determined,B,,,,11923
3767,17319,8,,,,Expert,,,,,Binding affinity at rat 5-hydroxytryptamine 7 receptor.,B,,,,11923
3768,17342,8,,,,Expert,1898.0,,Hypothalamus,,Binding affinity towards 5-hydroxytryptamine receptor 7 on rat hypothalamus membranes using [3H]5-CT as radioligand.,B,,,,11923
3769,17342,8,,,,Autocuration,,,,,Binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor was determined using [3H]5-HT as radioligand,B,,,,11923
3770,3680,8,,,,Expert,1898.0,,Hypothalamus,,Binding affinity against 5-hydroxytryptamine 7 receptor using [3H]-5-CT in rat hypothalamus membranes,B,,,,11923
3771,3680,8,,,,Expert,,,,,Binding affinity towards 5-hydroxytryptamine 7 receptor,B,,,,11923
3772,17319,9,,722.0,,Expert,,HEK293,,10116.0,Agonistic activity against rat 5-HT7 adenyl cyclase expressed by HEK293 cells,F,,Rattus norvegicus,,11923
3773,17319,9,,722.0,,Expert,,HEK293,,10116.0,Agonistic activity against rat 5-HT7 adenyl cyclase expressed in HEK293 cells; Active,F,,Rattus norvegicus,,11923
3774,17319,9,,722.0,,Autocuration,,HEK293,,10116.0,Agonistic activity against rat 5-HT7-adenyl cyclase expressed by HEK293 cells; Active,F,,Rattus norvegicus,,11923
3775,4820,8,,,,Expert,,,,,Binding affinity towards 5-hydroxytryptamine 7 receptor,B,,,,10209
3776,4639,8,,,,Autocuration,,,,,Percentage of displacement at 5-hydroxytryptamine 7 receptor at 10e-8 M,B,,,,10209
3777,6011,8,,,,Autocuration,,,,,Inhibition of binding towards 5-hydroxytryptamine 7 receptor at 100 nM concentration,B,,,,10209
3778,17066,9,,,,Expert,,,,9606.0,Binding affinity towards human 5-hydroxytryptamine 7 receptor,B,,Homo sapiens,,10209
3779,17066,8,,,,Expert,,,,,Binding affinity of compound towards rodent 5-hydroxytryptamine 7 receptor,B,,,,10209
3780,17515,8,,,,Autocuration,,,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor; inactive at 10 uM,B,,,,10209
3781,4373,8,,,,Autocuration,,,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,B,,,,10209
3782,17066,8,,,,Expert,,,,,Antagonistic activity towards 5-hydroxytryptamine 7 receptor was evaluated by cAMP assay,F,,,,10209
3783,4373,8,,,,Autocuration,,,,,Binding affinity for 5-hydroxytryptamine 7 receptor was determined,B,,,,10209
3784,4373,8,,,,Autocuration,,,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,B,,,,10209
3785,4687,8,,,,Autocuration,,,,,Evaluated for the binding affinity to 5-hydroxytryptamine 7 receptor,B,,,,10209
3786,17342,8,,,,Expert,,,,,Non-selective inhibitory activity was determined against 5-hydroxytryptamine 7 receptor,B,,,,10209
3787,16946,8,,,,Autocuration,,,,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-6 M,B,,,,10209
3788,16946,8,,,,Autocuration,,,,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-8 M,B,,,,10209
3789,16633,8,,,,Autocuration,,,,,Binding affinities against 5-hydroxytryptamine 7 receptor,B,,,,10209
3790,16633,8,,,,Autocuration,,,,,Binding affinities towards 5-hydroxytryptamine 7 receptor,B,,,,10209
3791,17066,8,,,,Expert,,,,,Binding affinity towards rodent 5-hydroxytryptamine 7 receptor,B,,,,10209
3792,16700,8,,,,Autocuration,,,,,The binding affinity towards 5-hydroxytryptamine 7 receptor; No affinity,B,,,,10209
3793,17386,8,,,,Autocuration,2116.0,,Ileum,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,B,,,,10209
3794,14080,8,,,,Autocuration,,,,,Compound was evaluated for the potency to inhibit oxidation of arachidonic acid by human recombinant 5-Lipoxygenase using a spectrophotometric assay,F,,,,55
3795,14080,9,,,,Expert,,,,9606.0,Inhibition of oxidation of arachidonic acid by human 5-Lipoxygenase using spectrophotometric assay,F,,Homo sapiens,,55
3796,409,8,,,,Autocuration,,,,,In vitro inhibition of human recombinant 5-lipoxygenase enzyme,B,,,,55
3797,409,8,,,,Autocuration,,,,,In vitro inhibition of human recombinant lipoxygenase enzyme,B,,,,55
3798,409,8,,,,Autocuration,,,,,In vitro inhibition of human recombinant lipoxygenase enzyme; No inhibition,B,,,,55
3799,11090,8,,,,Expert,178.0,,Blood,,Inhibition of 5-lipoxygenase in human whole blood.,B,,,,55
3800,11090,8,,,,Expert,178.0,,Blood,,Inhibition of 5-lipoxygenase in human whole blood.,B,,,,55
3801,948,8,,,,Autocuration,,,,,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of 5-HETE,B,,,,55
3802,948,8,,,,Autocuration,,,,,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of leukotriene B4 (LTB4),B,,,,55
3803,13622,8,,,,Expert,,,,,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human polymorphonuclear leukocytes.,F,,,,55
3804,13622,8,,,,Autocuration,178.0,,Blood,,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human whole blood,F,,,,55
3805,9637,8,,,,Autocuration,,,,,In vitro inhibition of 5-lipoxygenase from human polymorphs,B,,,,55
3806,11320,8,,,,Autocuration,,,,,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-LPO (5-lipoxygenase),B,,,,55
3807,11320,8,,,,Expert,,,,,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-lipoxygenase,B,,,,55
3808,6838,8,,,,Autocuration,,,,,In vitro inhibitory activity against 5-lipoxygenase in a human whole blood assay,B,,,,55
3809,17667,9,,,,Expert,178.0,,Blood,9606.0,Inhibition of 5-Lipoxygenase (5-LO) of human whole blood (HWB),B,,Homo sapiens,,55
3810,12703,8,,,,Autocuration,,,,,In vitro potency against human 5-Lipoxygenase,B,,,,55
3811,14312,9,,,,Expert,,,,9606.0,Inhibitory activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay,F,,Homo sapiens,,55
3812,14312,8,,,,Autocuration,178.0,,Blood,,Inhibition activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay; No data,F,,,,55
3813,5364,8,,,,Autocuration,,,,,Inhibition of 5-lipoxygenase activity of compound evaluated as determined by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,F,,,,55
3814,951,8,,,,Autocuration,,,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE,B,,,,55
3815,951,8,,,,Autocuration,,,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE; NA means Not active,B,,,,55
3816,951,8,,,,Autocuration,,,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4,B,,,,55
3817,951,8,,,,Autocuration,,,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4; NA means Not active,B,,,,55
3818,12365,8,,,,Autocuration,,,,,Inhibition of human 5-lipoxygenase in human cells,B,,,,55
3819,10603,8,,,,Expert,,,,,Inhibition of human neutrophil 5-lipoxygenase,B,,,,55
3820,10501,8,,,,Autocuration,,,,,Inhibitory activity against 5-lipoxygenase expressed from human polymorphonuclear cells,B,,,,55
3821,12281,8,,,,Expert,178.0,,Blood,,Inhibition of 5-lipoxygenase from human whole blood,B,,,,55
3822,2567,8,,,,Autocuration,,,,,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,B,,,,55
3823,2567,8,,,,Autocuration,,,,,Inhibitory concentration required against 5-lipoxygenase activity in intact cells of human neutrophils,B,,,,55
3824,10193,8,,,,Expert,,,,,In vitro inhibition of polymorphonuclear leukocyte derived human 5-lipoxygenase,B,,,,55
3825,10193,8,,,,Autocuration,,,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,B,,,,55
3826,13623,8,,,,Expert,,,,,Potency to inhibit oxidation of arachidonic acid by recombinant human 5-lipoxygenase,B,,,,55
3827,12780,8,,,,Autocuration,,,,,Tested against 5-lipoxygenase,B,,,,55
3828,12780,8,,,,Autocuration,,,,,Tested for activity against 5-Lipoxygenase (5-LO),B,,,,55
3829,12780,8,,,,Autocuration,,,,,Tested for activity against 5-lipoxygenase,B,,,,55
3830,11966,8,,,,Autocuration,,,,,Tested for inhibition of 5-HPETE production by human 5-LO,B,,,,55
3831,5364,8,,,,Autocuration,,,,,The 5-lipoxygenase activity by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,F,,,,55
3832,13165,8,,,,Expert,,,,,Inhibition of Human 5-lipoxygenase,B,,,,55
3833,5364,8,,,,Autocuration,,,,,The compound was evaluated for its inhibitory activity against 5-lipoxygenase using granulocytes-type cells,B,,,,55
3834,11311,8,,,,Autocuration,,,,,The compound was tested for inhibitory activity against 5-lipoxygenase in human polymorphonuclear leukocytes[PMNS],B,,,,55
3835,11311,8,,,,Autocuration,,,,,The compound was tested for inhibitory activity against LT synthesis in human polymorphonuclear leukocytes[PMNS],B,,,,55
3836,14863,8,,,,Autocuration,,,,,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50.,B,,,,55
3837,14863,8,,,,Autocuration,,,,,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50; Not tested,B,,,,55
3838,11087,8,,,,Autocuration,178.0,,Blood,,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in human whole blood (HWBL),B,,,,55
3839,455,8,,,,Autocuration,,,,,The compound was tested in vitro for inhibition against 5-lipoxygenase in intact human neutrophils,B,,,,55
3840,13183,8,,,,Autocuration,,,,,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),B,,,,55
3841,10319,8,,,,Expert,,,,,In vitro inhibitory activity against 5-lipoxygenase in human polymorphonuclear (PMN) cells,B,,,,55
3842,10193,8,,,,Autocuration,,,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,B,,,,55
3843,951,8,,,,Autocuration,,,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM,B,,,,55
3844,951,8,,,,Autocuration,,,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM; NA means Inactive,B,,,,55
3845,951,8,,,,Autocuration,,,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM,B,,,,55
3846,951,8,,,,Autocuration,,,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM; NA means Inactive,B,,,,55
3847,9859,8,,,,Expert,,,,,Inhibitory activity against 5-lipoxygenase at 10 uM concentration,B,,,,55
3848,9859,8,,,,Expert,,,,,Inhibitory activity against 5-lipoxygenase at 1 uM concentration,B,,,,55
3849,9859,8,,,,Autocuration,,,,,Inhibitory activity against lipoxygenase (LO) at 10 uM concentration,B,,,,55
3850,2567,8,,,,Autocuration,,,,,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,B,,,,55
3851,10193,8,,,,Autocuration,,,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 1 uM,B,,,,55
3852,10193,8,,,,Autocuration,,,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,B,,,,55
3853,949,8,,,,Autocuration,,,,,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; IA= Inactive,B,,,,55
3854,949,8,,,,Autocuration,,,,,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; value ranges from 70-90,B,,,,55
3855,10603,8,,,,Expert,,,,,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 0.1 uM,B,,,,55
3856,10603,8,,,,Expert,,,,,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,B,,,,55
3857,10603,8,,,,Autocuration,,,,,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,F,,,,55
3858,10603,8,,,,Expert,,,,,Inhibition of lipoxygenase at the concentration of 0.1 uM,B,,,,55
3859,10603,8,,,,Expert,,,,,Inhibition of lipoxygenase at the concentration of 1 uM,B,,,,55
3860,10193,8,,,,Autocuration,,,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell,B,,,,55
3861,14580,9,,,,Expert,,,,9606.0,Inhibition of 5-Lipoxygenase (5-LOX),B,,Homo sapiens,,55
3862,11090,8,,,,Expert,,,,,Inhibition of 5-lipoxygenase in mouse macrophages.,B,,,,17087
3863,11090,8,,,,Expert,,,,,Inhibition of 5-lipoxygenase in mouse macrophages.,B,,,,17087
3864,6339,8,,,,Autocuration,,,,,Inhibitory activity against lipoxygenase-2 in mice,B,,,,17087
3865,6339,8,,,,Expert,,,,,Inhibitory activity against murine lipoxygenase-2.,B,,,,17087
3866,12281,9,,,,Expert,,,,10090.0,Inhibition of 5-lipoxygenase from mouse macrophage,B,,Mus musculus,,17087
3867,11311,8,,,,Autocuration,,,,,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse macrophages,B,,,,17087
3868,11089,8,,,,Autocuration,,,,9823.0,The compound was tested for the inhibition of Arachidonate 5-lipoxygenase purified from porcine leukocytes.,B,,Sus scrofa,,55
3869,10091,8,,,,Autocuration,,,,9823.0,Inhibition of 5-lipoxygenase reaction catalyzed by purified enzyme from porcine leukocytes,B,,Sus scrofa,,55
3870,14352,8,,,,Autocuration,,,,9986.0,Inhibitory concentration against 5-lipoxygenase from isolated rabbit granulocytes,B,,Oryctolagus cuniculus,,55
3871,13329,9,,,,Expert,,,,10116.0,5-lipoxygenase Inhibitory activity against rat polymorphonuclear leucocytes using 5-HETE,B,,Rattus norvegicus,,12166
3872,13329,8,,,,Autocuration,,,,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE. ",B,,,,12166
3873,13329,8,,,,Autocuration,,,,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",B,,,,12166
3874,13329,8,,,,Autocuration,,,,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4.",B,,,,12166
3875,13329,8,,,,Expert,,,,,Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay (inhibition of 5-HETE formation),B,,,,12166
3876,13329,8,,,,Expert,,,,,"Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay, by ability to inhibit formation of LTB4 AT 10 uM",B,,,,12166
3877,13329,8,,,,Autocuration,,,,,Inhibition of 5-lipoxygenase pathway was evaluated in rat polymorphonuclear assay by compound (50 uM) ability to inhibit formation of 5-HETE,B,,,,12166
3878,11311,8,,,,Autocuration,,,,,The effective dose for inhibition of 5-lipoxygenase in rat blood leukocyte (ex vivo),B,,,,12166
3879,11311,8,,,,Autocuration,,,,,The effective dose for inhibition of 5-lipoxygenase in rat passive Arthus model after oral administration,B,,,,12166
3880,105,8,,702.0,,Autocuration,,RBL-1,,,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",B,,,,12166
3881,105,8,,702.0,,Autocuration,,RBL-1,,,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",B,,,,12166
3882,9138,8,,,,Autocuration,,,,,Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),B,,,,12166
3883,9138,8,,,,Autocuration,,,,,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),",B,,,,12166
3884,9138,8,,,,Autocuration,,,,,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO), (at a concentration of 0.2 nM ),",B,,,,12166
3885,14427,8,,,,Autocuration,,,,,5-LO inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,B,,,,12166
3886,13329,8,,,,Autocuration,,,,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",B,,,,12166
3887,13329,8,,,,Autocuration,,,,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4. ",B,,,,12166
3888,14427,9,,663.0,,Expert,,RBL-2H3,,10116.0,Inhibition of 5-lipoxygenase mediated conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cells,B,,Rattus norvegicus,,12166
3889,14427,8,,,,Autocuration,,,,,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,B,,,,12166
3890,14427,8,,,,Autocuration,,,,,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography.,B,,,,12166
3891,10293,8,,702.0,,Expert,,RBL-1,,,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line,B,,,,12166
3892,338,9,,702.0,,Expert,,RBL-1,,10116.0,Inhibition of 5-Lipoxygenase of rat basophilic leukemia cells,B,,Rattus norvegicus,,12166
3893,303,8,,,,Autocuration,,,,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase),B,,,,12166
3894,303,8,,702.0,,Autocuration,,RBL-1,,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) in intact RBL-1 cell line assay,B,,,,12166
3895,9247,8,,702.0,,Expert,,RBL-1,,,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-lipoxygenase,B,,,,12166
3896,9247,8,,702.0,,Autocuration,,RBL-1,,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,B,,,,12166
3897,137,8,,702.0,,Autocuration,,RBL-1,,,Compound was evaluated in an intact RBL-1 cell line for inhibition of 5-lipoxygenase,B,,,,12166
3898,11481,8,,,,Expert,,,,,Evaluated in vitro for its inhibitory activity against 5-lipoxygenase,B,,,,12166
3899,11481,8,,,,Expert,,,,,"Evaluated in vitro for its inhibitory activity against 5-lipoxygenase; N=Inactive, <50% inhibition at 10 uM concentration",B,,,,12166
3900,9029,8,,,,Expert,,,,,Inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase in vitro,B,,,,12166
3901,1701,8,,,,Autocuration,,,,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells,B,,,,12166
3902,1701,8,,,,Autocuration,,,,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 32 uM; Not active,B,,,,12166
3903,1701,8,,,,Autocuration,,,,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 50 uM; Not active,B,,,,12166
3904,1701,8,,,,Autocuration,,,,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells; No data,B,,,,12166
3905,13358,8,,702.0,,Expert,,RBL-1,,,Inhibition of 5-lipoxygenase by measuring 5-HETE levels in RBL-1 cell-free supernatant,F,,,,12166
3906,1175,8,,702.0,,Expert,,RBL-1,,,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells,B,,,,12166
3907,8797,8,,702.0,,Expert,,RBL-1,,,Ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells.,B,,,,12166
3908,8797,8,,,,Autocuration,,,,,Compound was tested for its ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells; No data,B,,,,12166
3909,577,9,,,,Expert,,,,10116.0,Inhibition of rat basophilic leukemia cell 5-lipoxygenase,B,,Rattus norvegicus,,12166
3910,9295,8,,702.0,,Expert,,RBL-1,,,In vitro inhibitory activity against RBL-1 5-LO,B,,,,12166
3911,9295,8,,702.0,,Autocuration,,RBL-1,,,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (insoluble above 45 uM),B,,,,12166
3912,9295,8,,702.0,,Autocuration,,RBL-1,,,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (time dependent),B,,,,12166
3913,9295,8,,,,Autocuration,,,,,Compound was tested for its inhibition activity against 5-LO of the whole cell in vitro in rat.,B,,,,12166
3914,9295,8,,,,Autocuration,,,,,Compound was tested for its inhibition activity against the 5-LO in isolated enzyme,B,,,,12166
3915,216,8,,,,Autocuration,,,,,Compound was tested for its inhibitory activity against 5-lipoxygenase in rat.,B,,,,12166
3916,11090,8,,702.0,,Autocuration,,RBL-1,,,Compound was tested for the inhibition of 5-lipoxygenase (5-LPO) in rat basophilic leukemia (RBL) cells.,B,,,,12166
3917,11090,8,,,,Autocuration,178.0,,Blood,,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in rat whole blood.,B,,,,12166
3918,10091,8,,,,Expert,,,,,Concentration required for 50 % inhibition of arachidonic acid oxidation by rat 5-lipoxygenase,B,,,,12166
3919,10274,8,,,,Autocuration,,,,,Concentration that produces 50% inhibition of A-23187-stimulated radiolabeled 5-HETE and TXB2 synthesis by PMN 5-lipoxygenase.,F,,,,12166
3920,13622,8,,,,Autocuration,,,,,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in rat polymorphonuclear leukocytes,F,,,,12166
3921,12118,8,,702.0,,Expert,,RBL-1,,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined,B,,,,12166
3922,12576,8,,,,Expert,,,,,In vitro inhibition of 5-lipoxygenase (5-HETE) derived from the 9000xg supernatant of RBL broken cell assay,B,,,,12166
3923,9546,8,,702.0,,Expert,,RBL-1,,,In vitro inhibition of 5-lipoxygenase from RBL-1 cells,B,,,,12166
3924,9521,8,,702.0,,Autocuration,,RBL-1,,,In vitro inhibition of 5-lipoxygenase in RBL-1 cells,B,,,,12166
3925,10626,8,,702.0,,Expert,,RBL-1,,,In vitro inhibition of 5-lipoxygenase pathway in rat basophilic leukemia (RBL-1) cells,B,,,,12166
3926,9225,8,,702.0,,Autocuration,,RBL-1,,,In vitro inhibition of RBL-1 5-lipoxygenase,B,,,,12166
3927,9225,8,,702.0,,Autocuration,,RBL-1,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.18-0.31,B,,,,12166
3928,9225,8,,702.0,,Autocuration,,RBL-1,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.3-1.6,B,,,,12166
3929,9225,8,,702.0,,Autocuration,,RBL-1,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.4-2.2,B,,,,12166
3930,9225,8,,702.0,,Autocuration,,RBL-1,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.72-1.07,B,,,,12166
3931,9225,8,,702.0,,Autocuration,,RBL-1,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.9-4.0,B,,,,12166
3932,9225,8,,702.0,,Autocuration,,RBL-1,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.5,B,,,,12166
3933,9225,8,,702.0,,Autocuration,,RBL-1,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.7,B,,,,12166
3934,9225,8,,702.0,,Autocuration,,RBL-1,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-2.4,B,,,,12166
3935,9225,8,,702.0,,Autocuration,,RBL-1,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.07-5.54,B,,,,12166
3936,9225,8,,702.0,,Autocuration,,RBL-1,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.1-1.6,B,,,,12166
3937,9225,8,,702.0,,Autocuration,,RBL-1,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.3-2.8,B,,,,12166
3938,9225,8,,702.0,,Autocuration,,RBL-1,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.4-3.2,B,,,,12166
3939,9225,8,,702.0,,Autocuration,,RBL-1,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.7-2.6,B,,,,12166
3940,9225,8,,702.0,,Autocuration,,RBL-1,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-2.8,B,,,,12166
3941,9225,8,,702.0,,Autocuration,,RBL-1,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-5.7,B,,,,12166
3942,9225,8,,702.0,,Autocuration,,RBL-1,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.9-2.4,B,,,,12166
3943,9225,8,,702.0,,Autocuration,,RBL-1,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.3-.8,B,,,,12166
3944,9225,8,,702.0,,Autocuration,,RBL-1,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.46-2.63,B,,,,12166
3945,9225,8,,702.0,,Autocuration,,RBL-1,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.3-3.5,B,,,,12166
3946,9225,8,,702.0,,Autocuration,,RBL-1,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.8-7.1,B,,,,12166
3947,9225,8,,702.0,,Autocuration,,RBL-1,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.0-6.4,B,,,,12166
3948,9225,8,,702.0,,Autocuration,,RBL-1,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.9-11.6,B,,,,12166
3949,9225,8,,702.0,,Autocuration,,RBL-1,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 7.5-11.8,B,,,,12166
3950,9401,8,,,,Expert,,,,,In vitro inhibitory activity against 5-lipoxygenase from rat basophilic leukemia cells.,B,,,,12166
3951,10325,8,,,,Autocuration,,,,,In vitro inhibitory activity against 5-Lipoxygenase in rat by Peritoneal 5-lipoxygenase assay,B,,,,12166
3952,1556,8,,663.0,,Expert,,RBL-2H3,,,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells.,F,,,,12166
3953,1556,8,,663.0,,Expert,,RBL-2H3,,,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells; Not tested,F,,,,12166
3954,961,9,,702.0,,Expert,,RBL-1,,10116.0,Inhibition of 5-lipoxygenase from rat basophilic leukemia(RBL-1) cells,B,,Rattus norvegicus,,12166
3955,6838,8,,,,Autocuration,,,,,In vitro inhibitory activity against 5-lipoxygenase in an RBL-2H3 cell lysate,B,,,,12166
3956,10325,8,,,,Expert,,,,,In vitro inhibition of 5-lipoxygenase in rat (peritoneal assay),B,,,,12166
3957,9209,9,,702.0,,Expert,,RBL-1,,10116.0,In vitro inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,B,,Rattus norvegicus,,12166
3958,11520,8,,702.0,,Expert,,RBL-1,,,inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cell line.,B,,,,12166
3959,137,8,,,,Autocuration,,,,,In vitro inhibitory activity against 5-lipoxygenase was determined,B,,,,12166
3960,4717,8,,702.0,,Autocuration,,RBL-1,,,In vitro inhibitory concentration against 5-lipoxygenase in RBL-1 cells,B,,,,12166
3961,10636,8,,702.0,,Expert,,RBL-1,,,Inhibition of 5-lipoxygenase in intact RBL-1 cell line,B,,,,12166
3962,14312,9,,,,Expert,,,,10116.0,Inhibitory activity against 5-lipoxygenase catalysis (5-LO) in sonicated rat basophilic leukemia cell lysate,F,,Rattus norvegicus,,12166
3963,1203,8,,702.0,,Autocuration,,RBL-1,,,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemia cells,B,,,,12166
3964,1203,8,,,,Autocuration,,,,,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemic cells,B,,,,12166
3965,13622,8,,702.0,,Expert,,RBL-1,,,Inhibition of 5-lipoxygenase catalysis in rat basophilic leukemia (RBL) cells by measuring 5-HETE product formation,B,,,,12166
3966,9793,8,,,,Autocuration,,,,,Inhibition of 5-lipoxygenase from rat peritoneal neutrophils after oral administration,B,,,,12166
3967,1143,9,,702.0,,Expert,,RBL-1,,10116.0,Inhibition of 5-lipoxygenase of rat basophilic leukemia (RBL) cell cytosolic enzymes,B,,Rattus norvegicus,,12166
3968,11854,9,,702.0,,Expert,,RBL-1,,10116.0,Inhibition 5-lipoxygenase mediated LTB4 formation in rat basophilic leukemia (RBL-1) cells,B,,Rattus norvegicus,,12166
3969,3595,8,,702.0,,Autocuration,,RBL-1,,,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),B,,,,12166
3970,3595,8,,702.0,,Autocuration,,RBL-1,,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),B,,,,12166
3971,10501,9,,702.0,,Expert,,RBL-1,,10116.0,Inhibition of 5-lipoxygenase in rat RBL-1 cells,B,,Rattus norvegicus,,12166
3972,12526,8,,702.0,,Expert,,RBL-1,,,Inhibition of 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,B,,,,12166
3973,10034,8,,,,Autocuration,349.0,,Limbic system,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 32 umol/kg,F,,,,10825
3974,10034,8,,,,Autocuration,349.0,,Limbic system,,Compound was tested for its effects on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,F,,,,10825
3975,10034,8,,,,Autocuration,,,,,Approximate dose levels for a half maximal reduction of 5-HTP levels,F,,,,10825
3976,10046,8,,,,Autocuration,10000000.0,,Hippocampus,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,B,,,,10576
3977,10046,8,,,,Autocuration,10000000.0,,Hippocampus,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,B,,,,10576
3978,10046,8,,,,Autocuration,,,,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,B,,,,10577
3979,12079,8,,,,Autocuration,178.0,,Blood,9615.0,Inhibitory concentration against human platelet 5-lipoxygenase in dog whole blood,F,,Canis lupus familiaris,,55
3980,12079,8,,,,Autocuration,178.0,,Blood,,Inhibitory concentration against human platelet 5-lipoxygenase in human whole blood,F,,,,55
3981,11311,8,,,,Autocuration,,,,,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat polymorphonuclear leukocytes[PMNS],B,,,,12166
3982,12338,8,,,,Expert,,,,,Inhibition of 5-lipoxygenase in bovine polymorphonuclear leukocytes,B,,,,17140
3983,12143,8,,,,Expert,,,,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL).,B,,,,17140
3984,12143,8,,,,Autocuration,,,,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL),B,,,,17140
3985,12143,8,,,,Expert,,,,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,B,,,,17140
3986,12143,8,,,,Autocuration,,,,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,B,,,,17140
3987,12365,8,,,,Expert,,,,,Inhibition of 5-lipoxygenase in bovine PMNL cell assay.,B,,,,17140
3988,13500,8,,,,Expert,,,,,Tested for inhibition of 5-lipoxygenase as inhibition of 5-HETE and LTB4 biosynthesis in bovine PMNL,B,,,,17140
3989,12832,8,,,,Autocuration,178.0,,Blood,9615.0,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,Canis lupus familiaris,,55
3990,12832,8,,,,Autocuration,178.0,,Blood,9615.0,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,Canis lupus familiaris,,55
3991,12832,8,,,,Autocuration,178.0,,Blood,9615.0,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,Canis lupus familiaris,,55
3992,12832,8,,,,Autocuration,178.0,,Blood,9615.0,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,Canis lupus familiaris,,55
3993,12832,8,,,,Autocuration,178.0,,Blood,9615.0,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,Canis lupus familiaris,,55
3994,12832,8,,,,Autocuration,178.0,,Blood,9615.0,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,Canis lupus familiaris,,55
3995,12832,8,,,,Autocuration,178.0,,Blood,9615.0,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,Canis lupus familiaris,,55
3996,12832,8,,,,Autocuration,178.0,,Blood,9615.0,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,Canis lupus familiaris,,55
3997,12832,8,,,,Autocuration,178.0,,Blood,9615.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,Canis lupus familiaris,,55
3998,12832,8,,,,Autocuration,178.0,,Blood,9615.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,Canis lupus familiaris,,55
3999,12832,8,,,,Autocuration,178.0,,Blood,9615.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 0.3 mg/kg",F,In vivo,Canis lupus familiaris,,55
4000,12832,8,,,,Autocuration,178.0,,Blood,9615.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",F,In vivo,Canis lupus familiaris,,55
4001,12832,8,,,,Autocuration,178.0,,Blood,9615.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 3.0 mg/kg",F,In vivo,Canis lupus familiaris,,55
4002,12832,8,,,,Autocuration,178.0,,Blood,9615.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,Canis lupus familiaris,,55
4003,12832,8,,,,Autocuration,178.0,,Blood,9615.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 0.3 mg/kg",F,In vivo,Canis lupus familiaris,,55
4004,12832,8,,,,Autocuration,178.0,,Blood,9615.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 1.0 mg/kg",F,In vivo,Canis lupus familiaris,,55
4005,12832,8,,,,Autocuration,178.0,,Blood,9615.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 3.0 mg/kg",F,In vivo,Canis lupus familiaris,,55
4006,12832,8,,,,Autocuration,178.0,,Blood,9615.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,Canis lupus familiaris,,55
4007,12832,8,,,,Autocuration,178.0,,Blood,9615.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 0.3 mg/kg",F,In vivo,Canis lupus familiaris,,55
4008,12832,8,,,,Autocuration,178.0,,Blood,9615.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 1.0 mg/kg",F,In vivo,Canis lupus familiaris,,55
4009,12832,8,,,,Autocuration,178.0,,Blood,9615.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 3.0 mg/kg",F,In vivo,Canis lupus familiaris,,55
4010,12832,8,,,,Autocuration,178.0,,Blood,9615.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,Canis lupus familiaris,,55
4011,12832,8,,,,Autocuration,178.0,,Blood,9615.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 0.3 mg/kg",F,In vivo,Canis lupus familiaris,,55
4012,12832,8,,,,Autocuration,178.0,,Blood,9615.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 1.0 mg/kg",F,In vivo,Canis lupus familiaris,,55
4013,12832,8,,,,Autocuration,178.0,,Blood,9615.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 3.0 mg/kg",F,In vivo,Canis lupus familiaris,,55
4014,12832,8,,,,Autocuration,178.0,,Blood,9615.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,Canis lupus familiaris,,55
4015,12832,8,,,,Autocuration,178.0,,Blood,9615.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 0.3 mg/kg",F,In vivo,Canis lupus familiaris,,55
4016,12832,8,,,,Autocuration,178.0,,Blood,9615.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 1.0 mg/kg",F,In vivo,Canis lupus familiaris,,55
4017,12832,8,,,,Autocuration,178.0,,Blood,9615.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 3.0 mg/kg",F,In vivo,Canis lupus familiaris,,55
4018,12832,8,,,,Autocuration,178.0,,Blood,9615.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,Canis lupus familiaris,,55
4019,12832,8,,,,Autocuration,178.0,,Blood,9615.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 0.3 mg/kg",F,In vivo,Canis lupus familiaris,,55
4020,12832,8,,,,Autocuration,178.0,,Blood,9615.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 1.0 mg/kg",F,In vivo,Canis lupus familiaris,,55
4021,12832,8,,,,Autocuration,178.0,,Blood,9615.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 3.0 mg/kg",F,In vivo,Canis lupus familiaris,,55
4022,12832,8,,,,Autocuration,178.0,,Blood,9615.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,Canis lupus familiaris,,55
4023,12832,8,,,,Autocuration,178.0,,Blood,9615.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 0.3 mg/kg",F,In vivo,Canis lupus familiaris,,55
4024,12832,8,,,,Autocuration,178.0,,Blood,9615.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 1.0 mg/kg",F,In vivo,Canis lupus familiaris,,55
4025,12832,8,,,,Autocuration,178.0,,Blood,9615.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 3.0 mg/kg",F,In vivo,Canis lupus familiaris,,55
4026,12832,8,,,,Autocuration,178.0,,Blood,9615.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,Canis lupus familiaris,,55
4027,12832,8,,,,Autocuration,178.0,,Blood,9615.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,Canis lupus familiaris,,55
4028,12832,8,,,,Autocuration,178.0,,Blood,9615.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,Canis lupus familiaris,,55
4029,12832,8,,,,Autocuration,178.0,,Blood,9615.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,Canis lupus familiaris,,55
4030,12832,8,,,,Autocuration,178.0,,Blood,9615.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,Canis lupus familiaris,,55
4031,12832,8,,,,Autocuration,178.0,,Blood,9615.0,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",F,In vivo,Canis lupus familiaris,,55
4032,12832,8,,,,Autocuration,178.0,,Blood,9615.0,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,Canis lupus familiaris,,55
4033,12832,8,,,,Autocuration,178.0,,Blood,9615.0,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,Canis lupus familiaris,,55
4034,12832,8,,,,Autocuration,178.0,,Blood,9615.0,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,Canis lupus familiaris,,55
4035,3595,8,,,,Autocuration,,,,9615.0,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r,B,,Canis lupus familiaris,,55
4036,3595,8,,,,Autocuration,,,,9615.0,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r to canine,B,,Canis lupus familiaris,,55
4037,3595,8,,,,Autocuration,,,,9615.0,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr,B,,Canis lupus familiaris,,55
4038,3595,8,,,,Autocuration,,,,9615.0,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr to canine,B,,Canis lupus familiaris,,55
4039,3595,8,,,,Autocuration,,,,9615.0,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr,B,,Canis lupus familiaris,,55
4040,3595,8,,,,Autocuration,,,,9615.0,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr to canine,B,,Canis lupus familiaris,,55
4041,3595,8,,,,Autocuration,,,,9615.0,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr,B,,Canis lupus familiaris,,55
4042,3595,8,,,,Autocuration,,,,9615.0,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr to canine,B,,Canis lupus familiaris,,55
4043,9203,8,,,,Autocuration,,,,10141.0,Ability to inhibit 5-lipoxygenase in guinea pig,B,,Cavia porcellus,,55
4044,82,8,,,,Expert,,,,10141.0,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-lipoxygenase in vitro (guinea pig PMN),B,,Cavia porcellus,,55
4045,11090,8,,,,Autocuration,,,,10141.0,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in guinea pig.,B,,Cavia porcellus,,55
4046,12832,8,,,,Autocuration,178.0,,Blood,10141.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 12 h, following intravenous administration at the dose of 1.0 mg/kg",B,,Cavia porcellus,,55
4047,1065,8,,,,Autocuration,,,,10141.0,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on 5-hydroxyeicosapentaenoic acid (5-HETE) production,B,,Cavia porcellus,,55
4048,1065,8,,,,Autocuration,,,,10141.0,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on LTB4 production,B,,Cavia porcellus,,55
4049,12832,8,,,,Expert,,,,10141.0,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]-AA to 5-HETE in guinea pig peritoneal polymorphonuclear leukocytes,B,,Cavia porcellus,,55
4050,12832,8,,,,Expert,,,,10141.0,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,B,,Cavia porcellus,,55
4051,12832,8,,,,Autocuration,,,,10141.0,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,B,,Cavia porcellus,,55
4052,10504,8,,,,Autocuration,,,,10141.0,Inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,B,,Cavia porcellus,,55
4053,7788,8,,,,Autocuration,,,,10141.0,Inhibitory activity against 5-lipoxygenase,B,,Cavia porcellus,,55
4054,10001,8,,,,Autocuration,,,,10141.0,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte,B,,Cavia porcellus,,55
4055,10193,8,,,,Autocuration,,,,10141.0,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant,B,,Cavia porcellus,,55
4056,13243,8,,,,Autocuration,,,,10141.0,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase,B,,Cavia porcellus,,55
4057,13243,8,,,,Autocuration,,,,10141.0,Inhibitory activity uM,B,,Cavia porcellus,,55
4058,969,8,,,,Autocuration,,,,10141.0,Inhibitory activity against 5-lipoxygenase in guinea pig leukocytes was determined,B,,Cavia porcellus,,55
4059,10001,8,,,,Autocuration,,,,10141.0,Inhibitory activity against 5-lipoxygenase at 10 uM,B,,Cavia porcellus,,55
4060,7788,8,,,,Autocuration,,,,10141.0,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,B,,Cavia porcellus,,55
4061,10001,8,,,,Autocuration,,,,10141.0,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte at 30 uM,B,,Cavia porcellus,,55
4062,10193,8,,,,Autocuration,,,,10141.0,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,B,,Cavia porcellus,,55
4063,13243,8,,,,Autocuration,,,,10141.0,Inhibitory activity uM,B,,Cavia porcellus,,55
4064,13243,8,,,,Autocuration,,,,10141.0,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase at 10 uM,B,,Cavia porcellus,,55
4065,13243,8,,,,Expert,,,,10141.0,Inhibitory activity uM,B,,Cavia porcellus,,55
4066,13243,8,,,,Autocuration,,,,10141.0,Inhibitory activity uM,F,,Cavia porcellus,,55
4067,10504,8,,,,Autocuration,,,,10141.0,Percent inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,B,,Cavia porcellus,,55
4068,7788,8,,,,Autocuration,,,,10141.0,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,B,,Cavia porcellus,,55
4069,10546,8,,,,Expert,2116.0,,Ileum,10141.0,Evaluated for inhibition of the formation and release of 5-lipoxygenase in isolated guinea pig ileum,F,,Cavia porcellus,,55
4070,13183,8,,,,Autocuration,,,,,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),B,,,,55
4071,13183,8,,,,Autocuration,,,,,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),B,,,,55
4072,2578,8,,,,Autocuration,,,,,Compound was evaluated for in vitro inhibition of recombinant human 5-lipoxygenase (5-LO),B,,,,55
4073,12780,8,,,,Expert,,,,,In vitro inhibition of human 5-Lipoxygenase.,B,,,,55
4074,7411,0,,,,Autocuration,2107.0,,Liver,10116.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,B,,Rattus norvegicus,Microsomes,22226
4075,7411,0,,,,Autocuration,2107.0,,Liver,10116.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,B,,Rattus norvegicus,Microsomes,22226
4076,7411,0,,,,Autocuration,2107.0,,Liver,10116.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,B,,Rattus norvegicus,Microsomes,22226
4077,7411,0,,,,Autocuration,2107.0,,Liver,10116.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM exposed 100 uM,B,,Rattus norvegicus,Microsomes,22226
4078,7411,0,,,,Autocuration,2107.0,,Liver,10116.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,B,,Rattus norvegicus,Microsomes,22226
4079,7411,0,,,,Autocuration,2107.0,,Liver,10116.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,B,,Rattus norvegicus,Microsomes,22226
4080,7411,0,,,,Autocuration,2107.0,,Liver,10116.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,B,,Rattus norvegicus,Microsomes,22226
4081,7411,0,,,,Autocuration,2107.0,,Liver,10116.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,B,,Rattus norvegicus,Microsomes,22226
4082,7411,0,,,,Autocuration,2107.0,,Liver,10116.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,B,,Rattus norvegicus,Microsomes,22226
4083,7411,0,,,,Autocuration,2107.0,,Liver,10116.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,B,,Rattus norvegicus,Microsomes,22226
4084,7411,0,,,,Autocuration,2107.0,,Liver,10116.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,B,,Rattus norvegicus,Microsomes,22226
4085,7411,0,,,,Autocuration,2107.0,,Liver,10116.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 27.5 uM,B,,Rattus norvegicus,Microsomes,22226
4086,7411,0,,,,Autocuration,2107.0,,Liver,10116.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,B,,Rattus norvegicus,Microsomes,22226
4087,7411,0,,,,Autocuration,2107.0,,Liver,10116.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,B,,Rattus norvegicus,Microsomes,22226
4088,7411,0,,,,Autocuration,2107.0,,Liver,10116.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,B,,Rattus norvegicus,Microsomes,22226
4089,7411,0,,,,Autocuration,2107.0,,Liver,10116.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to exposed to 3-methylcholanthrene at concentration of 200 uM,B,,Rattus norvegicus,Microsomes,22226
4090,7411,0,,,,Autocuration,2107.0,,Liver,10116.0,"Compound was evaluated for inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",B,,Rattus norvegicus,Microsomes,22226
4091,7411,0,,,,Autocuration,2107.0,,Liver,10116.0,"Compound was evaluated for inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",B,,Rattus norvegicus,Microsomes,22226
4092,7411,0,,,,Autocuration,2107.0,,Liver,10116.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 100 uM,B,,Rattus norvegicus,Microsomes,22226
4093,7411,0,,,,Autocuration,2107.0,,Liver,10116.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 200 uM,B,,Rattus norvegicus,Microsomes,22226
4094,7411,0,,,,Autocuration,2107.0,,Liver,10116.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 50 uM,B,,Rattus norvegicus,Microsomes,22226
4095,7411,0,,,,Autocuration,2107.0,,Liver,10116.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 5 uM,B,,Rattus norvegicus,Microsomes,22226
4096,7411,0,,,,Autocuration,2107.0,,Liver,10116.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 50 uM,B,,Rattus norvegicus,Microsomes,22226
4097,7411,0,,,,Autocuration,2107.0,,Liver,10116.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,B,,Rattus norvegicus,Microsomes,22226
4098,7411,0,,,,Autocuration,2107.0,,Liver,10116.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,B,,Rattus norvegicus,Microsomes,22226
4099,7411,0,,,,Autocuration,2107.0,,Liver,10116.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 1 uM,B,,Rattus norvegicus,Microsomes,22226
4100,7411,0,,,,Autocuration,2107.0,,Liver,10116.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 20 uM,B,,Rattus norvegicus,Microsomes,22226
4101,7411,0,,,,Autocuration,2107.0,,Liver,10116.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,B,,Rattus norvegicus,Microsomes,22226
4102,7411,0,,,,Autocuration,2107.0,,Liver,10116.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,B,,Rattus norvegicus,Microsomes,22226
4103,7411,0,,,,Autocuration,2107.0,,Liver,10116.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,B,,Rattus norvegicus,Microsomes,22226
4104,7411,0,,,,Autocuration,2107.0,,Liver,10116.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,B,,Rattus norvegicus,Microsomes,22226
4105,7411,0,,,,Autocuration,2107.0,,Liver,10116.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,B,,Rattus norvegicus,Microsomes,22226
4106,7411,0,,,,Autocuration,2107.0,,Liver,10116.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,B,,Rattus norvegicus,Microsomes,22226
4107,7411,0,,,,Autocuration,2107.0,,Liver,10116.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,B,,Rattus norvegicus,Microsomes,22226
4108,7411,0,,,,Autocuration,2107.0,,Liver,10116.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,B,,Rattus norvegicus,Microsomes,22226
4109,7411,0,,,,Autocuration,2107.0,,Liver,10116.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,B,,Rattus norvegicus,Microsomes,22226
4110,7411,0,,,,Autocuration,2107.0,,Liver,10116.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,B,,Rattus norvegicus,Microsomes,22226
4111,7411,0,,,,Autocuration,2107.0,,Liver,10116.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,B,,Rattus norvegicus,Microsomes,22226
4112,7411,0,,,,Autocuration,2107.0,,Liver,10116.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,B,,Rattus norvegicus,Microsomes,22226
4113,7411,0,,,,Autocuration,2107.0,,Liver,10116.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,B,,Rattus norvegicus,Microsomes,22226
4114,7411,0,,,,Autocuration,2107.0,,Liver,10116.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,B,,Rattus norvegicus,Microsomes,22226
4115,7411,0,,,,Autocuration,2107.0,,Liver,10116.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,B,,Rattus norvegicus,Microsomes,22226
4116,7411,0,,,,Autocuration,2107.0,,Liver,10116.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1000 uM,B,,Rattus norvegicus,Microsomes,22226
4117,7411,0,,,,Autocuration,2107.0,,Liver,10116.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1500 uM,B,,Rattus norvegicus,Microsomes,22226
4118,7411,0,,,,Autocuration,2107.0,,Liver,10116.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 27.5 uM,B,,Rattus norvegicus,Microsomes,22226
4119,7411,0,,,,Autocuration,2107.0,,Liver,10116.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 500 uM,B,,Rattus norvegicus,Microsomes,22226
4120,7411,0,,,,Autocuration,2107.0,,Liver,10116.0,Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,B,,Rattus norvegicus,Microsomes,22226
4121,7411,0,,,,Autocuration,,,,10116.0,Vmax determined by 7-ethoxycoumarin deethylation in the presence by liver microsomes from rats exposed to 3-methylcholanthrene at concentration of 10 uM,B,,Rattus norvegicus,Microsomes,22226
4122,7411,0,,,,Autocuration,2107.0,,Liver,10116.0,"Compound was evaluated for alpha -rate constant, in liver microsomes from 3-methylcholanthrene-exposed rats",B,,Rattus norvegicus,Microsomes,22226
4123,7411,0,,,,Autocuration,2107.0,,Liver,10116.0,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats",B,,Rattus norvegicus,Microsomes,22226
4124,7411,0,,,,Autocuration,2107.0,,Liver,10116.0,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats; competitive inhibition",B,,Rattus norvegicus,Microsomes,22226
4125,7411,0,,,,Autocuration,2107.0,,Liver,10116.0,"Compound was evaluated for alpha inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",B,,Rattus norvegicus,Microsomes,22226
4126,7411,0,,,,Autocuration,2107.0,,Liver,10116.0,"Compound was evaluated for alpha inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",B,,Rattus norvegicus,Microsomes,22226
4127,10797,1,,741.0,,Intermediate,,RPMI-8226,,9606.0,In vitro inhibition of 7226/S myeloma cancer cell line,F,,Homo sapiens,,80433
4128,6881,1,,993.0,,Intermediate,,BEL-7404 tumor cell line,,9606.0,In vitro antitumor activity of compound against 7404 cell line (human liver carcinoma cells),F,,Homo sapiens,,80698
4129,3838,1,,391.0,,Intermediate,,786-0,,9606.0,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,F,,Homo sapiens,,80640
4130,3838,1,,391.0,,Intermediate,,786-0,,9606.0,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,F,,Homo sapiens,,80640
4131,12981,1,,505.0,,Expert,,V79,,10029.0,Net accumulation of the [99mTc]Isonitrile complex was measured in 77A cell lines in the presence of Verapamil.,F,,Cricetulus griseus,,81264
4132,12981,1,,505.0,,Expert,,V79,,10029.0,Verapamil index represents the ratio of net uptake in the presense of verapamil over control in 77A cell lines.,F,,Cricetulus griseus,,81264
4133,7653,1,,1119.0,,Intermediate,,7800C1 cell line,,10116.0,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 10 ug/mL dose,F,,Rattus norvegicus,,80635
4134,7653,1,,1119.0,,Intermediate,,7800C1 cell line,,10116.0,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 2 ug/mL dose,F,,Rattus norvegicus,,80635
4135,7653,1,,1119.0,,Intermediate,,7800C1 cell line,,10116.0,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 20 ug/mL dose,F,,Rattus norvegicus,,80635
4136,7653,1,,1119.0,,Intermediate,,7800C1 cell line,,10116.0,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 5 ug/mL dose,F,,Rattus norvegicus,,80635
4137,7653,1,,1119.0,,Intermediate,,7800C1 cell line,,10116.0,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 50 ug/mL dose,F,,Rattus norvegicus,,80635
4138,7653,1,,1119.0,,Intermediate,,7800C1 cell line,,10116.0,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 75 ug/mL dose,F,,Rattus norvegicus,,80635
4139,17229,1,,391.0,,Intermediate,,786-0,,9606.0,In vitro antitumor activity against renal 786-0 tumor cell lines,F,,Homo sapiens,,80640
4140,12858,1,,391.0,,Intermediate,,786-0,,9606.0,Cytotoxic activity against 786-0 Renal cancer cell line,F,,Homo sapiens,,80640
4141,16325,1,,391.0,,Intermediate,,786-0,,9606.0,Growth inhibitory activity was determined against 786-0 cancer cell line of Renal cancer,F,,Homo sapiens,,80640
4142,16325,1,,391.0,,Intermediate,,786-0,,9606.0,Growth inhibitory activity was determined against 786-0 cancer cell line of renal cancer,F,,Homo sapiens,,80640
4143,5858,1,,391.0,,Intermediate,,786-0,,9606.0,In vitro antitumor activity against human renal 786-0 cell line,F,,Homo sapiens,,80640
4144,16325,1,,391.0,,Intermediate,,786-0,,9606.0,Inhibition of Renal cancer in 786-0 cancer cell lines,F,,Homo sapiens,,80640
4145,14696,1,,391.0,,Intermediate,,786-0,,9606.0,Inhibition of the growth of renal cancer(786-0) cell line. value in parentheses is percent inhibition at 0.01 uM,F,,Homo sapiens,,80640
4146,3786,1,,391.0,,Intermediate,,786-0,,9606.0,The compound was tested for its cytotoxic activity against the following renal cancer cell lines 786-0,F,,Homo sapiens,,80640
4147,14696,1,,391.0,,Intermediate,,786-0,,9606.0,inhibition of the growth of renal cancer(786-0) cell line,F,,Homo sapiens,,80640
4148,14769,1,,391.0,,Intermediate,,786-0,,9606.0,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),F,,Homo sapiens,,80640
4149,15354,1,,391.0,,Intermediate,,786-0,,9606.0,Compound was tested for the growth inhibition of 786-0 renal tumor cell line,F,,Homo sapiens,,80640
4150,14255,1,,391.0,,Intermediate,,786-0,,9606.0,The IC50 value was measured on 786-0 cell line in ovarian tumor,F,,Homo sapiens,,80640
4151,14255,1,,391.0,,Intermediate,,786-0,,9606.0,The IC50 value was measured on 786-0 cell line in ovarian tumor t,F,,Homo sapiens,,80640
4152,14255,1,,391.0,,Intermediate,,786-0,,9606.0,The IC50 value was measured on 786-0 cell line in renal tumor type.,F,,Homo sapiens,,80640
4153,14696,1,,391.0,,Intermediate,,786-0,,9606.0,Inhibition of the growth of renal cancer(786-0) cell line at 0.01 uM,F,,Homo sapiens,,80640
4154,12016,1,,391.0,,Intermediate,,786-0,,9606.0,Tested for cytotoxic activity against renal cancer 786-0 cell line,F,,Homo sapiens,,80640
4155,2597,1,,391.0,,Intermediate,,786-0,,9606.0,Compound was tested for growth inhibitory activity against 786-0 cell line,F,,Homo sapiens,,80640
4156,12526,8,,702.0,,Autocuration,,RBL-1,,,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; Inactive(N)= <50% inhibition at 10 uM,B,,,,12166
4157,12526,8,,702.0,,Autocuration,,RBL-1,,,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; N=Inactive,B,,,,12166
4158,14799,8,,,,Autocuration,,,,,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,B,,,,12166
4159,3595,8,,702.0,,Expert,,RBL-1,,,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),B,,,,12166
4160,3595,8,,702.0,,Expert,,RBL-1,,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),B,,,,12166
4161,12767,8,,,,Autocuration,,,,,Inhibitory activity against rat basophilic leukemia 5-lipoxygenase,B,,,,12166
4162,10997,8,,,,Autocuration,,,,,Inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes,B,,,,12166
4163,11388,8,,702.0,,Autocuration,,RBL-1,,,Inhibitory activity against 5-lipoxygenase of RBL-1 cell line,B,,,,12166
4164,167,8,,,,Autocuration,,,,,Inhibitory activity against RBL broken cell-supematant 5-lipoxygenase was evaluated,B,,,,12166
4165,167,8,,,,Autocuration,,,,,"Inhibitory activity against intact rat PMNL, LTB4 5-lipoxygenase was evaluated",B,,,,12166
4166,13744,8,,,,Expert,,,,,Inhibitory activity against rat 5-lipoxygenase by using continuous oxygen consumption assay.,B,,,,12166
4167,1630,8,,,,Autocuration,,,,,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase,B,,,,12166
4168,1630,8,,,,Autocuration,,,,,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase (5-LO),B,,,,12166
4169,969,9,,,,Expert,,,,10116.0,"Inhibitory activity against 5-lipoxygenase in rat neutrophils as inhibition of A 23,187-induced LTB4 production",B,,Rattus norvegicus,,12166
4170,13621,8,,702.0,,Autocuration,,RBL-1,,,Inhibitory concentration against 5-lipoxygenase in rat RBL-1 cells,B,,,,12166
4171,10089,8,,,,Autocuration,,,,,Inhibitory concentration to inhibit 5-lipoxygenase in the rat,B,,,,12166
4172,10193,8,,,,Expert,,,,,In vitro inhibition of rat polymorphonuclear leukocyte 5-lipoxygenase,B,,,,12166
4173,11966,8,,,,Autocuration,,,,,Tested for inhibition of 5-HPETE production by rat 5-LO; value ranges from 16-36 nM,B,,,,12166
4174,12251,8,,,,Autocuration,,,,,Tested for inhibition of 5-LO by measuring the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,B,,,,12166
4175,211,8,,702.0,,Autocuration,,RBL-1,,,Tested for inhibition of 5-Lipoxygenase (ARBL) in calcium-stimulated rat basophilic leukemia cells(RBL-1),B,,,,12166
4176,12251,8,,,,Expert,,,,,Inhibition of 5-lipoxygenase measured by the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,F,,,,12166
4177,12495,8,,702.0,,Autocuration,,RBL-1,,,Tested for inhibitory activity against 5-lipoxygenase in microsome of RBL-1 cells,B,,,,12166
4178,414,8,,,,Autocuration,,,,,Tested for its inhibitory activity against 5-lipoxygenase,B,,,,12166
4179,414,8,,,,Autocuration,,,,,Tested for its inhibitory activity against 5-lipoxygenase; Not determined,B,,,,12166
4180,10325,8,,,,Expert,,,,,"Iin vitro inhibition of 5-lipoxygenase activity in rat basophil leukemia type 1(RBL1) cell homogenates, (reduction of [14C]-5-HETE formation)",B,,,,12166
4181,11966,8,,,,Expert,,,,,In vitro test for inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,B,,,,12166
4182,165,8,,702.0,,Expert,,RBL-1,,,In vitro inhibition of 5-lipoxygenase activity in RBL-1 cells.,B,,,,12166
4183,165,8,,702.0,,Autocuration,,RBL-1,,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells; No significant inhibitory activity up to 30 uM,B,,,,12166
4184,165,8,,702.0,,Autocuration,,RBL-1,,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,B,,,,12166
4185,165,8,,702.0,,Expert,,RBL-1,,,In vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,B,,,,12166
4186,11311,8,,,,Autocuration,,,,,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse,B,,,,12166
4187,11311,8,,702.0,,Autocuration,,RBL-1,,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1,B,,,,12166
4188,11311,8,,702.0,,Autocuration,,RBL-1,,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,B,,,,12166
4189,11311,8,,,,Autocuration,,,,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS],B,,,,12166
4190,11311,8,,,,Autocuration,,,,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vitro),B,,,,12166
4191,11311,8,,,,Autocuration,,,,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vivo),B,In vivo,,,12166
4192,11311,8,,663.0,,Autocuration,,RBL-2H3,,,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in RBL-2H3 cells,F,,,,12166
4193,11311,8,,663.0,,Autocuration,,RBL-2H3,,,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in rat RBL-2H3 cells,F,,,,12166
4194,11311,8,,,,Autocuration,,,,,The compound was tested for inhibitory activity against 5-lipoxygenase using rat polymorphonuclear leukocytes[PMNS],B,,,,12166
4195,11732,8,,,,Autocuration,,,,,The compound was tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase,B,,,,12166
4196,11732,8,,,,Expert,,,,,Tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase.,B,,,,12166
4197,11087,8,,,,Expert,,,,,In vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells,B,,,,12166
4198,11087,8,,,,Autocuration,,,,,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells,B,,,,12166
4199,11087,8,,702.0,,Autocuration,,RBL-1,,,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in homogenized rat basophilic leukemia (RBL-1) cells,B,,,,12166
4200,11087,9,,,,Expert,,,,10116.0,Inhibition of 5-lipoxygenase (5-lo) in intact rat polymorphonuclear leukocyte RPMNL,B,,Rattus norvegicus,,12166
4201,496,8,,702.0,,Autocuration,,RBL-1,,,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells,B,,,,12166
4202,13986,8,,702.0,,Expert,,RBL-1,,,Inhibition of 5-lipoxygenase on rat basophil leukemia cell line lysate (RBL-1 2H3 subline) by measuring 5-HETE production,F,,,,12166
4203,11520,8,,,,Autocuration,,,,,Compound was evaluated for the inhibition of 5-lipoxygenase,B,,,,12166
4204,10293,8,,702.0,,Autocuration,,RBL-1,,,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line at a concentration of 25 uM,B,,,,12166
4205,303,8,,702.0,,Autocuration,,RBL-1,,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay,B,,,,12166
4206,303,8,,702.0,,Autocuration,,RBL-1,,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay; Less than 5% inhibition at 10 uM reported as not active,B,,,,12166
4207,9247,8,,702.0,,Autocuration,,RBL-1,,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 10 uM,B,,,,12166
4208,9247,9,,702.0,,Expert,,RBL-1,,10116.0,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM,B,,Rattus norvegicus,,12166
4209,9247,8,,702.0,,Autocuration,,RBL-1,,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,B,,,,12166
4210,9247,8,,702.0,,Autocuration,,RBL-1,,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 30 uM,B,,,,12166
4211,9247,8,,702.0,,Autocuration,,RBL-1,,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 300 uM,B,,,,12166
4212,9247,8,,702.0,,Autocuration,,RBL-1,,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 33 uM,B,,,,12166
4213,9247,8,,702.0,,Autocuration,,RBL-1,,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 40 uM,B,,,,12166
4214,9247,8,,702.0,,Autocuration,,RBL-1,,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 75 uM,B,,,,12166
4215,11481,9,,,,Expert,,,,10116.0,Inhibitory activity against 5-lipoxygenase at 10 uM,B,,Rattus norvegicus,,12166
4216,105,8,,,,Autocuration,,,,,In vitro inhibition of 5-lipoxygenase; NS means no significant inhibition,B,,,,12166
4217,9029,8,,,,Expert,,,,,In vitro inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase at 10 uM,B,,,,12166
4218,1175,8,,702.0,,Expert,,RBL-1,,,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells at 20 uM,B,,,,12166
4219,12118,8,,702.0,,Autocuration,,RBL-1,,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 100 uM,B,,,,12166
4220,12118,8,,702.0,,Autocuration,,RBL-1,,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 10e-4 M,B,,,,12166
4221,12118,8,,702.0,,Autocuration,,RBL-1,,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determinedb at 100 uM,B,,,,12166
4222,9225,8,,702.0,,Autocuration,,RBL-1,,,In vitro inhibition of RBL-1 5-lipoxygenase at 20 uM,B,,,,12166
4223,9401,8,,,,Autocuration,,,,,In vitro inhibitory activity against 5-Lipoxygenase from rat basophilic leukemia cells at 30 uM concentration,B,,,,12166
4224,137,8,,,,Autocuration,,,,,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,B,,,,12166
4225,137,8,,,,Autocuration,,,,,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,B,,,,12166
4226,4717,8,,702.0,,Autocuration,,RBL-1,,,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,B,,,,12166
4227,3595,8,,702.0,,Autocuration,,RBL-1,,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,B,,,,12166
4228,10501,8,,702.0,,Autocuration,,RBL-1,,,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at 40 uM concentration,B,,,,12166
4229,10501,8,,702.0,,Autocuration,,RBL-1,,,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM,B,,,,12166
4230,10501,8,,702.0,,Autocuration,,RBL-1,,,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM.,B,,,,12166
4231,12526,8,,702.0,,Autocuration,,RBL-1,,,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,B,,,,12166
4232,14799,9,,702.0,,Expert,,RBL-1,,10116.0,Inhibition of 5-lipoxygenase of rat basophilic leukemia cells at 30 uM,B,,Rattus norvegicus,,12166
4233,14799,8,,,,Autocuration,,,,,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells at 30 uM concentration; NT=Not tested,B,,,,12166
4234,3595,8,,702.0,,Autocuration,,RBL-1,,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,B,,,,12166
4235,3595,8,,702.0,,Expert,,RBL-1,,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,B,,,,12166
4236,12526,8,,702.0,,Autocuration,,RBL-1,,,Inhibitory activity at 10 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,B,,,,12166
4237,12526,8,,702.0,,Autocuration,,RBL-1,,,Inhibitory activity at 1 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,B,,,,12166
4238,10193,8,,,,Autocuration,,,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,B,,,,12166
4239,10193,8,,,,Autocuration,,,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,B,,,,12166
4240,10193,8,,,,Autocuration,,,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,B,,,,12166
4241,10193,8,,,,Autocuration,,,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 3 uM,B,,,,12166
4242,9138,8,,,,Expert,,,,,Percent inhibition of rat neutrophil 5-lipoxygenase (5-LO),B,,,,12166
4243,9138,8,,,,Autocuration,,,,,Percent inhibition of rat neutrophil 5- Lipoxygenase (5-LO) at 100 uM,B,,,,12166
4244,11966,8,,,,Autocuration,,,,,Tested in vitro for the inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,B,,,,12166
4245,165,8,,702.0,,Autocuration,,RBL-1,,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 100 uM,B,,,,12166
4246,165,8,,702.0,,Autocuration,,RBL-1,,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 30 uM,B,,,,12166
4247,11311,8,,663.0,,Autocuration,,RBL-2H3,,,The compound was tested for inhibition of 5-lipoxygenase in rat RBL-2H3 cells,B,,,,12166
4248,11311,8,,663.0,,Autocuration,,RBL-2H3,,,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,B,,,,12166
4249,11311,8,,663.0,,Autocuration,,RBL-2H3,,,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,F,,,,12166
4250,11311,8,,,,Autocuration,,,,,The compound was tested for inhibition of LTB4 synthesis on isolated 5-lipoxygenase,F,,,,12166
4251,11311,8,,,,Autocuration,,,,,The compound was tested for inhibition of isolated 5-lipoxygenase,B,,,,12166
4252,11311,8,,663.0,,Autocuration,,RBL-2H3,,,The compound was tested for inhibition of isolated 5-lipoxygenase translocation into rat RBL-2H3 cells,F,,,,12166
4253,11087,8,,,,Autocuration,,,,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 30 uM,B,,,,12166
4254,11087,8,,,,Autocuration,,,,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 32 uM,B,,,,12166
4255,11087,8,,,,Autocuration,,,,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells measured at a concentration of 30 uM,B,,,,12166
4256,11087,8,,,,Autocuration,,,,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,B,,,,12166
4257,11087,8,,,,Autocuration,,,,,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,B,,,,12166
4258,496,8,,702.0,,Autocuration,,RBL-1,,,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 1.0 uM,B,,,,12166
4259,496,8,,702.0,,Autocuration,,RBL-1,,,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 10 uM,B,,,,12166
4260,13986,8,,702.0,,Autocuration,,RBL-1,,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.1 uM,F,,,,12166
4261,13986,8,,702.0,,Autocuration,,RBL-1,,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.195 uM,F,,,,12166
4262,13986,8,,702.0,,Autocuration,,RBL-1,,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.2 at uM,F,,,,12166
4263,13986,8,,702.0,,Autocuration,,RBL-1,,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.25 uM,F,,,,12166
4264,13986,8,,702.0,,Autocuration,,RBL-1,,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39,F,,,,12166
4265,13986,8,,702.0,,Autocuration,,RBL-1,,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39 uM,F,,,,12166
4266,13986,8,,702.0,,Autocuration,,RBL-1,,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.195 uM,F,,,,12166
4267,13986,8,,702.0,,Autocuration,,RBL-1,,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.2 uM,F,,,,12166
4268,13986,8,,702.0,,Autocuration,,RBL-1,,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.39 uM,F,,,,12166
4269,13986,9,,,,Expert,,,,10116.0,Inhibition of 5-lipoxygenase on rat basophil leukemia cell (RBL-2H3) lysate as 5-HETE production at 32 uM,F,,Rattus norvegicus,,12166
4270,10193,8,,,,Autocuration,,,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase,B,,,,12166
4271,9295,8,,,,Autocuration,,,,,Compound was tested for the percent of inhibition against 5-LO at 10 uM,B,,,,12166
4272,4717,8,,702.0,,Autocuration,,RBL-1,,,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 1 uM concentration,B,,,,12166
4273,4717,8,,702.0,,Autocuration,,RBL-1,,,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,B,,,,12166
4274,11854,8,,702.0,,Autocuration,,RBL-1,,,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line,B,,,,12166
4275,11854,8,,702.0,,Autocuration,,RBL-1,,,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 10 uM,B,,,,12166
4276,11854,8,,702.0,,Autocuration,,RBL-1,,,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 16 uM,B,,,,12166
4277,10193,8,,,,Autocuration,,,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,B,,,,12166
4278,9295,8,,702.0,,Autocuration,,RBL-1,,,Percent inhibition against RBL-1 5-LO in vitro at 10 uM,B,,,,12166
4279,9295,8,,702.0,,Autocuration,,RBL-1,,,Percent inhibition against RBL-1 5-LO in vitro at 100 uM,B,,,,12166
4280,9295,8,,702.0,,Autocuration,,RBL-1,,,Percent inhibition against RBL-1 5-LO in vitro at 30 uM,B,,,,12166
4281,9295,8,,702.0,,Autocuration,,RBL-1,,,Percent inhibition against RBL-1 5-LO in vitro at 300 uM,B,,,,12166
4282,165,8,,702.0,,Autocuration,,RBL-1,,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 20 uM,B,,,,12166
4283,11311,8,,,,Autocuration,,,,,The compound was tested for inhibition against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] at 10 uM concentration,B,,,,12166
4284,10489,8,,702.0,,Expert,,RBL-1,,9606.0,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),B,,Homo sapiens,,12166
4285,10489,9,,702.0,,Expert,,RBL-1,,10116.0,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),B,,Rattus norvegicus,,12166
4286,10489,9,,702.0,,Expert,,RBL-1,,10116.0,Logarithmic value of inhibitory concentration against 5-lipoxygenase in rat basophilic leukemia cells (RBL-1),B,,Rattus norvegicus,,12166
4287,14799,9,,,,Autocuration,,,,10116.0,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,B,,Rattus norvegicus,,12166
4288,9295,8,,,,Autocuration,,,,3847.0,Compound was tested for the percent of inhibition against soybean 15-LO (at 100 uM),B,,Glycine max,,12054
4289,16811,0,,,,Autocuration,,,,,"Inhibitory activity against 5-lipoxygenase, by using soybean lipoxygenase spectrophotometric assay",B,,,,22226
4290,168,8,,,,Expert,,,,,In vitro inhibition of 5-Lipoxygenase; Inactive.,B,,,,55
4291,6309,8,,,,Autocuration,,,,,Inhibitory concentration against 5-lipoxygenase was determined; No inhibition,B,,,,55
4292,6309,8,,,,Autocuration,,,,,Inhibitory concentration against 5-lipoxygenase; No inhibition,B,,,,55
4293,3092,8,,702.0,,Autocuration,,RBL-1,,,Evaluated for inhibitory activity against RBL-1 cell 5-lipoxygenase in guinea pig,B,,,,55
4294,168,8,,,,Expert,,,,,Inhibitory activity against 5-lipoxygenase.,B,,,,55
4295,168,8,,,,Autocuration,,,,,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive,B,,,,55
4296,168,8,,,,Autocuration,,,,,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive at concentrations less than 32 uM,B,,,,55
4297,168,8,,,,Autocuration,,,,,Inhibitory Activity against 5-Lipoxygenase was determined; NA=No significant inhibitory activity up to 300 uM,B,,,,55
4298,12338,8,,,,Expert,,,,,Inhibitory concentration against arachidonic acid 5-lipoxygenation,F,,,,55
4299,4501,8,,,,Autocuration,,,,,Tested for the inhibitory activity against 5-lipoxygenase,B,,,,55
4300,1132,8,,,,Autocuration,,,,,Compound was tested for its inhibitory activity against 5-lipoxygenase,B,,,,55
4301,2117,8,,,,Autocuration,,,,,Compound was tested for inhibition of 5-lipoxygenase at 50 uM; NI means no inhibition was observed,B,,,,55
4302,168,8,,,,Autocuration,,,,,Inhibitory Activity against 5-Lipoxygenase at 30 uM was determined; Weakly active,B,,,,55
4303,168,8,,,,Autocuration,,,,,Inhibitory Activity against 5-Lipoxygenase at concentration 32 uM was determined,B,,,,55
4304,13575,8,,702.0,,Autocuration,,RBL-1,,,Concentration required to inhibit RBL-1 supernatant 5-lipoxygenase,B,,,,12166
4305,11089,8,,,,Autocuration,,,,,,B,,,,12166
4306,216,8,,,,Autocuration,,,,,Compound was tested for its binding activity towards 5-lipoxygenase activating protein (FLAP),B,,,,10102
4307,13165,8,,,,Autocuration,,,,,Inhibition of 5-lipoxygenase activating protein using human leukocyte membrane preparations,B,,,,10102
4308,3278,8,,,,Autocuration,,,,,Measuring the affinity of leukotriene synthesis inhibitor for 5-Lipoxygenase activating protein (FLAP) by using [125I]L-691831 as radioligand.,B,,,,10102
4309,3278,8,,,,Expert,,,,,Measuring the affinity of leukotriene synthesis inhibitor for 5-lipoxygenase activating protein by using [125I]L-691831 as radioligand.,B,,,,10102
4310,11966,8,,,,Autocuration,,,,,Tested for inhibition of leukotriene biosynthesis by binding to 5-lipoxygenase activating protein,B,,,,10102
4311,175,8,,,,Autocuration,,,,,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein",B,,,,10102
4312,175,8,,,,Autocuration,,,,,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein (FLAP)",B,,,,10102
4313,13449,8,,,,Autocuration,,,,,Binding affinity of compound for 5-lipoxygenase activating protein protein by FLAP binding assay,B,,,,10102
4314,12014,8,,,,Autocuration,,,,,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane,B,,,,11238
4315,12014,8,,,,Autocuration,,,,,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (R metabolically resistant),B,,,,11238
4316,12014,8,,,,Autocuration,,,,,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (S substrate),B,,,,11238
4317,99,2,,,,Intermediate,,,,,Inhibition of protein biosynthesis at the level of the peptidyl transferase center of the 50 s ribosomal subunit,B,,,,100284
4318,4349,0,,,,Autocuration,,,,9606.0,The dark toxicity against 543 human galactophore carcinoma cells,F,,Homo sapiens,,22226
4319,4071,1,,390.0,,Expert,,Panel (56 tumour cell lines),,9606.0,Tested in vitro for cytotoxicity against 56 human tumor cell lines,F,,Homo sapiens,,80623
4320,17589,1,,345.0,,Expert,,5637,,9606.0,Cytotoxic activity against human 5637 cell line at 20 uM expressed as percent growth value,F,,Homo sapiens,,80008
4321,15002,1,,345.0,,Intermediate,,5637,,9606.0,Antitumor activity was evaluated against human bladder carcinoma cell line 5637.,F,,Homo sapiens,,80008
4322,13958,1,,345.0,,Intermediate,,5637,,9606.0,"Compound was tested for antiproliferative activity against 5637, human bladder carcinoma cell line",F,,Homo sapiens,,80008
4323,17589,1,,345.0,,Expert,,5637,,9606.0,Growth inhibition against human 5637 cell lines,F,,Homo sapiens,,80008
4324,16748,1,,345.0,,Expert,,5637,,9606.0,Antitumor activity against human bladder carcinoma 5637 cells.,F,,Homo sapiens,,80008
4325,16747,1,,345.0,,Intermediate,,5637,,9606.0,Antitumor activity against human bladder carcinoma 5637 cells,F,,Homo sapiens,,80008
4326,16747,1,,345.0,,Intermediate,,5637,,9606.0,Antitumor activity against human bladder carcinoma 5637 cells,F,,Homo sapiens,,80008
4327,15285,9,,,,Expert,,,,9913.0,In vitro inhibition of bovine trypsin(Trp).,B,,Bos taurus,,10443
4328,3726,8,,407.0,,Expert,,CV-1,,9527.0,Transcriptional activation in CV-1 cells expressing retinoic acid gamma receptor,B,,Cercopithecidae,,240
4329,5033,8,,,,Autocuration,,,,,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-HT1B receptor,B,,,,10577
4330,11756,6,,,,Autocuration,,,,,In vitro antagonism of the 5-HT-3 receptor determined by inhibition of 5-HT-induced depolarization of the isolated rat vagus nerve.,F,,,,104698
4331,11953,0,,,,Autocuration,,,,,Concentration required to inhibit pressor response to serotonin after 15 min i.v. administration of compound mediated via activation of vascular 5-HT2 receptors in rat,F,In vivo,,,22226
4332,5033,9,,,,Intermediate,,,,10141.0,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-HT4 receptor,B,,Cavia porcellus,,20033
4333,11347,8,,,,Expert,,,,10116.0,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,A,,Rattus norvegicus,Microsomes,17045
4334,11347,8,,,,Expert,,,,10116.0,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,A,,Rattus norvegicus,Microsomes,17045
4335,1229,0,,,,Intermediate,,,,,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,F,,,,22226
4336,1229,0,,,,Intermediate,,,,,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,F,,,,22226
4337,17588,8,,,,Expert,,,,5691.0,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli,B,,Trypanosoma brucei,,11938
4338,17588,8,,,,Autocuration,,,,5691.0,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli; NI denotes no inhibition,B,,Trypanosoma brucei,,11938
4339,17588,8,,,,Expert,,,,9940.0,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver,B,,Ovis aries,,11938
4340,17588,8,,,,Autocuration,,,,9940.0,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver; NI denotes no inhibition,B,,Ovis aries,,11938
4341,16485,8,,,,Autocuration,,,,,log Kd which is the binding affinity against 6-phosphogluconate dehydrogenase,B,,,,11938
4342,4337,0,,,,Intermediate,,,,9606.0,Average inhibitory concentration against 60 human cell lines was reported,F,,Homo sapiens,,22226
4343,4112,0,,,,Expert,,,,9606.0,Inhibition of proliferation in NCI panel of 60 human tumor cell lines,F,,Homo sapiens,,22226
4344,16160,1,,542.0,,Intermediate,,Panel NCI-60 (60 carcinoma cell lines),,9606.0,Cancer specificity was measured from the +/- value under average log LC50 60-cell line,F,,Homo sapiens,,80315
4345,16160,1,,542.0,,Intermediate,,Panel NCI-60 (60 carcinoma cell lines),,9606.0,Cancer specificity was measured from the +/- value under average log LC50 60-cell line. ,F,,Homo sapiens,,80315
4346,17376,1,,542.0,,Expert,,Panel NCI-60 (60 carcinoma cell lines),,,In vitro mean growth inhibitory activity against 60-cell panel,F,,,,80315
4347,17376,1,,542.0,,Expert,,Panel NCI-60 (60 carcinoma cell lines),,,In vitro mean growth lethal concentration against 60-cell panel,F,,,,80315
4348,17376,1,,542.0,,Expert,,Panel NCI-60 (60 carcinoma cell lines),,,In vitro mean growth lethal concentration in colon subpanel against 60-cell panel,F,,,,80315
4349,17376,1,,542.0,,Expert,,Panel NCI-60 (60 carcinoma cell lines),,,In vitro mean growth lethal concentration in renal subpanel against 60-cell panel,F,,,,80315
4350,3241,4,,,,Autocuration,,,,,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,F,,,,104775
4351,3241,4,,,,Autocuration,,,,,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,F,,,,104775
4352,3725,8,,,,Expert,,,,,Transcriptional activation in CV-1 expressing retinoid X receptor RXR alpha,B,,,,275
4353,10805,1,,,,Expert,,,,5833.0,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase,F,,Plasmodium falciparum,,50425
4354,10805,1,,,,Expert,,,,5833.0,In vitro inhibition of Plasmodium falciparum 68 neutral proteinase activity by reinvasion of red blood cells,F,,Plasmodium falciparum,,50425
4355,10805,1,,,,Expert,,,,5833.0,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase.,F,,Plasmodium falciparum,,50425
4356,10805,1,,,,Expert,,,,5833.0,Substrate affinity for Plasmodium falciparum 68 neutral proteinase.,F,,Plasmodium falciparum,,50425
4357,10805,1,,,,Intermediate,,,,5833.0,Reaction velocity for Plasmodium falciparum 68 neutral proteinase.,F,,Plasmodium falciparum,,50425
4358,10144,1,,850.0,,Intermediate,,6C3HED,,10090.0,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,F,,Mus musculus,,80628
4359,10144,1,,850.0,,Intermediate,,6C3HED,,10090.0,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,F,,Mus musculus,,80628
4360,10144,1,,850.0,,Intermediate,,6C3HED,,10090.0,Percent inhibition against 6C3HED lymphosarcoma at dose 200 mg/kg in C3H mice,F,,Mus musculus,,80628
4361,10144,1,,850.0,,Intermediate,,6C3HED,,10090.0,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,F,,Mus musculus,,80628
4362,10144,1,,850.0,,Intermediate,,6C3HED,,10090.0,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,F,,Mus musculus,,80628
4363,10144,1,,850.0,,Intermediate,,6C3HED,,10090.0,Percent inhibition against 6C3HED lymphosarcoma at dose 6 mg/kg in C3H mice,F,,Mus musculus,,80628
4364,10685,0,,,,Autocuration,,,,10090.0,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 100 mg/kg,F,In vivo,Mus musculus,,22224
4365,10685,0,,,,Autocuration,,,,10090.0,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 150 mg/kg,F,In vivo,Mus musculus,,22224
4366,10685,0,,,,Autocuration,,,,10090.0,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 1600 mg/kg (intraperitoneal dosing for 8 days),F,In vivo,Mus musculus,,22224
4367,10685,0,,,,Autocuration,,,,10090.0,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 200 mg/kg,F,In vivo,Mus musculus,,22224
4368,10685,0,,,,Autocuration,,,,10090.0,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 225 mg/kg,F,In vivo,Mus musculus,,22224
4369,10685,0,,,,Autocuration,,,,10090.0,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 270 mg/kg,F,In vivo,Mus musculus,,22224
4370,10685,0,,,,Autocuration,,,,10090.0,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 275 mg/kg,F,In vivo,Mus musculus,,22224
4371,10685,0,,,,Autocuration,,,,10090.0,"Antitumor activity in vivo against the 6C3HED lymphosarcoma, dosed for 10 days at 300 mg/kg",F,In vivo,Mus musculus,,22224
4372,10685,0,,,,Autocuration,,,,10090.0,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (intraperitoneal dosing for 8 days),F,In vivo,Mus musculus,,22224
4373,10685,0,,,,Autocuration,,,,10090.0,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (ip dosing daily for 8 days),F,In vivo,Mus musculus,,22224
4374,10685,0,,,,Autocuration,,,,10090.0,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 600 mg/kg,F,In vivo,Mus musculus,,22224
4375,10144,0,,,,Autocuration,,,,10090.0,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,F,,Mus musculus,,22224
4376,10144,0,,,,Autocuration,,,,10090.0,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,F,,Mus musculus,,22224
4377,10144,0,,,,Autocuration,,,,10090.0,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,F,,Mus musculus,,22224
4378,10144,0,,,,Autocuration,,,,10090.0,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,F,,Mus musculus,,22224
4379,10685,0,,,,Autocuration,,,,10090.0,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 100 mg/kg dosage administered for 8 days intraperitoneally,F,,Mus musculus,,22224
4380,10685,0,,,,Autocuration,,,,10090.0,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 10 days intraperitoneally,F,,Mus musculus,,22224
4381,10685,0,,,,Autocuration,,,,10090.0,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 8 days intraperitoneally,F,,Mus musculus,,22224
4382,10685,0,,,,Autocuration,,,,10090.0,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 50 mg/kg dosage administered for 8 days intraperitoneally,F,,Mus musculus,,22224
4383,10685,0,,,,Autocuration,,,,10090.0,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 100 mg/kg dosage administered for 8 days intraperitoneally; 0/10,A,,Mus musculus,,22224
4384,10685,0,,,,Autocuration,,,,10090.0,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 8 days perorally; 1/10,A,,Mus musculus,,22224
4385,10685,0,,,,Autocuration,,,,10090.0,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 10 days intraperitoneally; 1/10,A,,Mus musculus,,22224
4386,10685,0,,,,Autocuration,,,,10090.0,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 50 mg/kg dosage administered for 8 days perorally; 3/10,A,,Mus musculus,,22224
4387,8831,1,,850.0,,Intermediate,,6C3HED,,10090.0,"Compound was evaluated for the antitumor activity against 6C3HED lymphosarcoma for ip administration and daily x 8 schedule; Number of toxic deaths over total number of mice per group (T/C), 0/10 at dose of 35 mg/kg",F,,Mus musculus,,80628
4388,11704,0,,,,Autocuration,,,,,In vivo antitumor activity against 6C3HED tumor type after intraperitoneal administration of 400 mg/kg,F,In vivo,,,22224
4389,11704,1,,,,Intermediate,,,,10090.0,In vivo antitumor activity against 6C3HED tumor type was expressed as toxic deaths/total treated mice at 400 mg/kg dose; 2/10,A,,Mus musculus,,50594
4390,10685,1,,850.0,,Intermediate,,6C3HED,,10090.0,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line,F,In vivo,Mus musculus,,80628
4391,10685,1,,850.0,,Intermediate,,6C3HED,,10090.0,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line; 95-100% inhibition,F,In vivo,Mus musculus,,80628
4392,11368,1,,850.0,,Expert,,6C3HED,,10090.0,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 150 mg/kg given orally(daily x 8),F,,Mus musculus,,80628
4393,11368,1,,850.0,,Intermediate,,6C3HED,,10090.0,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 200 mg/kg given orally(daily x 8),F,,Mus musculus,,80628
4394,11368,1,,850.0,,Expert,,6C3HED,,10090.0,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 300 mg/kg given orally (daily x 8),F,,Mus musculus,,80628
4395,17763,0,,,,Autocuration,,,,1280.0,"Inhibition of Staphylococcus aureus 7,8-dihydroneopterin aldolase",B,,Staphylococcus aureus,,22226
4396,7411,0,,,,Autocuration,2107.0,,Liver,10116.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at a concentration of 5 uM,B,,Rattus norvegicus,Microsomes,22226
4397,7411,0,,,,Autocuration,2107.0,,Liver,10116.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,B,,Rattus norvegicus,Microsomes,22226
4398,7411,0,,,,Autocuration,2107.0,,Liver,10116.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 1 uM,B,,Rattus norvegicus,Microsomes,22226
4399,7411,0,,,,Autocuration,2107.0,,Liver,10116.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 20 uM,B,,Rattus norvegicus,Microsomes,22226
4400,7411,0,,,,Autocuration,2107.0,,Liver,10116.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 25 uM,B,,Rattus norvegicus,Microsomes,22226
4401,7411,0,,,,Autocuration,2107.0,,Liver,10116.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 50 uM,B,,Rattus norvegicus,Microsomes,22226
4402,7411,0,,,,Autocuration,2107.0,,Liver,10116.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 5 uM,B,,Rattus norvegicus,Microsomes,22226
4403,7411,0,,,,Autocuration,2107.0,,Liver,10116.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 10 uM,B,,Rattus norvegicus,Microsomes,22226
4404,7411,0,,,,Autocuration,2107.0,,Liver,10116.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,B,,Rattus norvegicus,Microsomes,22226
4405,7411,0,,,,Autocuration,2107.0,,Liver,10116.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,B,,Rattus norvegicus,Microsomes,22226
4406,7411,0,,,,Autocuration,2107.0,,Liver,10116.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,B,,Rattus norvegicus,Microsomes,22226
4407,7411,0,,,,Autocuration,2107.0,,Liver,10116.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,B,,Rattus norvegicus,Microsomes,22226
4408,347,0,,,,Autocuration,1969.0,,Plasma,9527.0,The apparent total plasma clearance in monkey,A,In vivo,Cercopithecidae,,22224
4409,3341,0,,,,Autocuration,,,,9527.0,Compound was evaluated for Hepatic clearance in monkey,A,In vivo,Cercopithecidae,,22224
4410,17853,0,,,,Autocuration,,,,9527.0,Lower clearance in monkey (i.v.) at 0.5 mpk,A,In vivo,Cercopithecidae,,22224
4411,4514,0,,,,Autocuration,,,,9527.0,Plasma clearance in rhesus monkey,A,In vivo,Cercopithecidae,,22224
4412,6062,0,,,,Autocuration,,,,9527.0,Plasma clearance for the compound was measured in monkey after an iv dose of 1 mg/kg,A,In vivo,Cercopithecidae,,22224
4413,6821,0,,,,Autocuration,,,,9527.0,Plasma clearance of compound was determined in monkey,A,In vivo,Cercopithecidae,,22224
4414,6057,0,,,,Autocuration,,,,9527.0,Plasma clearance was calculated in rhesus monkey,A,In vivo,Cercopithecidae,,22224
4415,5145,0,,,,Autocuration,,,,9527.0,Plasma clearance in rhesus monkey,A,In vivo,Cercopithecidae,,22224
4416,6641,0,,,,Autocuration,,,,9527.0,Plasma clearance in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),A,In vivo,Cercopithecidae,,22224
4417,5472,0,,,,Autocuration,,,,9527.0,Plasma clearance was evaluated in rhesus,A,In vivo,Cercopithecidae,,22224
4418,4257,0,,,,Autocuration,,,,9527.0,Plasma clearance value was determined in monkey after a 3 mg/kg of iv dose,A,In vivo,Cercopithecidae,,22224
4419,5546,0,,,,Autocuration,,,,9527.0,Plasma clearance was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,A,In vivo,Cercopithecidae,,22224
4420,5334,0,,,,Autocuration,,,,9527.0,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),A,In vivo,Cercopithecidae,,22224
4421,5334,0,,,,Autocuration,,,,9527.0,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),A,In vivo,Cercopithecidae,,22224
4422,17509,0,,,,Autocuration,,,,9527.0,Cmax 24 hr after 2 mg/kg oral administration in monkeys,A,In vivo,Cercopithecidae,,22224
4423,6535,0,,,,Autocuration,,,,9527.0,Cmax in monkey after administration of 1 mg/kg iv,A,In vivo,Cercopithecidae,,22224
4424,5668,0,,,,Autocuration,,,,9527.0,Cmax was determine after peroral administration at 10 mpk in Rhesus,A,In vivo,Cercopithecidae,,22224
4425,5922,0,,,,Autocuration,,,,9527.0,Cmax in cynomolgus monkey by iv administration,A,In vivo,Cercopithecidae,,22224
4426,5922,0,,,,Autocuration,,,,9527.0,Cmax in cynomolgus monkey by po administration,A,In vivo,Cercopithecidae,,22224
4427,6078,0,,,,Autocuration,,,,9527.0,Cmax value evaluated in monkey,A,In vivo,Cercopithecidae,,22224
4428,2661,0,,,,Autocuration,,,,9527.0,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female cynomolgus monkey,A,In vivo,Cercopithecidae,,22224
4429,3249,0,,,,Autocuration,1969.0,,Plasma,9527.0,Maximal concentration (Cmax) in rhesus monkey plasma at a dose of 5 mg/kg,A,In vivo,Cercopithecidae,,22224
4430,3249,0,,,,Autocuration,1969.0,,Plasma,9527.0,Maximal concentration (Cmax) in squirrel monkey plasma at a dose of 5 mg/kg,A,In vivo,Cercopithecidae,,22224
4431,5553,0,,,,Autocuration,1969.0,,Plasma,9527.0,Maximal plasma concentration in squirrel monkeys,A,In vivo,Cercopithecidae,,22224
4432,1916,0,,,,Autocuration,,,,9527.0,Maximum concentration was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,A,In vivo,Cercopithecidae,,22224
4433,6227,0,,,,Autocuration,1969.0,,Plasma,9527.0,Maximum plasma concentration (Cmax) in rhesus monkey(in vivo) at a dose of 5 mg/kg,A,In vivo,Cercopithecidae,,22224
4434,4809,0,,,,Autocuration,,,,9527.0,Pharmacokinetic parameter Cmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),A,In vivo,Cercopithecidae,,22224
4435,5355,0,,,,Autocuration,,,,9527.0,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means Not applicable,A,In vivo,Cercopithecidae,,22224
4436,5355,0,,,,Autocuration,,,,9527.0,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means not applicable,A,In vivo,Cercopithecidae,,22224
4437,5355,0,,,,Autocuration,,,,9527.0,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys;NA means not applicable,A,In vivo,Cercopithecidae,,22224
4438,5355,0,,,,Autocuration,,,,9527.0,The peak concentration (Cmax) value after oral administration in cynomolgus monkeys,A,In vivo,Cercopithecidae,,22224
4439,6221,0,,,,Autocuration,1969.0,,Plasma,9527.0,The peak plasma concentration after 5 hr administration (2.5 mg/kg) in monkey was determined,A,In vivo,Cercopithecidae,,22224
4440,167,0,,,,Autocuration,,,,9527.0,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 0.4 hours,A,,Cercopithecidae,,22224
4441,167,0,,,,Autocuration,,,,9527.0,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 1.0 hours,A,,Cercopithecidae,,22224
4442,4257,0,,,,Autocuration,,,,9443.0,Absolute bioavailability was evaluated in monkey,A,In vivo,monkey,,22224
4443,6221,0,,,,Autocuration,,,,9443.0,Bioavailability after oral administration (2.5 mg/kg) in monkey was determined,A,In vivo,monkey,,22224
4444,17667,0,,,,Autocuration,,,,9443.0,Bioavailability of compound at 3 mg/kg in monkey after i.v. administration,A,In vivo,monkey,,22224
4445,17267,0,,,,Autocuration,,,,9544.0,Bioavailability of compound was determined in rhesus monkey,A,In vivo,Macaca mulatta,,22224
4446,4256,0,,,,Autocuration,,,,38020.0,Bioavailability determined after oral administration in marmoset,A,In vivo,marmosets,,22224
4447,4256,0,,,,Autocuration,,,,9541.0,Oral bioavailability in cynomolgus monkey,A,In vivo,Macaca fascicularis,,22224
4448,17853,0,,,,Autocuration,,,,9443.0,Bioavailability in monkey (p.o.) at 2.0 mpk,A,In vivo,monkey,,22224
4449,16365,0,,,,Autocuration,,,,9443.0,Bioavailability was evaluated after oral administration in monkey,A,In vivo,monkey,,22224
4450,1916,0,,,,Autocuration,,,,9541.0,Bioavailability was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,A,In vivo,Macaca fascicularis,,22224
4451,5334,0,,,,Autocuration,,,,9544.0,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),A,In vivo,Macaca mulatta,,22224
4452,5334,0,,,,Autocuration,,,,9544.0,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),A,In vivo,Macaca mulatta,,22224
4453,17592,0,,,,Autocuration,,,,9443.0,Bioavailability of the compound was determined in monkey,A,In vivo,monkey,,22224
4454,1399,0,,,,Autocuration,,,,9521.0,Bioavailability in squirrel monkey (dose 5 mg/kg),A,In vivo,Saimiri sciureus,,22224
4455,4809,0,,,,Autocuration,,,,9443.0,Bioavailability was determined in monkey after (po) administration of a dose of 50 (uM/kg),A,In vivo,monkey,,22224
4456,3341,0,,,,Autocuration,,,,9443.0,Oral bioavailability in monkey,A,In vivo,monkey,,22224
4457,64,0,,,,Autocuration,,,,9521.0,Compound was tested for bioavailability in squirrel monkey,A,In vivo,Saimiri sciureus,,22224
4458,5005,0,,,,Autocuration,,,,9544.0,Oral bioavailability in Rhesus monkey,A,In vivo,Macaca mulatta,,22224
4459,5005,0,,,,Autocuration,,,,9544.0,Oral bioavailability in Rhesus monkey (dose of 0.75 mg/kg i.v. and 1.5 mg/kg p.o.),A,In vivo,Macaca mulatta,,22224
4460,5237,0,,,,Autocuration,,,,9541.0,Oral bioavailability in cynomolgus monkeys for the compound was determined; Acceptable,A,In vivo,Macaca fascicularis,,22224
4461,5237,0,,,,Autocuration,,,,9541.0,Oral bioavailability in cynomolgus monkeys was determined; Acceptable,A,In vivo,Macaca fascicularis,,22224
4462,5302,0,,,,Autocuration,,,,9443.0,Oral bioavailability in monkey (dose 5 mg/kg),A,In vivo,monkey,,22224
4463,17667,0,,,,Autocuration,,,,9443.0,Oral bioavailability of compound at 5 mg/kg in monkey,A,In vivo,monkey,,22224
4464,6161,1,,,,Intermediate,,,,9615.0,Pharmacokinetic profile in terms of half life was determined at a dose of 0.5 mg/kg administered intravenously in dog,A,In vivo,Canis lupus familiaris,,50588
4465,6161,1,,,,Intermediate,,,,9615.0,Pharmacokinetic profile in terms of half life was determined at a dose of 5 mg/kg administered intravenously in dog,A,In vivo,Canis lupus familiaris,,50588
4466,3854,1,,,,Intermediate,1969.0,,Plasma,9615.0,Plasma half life determined,A,,Canis lupus familiaris,,50588
4467,993,1,,,,Intermediate,1969.0,,Plasma,9615.0,Plasma half life in dog,A,,Canis lupus familiaris,,50588
4468,4514,1,,,,Intermediate,1969.0,,Plasma,9615.0,Plasma half-life in Beagle dogs,A,,Canis lupus familiaris,,50588
4469,5334,1,,,,Intermediate,1969.0,,Plasma,9615.0,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),A,In vivo,Canis lupus familiaris,,50588
4470,5334,1,,,,Intermediate,1969.0,,Plasma,9615.0,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg respectively in Beagle dog (male),A,In vivo,Canis lupus familiaris,,50588
4471,1466,1,,,,Intermediate,,,,9615.0,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in dog,A,In vivo,Canis lupus familiaris,,50588
4472,1466,1,,,,Intermediate,,,,9615.0,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in dog,A,In vivo,Canis lupus familiaris,,50588
4473,5313,1,,,,Intermediate,,,,9615.0,Tested for the half life period in dog,A,,Canis lupus familiaris,,50588
4474,5313,1,,,,Intermediate,,,,9615.0,Tested for the half life period in dog at dosage of 10 mpk,A,In vivo,Canis lupus familiaris,,50588
4475,3880,1,,,,Intermediate,,,,9615.0,The compound was tested for half life in dog,A,,Canis lupus familiaris,,50588
4476,3639,1,,,,Intermediate,1969.0,,Plasma,9615.0,"The compound was tested for time taken to decrease, half of its initial concentration in dog plasma.",A,,Canis lupus familiaris,,50588
4477,3880,1,,,,Intermediate,,,,9615.0,The half life was determined,A,,Canis lupus familiaris,,50588
4478,3918,1,,,,Intermediate,1969.0,,Plasma,9615.0,The plasma half-life in dogs,A,,Canis lupus familiaris,,50588
4479,16452,1,,,,Intermediate,1969.0,,Plasma,9615.0,suboptimal plasma half-life caused a10% prolongation of QTc interval in dogs at a plasma level of 2.5 M,A,,Canis lupus familiaris,,50588
4480,17796,1,,,,Intermediate,,,,9615.0,Half life in dog,A,,Canis lupus familiaris,,50588
4481,5983,1,,,,Intermediate,,,,9615.0,Pharmacokinetic property (t1/2beta) was measured in dog at the dose of 0.032 mg/kg i.v.,A,In vivo,Canis lupus familiaris,,50588
4482,1466,1,,,,Intermediate,,,,9615.0,tmax upon peroral administration of 10.0 mg/Kg dose in dog,A,In vivo,Canis lupus familiaris,,50588
4483,16456,1,,,,Intermediate,,,,9615.0,Volume of distribution in Beagle dogs after intravenous administration at a dose of 10 mg/kg,A,In vivo,Canis lupus familiaris,,50588
4484,6113,1,,,,Expert,,,,9669.0,Cmax in ferrets after 30 mg/kg oral dose,A,In vivo,Mustela putorius furo,,50506
4485,6113,1,,,,Expert,,,,9669.0,Emesis in ferrets at 30 mg/kg oral dose,F,In vivo,Mustela putorius furo,,50506
4486,17796,0,,,,Autocuration,,,,9541.0,Bioavailability in cynomolgus monkey,A,In vivo,Macaca fascicularis,,22224
4487,17796,1,,,,Intermediate,,,,9541.0,Volume of distribution in cynomolgus,A,In vivo,Macaca fascicularis,,100710
4488,5308,0,,,,Autocuration,1969.0,,Plasma,10141.0,AUC tested in guinea pig when 3 mg/kg dose was given perorally,A,,Cavia porcellus,,22224
4489,4877,0,,,,Autocuration,,,,10141.0,Tested for concentration as Area Under Curve against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,A,,Cavia porcellus,,22224
4490,4876,0,,,,Autocuration,,,,10141.0,"Tested for the pharmacokinetic parameter in guinea pig, administered orally at 5 mg/kg",A,,Cavia porcellus,,22224
4491,4878,0,,,,Autocuration,1969.0,,Plasma,10141.0,AUC in guinea pig after 3mg/kg oral dose,A,In vivo,Cavia porcellus,,22224
4492,5308,0,,,,Autocuration,,,,10141.0,Bioavailability in guinea pig was tested,A,In vivo,Cavia porcellus,,22224
4493,4877,0,,,,Autocuration,,,,10141.0,Tested for oral bioavailability in guinea pig at 5 mg/kg,A,In vivo,Cavia porcellus,,22224
4494,4876,0,,,,Autocuration,,,,10141.0,Tested for the oral bioavailability of the compound,A,In vivo,Cavia porcellus,,22224
4495,4876,0,,,,Autocuration,,,,10141.0,Compound at a dose 5 mg/kg was administered orally to guinea pig and the pharmacokinetic parameter (Cmax) was reported,A,In vivo,Cavia porcellus,,22224
4496,5308,0,,,,Autocuration,,,,10141.0,Maximum plsma drug concentration in guinea pig when 3 mg/kg dose was given perorally,A,In vivo,Cavia porcellus,,22224
4497,4877,0,,,,Autocuration,2048.0,,Lung,10141.0,Tested for maximum concentration against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,A,In vivo,Cavia porcellus,,22224
4498,4878,0,,,,Autocuration,,,,10141.0,Cmax in guinea pig after 3mg/kg oral dose,A,In vivo,Cavia porcellus,,22224
4499,5689,0,,,,Autocuration,178.0,,Blood,10141.0,Distribution in blood expressed as [18F]- organ uptake in % of injected activity/gram,A,,Cavia porcellus,,22224
4500,5689,0,,,,Autocuration,955.0,,Brain,10141.0,Distribution in brain expressed as [18F]- organ uptake in % of injected activity/gram,A,,Cavia porcellus,,22224
4501,5689,0,,,,Autocuration,,,,10141.0,Distribution in heart expressed as [18F]- organ uptake in % of injected activity/gram,A,,Cavia porcellus,,22224
4502,5689,0,,,,Autocuration,160.0,,Intestine,10141.0,Distribution in intestine expressed as [18F]- organ uptake in % of injected activity/gram,A,,Cavia porcellus,,22224
4503,5689,0,,,,Autocuration,2113.0,,Kidney,10141.0,Distribution in kidney expressed as [18F]- organ uptake in % of injected activity/gram,A,,Cavia porcellus,,22224
4504,5689,0,,,,Autocuration,2107.0,,Liver,10141.0,Distribution in liver expressed as [18F]- organ uptake in % of injected activity/gram,A,,Cavia porcellus,,22224
4505,5689,0,,,,Autocuration,,,,10141.0,Distribution in lung expressed as [18F]- organ uptake in % of injected activity/gram,A,,Cavia porcellus,,22224
4506,5689,0,,,,Autocuration,2106.0,,Spleen,10141.0,Distribution in spleen expressed as [18F]- organ uptake in % of injected activity/gram,A,,Cavia porcellus,,22224
4507,14465,0,,,,Autocuration,,,,10141.0,Elimination T1/2 in Guinea pig (PO dose),A,In vivo,Cavia porcellus,,22224
4508,5689,0,,,,Autocuration,,,,10141.0,Partition coefficient was measured as -log (counts per min ),A,,Cavia porcellus,,22224
4509,611,0,,,,Autocuration,,,,10141.0,Biological half life when administered at 0.1 umol/kg intravenously to guinea pig in GR-64349 antagonism,A,In vivo,Cavia porcellus,,22224
4510,611,0,,,,Autocuration,,,,10141.0,Biological half life when administered at 5 umol/kg intravenously to guinea pig in GR-64349 antagonism,A,In vivo,Cavia porcellus,,22224
4511,14465,0,,,,Autocuration,,,,10141.0,Elimination T1/2 in Guinea pig (PO dose),A,In vivo,Cavia porcellus,,22224
4512,4876,0,,,,Autocuration,,,,10141.0,"Tested for the half life period of the compound, intravenously",A,In vivo,Cavia porcellus,,22224
4513,5689,0,,,,Autocuration,,,,10141.0,Half-life was measured,A,,Cavia porcellus,,22224
4514,7515,0,,,,Autocuration,,,,10141.0,The time required for onset of inotropy after addition of a single dose of delta F75,A,,Cavia porcellus,,22224
4515,17667,0,,,,Autocuration,,,,10141.0,Bioavailability of compound at 10 mg/kg in guinea pig after i.v. administration,A,In vivo,Cavia porcellus,,22224
4516,17667,0,,,,Autocuration,,,,10141.0,Bioavailability of compound at 3 mg/kg in guinea pig after i.v. administration,A,In vivo,Cavia porcellus,,22224
4517,4727,0,,,,Autocuration,,,,10029.0,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,A,In vivo,Cricetulus griseus,,22224
4518,10107,1,,,,Intermediate,,,,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,Mus musculus,,50594
4519,10107,1,,,,Intermediate,,,,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,In vivo,Mus musculus,,50594
4520,10107,1,,,,Intermediate,,,,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,Mus musculus,,50594
4521,10107,1,,,,Intermediate,,,,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,Mus musculus,,50594
4522,10107,1,,,,Intermediate,,,,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hr,A,In vivo,Mus musculus,,50594
4523,10107,1,,,,Intermediate,,,,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,Mus musculus,,50594
4524,10107,1,,,,Intermediate,,,,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,Mus musculus,,50594
4525,3655,1,,,,Intermediate,178.0,,Blood,10090.0,Biodistribution of the injected compound in blood of female BALB/C mice for 0.5 hours,A,In vivo,Mus musculus,,50594
4526,3655,1,,,,Intermediate,178.0,,Blood,10090.0,Biodistribution of the injected compound in blood of female BALB/C mice for 2.5 hours,A,In vivo,Mus musculus,,50594
4527,3655,1,,,,Intermediate,178.0,,Blood,10090.0,Biodistribution of the injected compound in blood of female BALB/C mice for 5 hours,A,In vivo,Mus musculus,,50594
4528,3655,1,,,,Intermediate,10000001.0,,Bone,10090.0,Biodistribution of the injected compound in bone of female BALB/C mice for 0.5 hours,A,In vivo,Mus musculus,,50594
4529,3655,1,,,,Intermediate,10000001.0,,Bone,10090.0,Biodistribution of the injected compound in bone of female BALB/C mice for 2.5 hours,A,In vivo,Mus musculus,,50594
4530,3655,1,,,,Intermediate,10000001.0,,Bone,10090.0,Biodistribution of the injected compound in bone of female BALB/C mice for 5 hours,A,In vivo,Mus musculus,,50594
4531,3655,1,,,,Intermediate,955.0,,Brain,10090.0,Biodistribution of the injected compound in brain of female BALB/C mice for 0.5 hours,A,In vivo,Mus musculus,,50594
4532,3655,1,,,,Intermediate,955.0,,Brain,10090.0,Biodistribution of the injected compound in brain of female BALB/C mice for 2.5 hours,A,In vivo,Mus musculus,,50594
4533,3655,1,,,,Intermediate,955.0,,Brain,10090.0,Biodistribution of the injected compound in brain of female BALB/C mice for 5 hours,A,In vivo,Mus musculus,,50594
4534,3655,1,,,,Intermediate,948.0,,Heart,10090.0,Biodistribution of the injected compound in heart of female BALB/C mice for 0.5 hours,A,In vivo,Mus musculus,,50594
4535,3655,1,,,,Intermediate,948.0,,Heart,10090.0,Biodistribution of the injected compound in heart of female BALB/C mice for 2.5 hours,A,In vivo,Mus musculus,,50594
4536,3655,1,,,,Intermediate,948.0,,Heart,10090.0,Biodistribution of the injected compound in heart of female BALB/C mice for 5 hours,A,In vivo,Mus musculus,,50594
4537,3655,1,,,,Intermediate,160.0,,Intestine,10090.0,Biodistribution of the injected compound in intestines of female BALB/C mice for 0.5 hours,A,In vivo,Mus musculus,,50594
4538,3655,1,,,,Intermediate,160.0,,Intestine,10090.0,Biodistribution of the injected compound in intestines of female BALB/C mice for 2.5 hours,A,In vivo,Mus musculus,,50594
4539,3655,1,,,,Intermediate,160.0,,Intestine,10090.0,Biodistribution of the injected compound in intestines of female BALB/C mice for 5 hours,A,In vivo,Mus musculus,,50594
4540,3655,1,,,,Intermediate,2113.0,,Kidney,10090.0,Biodistribution of the injected compound in kidneys of female BALB/C mice for 0.5 hours,A,In vivo,Mus musculus,,50594
4541,3655,1,,,,Intermediate,2113.0,,Kidney,10090.0,Biodistribution of the injected compound in kidneys of female BALB/C mice for 2.5 hours,A,In vivo,Mus musculus,,50594
4542,3655,1,,,,Intermediate,2113.0,,Kidney,10090.0,Biodistribution of the injected compound in kidneys of female BALB/C mice for 5 hours,A,In vivo,Mus musculus,,50594
4543,3655,1,,,,Intermediate,2107.0,,Liver,10090.0,Biodistribution of the injected compound in liver of female BALB/C mice for 0.5 hours,A,In vivo,Mus musculus,,50594
4544,3655,1,,,,Intermediate,2107.0,,Liver,10090.0,Biodistribution of the injected compound in liver of female BALB/C mice for 2.5 hours,A,In vivo,Mus musculus,,50594
4545,3655,1,,,,Intermediate,2107.0,,Liver,10090.0,Biodistribution of the injected compound in liver of female BALB/C mice for 5 hours,A,In vivo,Mus musculus,,50594
4546,3655,1,,,,Intermediate,2048.0,,Lung,10090.0,Biodistribution of the injected compound in lung of female BALB/C mice for 0.5 hours,A,In vivo,Mus musculus,,50594
4547,3655,1,,,,Intermediate,2048.0,,Lung,10090.0,Biodistribution of the injected compound in lung of female BALB/C mice for 2.5 hours,A,In vivo,Mus musculus,,50594
4548,3655,1,,,,Intermediate,2048.0,,Lung,10090.0,Biodistribution of the injected compound in lung of female BALB/C mice for 5 hours,A,In vivo,Mus musculus,,50594
4549,3655,1,,,,Intermediate,2385.0,,Muscle tissue,10090.0,Biodistribution of the injected compound in muscle of female BALB/C mice for 0.5 hours,A,In vivo,Mus musculus,,50594
4550,3655,1,,,,Intermediate,2385.0,,Muscle tissue,10090.0,Biodistribution of the injected compound in muscle of female BALB/C mice for 2.5 hours,A,In vivo,Mus musculus,,50594
4551,3655,1,,,,Intermediate,2385.0,,Muscle tissue,10090.0,Biodistribution of the injected compound in muscle of female BALB/C mice for 5 hours,A,In vivo,Mus musculus,,50594
4552,3655,1,,,,Intermediate,2106.0,,Spleen,10090.0,Biodistribution of the injected compound in spleen of female BALB/C mice for 0.5 hours,A,In vivo,Mus musculus,,50594
4553,3655,1,,,,Intermediate,2106.0,,Spleen,10090.0,Biodistribution of the injected compound in spleen of female BALB/C mice for 2.5 hours,A,In vivo,Mus musculus,,50594
4554,3655,1,,,,Intermediate,2106.0,,Spleen,10090.0,Biodistribution of the injected compound in spleen of female BALB/C mice for 5 hours,A,In vivo,Mus musculus,,50594
4555,3655,1,,,,Intermediate,945.0,,Stomach,10090.0,Biodistribution of the injected compound in stomach of female BALB/C mice for 0.5 hours,A,In vivo,Mus musculus,,50594
4556,3655,1,,,,Intermediate,945.0,,Stomach,10090.0,Biodistribution of the injected compound in stomach of female BALB/C mice for 2.5 hours,A,In vivo,Mus musculus,,50594
4557,3655,1,,,,Intermediate,945.0,,Stomach,10090.0,Biodistribution of the injected compound in stomach of female BALB/C mice for 5 hours,A,In vivo,Mus musculus,,50594
4558,16597,1,,,,Intermediate,,,,10090.0,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,A,In vivo,Mus musculus,,50594
4559,16597,1,,,,Intermediate,,,,10090.0,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,F,In vivo,Mus musculus,,50594
4560,16597,1,,,,Intermediate,,,,10090.0,MRT value at a dose of 10 mg/kg intravenous administration in mice.,A,In vivo,Mus musculus,,50594
4561,16597,1,,,,Intermediate,,,,10090.0,MRT value at a dose of 10 mg/kg peroral administration in mice.,A,In vivo,Mus musculus,,50594
4562,17764,1,,,,Intermediate,,,,10090.0,Mean-residence time of compound after intravenous administration in mice at 24 uM/kg,A,In vivo,Mus musculus,,50594
4563,17764,1,,,,Intermediate,,,,10090.0,Mean-residence time was determined for compound after intraperitoneal administration in mice at 18 uM/kg,F,In vivo,Mus musculus,,50594
4564,3830,1,,478.0,,Intermediate,,A2780,,9606.0,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C after 96 hr,F,,Homo sapiens,,81034
4565,3829,1,,478.0,,Intermediate,,A2780,,9606.0,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C for 96 hr,F,,Homo sapiens,,81034
4566,2040,1,,478.0,,Intermediate,,A2780,,9606.0,Compound was evaluated for cytotoxicity against A2780 cell lines.,F,,Homo sapiens,,81034
4567,15684,1,,478.0,,Intermediate,,A2780,,9606.0,Potentiation of growth inhibition of A2780 by compound alone in experiment 1,F,,Homo sapiens,,81034
4568,15684,1,,478.0,,Intermediate,,A2780,,9606.0,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,F,,Homo sapiens,,81034
4569,15684,1,,478.0,,Intermediate,,A2780,,9606.0,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,F,,Homo sapiens,,81034
4570,15684,1,,478.0,,Intermediate,,A2780,,9606.0,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,F,,Homo sapiens,,81034
4571,15684,1,,478.0,,Intermediate,,A2780,,9606.0,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,F,,Homo sapiens,,81034
4572,15684,1,,478.0,,Intermediate,,A2780,,9606.0,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,F,,Homo sapiens,,81034
4573,2859,1,,478.0,,Intermediate,,A2780,,9606.0,Compound was evaluated for cytotoxicity against A2780 cell line,F,,Homo sapiens,,81034
4574,5618,1,,478.0,,Intermediate,,A2780,,9606.0,In vitro inhibitory activity against human tumor cell line A2780,F,,Homo sapiens,,81034
4575,15684,1,,478.0,,Intermediate,,A2780,,9606.0,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 1,F,,Homo sapiens,,81034
4576,15684,1,,478.0,,Intermediate,,A2780,,9606.0,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,F,,Homo sapiens,,81034
4577,15684,1,,478.0,,Intermediate,,A2780,,9606.0,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,F,,Homo sapiens,,81034
4578,15684,1,,478.0,,Intermediate,,A2780,,9606.0,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,F,,Homo sapiens,,81034
4579,2113,1,,478.0,,Intermediate,,A2780,,9606.0,The compound was tested for cytotoxic potency against A2780 human tumor cell lines,F,,Homo sapiens,,81034
4580,2113,1,,478.0,,Intermediate,,A2780,,9606.0,The compound was tested for cytotoxic potency against A2780 human tumor cell lines.,F,,Homo sapiens,,81034
4581,16745,1,,478.0,,Intermediate,,A2780,,9606.0,cytotoxicity against A2780 cells incubated for 24 hr in MTT assay.,F,,Homo sapiens,,81034
4582,16597,1,,478.0,,Expert,,A2780,,9606.0,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,F,,Homo sapiens,,81034
4583,15684,1,,478.0,,Intermediate,,A2780,,9606.0,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,F,,Homo sapiens,,81034
4584,15684,1,,478.0,,Intermediate,,A2780,,9606.0,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,F,,Homo sapiens,,81034
4585,2040,1,,478.0,,Intermediate,,A2780,,9606.0,Compound was evaluated for cytotoxicity against A2780 cis cell lines.,F,,Homo sapiens,,81034
4586,2040,1,,478.0,,Intermediate,,A2780,,9606.0,Relative resistance factor in A2780 cisplatin-resistant line,F,,Homo sapiens,,81034
4587,16165,1,,478.0,,Intermediate,,A2780,,9606.0,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells,F,,Homo sapiens,,81034
4588,16165,1,,478.0,,Intermediate,,A2780,,9606.0,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells.,F,,Homo sapiens,,81034
4589,16597,1,,478.0,,Expert,,A2780,,9606.0,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,F,,Homo sapiens,,81034
4590,16597,1,,478.0,,Expert,,A2780,,9606.0,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,F,,Homo sapiens,,81034
4591,3992,1,,478.0,,Intermediate,,A2780,,9606.0,Cytotoxicity against A2780 ovarian carcinoma cells was evaluated using standard sulforhodamine 96h assay test,F,,Homo sapiens,,81034
4592,10553,1,,478.0,,Intermediate,,A2780,,9606.0,In vitro cytotoxicity was determined against A2780 human ovarian cell line using NCI screen,F,,Homo sapiens,,81034
4593,15608,1,,478.0,,Intermediate,,A2780,,9606.0,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin,F,,Homo sapiens,,81034
4594,15608,1,,478.0,,Intermediate,,A2780,,9606.0,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 1,F,,Homo sapiens,,81034
4595,15608,1,,478.0,,Intermediate,,A2780,,9606.0,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 2,F,,Homo sapiens,,81034
4596,15608,1,,478.0,,Intermediate,,A2780,,9606.0,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 3,F,,Homo sapiens,,81034
4597,15608,1,,478.0,,Intermediate,,A2780,,9606.0,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 5,F,,Homo sapiens,,81034
4598,15608,1,,478.0,,Intermediate,,A2780,,9606.0,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 8,F,,Homo sapiens,,81034
4599,15569,1,,478.0,,Intermediate,,A2780,,9606.0,Cytotoxic activity in a panel of Human ovarian tumor A2780/CDDP cell line after 96h of drug exposure,F,,Homo sapiens,,81034
4600,17420,1,,478.0,,Intermediate,,A2780,,9606.0,Antiproliferative effect of compound on A2780/DX cell line,F,,Homo sapiens,,81034
4601,17420,1,,478.0,,Intermediate,,A2780,,9606.0,Antiproliferative effect of compound on A2780/DX cell line; n.d. indicates not determined,F,,Homo sapiens,,81034
4602,15099,1,,478.0,,Intermediate,,A2780,,9606.0,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/DX(RI),F,,Homo sapiens,,81034
4603,15099,1,,478.0,,Intermediate,,A2780,,9606.0,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/Dx(RI),F,,Homo sapiens,,81034
4604,17672,1,,478.0,,Intermediate,,A2780,,9606.0,Cytotoxicity against ovarian carcinoma A2780/cis tumor cell lines,F,,Homo sapiens,,81034
4605,17672,1,,478.0,,Intermediate,,A2780,,9606.0,Cytotoxicity against ovarian carcinoma A2780/cis90 tumor cell lines,F,,Homo sapiens,,81034
4606,17270,1,,478.0,,Intermediate,,A2780,,9606.0,In vitro cytotoxicity against A2780ADR cell line,F,,Homo sapiens,,81034
4607,17270,1,,478.0,,Intermediate,,A2780,,9606.0,In vitro cytotoxicity against A2780CIS cell line,F,,Homo sapiens,,81034
4608,5574,1,,478.0,,Intermediate,,A2780,,9606.0,In vitro cytotoxic activity against human tumor cell line A2780CisR after incubation for 96 hours,F,,Homo sapiens,,81034
4609,2113,1,,478.0,,Intermediate,,A2780,,9606.0,The compound was tested for cytotoxic potency against A2780R human tumor cell lines.,F,,Homo sapiens,,81034
4610,16913,1,,478.0,,Intermediate,,A2780,,9606.0,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-resistant A2780/R human tumor cell lines",F,,Homo sapiens,,81034
4611,16913,1,,478.0,,Intermediate,,A2780,,9606.0,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-resistant A2780/R human tumor cell lines",F,,Homo sapiens,,81034
4612,17839,0,,,,Autocuration,,,,9544.0,Oral bioavailability of compound in rhesus macaques,A,In vivo,Macaca mulatta,,22224
4613,6821,0,,,,Autocuration,,,,9443.0,Oral bioavailability in monkey,A,In vivo,monkey,,22224
4614,6078,0,,,,Autocuration,,,,9443.0,Oral bioavailability evaluated in monkey,A,In vivo,monkey,,22224
4615,6535,0,,,,Autocuration,,,,9443.0,Oral bioavailability in monkey (dose 1 mg/kg p.o.),A,In vivo,monkey,,22224
4616,4449,0,,,,Autocuration,,,,9544.0,Oral bioavailability in Rhesus monkey,A,In vivo,Macaca mulatta,,22224
4617,6057,0,,,,Autocuration,,,,9544.0,Oral bioavailability was calculated in rhesus monkey,A,In vivo,Macaca mulatta,,22224
4618,5922,0,,,,Autocuration,,,,9541.0,Oral bioavailability in cynomolgus monkey,A,In vivo,Macaca fascicularis,,22224
4619,5940,0,,,,Autocuration,,,,9443.0,Oral bioavailability in monkey,A,In vivo,monkey,,22224
4620,6265,0,,,,Autocuration,,,,9443.0,Oral bioavailability in monkey,A,In vivo,monkey,,22224
4621,6265,0,,,,Autocuration,,,,9443.0,Oral bioavailability in monkey (dose 1 mg/kg),A,In vivo,monkey,,22224
4622,6265,0,,,,Autocuration,,,,9443.0,Oral bioavailability in monkey (dose 5 mg/kg),A,In vivo,monkey,,22224
4623,5940,0,,,,Autocuration,,,,9443.0,Oral bioavailability in monkey,A,In vivo,monkey,,22224
4624,5940,0,,,,Autocuration,,,,9443.0,Oral bioavailability in monkey,A,In vivo,monkey,,22224
4625,4514,0,,,,Autocuration,,,,9544.0,Oral bioavailability in rhesus monkey,A,In vivo,Macaca mulatta,,22224
4626,5546,0,,,,Autocuration,,,,9544.0,Oral bioavailability in rhesus monkey at a dose of 2 mg/kg by po administration,A,In vivo,Macaca mulatta,,22224
4627,5553,0,,,,Autocuration,,,,9521.0,Oral bioavailability in squirrel monkey at a dose of 10 mg/kg,A,In vivo,Saimiri sciureus,,22224
4628,6641,0,,,,Autocuration,,,,9443.0,Oral bioavailability in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),A,In vivo,monkey,,22224
4629,5472,0,,,,Autocuration,,,,9544.0,Oral bioavailability in Rhesus monkey,A,In vivo,Macaca mulatta,,22224
4630,5668,0,,,,Autocuration,,,,9544.0,Oral bioavailability in Rhesus monkey (dose 10 mg/kg p.o.),A,In vivo,Macaca mulatta,,22224
4631,5711,0,,,,Autocuration,,,,9443.0,Oral bioavailability in monkey at 10 mg/kg of the compound,A,In vivo,monkey,,22224
4632,5145,0,,,,Autocuration,,,,9544.0,Bioavailability in Rhesus monkey,A,In vivo,Macaca mulatta,,22224
4633,3443,0,,,,Autocuration,,,,9527.0,Glomerular Filtration Rate(GFR) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,,Cercopithecidae,,22224
4634,3443,0,,,,Autocuration,,,,9527.0,Glomerular Filtration Rate(GFR)of the compound compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,,Cercopithecidae,,22224
4635,3249,0,,,,Autocuration,,,,9527.0,Half life by ''Cr'' assay in rhesus monkey at a dose of 5 mg/kg,A,In vivo,Cercopithecidae,,22224
4636,3249,0,,,,Autocuration,,,,9527.0,Half life the of compound was determined by ''Cr'' assay in squirrel monkey at a dose of 5 mg/kg,A,In vivo,Cercopithecidae,,22224
4637,5355,0,,,,Autocuration,,,,9527.0,Mean residence time was determined after intravenous administration in cynomolgus monkeys,A,In vivo,Cercopithecidae,,22224
4638,5355,0,,,,Autocuration,,,,9527.0,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means Not applicable,A,In vivo,Cercopithecidae,,22224
4639,5355,0,,,,Autocuration,,,,9527.0,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means not applicable,A,In vivo,Cercopithecidae,,22224
4640,4809,0,,,,Autocuration,,,,9527.0,Pharmacokinetic parameter MRT was determined in monkey after (iv) administration of a dose of 13 (uM/kg),A,In vivo,Cercopithecidae,,22224
4641,4809,0,,,,Autocuration,,,,9527.0,Pharmacokinetic parameter MRT was determined in monkey after (po) administration of a dose of 50 (uM/kg),A,In vivo,Cercopithecidae,,22224
4642,14294,0,,,,Autocuration,,,,9527.0,Metabolism of compound in monkey S9 microsomes ('+''indicates <20% largest observed peak),A,,Cercopithecidae,Microsomes,22224
4643,14294,0,,,,Autocuration,,,,9527.0,Metabolism of compound in monkey S9 microsomes ('++''indicates 20-50% largest observed peak),A,,Cercopithecidae,Microsomes,22224
4644,14294,0,,,,Autocuration,,,,9527.0,Metabolism of compound in monkey S9 microsomes ('+++'indicates 50-80% largest observed peak),A,,Cercopithecidae,Microsomes,22224
4645,14294,0,,,,Autocuration,,,,9527.0,Metabolism of compound in monkey S9 microsomes ('++++' indicates largest observed peak),A,,Cercopithecidae,Microsomes,22224
4646,3443,0,,,,Autocuration,,,,9527.0,Plasma clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,In vivo,Cercopithecidae,,22224
4647,3443,0,,,,Autocuration,,,,9527.0,Plasma clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,In vivo,Cercopithecidae,,22224
4648,11271,0,,,,Autocuration,,,,9527.0,Clearance from plasma(with matabolite-corrected plasma radioactivity-time integral) at 30 min after administration.,A,,Cercopithecidae,,22224
4649,3443,0,,,,Autocuration,,,,9527.0,Renal clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,,Cercopithecidae,,22224
4650,3443,0,,,,Autocuration,,,,9527.0,Renal clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,,Cercopithecidae,,22224
4651,6821,0,,,,Autocuration,,,,9527.0,Elimination Half-life of compound was determined in monkey,A,,Cercopithecidae,,22224
4652,17267,0,,,,Autocuration,,,,9527.0,Half life of compound was determined in rhesus monkey,A,,Cercopithecidae,,22224
4653,5819,0,,,,Autocuration,1969.0,,Plasma,9527.0,Half life in monkey plasma,A,,Cercopithecidae,,22224
4654,5819,0,,,,Autocuration,1969.0,,Plasma,9527.0,Half life in monkey plasma; Not detected,A,,Cercopithecidae,,22224
4655,1916,0,,,,Autocuration,,,,9527.0,Half life period was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,A,In vivo,Cercopithecidae,,22224
4656,17509,0,,,,Autocuration,,,,9527.0,Half-life 24 hr after 2 mg/kg iv administration in monkeys,A,In vivo,Cercopithecidae,,22224
4657,1399,0,,,,Autocuration,,,,9527.0,Terminal half life of the compound.,A,,Cercopithecidae,,22224
4658,1916,0,,,,Autocuration,,,,9527.0,Maximum time was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,A,In vivo,Cercopithecidae,,22224
4659,4809,0,,,,Autocuration,,,,9527.0,Pharmacokinetic parameter Tmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),A,In vivo,Cercopithecidae,,22224
4660,5546,0,,,,Autocuration,,,,9527.0,Unbound plasma was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,A,,Cercopithecidae,,22224
4661,3443,0,,,,Autocuration,1088.0,,Urine,9527.0,Urinary recovery evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,,Cercopithecidae,,22224
4662,3443,0,,,,Autocuration,1088.0,,Urine,9527.0,Urinary recovery compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,,Cercopithecidae,,22224
4663,4257,0,,,,Autocuration,,,,9527.0,Volume of distribution was determined in monkey after a 3 mg/kg of iv dose,A,In vivo,Cercopithecidae,,22224
4664,6221,0,,,,Autocuration,,,,9527.0,Volume distribution after oral administration (2.5 mg/kg) in monkey was determined,A,In vivo,Cercopithecidae,,22224
4665,5472,0,,,,Autocuration,,,,9527.0,Volume of distribution was evaluated in rhesus,A,In vivo,Cercopithecidae,,22224
4666,4727,0,,,,Autocuration,,,,10029.0,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,A,In vivo,Cricetulus griseus,,22224
4667,4727,0,,,,Autocuration,,,,10029.0,Plasma clearance was measured in hamster at the dose of 3 mg/kg by intravenous administration,A,In vivo,Cricetulus griseus,,22224
4668,4727,0,,,,Autocuration,,,,10029.0,Bioavailability in hamster was determined,A,In vivo,Cricetulus griseus,,22224
4669,4727,0,,,,Autocuration,,,,10029.0,Bioavailability in hamster at a dose of 3 mg/kg by intravenous administration,A,In vivo,Cricetulus griseus,,22224
4670,4727,0,,,,Autocuration,,,,10029.0,Bioavailability in hamster at a dose of 3 mg/kg by oral administration,A,In vivo,Cricetulus griseus,,22224
4671,4727,0,,,,Autocuration,178.0,,Blood,10029.0,Half life of compound was determined in hamster blood,A,,Cricetulus griseus,,22224
4672,1452,0,,,,Autocuration,,,,9823.0,Michaelis-Menten constant of the compound.,A,,Sus scrofa,,22224
4673,1452,0,,,,Autocuration,,,,9823.0,Vmax value was measured at 0 uM concentration of silyl ether.,A,,Sus scrofa,,22224
4674,1452,0,,,,Autocuration,,,,9823.0,Vmax value was measured at 10 uM concentration of silyl ether.,A,,Sus scrofa,,22224
4675,1452,0,,,,Autocuration,,,,9823.0,Vmax value was measured at 5 uM concentration of silyl ether.,A,,Sus scrofa,,22224
4676,11706,9,,,,Expert,,,,9606.0,Inactivation of human leukocyte (neutrophil) elastase(HLE)(HNE) as rate constant,B,,Homo sapiens,,235
4677,1916,0,,,,Autocuration,,,,9606.0,Area under curve was evaluated against man at a dose of 10 mg/kg after po administration,A,,Homo sapiens,,22224
4678,17791,0,,,,Autocuration,,,,9606.0,Compound was evaluated for area under the curve expressed as (h*ug/ml),A,,Homo sapiens,,22224
4679,7766,0,,,,Autocuration,,,,9606.0,Active metabolite of ifosfamide determined in humans; A-Active,A,,Homo sapiens,,22224
4680,6567,0,,,,Autocuration,,,,9606.0,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis,A,,Homo sapiens,,22224
4681,6567,0,,,,Autocuration,,,,9606.0,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; -0.5 to 1,A,,Homo sapiens,,22224
4682,6567,0,,,,Autocuration,,,,9606.0,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; 1-2,A,,Homo sapiens,,22224
4683,6567,0,,,,Autocuration,,,,9606.0,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; trace,A,,Homo sapiens,,22224
4684,17791,0,,,,Autocuration,,,,9606.0,Compound was evaluated for oral bioavailability in human,A,,Homo sapiens,,22224
4685,7766,0,,,,Autocuration,1088.0,,Urine,9606.0,Metabolite of ifosfamide determined in urine; NF-Not found,A,,Homo sapiens,,22224
4686,6852,0,,,,Autocuration,,,,9606.0,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection (Group A and B),A,,Homo sapiens,,22224
4687,6852,0,,,,Autocuration,,,,9606.0,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics,A,,Homo sapiens,,22224
4688,6852,0,,,,Autocuration,,,,9606.0,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics and lactose,A,,Homo sapiens,,22224
4689,6852,0,,,,Autocuration,,,,9606.0,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics,A,,Homo sapiens,,22224
4690,6852,0,,,,Autocuration,,,,9606.0,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics and lactose,A,,Homo sapiens,,22224
4691,6852,0,,,,Autocuration,,,,9606.0,Percent of compound in cirrhotic patients of sterile ascitic fluid (Group C),A,,Homo sapiens,,22224
4692,6852,0,,,,Autocuration,,,,9606.0,Percent of compound in healthy individuals (Group D),A,,Homo sapiens,,22224
4693,4397,0,,,,Autocuration,2107.0,,Liver,9606.0,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,A,,Homo sapiens,Microsomes,22224
4694,17409,0,,,,Autocuration,,,,9606.0,Binding towards human plasma protein at 10 uM,A,,Homo sapiens,,22224
4695,17409,0,,,,Autocuration,,,,9606.0,Binding towards human plasma protein at 100 uM,A,,Homo sapiens,,22224
4696,17176,0,,,,Autocuration,,,,9606.0,Human plasma protein binding activity was determined,A,,Homo sapiens,,22224
4697,15444,0,,,,Autocuration,,,,9606.0,The ability binding to plasma (Binding classified based on injection of compound at 80 concentration.),A,,Homo sapiens,,22224
4698,17267,0,,,,Autocuration,,,,9606.0,Percent binding of compound towards human plasma protein was determined,A,,Homo sapiens,,22224
4699,5944,0,,,,Autocuration,2107.0,,Liver,9606.0,Plasma clearance in human liver microsomes,A,In vitro,Homo sapiens,Microsomes,22224
4700,5668,0,,,,Autocuration,2107.0,,Liver,9606.0,In vitro intrinsic clearance in human liver microsome,A,In vitro,Homo sapiens,Microsomes,22224
4701,5669,0,,,,Autocuration,2107.0,,Liver,9606.0,In vitro intrinsic clearance in human liver microsome,A,In vitro,Homo sapiens,Microsomes,22224
4702,5041,0,,,,Autocuration,,,,9606.0,In vitro microsome metabolism clearance in human was determined,A,In vitro,Homo sapiens,Microsomes,22224
4703,5041,0,,,,Autocuration,,,,9606.0,In vitro microsome metabolism clearance in human was determined; High,A,In vitro,Homo sapiens,Microsomes,22224
4704,5041,0,,,,Autocuration,,,,9606.0,In vitro microsome metabolism clearance in human was determined; ND denotes no data,A,In vitro,Homo sapiens,Microsomes,22224
4705,5676,0,,,,Autocuration,2107.0,,Liver,9606.0,Pharmacokinetic property (clearance) in human liver microsome,A,In vitro,Homo sapiens,Microsomes,22224
4706,5944,0,,,,Autocuration,2107.0,,Liver,9606.0,Plasma clearance in human liver microsomes,A,In vitro,Homo sapiens,Microsomes,22224
4707,17538,0,,,,Autocuration,2107.0,,Liver,9606.0,In vitro clearance in human liver microsomes,A,In vitro,Homo sapiens,Microsomes,22224
4708,6331,0,,,,Autocuration,2107.0,,Liver,9606.0,Intrinsic clearance in human liver microsomes was determined,A,In vitro,Homo sapiens,Microsomes,22224
4709,5948,0,,,,Autocuration,2107.0,,Liver,9606.0,Intrinsic clearance in human liver microsomes was determined,A,In vitro,Homo sapiens,Microsomes,22224
4710,5965,0,,,,Autocuration,,,,9606.0,Cmax (Tissue distribution) of compound was determined at a dose of 5 mg/kg in human,A,In vivo,Homo sapiens,,22224
4711,1916,0,,,,Autocuration,,,,9606.0,Maximum concentration was evaluated against man at a dose of 10 mg/kg after po administration,A,In vivo,Homo sapiens,,22224
4712,5965,0,,,,Autocuration,,,,9606.0,Cmin (Clearance) of compound was determined at a dose of 5 mg/kg in human,A,,Homo sapiens,,22224
4713,1299,0,,,,Autocuration,,,,9606.0,Stability in human plasma 2 hr after incubation expressed as percent concentration,A,,Homo sapiens,,22224
4714,1299,0,,,,Autocuration,,,,9606.0,Stability in human plasma 4 hr after incubation expressed as percent concentration,A,,Homo sapiens,,22224
4715,7766,0,,,,Autocuration,1088.0,,Urine,9606.0,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 3 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,,Homo sapiens,,22224
4716,7766,0,,,,Autocuration,1088.0,,Urine,9606.0,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 7 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,,Homo sapiens,,22224
4717,7766,0,,,,Autocuration,1088.0,,Urine,9606.0,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 6 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,,Homo sapiens,,22224
4718,7766,0,,,,Autocuration,1088.0,,Urine,9606.0,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 8 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,,Homo sapiens,,22224
4719,17764,1,,,,Intermediate,,,,10090.0,Mean-residence time was determined for compound after intraperitoneal administration in mice at 23 uM/kg,F,In vivo,Mus musculus,,50594
4720,17764,1,,,,Intermediate,,,,10090.0,Mean-residence time was determined for compound after intraperitoneal administration in mice at 25 uM/kg,F,In vivo,Mus musculus,,50594
4721,17764,1,,,,Intermediate,,,,10090.0,Mean-residence time was determined for compound after intraperitoneal administration in mice at 26 uM/kg,F,In vivo,Mus musculus,,50594
4722,17764,1,,,,Intermediate,,,,10090.0,Mean-residence time was determined for compound intravenous administration in mice at 23 uM/kg,F,In vivo,Mus musculus,,50594
4723,14294,1,,,,Intermediate,,,,10090.0,Metabolism of compound in Mouse S9 microsomes ('++++'indicates largest observed peak),A,,Mus musculus,,50594
4724,14294,1,,,,Intermediate,,,,10090.0,Metabolism of compound in mouse S9 microsomes ('+''indicates <20% largest observed peak),A,,Mus musculus,,50594
4725,14294,1,,,,Intermediate,,,,10090.0,Metabolism of compound in mouse S9 microsomes ('++++' indicates largest observed peak),A,,Mus musculus,,50594
4726,6251,1,,,,Intermediate,2107.0,,Liver,10090.0,In vitro metabolic potential in mouse liver microsomes,A,,Mus musculus,,50594
4727,17582,1,,,,Intermediate,,,,10090.0,Ability of compound to bind to plasma protein was evaluated in HSA cells,A,,Mus musculus,,50594
4728,17811,1,,,,Intermediate,2369.0,,Adrenal gland,10090.0,Compound was tested for radioactivity level in mice adrenal glands (Compound is radiolabeled),A,,Mus musculus,,50594
4729,17811,1,,,,Intermediate,955.0,,Brain,10090.0,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.2-4.9% ID/g,A,,Mus musculus,,50594
4730,17811,1,,,,Intermediate,955.0,,Brain,10090.0,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.6-4.4% ID/g,A,,Mus musculus,,50594
4731,17811,1,,,,Intermediate,,,,10090.0,Compound was tested for radioactivity level in mice heart (Compound is radiolabeled),A,,Mus musculus,,50594
4732,17811,1,,,,Intermediate,2113.0,,Kidney,10090.0,Compound was tested for radioactivity level in mice kidney (Compound is radiolabeled),A,,Mus musculus,,50594
4733,17811,1,,,,Intermediate,,,,10090.0,Compound was tested for radioactivity level in mice lungs (Compound is radiolabeled),A,,Mus musculus,,50594
4734,5288,1,,,,Intermediate,,,,10090.0,Tested for urinary recovery in mice after subcutaneous administration of 20 mg/Kg,A,,Mus musculus,,50594
4735,2717,1,,,,Intermediate,1977.0,,Serum,10090.0,Compound was evaluated for its potency in CDF1 mice and the serum cholesterol levels were determined,A,,Mus musculus,,50594
4736,2717,1,,,,Intermediate,1977.0,,Serum,10090.0,Compound was evaluated for its potency in CDF1 mice and the serum metabolite levels were determined,A,,Mus musculus,,50594
4737,2717,1,,,,Intermediate,1977.0,,Serum,10090.0,Compound was evaluated for its potency in CDF1 mice and the serum triglyceride levels were determined,A,,Mus musculus,,50594
4738,17753,1,,,,Intermediate,1969.0,,Plasma,10090.0,Half life of compound was determined in plasma of mice at 24 mg/Kg,A,In vivo,Mus musculus,,50594
4739,17753,1,,,,Intermediate,1969.0,,Plasma,10090.0,Half life of compound was determined in plasma of mice at 40 mg/Kg,A,In vivo,Mus musculus,,50594
4740,17753,1,,,,Intermediate,1969.0,,Plasma,10090.0,Half life of compound was determined in plasma of mice at 5 mg/Kg,A,In vivo,Mus musculus,,50594
4741,17764,1,,,,Intermediate,,,,10090.0,Half life after intraperitoneal administration in mice at 18 uM/kg,F,In vivo,Mus musculus,,50594
4742,17764,1,,,,Intermediate,,,,10090.0,Half life after intraperitoneal administration in mice at 23 uM/kg,F,In vivo,Mus musculus,,50594
4743,17764,1,,,,Intermediate,,,,10090.0,Half life after intraperitoneal administration in mice at 25 uM/kg,F,In vivo,Mus musculus,,50594
4744,17764,1,,,,Intermediate,,,,10090.0,Half life after intraperitoneal administration in mice at 26 uM/kg,F,In vivo,Mus musculus,,50594
4745,17764,1,,,,Intermediate,,,,10090.0,Half life after intravenous administration in mice at 23 uM/kg,F,In vivo,Mus musculus,,50594
4746,17764,1,,,,Intermediate,,,,10090.0,Half life after intravenous administration in mice at 24 uM/kg,A,In vivo,Mus musculus,,50594
4747,16597,1,,,,Intermediate,,,,10090.0,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,A,In vivo,Mus musculus,,50594
4748,2675,1,,,,Intermediate,,,,10090.0,Maximum time required to reach Cp max was evaluated in mice after intravenous administration; T max Not determined,A,In vivo,Mus musculus,,50594
4749,2675,1,,,,Intermediate,,,,10090.0,Maximum time required to reach Cp max was evaluated in mice after oral administration,A,In vivo,Mus musculus,,50594
4750,16597,1,,,,Intermediate,,,,10090.0,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2),A,In vivo,Mus musculus,,50594
4751,4890,1,,,,Intermediate,,,,10090.0,"Compound was evaluated for the pharmacokinetic parameter, Terminal half life period",A,In vivo,Mus musculus,,50594
4752,429,1,,,,Intermediate,,,,10090.0,Evaluated for pharmacokinetic parameter half-life in mouse at the dose 20 mg/kg,A,In vivo,Mus musculus,,50594
4753,17837,1,,,,Intermediate,178.0,,Blood,10090.0,Half life of compound in mouse blood following i.v. administration of 10 mg/kg,A,In vivo,Mus musculus,,50594
4754,16597,1,,,,Intermediate,,,,10090.0,Half life at a dose of 10 mg/kg intravenous administration in mice.,A,In vivo,Mus musculus,,50594
4755,16597,1,,,,Intermediate,,,,10090.0,Half life at a dose of 10 mg/kg peroral administration in mice.,A,In vivo,Mus musculus,,50594
4756,6619,1,,,,Intermediate,,,,10090.0,Half life in ob/ob mice,A,,Mus musculus,,50594
4757,4066,1,,,,Intermediate,,,,10090.0,Half-life at a single subcutaneous administration of 40 mg/kg in mice,A,In vivo,Mus musculus,,50594
4758,4239,1,,,,Intermediate,,,,10090.0,Half-life was measured in mouse,A,,Mus musculus,,50594
4759,5969,1,,,,Intermediate,,,,10090.0,In vivo half life period was determined in murine septicemia at dose of 50 mg/kg,A,In vivo,Mus musculus,,50594
4760,8999,1,,,,Intermediate,,,,10090.0,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation,A,,Mus musculus,,50594
4761,8999,1,,,,Intermediate,,,,10090.0,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation; 10 % hydrolysis at 60 mins,A,,Mus musculus,,50594
4762,17641,1,,,,Intermediate,955.0,,Brain,10090.0,T2 in brain of mice at the oral dose of 50 mg/kg,A,,Mus musculus,,50594
4763,17641,1,,,,Intermediate,2113.0,,Kidney,10090.0,T2 in kidney of mice at the oral dose of 50 mg/kg,A,,Mus musculus,,50594
4764,17641,1,,,,Intermediate,2107.0,,Liver,10090.0,T2 in liver of mice at the oral dose of 50 mg/kg,A,,Mus musculus,,50594
4765,17641,1,,,,Intermediate,2048.0,,Lung,10090.0,T2 in lungs of mice at the oral dose of 50 mg/kg,A,,Mus musculus,,50594
4766,17641,1,,,,Intermediate,2106.0,,Spleen,10090.0,T2 in spleen of mice at the oral dose of 50 mg/kg,A,,Mus musculus,,50594
4767,16597,1,,,,Intermediate,,,,10090.0,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,A,In vivo,Mus musculus,,50594
4768,4890,1,,,,Intermediate,,,,10090.0,"Compound was evaluated for the pharmacokinetic parameter, maximum time constant",A,In vivo,Mus musculus,,50594
4769,429,1,,,,Intermediate,,,,10090.0,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg,A,In vivo,Mus musculus,,50594
4770,429,1,,,,Intermediate,,,,10090.0,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg was determined,A,In vivo,Mus musculus,,50594
4771,5969,1,,,,Intermediate,,,,10090.0,In vivo Tmax was determined in murine septicemia at dose of 100 mg/kg,A,In vivo,Mus musculus,,50594
4772,16913,1,,478.0,,Intermediate,,A2780,,9606.0,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",F,,Homo sapiens,,81034
4773,16913,1,,478.0,,Intermediate,,A2780,,9606.0,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",F,,Homo sapiens,,81034
4774,16913,1,,478.0,,Intermediate,,A2780,,9606.0,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-sensitive A2780/S human tumor cell lines",F,,Homo sapiens,,81034
4775,16913,1,,478.0,,Intermediate,,A2780,,9606.0,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-sensitive A2780/S human tumor cell lines",F,,Homo sapiens,,81034
4776,16913,1,,478.0,,Intermediate,,A2780,,9606.0,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",F,,Homo sapiens,,81034
4777,16913,1,,478.0,,Intermediate,,A2780,,9606.0,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",F,,Homo sapiens,,81034
4778,17270,1,,478.0,,Intermediate,,A2780,,9606.0,In vitro cytotoxicity against A2780TAX cell line,F,,Homo sapiens,,81034
4779,5618,1,,481.0,,Intermediate,,A2780cisR,,9606.0,In vitro inhibitory activity against human tumor cell line A2780cis,F,,Homo sapiens,,80017
4780,17777,1,,478.0,,Expert,,A2780,,9606.0,Growth inhibition against A2780 cisplatin resistant wild-type ovarian cell lines,F,,Homo sapiens,,81034
4781,16112,1,,481.0,,Intermediate,,A2780cisR,,9606.0,Antitumor activity of compound for 96-h exposure in A2780cisR (acquired resistance to cisplatin) human ovarian cell line,F,,Homo sapiens,,80017
4782,15748,1,,481.0,,Intermediate,,A2780cisR,,9606.0,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),F,,Homo sapiens,,80017
4783,6633,1,,478.0,,Intermediate,,A2780,,9606.0,Concentration required to inhibit A2780cisR cell growth when compared with control after incubation for 96 h at 37 C,F,,Homo sapiens,,81034
4784,16930,1,,478.0,,Intermediate,,A2780,,9606.0,Compound was evaluated against human Ovarian carcinoma cell line A2780cisR,F,,Homo sapiens,,81034
4785,17496,1,,478.0,,Intermediate,,A2780,,9606.0,Cytotoxicity against human ovarian carcinoma A2780cisR cell line,F,,Homo sapiens,,81034
4786,12989,1,,478.0,,Expert,,A2780,,9606.0,In vitro antitumor activity against A2780cisR cell line.,F,,Homo sapiens,,81034
4787,4840,1,,478.0,,Intermediate,,A2780,,9606.0,Tested for the cytotoxicity in A2780cisR ovarian cell line (cisR denotes resistance to cisplatin),F,,Homo sapiens,,81034
4788,12989,1,,478.0,,Expert,,A2780,,9606.0,Resistant factor determined between IC50 of resistant line to that of A2780cisR cell line,F,,Homo sapiens,,81034
4789,16745,1,,481.0,,Intermediate,,A2780cisR,,9606.0,cytotoxicity against A2780cisR cells incubated for 24 hr in MTT assay,F,,Homo sapiens,,80017
4790,16597,1,,478.0,,Expert,,A2780,,9606.0,Inhibition of A2780 / DDP-S human ovarian carcinoma cell proliferation,F,,Homo sapiens,,81034
4791,16547,9,,,,Expert,,,,10116.0,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes,B,,Rattus norvegicus,,11736
4792,16547,8,,,,Expert,,,,,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),F,,,,11736
4793,16547,9,,,,Expert,,,,10116.0,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),F,,Rattus norvegicus,,11736
4794,15856,9,,722.0,,Expert,,HEK293,,9606.0,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells uisng [3H]ZM-241385 or [125I]-IABOPX,F,,Homo sapiens,,278
4795,15856,9,,722.0,,Expert,,HEK293,,9606.0,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells using [3H]ZM-241385 (or) [125 I]IABOPX at 10e-5 M,F,,Homo sapiens,,278
4796,16547,9,,,,Expert,,,,10090.0,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes,B,,Mus musculus,,11831
4797,16547,8,,,,Expert,,,,,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),F,,,,11831
4798,16547,9,,,,Expert,,,,10090.0,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),F,,Mus musculus,,11831
4799,17402,8,,,,Expert,,,,,Ability to displace the binding of [3H]-MRE 3008-F20 to the ligand binding site of CHO:hA3 (human Adenosine receptor) at concentration of 10 uM,B,,,,280
4800,11746,0,,574.0,,Autocuration,,T-cells,,9606.0,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01),F,,Homo sapiens,,22226
4801,11746,0,,574.0,,Autocuration,,T-cells,,9606.0,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01); Not active,F,,Homo sapiens,,22226
4802,5455,1,,455.0,,Intermediate,,A-375,,9606.0,Compound was evaluated for cytotoxic activity against human melanoma cell line A375,F,,Homo sapiens,,80018
4803,2068,1,,455.0,,Intermediate,,A-375,,9606.0,In vitro antitumor activity against A375 (melanoma) human tumor cell lines.,F,,Homo sapiens,,80018
4804,2683,1,,455.0,,Intermediate,,A-375,,9606.0,In vitro antitumor activity against A375cell line extracted form melanoma,F,,Homo sapiens,,80018
4805,15313,1,,455.0,,Expert,,A-375,,9606.0,Inhibition of cell growth in (A375) melan cell line,F,,Homo sapiens,,80018
4806,13739,1,,455.0,,Intermediate,,A-375,,9606.0,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines A375,F,,Homo sapiens,,80018
4807,13739,1,,455.0,,Intermediate,,A-375,,9606.0,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines. A375,F,,Homo sapiens,,80018
4808,14750,1,,455.0,,Intermediate,,A-375,,9606.0,Compound was tested in vitro for cytotoxicity against A375 cell lines from melanoma.,F,,Homo sapiens,,80018
4809,14777,1,,797.0,,Intermediate,,A-427,,9606.0,Antiproliferative activity measured against A427 human lung carcinoma,F,,Homo sapiens,,80019
4810,14777,1,,797.0,,Intermediate,,A-427,,9606.0,Antiproliferative activity measured against A427 human lung carcinoma,F,,Homo sapiens,,80019
4811,17672,1,,797.0,,Intermediate,,A-427,,9606.0,Cytotoxicity against lung carcinoma A427 tumor cell lines,F,,Homo sapiens,,80019
4812,14368,1,,797.0,,Intermediate,,A-427,,9606.0,Inhibition of large cell lung carcinoma (A427),F,,Homo sapiens,,80019
4813,14368,1,,797.0,,Intermediate,,A-427,,9606.0,Inhibition of large cell lung carcinoma (A427) after 48-h treatment,F,,Homo sapiens,,80019
4814,13866,1,,797.0,,Intermediate,,A-427,,9606.0,Inhibitory activity against A427 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,F,,Homo sapiens,,80019
4815,2545,1,,797.0,,Intermediate,,A-427,,9606.0,Inhibitory concentration in human lung carcinoma A427 cell line,F,,Homo sapiens,,80019
4816,2545,1,,797.0,,Intermediate,,A-427,,9606.0,Inhibitory concentration in human lung carcinoma A427/VCR cell line,F,,Homo sapiens,,80019
4817,6062,0,,,,Autocuration,,,,9527.0,Terminal phase volume of distribution was measured in monkey after an iv dose of 1 mg/kg,A,In vivo,Cercopithecidae,,22224
4818,4578,0,,,,Autocuration,,,,9527.0,Tested for volume of distribution upon iv administration to african green monkey,A,In vivo,Cercopithecidae,,22224
4819,17592,0,,,,Autocuration,,,,9527.0,Volume of distribution in monkey,A,In vivo,Cercopithecidae,,22224
4820,5005,0,,,,Autocuration,,,,9544.0,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,A,In vivo,Macaca mulatta,,22224
4821,5005,0,,,,Autocuration,,,,9544.0,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.,A,In vivo,Macaca mulatta,,22224
4822,5922,0,,,,Autocuration,,,,9527.0,Pharmacokinetic property(Vdss) in cynomolgus monkey,A,In vivo,Cercopithecidae,,22224
4823,5355,0,,,,Autocuration,,,,9527.0,The distribution volume after intravenous administration in cynomolgus monkeys,A,In vivo,Cercopithecidae,,22224
4824,5355,0,,,,Autocuration,,,,9527.0,The distribution volume after oral administration in cynomolgus monkeys; NA means Not applicable,A,In vivo,Cercopithecidae,,22224
4825,5355,0,,,,Autocuration,,,,9527.0,The distribution volume after oral administration in cynomolgus monkeys; NA means not applicable,A,In vivo,Cercopithecidae,,22224
4826,6057,0,,,,Autocuration,,,,9527.0,Volume displacement was calculated in rhesus monkey,A,In vivo,Cercopithecidae,,22224
4827,5145,0,,,,Autocuration,,,,9527.0,Volume of distribution in steady state was determined in rhesus monkey,A,In vivo,Cercopithecidae,,22224
4828,6821,0,,,,Autocuration,,,,9527.0,Volume of distribution of compound was determined in monkey,A,In vivo,Cercopithecidae,,22224
4829,5334,0,,,,Autocuration,,,,9527.0,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),A,In vivo,Cercopithecidae,,22224
4830,5334,0,,,,Autocuration,,,,9527.0,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),A,In vivo,Cercopithecidae,,22224
4831,6641,0,,,,Autocuration,,,,9527.0,Volumes of distribution in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),A,In vivo,Cercopithecidae,,22224
4832,2661,0,,,,Autocuration,,,,9527.0,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female cynomolgus monkey,A,In vivo,Cercopithecidae,,22224
4833,6535,0,,,,Autocuration,,,,9527.0,Volume distribution in monkey after administration of 1 mg/kg iv,A,In vivo,Cercopithecidae,,22224
4834,4809,0,,,,Autocuration,,,,9527.0,Volume distribution was determined in monkey after (iv) administration of a dose of 13 (uM/kg),A,In vivo,Cercopithecidae,,22224
4835,6062,0,,,,Autocuration,,,,9527.0,Volume of distribution was measured in monkey after an iv dose of 1 mg/kg,A,In vivo,Cercopithecidae,,22224
4836,3443,0,,,,Autocuration,,,,9527.0,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,In vivo,Cercopithecidae,,22224
4837,4578,0,,,,Autocuration,,,,9527.0,Oral systemic bioavailability upon iv administration to african green monkey,A,In vivo,Cercopithecidae,,22224
4838,4809,0,,,,Autocuration,,,,9527.0,Plasma clearance was determined in monkey after (iv) administration of a dose of 13 (uM/kg),A,In vivo,Cercopithecidae,,22224
4839,11271,0,,,,Autocuration,,,,9527.0,Baboon plasma free fraction. ,A,,Cercopithecidae,,22224
4840,6057,0,,,,Autocuration,,,,9527.0,Area under the curve was calculated in rhesus monkey after iv administration,A,,Cercopithecidae,,22224
4841,6057,0,,,,Autocuration,,,,9527.0,Area under the curve was calculated in rhesus monkey after peroral administration,A,,Cercopithecidae,,22224
4842,17853,0,,,,Autocuration,,,,9527.0,Dose-normalized area under curve in monkey (p.o.) at 2.0 mpk,A,,Cercopithecidae,,22224
4843,5302,0,,,,Autocuration,,,,9527.0,Half life period in monkey after 5 mg/kg dose,A,In vivo,Cercopithecidae,,22224
4844,4257,0,,,,Autocuration,,,,9527.0,Half-life was determined in monkey after 3 mg/kg of i.v. dose,A,In vivo,Cercopithecidae,,22224
4845,4257,0,,,,Autocuration,,,,9527.0,Half-life was determined in monkey after 3 mg/kg of i.v. dose; Not determined,A,In vivo,Cercopithecidae,,22224
4846,13501,0,,,,Autocuration,1969.0,,Plasma,9527.0,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,A,In vivo,Cercopithecidae,,22224
4847,5394,0,,,,Autocuration,,,,9527.0,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for half life after administration into monkey at 3 mg/kg,A,In vivo,Cercopithecidae,,22224
4848,2661,0,,,,Autocuration,,,,9527.0,Compound was evaluated for half-life after treatment with iv dose of 1 mgkg to female cynomolgus monkey,A,In vivo,Cercopithecidae,,22224
4849,3341,0,,,,Autocuration,,,,9527.0,Compound was evaluated for terminal half life in monkey,A,,Cercopithecidae,,22224
4850,3045,0,,,,Autocuration,,,,9527.0,Compound was evaluated for the half life period after iv administration in cynomolgus monkey,A,In vivo,Cercopithecidae,,22224
4851,5005,0,,,,Autocuration,1969.0,,Plasma,9544.0,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,A,In vivo,Macaca mulatta,,22224
4852,4847,0,,,,Autocuration,,,,9527.0,Half life of compound was determined in squirrel monkey,A,,Cercopithecidae,,22224
4853,4256,0,,,,Autocuration,,,,9541.0,Half life after iv administration in cynomolgus monkey,A,In vivo,Macaca fascicularis,,22224
4854,6535,0,,,,Autocuration,1969.0,,Plasma,9527.0,Half life in monkey plasma after administration of 1 mg/kg iv,A,In vivo,Cercopithecidae,,22224
4855,6057,0,,,,Autocuration,,,,9527.0,Half life was calculated in rhesus monkey,A,,Cercopithecidae,,22224
4856,17592,0,,,,Autocuration,,,,9527.0,Half life in monkey,A,,Cercopithecidae,,22224
4857,6641,0,,,,Autocuration,,,,9527.0,Half life in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),A,In vivo,Cercopithecidae,,22224
4858,5472,0,,,,Autocuration,,,,9527.0,Half life was evaluated in rhesus,A,,Cercopithecidae,,22224
4859,6221,0,,,,Autocuration,,,,9527.0,Half life period after oral administration (2.5 mg/kg) in monkey was determined,A,In vivo,Cercopithecidae,,22224
4860,5668,0,,,,Autocuration,,,,9527.0,Half life period was determine after peroral administration at 10 mpk in Rhesus,A,In vivo,Cercopithecidae,,22224
4861,4809,0,,,,Autocuration,,,,9527.0,Half life period was determined in monkey after (iv) administration of a dose of 13 (uM/kg),A,In vivo,Cercopithecidae,,22224
4862,5546,0,,,,Autocuration,,,,9527.0,Half life period was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,A,In vivo,Cercopithecidae,,22224
4863,5553,0,,,,Autocuration,,,,9527.0,Half life period was determined in squirrel monkey after iv administration at a dose of 5 mg/kg,A,In vivo,Cercopithecidae,,22224
4864,6078,0,,,,Autocuration,,,,9527.0,Half-life was calculated in monkey,A,,Cercopithecidae,,22224
4865,5147,0,,,,Autocuration,,,,9527.0,Half-life in Squirrel monkey,A,,Cercopithecidae,,22224
4866,5145,0,,,,Autocuration,,,,9527.0,Half-life in rhesus monkey,A,,Cercopithecidae,,22224
4867,6062,0,,,,Autocuration,,,,9527.0,Half-life was measured in monkey after an iv dose of 1 mg/kg,A,In vivo,Cercopithecidae,,22224
4868,5355,0,,,,Autocuration,,,,9527.0,Half-life period after intravenous administration in cynomolgus monkeys,A,In vivo,Cercopithecidae,,22224
4869,5355,0,,,,Autocuration,,,,9527.0,Half-life period after oral administration in cynomolgus monkeys,A,In vivo,Cercopithecidae,,22224
4870,5355,0,,,,Autocuration,,,,9527.0,Half-life period after oral administration in cynomolgus monkeys; ND meansn Not determined,A,In vivo,Cercopithecidae,,22224
4871,7766,0,,,,Autocuration,1088.0,,Urine,9606.0,Portion of holoxan excreted in the form of the metabolite from 1500 mL of urine on day 9 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,,Homo sapiens,,22224
4872,7766,0,,,,Autocuration,1088.0,,Urine,9606.0,Portion of holoxan excreted in the form of the metabolite from 1600 mL of urine on day 10 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,,Homo sapiens,,22224
4873,7766,0,,,,Autocuration,1088.0,,Urine,9606.0,Portion of holoxan excreted in the form of the metabolite from 1700 mL of urine on day 5 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,,Homo sapiens,,22224
4874,7766,0,,,,Autocuration,1088.0,,Urine,9606.0,Portion of holoxan excreted in the form of the metabolite from 2310 mL of urine on day 4 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,,Homo sapiens,,22224
4875,7766,0,,,,Autocuration,1088.0,,Urine,9606.0,Percent ratio of the enantiomeric form (+)R extracted from the urine of alveolar rhabdomyosarcoma patients was determined,A,,Homo sapiens,,22224
4876,7766,0,,,,Autocuration,1088.0,,Urine,9606.0,Percent ratio of the enantiomeric form (+)R extracted from the urine of embryonal rhabdomyosarcoma patients was determined,A,,Homo sapiens,,22224
4877,7766,0,,,,Autocuration,1088.0,,Urine,9606.0,Percent ratio of the enantiomeric form (-)S extracted from the urine of alveolar rhabdomyosarcoma patients was determined,A,,Homo sapiens,,22224
4878,7766,0,,,,Autocuration,1088.0,,Urine,9606.0,Percent ratio of the enantiomeric form (-)S extracted from the urine of embryonal rhabdomyosarcoma patients was determined,A,,Homo sapiens,,22224
4879,1916,0,,,,Autocuration,,,,9606.0,Bioavailability was evaluated in man at a dose of 10 mg/kg after po administration; not determined,A,In vivo,Homo sapiens,,22224
4880,16643,0,,,,Autocuration,,,,9606.0,Oral bioavailability in human,A,In vivo,Homo sapiens,,22224
4881,17248,0,,,,Autocuration,,,,9606.0,Compound was tested for human plasma protein binding,A,,Homo sapiens,,22224
4882,17248,0,,,,Autocuration,,,,9606.0,Compound was tested for human plasma protein binding; Not determined,A,,Homo sapiens,,22224
4883,6241,0,,,,Autocuration,,,,9606.0,Protein binding activity of compound in human plasma; % Free,A,,Homo sapiens,,22224
4884,17716,0,,,,Autocuration,,,,9606.0,Unbound fraction (plasma),A,,Homo sapiens,,22224
4885,17605,0,,,,Autocuration,1969.0,,Plasma,9606.0,Half life for the hydrolysis of compound in human blood serum,A,,Homo sapiens,,22224
4886,17625,0,,,,Autocuration,1969.0,,Plasma,9606.0,Half life period in human plasma using phosphate buffer (0.08 M),A,,Homo sapiens,,22224
4887,17625,0,,,,Autocuration,1969.0,,Plasma,9606.0,Half life period in human plasma using phosphate buffer (0.1 M),A,,Homo sapiens,,22224
4888,17747,0,,,,Autocuration,1969.0,,Plasma,9606.0,Half-life in human plasma was determined,A,,Homo sapiens,,22224
4889,15613,0,,,,Autocuration,,,,9606.0,Concentration required for 50% toxicity in metastatic lung carcinoma (MV522) cells.,A,,Homo sapiens,,22224
4890,354,0,,,,Autocuration,,,,9606.0,Effect of compound on gelation time of human serum induced by dithiothreitol (DTT),A,,Homo sapiens,,22224
4891,3741,0,,,,Autocuration,,,,9606.0,"Rate constant in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",A,,Homo sapiens,,22224
4892,3741,0,,,,Autocuration,,,,9606.0,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",A,,Homo sapiens,,22224
4893,3741,0,,,,Autocuration,,,,9606.0,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",A,,Homo sapiens,,22224
4894,17599,0,,,,Autocuration,,,,9606.0,Partition coefficient (logP),A,,Homo sapiens,,22224
4895,5486,0,,,,Autocuration,,,,9606.0,In vitro metabolic stability in human was measured as pmol/min/mg/protein,A,,Homo sapiens,,22224
4896,5600,0,,,,Autocuration,,,,9606.0,In vitro metabolic stability determined after 30 min of incubation in human hepatic microsomes,A,,Homo sapiens,Microsomes,22224
4897,14294,0,,,,Autocuration,,,,9606.0,Metabolism of compound in human liver slices (male) ('+''indicates <20% largest observed peak),A,,Homo sapiens,,22224
4898,14294,0,,,,Autocuration,,,,9606.0,Metabolism of compound in human liver slices (male) ('++''indicates 20-50% largest observed peak),A,,Homo sapiens,,22224
4899,14294,0,,,,Autocuration,,,,9606.0,Metabolism of compound in human liver slices (male) ('++++' indicates largest observed peak),A,,Homo sapiens,,22224
4900,14294,0,,,,Autocuration,,,,9606.0,Metabolism of compound in human microsomes ('+''indicates <20% largest observed peak),A,,Homo sapiens,Microsomes,22224
4901,14294,0,,,,Autocuration,,,,9606.0,Metabolism of compound in human microsomes ('++++' indicates largest observed peak),A,,Homo sapiens,Microsomes,22224
4902,14294,0,,,,Autocuration,,,,9606.0,Metabolism of compound in human microsomes; Trace,A,,Homo sapiens,Microsomes,22224
4903,6260,0,,,,Autocuration,2107.0,,Liver,9606.0,Percent of compound remaining after 120 min of Metabolization upon incubation with human liver microsomes,A,,Homo sapiens,Microsomes,22224
4904,6187,0,,,,Autocuration,,,,9606.0,Percent metabolized in an in vitro human liver microsomal incubation assay after 60 min,A,,Homo sapiens,Microsomes,22224
4905,6251,0,,,,Autocuration,2107.0,,Liver,9606.0,In vitro metabolic potential in human liver microsomes,A,,Homo sapiens,Microsomes,22224
4906,3246,0,,,,Autocuration,,,,9606.0,Metabolism by recombinant human NAD(P)H:quinone oxidoreductase (NQO1) was evaluated,A,,Homo sapiens,,22224
4907,17313,0,,,,Autocuration,,,,9606.0,Tested for human plasma protein binding of the compound; Not tested,A,,Homo sapiens,,22224
4908,6227,0,,,,Autocuration,,,,9606.0,Compound was tested for percent protein binding (PB) in human,A,,Homo sapiens,,22224
4909,5530,0,,,,Autocuration,1969.0,,Plasma,9606.0,Protein binding in human plasma,A,,Homo sapiens,,22224
4910,6108,0,,,,Autocuration,,,,9606.0,Permeability coefficient (B to A) in Caco-2 cell,A,,Homo sapiens,,22224
4911,6108,0,,,,Autocuration,,,,9606.0,Permeability directional ratio (PB-A/PA-B) in Caco-2 cell,A,,Homo sapiens,,22224
4912,2774,0,,,,Autocuration,,,,9606.0,Apparent permeability coefficient (Papp) was determined in human Caco-2 cell monolayer (n = 3),A,,Homo sapiens,,22224
4913,16643,0,,,,Autocuration,,,,9606.0,In vitro rate of absorption observed as Caco-2 permeability in humans,A,,Homo sapiens,,22224
4914,17582,0,,495.0,,Autocuration,,Caco-2,,9606.0,Cellular permeability of compound was determined in Caco-2 cells; High,A,,Homo sapiens,,22224
4915,6838,0,,495.0,,Autocuration,,Caco-2,,9606.0,Permeability in Caco-2 cells of compound,A,,Homo sapiens,,22224
4916,6108,0,,,,Autocuration,,,,9606.0,Permeability coefficient (A to B) in Caco-2 cell,A,,Homo sapiens,,22224
4917,6108,0,,,,Autocuration,,,,9606.0,Permeability coefficient (B to A) in Caco-2 cell,A,,Homo sapiens,,22224
4918,6108,0,,,,Autocuration,,,,9606.0,Permeability coefficient (Papp) (Caco-2 cell monolayer),A,,Homo sapiens,,22224
4919,2146,0,,,,Autocuration,,,,9606.0,Compound was measured for binding rate for human serum at a carbapenem concentration of 10 ug/mL,A,,Homo sapiens,,22224
4920,4514,0,,,,Autocuration,,,,9606.0,Compound was tested for protein binding in human plasma,A,,Homo sapiens,,22224
4921,6108,0,,,,Autocuration,,,,9606.0,Transcellular permeability of the [(PA-B+PB-A)/2)] compound was determined in Caco-2 cell,A,,Homo sapiens,,22224
4922,7766,0,,,,Autocuration,1088.0,,Urine,9606.0,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 3,A,,Homo sapiens,,22224
4923,5969,1,,,,Intermediate,,,,10090.0,In vivo Tmax was determined in murine septicemia at dose of 50 mg/kg,A,In vivo,Mus musculus,,50594
4924,3277,1,,,,Intermediate,,,,10090.0,Maximum time was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),A,In vivo,Mus musculus,,50594
4925,3802,1,,,,Intermediate,,,,10090.0,Tested for Tmax value at the dose of 10 mg/kg when administered perorally in mouse,A,In vivo,Mus musculus,,50594
4926,2862,1,,,,Intermediate,1969.0,,Plasma,10090.0,Time taken to reach maximum concentration in plasma upon oral administration in mouse,A,In vivo,Mus musculus,,50594
4927,6348,1,,,,Intermediate,1969.0,,Plasma,10090.0,Time to reach maximum plasma concentration was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,A,In vivo,Mus musculus,,50594
4928,17764,1,,,,Intermediate,,,,10090.0,Tmax after intraperitoneal administration in mice at 23 uM/kg,F,In vivo,Mus musculus,,50594
4929,5781,1,,,,Intermediate,,,,10090.0,Tmax after oral administration at 30 mg/kg in ICR mouse,A,In vivo,Mus musculus,,50594
4930,17764,1,,,,Intermediate,,,,10090.0,Tmax after peroral administration in mice at 2.4 uM/kg,A,In vivo,Mus musculus,,50594
4931,4066,1,,,,Intermediate,,,,10090.0,Tmax at a single subcutaneous administration of 40 mg/kg in mice,A,In vivo,Mus musculus,,50594
4932,17641,1,,,,Intermediate,955.0,,Brain,10090.0,Tmax in brain of mice at the oral dose of 50 mg/kg,A,In vivo,Mus musculus,,50594
4933,17641,1,,,,Intermediate,2113.0,,Kidney,10090.0,Tmax in kidney of mice at the oral dose of 50 mg/kg,A,In vivo,Mus musculus,,50594
4934,17641,1,,,,Intermediate,2107.0,,Liver,10090.0,Tmax in liver of mice at the oral dose of 50 mg/kg,A,In vivo,Mus musculus,,50594
4935,17641,1,,,,Intermediate,2048.0,,Lung,10090.0,Tmax in lungs of mice at the oral dose of 50 mg/kg,A,In vivo,Mus musculus,,50594
4936,17764,1,,,,Intermediate,,,,10090.0,Tmax in mice at 18 uM/kg i.p. administration,F,In vivo,Mus musculus,,50594
4937,17764,1,,,,Intermediate,,,,10090.0,Tmax in mice at 23 uM/kg i.v. administration,F,In vivo,Mus musculus,,50594
4938,17764,1,,,,Intermediate,,,,10090.0,Tmax in mice at 25 uM/kg i.p. administration,F,In vivo,Mus musculus,,50594
4939,17764,1,,,,Intermediate,,,,10090.0,Tmax in mice at 26 uM/kg i.p. administration,F,In vivo,Mus musculus,,50594
4940,17641,1,,,,Intermediate,2106.0,,Spleen,10090.0,Tmax in spleen of mice at the oral dose of 50 mg/kg,A,In vivo,Mus musculus,,50594
4941,16597,1,,,,Intermediate,,,,10090.0,Tmax value at a dose of 10 mg/kg intravenous administration in mice.,A,In vivo,Mus musculus,,50594
4942,16597,1,,,,Intermediate,,,,10090.0,Tmax value at a dose of 10 mg/kg peroral administration in mice.,A,In vivo,Mus musculus,,50594
4943,5951,1,,,,Intermediate,,,,10090.0,Tmax value in IRC mice,A,,Mus musculus,,50594
4944,5506,1,,,,Intermediate,,,,10090.0,Tmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,A,In vivo,Mus musculus,,50594
4945,5506,1,,,,Intermediate,,,,10090.0,Tmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,A,In vivo,Mus musculus,,50594
4946,429,1,,,,Intermediate,1088.0,,Urine,10090.0,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg ( 0-24 hr ),A,,Mus musculus,,50594
4947,429,1,,,,Intermediate,1088.0,,Urine,10090.0,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg (0-24 hr),A,,Mus musculus,,50594
4948,4066,1,,,,Intermediate,1088.0,,Urine,10090.0,Urinary recovery by disk method using Streptococcus pyogenes (0-24 h),A,,Mus musculus,,50594
4949,17734,1,,,,Intermediate,,,,10090.0,The first compartment constitutes the majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,A,,Mus musculus,,50594
4950,17734,1,,,,Intermediate,,,,10090.0,The second majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,A,,Mus musculus,,50594
4951,6062,1,,,,Intermediate,,,,10090.0,Terminal phase volume of distribution was measured in mouse after an iv dose of 1 mg/kg,A,In vivo,Mus musculus,,50594
4952,5969,1,,,,Intermediate,,,,10090.0,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 100 mg/kg,A,In vivo,Mus musculus,,50594
4953,5969,1,,,,Intermediate,,,,10090.0,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg,A,In vivo,Mus musculus,,50594
4954,5969,1,,,,Intermediate,,,,10090.0,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,A,In vivo,Mus musculus,,50594
4955,5980,1,,,,Intermediate,,,,10090.0,Vd in mice,A,In vivo,Mus musculus,,50594
4956,17592,1,,,,Intermediate,,,,10090.0,Volume of distribution in mouse,A,In vivo,Mus musculus,,50594
4957,6348,1,,,,Intermediate,,,,10090.0,Volume of distribution was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,A,In vivo,Mus musculus,,50594
4958,17753,1,,,,Intermediate,,,,10090.0,Volume of distribution of compound in plasma was determined at 24 mg/Kg,A,In vivo,Mus musculus,,50594
4959,17753,1,,,,Intermediate,,,,10090.0,Volume of distribution of compound in plasma was determined at 40 mg/Kg,A,In vivo,Mus musculus,,50594
4960,17753,1,,,,Intermediate,,,,10090.0,Volume of distribution of compound in plasma was determined at 5 mg/Kg,A,In vivo,Mus musculus,,50594
4961,4239,1,,,,Intermediate,,,,10090.0,Pharmacokinetic property (vdss) was measured in mouse,A,In vivo,Mus musculus,,50594
4962,2862,1,,,,Intermediate,,,,10090.0,Value distribution upon iv administration in mouse,A,In vivo,Mus musculus,,50594
4963,17734,1,,,,Intermediate,,,,10090.0,Volume of distribution after intraperitoneal administration of 100 mg/kg in mice,A,In vivo,Mus musculus,,50594
4964,2675,1,,,,Intermediate,,,,10090.0,Volume of distribution was evaluated in mice after intravenous administration,A,In vivo,Mus musculus,,50594
4965,2675,1,,,,Intermediate,,,,10090.0,Volume of distribution was evaluated in mice after oral administration,A,In vivo,Mus musculus,,50594
4966,17837,1,,,,Intermediate,,,,10090.0,Steady state volume of distribution of compound in mouse blood following i.v. administration of 10 mg/kg,A,In vivo,Mus musculus,,50594
4967,5727,1,,,,Intermediate,,,,10090.0,Steady state volume of distribution was determined in mice,A,In vivo,Mus musculus,,50594
4968,17852,1,,,,Intermediate,,,,10090.0,Volume distribution (steady state) of compound was determined in mouse,A,In vivo,Mus musculus,,50594
4969,17764,1,,,,Intermediate,,,,10090.0,Volume of solubility in solution after intravenous administration in mice at 24 uM/kg,A,In vivo,Mus musculus,,50594
4970,16597,1,,,,Intermediate,,,,10090.0,Vss value at a dose of 10 mg/kg intravenous administration in mice.,A,In vivo,Mus musculus,,50594
4971,6062,1,,,,Intermediate,,,,10090.0,Volume of distribution was measured in mouse after an iv dose of 1 mg/kg,A,In vivo,Mus musculus,,50594
4972,16438,1,,,,Intermediate,2113.0,,Kidney,10090.0,Biodistribution of compound (oxidized form) in in kidney tissue,A,In vivo,Mus musculus,,50594
4973,16438,1,,,,Intermediate,178.0,,Blood,10090.0,Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip administration in DMSO solution,A,In vivo,Mus musculus,,50594
4974,16438,1,,,,Intermediate,178.0,,Blood,10090.0,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",A,In vivo,Mus musculus,,50594
4975,16438,1,,,,Intermediate,178.0,,Blood,10090.0,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,Mus musculus,,50594
4976,10708,1,,797.0,,Intermediate,,A-427,,9606.0,Evaluated for the inhibitory concentration required to cause growth inhibition of A427Mer- cell line of lung using the MTT Cytotoxicity Assay,F,,Homo sapiens,,80019
4977,16597,1,,500.0,,Expert,,A-431,,9606.0,Inhibition of A431 human squamous cell carcinoma cell proliferation,F,,Homo sapiens,,80852
4978,16062,1,,500.0,,Expert,,A-431,,9606.0,Inhibition of cell growth of human epidermoid carcinoma xenograft (A431) model using cell based assay,F,,Homo sapiens,,80852
4979,16062,1,,500.0,,Expert,,A-431,,9606.0,Inhibition of human epidermoid carcinoma xenograft (A431) tumor growth,F,,Homo sapiens,,80852
4980,16958,1,,500.0,,Expert,,A-431,,9606.0,Concentration required to inhibit growth of human carcinoma epidermoid (A431) cell line,F,,Homo sapiens,,80852
4981,6700,1,,500.0,,Expert,,A-431,,9606.0,Inhibition of A431 human carcinoma cell proliferation,F,,Homo sapiens,,80852
4982,17226,1,,500.0,,Expert,,A-431,,9606.0,In vitro inhibition of A431 (human carcinoma) cell basal growth.,F,,Homo sapiens,,80852
4983,6828,1,,500.0,,Intermediate,,A-431,,9606.0,Inhibitory concentration of compound against growth of human A431 cell line; Resistant,F,,Homo sapiens,,80852
4984,12314,1,,500.0,,Intermediate,,A-431,,9606.0,In vitro cytotoxicity against epidermoid carcinoma cell line,F,,Homo sapiens,,80852
4985,13412,9,,500.0,,Expert,,A-431,,9606.0,"In vivo efficacy following oral administration in nude mouse tumor model, xenograft A431 cells expressing EGF-R",F,,Homo sapiens,,9
4986,13299,1,,500.0,,Intermediate,,A-431,,9606.0,Antiproliferative activity of compound was measured on human tumor cell line A431.,F,,Homo sapiens,,80852
4987,17420,1,,500.0,,Intermediate,,A-431,,9606.0,Antiproliferative effect of compound on A431 cell line expressing mutant p53,F,,Homo sapiens,,80852
4988,13678,1,,500.0,,Intermediate,,A-431,,9606.0,Compound was evaluated for cell growth inhibition against A 431 cell line by irradiation in the presence of examined compound,F,,Homo sapiens,,80852
4989,14171,8,,500.0,,Expert,,A-431,,,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells.,F,,,,9
4990,6333,1,,500.0,,Expert,,A-431,,9606.0,Tested for antiproliferative activity against human A431 cells,F,,Homo sapiens,,80852
4991,2356,9,,500.0,,Expert,,A-431,,9606.0,Inhibition of epidermal growth factor receptor (EGF-R) autophosphorylation in A431 cells,F,,Homo sapiens,,9
4992,15578,1,,500.0,,Expert,,A-431,,9606.0,Concentration needed to inhibit 50% growth of the human A431 (epidermoid carcinoma) cell lines,F,,Homo sapiens,,80852
4993,5126,1,,500.0,,Expert,,A-431,,9606.0,Inhibition of A431 cell proliferation,F,,Homo sapiens,,80852
4994,6844,1,,500.0,,Expert,,A-431,,9606.0,Cytotoxic effect on A431 human epidermoid carcinoma cells,F,,Homo sapiens,,80852
4995,6844,1,,500.0,,Expert,,A-431,,9606.0,Cytotoxic effect on A431 human epidermoid carcinoma cells (No response to 1 mM),F,,Homo sapiens,,80852
4996,4925,1,,500.0,,Intermediate,,A-431,,9606.0,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line,F,,Homo sapiens,,80852
4997,4925,1,,500.0,,Intermediate,,A-431,,9606.0,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line; NT=Not tested,F,,Homo sapiens,,80852
4998,13978,1,,500.0,,Intermediate,,A-431,,9606.0,In vitro Growth Inhibitory activity against A431 Human vulva cancer cell line,F,,Homo sapiens,,80852
4999,16786,1,,500.0,,Intermediate,,A-431,,9606.0,In vitro cytotoxicity of compound against human A431 (epidermoid) cancer cell line after 72 hr of drug exposure,F,,Homo sapiens,,80852
5000,13412,8,,500.0,,Expert,,A-431,,,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells expressing EGF-R,F,,,,9
5001,17824,1,,500.0,,Intermediate,,A-431,,9606.0,In vivo antiproliferative activity against A431 cell line,F,,Homo sapiens,,80852
5002,12751,9,,500.0,,Expert,,A-431,,9606.0,Inhibition of EGF-dependent autophosphorylation of EGF-R in human A431 cells,F,,Homo sapiens,,9
5003,12380,1,,500.0,,Expert,,A-431,,9606.0,Inhibition of A431 human epidermoid carcinoma cell proliferation,F,,Homo sapiens,,80852
5004,4959,9,,500.0,,Expert,,A-431,,9606.0,Inhibition of autophosphorylation of human epidermal growth factor-receptor (EGF-R) expressed in A431 cells,F,,Homo sapiens,,9
5005,6333,1,,500.0,,Intermediate,,A-431,,9606.0,Inhibitory effect on nonphospho-Src after EGF (100 uM) stimulation of A431 cells (control=178),F,,Homo sapiens,,80852
5006,6333,1,,500.0,,Intermediate,,A-431,,9606.0,Inhibitory effect on phospho-Src (Tyr416) after EGF (100 uM) stimulation of A431 cells (38),F,,Homo sapiens,,80852
5007,6333,1,,500.0,,Intermediate,,A-431,,9606.0,Inhibitory effect on phospho-Src/nonphospho after EGF (100 uM) stimulation of A431 cells (21),F,,Homo sapiens,,80852
5008,5296,9,,,,Expert,,,,9606.0,Inhibition of EGFR overexpressing A431 cell proliferation,F,,Homo sapiens,,9
5009,12624,1,,500.0,,Expert,,A-431,,9606.0,Inhibition of A431 cell proliferation,F,,Homo sapiens,,80852
5010,14926,9,,500.0,,Expert,,A-431,,9606.0,No inhibition of EGFR phosphorylation in A431 cells 8 hour after washing cells free of the inhibitor,F,,Homo sapiens,,9
5011,14926,9,,500.0,,Expert,,A-431,,9606.0,"Partial inhibition of EGFR phosphorylation in A431 cells, 8 hour after washing cells free of the inhibitor",F,,Homo sapiens,,9
5012,14926,8,,500.0,,Expert,,A-431,,,Irreversible inhibition of ATP binding site of EGFR (lack of phosphorylated EGFR) in A431 cells 8 hour after washing cells free of the inhibitor),F,,,,9
5013,15144,1,,500.0,,Intermediate,,A-431,,9606.0,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,F,,Homo sapiens,,80852
5014,15144,1,,500.0,,Intermediate,,A-431,,9606.0,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,F,,Homo sapiens,,80852
5015,5245,1,,500.0,,Intermediate,,A-431,,9606.0,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration at 2 uM after 48 h; Did not affect the viability,F,,Homo sapiens,,80852
5016,5245,1,,500.0,,Intermediate,,A-431,,9606.0,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration in the range of 1-10 uM after 48 h; Did not affect the viability,F,,Homo sapiens,,80852
5017,5245,1,,500.0,,Intermediate,,A-431,,9606.0,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,F,,Homo sapiens,,80852
5018,5245,1,,500.0,,Intermediate,,A-431,,9606.0,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 0.01 uM after 48 h; Cell death,F,,Homo sapiens,,80852
5019,5245,1,,500.0,,Intermediate,,A-431,,9606.0,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 2 uM after 48 h; Cell death,F,,Homo sapiens,,80852
5020,5922,0,,,,Autocuration,,,,9527.0,Half-life period in cynomolgus monkey,A,,Cercopithecidae,,22224
5021,1116,0,,,,Autocuration,1969.0,,Plasma,9527.0,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in monkey plasma",A,In vitro,Cercopithecidae,,22224
5022,17853,0,,,,Autocuration,,,,9527.0,Longer half-life in monkey (i.v.) at 0.5 mpk,A,In vivo,Cercopithecidae,,22224
5023,993,0,,,,Autocuration,1969.0,,Plasma,9527.0,Plasma half life in monkey,A,,Cercopithecidae,,22224
5024,4514,0,,,,Autocuration,1969.0,,Plasma,9527.0,Plasma half-life in rhesus monkey,A,,Cercopithecidae,,22224
5025,5334,0,,,,Autocuration,1969.0,,Plasma,9527.0,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),A,In vivo,Cercopithecidae,,22224
5026,5334,0,,,,Autocuration,1969.0,,Plasma,9527.0,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),A,In vivo,Cercopithecidae,,22224
5027,4578,0,,,,Autocuration,,,,9527.0,Tested for half life upon iv administration to african green monkey,A,In vivo,Cercopithecidae,,22224
5028,2661,0,,,,Autocuration,,,,9527.0,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female cynomolgus monkey,A,In vivo,Cercopithecidae,,22224
5029,5355,0,,,,Autocuration,,,,9527.0,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means Not applicable,A,In vivo,Cercopithecidae,,22224
5030,5355,0,,,,Autocuration,,,,9527.0,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means not applicable,A,In vivo,Cercopithecidae,,22224
5031,5355,0,,,,Autocuration,,,,9527.0,The time for peak concentration value after oral administration in cynomolgus monkeys,A,In vivo,Cercopithecidae,,22224
5032,11271,0,,,,Autocuration,,,,9527.0,Percentage of tracer or metabolite (CO2) in baboon plasma at 10 min after injection of the compound,A,,Cercopithecidae,,22224
5033,11271,0,,,,Autocuration,,,,9527.0,Percentage of tracer or metabolite (CO2) in baboon plasma at 1 min after injection of the compound,A,,Cercopithecidae,,22224
5034,11271,0,,,,Autocuration,,,,9527.0,Percentage of tracer or metabolite (CO2) in baboon plasma at 30 min after injection of the compound,A,,Cercopithecidae,,22224
5035,11271,0,,,,Autocuration,,,,9527.0,Percentage of tracer or metabolite (CO2) in baboon plasma at 5 min after injection of the compound,A,,Cercopithecidae,,22224
5036,11271,0,,,,Autocuration,,,,9527.0,Percentage of tracer or metabolite(EME) in baboon plasma at 10 min after injection of the compound,A,,Cercopithecidae,,22224
5037,11271,0,,,,Autocuration,,,,9527.0,Percentage of tracer or metabolite(EME) in baboon plasma at 1 min after injection of the compound,A,,Cercopithecidae,,22224
5038,11271,0,,,,Autocuration,,,,9527.0,Percentage of tracer or metabolite(EME) in baboon plasma at 30 min after injection of the compound,A,,Cercopithecidae,,22224
5039,11271,0,,,,Autocuration,,,,9527.0,Percentage of tracer or metabolite(EME) in baboon plasma at 5 min after injection of the compound,A,,Cercopithecidae,,22224
5040,11271,0,,,,Autocuration,,,,9527.0,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 10 min after injection of the compound,A,,Cercopithecidae,,22224
5041,11271,0,,,,Autocuration,,,,9527.0,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 1 min after injection of the compound,A,,Cercopithecidae,,22224
5042,11271,0,,,,Autocuration,,,,9527.0,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 30 min after injection of the compound,A,,Cercopithecidae,,22224
5043,11271,0,,,,Autocuration,,,,9527.0,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 5 min after injection of the compound,A,,Cercopithecidae,,22224
5044,11271,0,,,,Autocuration,,,,9527.0,Percentage of tracer or metabolite (unchanged) in baboon plasma at 10 min after injection of the compound,A,,Cercopithecidae,,22224
5045,11271,0,,,,Autocuration,,,,9527.0,Percentage of tracer or metabolite (unchanged) in baboon plasma at 1 min after injection of the compound,A,,Cercopithecidae,,22224
5046,11271,0,,,,Autocuration,,,,9527.0,Percentage of tracer or metabolite (unchanged) in baboon plasma at 30 min after injection of the compound,A,,Cercopithecidae,,22224
5047,11271,0,,,,Autocuration,,,,9527.0,Percentage of tracer or metabolite (unchanged) in baboon plasma at 5 min after injection of the compound,A,,Cercopithecidae,,22224
5048,5809,1,,,,Intermediate,,,,10116.0,Bioavailability in rat (cannulated) (dose 2 mg/kg),A,In vivo,Rattus norvegicus,,50597
5049,17720,1,,,,Intermediate,1969.0,,Plasma,10116.0,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration,A,In vivo,Rattus norvegicus,,50597
5050,3546,1,,,,Intermediate,1969.0,,Plasma,10116.0,AUC value in rat after IV administration at a dose of 10 mg/kg,A,,Rattus norvegicus,,50597
5051,3546,1,,,,Intermediate,1969.0,,Plasma,10116.0,AUC value in rat after oral administration at a dose of 10 mg/kg,A,,Rattus norvegicus,,50597
5052,3546,1,,,,Intermediate,,,,10116.0,Cmax value in rat after oral administration at a dose of 10 mg/kg,A,In vivo,Rattus norvegicus,,50597
5053,3546,1,,,,Intermediate,,,,10116.0,Bioavailability in rat after oral administration at a dose of 10 mg/kg,A,In vivo,Rattus norvegicus,,50597
5054,3546,1,,,,Intermediate,,,,10116.0,Tmax value in rat after oral administration at a dose of 10 mg/kg,A,In vivo,Rattus norvegicus,,50597
5055,3546,1,,,,Intermediate,,,,10116.0,Vc value in rat after IV administration at a dose of 10 mg/kg,A,,Rattus norvegicus,,50597
5056,3546,1,,,,Intermediate,,,,10116.0,Half life period in rat after IV administration at a dose of 10 mg/kg,A,In vivo,Rattus norvegicus,,50597
5057,10625,0,,,,Autocuration,,,,9557.0,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,A,,Papio hamadryas,,22224
5058,10625,0,,,,Autocuration,,,,9557.0,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 0.5 min after injection in baboon; (Range = 0.08-0.11),A,,Papio hamadryas,,22224
5059,10625,0,,,,Autocuration,,,,9557.0,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 1.5 min after injection in baboon; (Range = 0.08-0.11),A,,Papio hamadryas,,22224
5060,10625,0,,,,Autocuration,,,,9557.0,The amount of unchanged tracer in baboon plasma was determined 1 min after injection of the carbon-11 labeled compound,A,,Papio hamadryas,,22224
5061,10625,0,,,,Autocuration,,,,9557.0,The amount of unchanged tracer in baboon plasma was determined 10 min after injection of the carbon-11 labeled compound,A,,Papio hamadryas,,22224
5062,10625,0,,,,Autocuration,,,,9557.0,The amount of unchanged tracer in baboon plasma was determined 30 min after injection of the carbon-11 labeled compound,A,,Papio hamadryas,,22224
5063,10625,0,,,,Autocuration,,,,9557.0,The amount of unchanged tracer in baboon plasma was determined 60 min after injection of the carbon-11 labeled compound,A,,Papio hamadryas,,22224
5064,10625,0,,,,Autocuration,,,,9557.0,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,A,,Papio hamadryas,,22224
5065,3510,0,,,,Autocuration,,,,9615.0,Area under curve after 1 mpk peroral administration to beagles,A,,beagle,,22224
5066,3510,0,,,,Autocuration,,,,9615.0,Area under curve after 2 mpk peroral administration to beagles,A,,beagle,,22224
5067,3510,0,,,,Autocuration,,,,9615.0,Cmax value after 1 mpk peroral administration to beagles,A,In vivo,beagle,,22224
5068,7766,0,,,,Autocuration,1088.0,,Urine,9606.0,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 7,A,,Homo sapiens,,22224
5069,7766,0,,,,Autocuration,1088.0,,Urine,9606.0,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 6,A,,Homo sapiens,,22224
5070,7766,0,,,,Autocuration,1088.0,,Urine,9606.0,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 8,A,,Homo sapiens,,22224
5071,7766,0,,,,Autocuration,1088.0,,Urine,9606.0,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1500 mL of urine tested on day 9,A,,Homo sapiens,,22224
5072,7766,0,,,,Autocuration,1088.0,,Urine,9606.0,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1600 mL of urine tested on day 10,A,,Homo sapiens,,22224
5073,7766,0,,,,Autocuration,1088.0,,Urine,9606.0,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1700 mL of urine tested on day 5,A,,Homo sapiens,,22224
5074,7766,0,,,,Autocuration,1088.0,,Urine,9606.0,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 2310 mL of urine tested on day 4,A,,Homo sapiens,,22224
5075,16643,0,,,,Autocuration,2107.0,,Liver,9606.0,Metabolic stability observed at 30 min after administration in human liver microsomes,A,,Homo sapiens,Microsomes,22224
5076,6852,0,,,,Autocuration,,,,9606.0,Percent recovery of 100 ug/mL compound after administration in cirrhotic patients,A,,Homo sapiens,,22224
5077,6852,0,,,,Autocuration,,,,9606.0,Percent recovery of 10 ug/mL compound after administration in cirrhotic patients,A,,Homo sapiens,,22224
5078,6852,0,,,,Autocuration,,,,9606.0,Percent recovery of 500 ug/mL compound after administration in cirrhotic patients,A,,Homo sapiens,,22224
5079,6567,0,,,,Autocuration,2107.0,,Liver,9606.0,"Compound remaining after incubation with 2 mg/mL of human liver microsomes at 37 degrees C for 30 min in a pH 7.4, 0.05 M phosphate buffer",A,,Homo sapiens,Microsomes,22224
5080,6570,0,,,,Autocuration,,,,9606.0,Metabolic stability (% remaining at 30 mins) in human S9.,A,,Homo sapiens,,22224
5081,6570,0,,,,Autocuration,,,,9606.0,Metabolic stability determined as remaining percent after 30 min of incubation in human isolated liver S9 preparations; N/D= Not determined,A,,Homo sapiens,,22224
5082,5237,0,,,,Autocuration,2107.0,,Liver,9606.0,Percent parent compound remaining after 20 min incubation with human liver microsomes,A,,Homo sapiens,Microsomes,22224
5083,5237,0,,,,Autocuration,2107.0,,Liver,9606.0,Percent parent compound remaining after 20 min incubation with human liver microsomes; ND=No data,A,,Homo sapiens,Microsomes,22224
5084,5237,0,,,,Autocuration,2107.0,,Liver,9606.0,Percent parent compound remaining after 20 min incubation with human liver microsomes; No data,A,,Homo sapiens,Microsomes,22224
5085,5202,0,,,,Autocuration,,,,9606.0,First pass metabolism and metabolic bioavailability using human hepatic microsomes,A,,Homo sapiens,,22224
5086,5481,0,,,,Autocuration,,,,9606.0,Percent compound remaining in human plasma after incubation for 60 min at 37 C.,A,,Homo sapiens,,22224
5087,5481,0,,,,Autocuration,,,,9606.0,Percent remaining in human plasma after incubation for 60 min at 37 C.,A,,Homo sapiens,,22224
5088,3956,0,,,,Autocuration,,,,9606.0,The percent remaining in human plasma after 30 min was determined,A,,Homo sapiens,,22224
5089,5074,0,,,,Autocuration,1969.0,,Plasma,9606.0,Conversion rate of the prodrug in human plasma,A,,Homo sapiens,,22224
5090,5074,0,,,,Autocuration,1969.0,,Plasma,9606.0,Conversion rate of the prodrug in human plasma; ND means no data,A,,Homo sapiens,,22224
5091,4727,0,,,,Autocuration,178.0,,Blood,9606.0,Half life of compound was determined in human blood,A,,Homo sapiens,,22224
5092,5965,0,,,,Autocuration,,,,9606.0,Half life of compound was determined in man with once daily dosing,A,,Homo sapiens,,22224
5093,5732,0,,,,Autocuration,,,,9606.0,Half life in human microsomes,A,In vitro,Homo sapiens,Microsomes,22224
5094,5819,0,,,,Autocuration,1969.0,,Plasma,9606.0,Half life in human plasma,A,,Homo sapiens,,22224
5095,5819,0,,,,Autocuration,1969.0,,Plasma,9606.0,Half life in human plasma; Not detected,A,,Homo sapiens,,22224
5096,1916,0,,,,Autocuration,,,,9606.0,Half life period was evaluated against man at a dose of 10 mg/kg after po administration,A,In vivo,Homo sapiens,,22224
5097,6597,0,,,,Autocuration,2107.0,,Liver,9606.0,Half-life for oxidative metabolic stability was determined using rat liver microsomes,A,In vitro,Homo sapiens,Microsomes,22224
5098,5229,0,,,,Autocuration,1969.0,,Plasma,9606.0,Half-life in human plasma,A,,Homo sapiens,,22224
5099,5229,0,,,,Autocuration,1969.0,,Plasma,9606.0,Half-life of the parent prodrug in plasma,A,,Homo sapiens,,22224
5100,2192,0,,,,Autocuration,1969.0,,Plasma,9606.0,In vitro half life in human plasma was determined,A,In vitro,Homo sapiens,,22224
5101,3032,0,,,,Autocuration,2107.0,,Liver,9606.0,The compound was tested In Vitro for half life in human liver microsomes.,A,In vitro,Homo sapiens,Microsomes,22224
5102,1916,0,,,,Autocuration,,,,9606.0,Maximum time was evaluated against man at a dose of 10 mg/kg after po administration,A,In vivo,Homo sapiens,,22224
5103,17716,0,,,,Autocuration,,,,9606.0,Observed volume of distribution,A,In vivo,Homo sapiens,,22224
5104,15778,0,,,,Autocuration,,,,9606.0,Oral bioavailability in human,A,In vivo,Homo sapiens,,22224
5105,17313,0,,,,Autocuration,,,,9606.0,Tested for human plasma protein binding of the compound,A,,Homo sapiens,,22224
5106,4231,0,,,,Autocuration,,,,9606.0,"First order rate constant, k was determined in human plasma",A,,Homo sapiens,,22224
5107,4755,0,,,,Autocuration,,,,9606.0,Observed rate constant in 80% human plasma at 37 degree Centigrade,A,,Homo sapiens,,22224
5108,4755,0,,,,Autocuration,,,,9606.0,Observed rate constant in 80% human plasma at 37 degree Centigrade,A,,Homo sapiens,,22224
5109,16907,0,,,,Autocuration,2107.0,,Liver,9606.0,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,A,,Homo sapiens,Microsomes,22224
5110,10839,0,,,,Autocuration,,,,9606.0,The compound was tested for the plasma binding in human,A,,Homo sapiens,,22224
5111,10839,0,,,,Autocuration,,,,9606.0,Plasma protein binding (human),A,,Homo sapiens,,22224
5112,3199,0,,,,Autocuration,2107.0,,Liver,9606.0,Compound was evaluated for half-life in human liver microsomes,A,In vitro,Homo sapiens,Microsomes,22224
5113,1345,0,,,,Autocuration,178.0,,Blood,9606.0,Half life measured in vitro for its stability in human blood,A,In vitro,Homo sapiens,,22224
5114,4297,0,,,,Autocuration,1977.0,,Serum,9606.0,Half life in human serum,A,,Homo sapiens,,22224
5115,4297,0,,,,Autocuration,1977.0,,Serum,9606.0,Half life in human serum; ND=not determined,A,,Homo sapiens,,22224
5116,4297,0,,,,Autocuration,,,,9606.0,Half life were determined in CEM-SS cell extract in decomposition step 1,A,,Homo sapiens,,22224
5117,4297,0,,,,Autocuration,,,,9606.0,Half life were determined in CEM-SS cell extract in decomposition step 2,A,,Homo sapiens,,22224
5118,4231,0,,,,Autocuration,1969.0,,Plasma,9606.0,Half life of the in human plasma,A,,Homo sapiens,,22224
5119,5633,0,,,,Autocuration,,,,9606.0,Half life period in human hepatic S9 fraction was determined,A,In vitro,Homo sapiens,S9,22224
5120,5633,0,,,,Autocuration,2107.0,,Liver,9606.0,Half life period in human liver microsome was determined,A,In vitro,Homo sapiens,Microsomes,22224
5121,17791,0,,,,Autocuration,,,,9606.0,Half life period was determined; 6-7,A,,Homo sapiens,,22224
5122,17791,0,,,,Autocuration,,,,9606.0,Half life period was evaluated in human,A,,Homo sapiens,,22224
5123,3160,0,,,,Autocuration,1969.0,,Plasma,9606.0,Half life time in human plasma,A,,Homo sapiens,,22224
5124,16438,1,,,,Intermediate,955.0,,Brain,10090.0,"Biodistribution in mice as total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,Mus musculus,,50594
5125,16438,1,,,,Intermediate,948.0,,Heart,10090.0,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,In vivo,Mus musculus,,50594
5126,16438,1,,,,Intermediate,948.0,,Heart,10090.0,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,Mus musculus,,50594
5127,16438,1,,,,Intermediate,2113.0,,Kidney,10090.0,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,In vivo,Mus musculus,,50594
5128,16438,1,,,,Intermediate,2113.0,,Kidney,10090.0,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",A,In vivo,Mus musculus,,50594
5129,16438,1,,,,Intermediate,2113.0,,Kidney,10090.0,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,Mus musculus,,50594
5130,16438,1,,,,Intermediate,2107.0,,Liver,10090.0,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,In vivo,Mus musculus,,50594
5131,16438,1,,,,Intermediate,2107.0,,Liver,10090.0,Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after ip administration in DMSO solution,A,In vivo,Mus musculus,,50594
5132,16438,1,,,,Intermediate,2107.0,,Liver,10090.0,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,Mus musculus,,50594
5133,16438,1,,,,Intermediate,2106.0,,Spleen,10090.0,Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip administration in DMSO solution,A,In vivo,Mus musculus,,50594
5134,16438,1,,,,Intermediate,2106.0,,Spleen,10090.0,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",A,In vivo,Mus musculus,,50594
5135,16438,1,,,,Intermediate,2106.0,,Spleen,10090.0,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,Mus musculus,,50594
5136,16438,1,,,,Intermediate,955.0,,Brain,10090.0,"Biodistribution in mice, total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO",A,In vivo,Mus musculus,,50594
5137,16438,1,,,,Intermediate,178.0,,Blood,10090.0,Biodistribution of compound (oxidized form) in blood tissue,A,In vivo,Mus musculus,,50594
5138,16438,1,,,,Intermediate,178.0,,Blood,10090.0,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,In vivo,Mus musculus,,50594
5139,16438,1,,,,Intermediate,178.0,,Blood,10090.0,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",A,In vivo,Mus musculus,,50594
5140,16438,1,,,,Intermediate,178.0,,Blood,10090.0,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO",A,In vivo,Mus musculus,,50594
5141,16438,1,,,,Intermediate,178.0,,Blood,10090.0,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,Mus musculus,,50594
5142,16438,1,,,,Intermediate,178.0,,Blood,10090.0,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",A,In vivo,Mus musculus,,50594
5143,16438,1,,,,Intermediate,955.0,,Brain,10090.0,Biodistribution of compound (oxidized form) in brain tissue of mice,A,In vivo,Mus musculus,,50594
5144,16438,1,,,,Intermediate,955.0,,Brain,10090.0,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,In vivo,Mus musculus,,50594
5145,16438,1,,,,Intermediate,955.0,,Brain,10090.0,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO",A,In vivo,Mus musculus,,50594
5146,16438,1,,,,Intermediate,955.0,,Brain,10090.0,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,Mus musculus,,50594
5147,16438,1,,,,Intermediate,955.0,,Brain,10090.0,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",A,In vivo,Mus musculus,,50594
5148,16438,1,,,,Intermediate,955.0,,Brain,10090.0,"Biodistribution of compound (oxidized form) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO solution",A,In vivo,Mus musculus,,50594
5149,16438,1,,,,Intermediate,948.0,,Heart,10090.0,Biodistribution of compound (oxidized form) in heart tissue of mice,A,In vivo,Mus musculus,,50594
5150,16438,1,,,,Intermediate,948.0,,Heart,10090.0,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,In vivo,Mus musculus,,50594
5151,16438,1,,,,Intermediate,948.0,,Heart,10090.0,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,In vivo,Mus musculus,,50594
5152,16438,1,,,,Intermediate,948.0,,Heart,10090.0,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO",A,In vivo,Mus musculus,,50594
5153,16438,1,,,,Intermediate,948.0,,Heart,10090.0,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,Mus musculus,,50594
5154,16438,1,,,,Intermediate,948.0,,Heart,10090.0,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",A,In vivo,Mus musculus,,50594
5155,16438,1,,,,Intermediate,2113.0,,Kidney,10090.0,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,In vivo,Mus musculus,,50594
5156,16438,1,,,,Intermediate,2113.0,,Kidney,10090.0,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",A,In vivo,Mus musculus,,50594
5157,16438,1,,,,Intermediate,2113.0,,Kidney,10090.0,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO",A,In vivo,Mus musculus,,50594
5158,16438,1,,,,Intermediate,2113.0,,Kidney,10090.0,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,Mus musculus,,50594
5159,16438,1,,,,Intermediate,2113.0,,Kidney,10090.0,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",A,In vivo,Mus musculus,,50594
5160,16438,1,,,,Intermediate,2107.0,,Liver,10090.0,Biodistribution of compound (oxidized form) in liver tissue,A,In vivo,Mus musculus,,50594
5161,16438,1,,,,Intermediate,2107.0,,Liver,10090.0,"Biodistribution of compound (oxidized form) in liver tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,In vivo,Mus musculus,,50594
5162,16438,1,,,,Intermediate,2107.0,,Liver,10090.0,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO",A,In vivo,Mus musculus,,50594
5163,5245,1,,500.0,,Intermediate,,A-431,,9606.0,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration in the range of 1-10 uM of the compound after 48 h; Cell death,F,,Homo sapiens,,80852
5164,5245,1,,500.0,,Intermediate,,A-431,,9606.0,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,F,,Homo sapiens,,80852
5165,16289,1,,500.0,,Expert,,A-431,,,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 10-24 days)",F,,,,80852
5166,16289,1,,500.0,,Expert,,A-431,,,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 12-26 days)",F,,,,80852
5167,16093,9,,500.0,,Expert,,A-431,,9606.0,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,F,,Homo sapiens,,9
5168,16825,1,,500.0,,Intermediate,,A-431,,9606.0,"Concentration required to inhibit the epidermoid A431 cell growth by 50%, P53 status of cell line used was wild-type. ",F,,Homo sapiens,,80852
5169,4848,1,,500.0,,Intermediate,,A-431,,9606.0,Inhibitory activity against proliferation of human epidermoid carcinoma (A431) cells,F,,Homo sapiens,,80852
5170,14827,9,,500.0,,Expert,,A-431,,9606.0,Inhibition of EGF-dependent autophosphorylation of EGF-R in A431 cells,F,,Homo sapiens,,9
5171,14827,9,,500.0,,Expert,,A-431,,9606.0,Inhibition of autophosphorylation of epidermal growth factor receptor in A431 cells in culture,F,,Homo sapiens,,9
5172,16289,1,,500.0,,Expert,,A-431,,,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 10-24 days)",F,,,,80852
5173,16289,1,,500.0,,Expert,,A-431,,,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",F,,,,80852
5174,16289,1,,500.0,,Expert,,A-431,,,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",F,,,,80852
5175,16289,1,,500.0,,Expert,,A-431,,,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 24",F,,,,80852
5176,16289,1,,500.0,,Expert,,A-431,,,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 26",F,,,,80852
5177,16289,9,,500.0,,Expert,,A-431,,9606.0,"Irreversible inhibition of EGF-R phosphorylation in A431 cells, 8 hr after washing cells free of compound",F,,Homo sapiens,,9
5178,16289,8,,500.0,,Expert,,A-431,,,Irreversible inhibition of formation of phosphorylated EGFR in A431 cells 8 hr after washing cells free of compound,F,,,,9
5179,16289,1,,500.0,,Expert,,A-431,,,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 10-24",F,,,,80852
5180,16289,1,,500.0,,Expert,,A-431,,,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",F,,,,80852
5181,16289,1,,500.0,,Expert,,A-431,,,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",F,,,,80852
5182,14555,1,,500.0,,Expert,,A-431,,10090.0,"Ratio of treated and control A431 cell tumor mass in mice at 5 mg/kg peroral dose, days 7-21 administration",F,,Mus musculus,,80852
5183,14555,1,,500.0,,Expert,,A-431,,10090.0,"Difference in days for treated (T) and control (C) A431 cell tumors to reach 750 mg in mice at 5 mg/kg peroral dose, days 7-21 administration",F,,Mus musculus,,80852
5184,14555,1,,500.0,,Expert,,A-431,,10090.0,"Net reduction in tumor burden between first and last treatments of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",F,,Mus musculus,,80852
5185,14555,1,,500.0,,Expert,,A-431,,10090.0,"Weight change of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",F,,Mus musculus,,80852
5186,1937,1,,500.0,,Expert,,A-431,,9606.0,In vitro antiproliferative effect against A431 human epidermoid carcinoma cells,F,,Homo sapiens,,80852
5187,13739,1,,500.0,,Intermediate,,A-431,,9606.0,In vitro tumor cell growth inhibitory activity against Human leiomyosarcoma A431 cell lines,F,,Homo sapiens,,80852
5188,3558,1,,500.0,,Intermediate,,A-431,,9606.0,Cytotoxicity against A437 cells is the dose giving 50% decrease in the formation of formazan dye,F,,Homo sapiens,,80852
5189,3558,1,,500.0,,Intermediate,,A-431,,9606.0,Dose giving a 50% decrease in the living cell number (A437 cells),F,,Homo sapiens,,80852
5190,17686,1,,646.0,,Expert,,A549,,9606.0,In vitro inhibitory concentration against proliferation of A459 cell line.,F,,Homo sapiens,,80682
5191,5305,1,,646.0,,Intermediate,,A549,,9606.0,Inhibitory concentration of compound for cytotoxicity against A459 human lung cells was determined,F,,Homo sapiens,,80682
5192,3614,1,,646.0,,Intermediate,,A549,,9606.0,Inhibition of growth of human NSCL non small cell lung carcinoma cell line (A459) after 72 hr of drug exposure,F,,Homo sapiens,,80682
5193,17229,1,,624.0,,Intermediate,,A498,,9606.0,In vitro antitumor activity against renal A498 tumor cell lines,F,,Homo sapiens,,80021
5194,15935,1,,624.0,,Intermediate,,A498,,9606.0,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors",F,,Homo sapiens,,80021
5195,15935,1,,624.0,,Intermediate,,A498,,9606.0,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors in folate deficient medium",F,,Homo sapiens,,80021
5196,15560,1,,624.0,,Intermediate,,A498,,9606.0,Cytotoxicity against A498 Tumor cell line in SRB Cell viability test,F,,Homo sapiens,,80021
5197,13891,1,,624.0,,Intermediate,,A498,,9606.0,Cytotoxicity concentration against human kidney carcinoma A-498 cell line,F,,Homo sapiens,,80021
5198,13891,1,,624.0,,Intermediate,,A498,,9606.0,Cytotoxicity concentration against human kidney carcinoma A-498 cell line; NT =Not tested,F,,Homo sapiens,,80021
5199,13788,1,,624.0,,Intermediate,,A498,,9606.0,Cytotoxicity on kidney carcinoma (A-498) cell line,F,,Homo sapiens,,80021
5200,15403,1,,624.0,,Intermediate,,A498,,9606.0,Compound was evaluated against Human cell line renal A498,F,,Homo sapiens,,80021
5201,1009,1,,624.0,,Intermediate,,A498,,9606.0,Compound was tested for inhibition of A498 human renal cancer cell line,F,,Homo sapiens,,80021
5202,1043,1,,624.0,,Intermediate,,A498,,9606.0,Growth inhibitory activity against A498 human cancer cell line,F,,Homo sapiens,,80021
5203,5858,1,,624.0,,Intermediate,,A498,,9606.0,In vitro antitumor activity against human renal A498 cell line,F,,Homo sapiens,,80021
5204,5958,1,,624.0,,Intermediate,,A498,,9606.0,In vitro cytotoxic activity against renal (A498) cell line,F,,Homo sapiens,,80021
5205,5506,1,,624.0,,Intermediate,,A498,,9606.0,In vitro cytotoxic activity against human renal cancer (A498) cell line,F,,Homo sapiens,,80021
5206,12781,1,,624.0,,Intermediate,,A498,,9606.0,Tested for cytostatic activity against renal A498 cell line,F,,Homo sapiens,,80021
5207,14399,1,,624.0,,Intermediate,,A498,,9606.0,The compound was tested for the concentration to inhibit 50% of renal A498 cell lines.,F,,Homo sapiens,,80021
5208,5958,1,,624.0,,Expert,,A498,,9606.0,In vitro cytotoxic activity against renal (A498) cell line at a concentration of 10e-5 M,F,,Homo sapiens,,80021
5209,3510,0,,,,Autocuration,,,,9615.0,Cmax value after 2 mpk peroral administration to beagles,A,In vivo,beagle,,22224
5210,3510,0,beagle,,,Autocuration,,,,9615.0,Bioavailability,A,In vivo,Canis lupus familiaris,,22224
5211,3510,0,beagle,,,Autocuration,,,,9615.0,Bioavailability after 1 mpk peroral administration to beagles,A,In vivo,Canis lupus familiaris,,22224
5212,3510,0,beagle,,,Autocuration,,,,9615.0,Bioavailability after 2 mpk peroral administration to beagles,A,In vivo,Canis lupus familiaris,,22224
5213,3085,0,,,,Autocuration,,,,9913.0,Specificity constant of the BSA-catalyzed deprotonation of compound at pH 9,A,,Bos taurus,,22224
5214,3085,0,,,,Autocuration,,,,9913.0,Specificity constant of the bovine serum albumin catalyzed reaction expressed as (kcat/KM)/kuncat,A,,Bos taurus,,22224
5215,3085,0,,,,Autocuration,,,,9913.0,Michaelis-Menten kinetics of the bovine serum albumin catalyzed reaction of the compound,A,,Bos taurus,,22224
5216,9372,0,,,,Autocuration,,,,9913.0,Solubility against bovine alpha-chymotrypsin,A,,Bos taurus,,22224
5217,3085,0,,,,Autocuration,,,,9913.0,Rate constant of the bovine serum albumin catalyzed reaction of the compound,A,,Bos taurus,,22224
5218,3085,0,,,,Autocuration,,,,9913.0,Rate constant of the bovine serum albumin catalyzed reaction of the compound,A,,Bos taurus,,22224
5219,1469,0,,,,Autocuration,2106.0,,Spleen,9913.0,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards calf spleen (CS-PDE) at a concentration of 20 microg,A,,Bos taurus,,22224
5220,4297,0,,,,Autocuration,,,,9913.0,Half life in culture medium containing 10% of heat inactivated foetal calf serum,A,,Bos taurus,,22224
5221,4297,0,,,,Autocuration,,,,9913.0,Half life in culture medium containing 10% of heat inactivated foetal calf serum; ND=not determined,A,,Bos taurus,,22224
5222,17585,0,,,,Autocuration,,,,9913.0,Ability to get deaminated by adenosine deaminase (ADA); Expressed as t1/2,A,,Bos taurus,,22224
5223,1336,0,,,,Autocuration,2106.0,,Spleen,9913.0,Enzymatic stability was assessed with bovine spleen phosphodiesterase (BS PDE) exonuclase,A,,Bos taurus,,22224
5224,3085,0,,,,Autocuration,,,,9913.0,Half life in presence of 2 mg/mL BSA at pH 8.8,A,,Bos taurus,,22224
5225,2857,0,,,,Autocuration,,,,9913.0,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 1,A,,Bos taurus,,22224
5226,2857,0,,,,Autocuration,,,,9913.0,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2,A,,Bos taurus,,22224
5227,2857,0,,,,Autocuration,,,,9913.0,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2; Not determined,A,,Bos taurus,,22224
5228,1540,0,,,,Autocuration,,,,9913.0,Half-life in the culture medium (RPMI 1640+10% fetal calf serum FCS),A,,Bos taurus,,22224
5229,6316,1,,,,Intermediate,1969.0,,Plasma,9615.0,AUC (Area Under Plasma concentration-time curve) was after oral administration at 5 mg/kg,A,,Canis lupus familiaris,,50588
5230,17594,1,,,,Intermediate,1969.0,,Plasma,9615.0,AUC after administration at 100 mg/kg/day in dogs,A,,Canis lupus familiaris,,50588
5231,4953,1,,,,Intermediate,1969.0,,Plasma,9615.0,AUC in dog at 0-24 hr by peroral administration at 3 mpk,A,,Canis lupus familiaris,,50588
5232,16907,1,,,,Intermediate,1969.0,,Plasma,9615.0,AUC value after 15 mg/kg iv dose in Dogs,A,,Canis lupus familiaris,,50588
5233,16907,1,,,,Intermediate,1969.0,,Plasma,9615.0,AUC value after 30 mg/kg po dose in Dogs,A,,Canis lupus familiaris,,50588
5234,2959,1,,,,Intermediate,1969.0,,Plasma,9615.0,AUC value after administration of 4 mg/Kg oral dose in dog,A,,Canis lupus familiaris,,50588
5235,17594,1,,,,Intermediate,1969.0,,Plasma,9615.0,AUC0-infinity after single intravenous bolus of 1 mg/kg in dogs,A,,Canis lupus familiaris,,50588
5236,5356,1,,,,Intermediate,,,,9615.0,Area Under Curve for the compound was determined in dogs at 1 mg/kg oral dosing; 25-50 ug min/mL,A,,Canis lupus familiaris,,50588
5237,16807,1,,,,Intermediate,,,,9615.0,Area under curve (AUC) value in dogs after an intravenous dose of 0.2 mg/Kg in 0.025 M aqueous methanesulfonic acid solution with 5% mannitol at a concentration of 0.2,A,,Canis lupus familiaris,,50588
5238,4527,1,,,,Intermediate,,,,9615.0,Area under curve by intravenous administration at a dose of 1 uM/kg in dog was determined,A,,Canis lupus familiaris,,50588
5239,4527,1,,,,Intermediate,,,,9615.0,Area under curve by oral administration at a dose of 10 uM/kg in dog was determined,A,,Canis lupus familiaris,,50588
5240,15660,1,,,,Intermediate,,,,9615.0,Area under curve determined in dogs after intravenous administration of 3 mg/kg,A,,Canis lupus familiaris,,50588
5241,15660,1,,,,Intermediate,,,,9615.0,Area under curve determined in dogs after oral administration of 10 mg/kg,A,,Canis lupus familiaris,,50588
5242,5802,1,,,,Intermediate,,,,9615.0,Area under curve of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,A,,Canis lupus familiaris,,50588
5243,3598,1,,,,Expert,,,,9615.0,Area under curve of compound determined in dog after iv administration at a dose of 10 mg/kg,A,,Canis lupus familiaris,,50588
5244,3598,1,,,,Expert,,,,9615.0,Area under curve of compound from zero time to infinity determined in dog after iv administration at a dose of 10 mg/kg,A,,Canis lupus familiaris,,50588
5245,5944,1,,,,Intermediate,,,,9615.0,Area under curve determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),A,,Canis lupus familiaris,,50588
5246,5944,1,,,,Intermediate,,,,9615.0,Area under curve determined in dog at a dose of 10 mg/kg by oral administration,A,,Canis lupus familiaris,,50588
5247,5944,1,,,,Intermediate,,,,9615.0,Area under curve determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),A,,Canis lupus familiaris,,50588
5248,5944,1,,,,Intermediate,,,,9615.0,Area under curve determined in dog at a dose of 5 mg/kg by oral administration,A,,Canis lupus familiaris,,50588
5249,4186,1,,,,Intermediate,,,,9615.0,Area under curve in dog after administration of 20 mg/kg dose through peroral route,A,,Canis lupus familiaris,,50588
5250,5007,1,,,,Intermediate,,,,9615.0,Area under curve in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),A,,Canis lupus familiaris,,50588
5251,5668,1,,,,Intermediate,,,,9615.0,Area under curve was determine after peroral administration at 10 mpk in dog,A,,Canis lupus familiaris,,50588
5252,5668,1,,,,Intermediate,,,,9615.0,Area under curve was determine after peroral administration at 5 mpk in dog,A,,Canis lupus familiaris,,50588
5253,5006,1,,,,Intermediate,,,,9615.0,Area under curve was determined,A,,Canis lupus familiaris,,50588
5254,5006,1,,,,Intermediate,,,,9615.0,Area under curve in dogs,A,,Canis lupus familiaris,,50588
5255,3771,1,,,,Intermediate,,,,9615.0,Area under curve in dogs at 10 mg/kg dose fo oral administration,A,,Canis lupus familiaris,,50588
5256,3771,1,,,,Intermediate,,,,9615.0,Area under curve in dogs at 10 mg/kg dose fo oral administration (Evokes hyperglycerolemia),A,,Canis lupus familiaris,,50588
5257,3771,1,,,,Intermediate,,,,9615.0,Area under curve in dogs at 3 mg/kg dose fo intravenous administration,A,,Canis lupus familiaris,,50588
5258,1916,1,,,,Intermediate,,,,9615.0,Area under curve was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,A,,Canis lupus familiaris,,50588
5259,5302,1,,,,Intermediate,,,,9615.0,Area under curve value in dog at a dose of 5 mg/kg,A,,Canis lupus familiaris,,50588
5260,5600,1,,,,Intermediate,,,,9615.0,Area under curve was determined after 0.1 mg/kg iv administration in dog,A,,Canis lupus familiaris,,50588
5261,5600,1,,,,Intermediate,,,,9615.0,Area under curve was determined after 0.3 mg/kg po administration in dog,A,,Canis lupus familiaris,,50588
5262,17764,1,,,,Intermediate,,,,9615.0,Area under curve was determined for compound after intravenous administration in dogs at 1.2 uM/kg,A,,Canis lupus familiaris,,50588
5263,4368,1,,,,Intermediate,,,,9615.0,Area under curve was determined for the compound by intravenous administration of 1.2 mg/kg in dog,A,,Canis lupus familiaris,,50588
5264,5318,0,,,,Autocuration,,,,9606.0,Tested for half life period at 37 degree Celsius in PBS buffer at 10.5 pH containing human serum esterase,A,,Homo sapiens,,22224
5265,5318,0,,,,Autocuration,,,,9606.0,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,A,,Homo sapiens,,22224
5266,5318,0,,,,Autocuration,,,,9606.0,Tested for half life period at 37 degree Celsius in PBS buffer at 8.0 pH containing human serum esterase,A,,Homo sapiens,,22224
5267,5318,0,,,,Autocuration,,,,9606.0,Tested for half life period at 37 degree Celsius in PBS buffer at 8.8 pH containing human serum esterase,A,,Homo sapiens,,22224
5268,14518,0,,,,Autocuration,178.0,,Blood,9606.0,Time taken to reduce 50% of the concentration of compound in blood plasma,A,,Homo sapiens,,22224
5269,2209,0,,,,Autocuration,1969.0,,Plasma,9606.0,"Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",A,,Homo sapiens,,22224
5270,6787,0,,,,Autocuration,1969.0,,Plasma,9606.0,Half life in human plasma,A,,Homo sapiens,,22224
5271,4898,0,,,,Autocuration,1969.0,,Plasma,9606.0,Half life in human plasma was reported,A,,Homo sapiens,,22224
5272,6072,0,,,,Autocuration,1977.0,,Serum,9606.0,Half life in human serum,A,,Homo sapiens,,22224
5273,16907,0,,,,Autocuration,1969.0,,Plasma,9606.0,Half life upon exposure to human plasma,A,,Homo sapiens,,22224
5274,5656,0,,,,Autocuration,,,,9606.0,t1/2 in human microsomes,A,In vitro,Homo sapiens,Microsomes,22224
5275,4755,0,,,,Autocuration,1969.0,,Plasma,9606.0,Half life period in 80% human plasma at 37 degree Centigrade,A,,Homo sapiens,,22224
5276,17503,0,,,,Autocuration,14.0,,Zone of skin,9606.0,Half-life for rate of hydrolysis was determined in in human skin homogenate (pH 7.4),A,,Homo sapiens,,22224
5277,12357,0,,,,Autocuration,1969.0,,Plasma,9606.0,Half-life measured in in vitro Cathepsin B assay in human plasma,A,In vitro,Homo sapiens,,22224
5278,3076,0,,,,Autocuration,,,,9606.0,Half-life at initial concentration of 5*10e-5 M in CEM cell extract,A,,Homo sapiens,,22224
5279,6410,0,,,,Autocuration,2107.0,,Liver,9606.0,Half-life determined by human liver microsome stability assay at a concentration of 5 uM,A,In vitro,Homo sapiens,Microsomes,22224
5280,3741,0,,,,Autocuration,1969.0,,Plasma,9606.0,"Half-life in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",A,,Homo sapiens,,22224
5281,3741,0,,,,Autocuration,1969.0,,Plasma,9606.0,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",A,,Homo sapiens,,22224
5282,3741,0,,,,Autocuration,1969.0,,Plasma,9606.0,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",A,,Homo sapiens,,22224
5283,1540,0,,,,Autocuration,,,,9606.0,Half-life in the CEM cell extracts,A,,Homo sapiens,,22224
5284,2905,0,,,,Autocuration,1969.0,,Plasma,9606.0,Half-life was calculated by Human plasma stability assay at 37 degree Centigrade,A,,Homo sapiens,,22224
5285,2905,0,,,,Autocuration,1969.0,,Plasma,9606.0,Half-life was calculated by Human plasma stability assay at 37 degree centigrade; Not hydrolyzed,A,,Homo sapiens,,22224
5286,5523,0,,,,Autocuration,,,,9606.0,Half-life was determined,A,,Homo sapiens,,22224
5287,1499,0,,,,Autocuration,178.0,,Blood,9606.0,Half-life (human blood stability),A,,Homo sapiens,,22224
5288,1499,0,,,,Autocuration,178.0,,Blood,9606.0,Half-life (human blood stability); no data,A,,Homo sapiens,,22224
5289,17065,0,,,,Autocuration,1969.0,,Plasma,9606.0,Half-life in human plasma,A,,Homo sapiens,,22224
5290,6861,0,,,,Autocuration,,,,9606.0,CYP3A4 metabolism half-life (t1/2),A,,Homo sapiens,,22224
5291,1499,0,,,,Autocuration,178.0,,Blood,9606.0,Half-life was determined; 88% of parent remained after incubation for 120 min (human blood stability),A,,Homo sapiens,,22224
5292,530,0,,,,Autocuration,1969.0,,Plasma,9606.0,In vitro half life in human plasma,A,In vitro,Homo sapiens,,22224
5293,1116,0,,,,Autocuration,1969.0,,Plasma,9606.0,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in human plasma",A,In vitro,Homo sapiens,,22224
5294,6695,0,,,,Autocuration,1969.0,,Plasma,9606.0,In vitro hydrolysis in human plasma,A,In vitro,Homo sapiens,,22224
5295,6695,0,,,,Autocuration,1969.0,,Plasma,9606.0,In vitro hydrolysis in human plasma; no data,A,In vitro,Homo sapiens,,22224
5296,10,0,,,,Autocuration,2107.0,,Liver,9606.0,In vitro metabolic stability at 5 uM was determined by incubating with human liver microsomes at 37 degree C,A,In vitro,Homo sapiens,Microsomes,22224
5297,993,0,,,,Autocuration,1969.0,,Plasma,9606.0,Plasma half life in human,A,,Homo sapiens,,22224
5298,15429,0,,,,Autocuration,1969.0,,Plasma,9606.0,Stability after incubation with human plasma (at 37 degree C),A,,Homo sapiens,,22224
5299,1675,0,,,,Autocuration,1969.0,,Plasma,9606.0,T1/2 was evaluated in human plasma,A,,Homo sapiens,,22224
5300,2209,0,,,,Autocuration,1969.0,,Plasma,9606.0,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",A,,Homo sapiens,,22224
5301,2209,0,,,,Autocuration,1969.0,,Plasma,9606.0,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I); Not determined",A,,Homo sapiens,,22224
5302,5318,0,,,,Autocuration,,,,9606.0,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,A,,Homo sapiens,,22224
5303,2412,0,,,,Autocuration,,,,9606.0,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase,A,In vitro,Homo sapiens,,22224
5304,2412,0,,,,Autocuration,,,,9606.0,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase; ND=Not determined,A,In vitro,Homo sapiens,,22224
5305,2906,0,,,,Autocuration,1969.0,,Plasma,9606.0,The release rate of the free drug from the substrate in human plasma by human plasma stability assay,A,,Homo sapiens,,22224
5306,2906,0,,,,Autocuration,1969.0,,Plasma,9606.0,The release rate of the free drug from the substrate in human plasma by human plasma stability assay; Not hydrolyzed,A,,Homo sapiens,,22224
5307,5495,0,,,,Autocuration,,,,9606.0,Time taken for 50% to be consumed by serum PON1 was determined,A,,Homo sapiens,,22224
5308,5495,0,,,,Autocuration,,,,9606.0,Time taken for 50% to be consumed by serum PON1; NH is Not hydrolysed,A,,Homo sapiens,,22224
5309,4397,0,,,,Autocuration,2107.0,,Liver,9606.0,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,A,,Homo sapiens,Microsomes,22224
5310,2413,0,,,,Autocuration,,,,10095.0,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,,Mus sp.,,22224
5311,2413,0,,,,Autocuration,,,,10095.0,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,,Mus sp.,,22224
5312,2413,0,,,,Autocuration,,,,10095.0,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,,Mus sp.,,22224
5313,2413,0,,,,Autocuration,,,,10095.0,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,,Mus sp.,,22224
5314,2413,0,,,,Autocuration,,,,10095.0,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,,Mus sp.,,22224
5315,2413,0,,,,Autocuration,,,,10095.0,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 24 hour,A,,Mus sp.,,22224
5316,6058,1,,391.0,,Intermediate,,786-0,,9606.0,Compound tested for growth inhibition of renal cancer cell line 786-0,F,,Homo sapiens,,80640
5317,17708,1,,391.0,,Intermediate,,786-0,,9606.0,Compound was tested for 50% growth inhibition against human renal cancer 786-0 cell line,F,,Homo sapiens,,80640
5318,14017,1,,391.0,,Expert,,786-0,,9606.0,Concentration which reduced cell growth to 50 % of level against 786-0 renal cancer line,F,,Homo sapiens,,80640
5319,16818,1,,391.0,,Intermediate,,786-0,,9606.0,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-4 concentration",F,,Homo sapiens,,80640
5320,16818,1,,391.0,,Intermediate,,786-0,,9606.0,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-6 concentration",F,,Homo sapiens,,80640
5321,16818,1,,391.0,,Intermediate,,786-0,,9606.0,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-8 concentration",F,,Homo sapiens,,80640
5322,11970,1,,391.0,,Intermediate,,786-0,,9606.0,Tested for cytotoxicity against 786-0 cell lines in renal cancer,F,,Homo sapiens,,80640
5323,12400,1,,391.0,,Intermediate,,786-0,,9606.0,Tested in vitro for cytotoxicity in 786-0 cell line of Renal cancer,F,,Homo sapiens,,80640
5324,12888,1,,391.0,,Expert,,786-0,,9606.0,Cytotoxic effect on renal cancer line 786-0,F,,Homo sapiens,,80640
5325,15300,1,,391.0,,Intermediate,,786-0,,9606.0,In vitro antitumor activity against Renal cancer 786-0 cell lines by 6-day assay,F,,Homo sapiens,,80640
5326,14769,1,,391.0,,Intermediate,,786-0,,9606.0,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),F,,Homo sapiens,,80640
5327,15895,1,,391.0,,Intermediate,,786-0,,9606.0,"Cytotoxicity against NCI tumor panel, 786-0 renal cancer cell line",F,,Homo sapiens,,80640
5328,17376,1,,391.0,,Intermediate,,786-0,,9606.0,Concentration of compound that cause 50% cytotoxicity of 786-0 renal cancer cell line,F,,Homo sapiens,,80640
5329,14882,1,,391.0,,Intermediate,,786-0,,9606.0,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration that inhibits 50% net cell growth).,F,,Homo sapiens,,80640
5330,14882,1,,391.0,,Intermediate,,786-0,,9606.0,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration leading to 50% net cell death),F,,Homo sapiens,,80640
5331,15176,1,,391.0,,Intermediate,,786-0,,9606.0,Growth inhibition of the 786-O Renal cancer cell line for 2-day in vitro assay.,F,,Homo sapiens,,80640
5332,12696,1,,391.0,,Intermediate,,786-0,,9606.0,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,F,,Homo sapiens,,80640
5333,2496,1,,391.0,,Intermediate,,786-0,,9606.0,The compound was tested in vitro for cytotoxic activity against 786-O cell line (human perirenal carcinoma),F,,Homo sapiens,,80640
5334,11831,1,,972.0,,Intermediate,,791T cell line,,9606.0,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression,F,,Homo sapiens,,80641
5335,11831,1,,972.0,,Intermediate,,791T cell line,,9606.0,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression (49% inhibition achieved at 100 micro g/mL),F,,Homo sapiens,,80641
5336,11831,1,,972.0,,Intermediate,,791T cell line,,9606.0,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression; <20% inhibition achieved,F,,Homo sapiens,,80641
5337,11831,1,,972.0,,Intermediate,,791T cell line,,9606.0,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H1: MSR-33),F,,Homo sapiens,,80641
5338,11831,1,,972.0,,Intermediate,,791T cell line,,9606.0,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H2: MSR-26),F,,Homo sapiens,,80641
5339,11831,1,,972.0,,Intermediate,,791T cell line,,9606.0,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H3: MSR-28); <20% inhibition achieved,F,,Homo sapiens,,80641
5340,11831,1,,972.0,,Intermediate,,791T cell line,,9606.0,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H1: MSR-33),F,,Homo sapiens,,80641
5341,11831,1,,972.0,,Intermediate,,791T cell line,,9606.0,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26),F,,Homo sapiens,,80641
5342,11831,1,,972.0,,Intermediate,,791T cell line,,9606.0,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26) (less than 20% inhibition achieved),F,,Homo sapiens,,80641
5343,11831,1,,972.0,,Intermediate,,791T cell line,,9606.0,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H3: MSR-28); <20% inhibition achieved,F,,Homo sapiens,,80641
5344,12782,1,,391.0,,Intermediate,,786-0,,9606.0,Growth inhibitory concentration against tumor cells in culture renal cancer 796-0 cell line,F,,Homo sapiens,,80640
5345,1229,0,,,,Intermediate,,,,,In vitro anticancer activity against 8 NCI CNS cancer cell lines; inactive,F,,,,22226
5346,15313,1,,741.0,,Expert,,RPMI-8226,,9606.0,Inhibition of cell growth in drug resistant 8226 myeloma cell line,F,,Homo sapiens,,80433
5347,15313,1,,741.0,,Expert,,RPMI-8226,,9606.0,Inhibition of cell growth in drug sensitive 8226 myeloma cell line,F,,Homo sapiens,,80433
5348,11544,1,,741.0,,Intermediate,,RPMI-8226,,9606.0,In vitro inhibition of tumor cell growth in the human myeloma 8226 system.,F,,Homo sapiens,,80433
5349,9424,1,,741.0,,Intermediate,,RPMI-8226,,9606.0,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,F,,Homo sapiens,,80433
5350,9424,1,,741.0,,Intermediate,,RPMI-8226,,9606.0,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,F,,Homo sapiens,,80433
5351,9424,1,,741.0,,Intermediate,,RPMI-8226,,9606.0,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),F,,Homo sapiens,,80433
5352,9424,1,,741.0,,Intermediate,,RPMI-8226,,9606.0,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),F,,Homo sapiens,,80433
5353,9424,1,,741.0,,Intermediate,,RPMI-8226,,9606.0,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),F,,Homo sapiens,,80433
5354,9424,1,,741.0,,Intermediate,,RPMI-8226,,9606.0,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),F,,Homo sapiens,,80433
5355,9424,1,,741.0,,Intermediate,,RPMI-8226,,9606.0,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),F,,Homo sapiens,,80433
5356,9424,1,,741.0,,Intermediate,,RPMI-8226,,9606.0,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),F,,Homo sapiens,,80433
5357,9424,1,,741.0,,Intermediate,,RPMI-8226,,9606.0,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),F,,Homo sapiens,,80433
5358,14769,1,,624.0,,Intermediate,,A498,,9606.0,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),F,,Homo sapiens,,80021
5359,15354,1,,624.0,,Intermediate,,A498,,9606.0,Compound was tested for the growth inhibition of A498 renal tumor cell line,F,,Homo sapiens,,80021
5360,17445,1,,624.0,,Intermediate,,A498,,9606.0,In vitro cytotoxicity against human tumor A498 cell line (renal cancer),F,,Homo sapiens,,80021
5361,4337,1,,624.0,,Intermediate,,A498,,9606.0,In vitro inhibitory concentration against renal cancer cell line A498,F,,Homo sapiens,,80021
5362,15277,1,,624.0,,Intermediate,,A498,,9606.0,Cytotoxicity against A 498 tumor cell line,F,,Homo sapiens,,80021
5363,4812,1,,624.0,,Intermediate,,A498,,9606.0,In vitro antitumor activity against A498 human cancer cell line,F,,Homo sapiens,,80021
5364,4812,1,,624.0,,Intermediate,,A498,,9606.0,In vitro antitumor activity against A498 human cancer cell line (Data from NCI-screening),F,,Homo sapiens,,80021
5365,4995,1,,624.0,,Intermediate,,A498,,9606.0,Inhibitory dose required against A498 human tumor cell lines,F,,Homo sapiens,,80021
5366,5847,1,,624.0,,Intermediate,,A498,,9606.0,Anticancer activity against one renal cancer (A498 cell line),F,,Homo sapiens,,80021
5367,6557,1,,624.0,,Intermediate,,A498,,9606.0,In vitro cytotoxicity against melanoma A498 cell line,F,,Homo sapiens,,80021
5368,2597,1,,624.0,,Intermediate,,A498,,9606.0,Compound was tested for growth inhibitory activity against A498 cell line,F,,Homo sapiens,,80021
5369,6058,1,,624.0,,Intermediate,,A498,,9606.0,Compound tested for growth inhibition of renal cancer cell line A498,F,,Homo sapiens,,80021
5370,17708,1,,624.0,,Intermediate,,A498,,9606.0,Compound was tested for 50% growth inhibition against human renal cancer A498 cell line,F,,Homo sapiens,,80021
5371,15176,1,,624.0,,Intermediate,,A498,,9606.0,Growth inhibition of the A498 Renal cancer cell line for 2-day in vitro assay.,F,,Homo sapiens,,80021
5372,15300,1,,624.0,,Intermediate,,A498,,9606.0,In vitro antitumor activity against Renal cancer A498 cell lines by 6-day assay,F,,Homo sapiens,,80021
5373,11970,1,,624.0,,Intermediate,,A498,,9606.0,Tested for cytotoxicity against A498 cell lines in renal cancer,F,,Homo sapiens,,80021
5374,12400,1,,624.0,,Intermediate,,A498,,9606.0,Tested in vitro for cytotoxicity in A498 cell line of Renal cancer,F,,Homo sapiens,,80021
5375,12888,1,,624.0,,Expert,,A498,,9606.0,Cytotoxic effect on renal cancer lines A498,F,,Homo sapiens,,80021
5376,3030,1,,624.0,,Intermediate,,A498,,9606.0,Antitumor activity was evaluated for reduction of growth of renal cancer (A498) cells at a concentration of 100 uM,F,,Homo sapiens,,80021
5377,14769,1,,624.0,,Intermediate,,A498,,9606.0,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),F,,Homo sapiens,,80021
5378,17376,1,,624.0,,Intermediate,,A498,,9606.0,Concentration of compound that cause 50% cytotoxicity of A498 renal cancer cell line,F,,Homo sapiens,,80021
5379,16558,1,,624.0,,Intermediate,,A498,,9606.0,Growth inhibitory activity against A498-2LM human solid tumor cell line using MTT assay,F,,Homo sapiens,,80021
5380,5194,1,,624.0,,Intermediate,,A498,,9606.0,Cytotoxicity against human kidney carcinoma cell lines A4982LM,F,,Homo sapiens,,80021
5381,10708,1,,624.0,,Intermediate,,A498,,9606.0,Evaluated for the inhibitory concentration required to cause growth inhibition of A498Rem- renal cell line using the MTT Cytotoxicity Assay,F,,Homo sapiens,,80021
5382,16880,1,,646.0,,Expert,,A549,,9606.0,Antiproliferative activity in vitro against A549 (human non-small lung carcinoma) cell line.,F,,Homo sapiens,,80682
5383,10196,1,,646.0,,Intermediate,,A549,,9606.0,Antitumor activity against A549 human lung carcinoma cell line,F,,Homo sapiens,,80682
5384,10196,1,,646.0,,Intermediate,,A549,,9606.0,Antitumor activity against A549 human lung carcinoma cell line in experiment 1,F,,Homo sapiens,,80682
5385,10196,1,,646.0,,Intermediate,,A549,,9606.0,Antitumor activity against A549 human lung carcinoma cell line in experiment 2,F,,Homo sapiens,,80682
5386,12083,1,,646.0,,Intermediate,,A549,,9606.0,"Concentration required to inhibit tumor growth in A549, human lung carcinoma (NSCLC) cell line",F,,Homo sapiens,,80682
5387,16464,1,,646.0,,Expert,,A549,,9606.0,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay,F,,Homo sapiens,,80682
5388,16464,1,,646.0,,Intermediate,,A549,,9606.0,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,F,,Homo sapiens,,80682
5389,16470,1,,646.0,,Expert,,A549,,9606.0,In vitro cytotoxic activity against human lung A549 cell line,F,,Homo sapiens,,80682
5390,16470,1,,646.0,,Intermediate,,A549,,9606.0,In vitro cytotoxic activity against human lung A549 cell line ( standard deviation in parenthesis),F,,Homo sapiens,,80682
5391,16470,1,,646.0,,Intermediate,,A549,,9606.0,In vitro cytotoxic activity against human lung A549 cell line),F,,Homo sapiens,,80682
5392,16470,1,,646.0,,Intermediate,,A549,,9606.0,In vitro cytotoxic activity against human lung A549 cell line;NT is not tested,F,,Homo sapiens,,80682
5393,16582,1,,646.0,,Expert,,A549,,9606.0,In vitro cytotoxicity against human non small-cell-lung cell line A549.,F,,Homo sapiens,,80682
5394,15935,1,,646.0,,Intermediate,,A549,,9606.0,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors",F,,Homo sapiens,,80682
5395,15935,1,,646.0,,Intermediate,,A549,,9606.0,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors in folate deficient medium",F,,Homo sapiens,,80682
5396,16597,1,,646.0,,Expert,,A549,,9606.0,Inhibition of A549 human lung carcinoma cell proliferation,F,,Homo sapiens,,80682
5397,17376,1,,646.0,,Intermediate,,A549,,9606.0,Inhibitory activity against A549 lung adenocarcinoma cell line,F,,Homo sapiens,,80682
5398,16496,1,,646.0,,Intermediate,,A549,,9606.0,Inhibitory concentration required to reduce A549 tumor cell growth by 50% in MTT assay,F,,Homo sapiens,,80682
5399,16152,1,,646.0,,Intermediate,,A549,,9606.0,in vitro anticancer activity against cultured A549 human tumor(lung) cell line,F,,Homo sapiens,,80682
5400,16152,1,,646.0,,Intermediate,,A549,,9606.0,in vitro inhibition of tumor cell growth in cultured A549 human tumor cell line,F,,Homo sapiens,,80682
5401,16464,1,,646.0,,Intermediate,,A549,,9606.0,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,F,,Homo sapiens,,80682
5402,2288,1,,646.0,,Intermediate,,A549,,9606.0,Cytotoxicity was evaluated against A549 non-small cell lung carcinoma human cancer cell line,F,,Homo sapiens,,80682
5403,17350,1,,646.0,,Intermediate,,A549,,9606.0,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,F,,Homo sapiens,,80682
5404,4090,1,,646.0,,Expert,,A549,,9606.0,Inhibition of A549 cancer cell proliferation,F,,Homo sapiens,,80682
5405,4090,1,,646.0,,Expert,,A549,,9606.0,Inhibition of A549 cancer cell proliferation (Not tested),F,,Homo sapiens,,80682
5406,17350,1,,646.0,,Intermediate,,A549,,9606.0,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,F,,Homo sapiens,,80682
5407,4197,1,,646.0,,Intermediate,,A549,,9606.0,In vitro inhibitory concentration required against human lung A549 carcinoma cells proliferation,F,,Homo sapiens,,80682
5408,17072,1,,646.0,,Intermediate,,A549,,9606.0,Antiproliferative potency determined as inhibitory concentration against A549 cells,F,,Homo sapiens,,80682
5409,17072,1,,646.0,,Intermediate,,A549,,9606.0,Percent assembly of bovine brain tubulin induced by compound at 10 uM versus that caused by 10 uM paclitaxel,F,,Homo sapiens,,80682
5410,5194,1,,646.0,,Intermediate,,A549,,9606.0,Cytotoxicity against Renal cell lines A549 was determined,F,,Homo sapiens,,80682
5411,4257,1,,,,Intermediate,,,,9615.0,Area under curve was determined in dog after a 3 mg/kg of oral dose,A,,Canis lupus familiaris,,50588
5412,6123,1,,,,Intermediate,,,,9615.0,Area under curve was determined in dog after oral administration at 1 mg/kg,A,,Canis lupus familiaris,,50588
5413,1337,1,,,,Intermediate,,,,9615.0,Area under curve was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,A,,Canis lupus familiaris,,50588
5414,1337,1,,,,Intermediate,,,,9615.0,Area under curve was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,A,,Canis lupus familiaris,,50588
5415,8833,1,,,,Intermediate,,,,9615.0,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-2 mins),A,,Canis lupus familiaris,,50588
5416,8833,1,,,,Intermediate,,,,9615.0,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-5 mins),A,,Canis lupus familiaris,,50588
5417,8833,1,,,,Intermediate,,,,9615.0,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of (0-15 mins),A,,Canis lupus familiaris,,50588
5418,8833,1,,,,Intermediate,,,,9615.0,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of( 0-120 mins),A,,Canis lupus familiaris,,50588
5419,17657,1,,,,Intermediate,1969.0,,Plasma,9615.0,Area under plasma concentration time curve in dog upon oral administration,A,,Canis lupus familiaris,,50588
5420,17650,1,,,,Intermediate,1969.0,,Plasma,9615.0,Area under plasma concentration time curve was measured in dogs after an oral dose of 10 uM/kg,A,,Canis lupus familiaris,,50588
5421,1977,1,,,,Intermediate,,,,9615.0,Area under the curve for compound was evaluated in dog at a dose of 10 mg/kg.,A,,Canis lupus familiaris,,50588
5422,1977,1,,,,Intermediate,,,,9615.0,Area under the curve for compound was evaluated in dog at a dose of 20 mg/kg.,A,,Canis lupus familiaris,,50588
5423,3132,1,,,,Intermediate,,,,9615.0,Area under the curve for the compound was obtained when tested in dog,A,,Canis lupus familiaris,,50588
5424,5473,1,,,,Intermediate,,,,9615.0,Area under the curve at a dose of 1 mg/kg,A,,Canis lupus familiaris,,50588
5425,5474,1,,,,Intermediate,,,,9615.0,Area under the curve at a dose of 1 mg/kg (oral),A,,Canis lupus familiaris,,50588
5426,5474,1,,,,Intermediate,,,,9615.0,Area under the curve at i.v. dose of 0.2 mg/kg,A,,Canis lupus familiaris,,50588
5427,6062,1,,,,Intermediate,,,,9615.0,Area under the curve was measured in dog after an iv dose of 1 mg/kg,A,,Canis lupus familiaris,,50588
5428,4709,1,,,,Intermediate,,,,9615.0,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in dog,A,,Canis lupus familiaris,,50588
5429,2652,1,,,,Intermediate,,,,9615.0,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 1 mpk perorally,A,,Canis lupus familiaris,,50588
5430,2652,1,,,,Intermediate,,,,9615.0,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 5 mpk perorally,A,,Canis lupus familiaris,,50588
5431,2877,1,,,,Intermediate,,,,9615.0,Compound was evaluated for area under the curve in dog blood.,A,,Canis lupus familiaris,,50588
5432,5444,1,,,,Intermediate,,,,9615.0,In vivo area under curve was calculated by peroral administration at 1 mg/kg in fasted dog,A,,Canis lupus familiaris,,50588
5433,5130,1,,,,Intermediate,1969.0,,Plasma,9615.0,AUC in dog after oral dose (1 mg/kg),A,,Canis lupus familiaris,,50588
5434,6265,1,,,,Intermediate,,,,9615.0,Pharmacokinetic (PK) property (AUC) was determined in dog at the single oral dose of 1 mg/kg,A,,Canis lupus familiaris,,50588
5435,4657,1,,,,Intermediate,,,,9615.0,"Pharmacokinetic data in dogs at dose of 1 mg/kg perorally, and the area under curve (AUC) was reported.",A,,Canis lupus familiaris,,50588
5436,16367,1,,,,Intermediate,,,,9615.0,Pharmacokinetic parameter AUC after intravenous administration to dogs,A,,Canis lupus familiaris,,50588
5437,16367,1,,,,Intermediate,,,,9615.0,Pharmacokinetic parameter AUC after oral administration to dogs,A,,Canis lupus familiaris,,50588
5438,9579,1,,,,Intermediate,,,,9615.0,Pharmacokinetic parameter AUC was determined in dog after oral administration of 17b,A,,Canis lupus familiaris,,50588
5439,9579,1,,,,Intermediate,,,,9615.0,Pharmacokinetic parameter AUC was determined in dog after oral administration of 2b,A,,Canis lupus familiaris,,50588
5440,5983,1,,,,Intermediate,,,,9615.0,Pharmacokinetic property (AUC) was measured in dog at the dose of 0.032 mg/kg p.o.,A,,Canis lupus familiaris,,50588
5441,6241,1,,,,Intermediate,,,,9615.0,Pharmacokinetic property in dogs after oral administration at 1 mg/kg,A,,Canis lupus familiaris,,50588
5442,5313,1,,,,Intermediate,,,,9615.0,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog",A,,Canis lupus familiaris,,50588
5443,5313,1,,,,Intermediate,,,,9615.0,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog at dosage of 10 mpk",A,,Canis lupus familiaris,,50588
5444,6642,1,,,,Intermediate,,,,9615.0,Oral AUCN in dog ( (dosed as a mixture of five compounds at 0.5 mpk each via iv only),A,,Canis lupus familiaris,,50588
5445,6642,1,,,,Intermediate,,,,9615.0,Oral AUCN in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),A,,Canis lupus familiaris,,50588
5446,6641,1,,,,Intermediate,,,,9615.0,Oral AUCN in dog (dosed at 0.5 mpk iv ),A,,Canis lupus familiaris,,50588
5447,6642,1,,,,Intermediate,,,,9615.0,Oral AUCN in dog (dosed at 0.5 mpk iv ),A,,Canis lupus familiaris,,50588
5448,17791,1,,,,Intermediate,,,,9615.0,Compound was evaluated for oral bioavailability in dog; 90-100,A,,Canis lupus familiaris,,50588
5449,17655,1,,,,Intermediate,,,,9615.0,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay,A,,Canis lupus familiaris,,50588
5450,17655,1,,,,Intermediate,,,,9615.0,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay; Not determined,A,,Canis lupus familiaris,,50588
5451,6596,1,,,,Intermediate,,,,9615.0,PAPP (membrane permeability) in dog kidney cell monolayer assay,A,,Canis lupus familiaris,,50588
5452,3880,1,,,,Intermediate,,,,9615.0,Oral bioavailability in dog,A,,Canis lupus familiaris,,50588
5453,16367,1,,,,Intermediate,,,,9615.0,Bioavailability administered orally at a dose of 10 mg/kg to dogs,A,,Canis lupus familiaris,,50588
5454,17409,1,,,,Intermediate,1969.0,,Plasma,9615.0,Plasma protein binding towards dog plasma at 10 uM,A,,Canis lupus familiaris,,50588
5455,17409,1,,,,Intermediate,1969.0,,Plasma,9615.0,Plasma protein binding towards dog plasma at 100 uM,A,,Canis lupus familiaris,,50588
5456,2959,1,,,,Intermediate,,,,9615.0,Bioavailability in dog (dose 4 mg/kg p.o.),A,In vivo,Canis lupus familiaris,,50588
5457,13501,1,,,,Intermediate,,,,9615.0,Bioavailability was determined after oral administration of compound 18 at a dose of 2 mg/kg to dog,A,In vivo,Canis lupus familiaris,,50588
5458,4527,1,,,,Intermediate,,,,9615.0,Bioavailability by oral administration at a dose of 10 uM/kg in dog was determined,A,In vivo,Canis lupus familiaris,,50588
5459,15145,1,,,,Intermediate,,,,9615.0,Bioavailability in dogs,A,In vivo,Canis lupus familiaris,,50588
5460,4219,1,,,,Intermediate,,,,9615.0,Bioavailability,A,In vivo,Canis lupus familiaris,,50588
5461,17538,1,,,,Intermediate,,,,9615.0,Oral bioavailability in dog (dose 10 mg/kg),A,In vivo,Canis lupus familiaris,,50588
5462,17538,1,,,,Intermediate,,,,9615.0,Bioavailability in dog after po administration at a dose of 10 mg/kg; nd is not determined,A,In vivo,Canis lupus familiaris,,50588
5463,1466,1,,,,Intermediate,,,,9615.0,Bioavailability in dog (dose 10.0 mg/kg p.o.),A,In vivo,Canis lupus familiaris,,50588
5464,17650,1,,,,Intermediate,,,,9615.0,Bioavailability was measured in dogs after an oral dose of 10 uM/kg,A,In vivo,Canis lupus familiaris,,50588
5465,3132,1,,,,Intermediate,,,,9615.0,Bioavailability was obtained by the comparison of AUC of intravenous dosing and AUC of oral dosing in dog,A,In vivo,Canis lupus familiaris,,50588
5466,2413,0,,,,Autocuration,,,,10095.0,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,,Mus sp.,,22224
5467,2413,0,,,,Autocuration,2107.0,,Liver,10095.0,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,,Mus sp.,,22224
5468,2413,0,,,,Autocuration,2107.0,,Liver,10095.0,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 24 hour,A,,Mus sp.,,22224
5469,2413,0,,,,Autocuration,2107.0,,Liver,10095.0,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,,Mus sp.,,22224
5470,2413,0,,,,Autocuration,,,,10095.0,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,,Mus sp.,,22224
5471,2413,0,,,,Autocuration,,,,10095.0,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,,Mus sp.,,22224
5472,2413,0,,,,Autocuration,2385.0,,Muscle tissue,10095.0,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,,Mus sp.,,22224
5473,2413,0,,,,Autocuration,2385.0,,Muscle tissue,10095.0,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 24 hour,A,,Mus sp.,,22224
5474,2413,0,,,,Autocuration,2385.0,,Muscle tissue,10095.0,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,,Mus sp.,,22224
5475,2413,0,,,,Autocuration,2106.0,,Spleen,10095.0,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,,Mus sp.,,22224
5476,2413,0,,,,Autocuration,2106.0,,Spleen,10095.0,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,,Mus sp.,,22224
5477,2413,0,,,,Autocuration,,,,10095.0,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,,Mus sp.,,22224
5478,2413,0,,,,Autocuration,,,,10095.0,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 24 hour,A,,Mus sp.,,22224
5479,2413,0,,,,Autocuration,,,,10095.0,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,,Mus sp.,,22224
5480,2413,0,,,,Autocuration,,,,10095.0,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 24 hour,A,,Mus sp.,,22224
5481,2413,0,,,,Autocuration,,,,10095.0,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,,Mus sp.,,22224
5482,17827,0,,,,Autocuration,,,,9527.0,Compound (i.v.) was evaluated for elimination rate constants in brainstem of rhesus monkeys (Radiolabeled compound),A,,Cercopithecidae,,22224
5483,17827,0,,,,Autocuration,2037.0,,Cerebellum,9527.0,Compound (i.v.) was evaluated for elimination rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),A,,Cercopithecidae,,22224
5484,17827,0,,,,Autocuration,1870.0,,Frontal cortex,9527.0,Compound (i.v.) was evaluated for elimination rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),A,,Cercopithecidae,,22224
5485,17827,0,,,,Autocuration,,,,9527.0,Compound (i.v.) was evaluated for elimination rate constants in jaw bone of rhesus monkeys; NA = not active (Radiolabeled compound),A,,Cercopithecidae,,22224
5486,17827,0,,,,Autocuration,2435.0,,Striatum,9527.0,Compound (i.v.) was evaluated for elimination rate constants in striatum of rhesus monkey (Radiolabeled compound),A,,Cercopithecidae,,22224
5487,17827,0,,,,Autocuration,,,,9527.0,Compound (i.v.) was evaluated for uptake rate constants in brainstem of rhesus monkeys (Radiolabeled compound),A,,Cercopithecidae,,22224
5488,17827,0,,,,Autocuration,2037.0,,Cerebellum,9527.0,Compound (i.v.) was evaluated for uptake rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),A,,Cercopithecidae,,22224
5489,17827,0,,,,Autocuration,1870.0,,Frontal cortex,9527.0,Compound (i.v.) was evaluated for uptake rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),A,,Cercopithecidae,,22224
5490,17827,0,,,,Autocuration,,,,9527.0,Compound (i.v.) was evaluated for uptake rate constants in jaw bone of rhesus monkey (Radiolabeled compound),A,,Cercopithecidae,,22224
5491,17827,0,,,,Autocuration,2435.0,,Striatum,9527.0,Compound (i.v.) was evaluated for uptake rate constants in striatum of rhesus monkeys (Radiolabeled compound),A,,Cercopithecidae,,22224
5492,17791,0,,,,Autocuration,,,,9527.0,Compound was evaluated for oral bioavailability in rats,A,,Cercopithecidae,,22224
5493,17667,0,,,,Autocuration,1969.0,,Plasma,9527.0,Maximum concentration of compound found in plasma at 5 mg/kg after oral administration,A,In vivo,Cercopithecidae,,22224
5494,17791,0,,,,Autocuration,,,,9527.0,Half life period was evaluated in monkey,A,,Cercopithecidae,,22224
5495,110,0,,,,Autocuration,,,,9527.0,Half-life in rhesus monkeys by intravenous administration of dose,A,In vivo,Cercopithecidae,,22224
5496,5781,1,,,,Intermediate,1969.0,,Plasma,10090.0,AUC (0-6 hr) after oral administration at 30 mg/kg in ICR mouse,A,,Mus musculus,,50594
5497,17734,1,,,,Intermediate,1969.0,,Plasma,10090.0,AUC after intraperitoneal administration of 100 mg/kg in mice,A,,Mus musculus,,50594
5498,17718,1,,,,Intermediate,1969.0,,Plasma,10090.0,AUC value was determined after oral administration,A,,Mus musculus,,50594
5499,4573,1,,,,Intermediate,,,,10090.0,Area under curve (AUC) determined at a dose 10 mg/kg administered intraperitoneally to mice,A,,Mus musculus,,50594
5500,3277,1,,,,Intermediate,,,,10090.0,Area under curve (AUC) was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),A,,Mus musculus,,50594
5501,2862,1,,,,Intermediate,,,,10090.0,Area under curve by ioral administration in mouse,A,,Mus musculus,,50594
5502,2862,1,,,,Intermediate,,,,10090.0,Area under curve by iv administration in mouse,A,,Mus musculus,,50594
5503,5951,1,,,,Intermediate,,,,10090.0,Area under curve at 0-8 hr in IRC mice after peroral administration,A,,Mus musculus,,50594
5504,17729,1,,,,Intermediate,,,,10090.0,Area under curve when injected i.p. in mice at a dose of 50 mg/kg,A,,Mus musculus,,50594
5505,17728,1,,,,Intermediate,,,,10090.0,Area under curve when injected intraperitoneally in BALB/C mice at a dose of 20 mg/kg,A,,Mus musculus,,50594
5506,17728,1,,,,Intermediate,,,,10090.0,Area under curve when injected intravenously in BALB/C mice at a dose of 20 mg/kg,A,,Mus musculus,,50594
5507,17729,1,,,,Intermediate,,,,10090.0,Area under curve when injected intravenously in mice at a dose of 20 mg/kg,A,,Mus musculus,,50594
5508,9424,1,,741.0,,Intermediate,,RPMI-8226,,9606.0,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,F,,Homo sapiens,,80433
5509,9424,1,,741.0,,Intermediate,,RPMI-8226,,9606.0,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,F,,Homo sapiens,,80433
5510,9424,1,,741.0,,Intermediate,,RPMI-8226,,9606.0,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),F,,Homo sapiens,,80433
5511,9424,1,,741.0,,Intermediate,,RPMI-8226,,9606.0,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),F,,Homo sapiens,,80433
5512,9424,1,,741.0,,Intermediate,,RPMI-8226,,9606.0,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),F,,Homo sapiens,,80433
5513,9424,1,,741.0,,Intermediate,,RPMI-8226,,9606.0,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),F,,Homo sapiens,,80433
5514,9424,1,,741.0,,Intermediate,,RPMI-8226,,9606.0,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),F,,Homo sapiens,,80433
5515,9424,1,,741.0,,Intermediate,,RPMI-8226,,9606.0,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),F,,Homo sapiens,,80433
5516,9424,1,,741.0,,Intermediate,,RPMI-8226,,9606.0,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,F,,Homo sapiens,,80433
5517,9424,1,,741.0,,Intermediate,,RPMI-8226,,9606.0,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,F,,Homo sapiens,,80433
5518,9424,1,,741.0,,Intermediate,,RPMI-8226,,9606.0,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),F,,Homo sapiens,,80433
5519,9424,1,,741.0,,Intermediate,,RPMI-8226,,9606.0,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),F,,Homo sapiens,,80433
5520,9424,1,,741.0,,Intermediate,,RPMI-8226,,9606.0,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),F,,Homo sapiens,,80433
5521,9424,1,,741.0,,Intermediate,,RPMI-8226,,9606.0,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),F,,Homo sapiens,,80433
5522,9424,1,,741.0,,Intermediate,,RPMI-8226,,9606.0,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),F,,Homo sapiens,,80433
5523,9424,1,,741.0,,Intermediate,,RPMI-8226,,9606.0,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),F,,Homo sapiens,,80433
5524,9424,1,,741.0,,Expert,,RPMI-8226,,9606.0,In vitro inhibition of human 8226 myeloma tumor cell line growth.,F,,Homo sapiens,,80433
5525,11544,1,,741.0,,Intermediate,,RPMI-8226,,9606.0,In vitro inhibition of tumor cell growth in the human myeloma 8226/ADR system.,F,,Homo sapiens,,80433
5526,17378,1,,741.0,,Intermediate,,RPMI-8226,,9606.0,Cytotoxicity of compound against 8226/DOX1V cells,F,,Homo sapiens,,80433
5527,17378,1,,741.0,,Intermediate,,RPMI-8226,,9606.0,Cytotoxicity of compound against 8226/S cells,F,,Homo sapiens,,80433
5528,17079,1,,741.0,,Intermediate,,RPMI-8226,,9606.0,Inhibitory concentration against 8226 myeloma cancer cell line,F,,Homo sapiens,,80433
5529,17079,1,,741.0,,Intermediate,,RPMI-8226,,9606.0,Inhibitory concentration against 8226/Dox40 (Dox-Re) cancer cell line,F,,Homo sapiens,,80433
5530,13466,1,,854.0,,Intermediate,,833K,,9606.0,Inhibition of cell growth was studied in human teratocarcinoma (833K).,F,,Homo sapiens,,80647
5531,13466,1,,854.0,,Intermediate,,833K,,9606.0,Inhibition of cell growth was studied in human teratocarcinoma (833K); ND ='not determined',F,,Homo sapiens,,80647
5532,2392,1,,854.0,,Expert,,833K,,9606.0,Tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells,F,,Homo sapiens,,80647
5533,2392,1,,854.0,,Intermediate,,833K,,9606.0,The compound was tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells; No data,F,,Homo sapiens,,80647
5534,6608,0,,,,Autocuration,,,,,Inhibitory activity against caspase-1,B,,,,22226
5535,10199,8,,,,Autocuration,,,,1351.0,Percent inhibition of DAla-DAla Ligase at 10e -3 M of the compound,B,,Enterococcus faecalis,,45
5536,17749,1,,705.0,,Intermediate,,8701-BC,,9606.0,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM) for 72 hr using MTT assay,F,,Homo sapiens,,80648
5537,17749,1,,705.0,,Intermediate,,8701-BC,,9606.0,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM,F,,Homo sapiens,,80648
5538,1229,0,,,,Intermediate,,,,,In vitro anticancer activity against 9 NCI colon cancer cell lines; inactive,F,,,,22226
5539,1229,0,,,,Intermediate,,,,,In vitro anticancer activity against 9 NCI melanoma cell lines; inactive,F,,,,22226
5540,1229,0,,,,Intermediate,,,,,In vitro anticancer activity against 9 NCI renal cancer cell lines; inactive,F,,,,22226
5541,6390,0,,,,Autocuration,,,,,Inhibitory activity was determined against 9-cis-epoxycarotenoid dioxygenase (NCED) expressed in Escherichia coli in presence of 9''-cis-neo-xanthin,B,,,,22226
5542,16219,0,,,,Autocuration,,,,1314.0,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,F,,Streptococcus pyogenes,,22226
5543,16219,0,,,,Autocuration,,,,1314.0,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,F,,Streptococcus pyogenes,,22226
5544,17043,8,,,,Autocuration,,,,,Percent inhibition against Cdc25C phosphatase at 50 uM of compound,B,,,,11922
5545,6929,1,,324.0,,Intermediate,,KB ,,9606.0,Tested for in vitro cytotoxic potency of compound in 9KB assay,F,,Homo sapiens,,81115
5546,6929,1,,324.0,,Intermediate,,KB ,,9606.0,Tested for in vitro cytotoxic potency of compound in 9KB assay,A,,Homo sapiens,,81115
5547,7083,0,,,,Autocuration,,,,9606.0,In vitro cytotoxicity of compound was tested against 9KB cells.,F,,Homo sapiens,,22226
5548,12446,1,,392.0,,Intermediate,,9L,,10116.0,Cytotoxic concentration against 9L cells was determined on day 3,F,,Rattus norvegicus,,80653
5549,15345,1,,392.0,,Expert,,9L,,10116.0,Tested in vitro for anticancer activity against 9L cells,F,,Rattus norvegicus,,80653
5550,15345,1,,392.0,,Expert,,9L,,10116.0,Tested in vitro for anticancer activity against 9L cells; Not determined,F,,Rattus norvegicus,,80653
5551,6301,1,,646.0,,Intermediate,,A549,,9606.0,In vitro inhibitory activity against human A549 non-small cell lung tumor; Active,F,,Homo sapiens,,80682
5552,4833,1,,646.0,,Intermediate,,A549,,9606.0,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; No inhibition,F,,Homo sapiens,,80682
5553,4833,1,,646.0,,Intermediate,,A549,,9606.0,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Significant inhibition,F,,Homo sapiens,,80682
5554,4833,1,,646.0,,Intermediate,,A549,,9606.0,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Slight inhibition,F,,Homo sapiens,,80682
5555,13330,1,,646.0,,Expert,,A549,,9606.0,Cytotoxicity against human lung carcinoma A549 cell line,F,,Homo sapiens,,80682
5556,17517,9,,646.0,,Expert,,A549,,9606.0,Ability to induce human IL-6 assay in A549 lung carcinoma cell line.,F,,Homo sapiens,,25
5557,17517,9,,646.0,,Expert,,A549,,9606.0,"Ability to induce human IL-6 assay in A549 lung carcinoma cell line; n.r.: not reported, EC50 values not reported in cases were %dex e 35%.",F,,Homo sapiens,,25
5558,14425,1,,646.0,,Intermediate,,A549,,9606.0,"In vitro growth inhibition of A549, lung carcinoma",F,,Homo sapiens,,80682
5559,14425,1,,646.0,,Intermediate,,A549,,9606.0,"In vitro growth inhibition of A549, lung carcinoma.",F,,Homo sapiens,,80682
5560,5228,1,,646.0,,Expert,,A549,,9606.0,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,F,,Homo sapiens,,80682
5561,5351,1,,646.0,,Intermediate,,A549,,9606.0,Cytotoxic activity against human lung cancer A549 cell line was determined,F,,Homo sapiens,,80682
5562,12198,1,,646.0,,Expert,,A549,,9606.0,Cytotoxicity against human solid tumor lung carcinoma A549 cell line,F,,Homo sapiens,,80682
5563,13891,1,,646.0,,Intermediate,,A549,,9606.0,Cytotoxicity concentration against human lung carcinoma A-549 cell line,F,,Homo sapiens,,80682
5564,5677,1,,646.0,,Expert,,A549,,9606.0,Cytotoxicity in A549 (human carcinoma) cell line.,F,,Homo sapiens,,80682
5565,13788,1,,646.0,,Intermediate,,A549,,9606.0,Cytotoxicity on lung carcinoma (A-549) cell line,F,,Homo sapiens,,80682
5566,13384,1,,646.0,,Expert,,A549,,9606.0,Effective dose against 50% reduction in Human lung carcinoma (A-549) cell number after 3-day incubation.,F,,Homo sapiens,,80682
5567,6726,1,,646.0,,Intermediate,,A549,,9606.0,Effective dose of compound against replication of A549 cell line was evaluated,F,,Homo sapiens,,80682
5568,3455,1,,646.0,,Expert,,A549,,9606.0,In vitro cytotoxic activity was determined against lung carcinoma (A549) cell line,F,,Homo sapiens,,80682
5569,5726,1,,646.0,,Intermediate,,A549,,9606.0,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line),F,,Homo sapiens,,80682
5570,5726,1,,646.0,,Intermediate,,A549,,9606.0,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line); NA is not active,F,,Homo sapiens,,80682
5571,3936,1,,646.0,,Intermediate,,A549,,9606.0,The compound was evaluated for antiproliferative activity against A549 cell line,F,,Homo sapiens,,80682
5572,14991,1,,646.0,,Intermediate,,A549,,9606.0,The compound was tested for tumor cell growth inhibitory activity against human lung carcinoma (A549) cell line.,F,,Homo sapiens,,80682
5573,5243,1,,646.0,,Intermediate,,A549,,9606.0,Concentration required for growth inhibition of human lung carcinoma cell line A549,F,,Homo sapiens,,80682
5574,12858,1,,646.0,,Intermediate,,A549,,9606.0,Cytotoxic activity against A549/ATCC non-small cell-lung cancer cell line,F,,Homo sapiens,,80682
5575,6776,1,,646.0,,Intermediate,,A549,,9606.0,Growth inhibition against A549 cell line was evaluated,F,,Homo sapiens,,80682
5576,16558,1,,646.0,,Intermediate,,A549,,9606.0,Growth inhibitory activity against A549 human solid tumor cell line using MTT assay,F,,Homo sapiens,,80682
5577,4583,1,,646.0,,Expert,,A549,,9606.0,Inhibition of anchorage independent growth of human tumor cell line A549 K-ras-transformed in soft agar,F,,Homo sapiens,,80682
5578,13514,1,,646.0,,Intermediate,,A549,,9606.0,Inhibitor activity against A549 (Human lung carcinoma)cell line with varying concentration of the drug for 72 hrs,F,,Homo sapiens,,80682
5579,15166,1,,646.0,,Expert,,A549,,9606.0,Chemosensitivity against DT-diaphorase rich A549 cell lines,F,,Homo sapiens,,80682
5580,13873,1,,646.0,,Intermediate,,A549,,9606.0,Compound tested against A549 lung carcinoma in the sulforhodamine B assay.,F,,Homo sapiens,,80682
5581,6447,1,,646.0,,Expert,,A549,,9606.0,In vitro cytotoxicity against human A549 (lung cancer) cell line.,F,,Homo sapiens,,80682
5582,2068,1,,646.0,,Intermediate,,A549,,9606.0,In vitro antitumor activity against A549 (lung) human tumor cell lines.,F,,Homo sapiens,,80682
5583,1863,1,,646.0,,Expert,,A549,,9606.0,In vitro cytotoxic activity against human lung carcinoma A549 cell line,F,,Homo sapiens,,80682
5584,13873,1,,646.0,,Intermediate,,A549,,9606.0,Compound was tested against A549 lung cancer cell line in the sulforhodamine B assay.,F,,Homo sapiens,,80682
5585,13873,1,,646.0,,Intermediate,,A549,,9606.0,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,F,,Homo sapiens,,80682
5586,13873,1,,646.0,,Expert,,A549,,9606.0,Tested against A549 lung carcinoma in the sulforhodamine B assay.,F,,Homo sapiens,,80682
5587,579,1,,646.0,,Intermediate,,A549,,9606.0,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction),F,,Homo sapiens,,80682
5588,579,1,,646.0,,Intermediate,,A549,,9606.0,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction).,F,,Homo sapiens,,80682
5589,4584,1,,646.0,,Intermediate,,A549,,9606.0,Compound was tested for inhibition of growth of human lung carcinoma cell line A549 up to a conc of 10 uM; NI means no inhibition,F,,Homo sapiens,,80682
5590,5421,1,,646.0,,Expert,,A549,,9606.0,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line,F,,Homo sapiens,,80682
5591,5421,1,,646.0,,Intermediate,,A549,,9606.0,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,F,,Homo sapiens,,80682
5592,5421,1,,646.0,,Intermediate,,A549,,9606.0,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,F,,Homo sapiens,,80682
5593,5421,1,,646.0,,Intermediate,,A549,,9606.0,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line; NA=Not assayed,F,,Homo sapiens,,80682
5594,14188,1,,646.0,,Intermediate,,A549,,9606.0,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay.,F,,Homo sapiens,,80682
5595,14188,1,,646.0,,Intermediate,,A549,,9606.0,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay; UA=Potency was so low that the IC50 was unachievable.,F,,Homo sapiens,,80682
5596,15354,1,,646.0,,Intermediate,,A549,,9606.0,Compound was tested for the growth inhibition of A549 lung tumor cell line,F,,Homo sapiens,,80682
5597,14253,1,,646.0,,Expert,,A549,,9606.0,Growth inhibition of human non-small-lung carcinoma (A549) cell line,F,,Homo sapiens,,80682
5598,13873,1,,646.0,,Intermediate,,A549,,9606.0,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,F,,Homo sapiens,,80682
5599,3043,1,,,,Intermediate,,,,9615.0,Oral bioavailability in dog (conscious),A,In vivo,Canis lupus familiaris,,50588
5600,3045,1,,,,Intermediate,,,,9615.0,Compound was evaluated for the oral bioavailability after oral administration in dog.,A,In vivo,Canis lupus familiaris,,50588
5601,3022,1,,,,Intermediate,,,,9615.0,Compound was tested for percent of oral bioavailability at 10 mg/ml dose in dogs,A,In vivo,Canis lupus familiaris,,50588
5602,4453,1,,,,Intermediate,,,,9615.0,Oral bioavailability in dog,A,In vivo,Canis lupus familiaris,,50588
5603,1696,1,,,,Intermediate,,,,9615.0,Oral bioavailability in dog,A,In vivo,Canis lupus familiaris,,50588
5604,5045,1,,,,Intermediate,,,,9615.0,Oral bioavailability in dog,A,In vivo,Canis lupus familiaris,,50588
5605,5356,1,,,,Intermediate,,,,9615.0,Oral bioavailability in dog (fasted),A,In vivo,Canis lupus familiaris,,50588
5606,17764,1,,,,Intermediate,,,,9615.0,Oral bioavailability after intravenous administration in dogs at 1.2 uM/kg,A,In vivo,Canis lupus familiaris,,50588
5607,6448,1,,,,Intermediate,,,,9615.0,Oral bioavailability in dog,A,In vivo,Canis lupus familiaris,,50588
5608,1475,1,,,,Intermediate,,,,9615.0,Oral bioavailability in dog,A,In vivo,Canis lupus familiaris,,50588
5609,3788,1,,,,Intermediate,,,,9615.0,Percent bioavailability in dog,A,In vivo,Canis lupus familiaris,,50588
5610,3639,1,,,,Intermediate,,,,9615.0,Percent oral bioavailability of intravenously administered compound (6 mg/kg) was tested in dog,A,In vivo,Canis lupus familiaris,,50588
5611,13397,1,,,,Intermediate,,,,9615.0,Oral bioavailability in dog,A,In vivo,Canis lupus familiaris,,50588
5612,2137,1,,,,Intermediate,,,,9615.0,The compound was evaluated for bioavailability in dogs; 34-44,A,In vivo,Canis lupus familiaris,,50588
5613,2959,1,,,,Intermediate,,,,9615.0,Bioavailability in dog (dose 4 mg/kg p.o.),A,In vivo,Canis lupus familiaris,,50588
5614,6448,1,,,,Intermediate,,,,9615.0,Oral bioavailability in dog,A,In vivo,Canis lupus familiaris,,50588
5615,6084,1,,,,Intermediate,,,,9615.0,8 hour trough Blood level in dog was measured after administration of compound,A,,Canis lupus familiaris,,50588
5616,3639,1,,,,Intermediate,1969.0,,Plasma,9615.0,The compound was tested for maximum concentration ( Cmax ) in dog plasma.,A,In vivo,Canis lupus familiaris,,50588
5617,6316,1,,,,Intermediate,,,,9615.0,C24 after oral administration at 5 mg/kg,A,,Canis lupus familiaris,,50588
5618,5238,1,,,,Intermediate,,,,9615.0,Clearance after oral and iv dosing in dogs,A,,Canis lupus familiaris,,50588
5619,17796,1,,,,Intermediate,1969.0,,Plasma,9615.0,Clearance of the drug was measured in the plasma of dog,A,,Canis lupus familiaris,,50588
5620,2652,1,,,,Intermediate,,,,9615.0,Compound was evaluated for Clearance in dogs at a dose of 1 mpk intravenously,A,,Canis lupus familiaris,,50588
5621,5654,1,,,,Intermediate,,,,9615.0,CL (clearance) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,A,In vivo,Canis lupus familiaris,,50588
5622,6621,1,,,,Intermediate,,,,9615.0,Clearance of compound was determined in dogs,A,In vivo,Canis lupus familiaris,,50588
5623,6505,1,,,,Intermediate,,,,9615.0,Clearance on i.v. administration of 2 mg/kg was measured in dog,A,In vivo,Canis lupus familiaris,,50588
5624,5802,1,,,,Intermediate,,,,9615.0,Clearance of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,A,In vivo,Canis lupus familiaris,,50588
5625,17267,1,,,,Intermediate,,,,9615.0,Plasma clearance in dog was determined,A,In vivo,Canis lupus familiaris,,50588
5626,4521,1,,,,Intermediate,,,,9615.0,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,A,In vivo,Canis lupus familiaris,,50588
5627,6535,1,,,,Intermediate,,,,9615.0,Plasma clearance in dog after administration of 0.25 mg/kg iv,A,In vivo,Canis lupus familiaris,,50588
5628,6535,1,,,,Intermediate,,,,9615.0,Plasma clearance in dog after administration of 1 mg/kg iv,A,In vivo,Canis lupus familiaris,,50588
5629,6535,1,,,,Intermediate,,,,9615.0,Plasma clearance in dogs,A,In vivo,Canis lupus familiaris,,50588
5630,5542,1,,,,Intermediate,,,,9615.0,Plasma clearance by iv administration in dog at a dose of 0.3 mg/kg,A,In vivo,Canis lupus familiaris,,50588
5631,5199,1,,,,Intermediate,,,,9615.0,Plasma clearance was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,A,In vivo,Canis lupus familiaris,,50588
5632,16907,1,,,,Intermediate,,,,9615.0,Plasma clearance after 15 mg/kg iv dose in Dogs,A,In vivo,Canis lupus familiaris,,50588
5633,16907,1,,,,Intermediate,,,,9615.0,Plasma clearance after 30 mg/kg po dose in Dogs,A,In vivo,Canis lupus familiaris,,50588
5634,16367,1,,,,Intermediate,,,,9615.0,Plasma administration to dogs,A,In vivo,Canis lupus familiaris,,50588
5635,5505,1,,,,Intermediate,,,,9615.0,Plasma clearance was determined,A,In vivo,Canis lupus familiaris,,50588
5636,6215,1,,,,Intermediate,,,,9615.0,Systemic clearance after intravenous administration (0.5 mg/kg) was determined in dog,A,In vivo,Canis lupus familiaris,,50588
5637,1466,1,,,,Intermediate,,,,9615.0,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in dog,A,In vivo,Canis lupus familiaris,,50588
5638,5007,2,,,,Intermediate,2107.0,,Liver,9606.0,Intrinsic clearance in human liver microsomes,A,In vitro,Homo sapiens,Microsomes,102164
5639,5007,2,,,,Intermediate,2107.0,,Liver,9606.0,Intrinsic clearance in human liver microsomes,A,In vitro,Homo sapiens,Microsomes,102164
5640,16452,1,,,,Intermediate,,,,9615.0,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,A,In vivo,Canis lupus familiaris,,50588
5641,16452,1,,,,Intermediate,,,,9615.0,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,A,In vivo,Canis lupus familiaris,,50588
5642,16452,1,,,,Intermediate,,,,9615.0,Clearance in dog (dose 1 mg/kg i.v.),A,In vivo,Canis lupus familiaris,,50588
5643,6221,1,,,,Intermediate,,,,9615.0,Plasma clearance after oral administration (2.5 mg/kg) in dog was determined,A,In vivo,Canis lupus familiaris,,50588
5644,5007,1,,,,Intermediate,,,,9615.0,Plasma clearance in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),A,In vivo,Canis lupus familiaris,,50588
5645,5668,1,,,,Intermediate,,,,9615.0,Plasma clearance after peroral administration at 10 mpk in dog,A,In vivo,Canis lupus familiaris,,50588
5646,5668,1,,,,Intermediate,,,,9615.0,Plasma clearance after peroral administration at 5 mpk in dog,A,In vivo,Canis lupus familiaris,,50588
5647,5668,1,,,,Intermediate,,,,9615.0,Plasma clearance after peroral administration at 5 mg/kg in dog,A,In vivo,Canis lupus familiaris,,50588
5648,15660,1,,,,Intermediate,,,,9615.0,Plasma clearance was measured in dog,A,In vivo,Canis lupus familiaris,,50588
5649,15660,1,,,,Intermediate,,,,9615.0,Plasma clearance was measured in dog,A,In vivo,Canis lupus familiaris,,50588
5650,5983,1,,,,Intermediate,,,,9615.0,Pharmacokinetic property (CLtot) was measured in dog at the dose of 0.032 mg/kg i.v.,A,In vivo,Canis lupus familiaris,,50588
5651,5600,1,,,,Intermediate,,,,9615.0,Total clearance was determined after 0.1 mg/kg iv administration in dog,A,In vivo,Canis lupus familiaris,,50588
5652,17764,1,,,,Intermediate,,,,9615.0,Clearance of compound after intravenous administration in dogs at 1.2 uM/kg,A,In vivo,Canis lupus familiaris,,50588
5653,6039,1,,,,Intermediate,,,,9615.0,Clearance after intravenous administration of 0.5 mg/kg in dog was determined,A,In vivo,Canis lupus familiaris,,50588
5654,6039,1,,,,Intermediate,,,,9615.0,Clearance after intravenous administration of 1.0 mg/kg in dog was determined,A,In vivo,Canis lupus familiaris,,50588
5655,6039,1,,,,Intermediate,,,,9615.0,Clearance after peroral administration of 0.2 mg/kg in dog was determined,A,In vivo,Canis lupus familiaris,,50588
5656,4368,1,,,,Intermediate,,,,9615.0,Clearance by intravenous administration of 1.2 mg/kg in dog,A,In vivo,Canis lupus familiaris,,50588
5657,4305,1,,,,Intermediate,,,,9615.0,Clearance by iv administration in dogs at a dose of 1 mg/kg,A,In vivo,Canis lupus familiaris,,50588
5658,1918,1,,,,Intermediate,1969.0,,Plasma,9615.0,Clearance value was evaluated in dog plasma,A,In vivo,Canis lupus familiaris,,50588
5659,6005,1,,,,Intermediate,,,,9615.0,Clearance was evaluated after i.v. administration in dog at a dose of 1 mg/kg,A,In vivo,Canis lupus familiaris,,50588
5660,4839,1,,,,Intermediate,1969.0,,Plasma,9615.0,Compound was tested for plasma clearance in dog,A,In vivo,Canis lupus familiaris,,50588
5661,4239,1,,,,Intermediate,,,,9615.0,Pharmacokinetic property (Plasma clearance) was measured in dog,A,In vivo,Canis lupus familiaris,,50588
5662,17729,1,,,,Intermediate,,,,10090.0,Area under curve when injected perorally in mice at a dose of 50 mg/kg,A,,Mus musculus,,50594
5663,17728,1,,,,Intermediate,,,,10090.0,Area under curve when injected perorally in BALB/C mice at a dose of 50 mg/kg,A,,Mus musculus,,50594
5664,5302,1,,,,Intermediate,,,,10090.0,Area under curve value in mouse at a dose of 10 mg/kg,A,,Mus musculus,,50594
5665,5506,1,,,,Intermediate,,,,10090.0,Area under curve was determined at a dose of 100 mg/kg (i.p.) in Mice,A,,Mus musculus,,50594
5666,5506,1,,,,Intermediate,,,,10090.0,Area under curve was determined at a dose of 200 mg/kg (i.p.) in Mice,A,,Mus musculus,,50594
5667,17764,1,,,,Intermediate,,,,10090.0,Area under curve was determined for compound after intraperitoneal administration in mice at 18 uM/kg,F,,Mus musculus,,50594
5668,17764,1,,,,Intermediate,,,,10090.0,Area under curve was determined for compound after intraperitoneal administration in mice at 23 uM/kg,F,,Mus musculus,,50594
5669,17764,1,,,,Intermediate,,,,10090.0,Area under curve was determined for compound after intraperitoneal administration in mice at 25 uM/kg,F,,Mus musculus,,50594
5670,17764,1,,,,Intermediate,,,,10090.0,Area under curve was determined for compound after intraperitoneal administration in mice at 26 uM/kg,F,,Mus musculus,,50594
5671,17764,1,,,,Intermediate,,,,10090.0,Area under curve was determined for compound after intravenous administration in mice at 24 uM/kg,A,,Mus musculus,,50594
5672,17753,1,,,,Intermediate,,,,10090.0,Area under curve was determined for the compound at 24 mg/Kg,A,,Mus musculus,,50594
5673,17753,1,,,,Intermediate,,,,10090.0,Area under curve was determined for the compound at 40 mg/Kg,A,,Mus musculus,,50594
5674,17753,1,,,,Intermediate,,,,10090.0,Area under curve was determined for the compound at 5 mg/Kg,A,,Mus musculus,,50594
5675,3132,1,,,,Intermediate,,,,10090.0,Area under the curve for the compound is obtained at dose 25 mg/kg,A,,Mus musculus,,50594
5676,3132,1,,,,Intermediate,,,,10090.0,Area under the curve for the compound was obtained when tested in mouse,A,,Mus musculus,,50594
5677,17837,1,,,,Intermediate,,,,10090.0,Area under the curve of compound in mouse blood following i.v. administration of 10 mg/kg,A,,Mus musculus,,50594
5678,17837,1,,,,Intermediate,,,,10090.0,Area under the curve of compound in mouse blood following p.o. administration of 30 mg/kg,A,,Mus musculus,,50594
5679,6062,1,,,,Intermediate,,,,10090.0,Area under the curve was measured in mouse after an iv dose of 1 mg/kg,A,,Mus musculus,,50594
5680,4066,1,,,,Intermediate,,,,10090.0,Area under the curve was determined for the compound at a single subcutaneous administration of 40 mg/kg in mice,A,,Mus musculus,,50594
5681,16597,1,,,,Intermediate,,,,10090.0,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),A,,Mus musculus,,50594
5682,14239,1,,,,Intermediate,,,,10090.0,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice,A,,Mus musculus,,50594
5683,14239,1,,,,Intermediate,,,,10090.0,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice,A,,Mus musculus,,50594
5684,4890,1,,,,Intermediate,,,,10090.0,"Compound was evaluated for the pharmacokinetic parameter, area under curve",A,,Mus musculus,,50594
5685,429,1,,,,Intermediate,,,,10090.0,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr ),A,,Mus musculus,,50594
5686,429,1,,,,Intermediate,,,,10090.0,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr),A,,Mus musculus,,50594
5687,5969,1,,,,Intermediate,,,,10090.0,In vivo area under curve (AUC) was determined in murine septicemia at dose of 100 mg/kg,A,,Mus musculus,,50594
5688,5969,1,,,,Intermediate,,,,10090.0,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg,A,,Mus musculus,,50594
5689,5969,1,,,,Intermediate,,,,10090.0,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,A,,Mus musculus,,50594
5690,6091,1,,,,Intermediate,,,,10090.0,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse,A,,Mus musculus,,50594
5691,6091,1,,,,Intermediate,,,,10090.0,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse;ND=Not determined,A,,Mus musculus,,50594
5692,6091,1,,,,Intermediate,,,,10090.0,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice,A,,Mus musculus,,50594
5693,6091,1,,,,Intermediate,,,,10090.0,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice;ND=Not determined,A,,Mus musculus,,50594
5694,6178,1,,,,Intermediate,,,,10090.0,Pharmacokinetic property (AUC) was determined after ip administration of 32 mg/kg in mice,A,,Mus musculus,,50594
5695,6178,1,,,,Intermediate,,,,10090.0,Pharmacokinetic property (AUC) was determined after po administration of 32 mg/kg in mice,A,,Mus musculus,,50594
5696,6619,1,,,,Intermediate,,,,10090.0,"Reduction in area under curve was determined in DIO mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",A,,Mus musculus,,50594
5697,6619,1,,,,Intermediate,,,,10090.0,"Reduction in area under curve was determined in ob/ob mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",A,,Mus musculus,,50594
5698,3760,1,,,,Intermediate,,,,10090.0,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered intravenously in mice",A,,Mus musculus,,50594
5699,3760,1,,,,Intermediate,,,,10090.0,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered perorally in mice",A,,Mus musculus,,50594
5700,3760,1,,,,Intermediate,,,,10090.0,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered intravenously in mice",A,,Mus musculus,,50594
5701,3760,1,,,,Intermediate,,,,10090.0,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered perorally in mice",A,,Mus musculus,,50594
5702,3192,1,,,,Intermediate,,,,10090.0,The area under curve in vivo in mouse blood level after oral administration at dose 50 mk/kg e-1,A,,Mus musculus,,50594
5703,3192,1,,,,Intermediate,,,,10090.0,The area under curve in vivo in mouse blood level after subcutaneous administration at dose 50 mk/kg e-1,A,,Mus musculus,,50594
5704,2675,1,,,,Intermediate,,,,10090.0,Area under the curve was evaluated in mice after intravenous administration,A,,Mus musculus,,50594
5705,2675,1,,,,Intermediate,,,,10090.0,Area under the curve was evaluated in mice after oral administration,A,,Mus musculus,,50594
5706,16597,1,,,,Intermediate,1969.0,,Plasma,10090.0,AUC total value at a dose of 10 mg/kg intravenous administration in mice.,A,,Mus musculus,,50594
5707,16597,1,,,,Intermediate,1969.0,,Plasma,10090.0,AUC total value at a dose of 10 mg/kg peroral administration in mice.,A,,Mus musculus,,50594
5708,16597,1,,,,Intermediate,,,,10090.0,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),A,,Mus musculus,,50594
5709,17734,1,,,,Intermediate,,,,10090.0,AUMC after intraperitoneal administration of 100 mg/kg in mice,A,,Mus musculus,,50594
5710,7767,1,,,,Intermediate,178.0,,Blood,10090.0,Biodistribution in blood was determined in mice after iv administration at 15 min Value expressed as percent injected dose per gram,A,In vivo,Mus musculus,,50594
5711,15345,1,,392.0,,Intermediate,,9L,,,The compound was tested in vitro for anticancer activity against 9L cells,F,,,,80653
5712,2181,0,,,,Autocuration,,,,10116.0,Anti proliferation activity determined; Weak effect,F,,Rattus norvegicus,,22226
5713,2181,0,,,,Autocuration,,,,10116.0,Inhibition of cell growth by compound at a concentration of 100 uM in 9Ltk+ cells; Completely stopped the process,F,,Rattus norvegicus,,22226
5714,2181,0,,,,Autocuration,,,,10116.0,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells,F,,Rattus norvegicus,,22226
5715,2181,0,,,,Autocuration,,,,10116.0,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells; Completely stopped the process,F,,Rattus norvegicus,,22226
5716,10486,0,,,,Autocuration,,,,10090.0,The cytotoxic activity was in vitro tested by 9PS assay method,F,,Mus musculus,,22226
5717,10486,0,,,,Autocuration,,,,10090.0,The cytotoxic activity was in vitro tested by 9PS assay method.,F,,Mus musculus,,22226
5718,15508,0,,,,Autocuration,,,,,Partition coefficient (logD6.5),A,,,,22224
5719,5242,1,,478.0,,Expert,,A2780,,9606.0,Inhibitory concentration in vitro for cytotoxic activity against A 2780 human ovarian carcinoma cells,F,,Homo sapiens,,81034
5720,16167,1,,455.0,,Intermediate,,A-375,,9606.0,Effective concentration against A 375 cell line growth (DFMO concentration is 5.0 mM),F,,Homo sapiens,,80018
5721,4782,1,,500.0,,Expert,,A-431,,9606.0,Inhibitory concentration required against A 431 human epidermoid carcinoma cell line,F,,Homo sapiens,,80852
5722,16093,9,,500.0,,Expert,,A-431,,9606.0,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,F,,Homo sapiens,,9
5723,2596,1,,624.0,,Intermediate,,A498,,9606.0,Compound was evaluated for in vitro cytotoxicity against A 498 cancer cell line,F,,Homo sapiens,,80021
5724,2596,1,,624.0,,Intermediate,,A498,,9606.0,in vitro cytotoxicity against A 498 cancer cell line,F,,Homo sapiens,,80021
5725,3239,1,,624.0,,Intermediate,,A498,,9606.0,In vitro cytotoxic activity against renal (A 498) cancer cell line.,F,,Homo sapiens,,80021
5726,1847,1,,624.0,,Intermediate,,A498,,9606.0,Cytotoxic activity against A 498 renal cancer cell lines.,F,,Homo sapiens,,80021
5727,10553,1,,624.0,,Intermediate,,A498,,9606.0,In vitro cytotoxicity was determined against A 498 human renal tumor cell line using NCI screen,F,,Homo sapiens,,80021
5728,16219,0,,,,Autocuration,,,,1280.0,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,F,,Staphylococcus aureus,,22226
5729,16219,0,,,,Autocuration,,,,1280.0,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,F,,Staphylococcus aureus,,22226
5730,16219,0,,,,Autocuration,,,,1280.0,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,F,,Staphylococcus aureus,,22226
5731,16219,0,,,,Autocuration,,,,1280.0,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,F,,Staphylococcus aureus,,22226
5732,4782,1,,646.0,,Intermediate,,A549,,9606.0,Inhibitory concentration required against A 549 lung cancer cell line,F,,Homo sapiens,,80682
5733,11805,1,,646.0,,Intermediate,,A549,,9606.0,Growth inhibition of A 549 cell line by MTT reduction for 3 days of incubation time,F,,Homo sapiens,,80682
5734,11805,1,,646.0,,Intermediate,,A549,,9606.0,Growth inhibition of A 549 cell line by MTT reduction for 7 days of incubation time,F,,Homo sapiens,,80682
5735,2007,1,,646.0,,Intermediate,,A549,,9606.0,In vitro cytotoxicity against lung cancer A 549 cell lines,F,,Homo sapiens,,80682
5736,4594,1,,646.0,,Intermediate,,A549,,9606.0,Compound was tested for its cytotoxicity against A 549 cell line,F,,Homo sapiens,,80682
5737,6018,1,,646.0,,Expert,,A549,,9606.0,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.",F,,Homo sapiens,,80682
5738,6018,1,,646.0,,Intermediate,,A549,,9606.0,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.; No data",F,,Homo sapiens,,80682
5739,3599,1,,646.0,,Expert,,A549,,9606.0,In vitro cytotoxic activity against A 549 (non-small cell lung) using SRB (sulforhodamine B) assay,F,,Homo sapiens,,80682
5740,2551,1,,646.0,,Intermediate,,A549,,9606.0,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,F,,Homo sapiens,,80682
5741,16132,1,,646.0,,Expert,,A549,,9606.0,In vitro inhibition of A549 (human lung cancer) cell growth.,F,,Homo sapiens,,80682
5742,16132,1,,646.0,,Intermediate,,A549,,9606.0,Cytotoxic related antitumor activity against human cancer cell lines A 549; No data available,F,,Homo sapiens,,80682
5743,2551,1,,646.0,,Expert,,A549,,9606.0,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,F,,Homo sapiens,,80682
5744,2551,1,,646.0,,Expert,,A549,,9606.0,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay; not active (> 100 uM),F,,Homo sapiens,,80682
5745,11913,0,,,,Autocuration,,,,,Tested against A II at (100 ng/kg iv) in Dawley rats (n=2). 24 h,F,,,,22226
5746,12621,4,,,,Autocuration,,,,,The duration of action for the % peak inhibition of A II pressor response for dose of 0.1 mg/kg intravenous administration in conscious dogs.,F,In vivo,,,104694
5747,12621,4,,,,Autocuration,,,,,The duration of action for the % peak inhibition of A II pressor response for dose of 1.0 mg/kg peroral administration in rhesus monkeys.,F,In vivo,,,104694
5748,12621,4,,,,Autocuration,,,,,The duration of action for the % peak inhibition of angiotensin II pressor response for dose of 0.1 mg/kg peroral administration in conscious rats.,F,In vivo,,,104694
5749,12621,4,,,,Autocuration,,,,,The compound was evaluated for the % peak inhibition of A II pressor response for dose of 0.3 mg/kg peroral administration in rhesus monkeys.,F,In vivo,,,104694
5750,12621,4,,,,Autocuration,,,,,The compound was evaluated for the percentage of inhibition of A II pressor response in rats for peroral administration.,F,In vivo,,,104694
5751,3600,1,,624.0,,Expert,,A498,,9606.0,Inhibition of A-498 human Renal cell proliferation,F,,Homo sapiens,,80021
5752,1796,0,,,,Autocuration,,,,10116.0,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 0.1 uM",F,,Rattus norvegicus,,22226
5753,1796,0,,,,Autocuration,,,,10116.0,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 1 uM",F,,Rattus norvegicus,,22226
5754,1796,0,,,,Autocuration,,,,10116.0,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 10 uM",F,,Rattus norvegicus,,22226
5755,16464,1,,622.0,,Expert,,A 172,,9606.0,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay,F,,Homo sapiens,,80012
5756,16464,1,,622.0,,Intermediate,,A 172,,9606.0,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,F,,Homo sapiens,,80012
5757,16464,1,,622.0,,Intermediate,,A 172,,9606.0,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,F,,Homo sapiens,,80012
5758,13617,1,,646.0,,Expert,,A549,,9606.0,Concentration required to inhibit growth of human tumor A549 (NSCL) cell line.,F,,Homo sapiens,,80682
5759,4584,1,,646.0,,Intermediate,,A549,,9606.0,Concentration which produces 50% inhibition of growth of human lung carcinoma cell line A549,F,,Homo sapiens,,80682
5760,13799,1,,646.0,,Expert,,A549,,9606.0,Cytotoxic activity evaluated against A549 tumor cells,F,,Homo sapiens,,80682
5761,16726,1,,646.0,,Intermediate,,A549,,9606.0,Cytotoxic potentiation of Topotecan (TP) by the compound in human lung carcinoma A549 cell line,F,,Homo sapiens,,80682
5762,16109,1,,646.0,,Intermediate,,A549,,9606.0,Cytotoxicity against A549 cells when the drug is exposed for a time of 1 hr,F,,Homo sapiens,,80682
5763,16109,1,,646.0,,Intermediate,,A549,,9606.0,Cytotoxicity against A549 cells when the drug is exposed for a time of 96 hrs,F,,Homo sapiens,,80682
5764,15474,1,,646.0,,Intermediate,,A549,,9606.0,Cytotoxicity against A549 tumor cell line determined by WST-1 assay,F,,Homo sapiens,,80682
5765,6851,1,,646.0,,Intermediate,,A549,,9606.0,Cytotoxicity of compound against A549 cell line,F,,Homo sapiens,,80682
5766,17534,1,,646.0,,Expert,,A549,,9606.0,Cytotoxicity against human lung cell carcinoma A549 cell line,F,,Homo sapiens,,80682
5767,2621,1,,646.0,,Intermediate,,A549,,9606.0,Cytotoxicity against human lung carcinoma A549 cell line using MTT assay,F,,Homo sapiens,,80682
5768,830,1,,646.0,,Intermediate,,A549,,9606.0,Cytotoxicity was evaluated in vitro against A549 (non-small cell lung carcinoma) human tumor cell lines,F,,Homo sapiens,,80682
5769,14255,1,,646.0,,Intermediate,,A549,,9606.0,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum,F,,Homo sapiens,,80682
5770,14255,1,,646.0,,Intermediate,,A549,,9606.0,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum; Not determined,F,,Homo sapiens,,80682
5771,1590,1,,646.0,,Intermediate,,A549,,9606.0,In vitro antitumor activity against A549 human NSCLC lung carcinoma cells,F,,Homo sapiens,,80682
5772,6146,1,,646.0,,Expert,,A549,,9606.0,In vitro concentration required to inhibit the TNF-alpha-induced RANTES production in A549 human lung epithelium cell line,F,,Homo sapiens,,80682
5773,17427,1,,646.0,,Expert,,A549,,9606.0,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,F,,Homo sapiens,,80682
5774,5280,1,,646.0,,Intermediate,,A549,,9606.0,In vitro cytotoxicity against parental and drug resistant lung human tumor cell line A549,F,,Homo sapiens,,80682
5775,16786,1,,646.0,,Intermediate,,A549,,9606.0,In vitro cytotoxicity of compound against human A549 (non small cell lung) cancer cell line after 72 hr of drug exposure,F,,Homo sapiens,,80682
5776,5895,1,,646.0,,Intermediate,,A549,,9606.0,In vitro cytotoxicity against A549 (human lung cancer),F,,Homo sapiens,,80682
5777,14297,1,,646.0,,Expert,,A549,,9606.0,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,F,,Homo sapiens,,80682
5778,17824,1,,646.0,,Intermediate,,A549,,9606.0,In vivo antiproliferative activity against A549 cell line,F,,Homo sapiens,,80682
5779,14368,1,,646.0,,Intermediate,,A549,,9606.0,Inhibition of non-small-cell lung adenocarcinoma (A549),F,,Homo sapiens,,80682
5780,14368,1,,646.0,,Intermediate,,A549,,9606.0,Inhibition of non-small-cell lung adenocarcinoma (A549) after 48-h treatment,F,,Homo sapiens,,80682
5781,14254,1,,646.0,,Intermediate,,A549,,9606.0,Inhibition of the growth against human non-small-lung carcinoma (A549) cell line after 72 hr exposure,F,,Homo sapiens,,80682
5782,15897,1,,646.0,,Intermediate,,A549,,9606.0,Inhibitory activity against A549 cell line using MTT assay(Wild type p53),F,,Homo sapiens,,80682
5783,13866,1,,646.0,,Intermediate,,A549,,9606.0,Inhibitory activity against A549 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,F,,Homo sapiens,,80682
5784,13370,1,,646.0,,Intermediate,,A549,,9606.0,Inhibitory activity of compound against human A549 lung carcinoma cell line.,F,,Homo sapiens,,80682
5785,4862,1,,646.0,,Intermediate,,A549,,9606.0,Inhibitory activity against A549 lung cancer cell line,F,,Homo sapiens,,80682
5786,4862,1,,646.0,,Intermediate,,A549,,9606.0,Inhibitory activity against Taxol-resistant A549 lung cancer cell line,F,,Homo sapiens,,80682
5787,4862,1,,646.0,,Intermediate,,A549,,9606.0,Inhibitory activity against Taxol-resistant A549 lung cancer cell line; not determined,F,,Homo sapiens,,80682
5788,15970,1,,646.0,,Intermediate,,A549,,9606.0,Inhibitory concentration against A549 (lung cancer) cell line,F,,Homo sapiens,,80682
5789,17713,1,,646.0,,Expert,,A549,,9606.0,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,F,,Homo sapiens,,80682
5790,4833,1,,646.0,,Intermediate,,A549,,9606.0,Tested in vitro for inhibitory effect on the growth of human A-549 cancer cell line,F,,Homo sapiens,,80682
5791,13736,1,,646.0,,Expert,,A549,,9606.0,Activity against A549 cancer cell line.,F,,Homo sapiens,,80682
5792,4312,1,,646.0,,Intermediate,,A549,,9606.0,The compound was evaluated for cytotoxicity against A549 cell line,F,,Homo sapiens,,80682
5793,5421,1,,646.0,,Intermediate,,A549,,9606.0,The compound was examined for its ability to block tumor necrosis factor alpha (TNF alpha) induced IL-8 production in A549 human lung carcinoma cell line using an ELISA,F,,Homo sapiens,,80682
5794,5421,1,,646.0,,Intermediate,,A549,,9606.0,The compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,F,,Homo sapiens,,80682
5795,14717,1,,646.0,,Intermediate,,A549,,9606.0,Growth inhibitory activity was measured for human A549 tumor cell line.,F,,Homo sapiens,,80682
5796,4634,1,,646.0,,Intermediate,,A549,,9606.0,Inhibitory activity against A549 lung cancer cell line,F,,Homo sapiens,,80682
5797,1149,1,,646.0,,Intermediate,,A549,,9606.0,Inhibitory activity against A549 cell line; inactive,F,,Homo sapiens,,80682
5798,5421,1,,646.0,,Expert,,A549,,9606.0,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,F,,Homo sapiens,,80682
5799,5421,1,,646.0,,Expert,,A549,,9606.0,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,F,,Homo sapiens,,80682
5800,5421,1,,646.0,,Intermediate,,A549,,9606.0,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,F,,Homo sapiens,,80682
5801,3320,1,,646.0,,Intermediate,,A549,,9606.0,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-4 (M/L),F,,Homo sapiens,,80682
5802,3320,1,,646.0,,Intermediate,,A549,,9606.0,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-5 (M/L),F,,Homo sapiens,,80682
5803,3320,1,,646.0,,Intermediate,,A549,,9606.0,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-6 (M/L),F,,Homo sapiens,,80682
5804,3320,1,,646.0,,Intermediate,,A549,,9606.0,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-7 (M/L),F,,Homo sapiens,,80682
5805,3320,1,,646.0,,Intermediate,,A549,,9606.0,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-8 (M/L),F,,Homo sapiens,,80682
5806,5726,1,,646.0,,Intermediate,,A549,,9606.0,In vitro percent inhibition evaluated against human lung cancer (A549 cell line) at >20 ug/mL,F,,Homo sapiens,,80682
5807,17800,1,,,,Intermediate,,,,9615.0,Plasma clearance (in vivo) in mongrel dogs was determined,A,In vivo,Canis lupus familiaris,,50588
5808,5985,1,,,,Intermediate,,,,9615.0,Plasma clearance was measured in dog,A,In vivo,Canis lupus familiaris,,50588
5809,5530,1,,,,Intermediate,,,,9615.0,Plasma clearance in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,A,In vivo,Canis lupus familiaris,,50588
5810,5530,1,,,,Intermediate,,,,9615.0,Plasma clearance in vivo in dog by intravenous administration at a dose of 1 mg/kg,A,In vivo,Canis lupus familiaris,,50588
5811,4839,1,,,,Intermediate,1969.0,,Plasma,9615.0,Tested for plasma clearance in dog,A,In vivo,Canis lupus familiaris,,50588
5812,3639,1,,,,Intermediate,,,,9615.0,The compound was tested for clearance in dog plasma.,A,In vivo,Canis lupus familiaris,,50588
5813,4838,1,,,,Intermediate,,,,9615.0,"The pharmacokinetic parameter, clearance was reported in dog after intravenous administration",A,In vivo,Canis lupus familiaris,,50588
5814,4137,1,,,,Intermediate,,,,9615.0,Clearance value of compound was determined after intravenous administration of 1 mg/kg/h in dog,A,In vivo,Canis lupus familiaris,,50588
5815,5017,1,,,,Intermediate,1969.0,,Plasma,9615.0,Compound was tested for its ability of plasma clearance when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),A,In vivo,Canis lupus familiaris,,50588
5816,17538,1,,,,Intermediate,2107.0,,Liver,9615.0,In vitro clearance in dog liver microsomes,A,In vitro,Canis lupus familiaris,Microsomes,50588
5817,6161,1,,,,Intermediate,,,,9615.0,Pharmacokinetic profile in terms of clearance was determined at a dose of 0.5 mg/kg administered intravenously in dog,A,In vivo,Canis lupus familiaris,,50588
5818,6161,1,,,,Intermediate,,,,9615.0,Pharmacokinetic profile in terms of clearance was determined at a dose of 5 mg/kg administered intravenously in dog,A,In vivo,Canis lupus familiaris,,50588
5819,1696,1,,,,Intermediate,,,,9615.0,Plasma clearance in dog,A,In vivo,Canis lupus familiaris,,50588
5820,6762,1,,,,Intermediate,,,,9615.0,Clearance rate in dog,A,In vivo,Canis lupus familiaris,,50588
5821,5932,1,,,,Intermediate,1969.0,,Plasma,9615.0,Plasma concentration in dogs after 2 hr at 30mg/kg oral dose,A,In vivo,Canis lupus familiaris,,50588
5822,6305,1,,,,Intermediate,,,,9615.0,Clearance in dogs,A,In vivo,Canis lupus familiaris,,50588
5823,4942,1,,,,Intermediate,,,,9615.0,Plasma clearance in dogs,A,In vivo,Canis lupus familiaris,,50588
5824,4219,1,,,,Intermediate,,,,9615.0,Plasma clearance was determined,A,In vivo,Canis lupus familiaris,,50588
5825,17853,1,,,,Intermediate,,,,9615.0,Lower clearance in dog (i.v.) at 0.5 mpk,A,In vivo,Canis lupus familiaris,,50588
5826,4514,1,,,,Intermediate,,,,9615.0,Plasma clearance in Beagle dogs,A,In vivo,Canis lupus familiaris,,50588
5827,6448,1,,,,Intermediate,,,,9615.0,Plasma clearance (Clp) in dog,A,In vivo,Canis lupus familiaris,,50588
5828,6227,1,,,,Intermediate,,,,9615.0,Plasma clearance (pharmacokinetic parameter) in dog (in vivo) at a dose of 1 mg/kg,A,In vivo,Canis lupus familiaris,,50588
5829,6227,1,,,,Intermediate,,,,9615.0,Plasma clearance (pharmacokinetic parameter) in dog was determined,A,In vivo,Canis lupus familiaris,,50588
5830,6062,1,,,,Intermediate,,,,9615.0,Plasma clearance for the compound was measured in dog after an iv dose of 1 mg/kg,A,In vivo,Canis lupus familiaris,,50588
5831,6821,1,,,,Intermediate,,,,9615.0,Plasma clearance of compound was determined in dog,A,In vivo,Canis lupus familiaris,,50588
5832,4709,1,,,,Intermediate,,,,9615.0,Plasma clearance after intravenous administration of 1 mg/kg in dog,A,In vivo,Canis lupus familiaris,,50588
5833,4521,1,,,,Intermediate,,,,9615.0,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,A,In vivo,Canis lupus familiaris,,50588
5834,5374,1,,,,Intermediate,,,,9615.0,Plasma clearance in dog was determined,A,In vivo,Canis lupus familiaris,,50588
5835,6057,1,,,,Intermediate,,,,9615.0,Plasma clearance was calculated in dog,A,In vivo,Canis lupus familiaris,,50588
5836,4727,1,,,,Intermediate,,,,9615.0,Plasma clearance at the dose of 2 mg/kg in dog,A,In vivo,Canis lupus familiaris,,50588
5837,5145,1,,,,Intermediate,,,,9615.0,Plasma clearance in dog,A,In vivo,Canis lupus familiaris,,50588
5838,17657,1,,,,Intermediate,,,,9615.0,Plasma clearance in dog,A,In vivo,Canis lupus familiaris,,50588
5839,17657,1,,,,Intermediate,,,,9615.0,Plasma clearance in dog; Unable to calculate,A,In vivo,Canis lupus familiaris,,50588
5840,5145,1,,,,Intermediate,,,,9615.0,Plasma clearance in rhesus monkey,A,In vivo,Canis lupus familiaris,,50588
5841,6642,1,,,,Intermediate,,,,9615.0,Plasma clearance in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),A,In vivo,Canis lupus familiaris,,50588
5842,6641,1,,,,Intermediate,,,,9615.0,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),A,In vivo,Canis lupus familiaris,,50588
5843,6642,1,,,,Intermediate,,,,9615.0,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),A,In vivo,Canis lupus familiaris,,50588
5844,5472,1,,,,Intermediate,,,,9615.0,Plasma clearance was evaluated in dog,A,In vivo,Canis lupus familiaris,,50588
5845,5472,1,,,,Intermediate,,,,9615.0,Plasma clearance was evaluated in dog; Not tested,A,In vivo,Canis lupus familiaris,,50588
5846,5472,1,,,,Intermediate,,,,9615.0,Plasma clearance was evaluated in rhesus,A,In vivo,Canis lupus familiaris,,50588
5847,5472,1,,,,Intermediate,,,,9615.0,Plasma clearance was evaluated in rhesus; Not tested,A,In vivo,Canis lupus familiaris,,50588
5848,4257,1,,,,Intermediate,,,,9615.0,Plasma clearance value was determined in dog after a 3 mg/kg of iv dose,A,In vivo,Canis lupus familiaris,,50588
5849,6679,1,,,,Intermediate,,,,9615.0,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,A,In vivo,Canis lupus familiaris,,50588
5850,5546,1,,,,Intermediate,,,,9615.0,Plasma clearance was determined in Beagle dog at a dose of 1 mg/kg by iv administration,A,In vivo,Canis lupus familiaris,,50588
5851,6348,1,,,,Intermediate,,,,9615.0,Plasma clearance was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,A,In vivo,Canis lupus familiaris,,50588
5852,5474,1,,,,Intermediate,,,,9615.0,Clearance value at a dose of 0.2 mg/kg i.v.,A,In vivo,Canis lupus familiaris,,50588
5853,6316,1,,,,Intermediate,1969.0,,Plasma,9615.0,Cmax (Maximum (Peak) plasma drug concentration) was after oral administration at 5 mg/kg,A,In vivo,Canis lupus familiaris,,50588
5854,17594,1,,,,Intermediate,,,,9615.0,Cmax after oral dose of compound at 3 mg/kg in dogs,A,In vivo,Canis lupus familiaris,,50588
5855,17594,1,,,,Intermediate,,,,9615.0,Cmax after single intravenous bolus of 1 mg/kg in dogs,A,In vivo,Canis lupus familiaris,,50588
5856,5802,1,,,,Intermediate,,,,9615.0,Cmax of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,A,In vivo,Canis lupus familiaris,,50588
5857,6535,1,,,,Intermediate,,,,9615.0,Cmax in dog after administration of 0.25 mg/kg iv; ND = not determined,A,In vivo,Canis lupus familiaris,,50588
5858,6535,1,,,,Intermediate,,,,9615.0,Cmax in dog after administration of 1 mg/kg iv,A,In vivo,Canis lupus familiaris,,50588
5859,1466,1,,,,Intermediate,1969.0,,Plasma,9615.0,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in dog,A,In vivo,Canis lupus familiaris,,50588
5860,6505,1,,,,Intermediate,,,,9615.0,Cmax on p.o. administration of 10 mg/kg was measured in dog,A,In vivo,Canis lupus familiaris,,50588
5861,5668,1,,,,Intermediate,,,,9615.0,Cmax was determine after peroral administration at 10 mpk in dog,A,In vivo,Canis lupus familiaris,,50588
5862,5668,1,,,,Intermediate,,,,9615.0,Cmax was determine after peroral administration at 5 mpk in dog,A,In vivo,Canis lupus familiaris,,50588
5863,5668,1,,,,Intermediate,,,,9615.0,Cmax was determine after peroral administration at 5 mg/kg in dog,A,In vivo,Canis lupus familiaris,,50588
5864,5600,1,,,,Intermediate,,,,9615.0,Cmax after 0.3 mg/kg po administration in dog,A,In vivo,Canis lupus familiaris,,50588
5865,17764,1,,,,Intermediate,,,,9615.0,Cmax after peroral administration in dogs at 2.4 uM/kg,A,In vivo,Canis lupus familiaris,,50588
5866,6123,1,,,,Intermediate,,,,9615.0,Cmax in dog after oral administration at 1 mg/kg,A,In vivo,Canis lupus familiaris,,50588
5867,6123,1,,,,Intermediate,,,,9615.0,Cmax in dog after oral administration at 1 mg/kg; Below the level of quantitation,A,In vivo,Canis lupus familiaris,,50588
5868,6757,1,,,,Intermediate,,,,9615.0,Cmax upon oral administration in male Beagle dog at 10 mg/kg,A,In vivo,Canis lupus familiaris,,50588
5869,16907,1,,,,Intermediate,,,,9615.0,Cmax value after 15 mg/kg iv dose in Dogs,A,In vivo,Canis lupus familiaris,,50588
5870,7767,1,,,,Intermediate,178.0,,Blood,10090.0,Biodistribution in blood was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,Mus musculus,,50594
5871,7767,1,,,,Intermediate,178.0,,Blood,10090.0,Biodistribution in blood was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,Mus musculus,,50594
5872,7767,1,,,,Intermediate,10000001.0,,Bone,10090.0,Biodistribution in bone was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,Mus musculus,,50594
5873,7767,1,,,,Intermediate,10000001.0,,Bone,10090.0,Biodistribution in bone was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,Mus musculus,,50594
5874,7767,1,,,,Intermediate,10000001.0,,Bone,10090.0,Biodistribution in bone was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,Mus musculus,,50594
5875,7767,1,,,,Intermediate,,,,10090.0,Biodistribution in fat and fur was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,Mus musculus,,50594
5876,7767,1,,,,Intermediate,,,,10090.0,Biodistribution in fat and fur was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,Mus musculus,,50594
5877,7767,1,,,,Intermediate,,,,10090.0,Biodistribution in fat and fur was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,Mus musculus,,50594
5878,7767,1,,,,Intermediate,948.0,,Heart,10090.0,Biodistribution in heart was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,Mus musculus,,50594
5879,7767,1,,,,Intermediate,948.0,,Heart,10090.0,Biodistribution in heart was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,Mus musculus,,50594
5880,7767,1,,,,Intermediate,948.0,,Heart,10090.0,Biodistribution in heart was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,Mus musculus,,50594
5881,7767,1,,,,Intermediate,2113.0,,Kidney,10090.0,Biodistribution in kidney was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,Mus musculus,,50594
5882,7767,1,,,,Intermediate,2113.0,,Kidney,10090.0,Biodistribution in kidney was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,Mus musculus,,50594
5883,7767,1,,,,Intermediate,2113.0,,Kidney,10090.0,Biodistribution in kidney was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,Mus musculus,,50594
5884,7767,1,,,,Intermediate,160.0,,Intestine,10090.0,Biodistribution in large intestine after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,Mus musculus,,50594
5885,7767,1,,,,Intermediate,160.0,,Intestine,10090.0,Biodistribution in large intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,Mus musculus,,50594
5886,7767,1,,,,Intermediate,160.0,,Intestine,10090.0,Biodistribution in large intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,Mus musculus,,50594
5887,7767,1,,,,Intermediate,2107.0,,Liver,10090.0,Biodistribution in liver was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,Mus musculus,,50594
5888,7767,1,,,,Intermediate,2107.0,,Liver,10090.0,Biodistribution in liver was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,Mus musculus,,50594
5889,7767,1,,,,Intermediate,2107.0,,Liver,10090.0,Biodistribution in liver was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,Mus musculus,,50594
5890,7767,1,,,,Intermediate,2048.0,,Lung,10090.0,Biodistribution in lung was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,Mus musculus,,50594
5891,7767,1,,,,Intermediate,2048.0,,Lung,10090.0,Biodistribution in lung was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,Mus musculus,,50594
5892,7767,1,,,,Intermediate,2048.0,,Lung,10090.0,Biodistribution in lung was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,Mus musculus,,50594
5893,7767,1,,,,Intermediate,2385.0,,Muscle tissue,10090.0,Biodistribution in muscle was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,Mus musculus,,50594
5894,7767,1,,,,Intermediate,2385.0,,Muscle tissue,10090.0,Biodistribution in muscle was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,Mus musculus,,50594
5895,7767,1,,,,Intermediate,2385.0,,Muscle tissue,10090.0,Biodistribution in muscle was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,Mus musculus,,50594
5896,7767,1,,,,Intermediate,,,,10090.0,Biodistribution in pancreatic tissue was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,Mus musculus,,50594
5897,7767,1,,,,Intermediate,,,,10090.0,Biodistribution in pancreatic tissue was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,Mus musculus,,50594
5898,7767,1,,,,Intermediate,,,,10090.0,Biodistribution in pancreatic tissue was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,Mus musculus,,50594
5899,7767,1,,,,Intermediate,160.0,,Intestine,10090.0,Biodistribution in small intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,Mus musculus,,50594
5900,7767,1,,,,Intermediate,160.0,,Intestine,10090.0,Biodistribution in small intestine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,Mus musculus,,50594
5901,7767,1,,,,Intermediate,160.0,,Intestine,10090.0,Biodistribution in small intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,Mus musculus,,50594
5902,7767,1,,,,Intermediate,2106.0,,Spleen,10090.0,Biodistribution in spleen was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,Mus musculus,,50594
5903,7767,1,,,,Intermediate,2106.0,,Spleen,10090.0,Biodistribution in spleen was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,Mus musculus,,50594
5904,7767,1,,,,Intermediate,2106.0,,Spleen,10090.0,Biodistribution in spleen was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,Mus musculus,,50594
5905,7767,1,,,,Intermediate,945.0,,Stomach,10090.0,Biodistribution in stomach was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,Mus musculus,,50594
5906,7767,1,,,,Intermediate,945.0,,Stomach,10090.0,Biodistribution in stomach was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,Mus musculus,,50594
5907,2036,1,,622.0,,Expert,,A 172,,9606.0,Cytotoxicity against A-172 human tumor cell lines,F,,Homo sapiens,,80012
5908,2357,1,,622.0,,Intermediate,,A 172,,9606.0,Compound was evaluated for the in vitro cytotoxicity against A-172 human glioblastoma cell line,F,,Homo sapiens,,80012
5909,1457,1,,623.0,,Intermediate,,A204,,9606.0,Antiproliferative activity of compound was tested against rhabdomyosarcoma (A-204) human tumor cells,F,,Homo sapiens,,80014
5910,4379,1,,478.0,,Intermediate,,A2780,,9606.0,Tested for antiproliferative activity against A-2780 tumoral cell line,F,,Homo sapiens,,81034
5911,1093,1,,455.0,,Intermediate,,A-375,,9606.0,Inhibitory concentration against melanoma A-375 cell line for cytotoxicity was determined,F,,Homo sapiens,,80018
5912,12152,1,,455.0,,Intermediate,,A-375,,9606.0,Tested in vitro against A-375 cell line human melanoma,F,,Homo sapiens,,80018
5913,16464,1,,797.0,,Expert,,A-427,,9606.0,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay,F,,Homo sapiens,,80019
5914,16464,1,,797.0,,Intermediate,,A-427,,9606.0,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,F,,Homo sapiens,,80019
5915,16582,1,,797.0,,Expert,,A-427,,9606.0,In vitro cytotoxicity against human non small-cell-lung cell line A-427.,F,,Homo sapiens,,80019
5916,16464,1,,797.0,,Intermediate,,A-427,,9606.0,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,F,,Homo sapiens,,80019
5917,10413,1,,797.0,,Intermediate,,A-427,,9606.0,Antitumor activity on A-427 lung carcinoma cell lines,F,,Homo sapiens,,80019
5918,6418,1,,797.0,,Intermediate,,A-427,,9606.0,Cytotoxic activity against human A-427 lung tumor cell line,F,,Homo sapiens,,80019
5919,17134,1,,797.0,,Expert,,A-427,,9606.0,In vitro antitumor effects against human A-427 cell lines.,F,,Homo sapiens,,80019
5920,16132,1,,797.0,,Expert,,A-427,,9606.0,In vitro inhibition of A-427 (human lung cancer) cell growth.,F,,Homo sapiens,,80019
5921,16132,1,,797.0,,Intermediate,,A-427,,9606.0,Cytotoxic related antitumor activity against human cancer cell lines A-427; No data available,F,,Homo sapiens,,80019
5922,16780,1,,797.0,,Intermediate,,A-427,,9606.0,Cytotoxic activity of compound against A-427 lung human tumor cell line,F,,Homo sapiens,,80019
5923,4085,1,,500.0,,Expert,,A-431,,9606.0,Cytotoxicity measured for the growth inhibition of A-431 Human epidermoid carcinoma cell line,F,,Homo sapiens,,80852
5924,1276,1,,624.0,,Intermediate,,A498,,9606.0,Cytotoxic activity was tested against human A-498 (Kidney carcinoma) cell line,F,,Homo sapiens,,80021
5925,3498,1,,624.0,,Expert,,A498,,9606.0,Cytotoxicity against A-498 cell line in the purdue cell culture screen was determined,F,,Homo sapiens,,80021
5926,1169,1,,624.0,,Intermediate,,A498,,9606.0,Cytotoxicity against human kidney carcinoma A-498cell lines,F,,Homo sapiens,,80021
5927,4450,1,,624.0,,Intermediate,,A498,,9606.0,In vitro cytotoxic activity against A-498 (human kidney carcinoma) cell line,F,,Homo sapiens,,80021
5928,3311,1,,624.0,,Intermediate,,A498,,9606.0,In vitro cytotoxicity against Renal A-498 human tumors following a 6 day exposure.,F,,Homo sapiens,,80021
5929,4461,1,,624.0,,Intermediate,,A498,,9606.0,Antitumor cytotoxic activity against A-498 cell line was determined,F,,Homo sapiens,,80021
5930,3311,1,,624.0,,Intermediate,,A498,,9606.0,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure.,F,,Homo sapiens,,80021
5931,3311,1,,624.0,,Intermediate,,A498,,9606.0,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure; ND is no data,F,,Homo sapiens,,80021
5932,1457,1,,624.0,,Intermediate,,A498,,9606.0,Antiproliferative activity of compound was tested against renal cancer (A-498) human tumor cells,F,,Homo sapiens,,80021
5933,3664,1,,624.0,,Intermediate,,A498,,9606.0,In vitro inhibitory activity against A-498 ovarian cancer cell lines,F,,Homo sapiens,,80021
5934,15895,1,,624.0,,Intermediate,,A498,,9606.0,"Cytotoxicity against NCI tumor panel, A-498 renal cancer cell line",F,,Homo sapiens,,80021
5935,11843,1,,646.0,,Intermediate,,A549,,9606.0,Inhibition of growth lung non-small cell carcinoma A-549 cell line,F,,Homo sapiens,,80682
5936,11843,1,,646.0,,Intermediate,,A549,,9606.0,Inhibition of growth of lung non-small cell carcinoma A-549 cell line,F,,Homo sapiens,,80682
5937,17705,1,,646.0,,Intermediate,,A549,,9606.0,In vitro antiproliferative activity against human A-549 NSCL cell line,F,,Homo sapiens,,80682
5938,17705,1,,646.0,,Intermediate,,A549,,9606.0,In vitro antiproliferative activity against human A-549 NSCL cell line; NS = Not significant,F,,Homo sapiens,,80682
5939,4369,1,,646.0,,Intermediate,,A549,,9606.0,Growth inhibition of A-549 human lung adenocarcinoma at 0.01 uM compound concentration in standard MTT assay,F,,Homo sapiens,,80682
5940,4369,1,,646.0,,Intermediate,,A549,,9606.0,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay,F,,Homo sapiens,,80682
5941,4369,1,,646.0,,Intermediate,,A549,,9606.0,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay; ND means No data,F,,Homo sapiens,,80682
5942,4369,1,,646.0,,Intermediate,,A549,,9606.0,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay,F,,Homo sapiens,,80682
5943,4369,1,,646.0,,Intermediate,,A549,,9606.0,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay; ND means No data,F,,Homo sapiens,,80682
5944,4369,1,,646.0,,Intermediate,,A549,,9606.0,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay,F,,Homo sapiens,,80682
5945,4369,1,,646.0,,Intermediate,,A549,,9606.0,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay; ND means No data,F,,Homo sapiens,,80682
5946,4787,1,,646.0,,Expert,,A549,,9606.0,In vitro effective concentration required to reduce the number of human lung carcinoma (A-549) after 3-day incubation,F,,Homo sapiens,,80682
5947,4787,1,,646.0,,Intermediate,,A549,,9606.0,In vitro effective concentration required to reduce the number of human lung carcinoma cells (A-549) after 3-day incubation,F,,Homo sapiens,,80682
5948,6513,1,,646.0,,Intermediate,,A549,,9606.0,Cytotoxic activity against A-549 cell line,F,,Homo sapiens,,80682
5949,6690,1,,646.0,,Intermediate,,A549,,9606.0,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 0.01 to 0.03,F,,Homo sapiens,,80682
5950,6690,1,,646.0,,Intermediate,,A549,,9606.0,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 10.4 to 118.1,F,,Homo sapiens,,80682
5951,12263,1,,646.0,,Expert,,A549,,9606.0,"Cytotoxicity in vitro expressed as 50% reduction in cell number after a 3-day incubation, in human lung carcinoma A-549 cell line",F,,Homo sapiens,,80682
5952,1054,1,,646.0,,Intermediate,,A549,,9606.0,Compound was tested for cytotoxic activity against human lung carcinoma (A-549),F,,Homo sapiens,,80682
5953,1359,1,,646.0,,Intermediate,,A549,,9606.0,Compound was tested for its cytotoxic activity in MTT assay against A-549 cell line (human lung carcinoma),F,,Homo sapiens,,80682
5954,3547,1,,646.0,,Intermediate,,A549,,9606.0,Cytotoxic activity against human lung carcinoma (A-549) cell line,F,,Homo sapiens,,80682
5955,5771,1,,646.0,,Expert,,A549,,9606.0,Cytotoxic activity towards A-549 cells,F,,Homo sapiens,,80682
5956,14425,1,,646.0,,Intermediate,,A549,,9606.0,"In vitro percent inhibition of A549, lung carcinoma.",F,,Homo sapiens,,80682
5957,14425,1,,646.0,,Intermediate,,A549,,9606.0,"In vitro percent inhibition of A549, lung carcinoma",F,,Homo sapiens,,80682
5958,14425,1,,646.0,,Intermediate,,A549,,9606.0,"In vitro percent inhibition of A549, lung carcinoma.",F,,Homo sapiens,,80682
5959,14425,1,,646.0,,Intermediate,,A549,,9606.0,"In vitro percent inhibition of A549, lung carcinoma.; Range 18-23",F,,Homo sapiens,,80682
5960,5280,1,,646.0,,Intermediate,,A549,,9606.0,Percentage inhibition against parental and drug resistant lung human tumor cell line A549 at 10 uM,F,,Homo sapiens,,80682
5961,15176,1,,646.0,,Intermediate,,A549,,9606.0,Growth inhibition of the A549/ATCC non-small cell lung cancer cell line for 2-day in vitro assay.,F,,Homo sapiens,,80682
5962,15300,1,,646.0,,Intermediate,,A549,,9606.0,In vitro antitumor activity against Non-small cell lung cancer A549/ATCC cell lines by 6-day assay,F,,Homo sapiens,,80682
5963,17824,1,,646.0,,Intermediate,,A549,,9606.0,"Antitumor activity against A549 non small cell carcinoma at dose range of 1.56-6.25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",F,,Homo sapiens,,80682
5964,17824,1,,646.0,,Intermediate,,A549,,9606.0,"Antitumor activity against A549 non small cell carcinoma at dose range of 25-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",F,,Homo sapiens,,80682
5965,17824,1,,646.0,,Intermediate,,A549,,9606.0,"Antitumor activity against A549 non small cell carcinoma at dose range of 3.12-12.5 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",F,,Homo sapiens,,80682
5966,17824,1,,646.0,,Intermediate,,A549,,9606.0,"Antitumor activity against A549 non small cell carcinoma at dose range of 6.25-25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",F,,Homo sapiens,,80682
5967,17824,1,,646.0,,Intermediate,,A549,,9606.0,"Antitumor activity against A549 non small cell carcinoma at dose range of 70-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",F,,Homo sapiens,,80682
5968,17824,1,,646.0,,Intermediate,,A549,,9606.0,"Antitumor activity against A549 non small cell carcinoma on day 14, 21, 28; activity expressed as maximum tolerated dose; NT = Not tested",F,,Homo sapiens,,80682
5969,17528,1,,646.0,,Intermediate,,A549,,9606.0,Optimal dose required to inhibit human non small cell lung A549 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q7dX3),F,,Homo sapiens,,80682
5970,6870,1,,646.0,,Expert,,A549,,9606.0,Cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration,F,,Homo sapiens,,80682
5971,6870,1,,646.0,,Intermediate,,A549,,9606.0,Compound was evaluated for cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,F,,Homo sapiens,,80682
5972,6870,1,,646.0,,Intermediate,,A549,,9606.0,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration,F,,Homo sapiens,,80682
5973,6870,1,,646.0,,Intermediate,,A549,,9606.0,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,F,,Homo sapiens,,80682
5974,16726,1,,646.0,,Intermediate,,A549,,9606.0,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,F,,Homo sapiens,,80682
5975,6170,1,,646.0,,Intermediate,,A549,,9606.0,"Concentration required for 50% inhibition of proliferation of lung cancer cell line, A549 with respect to paclitaxel was tested in vitro after 72 hr of incubation",F,,Homo sapiens,,80682
5976,6583,1,,646.0,,Expert,,A549,,9606.0,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-4 mol/L,F,,Homo sapiens,,80682
5977,6583,1,,646.0,,Expert,,A549,,9606.0,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-5 mol/L,F,,Homo sapiens,,80682
5978,6583,1,,646.0,,Expert,,A549,,9606.0,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-6 mol/L,F,,Homo sapiens,,80682
5979,6583,1,,646.0,,Expert,,A549,,9606.0,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-7 mol/L,F,,Homo sapiens,,80682
5980,6583,1,,646.0,,Expert,,A549,,9606.0,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-8 mol/L,F,,Homo sapiens,,80682
5981,17321,1,,646.0,,Intermediate,,A549,,9606.0,Tested for cytotoxicity against human lung adenocarcinoma A549 cell line,F,,Homo sapiens,,80682
5982,17528,1,,646.0,,Expert,,A549,,9606.0,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,F,,Homo sapiens,,80682
5983,12888,1,,646.0,,Expert,,A549,,9606.0,Cytotoxic effect on non-small-cell lung cancer cell line A549/ATCC,F,,Homo sapiens,,80682
5984,4312,1,,646.0,,Intermediate,,A549,,9606.0,Cytotoxicity of compound in synergy in 94% BCNU (10 uM) against A549 cell line,F,,Homo sapiens,,80682
5985,4312,1,,646.0,,Intermediate,,A549,,9606.0,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line,F,,Homo sapiens,,80682
5986,4312,1,,646.0,,Intermediate,,A549,,9606.0,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line; No data,F,,Homo sapiens,,80682
5987,17737,1,,646.0,,Intermediate,,A549,,10090.0,In vitro antiproliferative activity against A549 cell line,F,,Mus musculus,,80682
5988,6630,1,,646.0,,Intermediate,,A549,,,Synergism with indomethacin in A549 cells,F,,,,80682
5989,6630,1,,646.0,,Intermediate,,A549,,,Synergism with tolmetin in A549 cells,F,,,,80682
5990,6630,1,,646.0,,Intermediate,,A549,,,Synergism with sulindac in A549 cells,F,,,,80682
5991,6630,1,,646.0,,Intermediate,,A549,,,Antagonism of indomethacin in A549 cells,F,,,,80682
5992,6630,1,,646.0,,Intermediate,,A549,,,Antagonism of sulindac in A549 cells,F,,,,80682
5993,6630,1,,646.0,,Intermediate,,A549,,,Antagonism of tolmetin in A549 cells,F,,,,80682
5994,6630,1,,646.0,,Intermediate,,A549,,,Synergism with indomethacin in A549 cells,F,,,,80682
5995,6630,1,,646.0,,Intermediate,,A549,,,Synergism with sulindac in A549 cells,F,,,,80682
5996,6630,1,,646.0,,Intermediate,,A549,,,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tolmetin; Not available,F,,,,80682
5997,16907,1,,,,Intermediate,,,,9615.0,Cmax value after 30 mg/kg po dose in Dogs,A,In vivo,Canis lupus familiaris,,50588
5998,5944,1,,,,Intermediate,,,,9615.0,Cmax value determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),A,In vivo,Canis lupus familiaris,,50588
5999,5944,1,,,,Intermediate,,,,9615.0,Cmax value determined in dog at a dose of 10 mg/kg by oral administration,A,In vivo,Canis lupus familiaris,,50588
6000,5944,1,,,,Intermediate,,,,9615.0,Cmax value determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),A,In vivo,Canis lupus familiaris,,50588
6001,5944,1,,,,Intermediate,,,,9615.0,Cmax value determined in dog at a dose of 5 mg/kg by oral administration,A,In vivo,Canis lupus familiaris,,50588
6002,2959,1,,,,Intermediate,,,,9615.0,Cmax value after administration of 4 mg/Kg oral dose in dog,A,In vivo,Canis lupus familiaris,,50588
6003,6241,1,,,,Intermediate,,,,9615.0,Cmax value in dog,A,In vivo,Canis lupus familiaris,,50588
6004,6241,1,,,,Intermediate,,,,9615.0,Cmax value in dogs after oral administration at 1 mg/kg,A,In vivo,Canis lupus familiaris,,50588
6005,2652,1,,,,Intermediate,,,,9615.0,Bioavailability as Cmax in dogs at 5 mg/kg oral dose,A,In vivo,Canis lupus familiaris,,50588
6006,1806,1,,,,Intermediate,1969.0,,Plasma,9615.0,Compound was evaluated for maximum observed plasma concentration at dose 27.5 mg/kg DMP323 equiv in dogs,A,In vivo,Canis lupus familiaris,,50588
6007,1806,1,,,,Intermediate,1969.0,,Plasma,9615.0,Compound was evaluated for maximum observed plasma concentration at dose 7.7 mg/kg DMP323 equiv in dogs,A,In vivo,Canis lupus familiaris,,50588
6008,1021,1,,,,Intermediate,,,,9615.0,Concentration maxima after oral dosing in dogs,A,In vivo,Canis lupus familiaris,,50588
6009,1021,1,,,,Intermediate,,,,9615.0,Concentration maxima after oral dosing in dogs; not available,A,In vivo,Canis lupus familiaris,,50588
6010,1021,1,,,,Intermediate,,,,9615.0,Concentration maxima after oral dosing in dogs; not available,A,In vivo,Canis lupus familiaris,,50588
6011,5444,1,,,,Intermediate,,,,9615.0,In vivo maximal concentration was calculated at 0.4 mg/kg in dog; Not absorbed,A,In vivo,Canis lupus familiaris,,50588
6012,5444,1,,,,Intermediate,,,,9615.0,In vivo maximal concentration was calculated at 0.6 mg/kg in dog; Not absorbed,A,In vivo,Canis lupus familiaris,,50588
6013,5444,1,,,,Intermediate,,,,9615.0,In vivo maximal concentration was calculated at 1 mg/kg in dog,A,In vivo,Canis lupus familiaris,,50588
6014,5444,1,,,,Intermediate,,,,9615.0,In vivo maximal concentration was calculated at 1 mg/kg in dog; Not absorbed,A,In vivo,Canis lupus familiaris,,50588
6015,5444,1,,,,Intermediate,,,,9615.0,In vivo maximal concentration was calculated at 1 mg/kg in dog; Poor absorption,A,In vivo,Canis lupus familiaris,,50588
6016,5130,1,,,,Intermediate,1969.0,,Plasma,9615.0,Cmax in dog plasma after oral dose (1 mg/kg),A,In vivo,Canis lupus familiaris,,50588
6017,3249,1,,,,Intermediate,1969.0,,Plasma,9615.0,Maximal concentration (Cmax) in dog plasma at a dose of 5 mg/kg,A,In vivo,Canis lupus familiaris,,50588
6018,5473,1,,,,Intermediate,1969.0,,Plasma,9615.0,Maximal plasma concentration at a dose of 1 mg/kg,A,In vivo,Canis lupus familiaris,,50588
6019,5474,1,,,,Intermediate,1969.0,,Plasma,9615.0,Maximal plasma concentration at a dose of 1 mg/kg (oral),A,In vivo,Canis lupus familiaris,,50588
6020,4657,1,,,,Intermediate,1969.0,,Plasma,9615.0,Maximal plasma concentration required for pharmacokinetic data in dogs at dose of 1 mg/kg perorally,A,In vivo,Canis lupus familiaris,,50588
6021,3031,1,,,,Intermediate,,,,9615.0,Maximum concentration of compound in dog was evaluated.,A,In vivo,Canis lupus familiaris,,50588
6022,4527,1,,,,Intermediate,,,,9615.0,Maximum concentration by oral administration at a dose of 10 uM/kg in dog was determined,A,In vivo,Canis lupus familiaris,,50588
6023,4186,1,,,,Intermediate,,,,9615.0,Maximum concentration in dog after administration of 20 mg/kg dose through peroral route,A,In vivo,Canis lupus familiaris,,50588
6024,5007,1,,,,Intermediate,,,,9615.0,Maximum concentration in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),A,In vivo,Canis lupus familiaris,,50588
6025,3132,1,,,,Intermediate,1969.0,,Plasma,9615.0,Maximum concentration obtained in dog plasma was determined,A,In vivo,Canis lupus familiaris,,50588
6026,5006,1,,,,Intermediate,,,,9615.0,Maximum concentration was determined,A,In vivo,Canis lupus familiaris,,50588
6027,4727,1,,,,Intermediate,,,,9615.0,Maximum concentration at the dose of 2 mg/kg in dog,A,In vivo,Canis lupus familiaris,,50588
6028,1916,1,,,,Intermediate,,,,9615.0,Maximum concentration was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,A,In vivo,Canis lupus familiaris,,50588
6029,1918,1,,,,Intermediate,1969.0,,Plasma,9615.0,Maximum concentration was evaluated in dog plasma,A,In vivo,Canis lupus familiaris,,50588
6030,3045,1,,,,Intermediate,,,,9615.0,Maximum concentration was evaluated after 75 min after administration in dog,A,In vivo,Canis lupus familiaris,,50588
6031,9579,1,,,,Intermediate,1969.0,,Plasma,9615.0,Maximum plasma concentration determined in dog after oral administration of 17b,A,In vivo,Canis lupus familiaris,,50588
6032,9579,1,,,,Intermediate,1969.0,,Plasma,9615.0,Maximum plasma concentration determined in dog after oral administration of 2b,A,In vivo,Canis lupus familiaris,,50588
6033,933,1,,,,Intermediate,1969.0,,Plasma,9615.0,Maximum plasma concentration in dog,A,In vivo,Canis lupus familiaris,,50588
6034,17839,1,,,,Intermediate,1969.0,,Plasma,9615.0,Maximum plasma concentration of compound in dog following p.o. administration of 0.5 mg/kg,A,In vivo,Canis lupus familiaris,,50588
6035,17839,1,,,,Intermediate,1969.0,,Plasma,9615.0,Maximum plasma concentration of compound in dog following p.o. administration of 0.9 mg/kg,A,In vivo,Canis lupus familiaris,,50588
6036,17839,1,,,,Intermediate,1969.0,,Plasma,9615.0,Maximum plasma concentration of compound in dog following p.o. administration of 0.95 mg/kg,A,In vivo,Canis lupus familiaris,,50588
6037,17839,1,,,,Intermediate,1969.0,,Plasma,9615.0,Maximum plasma concentration of compound in dog following p.o. administration of 1 mg/kg,A,In vivo,Canis lupus familiaris,,50588
6038,6348,1,,,,Intermediate,1969.0,,Plasma,9615.0,Maximum plasma concentration of compound was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,A,In vivo,Canis lupus familiaris,,50588
6039,16367,1,,,,Intermediate,1969.0,,Plasma,9615.0,Maximum plasma concentration after oral administration to dogs at a dose of 10 mg/kg,A,In vivo,Canis lupus familiaris,,50588
6040,1337,1,,,,Intermediate,1969.0,,Plasma,9615.0,Maximum plasma concentration in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,A,In vivo,Canis lupus familiaris,,50588
6041,1337,1,,,,Intermediate,1969.0,,Plasma,9615.0,Maximum plasma concentration in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,A,In vivo,Canis lupus familiaris,,50588
6042,5199,1,,,,Intermediate,1969.0,,Plasma,9615.0,Maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,A,In vivo,Canis lupus familiaris,,50588
6043,17650,1,,,,Intermediate,1969.0,,Plasma,9615.0,Maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,A,In vivo,Canis lupus familiaris,,50588
6044,6679,1,,,,Intermediate,1969.0,,Plasma,9615.0,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration,A,In vivo,Canis lupus familiaris,,50588
6045,5356,1,,,,Intermediate,1969.0,,Plasma,9615.0,Maximum plasma concentration was determined as in dogs at 1 mg/kg oral dosing Cmax; 0.05-0.2 ug/mL,A,In vivo,Canis lupus familiaris,,50588
6046,5356,1,,,,Intermediate,1969.0,,Plasma,9615.0,Maximum plasma concentration was determined in dogs at 1 mg/kg oral dosing; 0.05-0.2 ug/mL,A,In vivo,Canis lupus familiaris,,50588
6047,6227,1,,,,Intermediate,1969.0,,Plasma,9615.0,Maximum plasma concentration (Cmax) in dog (in vivo) at a dose of 1 mg/kg,A,In vivo,Canis lupus familiaris,,50588
6048,6227,1,,,,Intermediate,1969.0,,Plasma,9615.0,Maximum plasma concentration (Cmax) in dog at a dose of 0.5 mg/kg,A,In vivo,Canis lupus familiaris,,50588
6049,6227,1,,,,Intermediate,1969.0,,Plasma,9615.0,Maximum plasma concentration (Cmax) in dog at a dose of 0.7 mg/kg,A,In vivo,Canis lupus familiaris,,50588
6050,6227,1,,,,Intermediate,1969.0,,Plasma,9615.0,Maximum plasma concentration (Cmax) in dog at a dose of 1 mg/kg,A,In vivo,Canis lupus familiaris,,50588
6051,3598,1,,,,Expert,1969.0,,Plasma,9615.0,Maximum plasma drug concentration of compound determined in dog after iv administration at a dose of 10 mg/kg,A,In vivo,Canis lupus familiaris,,50588
6052,4368,1,,,,Intermediate,,,,9615.0,Maximum concentration by intravenous administration of 1.2 mg/kg in dog,A,In vivo,Canis lupus familiaris,,50588
6053,6265,1,,,,Intermediate,,,,9615.0,Pharmacokinetic (PK) property (Cmax) was determined in dog at the single dose of 1 mg/kg,A,In vivo,Canis lupus familiaris,,50588
6054,7767,1,,,,Intermediate,945.0,,Stomach,10090.0,Biodistribution in stomach was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,Mus musculus,,50594
6055,7767,1,,,,Intermediate,1088.0,,Urine,10090.0,Biodistribution in urine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,Mus musculus,,50594
6056,7767,1,,,,Intermediate,1088.0,,Urine,10090.0,Biodistribution in urine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram; ND- No data,A,In vivo,Mus musculus,,50594
6057,7767,1,,,,Intermediate,1088.0,,Urine,10090.0,Biodistribution in urine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram; ND- No data,A,In vivo,Mus musculus,,50594
6058,17811,1,,,,Intermediate,,,,10090.0,Compound (0.09% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 120 min; No increase,A,,Mus musculus,,50594
6059,17811,1,,,,Intermediate,,,,10090.0,Compound (0.31% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 30 min; Low increase,A,,Mus musculus,,50594
6060,17827,1,,,,Intermediate,,,,10090.0,Compound (i.v.) was tested for maximum activity in mice (Radiolabeled compound),A,,Mus musculus,,50594
6061,17827,1,,,,Intermediate,178.0,,Blood,10090.0,Compound was evaluated for elimination rate constants in vivo in whole blood of normal mice (Radiolabeled compound),A,,Mus musculus,,50594
6062,17827,1,,,,Intermediate,,,,10090.0,Compound was evaluated for rate of bone uptake after administration of radiolabeled in mice (Radiolabeled compound),A,,Mus musculus,,50594
6063,17827,1,,,,Intermediate,,,,10090.0,Compound was evaluated for rate of bone uptake in mice (Radiolabeled compound),A,,Mus musculus,,50594
6064,17827,1,,,,Intermediate,,,,10090.0,Compound was evaluated for rate of bone uptake in mice; NA - not active (Radiolabeled compound),A,,Mus musculus,,50594
6065,17827,1,,,,Intermediate,178.0,,Blood,10090.0,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice (Radiolabeled compound),A,,Mus musculus,,50594
6066,17827,1,,,,Intermediate,178.0,,Blood,10090.0,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice; NA = not active (Radiolabeled compound),A,,Mus musculus,,50594
6067,17827,1,,,,Intermediate,,,,10090.0,Compound was evaluated for washout rate in mice (Radiolabeled compound),A,,Mus musculus,,50594
6068,17827,1,,,,Intermediate,,,,10090.0,Compound was evaluated for washout rate in mice after radiolabeled ligand injected,A,,Mus musculus,,50594
6069,17827,1,,,,Intermediate,,,,10090.0,"Maximum activity (i.v.) after in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",A,,Mus musculus,,50594
6070,17827,1,,,,Intermediate,,,,10090.0,"Maximum activity in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",A,,Mus musculus,,50594
6071,17827,1,,,,Intermediate,,,,10090.0,"Residual activity in mice at 120 minutes, expressed as [(ID%-kg)/g] (Radiolabeled compound)",A,,Mus musculus,,50594
6072,17257,1,,,,Intermediate,,,,10090.0,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice,A,,Mus musculus,,50594
6073,17257,1,,,,Intermediate,,,,10090.0,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice; Not detected.,A,,Mus musculus,,50594
6074,17257,1,,,,Intermediate,,,,10090.0,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice,A,,Mus musculus,,50594
6075,17257,1,,,,Intermediate,,,,10090.0,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice; Not determined,A,,Mus musculus,,50594
6076,17827,1,,,,Intermediate,,,,10090.0,Time at maximum activity in mice (Radiolabeled compound),A,,Mus musculus,,50594
6077,3760,1,,,,Intermediate,,,,10090.0,Percent oral bioavailability was determined after administration of compound at 5 mg/kg perorally in mice,A,,Mus musculus,,50594
6078,3760,1,,,,Intermediate,,,,10090.0,Percent oral bioavailability was determined after administration of compound at 50 mg/kg perorally in mice,A,,Mus musculus,,50594
6079,17409,1,,,,Intermediate,,,,10090.0,Binding towards mouse plasma protein at 10 uM,A,,Mus musculus,,50594
6080,17409,1,,,,Intermediate,,,,10090.0,Binding towards mouse plasma protein at 100 uM,A,,Mus musculus,,50594
6081,2675,1,,,,Intermediate,,,,10090.0,Bioavailability was evaluated in mice after intravenous administration,A,In vivo,Mus musculus,,50594
6082,2675,1,,,,Intermediate,,,,10090.0,Bioavailability was evaluated in mice after oral administration,A,In vivo,Mus musculus,,50594
6083,3132,1,,,,Intermediate,,,,10090.0,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse,A,In vivo,Mus musculus,,50594
6084,3132,1,,,,Intermediate,,,,10090.0,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse at dose 25 mg/kg,A,In vivo,Mus musculus,,50594
6085,16597,1,,,,Intermediate,,,,10090.0,Bioavailability at a dose of 10 mg/kg peroral administration in mice.,A,In vivo,Mus musculus,,50594
6086,2862,1,,,,Intermediate,,,,10090.0,Oral bioavailability in mouse,A,In vivo,Mus musculus,,50594
6087,17764,1,,,,Intermediate,,,,10090.0,Oral bioavailability after intravenous administration in mice at 24 uM/kg,A,In vivo,Mus musculus,,50594
6088,846,1,,,,Intermediate,955.0,,Brain,10090.0,Biodistribution of [123I]- labeled compound in mice brain was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,Mus musculus,,50594
6089,846,1,,,,Intermediate,955.0,,Brain,10090.0,Biodistribution of [123I]- labeled compound in mice brain was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,Mus musculus,,50594
6090,846,1,,,,Intermediate,955.0,,Brain,10090.0,Biodistribution of [123I]- labeled compound in mice brain was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,A,In vivo,Mus musculus,,50594
6091,846,1,,,,Intermediate,955.0,,Brain,10090.0,Biodistribution of [123I]- labeled compound in mice brain was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,Mus musculus,,50594
6092,846,1,,,,Intermediate,955.0,,Brain,10090.0,Biodistribution of [123I]- labeled compound in mice brain was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,A,In vivo,Mus musculus,,50594
6093,846,1,,,,Intermediate,955.0,,Brain,10090.0,Biodistribution of [123I]- labeled compound in mice brain was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,Mus musculus,,50594
6094,846,1,,,,Intermediate,948.0,,Heart,10090.0,Biodistribution of [123I]- labeled compound in mice heart was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,Mus musculus,,50594
6095,846,1,,,,Intermediate,948.0,,Heart,10090.0,Biodistribution of [123I]- labeled compound in mice heart was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,A,In vivo,Mus musculus,,50594
6096,846,1,,,,Intermediate,948.0,,Heart,10090.0,Biodistribution of [123I]- labeled compound in mice heart was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,Mus musculus,,50594
6097,846,1,,,,Intermediate,948.0,,Heart,10090.0,Biodistribution of [123I]- labeled compound in mice heart was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,Mus musculus,,50594
6098,1276,1,,646.0,,Intermediate,,A549,,9606.0,Cytotoxic activity was tested against human prostate cell line A-549 (lung carcinoma),F,,Homo sapiens,,80682
6099,3498,1,,646.0,,Expert,,A549,,9606.0,Cytotoxicity against A-549 cell line in the purdue cell culture screen was determined,F,,Homo sapiens,,80682
6100,1169,1,,646.0,,Intermediate,,A549,,9606.0,Cytotoxicity against human lung carcinoma A-549 cell lines,F,,Homo sapiens,,80682
6101,4450,1,,646.0,,Intermediate,,A549,,9606.0,In vitro cytotoxic activity against A-549 (human lung carcinoma) cell line,F,,Homo sapiens,,80682
6102,358,1,,646.0,,Intermediate,,A549,,9606.0,In vitro cytotoxicity against human lung carcinoma cell line A-549,F,,Homo sapiens,,80682
6103,358,1,,646.0,,Intermediate,,A549,,9606.0,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 3.6*10e-5 M,F,,Homo sapiens,,80682
6104,358,1,,646.0,,Intermediate,,A549,,9606.0,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.2*10e-5M,F,,Homo sapiens,,80682
6105,358,1,,646.0,,Intermediate,,A549,,9606.0,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.3*10e-5M,F,,Homo sapiens,,80682
6106,358,1,,646.0,,Intermediate,,A549,,9606.0,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 5.0*10e-5M,F,,Homo sapiens,,80682
6107,358,1,,646.0,,Intermediate,,A549,,9606.0,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 6.1*10e-5 M,F,,Homo sapiens,,80682
6108,358,1,,646.0,,Intermediate,,A549,,9606.0,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 7.4*10e-5 M,F,,Homo sapiens,,80682
6109,15167,1,,646.0,,Intermediate,,A549,,9606.0,In vitro cytotoxicity against A-549 human lung cancer cells,F,,Homo sapiens,,80682
6110,4139,1,,646.0,,Intermediate,,A549,,9606.0,In vitro cytotoxicity against human lung carcinoma (A-549) cell line,F,,Homo sapiens,,80682
6111,833,1,,646.0,,Intermediate,,A549,,9606.0,In vitro cytotoxicity in human tumor lung carcinoma A-549 cell lines,F,,Homo sapiens,,80682
6112,15718,1,,646.0,,Expert,,A549,,9606.0,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,F,,Homo sapiens,,80682
6113,12373,1,,646.0,,Intermediate,,A549,,9606.0,Tested in vitro for cytotoxicity against A-549 lung cancer cells,F,,Homo sapiens,,80682
6114,637,1,,646.0,,Intermediate,,A549,,9606.0,The compound was tested for cytotoxicity against A-549 cell in human lung carcinoma,F,,Homo sapiens,,80682
6115,14867,1,,646.0,,Expert,,A549,,9606.0,Cytotoxicity against human lung carcinoma cells (A-549) using SRB assay.,F,,Homo sapiens,,80682
6116,4461,1,,646.0,,Intermediate,,A549,,9606.0,Antitumor cytotoxic activity against A-549 cell line was determined,F,,Homo sapiens,,80682
6117,5406,1,,646.0,,Intermediate,,A549,,9606.0,"Tested for the cytotoxicity against the Non-small cell lung cancer cell line A-549, growth inhibition by 50% is reported",F,,Homo sapiens,,80682
6118,4457,1,,646.0,,Intermediate,,A549,,9606.0,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,F,,Homo sapiens,,80682
6119,1386,1,,646.0,,Expert,,A549,,9606.0,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,F,,Homo sapiens,,80682
6120,3265,1,,646.0,,Intermediate,,A549,,9606.0,Antitumoral activity was assayed against A-549 cell line,F,,Homo sapiens,,80682
6121,2359,1,,646.0,,Intermediate,,A549,,9606.0,Compound was evaluated for the cytotoxicity against A-549 tumor cell line after 3 days of incubation,F,,Homo sapiens,,80682
6122,4457,1,,646.0,,Intermediate,,A549,,9606.0,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,F,,Homo sapiens,,80682
6123,12454,1,,646.0,,Expert,,A549,,9606.0,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,F,,Homo sapiens,,80682
6124,1481,1,,646.0,,Intermediate,,A549,,9606.0,Compound was tested for inhibition of cell growth of A-549 cells,F,,Homo sapiens,,80682
6125,1750,1,,646.0,,Intermediate,,A549,,9606.0,Compound was tested for its inhibitory effect on the growth of A-549 tumor cell line from lung.,F,,Homo sapiens,,80682
6126,5065,1,,646.0,,Intermediate,,A549,,9606.0,Concentration required for 50% inhibition of growth in human lung carcinoma cell line was determined,F,,Homo sapiens,,80682
6127,808,1,,646.0,,Expert,,A549,,9606.0,In vitro cytotoxicity against A549-human lung carcinoma cells.,F,,Homo sapiens,,80682
6128,16364,1,,646.0,,Expert,,A549,,9606.0,Cytotoxic activity against cultured cells of A-549 human lung carcinoma.,F,,Homo sapiens,,80682
6129,1847,1,,646.0,,Intermediate,,A549,,9606.0,Cytotoxic activity against A-549 cell lines.,F,,Homo sapiens,,80682
6130,1747,1,,646.0,,Expert,,A549,,9606.0,Cytotoxicity was measured against neoplastic cultured A-549 cells of human lung carcinoma.,F,,Homo sapiens,,80682
6131,1003,1,,646.0,,Intermediate,,A549,,9606.0,Cytotoxicity against human A549 non small cell lung cell lines,F,,Homo sapiens,,80682
6132,15313,1,,646.0,,Expert,,A549,,9606.0,Inhibition of cell growth in (A-549) lung cell line,F,,Homo sapiens,,80682
6133,3122,1,,646.0,,Intermediate,,A549,,9606.0,Growth inhibitory effect of compound was measured on A-549 human lung adenocarcinoma cancer cell line,F,,Homo sapiens,,80682
6134,16049,1,,646.0,,Intermediate,,A549,,9606.0,In vitro antitumor activity against A-549 tumor cells.,F,,Homo sapiens,,80682
6135,17134,1,,646.0,,Expert,,A549,,9606.0,In vitro antitumor effects against human A-549 cell lines.,F,,Homo sapiens,,80682
6136,6406,1,,646.0,,Intermediate,,A549,,9606.0,In vitro cytotoxic activity of compound against A-549 cell line,F,,Homo sapiens,,80682
6137,627,1,,646.0,,Intermediate,,A549,,9606.0,In vitro cytotoxicity against human lung carcinoma A-549 cell line,F,,Homo sapiens,,80682
6138,12307,1,,646.0,,Intermediate,,A549,,9606.0,In vitro cytotoxicity against human non-small cell lung carcinoma A549,F,,Homo sapiens,,80682
6139,17861,1,,646.0,,Intermediate,,A549,,9606.0,In vitro cytotoxicity against human A-549 cancer cell line was evaluated,F,,Homo sapiens,,80682
6140,6682,1,,646.0,,Expert,,A549,,9606.0,In vitro cytotoxicity against the A-549 (human lung carcinoma) neoplastic cell line,F,,Homo sapiens,,80682
6141,6663,1,,646.0,,Intermediate,,A549,,9606.0,Inhibitory concentration of compound against A-549 cell line,F,,Homo sapiens,,80682
6142,2454,1,,646.0,,Intermediate,,A549,,9606.0,Tested for the cytostatic activity as inhibitory concentration against A-549 human pulmonary adenocarcinoma cells,F,,Homo sapiens,,80682
6143,14709,1,,646.0,,Intermediate,,A549,,9606.0,cytotoxic activity against leukemia (A-549) cancer cell line,F,,Homo sapiens,,80682
6144,15718,1,,646.0,,Expert,,A549,,9606.0,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,F,,Homo sapiens,,80682
6145,15718,1,,646.0,,Intermediate,,A549,,9606.0,Percent inhibition for cytotoxic activity against lung carcinoma (A-549) cell line,F,,Homo sapiens,,80682
6146,17130,1,,646.0,,Intermediate,,A549,,9606.0,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.1(ug/ml),F,,Homo sapiens,,80682
6147,17130,1,,646.0,,Intermediate,,A549,,9606.0,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.4(ug/ml),F,,Homo sapiens,,80682
6148,17130,1,,646.0,,Intermediate,,A549,,9606.0,Cytotoxic activity of compound against A-549 cell lines at concentration of 1.1 (ug/ml),F,,Homo sapiens,,80682
6149,17130,1,,646.0,,Intermediate,,A549,,9606.0,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml),F,,Homo sapiens,,80682
6150,6630,1,,646.0,,Intermediate,,A549,,,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tometin; Not available,F,,,,80682
6151,16726,1,,646.0,,Intermediate,,A549,,9606.0,Influence of PARP-1 cellular activity in human lung carcinoma A549 cells on %ADP Polymer formation at a concentration of 25 uM of the compound,F,,Homo sapiens,,80682
6152,17846,1,,646.0,,Intermediate,,A549,,9606.0,Cytotoxicity against A549 cells; No cytotoxicity,F,,Homo sapiens,,80682
6153,3415,1,,646.0,,Expert,,A549,,9606.0,Cytotoxicity against human lung carcinoma (A549) cell lines,F,,Homo sapiens,,80682
6154,3415,1,,646.0,,Expert,,A549,,9606.0,Cytotoxicity against human lung carcinoma (A549) cell lines; Not active,F,,Homo sapiens,,80682
6155,5609,1,,646.0,,Intermediate,,A549,,9606.0,In vitro anticancer activity against human lung (A549) cell line,F,,Homo sapiens,,80682
6156,17206,1,,646.0,,Intermediate,,A549,,9606.0,Percent growth inhibition at 200 uM PARP inhibitor in A549 cells,F,,Homo sapiens,,80682
6157,17206,1,,646.0,,Intermediate,,A549,,9606.0,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..006 uM compound concentration in A549 cells,F,,Homo sapiens,,80682
6158,17206,1,,646.0,,Intermediate,,A549,,9606.0,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..03 uM compound concentration in A549 cells,F,,Homo sapiens,,80682
6159,17206,1,,646.0,,Intermediate,,A549,,9606.0,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..15 uM compound concentration in A549 cells,F,,Homo sapiens,,80682
6160,17206,1,,646.0,,Intermediate,,A549,,9606.0,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..4 uM compound concentration in A549 cells,F,,Homo sapiens,,80682
6161,17206,1,,646.0,,Intermediate,,A549,,9606.0,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,F,,Homo sapiens,,80682
6162,16295,1,,646.0,,Expert,,A549,,9606.0,Inhibition of A549 human lung tumor cell proliferation,F,,Homo sapiens,,80682
6163,16825,1,,646.0,,Intermediate,,A549,,9606.0,"Concentration required to inhibit the lung A549 cell growth by 50%,P53 status of cell line used was wild-type. ",F,,Homo sapiens,,80682
6164,3439,1,,646.0,,Expert,,A549,,9606.0,In vitro cytotoxicity against human tumor cell line A549,F,,Homo sapiens,,80682
6165,10870,1,,646.0,,Intermediate,,A549,,9606.0,In vitro growth inhibitory activity against A549 human nonsmall cell lung carcinoma cells. ,F,,Homo sapiens,,80682
6166,4845,1,,646.0,,Intermediate,,A549,,9606.0,Inhibitory concentration of compound against proliferation of lung carcinoma A549 cell line,F,,Homo sapiens,,80682
6167,5822,1,,646.0,,Intermediate,,A549,,9606.0,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells,F,,Homo sapiens,,80682
6168,5822,1,,646.0,,Intermediate,,A549,,9606.0,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells,F,,Homo sapiens,,80682
6169,5822,1,,646.0,,Intermediate,,A549,,9606.0,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells: Not tested,F,,Homo sapiens,,80682
6170,16381,1,,646.0,,Intermediate,,A549,,9606.0,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,F,,Homo sapiens,,80682
6171,16381,1,,646.0,,Intermediate,,A549,,9606.0,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,F,,Homo sapiens,,80682
6172,16381,1,,646.0,,Intermediate,,A549,,9606.0,% inhibition against A549 cells (lung cancer) at 4 ug/mL,F,,Homo sapiens,,80682
6173,5609,1,,646.0,,Intermediate,,A549,,9606.0,In vitro anticancer activity against human lung (A549) cell line,F,,Homo sapiens,,80682
6174,4644,1,,646.0,,Intermediate,,A549,,9606.0,Inhibition of proliferation of A549 cells at concentration of 0.1 uM was determined,F,,Homo sapiens,,80682
6175,4644,1,,646.0,,Intermediate,,A549,,9606.0,Inhibition of proliferation of A549 cells at concentration of 100 uM was determined,F,,Homo sapiens,,80682
6176,4644,1,,646.0,,Intermediate,,A549,,9606.0,Inhibition of proliferation of A549 cells at concentration of 10 uM was determined,F,,Homo sapiens,,80682
6177,4644,1,,646.0,,Intermediate,,A549,,9606.0,Inhibition of proliferation of A549 cells at concentration of 1 uM was determined,F,,Homo sapiens,,80682
6178,5822,1,,646.0,,Intermediate,,A549,,9606.0,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells at 20 uM,F,,Homo sapiens,,80682
6179,3415,1,,646.0,,Expert,,A549,,9606.0,Percentage inhibition of human lung carcinoma (A549) cell lines,F,,Homo sapiens,,80682
6180,16726,1,,646.0,,Intermediate,,A549,,9606.0,Influence of PARP-1 cellular activity on NAD+ levels at a concentration of 25 uM of the compound,F,,Homo sapiens,,80682
6181,17206,1,,646.0,,Intermediate,,A549,,9606.0,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM); ND denotes not determined",F,,Homo sapiens,,80682
6182,17206,1,,646.0,,Intermediate,,A549,,9606.0,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells; ND denotes not determined,F,,Homo sapiens,,80682
6183,17206,1,,646.0,,Intermediate,,A549,,9606.0,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells; ND denotes not determined,F,,Homo sapiens,,80682
6184,17206,1,,646.0,,Intermediate,,A549,,9606.0,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM)",F,,Homo sapiens,,80682
6185,17206,1,,646.0,,Intermediate,,A549,,9606.0,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.006 uM",F,,Homo sapiens,,80682
6186,17206,1,,646.0,,Intermediate,,A549,,9606.0,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.03 uM",F,,Homo sapiens,,80682
6187,17206,1,,646.0,,Intermediate,,A549,,9606.0,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.15 uM",F,,Homo sapiens,,80682
6188,17206,1,,646.0,,Intermediate,,A549,,9606.0,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.4 uM",F,,Homo sapiens,,80682
6189,17206,1,,646.0,,Intermediate,,A549,,9606.0,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells,F,,Homo sapiens,,80682
6190,17206,1,,646.0,,Intermediate,,A549,,9606.0,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells,F,,Homo sapiens,,80682
6191,16726,1,,646.0,,Intermediate,,A549,,9606.0,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,F,,Homo sapiens,,80682
6192,17206,1,,646.0,,Intermediate,,A549,,9606.0,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.006 uM compound concentration in A549 cells,F,,Homo sapiens,,80682
6193,17206,1,,646.0,,Intermediate,,A549,,9606.0,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.03 uM compound concentration in A549 cells,F,,Homo sapiens,,80682
6194,17206,1,,646.0,,Intermediate,,A549,,9606.0,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.15 uM compound concentration in A549 cells,F,,Homo sapiens,,80682
6195,17206,1,,646.0,,Intermediate,,A549,,9606.0,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.4 uM compound concentration in A549 cells,F,,Homo sapiens,,80682
6196,6084,1,,,,Intermediate,,,,9615.0,Pharmacokinetic activity (Cmax) (10 mg/kg) was determined in dog,A,In vivo,Canis lupus familiaris,,50588
6197,6084,1,,,,Intermediate,,,,9615.0,Pharmacokinetic activity (Cmax) in dog,A,In vivo,Canis lupus familiaris,,50588
6198,4809,1,,,,Intermediate,,,,9615.0,Pharmacokinetic parameter Cmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),A,In vivo,Canis lupus familiaris,,50588
6199,5983,1,,,,Intermediate,,,,9615.0,Pharmacokinetic property (Cmax) was measured in dog at the dose of 0.032 mg/kg,A,In vivo,Canis lupus familiaris,,50588
6200,6251,1,,,,Intermediate,,,,9615.0,Plasma clearance rate by iv administration in dog at a dose of 6 mg/kg,A,In vivo,Canis lupus familiaris,,50588
6201,5932,1,,,,Intermediate,1969.0,,Plasma,9615.0,Cmax in dog plasma after 30mg/kg oral dose,A,In vivo,Canis lupus familiaris,,50588
6202,4273,1,,,,Intermediate,178.0,,Blood,9615.0,Tested for the peak blood level in dog,A,In vivo,Canis lupus familiaris,,50588
6203,5313,1,,,,Intermediate,,,,9615.0,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog",A,In vivo,Canis lupus familiaris,,50588
6204,5313,1,,,,Intermediate,,,,9615.0,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog at dosage of 10 mpk",A,In vivo,Canis lupus familiaris,,50588
6205,6221,1,,,,Intermediate,178.0,,Blood,9615.0,The peak blood concentration after 5 hr administration (2.5 mg/kg) in dog was determined,A,In vivo,Canis lupus familiaris,,50588
6206,4709,1,,,,Intermediate,,,,9615.0,Concentration in the plasma after intravenous administration of 1 mg/kg in dog,A,,Canis lupus familiaris,,50588
6207,167,1,,,,Intermediate,,,,9615.0,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Dog at maximum of 0.3 hours,A,,Canis lupus familiaris,,50588
6208,6241,1,,,,Intermediate,1969.0,,Plasma,9615.0,Final plasma concentration in dogs after oral administration at 1 mg/kg,A,,Canis lupus familiaris,,50588
6209,344,1,,,,Intermediate,,,,9615.0,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 300 min,A,,Canis lupus familiaris,,50588
6210,344,1,,,,Intermediate,,,,9615.0,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 30 min,A,,Canis lupus familiaris,,50588
6211,344,1,,,,Intermediate,,,,9615.0,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 60 min,A,,Canis lupus familiaris,,50588
6212,2189,1,,,,Intermediate,,,,9615.0,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by dogs,A,,Canis lupus familiaris,,50588
6213,2189,1,,,,Intermediate,1088.0,,Urine,9615.0,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs,A,,Canis lupus familiaris,,50588
6214,2189,1,,,,Intermediate,1088.0,,Urine,9615.0,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs; NA is <10% inhibition at 1 uM for binding data,A,,Canis lupus familiaris,,50588
6215,2189,1,,,,Intermediate,1088.0,,Urine,9615.0,Percent of radioactive dose in urine and feces excreted in 0-24 hr by dogs; NA is <10% inhibition at 1 uM for binding data,A,,Canis lupus familiaris,,50588
6216,4257,1,,,,Intermediate,,,,9615.0,Absolute bioavailability was evaluated in dog,A,In vivo,Canis lupus familiaris,,50588
6217,6221,1,,,,Intermediate,,,,9615.0,Bioavailability after oral administration (2.5 mg/kg) in dog was determined,A,In vivo,Canis lupus familiaris,,50588
6218,6215,1,,,,Intermediate,,,,9615.0,Bioavailability after peroral administration (1 mg/kg) was determined in dog,A,In vivo,Canis lupus familiaris,,50588
6219,17267,1,,,,Intermediate,,,,9615.0,Bioavailability in dog,A,In vivo,Canis lupus familiaris,,50588
6220,6621,1,,,,Intermediate,,,,9615.0,Bioavailability in dog,A,In vivo,Canis lupus familiaris,,50588
6221,3854,1,,,,Intermediate,,,,9615.0,Bioavailability after intravenous administration in dogs,A,In vivo,Canis lupus familiaris,,50588
6222,3854,1,,,,Intermediate,,,,9615.0,Bioavailability after peroral administration in dogs,A,In vivo,Canis lupus familiaris,,50588
6223,5007,1,,,,Intermediate,,,,9615.0,Bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),A,In vivo,Canis lupus familiaris,,50588
6224,4333,1,,,,Intermediate,,,,9615.0,Bioavailability in dog (Beagle) (male) (dose 3 mg/kg i.v. and 10 mg/kg p.o.) measured from 1 to 24 hr,A,In vivo,Canis lupus familiaris,,50588
6225,4333,1,,,,Intermediate,1969.0,,Plasma,9615.0,Bioavailability in plasma of male Beagle dogs treated with 3 mg/kg (i.v.) and 10 mg/kg (p.o.) measured from 1 to 24 hr; ND indicates not determined,A,In vivo,Canis lupus familiaris,,50588
6226,5006,1,,,,Intermediate,,,,9615.0,Bioavailability,A,In vivo,Canis lupus familiaris,,50588
6227,5199,1,,,,Intermediate,,,,9615.0,Bioavailability,A,In vivo,Canis lupus familiaris,,50588
6228,4368,1,,,,Intermediate,,,,9615.0,Bioavailability by intravenous administration of 1.2 mg/kg in dog,A,In vivo,Canis lupus familiaris,,50588
6229,3771,1,,,,Intermediate,,,,9615.0,Bioavailability in dog,A,In vivo,Canis lupus familiaris,,50588
6230,4953,1,,,,Intermediate,,,,9615.0,Bioavailability in dog,A,In vivo,Canis lupus familiaris,,50588
6231,5064,1,,,,Intermediate,,,,9615.0,Bioavailability in dog,A,In vivo,Canis lupus familiaris,,50588
6232,17657,1,,,,Intermediate,,,,9615.0,Bioavailability in dog,A,In vivo,Canis lupus familiaris,,50588
6233,17796,1,,,,Intermediate,,,,9615.0,Bioavailability in dog,A,In vivo,Canis lupus familiaris,,50588
6234,17853,1,,,,Intermediate,,,,9615.0,Bioavailability in dog (p.o.) at 2.0 mpk,A,In vivo,Canis lupus familiaris,,50588
6235,4521,1,,,,Intermediate,,,,9615.0,Bioavailability in dog (dose 2 mg/kg p.o. and 0.5 mg/kg i.v.),A,In vivo,Canis lupus familiaris,,50588
6236,4521,1,,,,Intermediate,,,,9615.0,Bioavailability in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,A,In vivo,Canis lupus familiaris,,50588
6237,5006,1,,,,Intermediate,,,,9615.0,Bioavailability in dog,A,In vivo,Canis lupus familiaris,,50588
6238,16365,1,,,,Intermediate,,,,9615.0,Bioavailability was evaluated after oral administration in dog,A,In vivo,Canis lupus familiaris,,50588
6239,1916,1,,,,Intermediate,,,,9615.0,Bioavailability was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,A,In vivo,Canis lupus familiaris,,50588
6240,1918,1,,,,Intermediate,,,,9615.0,Bioavailability was evaluated in dog,A,In vivo,Canis lupus familiaris,,50588
6241,4239,1,,,,Intermediate,,,,9615.0,Bioavailability in dog,A,In vivo,Canis lupus familiaris,,50588
6242,6505,1,,,,Intermediate,,,,9615.0,Bioavailability in dog,A,In vivo,Canis lupus familiaris,,50588
6243,5334,1,,,,Intermediate,,,,9615.0,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),A,In vivo,Canis lupus familiaris,,50588
6244,5334,1,,,,Intermediate,,,,9615.0,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),A,In vivo,Canis lupus familiaris,,50588
6245,4809,1,,,,Intermediate,,,,9615.0,Bioavailability was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),A,In vivo,Canis lupus familiaris,,50588
6246,6348,1,,,,Intermediate,,,,9615.0,Bioavailability was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,A,In vivo,Canis lupus familiaris,,50588
6247,6005,1,,,,Intermediate,,,,9615.0,Bioavailability was evaluated in dog after peroral administration at a dose of 1 mg/kg,A,In vivo,Canis lupus familiaris,,50588
6248,17804,1,,,,Intermediate,,,,9615.0,Bioavailability of compound in dog was determined after peroral administration,A,In vivo,Canis lupus familiaris,,50588
6249,3184,1,,,,Intermediate,,,,9615.0,Oral bioavailability in dog,A,In vivo,Canis lupus familiaris,,50588
6250,1806,1,,,,Intermediate,,,,9615.0,Compound was evaluated for oral bioavailability at different dose 27.5 mg/kg DMP323 equiv in dogs,A,In vivo,Canis lupus familiaris,,50588
6251,1806,1,,,,Intermediate,,,,9615.0,Compound was evaluated for oral bioavailability at different dose 7.7 mg/kg DMP323 equiv in dogs,A,In vivo,Canis lupus familiaris,,50588
6252,1806,1,,,,Intermediate,,,,9615.0,Compound was evaluated for oral bioavailability in dogs; 37-38 %,A,In vivo,Canis lupus familiaris,,50588
6253,4839,1,,,,Intermediate,,,,9615.0,Bioavailability in dog,A,In vivo,Canis lupus familiaris,,50588
6254,5017,1,,,,Intermediate,,,,9615.0,Oral bioavailability in dog (1 mg/kg p.o. and 0.2 mg/kg i.v.),A,In vivo,Canis lupus familiaris,,50588
6255,846,1,,,,Intermediate,948.0,,Heart,10090.0,Biodistribution of [123I]- labeled compound in mice heart was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,A,In vivo,Mus musculus,,50594
6256,846,1,,,,Intermediate,948.0,,Heart,10090.0,Biodistribution of [123I]- labeled compound in mice heart was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,Mus musculus,,50594
6257,846,1,,,,Intermediate,2113.0,,Kidney,10090.0,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,Mus musculus,,50594
6258,846,1,,,,Intermediate,2113.0,,Kidney,10090.0,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,Mus musculus,,50594
6259,846,1,,,,Intermediate,2113.0,,Kidney,10090.0,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,A,In vivo,Mus musculus,,50594
6260,846,1,,,,Intermediate,2113.0,,Kidney,10090.0,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,Mus musculus,,50594
6261,846,1,,,,Intermediate,2113.0,,Kidney,10090.0,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,A,In vivo,Mus musculus,,50594
6262,846,1,,,,Intermediate,2113.0,,Kidney,10090.0,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,Mus musculus,,50594
6263,846,1,,,,Intermediate,2107.0,,Liver,10090.0,Biodistribution of [123I]- labeled compound in mice liver was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,Mus musculus,,50594
6264,846,1,,,,Intermediate,2107.0,,Liver,10090.0,Biodistribution of [123I]- labeled compound in mice liver was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,Mus musculus,,50594
6265,846,1,,,,Intermediate,2107.0,,Liver,10090.0,Biodistribution of [123I]- labeled compound in mice liver was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,A,In vivo,Mus musculus,,50594
6266,846,1,,,,Intermediate,2107.0,,Liver,10090.0,Biodistribution of [123I]- labeled compound in mice liver was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,Mus musculus,,50594
6267,846,1,,,,Intermediate,2107.0,,Liver,10090.0,Biodistribution of [123I]- labeled compound in mice liver was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,A,In vivo,Mus musculus,,50594
6268,846,1,,,,Intermediate,2107.0,,Liver,10090.0,Biodistribution of [123I]- labeled compound in mice liver was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,Mus musculus,,50594
6269,846,1,,,,Intermediate,2048.0,,Lung,10090.0,Biodistribution of [123I]- labeled compound in mice lungs was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,Mus musculus,,50594
6270,846,1,,,,Intermediate,2048.0,,Lung,10090.0,Biodistribution of [123I]- labeled compound in mice lungs was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,Mus musculus,,50594
6271,846,1,,,,Intermediate,2048.0,,Lung,10090.0,Biodistribution of [123I]- labeled compound in mice lungs was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,A,In vivo,Mus musculus,,50594
6272,846,1,,,,Intermediate,2048.0,,Lung,10090.0,Biodistribution of [123I]- labeled compound in mice lungs was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,Mus musculus,,50594
6273,846,1,,,,Intermediate,2048.0,,Lung,10090.0,Biodistribution of [123I]- labeled compound in mice lungs was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,A,In vivo,Mus musculus,,50594
6274,846,1,,,,Intermediate,2048.0,,Lung,10090.0,Biodistribution of [123I]- labeled compound in mice lungs was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,Mus musculus,,50594
6275,6599,1,,42.0,,Intermediate,,CCRF S-180,,10090.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 1 hour,A,,Mus musculus,,50594
6276,6599,1,,42.0,,Intermediate,,CCRF S-180,,10090.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 2 hours,A,,Mus musculus,,50594
6277,6599,1,,42.0,,Intermediate,,CCRF S-180,,10090.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 30 minutes,A,,Mus musculus,,50594
6278,6599,1,,42.0,,Intermediate,,CCRF S-180,,10090.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 4 hours,A,,Mus musculus,,50594
6279,6599,1,,42.0,,Intermediate,,CCRF S-180,,10090.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 8 hours,A,,Mus musculus,,50594
6280,6599,1,,42.0,,Intermediate,955.0,CCRF S-180,Brain,10090.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice brain bearing S180 tumor cell line for 1 hour,A,,Mus musculus,,50594
6281,6599,1,,42.0,,Intermediate,955.0,CCRF S-180,Brain,10090.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 2 hours,A,,Mus musculus,,50594
6282,6599,1,,42.0,,Intermediate,955.0,CCRF S-180,Brain,10090.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 30 minutes,A,,Mus musculus,,50594
6283,6599,1,,42.0,,Intermediate,955.0,CCRF S-180,Brain,10090.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 4 hours,A,,Mus musculus,,50594
6284,6599,1,,42.0,,Intermediate,955.0,CCRF S-180,Brain,10090.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 8 hours,A,,Mus musculus,,50594
6285,6599,1,,42.0,,Intermediate,948.0,CCRF S-180,Heart,10090.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 1 hour,A,,Mus musculus,,50594
6286,6599,1,,42.0,,Intermediate,948.0,CCRF S-180,Heart,10090.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 2 hours,A,,Mus musculus,,50594
6287,6599,1,,42.0,,Intermediate,948.0,CCRF S-180,Heart,10090.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 30 minutes,A,,Mus musculus,,50594
6288,6599,1,,42.0,,Intermediate,948.0,CCRF S-180,Heart,10090.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 4 hours,A,,Mus musculus,,50594
6289,6599,1,,42.0,,Intermediate,948.0,CCRF S-180,Heart,10090.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 8 hours,A,,Mus musculus,,50594
6290,6599,1,,42.0,,Intermediate,2113.0,CCRF S-180,Kidney,10090.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 1 hour,A,,Mus musculus,,50594
6291,6599,1,,42.0,,Intermediate,2113.0,CCRF S-180,Kidney,10090.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 2 hours,A,,Mus musculus,,50594
6292,6599,1,,42.0,,Intermediate,2113.0,CCRF S-180,Kidney,10090.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 30 minutes,A,,Mus musculus,,50594
6293,17130,1,,646.0,,Intermediate,,A549,,9606.0,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml) on,F,,Homo sapiens,,80682
6294,17130,1,,646.0,,Intermediate,,A549,,9606.0,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml)on,F,,Homo sapiens,,80682
6295,17130,1,,646.0,,Intermediate,,A549,,9606.0,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml),F,,Homo sapiens,,80682
6296,17130,1,,646.0,,Intermediate,,A549,,9606.0,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml)),F,,Homo sapiens,,80682
6297,3263,1,,646.0,,Expert,,A549,,9606.0,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,F,,Homo sapiens,,80682
6298,6663,1,,646.0,,Expert,,A549,,9606.0,In vitro rate of inhibition of A-549 tumor cell growth at 10E-4 mol/L,F,,Homo sapiens,,80682
6299,6663,1,,646.0,,Expert,,A549,,9606.0,In vitro rate of inhibition of A-549 tumor cell growth at 10E-5 mol/L,F,,Homo sapiens,,80682
6300,6663,1,,646.0,,Expert,,A549,,9606.0,In vitro rate of inhibition of A-549 tumor cell growth at 10E-6 mol/L,F,,Homo sapiens,,80682
6301,6663,1,,646.0,,Expert,,A549,,9606.0,In vitro rate of inhibition of A-549 tumor cell growth at 10E-7 mol/L,F,,Homo sapiens,,80682
6302,6663,1,,646.0,,Expert,,A549,,9606.0,In vitro rate of inhibition of A-549 tumor cell growth at 10E-8 mol/L,F,,Homo sapiens,,80682
6303,6663,1,,646.0,,Intermediate,,A549,,9606.0,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.0625 uM,F,,Homo sapiens,,80682
6304,6663,1,,646.0,,Intermediate,,A549,,9606.0,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.125 uM,F,,Homo sapiens,,80682
6305,6663,1,,646.0,,Intermediate,,A549,,9606.0,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.25 uM,F,,Homo sapiens,,80682
6306,6663,1,,646.0,,Intermediate,,A549,,9606.0,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.5 uM,F,,Homo sapiens,,80682
6307,6663,1,,646.0,,Intermediate,,A549,,9606.0,Rate of inhibition of A-549 tumor cell growth at a concentration of 1 uM,F,,Homo sapiens,,80682
6308,3983,1,,646.0,,Intermediate,,A549,,9606.0,The compound was evaluated for its cytotoxic potency against A-549 cell line,F,,Homo sapiens,,80682
6309,11141,1,,646.0,,Expert,,A549,,9606.0,Cytotoxic concentration required to inhibit 50% cell growth in A-549 lung carcinoma cell lines,F,,Homo sapiens,,80682
6310,5076,1,,646.0,,Intermediate,,A549,,9606.0,Cytotoxic activity of compound against A-549 tumor cell line.,F,,Homo sapiens,,80682
6311,3311,1,,646.0,,Intermediate,,A549,,9606.0,In vitro cytotoxicity against Lung A-549 human tumors following a 6 day exposure.,F,,Homo sapiens,,80682
6312,3311,1,,646.0,,Intermediate,,A549,,9606.0,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure.,F,,Homo sapiens,,80682
6313,3311,1,,646.0,,Intermediate,,A549,,9606.0,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure; ND is no data,F,,Homo sapiens,,80682
6314,5076,1,,646.0,,Intermediate,,A549,,9606.0,Cytotoxic activity of compound against A-549 tumor cell line at conc. of 20 ug/mL,F,,Homo sapiens,,80682
6315,4150,1,,646.0,,Intermediate,,A549,,9606.0,Compound was tested for cytotoxic activity against A-549 human lung carcinoma (ATCC:CCL-185),F,,Homo sapiens,,80682
6316,2150,1,,646.0,,Expert,,A549,,9606.0,In vitro inhibitory concentration against cell culture of A-549 human lung carcinoma,F,,Homo sapiens,,80682
6317,4644,1,,646.0,,Intermediate,,A549,,9606.0,Concentration for in vitro cytotoxicity against A-549 human lung tumor cells,F,,Homo sapiens,,80682
6318,263,1,,646.0,,Intermediate,,A549,,9606.0,Dose required for in vitro cytotoxic activity against A-549 lung carcinoma cells at concentration of 10 ug/ml; NA is no cytotoxicity,F,,Homo sapiens,,80682
6319,11333,1,,646.0,,Intermediate,,A549,,9606.0,Cytotoxic concentration against A-549 tumor cells.,F,,Homo sapiens,,80682
6320,11333,1,,646.0,,Intermediate,,A549,,9606.0,Cytotoxic concentration against A-549 tumor cells; Inactive at 10 ug/mL.,F,,Homo sapiens,,80682
6321,15895,1,,646.0,,Intermediate,,A549,,9606.0,"Cytotoxicity against NCI tumor panel, A-549/ATCC non small-cell lung cancer cell line",F,,Homo sapiens,,80682
6322,16677,1,,,,Expert,,,,470.0,Minimum inhibitory concentration (lowest peptide concentration) required to prevent visible bacterial growth after 18 hr of incubation at 37 C in Mueller-Hinton broth against Acinetobacter baumannii 118A,F,,Acinetobacter baumannii,,50191
6323,10624,1,,,,Intermediate,,,,471.0,Activity against Acinetobacter calcoaceticus (AC54),F,,Acinetobacter calcoaceticus,,50192
6324,16717,1,,,,Expert,,,,5059.0,In vitro antifungal activity against Aspergillus flavus CM74,F,,Aspergillus flavus,,50274
6325,16717,1,,,,Expert,,,,5059.0,In vitro antifungal activity against Aspergillus flavus CM74,F,,Aspergillus flavus,,50274
6326,5513,1,,,,Intermediate,,,,746128.0,Inhibitory activity tested against Aspergillus fumigatus at 256 ug/mL concentration,F,,Aspergillus fumigatus,,50416
6327,15962,1,,,,Intermediate,,,,746128.0,In vitro minimum fungicidal concentration required to inhibit Aspergillus fumigatus(MFC),F,,Aspergillus fumigatus,,50416
6328,15962,1,,,,Intermediate,,,,746128.0,Antimicrobial activity against Aspergillus fumigatus (MIC),F,,Aspergillus fumigatus,,50416
6329,15962,1,,,,Intermediate,,,,746128.0,Antimicrobial activity against Aspergillus fumigatus (MIC),F,,Aspergillus fumigatus,,50416
6330,15962,1,,,,Intermediate,,,,746128.0,In vitro antimicrobial activity against Aspergillus fumigatus (MIC),F,,Aspergillus fumigatus,,50416
6331,16717,1,,,,Expert,,,,746128.0,In vitro antifungal activity against Aspergillus fumigatus 48238E,F,,Aspergillus fumigatus,,50416
6332,16717,1,,,,Expert,,,,746128.0,In vitro antifungal activity against Aspergillus fumigatus 48238E,F,,Aspergillus fumigatus,,50416
6333,8117,1,,,,Intermediate,,,,1655.0,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces naeslundii 631,F,,Actinomyces naeslundii,,50296
6334,8117,1,,,,Intermediate,,,,1656.0,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces viscosus M-100,F,,Actinomyces viscosus,,50366
6335,15472,1,,,,Intermediate,,,,6277.0,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),F,,Acanthocheilonema viteae,,50535
6336,15472,1,,,,Intermediate,,,,6277.0,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),F,,Acanthocheilonema viteae,,50535
6337,16443,1,,,,Intermediate,,,,714.0,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527,F,,Aggregatibacter actinomycetemcomitans,,50169
6338,16443,1,,,,Intermediate,,,,714.0,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2,F,,Aggregatibacter actinomycetemcomitans,,50169
6339,16443,1,,,,Intermediate,,,,714.0,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2; ND is Not Determined,F,,Aggregatibacter actinomycetemcomitans,,50169
6340,17206,1,,646.0,,Intermediate,,A549,,9606.0,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,F,,Homo sapiens,,80682
6341,17206,1,,646.0,,Intermediate,,A549,,9606.0,Percent ADP-ribose polymer formation at 25 uM compound concentration in A549 cells,F,,Homo sapiens,,80682
6342,16381,1,,646.0,,Intermediate,,A549,,9606.0,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,F,,Homo sapiens,,80682
6343,16381,1,,646.0,,Intermediate,,A549,,9606.0,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,F,,Homo sapiens,,80682
6344,16381,1,,646.0,,Intermediate,,A549,,9606.0,% inhibition against A549 cells (lung cancer) at 4 ug/mL,F,,Homo sapiens,,80682
6345,16381,1,,646.0,,Intermediate,,A549,,9606.0,GI values against A549 cells (lung cancer),F,,Homo sapiens,,80682
6346,17206,1,,646.0,,Intermediate,,A549,,9606.0,Effect on NAD+ depletion (% remaining versus vehicle control) 25 uM compound concentration in A549 cells,F,,Homo sapiens,,80682
6347,16325,1,,646.0,,Intermediate,,A549,,9606.0,Inhibitory activity against A549 human adenocarcinoma,F,,Homo sapiens,,80682
6348,10708,1,,646.0,,Intermediate,,A549,,9606.0,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 200 mg/kg,F,,Homo sapiens,,80682
6349,10708,1,,646.0,,Intermediate,,A549,,9606.0,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 100 mg/kg,F,,Homo sapiens,,80682
6350,17376,1,,646.0,,Intermediate,,A549,,9606.0,Inhibitory activity against A549 lung adenocarcinoma cell line,F,,Homo sapiens,,80682
6351,17376,1,,646.0,,Intermediate,,A549,,9606.0,Inhibitory activity against A549 lung adenocarcinoma cell line; not determined,F,,Homo sapiens,,80682
6352,17488,1,,646.0,,Intermediate,,A549,,9606.0,Cytotoxicity against human A549 lung cells,F,,Homo sapiens,,80682
6353,17404,1,,646.0,,Intermediate,,A549,,9606.0,In vivo percent inhibitory activity of intraperitoneally administered compound (50 mg/kg/day) against mice infected with A549 tumor,F,,Homo sapiens,,80682
6354,10958,1,,646.0,,Expert,,A549,,9606.0,Growth inhibition of A549 (human lung carcinoma) cell line.,F,,Homo sapiens,,80682
6355,17099,1,,646.0,,Expert,,A549,,9606.0,Effective dose required for inhibitory activity against A549 human tumor cell line.,F,,Homo sapiens,,80682
6356,17099,1,,646.0,,Intermediate,,A549,,9606.0,Effective dose required for inhibitory activity against A549 human tumor cell line; Not active,F,,Homo sapiens,,80682
6357,4096,1,,646.0,,Intermediate,,A549,,9606.0,Cytotoxicity was evaluated against A549 tumor cell lines; Inactive,F,,Homo sapiens,,80682
6358,4096,1,,646.0,,Expert,,A549,,9606.0,Cytotoxicity evaluated against A549 tumor cell lines; significant activity,F,,Homo sapiens,,80682
6359,4096,1,,646.0,,Intermediate,,A549,,9606.0,Cytotoxicity was evaluated against A549 tumor cell lines; Slightly active,F,,Homo sapiens,,80682
6360,2525,1,,646.0,,Intermediate,,A549,,9606.0,In vitro inhibitory activity against A549 tumor cell culture,F,,Homo sapiens,,80682
6361,2525,1,,646.0,,Intermediate,,A549,,9606.0,In vitro inhibitory activity against A549 tumor cell culture; IA= Inactive,F,,Homo sapiens,,80682
6362,5302,1,,646.0,,Intermediate,,A549,,9606.0,Activity against human lung cancer with mutated beta-tubulin (A549-T2415),F,,Homo sapiens,,80682
6363,16325,1,,646.0,,Intermediate,,A549,,9606.0,Growth inhibitory activity was determined against A549/ATCC cancer cell line of non-small cell lung cancer,F,,Homo sapiens,,80682
6364,16939,1,,646.0,,Intermediate,,A549,,9606.0,Inhibition of growth of A549/ATCC nonsmall cell lung cancer cell line,F,,Homo sapiens,,80682
6365,17229,1,,646.0,,Intermediate,,A549,,9606.0,In vitro antitumor activity against NSCL A549/ATCC tumor cell lines,F,,Homo sapiens,,80682
6366,17380,1,,646.0,,Intermediate,,A549,,9606.0,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells,F,,Homo sapiens,,80682
6367,17380,1,,646.0,,Intermediate,,A549,,9606.0,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells; No data,F,,Homo sapiens,,80682
6368,1903,1,,646.0,,Intermediate,,A549,,9606.0,In vitro cytotoxicity against human Non-small cell lung cancer A549/ATCC cell line.,F,,Homo sapiens,,80682
6369,3838,1,,646.0,,Intermediate,,A549,,9606.0,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,F,,Homo sapiens,,80682
6370,14696,1,,646.0,,Intermediate,,A549,,9606.0,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,F,,Homo sapiens,,80682
6371,3838,1,,646.0,,Intermediate,,A549,,9606.0,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,F,,Homo sapiens,,80682
6372,1522,1,,646.0,,Intermediate,,A549,,9606.0,Tested for in vitro cytotoxicity against non-small cell lung cancer cell line A549/ATCC,F,,Homo sapiens,,80682
6373,12400,1,,646.0,,Intermediate,,A549,,9606.0,Tested in vitro for cytotoxicity in A549/ATCC cell lines,F,,Homo sapiens,,80682
6374,14696,1,,646.0,,Intermediate,,A549,,9606.0,inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,F,,Homo sapiens,,80682
6375,14769,1,,646.0,,Intermediate,,A549,,9606.0,Compound was evaluated for in vitro activity against A549/ATCC lung cancer cell lines (Human tumor cells ),F,,Homo sapiens,,80682
6376,14696,1,,646.0,,Intermediate,,A549,,9606.0,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line at 0.01 uM,F,,Homo sapiens,,80682
6377,1888,1,,646.0,,Intermediate,,A549,,9606.0,Compound was evaluated for cytotoxic activity against non-small lung cancer A549/ATCC cell lines.,F,,Homo sapiens,,80682
6378,12016,1,,646.0,,Intermediate,,A549,,9606.0,Tested for cytotoxic activity against non-small cell lung cancer A549/ATCC cell line,F,,Homo sapiens,,80682
6379,6058,1,,646.0,,Intermediate,,A549,,9606.0,Compound tested for growth inhibition of non-small cell lung cancer cell line A549/ATCC,F,,Homo sapiens,,80682
6380,17708,1,,646.0,,Intermediate,,A549,,9606.0,Compound was tested for 50% growth inhibition against human non-small cell lung cancer A549/ATCC cell line,F,,Homo sapiens,,80682
6381,12301,1,,646.0,,Intermediate,,A549,,9606.0,Antitumor activity against A549/ATCC cell line,F,,Homo sapiens,,80682
6382,11970,1,,646.0,,Intermediate,,A549,,9606.0,Tested for cytotoxicity against A549/ATCC cell lines in non-small-cell lung cancer,F,,Homo sapiens,,80682
6383,11818,1,,646.0,,Expert,,A549,,9606.0,In vitro cytotoxicity against A549/ATCC cell line.,F,,Homo sapiens,,80682
6384,12400,1,,646.0,,Intermediate,,A549,,9606.0,Tested in vitro for cytotoxicity in A549/ATCC cell line of Non-Small Cell Lung Cancer,F,,Homo sapiens,,80682
6385,3381,1,,646.0,,Intermediate,,A549,,9606.0,In vitro inhibition of Non-Small Cell Lung Cancer A549/ATCC cell lines,F,,Homo sapiens,,80682
6386,17376,1,,646.0,,Intermediate,,A549,,9606.0,Concentration of compound that cause 50% cytotoxicity of A549/ATCC non small cell lung cancer cell line,F,,Homo sapiens,,80682
6387,10708,1,,646.0,,Intermediate,,A549,,9606.0,Evaluated for the inhibitory concentration required to cause growth inhibition of A549Rem- cell line of lung using the MTT Cytotoxicity Assay,F,,Homo sapiens,,80682
6388,2964,0,,,,Autocuration,,,,9606.0,Cytotoxicity was evaluated against A649 human mammary carcinoma cells,F,,Homo sapiens,,22226
6389,5005,0,,,,Intermediate,,,,9615.0,Compound was tested for oral bioavailability in dogs,A,In vivo,Canis lupus familiaris,,22224
6390,6229,1,,,,Intermediate,,,,9615.0,Compound was tested for orally bioavailable in dogs with a half life of 0.7 hr,A,In vivo,Canis lupus familiaris,,50588
6391,6229,1,,,,Intermediate,,,,9615.0,Compound was tested for orally bioavailable in dogs with a half life of 1.2h,A,In vivo,Canis lupus familiaris,,50588
6392,5374,1,,,,Intermediate,,,,9615.0,Oral bioavailability in dog,A,In vivo,Canis lupus familiaris,,50588
6393,5374,1,,,,Intermediate,,,,9615.0,Compound was tested for the oral bioavailability in dog; No availability,A,In vivo,Canis lupus familiaris,,50588
6394,6265,1,,,,Intermediate,,,,9615.0,Oral bioavailability in dog (dose 5 mg/kg),A,In vivo,Canis lupus familiaris,,50588
6395,5654,1,,,,Intermediate,,,,9615.0,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,A,In vivo,Canis lupus familiaris,,50588
6396,5654,1,,,,Intermediate,,,,9615.0,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,A,In vivo,Canis lupus familiaris,,50588
6397,16456,1,,,,Intermediate,,,,9615.0,Oral bioavailability in Beagle dogs after Per oral administration at dose of 50(mg/kg),A,In vivo,Canis lupus familiaris,,50588
6398,5302,1,,,,Intermediate,,,,9615.0,Oral bioavailability in dog (dose 5 mg/kg),A,In vivo,Canis lupus familiaris,,50588
6399,3624,1,,,,Intermediate,,,,9615.0,Oral bioavailability in dog (p.o. dosing of 0.05 M citric acid/0.05 M hydrochloric acid solution),A,In vivo,Canis lupus familiaris,,50588
6400,16452,1,,,,Intermediate,,,,9615.0,Oral bioavailability of active FTIs in dogs,A,In vivo,Canis lupus familiaris,,50588
6401,5802,1,,,,Intermediate,,,,9615.0,Oral bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),A,In vivo,Canis lupus familiaris,,50588
6402,3598,1,,,,Expert,,,,9615.0,Oral bioavailability of compound determined in dog after iv administration at a dose of 10 mg/kg,A,In vivo,Canis lupus familiaris,,50588
6403,17839,1,,,,Intermediate,,,,9615.0,Oral bioavailability in dog,A,In vivo,Canis lupus familiaris,,50588
6404,6762,1,,,,Intermediate,,,,9615.0,Oral bioavailability in dog,A,In vivo,Canis lupus familiaris,,50588
6405,6821,1,,,,Intermediate,,,,9615.0,Oral bioavailability in dog,A,In vivo,Canis lupus familiaris,,50588
6406,6821,1,,,,Intermediate,,,,9615.0,Oral bioavailability of compound was determined in dog; Not tested,A,In vivo,Canis lupus familiaris,,50588
6407,5210,1,,,,Intermediate,,,,9615.0,Oral bioavailability in dog,A,In vivo,Canis lupus familiaris,,50588
6408,6227,1,,,,Intermediate,,,,9615.0,Oral bioavailability (10 mg/kg) was determined in dog,A,In vivo,Canis lupus familiaris,,50588
6409,761,1,,,,Intermediate,,,,9615.0,Oral bioavailability,A,In vivo,Canis lupus familiaris,,50588
6410,761,1,,,,Intermediate,,,,9615.0,Oral bioavailability in dog (dosed as neat powder in hard gelatin capsule),A,In vivo,Canis lupus familiaris,,50588
6411,761,1,,,,Intermediate,,,,9615.0,Oral bioavailability administered in solution in rats,A,In vivo,Canis lupus familiaris,,50588
6412,16907,1,,,,Intermediate,,,,9615.0,Oral bioavailability after 30 mg/kg po dose in Dogs,A,In vivo,Canis lupus familiaris,,50588
6413,5474,1,,,,Intermediate,,,,9615.0,Oral bioavailability at a dose of 1 mg/kg in dogs,A,In vivo,Canis lupus familiaris,,50588
6414,6535,1,,,,Intermediate,,,,9615.0,Oral bioavailability in dog (dose 1 mg/kg p.o.),A,In vivo,Canis lupus familiaris,,50588
6415,6535,1,,,,Intermediate,,,,9615.0,Oral bioavailability in Dog; ND = not determined,A,In vivo,Canis lupus familiaris,,50588
6416,3352,1,,,,Intermediate,,,,9615.0,Oral bioavailability in dog,A,In vivo,Canis lupus familiaris,,50588
6417,6168,1,,,,Intermediate,,,,9615.0,Oral bioavailability in dog,A,In vivo,Canis lupus familiaris,,50588
6418,5988,1,,,,Intermediate,,,,9615.0,Oral bioavailability in dog,A,In vivo,Canis lupus familiaris,,50588
6419,4942,1,,,,Intermediate,,,,9615.0,Oral bioavailability in dog,A,In vivo,Canis lupus familiaris,,50588
6420,4942,1,,,,Intermediate,,,,9615.0,Oral bioavailability in dogs; No data,A,In vivo,Canis lupus familiaris,,50588
6421,14541,1,,,,Intermediate,,,,9615.0,Oral bioavailability measured in dogs,A,In vivo,Canis lupus familiaris,,50588
6422,4449,1,,,,Intermediate,,,,9615.0,Oral bioavailability in dog,A,In vivo,Canis lupus familiaris,,50588
6423,6057,1,,,,Intermediate,,,,9615.0,Oral bioavailability was calculated in dog,A,In vivo,Canis lupus familiaris,,50588
6424,5600,1,,,,Intermediate,,,,9615.0,Oral bioavailability after 0.3 mg/kg po administration in dog,A,In vivo,Canis lupus familiaris,,50588
6425,5542,1,,,,Intermediate,,,,9615.0,Oral bioavailability in dog (i.v. dosing),A,In vivo,Canis lupus familiaris,,50588
6426,5542,1,,,,Intermediate,,,,9615.0,Oral bioavailability in dog,A,In vivo,Canis lupus familiaris,,50588
6427,5546,1,,,,Intermediate,,,,9615.0,Oral bioavailability in Beagle dog at a dose of 2 mg/kg by po administration,A,In vivo,Canis lupus familiaris,,50588
6428,4514,1,,,,Intermediate,,,,9615.0,Oral bioavailability in Beagle dogs,A,In vivo,Canis lupus familiaris,,50588
6429,3624,1,,,,Intermediate,,,,9615.0,Oral bioavailability in dog,A,In vivo,Canis lupus familiaris,,50588
6430,3854,1,,,,Intermediate,,,,9615.0,Oral bioavailability in dog,A,In vivo,Canis lupus familiaris,,50588
6431,5836,1,,,,Intermediate,,,,9615.0,Oral bioavailability in dog,A,In vivo,Canis lupus familiaris,,50588
6432,5940,1,,,,Intermediate,,,,9615.0,Oral bioavailability in dog,A,In vivo,Canis lupus familiaris,,50588
6433,6168,1,,,,Intermediate,,,,9615.0,Oral bioavailability in dog,A,In vivo,Canis lupus familiaris,,50588
6434,6227,1,,,,Intermediate,,,,9615.0,Oral bioavailability in dog,A,In vivo,Canis lupus familiaris,,50588
6435,6251,1,,,,Intermediate,,,,9615.0,Oral bioavailability in dog,A,In vivo,Canis lupus familiaris,,50588
6436,6448,1,,,,Intermediate,,,,9615.0,Oral bioavailability in dog,A,In vivo,Canis lupus familiaris,,50588
6437,6647,1,,,,Intermediate,,,,9615.0,Oral bioavailability in dog,A,In vivo,Canis lupus familiaris,,50588
6438,5940,1,,,,Intermediate,,,,9615.0,Oral bioavailability in dog,A,In vivo,Canis lupus familiaris,,50588
6439,933,1,,,,Intermediate,,,,9615.0,Oral bioavailability in dog,A,In vivo,Canis lupus familiaris,,50588
6440,5210,1,,,,Intermediate,,,,9615.0,Oral bioavailability in dog,A,In vivo,Canis lupus familiaris,,50588
6441,6642,1,,,,Intermediate,,,,9615.0,Oral bioavailability in dog (dosed as a mixture of five compounds at 0.5 mg/kg each via i.v. only),A,In vivo,Canis lupus familiaris,,50588
6442,6641,1,,,,Intermediate,,,,9615.0,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),A,In vivo,Canis lupus familiaris,,50588
6443,6642,1,,,,Intermediate,,,,9615.0,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),A,In vivo,Canis lupus familiaris,,50588
6444,5472,1,,,,Intermediate,,,,9615.0,Oral bioavailability in dog,A,In vivo,Canis lupus familiaris,,50588
6445,5985,1,,,,Intermediate,,,,9615.0,Oral bioavailability in dog,A,In vivo,Canis lupus familiaris,,50588
6446,15660,1,,,,Intermediate,,,,9615.0,Oral bioavailability in dog,A,In vivo,Canis lupus familiaris,,50588
6447,5530,1,,,,Intermediate,,,,9615.0,Oral bioavailability in dog (dose 0.2 mg/kg i.v.),A,In vivo,Canis lupus familiaris,,50588
6448,5530,1,,,,Intermediate,,,,9615.0,Oral bioavailability in dog (dose 1 mg/kg i.v.),A,In vivo,Canis lupus familiaris,,50588
6449,6305,1,,,,Intermediate,,,,9615.0,Oral bioavailability (F) in dogs,A,In vivo,Canis lupus familiaris,,50588
6450,5210,1,,,,Intermediate,,,,9615.0,Oral bioavailability in dog,A,In vivo,Canis lupus familiaris,,50588
6451,5238,1,,,,Intermediate,,,,9615.0,Bioavailability in dog,A,In vivo,Canis lupus familiaris,,50588
6452,5668,1,,,,Intermediate,,,,9615.0,Oral bioavailability in dog (dose 10 mg/kg),A,In vivo,Canis lupus familiaris,,50588
6453,5668,1,,,,Intermediate,,,,9615.0,Oral bioavailability after peroral administration at 5 mpk in Dog,A,In vivo,Canis lupus familiaris,,50588
6454,5668,1,,,,Intermediate,,,,9615.0,Oral bioavailability in dog (dose 5 mg/kg),A,In vivo,Canis lupus familiaris,,50588
6455,6084,1,,,,Intermediate,,,,9615.0,Oral bioavailability in dog (dose 10 mg/kg),A,In vivo,Canis lupus familiaris,,50588
6456,6599,1,,42.0,,Intermediate,2113.0,CCRF S-180,Kidney,10090.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 4 hours,A,,Mus musculus,,50594
6457,6599,1,,42.0,,Intermediate,2113.0,CCRF S-180,Kidney,10090.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 8 hours,A,,Mus musculus,,50594
6458,6599,1,,42.0,,Intermediate,2107.0,CCRF S-180,Liver,10090.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 1 hour,A,,Mus musculus,,50594
6459,6599,1,,42.0,,Intermediate,2107.0,CCRF S-180,Liver,10090.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 2 hours,A,,Mus musculus,,50594
6460,6599,1,,42.0,,Intermediate,2107.0,CCRF S-180,Liver,10090.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 30 minutes,A,,Mus musculus,,50594
6461,6599,1,,42.0,,Intermediate,2107.0,CCRF S-180,Liver,10090.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 4 hours,A,,Mus musculus,,50594
6462,6599,1,,42.0,,Intermediate,2107.0,CCRF S-180,Liver,10090.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 8 hours,A,,Mus musculus,,50594
6463,6599,1,,42.0,,Intermediate,2048.0,CCRF S-180,Lung,10090.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 1 hour,A,,Mus musculus,,50594
6464,6599,1,,42.0,,Intermediate,2048.0,CCRF S-180,Lung,10090.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 2 hours,A,,Mus musculus,,50594
6465,6599,1,,42.0,,Intermediate,2048.0,CCRF S-180,Lung,10090.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 30 minutes,A,,Mus musculus,,50594
6466,6599,1,,42.0,,Intermediate,2048.0,CCRF S-180,Lung,10090.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 4 hours,A,,Mus musculus,,50594
6467,6599,1,,42.0,,Intermediate,2048.0,CCRF S-180,Lung,10090.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 8 hours,A,,Mus musculus,,50594
6468,6599,1,,42.0,,Intermediate,,CCRF S-180,,10090.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 1 hour,A,,Mus musculus,,50594
6469,6599,1,,42.0,,Intermediate,,CCRF S-180,,10090.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice muscle bearing S180 tumor cell line for 2 hours,A,,Mus musculus,,50594
6470,6599,1,,42.0,,Intermediate,,CCRF S-180,,10090.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 30 minutes,A,,Mus musculus,,50594
6471,6599,1,,42.0,,Intermediate,,CCRF S-180,,10090.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 4 hours,A,,Mus musculus,,50594
6472,6599,1,,42.0,,Intermediate,,CCRF S-180,,10090.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 8 hours,A,,Mus musculus,,50594
6473,6599,1,,42.0,,Intermediate,2106.0,CCRF S-180,Spleen,10090.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice spleen bearing S180 tumor cell line for 1 hour,A,,Mus musculus,,50594
6474,6599,1,,42.0,,Intermediate,2106.0,CCRF S-180,Spleen,10090.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 2 hours,A,,Mus musculus,,50594
6475,6599,1,,42.0,,Intermediate,2106.0,CCRF S-180,Spleen,10090.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 30 minutes,A,,Mus musculus,,50594
6476,6599,1,,42.0,,Intermediate,2106.0,CCRF S-180,Spleen,10090.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 4 hours,A,,Mus musculus,,50594
6477,6599,1,,42.0,,Intermediate,2106.0,CCRF S-180,Spleen,10090.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 8 hours,A,,Mus musculus,,50594
6478,6599,1,,42.0,,Intermediate,,CCRF S-180,,10090.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 1 hour,A,,Mus musculus,,50594
6479,6599,1,,42.0,,Intermediate,,CCRF S-180,,10090.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 2 hours,A,,Mus musculus,,50594
6480,6599,1,,42.0,,Intermediate,,CCRF S-180,,10090.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 30 minutes,A,,Mus musculus,,50594
6481,6599,1,,42.0,,Intermediate,,CCRF S-180,,10090.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 4 hours,A,,Mus musculus,,50594
6482,6599,1,,42.0,,Intermediate,,CCRF S-180,,10090.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 8 hours,A,,Mus musculus,,50594
6483,6599,1,,42.0,,Intermediate,,CCRF S-180,,10090.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 1 hour,A,,Mus musculus,,50594
6484,6599,1,,42.0,,Intermediate,,CCRF S-180,,10090.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 2 hours,A,,Mus musculus,,50594
6485,6599,1,,42.0,,Intermediate,,CCRF S-180,,10090.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 30 minutes,A,,Mus musculus,,50594
6486,6599,1,,42.0,,Intermediate,,CCRF S-180,,10090.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 4 hours,A,,Mus musculus,,50594
6487,6599,1,,42.0,,Intermediate,,CCRF S-180,,10090.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 8 hours,A,,Mus musculus,,50594
6488,6599,1,,42.0,,Intermediate,948.0,CCRF S-180,Heart,10090.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 1 hour,A,,Mus musculus,,50594
6489,6599,1,,42.0,,Intermediate,948.0,CCRF S-180,Heart,10090.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 2 hours,A,,Mus musculus,,50594
6490,6599,1,,42.0,,Intermediate,948.0,CCRF S-180,Heart,10090.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 30 minutes,A,,Mus musculus,,50594
6491,6599,1,,42.0,,Intermediate,948.0,CCRF S-180,Heart,10090.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 4 hours,A,,Mus musculus,,50594
6492,6599,1,,42.0,,Intermediate,948.0,CCRF S-180,Heart,10090.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 8 hours,A,,Mus musculus,,50594
6493,6599,1,,42.0,,Intermediate,2107.0,CCRF S-180,Liver,10090.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 1 hour,A,,Mus musculus,,50594
6494,6599,1,,42.0,,Intermediate,2107.0,CCRF S-180,Liver,10090.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 2 hours,A,,Mus musculus,,50594
6495,6599,1,,42.0,,Intermediate,2107.0,CCRF S-180,Liver,10090.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 30 minutes,A,,Mus musculus,,50594
6496,6599,1,,42.0,,Intermediate,2107.0,CCRF S-180,Liver,10090.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 4 hours,A,,Mus musculus,,50594
6497,6599,1,,42.0,,Intermediate,2107.0,CCRF S-180,Liver,10090.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 8 hours,A,,Mus musculus,,50594
6498,6599,1,,42.0,,Intermediate,2048.0,CCRF S-180,Lung,10090.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 1 hour,A,,Mus musculus,,50594
6499,6599,1,,42.0,,Intermediate,2048.0,CCRF S-180,Lung,10090.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/lung bearing S180 tumor cell line for 2 hours,A,,Mus musculus,,50594
6500,12269,1,,,,Intermediate,,,,107673.0,Compound tested for the antimicrobial activity against Acinetobacter anitratus,F,,aeinetobacter anitrotap,,50067
6501,12269,1,,,,Intermediate,,,,107673.0,Compound tested for the antimicrobial activity against Acinetobacter anitratus,F,,Acinetobacter calcoaceticus subsp. anitratus,,50067
6502,12269,1,,,,Intermediate,,,,107673.0,Compound tested for the antimicrobial activity against Acinetobacter anitratus,F,,Acinetobacter calcoaceticus subsp. anitratus,,50067
6503,12269,1,,,,Intermediate,,,,107673.0,Compound tested for the antimicrobial activity against Acinetobacter anitratus,F,,aeinetobacter anitrotap,,50067
6504,10624,1,,,,Intermediate,,,,471.0,Activity against Acinetobacter calcoaceticus (AC54),F,,Acinetobacter calcoaceticus,,50192
6505,17216,1,,,,Intermediate,,,,28377.0,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates no prolonged biological activity,F,,Anolis carolinensis,,50714
6506,17216,1,,,,Intermediate,,,,28377.0,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates prolonged biological activity,F,,Anolis carolinensis,,50714
6507,9560,1,,,,Intermediate,,,,1655.0,Chlorohexidine coefficient for Actinomyces naeslundii 631,F,,Actinomyces naeslundii,,50296
6508,9560,1,,,,Intermediate,,,,1655.0,Chlorohexidine coefficient for Actinomyces naeslundii B74,F,,Actinomyces naeslundii,,50296
6509,9560,1,,,,Intermediate,,,,1655.0,Chlorohexidine coefficient for Actinomyces naeslundii N/3,F,,Actinomyces naeslundii,,50296
6510,9560,1,,,,Intermediate,,,,1655.0,Chlorohexidine coefficient for Actinomyces naeslundii N/9,F,,Actinomyces naeslundii,,50296
6511,9560,1,,,,Intermediate,,,,1655.0,Plaque bactericidal index against Actinomyces naeslundii 631,F,,Actinomyces naeslundii,,50296
6512,9560,1,,,,Intermediate,,,,1655.0,Plaque bactericidal index against Actinomyces naeslundii N/9,F,,Actinomyces naeslundii,,50296
6513,9560,1,,,,Intermediate,,,,1655.0,Plaque bactericidal index against Actinomyces naeslundii B74,F,,Actinomyces naeslundii,,50296
6514,9560,1,,,,Intermediate,,,,1655.0,Plaque bactericidal index against Actinomyces naeslundii N/3,F,,Actinomyces naeslundii,,50296
6515,114,1,,,,Intermediate,,,,85549.0,Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay,F,,Artemia salina,,50056
6516,114,1,,,,Intermediate,,,,85549.0,"Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay; highest level tested, showed <100% activity",F,,Artemia salina,,50056
6517,10841,1,,,,Intermediate,,,,6253.0,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 0 uM,F,,Ascaris suum,,50532
6518,10841,1,,,,Intermediate,,,,6253.0,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 10 uM,F,,Ascaris suum,,50532
6519,10841,1,,,,Intermediate,,,,6253.0,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 200 uM,F,,Ascaris suum,,50532
6520,10841,1,,,,Intermediate,,,,6253.0,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 25 uM,F,,Ascaris suum,,50532
6521,10841,1,,,,Intermediate,,,,6253.0,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 3 uM,F,,Ascaris suum,,50532
6522,10841,1,,,,Intermediate,,,,6253.0,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 50 uM.,F,,Ascaris suum,,50532
6523,10841,1,,,,Intermediate,,,,6253.0,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 0 uM,F,,Ascaris suum,,50532
6524,10841,1,,,,Intermediate,,,,6253.0,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 10 uM,F,,Ascaris suum,,50532
6525,10841,1,,,,Intermediate,,,,6253.0,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 200 uM,F,,Ascaris suum,,50532
6526,10841,1,,,,Intermediate,,,,6253.0,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 25 uM,F,,Ascaris suum,,50532
6527,10841,1,,,,Intermediate,,,,6253.0,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 3 uM,F,,Ascaris suum,,50532
6528,10841,1,,,,Intermediate,,,,6253.0,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 50 uM,F,,Ascaris suum,,50532
6529,8117,1,,,,Intermediate,,,,1656.0,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,F,,Actinomyces viscosus,,50366
6530,8117,1,,,,Intermediate,,,,1656.0,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,F,,Actinomyces viscosus,,50366
6531,9560,1,,,,Intermediate,,,,1656.0,Chlorohexidine coefficient for Actinomyces viscosus 8A06,F,,Actinomyces viscosus,,50366
6532,9560,1,,,,Expert,,,,1656.0,Chlorohexidine coefficient for Actinomyces viscosus M-100,F,,Actinomyces viscosus,,50366
6533,9560,1,,,,Intermediate,,,,1656.0,Chlorohexidine coefficient for Actinomyces viscosus M-626,F,,Actinomyces viscosus,,50366
6534,9560,1,,,,Intermediate,,,,1656.0,Chlorohexidine coefficient for Actinomyces viscosus T14V,F,,Actinomyces viscosus,,50366
6535,9560,1,,,,Intermediate,,,,1656.0,Plaque bactericidal index against Actinomyces viscosus 8A06,F,,Actinomyces viscosus,,50366
6536,9560,1,,,,Intermediate,,,,1656.0,Plaque bactericidal index against Actinomyces viscosus M-100,F,,Actinomyces viscosus,,50366
6537,9560,1,,,,Expert,,,,1656.0,Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient,F,,Actinomyces viscosus,,50366
6538,9560,1,,,,Intermediate,,,,1656.0,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; d=Not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",F,,Actinomyces viscosus,,50366
6539,9560,1,,,,Intermediate,,,,1656.0,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",F,,Actinomyces viscosus,,50366
6540,9560,1,,,,Intermediate,,,,1656.0,Plaque bactericidal index against Actinomyces viscosus 626,F,,Actinomyces viscosus,,50366
6541,9560,1,,,,Intermediate,,,,1656.0,Plaque bactericidal index against Actinomyces viscosus T14V,F,,Actinomyces viscosus,,50366
6542,10986,1,,,,Intermediate,,,,6277.0,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 1.56 mg/kg/day(5 days) dose,F,,Acanthocheilonema viteae,,50535
6543,10986,1,,,,Intermediate,,,,6277.0,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 100 mg/kg/day(5 days) dose,F,,Acanthocheilonema viteae,,50535
6544,10986,1,,,,Intermediate,,,,6277.0,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 12.5 mg/kg/day(5 days) dose,F,,Acanthocheilonema viteae,,50535
6545,10986,1,,,,Intermediate,,,,6277.0,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 200 mg/kg/day(5 days) dose,F,,Acanthocheilonema viteae,,50535
6546,10986,1,,,,Intermediate,,,,6277.0,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 25 mg/kg/day(5 days) dose,F,,Acanthocheilonema viteae,,50535
6547,10708,1,,165.0,,Intermediate,,A673,,9606.0,Evaluated for the inhibitory concentration required to cause growth inhibition of A673Mer+ sarcoma cell line using the MTT Cytotoxicity Assay,F,,Homo sapiens,,80023
6548,10708,1,,645.0,,Intermediate,,A704,,9606.0,Evaluated for the inhibitory concentration required to cause growth inhibition of A704Rem- renal cell line using the MTT Cytotoxicity Assay,F,,Homo sapiens,,80661
6549,416,0,,,,Autocuration,,,,10116.0,Tested for inhibition of ET-1 induced phosphoinositide (PI) turnover in A7r5 smooth muscle cells,F,,Rattus norvegicus,,22226
6550,14354,1,,625.0,,Intermediate,,A9,,10090.0,Inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,F,,Mus musculus,,80024
6551,14354,1,,625.0,,Intermediate,,A9,,10090.0,Percent inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,F,,Mus musculus,,80024
6552,5116,1,,625.0,,Intermediate,,A9,,9606.0,Cytotoxicity against Beta- tubulin mutant expressing A9-PTX10 cell line of humans was tested,F,,Homo sapiens,,80024
6553,5116,1,,625.0,,Intermediate,,A9,,9606.0,Percentage inhibition at higher concentration (100 nM) against Beta- tubulin mutant expressing A9-PTX10 cell line,F,,Homo sapiens,,80024
6554,15694,1,,874.0,,Expert,,Human ovarian carcinoma cell line,,9606.0,Inhibition of human ovarian carcinoma (A90) FGF-R overexpressing cell proliferation,F,,Homo sapiens,,81037
6555,13038,1,,625.0,,Expert,,A9,,10090.0,"Tested for stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells, activity expressed as EC50 mM.",F,,Mus musculus,,80024
6556,13038,1,,625.0,,Expert,,A9,,10090.0,Stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells.,F,,Mus musculus,,80024
6557,10923,1,,625.0,,Expert,,A9,,10090.0,Increase in phosphoinositide (PI) metabolism in A9L-m1 cells at 100 uM.,F,,Mus musculus,,80024
6558,10923,1,,625.0,,Intermediate,,A9,,10090.0,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; - = Not determined,F,,Mus musculus,,80024
6559,10923,1,,625.0,,Intermediate,,A9,,10090.0,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; i = inactive,F,,Mus musculus,,80024
6560,10923,8,,,,Expert,,,,,"Increase in phosphoinositide (PI) metabolism in A9L-cholinergic receptor, muscarinic 3 expressing cells was measured at 100 uMolar",F,,,,10649
6561,10923,1,,625.0,,Intermediate,,A9,,10090.0,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; - = Not determined,F,,Mus musculus,,80024
6562,10923,1,,625.0,,Intermediate,,A9,,10090.0,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; i = inactive,F,,Mus musculus,,80024
6563,8158,1,,975.0,,Intermediate,,AA6,,10029.0,Ability to inhibit growth of AA-6 cells (a mutant cell line resistant to 8-azaadenine and lacks adenine phosphoryltransferase) was determined,F,,Cricetulus griseus,,80663
6564,15494,0,,,,Autocuration,,,,9606.0,Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied after 5 hrs of Incubation.,F,,Homo sapiens,,22226
6565,15494,0,,,,Autocuration,,,,9606.0,"Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied, after 5 hrs of Incubation.",F,,Homo sapiens,,22226
6566,12348,1,,974.0,,Intermediate,,AA5,,9606.0,Anti -HIV activity was measured against AA5/HIV-1(IIIB),F,,Homo sapiens,,80662
6567,12348,1,,974.0,,Intermediate,,AA5,,9606.0,Cytotoxicity was measured against AA5/HIV-1(IIIB),F,,Homo sapiens,,80662
6568,2726,1,,974.0,,Intermediate,,AA5,,9606.0,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in AA5 EBV-infected B-cell,F,,Homo sapiens,,80662
6569,2726,1,,379.0,,Intermediate,,U-937,,9606.0,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in U937 monocytic cell,F,,Homo sapiens,,80566
6570,10747,1,,274.0,,Intermediate,,UV4,,10029.0,Hypersensitivity factor obtained from in vitro cytotoxicities against Chinese hamster ovary derived AA8 / UV4 cell lines,F,,Cricetulus griseus,,80578
6571,11005,1,,185.0,,Expert,,CHO-AA8,,10029.0,"Inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",F,,Cricetulus griseus,,80089
6572,12687,1,,185.0,,Intermediate,,CHO-AA8,,10029.0,Average intracellular compound concentration when the hypoxic SER=1.6,F,,Cricetulus griseus,,80089
6573,12687,1,,185.0,,Intermediate,,CHO-AA8,,10029.0,Average intracellular compound concentration when the hypoxic SER=1.6.,F,,Cricetulus griseus,,80089
6574,12687,1,,185.0,,Intermediate,,CHO-AA8,,10029.0,Average intracellular compound concentration where the hypoxia sensitizer enhancement ratio (SER)=1.6,F,,Cricetulus griseus,,80089
6575,12687,1,,185.0,,Intermediate,,CHO-AA8,,10029.0,Average intracellular compound concentration where the sensitizer enhancement ratio (SER)=1.6 under hypoxia,F,,Cricetulus griseus,,80089
6576,12687,1,,185.0,,Intermediate,,CHO-AA8,,10029.0,Compound concentration at which sensitizer enhancement ratio =1.6 under hypoxia.,F,,Cricetulus griseus,,80089
6577,13436,1,,185.0,,Intermediate,,CHO-AA8,,10029.0,"Compound was tested for the concentration required to reduce cell survival under hypoxic conditions, using the cell line AA8 in the clonogenic assay.",F,,Cricetulus griseus,,80089
6578,13435,1,,185.0,,Intermediate,,CHO-AA8,,10029.0,"Concentration needed to reduce cell survival to 10% of control values, using 1 hour exposure of plateau phase AA8 cells at 10e6 cells/ml",F,,Cricetulus griseus,,80089
6579,13302,1,,185.0,,Intermediate,,CHO-AA8,,10029.0,Activity to reduce the surviving fraction to 10% (CT10) was used as an inverse measure of cytotoxic potency in aerobic conditions,F,,Cricetulus griseus,,80089
6580,12687,1,,185.0,,Intermediate,,CHO-AA8,,10029.0,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,F,,Cricetulus griseus,,80089
6581,12687,1,,185.0,,Intermediate,,CHO-AA8,,10029.0,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,A,,Cricetulus griseus,,80089
6582,12687,1,,185.0,,Intermediate,,CHO-AA8,,10029.0,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition.,A,,Cricetulus griseus,,80089
6583,12878,1,,185.0,,Expert,,CHO-AA8,,10029.0,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay,A,,Cricetulus griseus,,80089
6584,12878,1,,185.0,,Intermediate,,CHO-AA8,,10029.0,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay. Inactive at the solubility limit,A,,Cricetulus griseus,,80089
6585,14367,1,,185.0,,Expert,,CHO-AA8,,10029.0,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% controls in clonogenic assay,F,,Cricetulus griseus,,80089
6586,14367,1,,185.0,,Intermediate,,CHO-AA8,,10029.0,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% of controls in clonogenic assay,F,,Cricetulus griseus,,80089
6587,12398,1,,185.0,,Expert,,CHO-AA8,,36483.0,Aerobic cytotoxicity was assessed in a growth inhibition assay using log phase cultures of the chinese hamster ovary fibroblast line AA8,F,,hampster,,80089
6588,12878,1,,185.0,,Expert,,CHO-AA8,,10029.0,Aerobic growth inhibition in Chinese hamster cell line AA8,F,,Cricetulus griseus,,80089
6589,13820,1,,185.0,,Expert,,CHO-AA8,,10029.0,Cytotoxicity against AA8 cell and IC50 values were determined as drug concentration required to inhibit cell protein to 50%.,F,,Cricetulus griseus,,80089
6590,13436,1,,185.0,,Expert,,CHO-AA8,,10029.0,Inhibition of growth under aerobic conditions in AA8 cells,F,,Cricetulus griseus,,80089
6591,6084,1,,,,Intermediate,,,,9615.0,Oral bioavailability in dog (dose 10 mg/kg),A,In vivo,Canis lupus familiaris,,50588
6592,5711,1,,,,Intermediate,,,,9615.0,Oral bioavailability in dog at 10 mg/kg of the compound,A,In vivo,Canis lupus familiaris,,50588
6593,4353,1,,,,Intermediate,,,,9615.0,Oral bioavailability in dog (dose 5 uM/kg),A,In vivo,Canis lupus familiaris,,50588
6594,4353,1,,,,Intermediate,,,,9615.0,Oral bioavailability in dog (dose 5 uM/kg),A,In vivo,Canis lupus familiaris,,50588
6595,17800,1,,,,Intermediate,,,,9615.0,Oral bioavailability in dog (mongrel),A,In vivo,Canis lupus familiaris,,50588
6596,3994,1,,,,Intermediate,,,,9615.0,Oral bioavailability in dog (dose 10 mg/kg),A,In vivo,Canis lupus familiaris,,50588
6597,3994,1,,,,Intermediate,,,,9615.0,Oral bioavailability in dog (dose 10 mg/kg),F,In vivo,Canis lupus familiaris,,50588
6598,5145,1,,,,Intermediate,,,,9615.0,Bioavailability in dog,A,In vivo,Canis lupus familiaris,,50588
6599,16452,1,,,,Intermediate,,,,9615.0,Bioavailability in dog (dose 1 mg/kg i.v.),A,In vivo,Canis lupus familiaris,,50588
6600,16452,1,,,,Intermediate,,,,9615.0,Pharmacokinetic data for dose given to dogs intravenously (oral PK study in parentheses),A,In vivo,Canis lupus familiaris,,50588
6601,5983,1,,,,Intermediate,,,,9615.0,Pharmacokinetic property (F) was measured in dog at the dose of 0.032 mg/kg,A,In vivo,Canis lupus familiaris,,50588
6602,4273,1,,,,Intermediate,,,,9615.0,Bioavailability in dog,A,In vivo,Canis lupus familiaris,,50588
6603,12500,1,,,,Intermediate,,,,9615.0,Bioavailability in dog (dose 3-10 mg/kg),A,In vivo,Canis lupus familiaris,,50588
6604,12500,1,,,,Intermediate,1969.0,,Plasma,9615.0,The compound was tested for bioavailability of compound in plasma of dog; Complete,A,In vivo,Canis lupus familiaris,,50588
6605,3639,1,,,,Intermediate,,,,9615.0,Oral bioavailability in dog,A,In vivo,Canis lupus familiaris,,50588
6606,3880,1,,,,Intermediate,,,,9615.0,Oral bioavailability in dog,A,In vivo,Canis lupus familiaris,,50588
6607,4838,1,,,,Intermediate,,,,9615.0,Bioavailability in dog,A,In vivo,Canis lupus familiaris,,50588
6608,15600,1,,,,Intermediate,,,,9615.0,oral bioavailability was measured in dogs,A,In vivo,Canis lupus familiaris,,50588
6609,17248,1,,,,Intermediate,,,,9615.0,Compound was tested for plasma protein binding in dog; Not determined,A,,Canis lupus familiaris,,50588
6610,17248,1,,,,Intermediate,,,,9615.0,Compound was tested for plasma protein binding of dog,A,,Canis lupus familiaris,,50588
6611,17248,1,,,,Intermediate,,,,9615.0,Compound was tested for plasma protein binding of dog; Not determined,A,,Canis lupus familiaris,,50588
6612,17443,1,,,,Intermediate,,,,9615.0,Concentration in dogs after oral administration at dose of 1 mg/kg after 180 min.,A,,Canis lupus familiaris,,50588
6613,4186,1,,,,Intermediate,,,,9615.0,Apparent terminal elimination half-life in dog after administration of 20 mg/kg dose through peroral route,A,In vivo,Canis lupus familiaris,,50588
6614,3749,1,,,,Intermediate,,,,9615.0,Half life was determined,A,,Canis lupus familiaris,,50588
6615,3249,1,,,,Intermediate,,,,9615.0,Half life by ''Cr'' assay in dog at a dose of 5 mg/kg,A,In vivo,Canis lupus familiaris,,50588
6616,3022,1,,,,Intermediate,,,,9615.0,Half life was evaluated in dog,A,,Canis lupus familiaris,,50588
6617,3749,1,,,,Intermediate,,,,9615.0,Half life was determined,A,,Canis lupus familiaris,,50588
6618,2517,1,,,,Intermediate,,,,9615.0,Biodistribution of compound was measured in bile at 2 hr post-injection in canine deep vein thrombosis model (DVT),A,In vivo,Canis lupus familiaris,,50588
6619,2517,1,,,,Intermediate,948.0,,Heart,9615.0,Biodistribution of compound was measured in heart at 2 hr post-injection in canine deep vein thrombosis model (DVT),A,In vivo,Canis lupus familiaris,,50588
6620,2517,1,,,,Intermediate,2113.0,,Kidney,9615.0,Biodistribution of compound was measured in kidney at 2 hr post-injection in canine deep vein thrombosis model (DVT),A,In vivo,Canis lupus familiaris,,50588
6621,2517,1,,,,Intermediate,2107.0,,Liver,9615.0,Biodistribution of compound was measured in liver at 2 hr post-injection in canine deep vein thrombosis model (DVT),A,In vivo,Canis lupus familiaris,,50588
6622,2517,1,,,,Intermediate,2048.0,,Lung,9615.0,Biodistribution of compound was measured in lung at 2 hr post-injection in canine deep vein thrombosis model (DVT),A,In vivo,Canis lupus familiaris,,50588
6623,2517,1,,,,Intermediate,2106.0,,Spleen,9615.0,Biodistribution of compound was measured in spleen at 2 hr post-injection in canine deep vein thrombosis model (DVT),A,In vivo,Canis lupus familiaris,,50588
6624,3639,1,,,,Intermediate,,,,9615.0,LogP in dog,A,,Canis lupus familiaris,,50588
6625,6227,1,,,,Intermediate,,,,9615.0,Partition coefficient (logP),A,,Canis lupus familiaris,,50588
6626,6227,1,,,,Intermediate,,,,9615.0,Partition coefficient in dog,A,,Canis lupus familiaris,,50588
6627,17764,1,,,,Intermediate,,,,9615.0,Mean-residence time of compound after intravenous administration in dogs at 1.2 uM/kg,A,In vivo,Canis lupus familiaris,,50588
6628,4809,1,,,,Intermediate,,,,9615.0,Pharmacokinetic parameter MRT was determined in Beagle dogs after (po) administration of a dose of 28 (uM/kg),A,In vivo,Canis lupus familiaris,,50588
6629,5600,1,,,,Intermediate,,,,9615.0,In vitro metabolic stability determined after 30 min of incubation in dog hepatic microsomes,A,,Canis lupus familiaris,,50588
6630,14294,1,,,,Intermediate,,,,9615.0,Metabolism of compound in dog S9 microsomes ('++''indicates 20-50% largest observed peak),A,,Canis lupus familiaris,,50588
6631,14294,1,,,,Intermediate,,,,9615.0,Metabolism of compound in dog S9 microsomes ('++++' indicates largest observed peak),A,,Canis lupus familiaris,,50588
6632,14294,1,,,,Intermediate,,,,9615.0,Metabolism of compound in dog S9 microsomes; Trace,A,,Canis lupus familiaris,,50588
6633,6251,1,,,,Intermediate,2107.0,,Liver,9615.0,In vitro metabolic potential in dog liver microsomes,A,,Canis lupus familiaris,,50588
6634,3748,1,,,,Intermediate,,,,9615.0,Oral bioavailability of perorally administered compound (10 mg/kg) was tested in dogs,A,In vivo,Canis lupus familiaris,,50588
6635,2713,1,,,,Intermediate,,,,9615.0,Oral bioavailability in dog,A,In vivo,Canis lupus familiaris,,50588
6636,6512,1,,,,Intermediate,,,,9615.0,Oral bioavailability in dog,A,In vivo,Canis lupus familiaris,,50588
6637,6679,1,,,,Intermediate,,,,9615.0,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,A,In vivo,Canis lupus familiaris,,50588
6638,3749,1,,,,Intermediate,,,,9615.0,The compound was tested for bioavailability in dogs,A,In vivo,Canis lupus familiaris,,50588
6639,3749,1,,,,Intermediate,,,,9615.0,The compound was tested for oral bioavailability in dogs,A,In vivo,Canis lupus familiaris,,50588
6640,6742,1,,,,Intermediate,,,,9615.0,Oral bioavailability in dog,A,In vivo,Canis lupus familiaris,,50588
6641,6227,1,,,,Intermediate,,,,9615.0,Compound was tested for percent protein binding (PB) in dog,A,,Canis lupus familiaris,,50588
6642,6874,1,,,,Intermediate,,,,9615.0,Apparent permeability coefficient (Papp) for apical to basolateral flux was determined in MadinDarby Canine Kidney cells,A,,Canis lupus familiaris,,50588
6643,2877,1,,,,Intermediate,1969.0,,Plasma,9615.0,Compound was evaluated for plasma clearance.,A,In vivo,Canis lupus familiaris,,50588
6644,12500,1,,,,Intermediate,1969.0,,Plasma,9615.0,The compound was tested for plasma clearance in dog,A,In vivo,Canis lupus familiaris,,50588
6645,12500,1,,,,Intermediate,1969.0,,Plasma,9615.0,The compound was tested for plasma clearance in dog at dose of 3-10 mgkg,A,In vivo,Canis lupus familiaris,,50588
6646,4709,1,,,,Intermediate,,,,9615.0,Plasma protein binding was determined after intravenous administration of 1 mg/kg in dog,A,,Canis lupus familiaris,,50588
6647,5542,1,,,,Intermediate,2107.0,,Liver,9615.0,In vitro relative rate of metabolism was determined in dog liver microsomes,A,,Canis lupus familiaris,,50588
6648,17594,1,,,,Intermediate,,,,9615.0,Relative bioavailability after oral dose of compound at 3 mg/kg in dogs,A,In vivo,Canis lupus familiaris,,50588
6649,2652,1,,,,Intermediate,,,,9615.0,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,A,In vivo,Canis lupus familiaris,,50588
6650,17764,1,,,,Intermediate,,,,9615.0,Half life after intravenous administration in dogs at 1.2 uM/kg,A,In vivo,Canis lupus familiaris,,50588
6651,6599,1,,42.0,,Intermediate,2048.0,CCRF S-180,Lung,10090.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 30 minutes,A,,Mus musculus,,50594
6652,6599,1,,42.0,,Intermediate,2048.0,CCRF S-180,Lung,10090.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 4 hours,A,,Mus musculus,,50594
6653,6599,1,,42.0,,Intermediate,2048.0,CCRF S-180,Lung,10090.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 8 hours,A,,Mus musculus,,50594
6654,6599,1,,42.0,,Intermediate,,CCRF S-180,,10090.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 1 hour,A,,Mus musculus,,50594
6655,6599,1,,42.0,,Intermediate,,CCRF S-180,,10090.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 2 hours,A,,Mus musculus,,50594
6656,6599,1,,42.0,,Intermediate,,CCRF S-180,,10090.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 30 minutes,A,,Mus musculus,,50594
6657,6599,1,,42.0,,Intermediate,,CCRF S-180,,10090.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 4 hours,A,,Mus musculus,,50594
6658,6599,1,,42.0,,Intermediate,,CCRF S-180,,10090.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 8 hours,A,,Mus musculus,,50594
6659,17641,1,,,,Intermediate,955.0,,Brain,10090.0,C2 in brain of mice at the oral dose of 50 mg/kg,A,,Mus musculus,,50594
6660,17641,1,,,,Intermediate,2113.0,,Kidney,10090.0,C2 in kidney of mice at the oral dose of 50 mg/kg,A,,Mus musculus,,50594
6661,17641,1,,,,Intermediate,2107.0,,Liver,10090.0,C2 in liver of mice at the oral dose of 50 mg/kg,A,,Mus musculus,,50594
6662,17641,1,,,,Intermediate,2048.0,,Lung,10090.0,C2 in lungs of mice at the oral dose of 50 mg/kg,A,,Mus musculus,,50594
6663,17641,1,,,,Intermediate,2106.0,,Spleen,10090.0,C2 in spleen of mice at the oral dose of 50 mg/kg,A,,Mus musculus,,50594
6664,17852,1,,,,Intermediate,,,,10090.0,Plasma clearance in mouse,A,In vivo,Mus musculus,,50594
6665,17764,1,,,,Intermediate,,,,10090.0,Clearance of compound after intravenous administration in mice at 24 uM/kg,A,In vivo,Mus musculus,,50594
6666,17837,1,,,,Intermediate,,,,10090.0,Clearance from mouse blood following i.v. administration of 10 mg/kg,A,In vivo,Mus musculus,,50594
6667,2675,1,,,,Intermediate,,,,10090.0,Clearance was evaluated in mice after intravenous administration,A,In vivo,Mus musculus,,50594
6668,2675,1,,,,Intermediate,,,,10090.0,Clearance was evaluated in mice after oral administration,A,In vivo,Mus musculus,,50594
6669,4239,1,,,,Intermediate,,,,10090.0,Pharmacokinetic property (Plasma clearance) was measured in mouse,A,In vivo,Mus musculus,,50594
6670,17753,1,,,,Intermediate,,,,10090.0,Plasma clearance of compound was determined at 40 mg/Kg,A,In vivo,Mus musculus,,50594
6671,17753,1,,,,Intermediate,,,,10090.0,Plasma clearance of at 24 mg/Kg,A,In vivo,Mus musculus,,50594
6672,17753,1,,,,Intermediate,,,,10090.0,Plasma clearance at 24 mg/Kg,A,In vivo,Mus musculus,,50594
6673,17753,1,,,,Intermediate,,,,10090.0,Plasma clearance at 5 mg/Kg,A,In vivo,Mus musculus,,50594
6674,5727,1,,,,Intermediate,,,,10090.0,Plasma clearance in mice,A,In vivo,Mus musculus,,50594
6675,2862,1,,,,Intermediate,,,,10090.0,Plasma clearance value upon iv administration in mouse,A,In vivo,Mus musculus,,50594
6676,5980,1,,,,Intermediate,1969.0,,Plasma,10090.0,Total plasma clearance in mice,A,In vivo,Mus musculus,,50594
6677,17592,1,,,,Intermediate,,,,10090.0,Clearance in mouse,A,In vivo,Mus musculus,,50594
6678,17718,1,,,,Intermediate,,,,10090.0,Clearance value was determined,A,In vivo,Mus musculus,,50594
6679,16597,1,,,,Intermediate,,,,10090.0,Plasma clearance at a dose of 10 mg/kg intravenous administration in mice.,A,In vivo,Mus musculus,,50594
6680,17384,0,,,,Intermediate,,,,,Calculated partition coefficient (clogP),P,,,,22229
6681,6062,1,,,,Intermediate,,,,10090.0,Plasma clearance for the compound was measured in mouse after an iv dose of 1 mg/kg,A,In vivo,Mus musculus,,50594
6682,17734,1,,,,Intermediate,,,,10090.0,Plasma clearance rate after intraperitoneal administration of 100 mg/kg in mice,A,In vivo,Mus musculus,,50594
6683,6348,1,,,,Intermediate,,,,10090.0,Plasma clearance was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,A,In vivo,Mus musculus,,50594
6684,5969,1,,,,Intermediate,,,,10090.0,In vivo total clearance was determined in murine septicemia at dose of 100 mg/kg,A,In vivo,Mus musculus,,50594
6685,5969,1,,,,Intermediate,,,,10090.0,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg,A,In vivo,Mus musculus,,50594
6686,5969,1,,,,Intermediate,,,,10090.0,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,A,In vivo,Mus musculus,,50594
6687,16597,1,,,,Intermediate,,,,10090.0,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for Cmax,A,In vivo,Mus musculus,,50594
6688,5781,1,,,,Intermediate,,,,10090.0,Cmax after oral administration at 30 mg/kg in ICR mouse,A,In vivo,Mus musculus,,50594
6689,17764,1,,,,Intermediate,,,,10090.0,Cmax after peroral administration in mice at 2.4 uM/kg,A,In vivo,Mus musculus,,50594
6690,17641,1,,,,Intermediate,955.0,,Brain,10090.0,Cmax in brain of mice at the oral dose of 50 mg/kg,A,In vivo,Mus musculus,,50594
6691,17641,1,,,,Intermediate,2113.0,,Kidney,10090.0,Cmax in kidney of mice at the oral dose of 50 mg/kg,A,In vivo,Mus musculus,,50594
6692,17641,1,,,,Intermediate,2107.0,,Liver,10090.0,Cmax in liver of mice at the oral dose of 50 mg/kg,A,In vivo,Mus musculus,,50594
6693,17641,1,,,,Intermediate,2048.0,,Lung,10090.0,Cmax in lungs of mice at the oral dose of 50 mg/kg,A,In vivo,Mus musculus,,50594
6694,17764,1,,,,Intermediate,,,,10090.0,Cmax in mice at 18 uM/kg i.p. administration,F,In vivo,Mus musculus,,50594
6695,17764,1,,,,Intermediate,,,,10090.0,Cmax in mice at 23 uM/kg i.v. administration,F,In vivo,Mus musculus,,50594
6696,17764,1,,,,Intermediate,,,,10090.0,Cmax in mice at 24 uM/kg i.p. administration,F,In vivo,Mus musculus,,50594
6697,17764,1,,,,Intermediate,,,,10090.0,Cmax in mice at 25 uM/kg i.p. administration,F,In vivo,Mus musculus,,50594
6698,17764,1,,,,Intermediate,,,,10090.0,Cmax in mice at 26 uM/kg i.p. administration,F,In vivo,Mus musculus,,50594
6699,17641,1,,,,Intermediate,2106.0,,Spleen,10090.0,Cmax in spleen of mice at the oral dose of 50 mg/kg,A,In vivo,Mus musculus,,50594
6700,16597,1,,,,Intermediate,,,,10090.0,Cmax value at a dose of 10 mg/kg intravenous administration in mice.,A,In vivo,Mus musculus,,50594
6701,16597,1,,,,Intermediate,,,,10090.0,Cmax value at a dose of 10 mg/kg peroral administration in mice.,A,In vivo,Mus musculus,,50594
6702,5727,1,,,,Intermediate,,,,10090.0,Cmax value was determined,A,In vivo,Mus musculus,,50594
6703,5951,1,,,,Intermediate,,,,10090.0,Cmax value in IRC mice,A,In vivo,Mus musculus,,50594
6704,5506,1,,,,Intermediate,,,,10090.0,Cmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,A,In vivo,Mus musculus,,50594
6705,5506,1,,,,Intermediate,,,,10090.0,Cmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,A,In vivo,Mus musculus,,50594
6706,14239,1,,,,Intermediate,1969.0,,Plasma,10090.0,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice,A,In vivo,Mus musculus,,50594
6707,4890,1,,,,Intermediate,1969.0,,Plasma,10090.0,"Compound was evaluated for the pharmacokinetic parameter, maximum plasma concentration",A,In vivo,Mus musculus,,50594
6708,429,1,,,,Intermediate,,,,10090.0,Evaluated for pharmacokinetic parameter Cmax in mouse at the dose 20 mg/kg,A,In vivo,Mus musculus,,50594
6709,10986,1,,,,Intermediate,,,,6277.0,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 50 mg/kg/day(5 days) dose,F,,Acanthocheilonema viteae,,50535
6710,10986,1,,,,Intermediate,,,,6277.0,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 6.25 mg/kg/day(5 days) dose,F,,Acanthocheilonema viteae,,50535
6711,10986,1,,,,Intermediate,,,,6277.0,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 75 mg/kg/day(5 days) dose,F,,Acanthocheilonema viteae,,50535
6712,13227,1,,455.0,,Intermediate,,A-375,,9606.0,Inhibitory activity against human tumor cell line A0375 melanoma.,F,,Homo sapiens,,80018
6713,4481,9,,,,Expert,,,,10116.0,Displacement of [3H]N6-PIA binding from A1 receptor in whole rat brain membranes,B,,Rattus norvegicus,Brain membranes,12512
6714,16931,9,,,,Expert,,,,9606.0,Forskolin-induced cAMP production at human A1 adenosine receptor,F,,Homo sapiens,,114
6715,3850,8,,449.0,,Autocuration,,CHO,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1; change of less than 5% of allosteric enhancement.,F,,,,114
6716,3850,8,,449.0,,Autocuration,,CHO,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,F,,,,114
6717,3850,8,,449.0,,Expert,,CHO,,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM,F,,,,114
6718,3850,8,,449.0,,Expert,,CHO,,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration,F,,,,114
6719,3850,8,,449.0,,Autocuration,,CHO,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; An increase of cAmp content of cells,F,,,,114
6720,3850,8,,449.0,,Autocuration,,CHO,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement,F,,,,114
6721,3850,8,,449.0,,Autocuration,,CHO,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement.,F,,,,114
6722,3850,9,,449.0,,Expert,,CHO,,9606.0,Percent response to 10 uM PD-81723 on CHO cells expressing human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,F,,Homo sapiens,,114
6723,3850,8,,449.0,,Autocuration,,CHO,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM,F,,,,114
6724,3850,8,,449.0,,Autocuration,,CHO,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; change of less than 5% of allosteric enhancement.,F,,,,114
6725,3850,8,,449.0,,Expert,,CHO,,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration,F,,,,114
6726,3850,8,,449.0,,Autocuration,,CHO,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration; change of less than 5% of allosteric enhancement.,F,,,,114
6727,3850,8,,449.0,,Expert,,CHO,,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; An increase of cAmp content of cells,F,,,,114
6728,3850,8,,449.0,,Autocuration,,CHO,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM,F,,,,114
6729,3850,8,,449.0,,Autocuration,,CHO,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,F,,,,114
6730,3850,8,,449.0,,Autocuration,,CHO,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; change of less than 5% of allosteric enhancement.,F,,,,114
6731,3850,8,,449.0,,Expert,,CHO,,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration,F,,,,114
6732,3850,8,,449.0,,Autocuration,,CHO,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; An increase of cAmp content of cells,F,,,,114
6733,3850,8,,449.0,,Autocuration,,CHO,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; change of less than 5% of allosteric enhancement.,F,,,,114
6734,3850,8,,449.0,,Expert,,CHO,,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,F,,,,114
6735,12680,1,,164.0,,Intermediate,,A10,,9986.0,Ability to inhibit [125I]ET1 binding to vascular smooth muscle (vsm)- A10 cells,F,,Oryctolagus cuniculus,,80013
6736,1313,0,,164.0,,Autocuration,,A10,,10116.0,In vitro potassium channel opening activity in A10 (smooth muscle) cells,F,,Rattus norvegicus,,22226
6737,1313,0,,164.0,,Autocuration,,A10,,10116.0,In vitro potassium channel opening activity in A10 (smooth muscle) cells; Inactive,F,,Rattus norvegicus,,22226
6738,17567,1,,164.0,,Intermediate,,A10,,10116.0,Effect on membrane potential of mitochondria in A10 smooth muscle cells from rats,F,,Rattus norvegicus,,80013
6739,17567,1,,164.0,,Intermediate,,A10,,10116.0,Effect on membrane potential of mitochondria of A10 smooth muscle cells in rats,F,,Rattus norvegicus,,80013
6740,11819,1,,164.0,,Intermediate,,A10,,10116.0,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.001 uM,F,,Rattus norvegicus,,80013
6741,13436,1,,185.0,,Intermediate,,CHO-AA8,,10029.0,Compound was tested for aerobic growth inhibition against AA8 cells after 4 hr of exposure,F,,Cricetulus griseus,,80089
6742,12687,1,,185.0,,Intermediate,,CHO-AA8,,10029.0,Concentration required to reduce AA8 cell numbers to 50% of controls in a growth inhibition microassay,F,,Cricetulus griseus,,80089
6743,12651,1,,185.0,,Intermediate,,CHO-AA8,,10029.0,Concentration of the drug to inhibit chinese hamster ovary derived cell (AA8) growth in culture,F,,Cricetulus griseus,,80089
6744,13300,1,,185.0,,Intermediate,,CHO-AA8,,10029.0,Cytotoxicity in a growth inhibition assay against aerobic cultures of AA8 cells was determined,F,,Cricetulus griseus,,80089
6745,15296,1,,185.0,,Intermediate,,CHO-AA8,,10029.0,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,F,,Cricetulus griseus,,80089
6746,15328,1,,185.0,,Intermediate,,CHO-AA8,,10029.0,"Cytotoxicity in chinese hamster ovary tumor cell line-AA8, by growth inhibition assay.",F,,Cricetulus griseus,,80089
6747,13302,1,,185.0,,Intermediate,,CHO-AA8,,10029.0,Growth inhibition activity was measured in repair proficient AA8 cells under aerobic conditions (4 hours drug exposure),F,,Cricetulus griseus,,80089
6748,14367,1,,185.0,,Expert,,CHO-AA8,,10029.0,"Growth inhibition of aerobic AA8 cells, after 18 hours exposure",F,,Cricetulus griseus,,80089
6749,17002,1,,185.0,,Expert,,CHO-AA8,,10029.0,In vitro cellular toxicity against chinese hamster AA8 cell line after 4 hr of compound exposure,F,,Cricetulus griseus,,80089
6750,13436,1,,185.0,,Intermediate,,CHO-AA8,,10029.0,Inhibitory activity against AA8 cell growth in aerobic condition after 4 hr of exposure,F,,Cricetulus griseus,,80089
6751,13435,1,,185.0,,Intermediate,,CHO-AA8,,10029.0,Inhibitory activity against aerobic growth of AA8 cells.,F,,Cricetulus griseus,,80089
6752,10503,1,,185.0,,Intermediate,,CHO-AA8,,10029.0,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,A,,Cricetulus griseus,,80089
6753,10503,1,,185.0,,Expert,,CHO-AA8,,10029.0,In vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,F,,Cricetulus griseus,,80089
6754,10503,1,,185.0,,Intermediate,,CHO-AA8,,10029.0,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,F,,Cricetulus griseus,,80089
6755,15090,1,,185.0,,Expert,,CHO-AA8,,10029.0,Tested for growth inhibition against AA8 tumor cell line(chinese hamster ovary).,F,,Cricetulus griseus,,80089
6756,10368,1,,185.0,,Expert,,CHO-AA8,,10029.0,Cytotoxicity against AA8 cell line,F,,Cricetulus griseus,,80089
6757,12651,1,,185.0,,Intermediate,,CHO-AA8,,10029.0,Hypersensitivity factor(HF) was determined as ratio of IC50(AA8) to IC50(UV4),F,,Cricetulus griseus,,80089
6758,12687,1,,185.0,,Intermediate,,CHO-AA8,,10029.0,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),A,,Cricetulus griseus,,80089
6759,12687,1,,185.0,,Intermediate,,CHO-AA8,,10029.0,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),F,,Cricetulus griseus,,80089
6760,12687,1,,185.0,,Intermediate,,CHO-AA8,,10029.0,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),A,,Cricetulus griseus,,80089
6761,1890,1,,185.0,,Intermediate,,CHO-AA8,,10029.0,Compound was evaluated for cytotoxicity against CHO AA8 cell lines for 4 hr at pH-7.4,F,,Cricetulus griseus,,80089
6762,10747,1,,185.0,,Intermediate,,CHO-AA8,,10029.0,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,F,,Cricetulus griseus,,80089
6763,10747,1,,185.0,,Intermediate,,CHO-AA8,,10029.0,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,F,,Cricetulus griseus,,80089
6764,11616,0,,,,Autocuration,,,,10029.0,Maximum tolerated dose (MTD) in C3H/HeN mice (single ip dose),F,,Cricetulus griseus,,22224
6765,11616,1,,185.0,,Expert,,CHO-AA8,,10029.0,Concentration required to increase radiation sensitivity by 1.3 when AA8 cells are exposed to drug for 30 min before and during irradiation under hypoxic condition.,F,,Cricetulus griseus,,80089
6766,3471,0,,185.0,,Autocuration,,CHO-AA8,,10029.0,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under anoxic conditions,F,,Cricetulus griseus,,22224
6767,3471,0,,185.0,,Autocuration,,CHO-AA8,,10029.0,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under anoxic conditions,F,,Cricetulus griseus,,22224
6768,3471,0,,185.0,,Autocuration,,CHO-AA8,,10029.0,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under anoxic conditions,F,,Cricetulus griseus,,22224
6769,3471,0,,185.0,,Autocuration,,CHO-AA8,,10029.0,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under aerobic conditions,F,,Cricetulus griseus,,22224
6770,3471,0,,185.0,,Autocuration,,CHO-AA8,,10029.0,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under aerobic conditions,F,,Cricetulus griseus,,22224
6771,3471,0,,185.0,,Autocuration,,CHO-AA8,,10029.0,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under aerobic conditions,F,,Cricetulus griseus,,22224
6772,3471,0,,185.0,,Autocuration,,CHO-AA8,,10029.0,Ratio of oxygen dependence of cytotoxicities of AA8 cells in aerobic condition to anoxic condition,F,,Cricetulus griseus,,22224
6773,11616,1,,185.0,,Expert,,CHO-AA8,,10029.0,Concentration required to reduce AA8 cell survival by 10%,F,,Cricetulus griseus,,80089
6774,2656,0,,185.0,,Autocuration,,CHO-AA8,,10029.0,"Concentration required to reduce cell survival to 10% of controls under hypoxic conditions, using the AA8 (chinese hamster) aerobic cells",F,,Cricetulus griseus,,22224
6775,10518,0,,185.0,,Autocuration,,CHO-AA8,,10029.0,Tested for the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,F,,Cricetulus griseus,,22224
6776,10518,0,,185.0,,Autocuration,,CHO-AA8,,10029.0,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,F,,Cricetulus griseus,,22224
6777,10518,0,,185.0,,Autocuration,,CHO-AA8,,10029.0,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 0.8-1.5,F,,Cricetulus griseus,,22224
6778,10518,0,,185.0,,Autocuration,,CHO-AA8,,10029.0,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 1-2,F,,Cricetulus griseus,,22224
6779,16156,0,,185.0,,Autocuration,,CHO-AA8,,10029.0,Ability to reduce cell density of AA8 cells to 50% after 4 hr of exposure to air,F,,Cricetulus griseus,,22224
6780,2656,0,,185.0,,Autocuration,,CHO-AA8,,10029.0,Aerobic cytotoxic activity was evaluated by the growth inhibition of AA8 (chinese hamster) aerobic cells,F,,Cricetulus griseus,,22224
6781,11005,0,,,,Autocuration,,,,10029.0,"Compound was evaluated for the inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",F,,Cricetulus griseus,,22224
6782,11942,0,,185.0,,Autocuration,,CHO-AA8,,10029.0,Concentration for 50% inhibition of AA8 cells growth under aerobic conditions after 18 hours exposure,F,,Cricetulus griseus,,22224
6783,2128,0,,185.0,,Autocuration,,CHO-AA8,,10029.0,Concentration required for 50% inhibition of growth of AA8 cells following 4 hr drug exposure,F,,Cricetulus griseus,,22224
6784,16907,1,,,,Intermediate,,,,9615.0,Half life period after 15 mg/kg iv dose in Dogs,A,In vivo,Canis lupus familiaris,,50588
6785,16907,1,,,,Intermediate,,,,9615.0,Half life period after 30 mg/kg po dose in Dogs,A,In vivo,Canis lupus familiaris,,50588
6786,9579,1,,,,Intermediate,,,,9615.0,Half life was measured after oral 2b administration (tested in 6 dogs),A,In vivo,Canis lupus familiaris,,50588
6787,9579,1,,,,Intermediate,,,,9615.0,Half life was measured in dog after oral 17b administration,A,In vivo,Canis lupus familiaris,,50588
6788,9579,1,,,,Intermediate,,,,9615.0,Pharmacokinetic parameter T max determined in dog after oral administration of 17b,A,In vivo,Canis lupus familiaris,,50588
6789,9579,1,,,,Intermediate,,,,9615.0,Pharmacokinetic parameter T max determined in dog after oral administration of 2b,A,In vivo,Canis lupus familiaris,,50588
6790,16907,1,,,,Intermediate,,,,9615.0,Tmax value after 15 mg/kg iv dose in Dogs,A,In vivo,Canis lupus familiaris,,50588
6791,16907,1,,,,Intermediate,,,,9615.0,Tmax value after 30 mg/kg po dose in Dogs,A,In vivo,Canis lupus familiaris,,50588
6792,3184,1,,,,Intermediate,,,,9615.0,Compound was evaluated for its half life when administered intravenously in dog,A,In vivo,Canis lupus familiaris,,50588
6793,5017,1,,,,Intermediate,1969.0,,Plasma,9615.0,Compound was tested for plasma half life when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),A,In vivo,Canis lupus familiaris,,50588
6794,6821,1,,,,Intermediate,,,,9615.0,Elimination Half-life of compound was determined in dog,A,,Canis lupus familiaris,,50588
6795,17839,1,,,,Intermediate,,,,9615.0,Half life of compound in dog following oral administration,A,In vivo,Canis lupus familiaris,,50588
6796,17267,1,,,,Intermediate,,,,9615.0,Half life of compound was determined in dog,A,,Canis lupus familiaris,,50588
6797,4727,1,,,,Intermediate,178.0,,Blood,9615.0,Half life of compound was determined in dog blood,A,,Canis lupus familiaris,,50588
6798,5238,1,,,,Intermediate,,,,9615.0,Half life after oral and iv dosing in dogs,A,In vivo,Canis lupus familiaris,,50588
6799,4942,1,,,,Intermediate,,,,9615.0,Half life in dogs in hours,A,,Canis lupus familiaris,,50588
6800,6505,1,,,,Intermediate,,,,9615.0,Half life on i.v. administration of 2 mg/kg was measured in dog,A,In vivo,Canis lupus familiaris,,50588
6801,5130,1,,,,Intermediate,,,,9615.0,t1/2 in dog after oral dose (1 mg/kg),A,In vivo,Canis lupus familiaris,,50588
6802,1475,1,,,,Intermediate,,,,9615.0,Half life was evaluated in dog,A,,Canis lupus familiaris,,50588
6803,17804,1,,,,Intermediate,,,,9615.0,Half life period of compound was determined after intravenous administration at 2 mg/kg,A,In vivo,Canis lupus familiaris,,50588
6804,17804,1,,,,Intermediate,,,,9615.0,Half life period of compound was determined after peroral administration at 2 mg/kg,A,In vivo,Canis lupus familiaris,,50588
6805,6084,1,,,,Intermediate,,,,9615.0,Half life period (10 mg/kg) was determined in dog,A,In vivo,Canis lupus familiaris,,50588
6806,6084,1,,,,Intermediate,,,,9615.0,Half life period (10 mg/kg) was determined in dog,A,In vivo,Canis lupus familiaris,,50588
6807,5542,1,,,,Intermediate,,,,9615.0,Half life period by iv administration in dog at a dose of 0.3 mg/kg,A,In vivo,Canis lupus familiaris,,50588
6808,5542,1,,,,Intermediate,,,,9615.0,Half life period by po administration in dog at a dose of 0.3 mg/kg,A,In vivo,Canis lupus familiaris,,50588
6809,6084,1,,,,Intermediate,,,,9615.0,Half life period in dog,A,,Canis lupus familiaris,,50588
6810,6241,1,,,,Intermediate,,,,9615.0,Half life period in dogs after oral administration at 1 mg/kg,A,In vivo,Canis lupus familiaris,,50588
6811,1916,1,,,,Intermediate,,,,9615.0,Half life period was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,A,In vivo,Canis lupus familiaris,,50588
6812,6621,1,,,,Intermediate,,,,9615.0,Half-life of compound was determined in dogs,A,,Canis lupus familiaris,,50588
6813,1696,1,,,,Intermediate,1969.0,,Plasma,9615.0,Half-life in dog plasma,A,,Canis lupus familiaris,,50588
6814,17800,1,,,,Intermediate,,,,9615.0,Half-life in mongrel dogs was determined,A,,Canis lupus familiaris,,50588
6815,17657,1,,,,Intermediate,,,,9615.0,Half-life in dog upon oral administration,A,In vivo,Canis lupus familiaris,,50588
6816,17657,1,,,,Intermediate,,,,9615.0,Half-life in dog upon oral administration; Unable to calculate,A,In vivo,Canis lupus familiaris,,50588
6817,4239,1,,,,Intermediate,,,,9615.0,Half-life was measured in dog,A,,Canis lupus familiaris,,50588
6818,5985,1,,,,Intermediate,,,,9615.0,Half-life was measured in dog,A,,Canis lupus familiaris,,50588
6819,9932,1,,,,Intermediate,,,,9615.0,Half-recovery time (T1/2) of the vascular resistance decrease at ED30 in anesthetized dogs,A,,Canis lupus familiaris,,50588
6820,5199,1,,,,Intermediate,,,,9615.0,Oral half life was determined,A,In vivo,Canis lupus familiaris,,50588
6821,5199,1,,,,Intermediate,1969.0,,Plasma,9615.0,Plasma elimination half-life (08 h) was determined in canine following intravenous (iv) administration (1 mg/kg).,A,In vivo,Canis lupus familiaris,,50588
6822,1475,1,,,,Intermediate,1969.0,,Plasma,9615.0,Plasma half life was evaluated,A,,Canis lupus familiaris,,50588
6823,1475,1,,,,Intermediate,1969.0,,Plasma,9615.0,Plasma half life was evaluated in Dog,A,,Canis lupus familiaris,,50588
6824,1475,1,,,,Intermediate,1969.0,,Plasma,9615.0,Plasma half life was evaluated in dog,A,,Canis lupus familiaris,,50588
6825,6316,1,,,,Intermediate,,,,9615.0,T1/2 (Half-life) was after oral administration at 5 mg/kg,A,In vivo,Canis lupus familiaris,,50588
6826,4883,1,,,,Intermediate,,,,9615.0,Tested for the half life value in dog,A,,Canis lupus familiaris,,50588
6827,4727,1,,,,Intermediate,,,,9615.0,Maximum time at the dose of 2 mg/kg in dog,A,In vivo,Canis lupus familiaris,,50588
6828,1916,1,,,,Intermediate,,,,9615.0,Maximum time was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,A,In vivo,Canis lupus familiaris,,50588
6829,1337,1,,,,Intermediate,178.0,,Blood,9615.0,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,A,In vivo,Canis lupus familiaris,,50588
6830,1337,1,,,,Intermediate,178.0,,Blood,9615.0,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,A,In vivo,Canis lupus familiaris,,50588
6831,6265,1,,,,Intermediate,,,,9615.0,Pharmacokinetic (PK) property (Tmax) was determined in dog at the single dose of 1 mg/kg,A,In vivo,Canis lupus familiaris,,50588
6832,4809,1,,,,Intermediate,,,,9615.0,Pharmacokinetic parameter Tmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),A,In vivo,Canis lupus familiaris,,50588
6833,5983,1,,,,Intermediate,,,,9615.0,Pharmacokinetic property (Tmax) was measured in dog at the dose of 0.032 mg/kg p.o.,A,In vivo,Canis lupus familiaris,,50588
6834,5313,1,,,,Intermediate,,,,9615.0,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog",A,,Canis lupus familiaris,,50588
6835,5313,1,,,,Intermediate,,,,9615.0,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog at dosage of 10 mpk",A,In vivo,Canis lupus familiaris,,50588
6836,17650,1,,,,Intermediate,1969.0,,Plasma,9615.0,Time for maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,A,In vivo,Canis lupus familiaris,,50588
6837,5199,1,,,,Intermediate,1969.0,,Plasma,9615.0,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,A,In vivo,Canis lupus familiaris,,50588
6838,933,1,,,,Intermediate,1969.0,,Plasma,9615.0,Time taken for maximum plasma concentration in dog,A,,Canis lupus familiaris,,50588
6839,16367,1,,,,Intermediate,,,,9615.0,Time to reach Cmax after oral administration to dogs,A,In vivo,Canis lupus familiaris,,50588
6840,6348,1,,,,Intermediate,1969.0,,Plasma,9615.0,Time to reach maximum plasma concentration was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,A,In vivo,Canis lupus familiaris,,50588
6841,6316,1,,,,Intermediate,,,,9615.0,Tmax (time to reach maximum concentration) was after oral administration at 5 mg/kg,A,In vivo,Canis lupus familiaris,,50588
6842,6215,1,,,,Intermediate,,,,9615.0,Tmax after peroral administration (1 mg/kg) was determined in dog,A,In vivo,Canis lupus familiaris,,50588
6843,3598,1,,,,Expert,,,,9615.0,Tmax of compound determined in dog after iv administration at a dose of 10 mg/kg,A,In vivo,Canis lupus familiaris,,50588
6844,4527,1,,,,Intermediate,,,,9615.0,Tmax by oral administration at a dose of 10 uM/kg in dog was determined,A,In vivo,Canis lupus familiaris,,50588
6845,17764,1,,,,Intermediate,,,,9615.0,Tmax after peroral administration in dogs at 2.4 uM/kg,A,In vivo,Canis lupus familiaris,,50588
6846,5969,1,,,,Intermediate,,,,10090.0,In vivo Cmax in mice at dose of 100 mg/kg,A,In vivo,Mus musculus,,50594
6847,5969,1,,,,Intermediate,,,,10090.0,In vivo Cmax in mice at dose of 50 mg/kg,A,In vivo,Mus musculus,,50594
6848,4573,1,,,,Intermediate,,,,10090.0,Maximal concentration determined at a dose 10 mg/kg administered intraperitoneally to mice,A,In vivo,Mus musculus,,50594
6849,3277,1,,,,Intermediate,1969.0,,Plasma,10090.0,Maximum plasma concentration was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),A,In vivo,Mus musculus,,50594
6850,17734,1,,,,Intermediate,1969.0,,Plasma,10090.0,Maximum concentration in plasma was determined after intraperitoneal administration of 100 mg/kg in mice,A,In vivo,Mus musculus,,50594
6851,3132,1,,,,Intermediate,1969.0,,Plasma,10090.0,Maximum concentration obtained in mouse plasma was determined,A,In vivo,Mus musculus,,50594
6852,3132,1,,,,Intermediate,1969.0,,Plasma,10090.0,Maximum concentration obtained in mouse plasma was determined at dose 25 mg/kg,A,In vivo,Mus musculus,,50594
6853,6348,1,,,,Intermediate,1969.0,,Plasma,10090.0,Maximum plasma concentration of compound was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,A,In vivo,Mus musculus,,50594
6854,17729,1,,,,Intermediate,1969.0,,Plasma,10090.0,Maximum plasma concentration when injected i.p. in mice at a dose of 50 mg/kg,A,In vivo,Mus musculus,,50594
6855,17729,1,,,,Intermediate,1969.0,,Plasma,10090.0,Maximum plasma concentration when injected intravenously in mice at a dose of 20 mg/kg,A,In vivo,Mus musculus,,50594
6856,17729,1,,,,Intermediate,1969.0,,Plasma,10090.0,Maximum plasma concentration when injected perorally in mice at a dose of 50 mg/kg,A,In vivo,Mus musculus,,50594
6857,17728,1,,,,Intermediate,1969.0,,Plasma,10090.0,Maximal plasma concentration in BALB/C mice after 20 mg/kg intraperitoneal dose,A,In vivo,Mus musculus,,50594
6858,17728,1,,,,Intermediate,1969.0,,Plasma,10090.0,Maximal plasma concentration in BALB/C mice after 20 mg/kg intravenous dose,A,In vivo,Mus musculus,,50594
6859,17728,1,,,,Intermediate,1969.0,,Plasma,10090.0,Maximal plasma concentration in BALB/C mice after 50 mg/kg oral dose,A,In vivo,Mus musculus,,50594
6860,4066,1,,,,Intermediate,,,,10090.0,Peak concentration at a single subcutaneous administration of 40 mg/kg in mice,A,In vivo,Mus musculus,,50594
6861,6178,1,,,,Intermediate,,,,10090.0,Pharmacokinetic property (C(max)) was determined after ip administration of 32 mg/kg in mice,A,In vivo,Mus musculus,,50594
6862,6178,1,,,,Intermediate,,,,10090.0,Pharmacokinetic property (C(max)) was determined after po administration of 32 mg/kg in mice,A,In vivo,Mus musculus,,50594
6863,3760,1,,,,Intermediate,,,,10090.0,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg intravenously in mice,A,In vivo,Mus musculus,,50594
6864,3760,1,,,,Intermediate,,,,10090.0,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg perorally in mice,A,In vivo,Mus musculus,,50594
6865,3760,1,,,,Intermediate,,,,10090.0,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg intravenously in mice,A,In vivo,Mus musculus,,50594
6866,3760,1,,,,Intermediate,,,,10090.0,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg perorally in mice,A,In vivo,Mus musculus,,50594
6868,5961,1,,,,Intermediate,,,,10090.0,Cmax in male mice after 2 mg/kg oral dose,A,In vivo,Mus musculus,,50594
6869,6137,1,,,,Intermediate,,,,10090.0,Plasma concentration of 5-FU in HT-3 (human cervical cancer) xenograft mice at 1.38 mg/kg oral dose co-administered with 135 mg/kg Capecitabine,A,In vivo,Mus musculus,,50594
6870,3802,1,,,,Intermediate,,,,10090.0,Tested for Cmax value at the dose of 10 mg/kg when administered perorally in mouse,A,In vivo,Mus musculus,,50594
6871,3535,1,,,,Intermediate,,,,10090.0,Concentration in plasma (systemic) following oral dose in mouse at 0.25 hr,A,,Mus musculus,,50594
6872,3535,1,,,,Intermediate,,,,10090.0,Concentration in plasma (systemic) following oral dose in mouse at 1 hr,A,,Mus musculus,,50594
6873,3535,1,,,,Intermediate,,,,10090.0,Concentration in plasma (systemic) following oral dose in mouse at 24 hr,A,,Mus musculus,,50594
6874,3535,1,,,,Intermediate,,,,10090.0,Concentration in plasma (systemic) following oral dose in mouse at 2 hr,A,,Mus musculus,,50594
6875,3535,1,,,,Intermediate,,,,10090.0,Concentration in plasma (systemic) following oral dose in mouse at 4 hr,A,,Mus musculus,,50594
6876,3535,1,,,,Intermediate,,,,10090.0,Concentration in plasma (systemic) following oral dose in mouse at 6 hr,A,,Mus musculus,,50594
6877,2862,1,,,,Intermediate,1969.0,,Plasma,10090.0,Maximum concentration in plasma upon oral administration in mouse,A,,Mus musculus,,50594
6878,2675,1,,,,Intermediate,1969.0,,Plasma,10090.0,Maximum plasma concentration was evaluated in mice after oral administration,A,,Mus musculus,,50594
6879,2675,1,,,,Intermediate,1969.0,,Plasma,10090.0,Maximum plasma concentration was evaluated in mice after intravenous administration; Cp max Not determined,A,In vivo,Mus musculus,,50594
6880,5399,1,,,,Intermediate,,,,10090.0,Dose at which the compound induced fecal excretion in mice,A,,Mus musculus,,50594
6893,11819,1,,164.0,,Expert,,A10,,10116.0,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.01 uM,F,,Rattus norvegicus,,80013
6894,11819,1,,164.0,,Expert,,A10,,10116.0,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.1 uM,F,,Rattus norvegicus,,80013
6895,11819,1,,164.0,,Expert,,A10,,10116.0,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 1.0 uM,F,,Rattus norvegicus,,80013
6896,11819,1,,164.0,,Expert,,A10,,10116.0,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 10.0 uM,F,,Rattus norvegicus,,80013
6897,16361,1,,164.0,,Intermediate,,A10,,10116.0,In vitro [14C]- creatine uptake (1 mM) was determined in rat A10 smooth muscle cells at a concentration of (1 mM),F,,Rattus norvegicus,,80013
6898,2288,1,,393.0,,Intermediate,,A121,,9606.0,Cytotoxicity was evaluated against A121 ovarian carcinoma human cancer cell line,F,,Homo sapiens,,80655
6899,10404,1,,393.0,,Intermediate,,A121,,9606.0,Anticancer activity against human ovarian carcinoma A121 cells,F,,Homo sapiens,,80655
6900,14790,1,,393.0,,Intermediate,,A121,,9606.0,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 16.6 mM,F,,Homo sapiens,,80655
6901,14790,1,,393.0,,Intermediate,,A121,,9606.0,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 83 mM,F,,Homo sapiens,,80655
6902,14253,1,,393.0,,Expert,,A121,,9606.0,Growth inhibition of human ovarian carcinoma (A121) cell line,F,,Homo sapiens,,80655
6903,13617,1,,393.0,,Expert,,A121,,9606.0,Concentration required to inhibit growth of human tumor A121 (ovarian) cell line.,F,,Homo sapiens,,80655
6904,1003,1,,393.0,,Intermediate,,A121,,9606.0,Cytotoxicity against human A121 ovarian cells,F,,Homo sapiens,,80655
6905,830,1,,393.0,,Intermediate,,A121,,9606.0,Cytotoxicity was evaluated in vitro against A121 (ovarian carcinoma) human tumor cell lines,F,,Homo sapiens,,80655
6906,12307,1,,393.0,,Intermediate,,A121,,9606.0,In vitro cytotoxicity against human ovarian carcinoma A21,F,,Homo sapiens,,80655
6907,14254,1,,393.0,,Intermediate,,A121,,9606.0,Inhibition of the growth against human Ovarian Carcinoma (A121) cell line after 72 hr exposure,F,,Homo sapiens,,80655
6908,13370,1,,393.0,,Intermediate,,A121,,9606.0,Inhibitory activity of compound against human A121 ovarian cell line.,F,,Homo sapiens,,80655
6909,14790,1,,393.0,,Intermediate,,A121,,9606.0,Dose at which compound exhibits cytotoxicity in the A121 ovarian carcinoma cell line.,F,,Homo sapiens,,80655
6910,3614,1,,393.0,,Intermediate,,A121,,9606.0,Inhibition of growth of human ovarian tumor cell line (A121) after 72 hr of drug exposure,F,,Homo sapiens,,80655
6911,2664,1,,622.0,,Intermediate,,A 172,,9606.0,Compound was evaluated for in vitro antiproliferative activity against A172 human CNS cancer cell line,F,,Homo sapiens,,80012
6912,2037,1,,622.0,,Expert,,A 172,,9606.0,In vitro cytotoxicity against A172 human tumor cell lines.,F,,Homo sapiens,,80012
6913,14539,1,,622.0,,Intermediate,,A 172,,9606.0,Growth inhibition time for A172 Human Glioma cell growth at concentration 5 uM,F,,Homo sapiens,,80012
6914,2836,1,,622.0,,Intermediate,,A 172,,9606.0,Compound was evaluated for cytotoxicity against human glioblastoma (A172) cell line,F,,Homo sapiens,,80012
6915,10708,1,,622.0,,Intermediate,,A 172,,9606.0,Evaluated for the inhibitory concentration required to cause growth inhibition of A172Mer- cell line of central nervous system (CNS) using the MTT Cytotoxicity Assay,F,,Homo sapiens,,80012
6916,8975,4,,,,Autocuration,,,,9615.0,Association constant against A2 adenosine receptor,B,,Canis lupus familiaris,,104729
6917,7645,1,,1085.0,,Intermediate,,A2,,,In vitro effective dose that causes 50% inhibition of growth of A2 cell line - amelanotic melanoma,F,,fish,,80656
6918,11377,5,,,,Autocuration,,,,10116.0,Ratio of Ki for adenosine A2 and A1 receptor binding,B,,Rattus norvegicus,,104713
6919,13528,1,,623.0,,Expert,,A204,,9606.0,In vitro cytotoxicity against A204 human rhabdomyosarcoma cancer cell line,F,,Homo sapiens,,80014
6920,10160,1,,623.0,,Expert,,A204,,9606.0,In vitro antitumor activity against A204 rhabdomyosarcoma tumor cell line was determined,F,,Homo sapiens,,80014
6921,15144,1,,404.0,,Intermediate,,A2058,,9606.0,The compound was tested in vitro for antiproliferative activity against A2058 tumor cell lines,F,,Homo sapiens,,80015
6922,13160,1,,973.0,,Intermediate,,A253 cell line,,9606.0,Growth inhibition against Human squamous cell line(A 253),F,,Homo sapiens,,80657
6923,12898,1,,973.0,,Intermediate,,A253 cell line,,9606.0,Growth inhibition of human squamous carcinoma cell lines following continuous (120 hours) exposure to MTX and compound A253 cell line,F,,Homo sapiens,,80657
6924,13069,1,,973.0,,Intermediate,,A253 cell line,,9606.0,The compound was tested for Growth inhibition of the human squamous cell carcinoma A253 cells,F,,Homo sapiens,,80657
6925,15984,1,,973.0,,Intermediate,,A253 cell line,,9606.0,Growth inhibition of A253 cell lines.,F,,Homo sapiens,,80657
6926,15564,1,,973.0,,Intermediate,,A253 cell line,,9606.0,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h),F,,Homo sapiens,,80657
6927,15564,1,,973.0,,Intermediate,,A253 cell line,,9606.0,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,F,,Homo sapiens,,80657
6928,15564,1,,973.0,,Intermediate,,A253 cell line,,9606.0,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,F,,Homo sapiens,,80657
6929,4720,1,,478.0,,Intermediate,,A2780,,9606.0,In vitro cytotoxicity causing 50% growth inhibition was determined against A270 (human ovarian cancer)cell line,F,,Homo sapiens,,81034
6930,16112,1,,478.0,,Intermediate,,A2780,,9606.0,Antitumor activity of compound for 96-h exposure in A2780 human ovarian cell line,F,,Homo sapiens,,81034
6931,16597,1,,478.0,,Expert,,A2780,,9606.0,Cytotoxic activity against A2780 human ovarian carcinoma cell line,F,,Homo sapiens,,81034
6932,16378,1,,478.0,,Intermediate,,A2780,,9606.0,Cytotoxicity against human cancer cell lines A2780 (ovarian),F,,Homo sapiens,,81034
6933,16085,1,,478.0,,Expert,,A2780,,9606.0,Growth and colony formation inhibition of A2780 ovarian cancer cell lines,F,,Homo sapiens,,81034
6934,16317,1,,478.0,,Intermediate,,A2780,,9606.0,Inhibition of cell growth in human ovarian carcinoma cell line (A2780) using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay,F,,Homo sapiens,,81034
6935,15748,1,,478.0,,Intermediate,,A2780,,9606.0,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),F,,Homo sapiens,,81034
6936,16597,1,,478.0,,Expert,,A2780,,9606.0,Inhibition of A2780 / DDP-R human ovarian carcinoma cell proliferation,F,,Homo sapiens,,81034
6937,16597,1,,478.0,,Expert,,A2780,,9606.0,Inhibition of A2780 / TAX-R human ovarian carcinoma cell proliferation,F,,Homo sapiens,,81034
6938,16597,1,,478.0,,Expert,,A2780,,9606.0,Inhibition of A2780 / TAX-S human ovarian carcinoma cell proliferation,F,,Homo sapiens,,81034
6939,15608,1,,478.0,,Intermediate,,A2780,,9606.0,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 2,F,,Homo sapiens,,81034
6940,15608,1,,478.0,,Intermediate,,A2780,,9606.0,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 3,F,,Homo sapiens,,81034
6941,15608,1,,478.0,,Intermediate,,A2780,,9606.0,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 5,F,,Homo sapiens,,81034
6942,15296,0,,,,Autocuration,,,,10029.0,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,F,,Cricetulus griseus,,22224
6943,10251,0,,185.0,,Autocuration,,CHO-AA8,,10029.0,Evaluated for cytotoxicity under aerobic conditions against AA8 cells using microassay,A,,Cricetulus griseus,,22224
6944,10251,0,,185.0,,Autocuration,,CHO-AA8,,10029.0,Evaluated for growth inhibition of AA8 cells under aerobic conditions,F,,Cricetulus griseus,,22224
6945,10251,0,,185.0,,Autocuration,,CHO-AA8,,10029.0,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions,F,,Cricetulus griseus,,22224
6946,10251,0,,185.0,,Autocuration,,CHO-AA8,,10029.0,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions (air/N2),F,,Cricetulus griseus,,22224
6947,11858,0,,,,Autocuration,,,,10029.0,Growth inhibition against CHO-derived cell line AA8,F,,Cricetulus griseus,,22224
6948,11858,0,,185.0,,Autocuration,,CHO-AA8,,10029.0,Growth inhibition against CHO-derived cell line AA8 (Non toxic at solubility limit) [RB6145 used as positive control],F,,Cricetulus griseus,,22224
6949,11616,1,,185.0,,Expert,,CHO-AA8,,36483.0,Growth inhibition in CHO subline AA8 cells exposed for 18 hr under aerobic(air) conditions,F,,hampster,,80089
6950,11616,1,,185.0,,Expert,,CHO-AA8,,10029.0,Growth inhibitory activity against CHO subline AA8 cells exposed for 18 hr under aerobic conditions,F,,Cricetulus griseus,,80089
6951,10518,0,,185.0,,Autocuration,,CHO-AA8,,10029.0,Tested for the concentration of the drug to reduce cell numbers to 50 percent of controls against AA8 cells in the microassay,F,,Cricetulus griseus,,22224
6952,11396,0,,185.0,,Autocuration,,CHO-AA8,,10029.0,Growth inhibition of aerobic chinese hamster ovary fibroblast AA8 cell line using an exposure time of 18 hours,F,,Cricetulus griseus,,22224
6953,10518,0,,185.0,,Autocuration,,CHO-AA8,,10029.0,IC50 (air/N2) ratio of the drug to reduce cell numbers to 50 percent of controls using AA8 cells in the microassay,F,,Cricetulus griseus,,22224
6954,11616,1,,185.0,,Expert,,CHO-AA8,,10029.0,In vitro therapeutic index as ratio of CT10 and C1.3 calculated for AA8 cells.,F,,Cricetulus griseus,,80089
6955,14837,8,,,,Autocuration,,,,,compound was evaluated for association constant (Ka) of isolated serum protein AAG,F,,,,12675
6956,14837,8,,,,Autocuration,,,,,Number of binding sites (n) of isolated serum protein AAG,F,,,,12675
6957,16037,3,,,,Intermediate,,,,,Association constant for binding to AATT duplex,B,,,,22222
6958,16597,1,,416.0,,Expert,,ABAE,,9606.0,Inhibition of ABAE human fibroblast cell proliferation,F,,Homo sapiens,,100090
6959,8831,1,,1064.0,,Intermediate,,AC755,,10090.0,"Compound was evaluated for the antitumor activity against AC755 breast carcinoma for ip administration and daily x 10 schedule; Number of toxic deaths over total number of mice per group (T/C), 1/7 at dose of 25 mg/kg",F,,Mus musculus,,80668
6960,13419,9,,,,Expert,,,,9986.0,Percent change in total cholesterol(TC) versus (T0)- at which drug intervention begins at a dose of 25 mg/kg in the chronic cholesterol-fed rabbit model,F,,Oryctolagus cuniculus,,102444
6961,13419,9,,,,Expert,,,,9986.0,Oral bioactivity expressed as %inhibition after 4 hours of drug administration (dose 25 mg/kg) in rabbit bioassay,F,In vivo,Oryctolagus cuniculus,,102444
6962,15778,8,,,,Autocuration,,,,,Inhibitory activity against angiotensin-converting enzyme (ACE).,B,,,,69
6963,15778,8,,,,Autocuration,,,,,oral activity against angiotensin -converting enzyme ( ACE) and neutral endopeptidase in mouse.,B,,,,69
6964,12988,1,,978.0,,Intermediate,,ACH-2 cell line,,9606.0,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells,F,,Homo sapiens,,80669
6965,12988,1,,978.0,,Intermediate,,ACH-2 cell line,,9606.0,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells in the presence of PMA(phorbol 12-myristate 13-acetate),F,,Homo sapiens,,80669
6966,12988,0,,998.0,,Autocuration,,T cell line,,11676.0,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2,F,,Human immunodeficiency virus 1,,22224
6967,12988,0,,998.0,,Autocuration,,T cell line,,11676.0,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2 in the presence of PMA(phorbol 12-myristate 13-acetate),F,,Human immunodeficiency virus 1,,22224
6968,12988,0,,998.0,,Autocuration,,T cell line,,11676.0,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2i n the presence of PMA(phorbol 12-myristate 13-acetate),F,,Human immunodeficiency virus 1,,22224
6969,11843,1,,626.0,,Intermediate,,ACHN,,9606.0,Inhibition of growth of renal cancer ACHN cell line,F,,Homo sapiens,,80025
6970,16939,1,,626.0,,Intermediate,,ACHN,,9606.0,Inhibition of growth of ACHN renal cancer cell line,F,,Homo sapiens,,80025
6971,4782,1,,626.0,,Intermediate,,ACHN,,9606.0,Inhibitory concentration required against ACHN renal cancer cell line,F,,Homo sapiens,,80025
6972,6310,1,,626.0,,Expert,,ACHN,,9606.0,Concentration required to inhibit growth of human renal (ACHN) cell line,F,,Homo sapiens,,80025
6973,6310,1,,626.0,,Intermediate,,ACHN,,9606.0,Concentration required to inhibit growth of human renal (ACHN) cell line; nt = not tested,F,,Homo sapiens,,80025
6974,12858,1,,626.0,,Intermediate,,ACHN,,9606.0,Cytotoxic activity against ACHN Renal cancer cell line,F,,Homo sapiens,,80025
6975,17380,1,,626.0,,Intermediate,,ACHN,,9606.0,Cytotoxicity evaluation against ACHN renal cancer cells,F,,Homo sapiens,,80025
6976,5858,1,,626.0,,Intermediate,,ACHN,,9606.0,In vitro antitumor activity against human renal ACHN cell line,F,,Homo sapiens,,80025
6977,3838,1,,626.0,,Intermediate,,ACHN,,9606.0,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,F,,Homo sapiens,,80025
6978,3838,1,,626.0,,Intermediate,,ACHN,,9606.0,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,F,,Homo sapiens,,80025
6979,5406,1,,626.0,,Intermediate,,ACHN,,9606.0,"Tested for the cytotoxicity against the Renal cancer cell line ACHN, growth inhibition by 50% is reported",F,,Homo sapiens,,80025
6980,4071,1,,626.0,,Intermediate,,ACHN,,9606.0,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,F,,Homo sapiens,,80025
6981,4071,1,,626.0,,Expert,,ACHN,,9606.0,Tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,F,,Homo sapiens,,80025
6982,4071,1,,626.0,,Intermediate,,ACHN,,9606.0,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal); Not determined,F,,Homo sapiens,,80025
6983,15002,1,,626.0,,Intermediate,,ACHN,,9606.0,Antitumor activity was evaluated against human renal adenocarcinoma cell line ACHN.,F,,Homo sapiens,,80025
6984,14769,1,,626.0,,Intermediate,,ACHN,,9606.0,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),F,,Homo sapiens,,80025
6985,13958,1,,626.0,,Intermediate,,ACHN,,9606.0,"Compound was tested for antiproliferative activity against ACHN, human renal adenocarcinoma",F,,Homo sapiens,,80025
6986,1665,1,,626.0,,Intermediate,,ACHN,,9606.0,Compound was tested for its effect on the proliferation of ACHN human kidney adenocarcinoma,F,,Homo sapiens,,80025
6987,15354,1,,626.0,,Intermediate,,ACHN,,9606.0,Compound was tested for the growth inhibition of ACHN renal tumor cell line,F,,Homo sapiens,,80025
6988,15354,1,,626.0,,Intermediate,,ACHN,,9606.0,Compound was tested for the growth inhibition of ACHN renal tumor cell line; ND=Not determined,F,,Homo sapiens,,80025
6989,13978,1,,626.0,,Intermediate,,ACHN,,9606.0,In vitro Growth Inhibitory activity against ACHN Human kidney cancer cell line,F,,Homo sapiens,,80025
6990,6798,1,,626.0,,Intermediate,,ACHN,,9606.0,In vitro cytotoxicity against human renal adenocarcinoma (ACHN) tumor cell line,F,,Homo sapiens,,80025
6991,2959,1,,,,Intermediate,,,,9615.0,Tmax value after administration of 4 mg/Kg oral dose in dog,A,In vivo,Canis lupus familiaris,,50588
6992,9932,1,,,,Intermediate,,,,9615.0,"Time to peak response on lowering of vascular resistance, in dogs when administered intravenously",A,,Canis lupus familiaris,,50588
6993,5546,1,,,,Intermediate,,,,9615.0,Unbound plasma was determined in Beagle dog at a dose of 1 mg/kg by iv administration,A,,Canis lupus familiaris,,50588
6994,16907,1,,,,Intermediate,,,,9615.0,Volume distribution after 15 mg/kg iv dose in Dogs,A,In vivo,Canis lupus familiaris,,50588
6995,16907,1,,,,Intermediate,,,,9615.0,Volume distribution after 30 mg/kg po dose in Dogs,A,In vivo,Canis lupus familiaris,,50588
6996,4257,1,,,,Intermediate,,,,9615.0,Volume of distribution was determined in dog after a 3 mg/kg of iv dose,A,In vivo,Canis lupus familiaris,,50588
6997,4305,1,,,,Intermediate,,,,9615.0,Volume of distribution was determined by iv administration in dogs at a dose of 1 mg/kg,A,In vivo,Canis lupus familiaris,,50588
6998,5472,1,,,,Intermediate,,,,9615.0,Volume of distribution was evaluated in dog,A,In vivo,Canis lupus familiaris,,50588
6999,6062,1,,,,Intermediate,,,,9615.0,Terminal phase volume of distribution was measured in dog after an iv dose of 1 mg/kg,A,In vivo,Canis lupus familiaris,,50588
7000,3598,1,,,,Expert,,,,9615.0,Apparent volume of the central plasma compartment (Vc) of compound determined in dog after iv administration at a dose of 10 mg/kg,A,,Canis lupus familiaris,,50588
7001,12500,1,,,,Intermediate,,,,9615.0,The compound was tested for volume of distribution in dog,A,In vivo,Canis lupus familiaris,,50588
7002,12500,1,,,,Intermediate,,,,9615.0,The compound was tested for volume of distribution in dog at dose of 3-10 mgkg,A,In vivo,Canis lupus familiaris,,50588
7003,6227,1,,,,Intermediate,,,,9615.0,Vd (1 mg/kg) was determined in dog (in vivo),A,In vivo,Canis lupus familiaris,,50588
7004,6227,1,,,,Intermediate,,,,9615.0,Vd in dog,A,In vivo,Canis lupus familiaris,,50588
7005,4219,1,,,,Intermediate,,,,9615.0,Volume distribution was determined,A,In vivo,Canis lupus familiaris,,50588
7006,1696,1,,,,Intermediate,,,,9615.0,Volume of distribution in dog,A,In vivo,Canis lupus familiaris,,50588
7007,5542,1,,,,Intermediate,,,,9615.0,Volume of distribution by as 4 fold increase by iv administration in dogs,A,In vivo,Canis lupus familiaris,,50588
7008,5199,1,,,,Intermediate,,,,9615.0,Volume of distribution was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,A,In vivo,Canis lupus familiaris,,50588
7009,6348,1,,,,Intermediate,,,,9615.0,Volume of distribution was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,A,In vivo,Canis lupus familiaris,,50588
7010,4727,1,,,,Intermediate,,,,9615.0,Volume distribution at the dose of 2 mg/kg in dog,A,In vivo,Canis lupus familiaris,,50588
7011,16367,1,,,,Intermediate,,,,9615.0,Steady state volume of distribution was determined,A,In vivo,Canis lupus familiaris,,50588
7012,2652,1,,,,Intermediate,,,,9615.0,Bioavailability as Vdss in dogs at 1 mg/kg intravenous dose,A,In vivo,Canis lupus familiaris,,50588
7013,16452,1,,,,Intermediate,,,,9615.0,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,A,In vivo,Canis lupus familiaris,,50588
7014,16452,1,,,,Intermediate,,,,9615.0,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,A,In vivo,Canis lupus familiaris,,50588
7015,16452,1,,,,Intermediate,,,,9615.0,Bioavailability in dog (dose 1 mg/kg i.v.),A,In vivo,Canis lupus familiaris,,50588
7016,5334,1,,,,Intermediate,,,,9615.0,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),A,In vivo,Canis lupus familiaris,,50588
7017,4239,1,,,,Intermediate,,,,9615.0,Pharmacokinetic property (vdss) was measured in dog,A,In vivo,Canis lupus familiaris,,50588
7018,4709,1,,,,Intermediate,,,,9615.0,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in dog,A,In vivo,Canis lupus familiaris,,50588
7019,5600,1,,,,Intermediate,,,,9615.0,Vdss was determined after iv 0.1 mg/kg administration in dog,A,In vivo,Canis lupus familiaris,,50588
7020,6057,1,,,,Intermediate,,,,9615.0,Volume displacement was calculated in dog,A,In vivo,Canis lupus familiaris,,50588
7021,5654,1,,,,Intermediate,,,,9615.0,Volume distribution (Vdss) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,A,In vivo,Canis lupus familiaris,,50588
7022,5505,1,,,,Intermediate,,,,9615.0,Volume distribution constant was determined,A,In vivo,Canis lupus familiaris,,50588
7023,4527,1,,,,Intermediate,,,,9615.0,Volume distribution at a dose of 1 uM/kg in dog was determined,A,In vivo,Canis lupus familiaris,,50588
7024,4521,1,,,,Intermediate,,,,9615.0,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,A,In vivo,Canis lupus familiaris,,50588
7025,4521,1,,,,Intermediate,,,,9615.0,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,A,In vivo,Canis lupus familiaris,,50588
7026,15660,1,,,,Intermediate,,,,9615.0,Volume distribution (Vdss) was measured in dog,A,In vivo,Canis lupus familiaris,,50588
7027,15660,1,,,,Intermediate,,,,9615.0,Volume distribution (Vdss) was measured in dog,A,In vivo,Canis lupus familiaris,,50588
7028,6679,1,,,,Intermediate,,,,9615.0,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,A,In vivo,Canis lupus familiaris,,50588
7029,5145,1,,,,Intermediate,,,,9615.0,Volume of distribution in steady state was determined in dog,A,In vivo,Canis lupus familiaris,,50588
7030,6821,1,,,,Intermediate,,,,9615.0,Volume of distribution of compound was determined in dog,A,In vivo,Canis lupus familiaris,,50588
7031,4137,1,,,,Intermediate,,,,9615.0,Volume of distribution after intravenous administration of 1 mg/kg/h in dog,A,In vivo,Canis lupus familiaris,,50588
7032,5334,1,,,,Intermediate,,,,9615.0,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),A,In vivo,Canis lupus familiaris,,50588
7033,15660,1,,,,Intermediate,,,,9615.0,Volume of distribution (Vdss) was measured in dog,A,In vivo,Canis lupus familiaris,,50588
7034,6642,1,,,,Intermediate,,,,9615.0,Volumes of distribution in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),A,In vivo,Canis lupus familiaris,,50588
7035,6641,1,,,,Intermediate,,,,9615.0,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),A,In vivo,Canis lupus familiaris,,50588
7036,6642,1,,,,Intermediate,,,,9615.0,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),A,In vivo,Canis lupus familiaris,,50588
7037,11659,1,,,,Intermediate,,,,9615.0,Maximum rate of depolarization of the upstroke of the action potential,A,,Canis lupus familiaris,,50588
7038,6448,1,,,,Intermediate,,,,9615.0,Steady state volume distribution in dog,A,In vivo,Canis lupus familiaris,,50588
7039,5474,1,,,,Intermediate,,,,9615.0,Steady state volume of distribution at a dose of 0.2 mg/kg i.v.,A,In vivo,Canis lupus familiaris,,50588
7040,1466,1,,,,Intermediate,,,,9615.0,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in dog,A,In vivo,Canis lupus familiaris,,50588
7041,6535,1,,,,Intermediate,,,,9615.0,Volume distribution in dog after administration of 0.25 mg/kg iv; ND = not determined,A,In vivo,Canis lupus familiaris,,50588
7042,6535,1,,,,Intermediate,,,,9615.0,Volume distribution in dog after administration of 1 mg/kg iv,A,In vivo,Canis lupus familiaris,,50588
7043,17764,1,,,,Intermediate,,,,9615.0,Volume of solubility in solution after intravenous administration in dogs at 1.2 uM/kg,A,In vivo,Canis lupus familiaris,,50588
7044,6215,1,,,,Intermediate,,,,9615.0,Vss after intravenous administration (0.5 mg/kg) was determined in dog,A,In vivo,Canis lupus familiaris,,50588
7045,6505,1,,,,Intermediate,,,,9615.0,Vss on i.v. administration of 2 mg/kg was measured in dog,A,In vivo,Canis lupus familiaris,,50588
7046,3639,1,,,,Intermediate,,,,9615.0,Vss was determined,A,,Canis lupus familiaris,,50588
7047,3639,1,,,,Intermediate,,,,9615.0,Vss in dog,A,,Canis lupus familiaris,,50588
7048,6062,1,,,,Intermediate,,,,9615.0,Volume of distribution was measured in dog after an iv dose of 1 mg/kg,A,In vivo,Canis lupus familiaris,,50588
7049,4942,1,,,,Intermediate,,,,9615.0,Volume distribution in dogs,A,In vivo,Canis lupus familiaris,,50588
7050,17796,1,,,,Intermediate,,,,9615.0,Volume of distribution in dog,A,In vivo,Canis lupus familiaris,,50588
7051,4883,1,,,,Intermediate,,,,9615.0,Tested for the oral bioavailability in dog,A,In vivo,Canis lupus familiaris,,50588
7060,17837,1,,,,Intermediate,,,,10090.0,Bioavailability of compound in mouse blood following p.o. administration of 30 mg/kg,A,In vivo,Mus musculus,,50594
7061,17729,1,,,,Intermediate,,,,10090.0,Bioavailability after i.p. administration of 50 mg/kg of dose in mice,A,In vivo,Mus musculus,,50594
7062,17729,1,,,,Intermediate,,,,10090.0,Bioavailability after peroral administration of 50 mg/kg of dose in mice,A,In vivo,Mus musculus,,50594
7063,4239,1,,,,Intermediate,,,,10090.0,Bioavailability was measured in mouse,A,In vivo,Mus musculus,,50594
7064,17592,1,,,,Intermediate,,,,10090.0,Bioavailability in mouse,A,In vivo,Mus musculus,,50594
7065,6348,1,,,,Intermediate,,,,10090.0,Bioavailability was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,A,In vivo,Mus musculus,,50594
7066,2801,1,,,,Intermediate,,,,10090.0,Bioavailability in mouse,A,In vivo,Mus musculus,,50594
7067,2801,1,,,,Intermediate,,,,10090.0,Compound was evaluated for its bioavailability in mice at a dose of 1 mg/kg,A,In vivo,Mus musculus,,50594
7068,17718,1,,,,Intermediate,,,,10090.0,Oral bioavailability in mouse,A,In vivo,Mus musculus,,50594
7069,5727,1,,,,Intermediate,,,,10090.0,Oral availability at 50 mg/kg po in male mice,A,In vivo,Mus musculus,,50594
7070,5302,1,,,,Intermediate,,,,10090.0,Oral bioavailability in mouse (dose 10 mg/kg),A,In vivo,Mus musculus,,50594
7071,3598,1,,,,Expert,,,,10090.0,Oral bioavailability of compound determined in mouse after iv administration at a dose of 10 mg/kg,A,In vivo,Mus musculus,,50594
7072,5961,1,,,,Intermediate,,,,10090.0,"Bioavailability in male mice, 2mg/kg oral and 1 mg/kg intravenous dose",A,In vivo,Mus musculus,,50594
7074,6091,1,,,,Intermediate,,,,10090.0,Oral bioavailability in mouse,A,In vivo,Mus musculus,,50594
7075,6091,1,,,,Intermediate,,,,10090.0,Oral bioavailability in vivo in mice;ND=Not determined,A,In vivo,Mus musculus,,50594
7076,5711,1,,,,Intermediate,,,,10090.0,Oral bioavailability in mouse at 10 mg/kg of the compound,A,In vivo,Mus musculus,,50594
7077,17728,1,,,,Intermediate,,,,10090.0,Bioavailability in mouse (BALB/C) (dose 50 mg/kg i.p.),A,In vivo,Mus musculus,,50594
7078,17728,1,,,,Intermediate,,,,10090.0,Bioavailability in mouse (BALB/C) (dose 20 mg/kg i.v.),A,In vivo,Mus musculus,,50594
7079,3802,1,,,,Intermediate,,,,10090.0,Tested for bioavailability of the compound,A,In vivo,Mus musculus,,50594
7080,3802,1,,,,Intermediate,,,,10090.0,Tested for half life at the dose of 10 mg/kg when administered intravenously,A,In vivo,Mus musculus,,50594
7081,14029,1,,,,Intermediate,1969.0,,Plasma,10090.0,The plasma half life of compound was determined on EDTA prepared by mouse plasma. ,A,,Mus musculus,,50594
7082,14029,1,,,,Intermediate,1969.0,,Plasma,10090.0,The plasma half life of compound was determined on heparin prepared by human plasma. ,A,,Mus musculus,,50594
7083,14029,1,,,,Intermediate,1969.0,,Plasma,10090.0,The plasma half life of compound was determined on heparin prepared by human plasma; Not degraded,A,,Mus musculus,,50594
7084,14029,1,,,,Intermediate,1969.0,,Plasma,10090.0,The plasma half life of compound was determined on heparin prepared by mouse plasma. ,A,,Mus musculus,,50594
7085,14029,1,,,,Intermediate,1969.0,,Plasma,10090.0,The plasma half life of compound was determined on heparin prepared by mouse plasma; Not degraded,A,,Mus musculus,,50594
7086,17753,1,,,,Intermediate,,,,10090.0,Inhibitory concentration of compound was determined after intravenous administration in mice after 6 hours of exposure at 40 mg/Kg,F,,Mus musculus,,50594
7087,17753,1,,,,Intermediate,,,,10090.0,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 24 mg/Kg,A,,Mus musculus,,50594
7088,17753,1,,,,Intermediate,,,,10090.0,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 5 mg/Kg,A,,Mus musculus,,50594
7089,10107,1,,,,Intermediate,178.0,,Blood,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,Mus musculus,,50594
7090,10107,1,,,,Intermediate,178.0,,Blood,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,In vivo,Mus musculus,,50594
7091,10107,1,,,,Intermediate,178.0,,Blood,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,Mus musculus,,50594
7092,10107,1,,,,Intermediate,178.0,,Blood,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,Mus musculus,,50594
7093,10107,1,,,,Intermediate,178.0,,Blood,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,Mus musculus,,50594
7094,10107,1,,,,Intermediate,178.0,,Blood,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,Mus musculus,,50594
7095,10107,1,,,,Intermediate,178.0,,Blood,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,Mus musculus,,50594
7096,10107,1,,,,Intermediate,10000001.0,,Bone,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,Mus musculus,,50594
7097,10107,1,,,,Intermediate,10000001.0,,Bone,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,A,In vivo,Mus musculus,,50594
7098,15608,1,,478.0,,Intermediate,,A2780,,9606.0,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 8,F,,Homo sapiens,,81034
7099,3290,1,,478.0,,Expert,,A2780,,9606.0,In vitro cytotoxicity against human ovarian carcinoma cell line A2780 using sulforhodamine B (SRB) assay,F,,Homo sapiens,,81034
7100,2859,1,,478.0,,Intermediate,,A2780,,9606.0,Compound was evaluated for cytotoxicity against A2780 cell line,F,,Homo sapiens,,81034
7101,15688,1,,478.0,,Expert,,A2780,,9606.0,Inhibition of A2780 cell clonogenic assay,F,,Homo sapiens,,81034
7102,5642,1,,478.0,,Expert,,A2780,,9606.0,Cytotoxic effect on ovarian cancer cell line (A2780),F,,Homo sapiens,,81034
7103,6633,1,,478.0,,Intermediate,,A2780,,9606.0,Concentration required to inhibit A2780 cell growth when compared with control after incubation for 96 hr at 37 C,F,,Homo sapiens,,81034
7104,3906,1,,478.0,,Intermediate,,A2780,,9606.0,"MDR-reversing activity was measured by vincristine accumulation in the multidrug resistant 2780AD, a subline of A2780 ovarian carcinoma cells at 10 mg/mL",F,,Homo sapiens,,81034
7105,6788,1,,478.0,,Expert,,A2780,,9606.0,50% growth inhibition of A2780 (Human ovarian carcinoma) cell line compared with untreated control cells,F,,Homo sapiens,,81034
7106,17582,1,,478.0,,Expert,,A2780,,9606.0,Antiproliferative activity against human A2780 cells,F,,Homo sapiens,,81034
7107,17764,1,,478.0,,Expert,,A2780,,9606.0,Inhibition of human A2780 cell proliferation,F,,Homo sapiens,,81034
7108,17764,1,,478.0,,Expert,,A2780,,9606.0,Antiproliferative effect against human A2780 cell line was determined in a whole cell 72 hr cytotoxicity assay,F,,Homo sapiens,,81034
7109,17764,1,,478.0,,Expert,,A2780,,9606.0,Inhibition of human A2780 cell proliferation (No data),F,,Homo sapiens,,81034
7110,2815,1,,478.0,,Intermediate,,A2780,,9606.0,Cell cytotoxicity was determined against human ovarian cancer (A2780) cell line,F,,Homo sapiens,,81034
7111,16930,1,,478.0,,Intermediate,,A2780,,9606.0,Compound was evaluated against human Ovarian carcinoma cell line A2780,F,,Homo sapiens,,81034
7112,17777,1,,478.0,,Expert,,A2780,,9606.0,Growth inhibition against A2780 wild-type ovarian cell lines,F,,Homo sapiens,,81034
7113,17777,1,,478.0,,Intermediate,,A2780,,9606.0,Compound was evaluated for growth inhibition against A2780 wild-type ovarian cell lines; No data,F,,Homo sapiens,,81034
7114,16936,5,,,,Autocuration,,,,9606.0,Inhibition of tubulin polymerization in human ovarian cancer cell lines,F,,Homo sapiens,,104766
7115,13759,1,,478.0,,Intermediate,,A2780,,9606.0,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,F,,Homo sapiens,,81034
7116,13759,1,,478.0,,Intermediate,,A2780,,9606.0,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,F,,Homo sapiens,,81034
7117,13759,1,,478.0,,Intermediate,,A2780,,9606.0,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,F,,Homo sapiens,,81034
7118,13759,1,,478.0,,Intermediate,,A2780,,9606.0,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,F,,Homo sapiens,,81034
7119,15292,1,,478.0,,Intermediate,,A2780,,9606.0,Compound was tested for inhibitory activity against A2780 human ovarian carcinoma cell line; activity expressed in Mean IC50 values,F,,Homo sapiens,,81034
7120,15292,1,,478.0,,Intermediate,,A2780,,9606.0,Compound was tested for inhibitory activity against A2780cisR human ovarian carcinoma cell line; activity expressed in Mean IC50 values,F,,Homo sapiens,,81034
7121,15069,1,,478.0,,Expert,,A2780,,9606.0,In vitro inhibition of human ovarian cell line A2780,F,,Homo sapiens,,81034
7122,15069,1,,478.0,,Expert,,A2780,,9606.0,"In vitro inhibition of human ovarian cell line, resistant to cisplatin (A2780cisR).",F,,Homo sapiens,,81034
7123,14073,1,,478.0,,Intermediate,,A2780,,9606.0,Concentration of compound to inhibit the growth of human A2780 ovarian carcinoma cells(in vitro),F,,Homo sapiens,,81034
7124,14553,1,,478.0,,Expert,,A2780,,9606.0,Concentration required to inhibit A2780-cell growth by 50%,F,,Homo sapiens,,81034
7125,13040,1,,478.0,,Expert,,A2780,,9606.0,Concentration required to inhibit the cell growth by 50 % after 96 hr A2780 leukemic cells.,F,,Homo sapiens,,81034
7126,6891,1,,478.0,,Expert,,A2780,,9606.0,Cytotoxic effect on human ovarian (A2780) cancer cell line,F,,Homo sapiens,,81034
7127,15569,1,,478.0,,Intermediate,,A2780,,9606.0,Cytotoxic activity in a panel of Human ovarian tumor A2780 cell line after 96h of drug exposure,F,,Homo sapiens,,81034
7128,14190,1,,478.0,,Expert,,A2780,,9606.0,Cytotoxic potency required to inhibit A2780 cell growth by 50% after cell drug contact for 96 hrs,F,,Homo sapiens,,81034
7129,15014,1,,478.0,,Expert,,A2780,,9606.0,Cytotoxicity measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,F,,Homo sapiens,,81034
7130,15014,1,,478.0,,Intermediate,,A2780,,9606.0,Cytotoxicity activity of the compound was measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,F,,Homo sapiens,,81034
7131,17496,1,,478.0,,Intermediate,,A2780,,9606.0,Cytotoxicity against human ovarian carcinoma A2780 cell line,F,,Homo sapiens,,81034
7132,13617,1,,478.0,,Intermediate,,A2780,,9606.0,"Cytotoxicity against A2780-C25, oxaliplatin-resistant Ovarian carcinoma cell line",F,,Homo sapiens,,81034
7133,13617,1,,478.0,,Intermediate,,A2780,,9606.0,"Cytotoxicity against A2780-CP3, cisplatin-resistant Ovarian carcinoma cell line",F,,Homo sapiens,,81034
7134,13617,1,,478.0,,Intermediate,,A2780,,9606.0,"Cytotoxicity against A2780-DX5, Doxorubicin-resistant Ovarian carcinoma cell line",F,,Homo sapiens,,81034
7135,13617,1,,478.0,,Intermediate,,A2780,,9606.0,"Cytotoxicity against A2780-WT, human ovarian carcinoma cell line",F,,Homo sapiens,,81034
7136,17672,1,,478.0,,Intermediate,,A2780,,9606.0,Cytotoxicity against ovarian carcinoma A2780 tumor cell lines,F,,Homo sapiens,,81034
7137,4544,1,,478.0,,Intermediate,,A2780,,9606.0,Dose of required to inhibit growth of cisplatin resistant human ovarian carcinoma (A2780 cisR) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,F,,Homo sapiens,,81034
7138,4544,1,,478.0,,Intermediate,,A2780,,9606.0,Dose of required to inhibit growth of human ovarian carcinoma (A2780) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,F,,Homo sapiens,,81034
7139,16317,1,,478.0,,Intermediate,,A2780,,9606.0,"Growth inhibition in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant) using the 96 hour exposure sulforhodamine B (SRB) growth delay assay",F,,Homo sapiens,,81034
7140,15099,1,,478.0,,Intermediate,,A2780,,9606.0,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780,F,,Homo sapiens,,81034
7141,13978,1,,478.0,,Intermediate,,A2780,,9606.0,In vitro Growth Inhibitory activity against A2780 Human ovarian cancer cell line,F,,Homo sapiens,,81034
7142,12989,1,,478.0,,Expert,,A2780,,9606.0,In vitro antitumor activity against A2780 cell line.,F,,Homo sapiens,,81034
7143,5574,1,,478.0,,Intermediate,,A2780,,9606.0,In vitro cytotoxic activity against human tumor cell line A2780 after incubation for 96 hours,F,,Homo sapiens,,81034
7144,13528,1,,478.0,,Expert,,A2780,,9606.0,In vitro cytotoxicity against A2780 human ovarian cancer cell line,F,,Homo sapiens,,81034
7145,12782,1,,626.0,,Intermediate,,ACHN,,9606.0,Inhibitory activity against kidney A-CHN tumor cell growth in culture,F,,Homo sapiens,,80025
7146,14255,1,,626.0,,Intermediate,,ACHN,,9606.0,The IC50 value was measured on ACHN cell line in renal tumor type.,F,,Homo sapiens,,80025
7147,16364,1,,626.0,,Intermediate,,ACHN,,9606.0,Concentration required for killing 50% of cells of renal ACHN cell lines was determined in vitro,F,,Homo sapiens,,80025
7148,17376,1,,626.0,,Expert,,ACHN,,9606.0,In vitro lethal concentration against most sensitive ACHN cell line,F,,Homo sapiens,,80025
7149,12016,1,,626.0,,Intermediate,,ACHN,,9606.0,Tested for cytotoxic activity against renal cancer ACHN cell line,F,,Homo sapiens,,80025
7150,6058,1,,626.0,,Intermediate,,ACHN,,9606.0,Compound tested for growth inhibition of renal cancer cell line ACHN,F,,Homo sapiens,,80025
7151,17708,1,,626.0,,Intermediate,,ACHN,,9606.0,Compound was tested for 50% growth inhibition against human renal cancer ACHN cell line,F,,Homo sapiens,,80025
7152,15176,1,,626.0,,Intermediate,,ACHN,,9606.0,Growth inhibition of the ACHN Renal cancer cell line for 2-day in vitro assay.,F,,Homo sapiens,,80025
7153,2806,1,,626.0,,Intermediate,,ACHN,,9606.0,In vitro anticancer activity against ACHN renal cancer cell line,F,,Homo sapiens,,80025
7154,15300,1,,626.0,,Intermediate,,ACHN,,9606.0,In vitro antitumor activity against Renal cancer ACHN cell lines by 6-day assay,F,,Homo sapiens,,80025
7155,16364,1,,626.0,,Intermediate,,ACHN,,9606.0,Percent selectivity was evaluated in renal ACHN cell lines,F,,Homo sapiens,,80025
7156,13859,1,,626.0,,Intermediate,,ACHN,,9606.0,In vitro inhibitory activity against renal ACHN cancer cell line,F,,Homo sapiens,,80025
7157,11970,1,,626.0,,Intermediate,,ACHN,,9606.0,Tested for cytotoxicity against ACHN cell lines in renal cancer,F,,Homo sapiens,,80025
7158,2450,1,,626.0,,Intermediate,,ACHN,,9606.0,Tested for the in vitro cytotoxicity against ACHN renal cancer cell line,F,,Homo sapiens,,80025
7159,12696,1,,626.0,,Intermediate,,ACHN,,9606.0,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,F,,Homo sapiens,,80025
7160,12400,1,,626.0,,Intermediate,,ACHN,,9606.0,Tested in vitro for cytotoxicity in ACHN cell line of Renal cancer,F,,Homo sapiens,,80025
7161,12888,1,,626.0,,Expert,,ACHN,,9606.0,Cytotoxic effect on renal cancer line ACHN,F,,Homo sapiens,,80025
7162,3156,1,,626.0,,Intermediate,,ACHN,,9606.0,In vitro anti-cancer activity against ACHN(Renal) human tumor cell line,F,,Homo sapiens,,80025
7163,3381,1,,626.0,,Intermediate,,ACHN,,9606.0,In vitro inhibition of Renal Cancer ACHN cell lines,F,,Homo sapiens,,80025
7164,16747,1,,626.0,,Intermediate,,ACHN,,9606.0,Antitumor activity against human renal adenocarcinoma ACHN cells,F,,Homo sapiens,,80025
7165,16748,1,,626.0,,Expert,,ACHN,,9606.0,Antitumor activity against human renal adenocarcinoma ACHN cells.,F,,Homo sapiens,,80025
7166,12062,1,,626.0,,Intermediate,,ACHN,,9606.0,Inhibitory concentration required to decrease cell viability in cell growth culture against kidney cells ACHN,F,,Homo sapiens,,80025
7167,14769,1,,626.0,,Intermediate,,ACHN,,9606.0,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),F,,Homo sapiens,,80025
7168,15895,1,,626.0,,Intermediate,,ACHN,,9606.0,"Cytotoxicity against NCI tumor panel, ACHN renal cancer cell line",F,,Homo sapiens,,80025
7169,17376,1,,626.0,,Intermediate,,ACHN,,9606.0,Concentration of compound that cause 50% cytotoxicity of ACHN renal cancer cell line,F,,Homo sapiens,,80025
7170,14882,1,,626.0,,Intermediate,,ACHN,,9606.0,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration that inhibits 50% net cell growth).,F,,Homo sapiens,,80025
7171,14882,1,,626.0,,Intermediate,,ACHN,,9606.0,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration leading to 50% net cell death).,F,,Homo sapiens,,80025
7172,15661,1,,626.0,,Intermediate,,ACHN,,9606.0,Cytotoxicity was tested against renal cancer ACHN tumor cell lines.,F,,Homo sapiens,,80025
7173,9680,0,,,,Autocuration,,,,,Keff is the effective biomolecular rate constant on paraxon for reactivation at pH 7.8 at 25 degree Centigrade,A,,,,22224
7174,14579,8,,,,Autocuration,,,,,Compound tested for relative response using 1 uM ACh as agonist against AChM1 receptor.,F,,,,10647
7175,17290,1,,468.0,,Expert,,HEL,,10358.0,Antiviral activity against AD169 strain of cytomegalovirus (CMV) in HEL (human erythroleukemia) cells.,F,,Cytomegalovirus,,50529
7176,17290,1,,,,Intermediate,,,,10358.0,Antiviral activity against AD169 strain of cytomegalovirus (CMV); ND=No data,F,,Cytomegalovirus,,50529
7177,15891,8,,,,Autocuration,,,,,Compound was evaluated for its inhibitory activity against calf intestinal Adenosine deaminase (ADA),B,,,,12159
7178,15890,8,,,,Autocuration,,,,,Evaluated for the inhibition of calf intestinal Adenosine deaminase (ADA),B,,,,12159
7179,3801,1,,979.0,,Intermediate,,ADDP cell line,,9913.0,Inhibitory activity against ovarian tumor cell line ADDP after 72 hr continuous exposure to compound,F,,Bos taurus,,80670
7180,9222,1,,980.0,,Intermediate,,ADJ/PC6,,10090.0,Tumor growth inhibition activity after subcutaneous transplanted tumor in ADJ-PC6 plasmacytoma cells,F,,Mus musculus,,80671
7181,9222,1,,980.0,,Intermediate,,ADJ/PC6,,10090.0,Tumor growth inhibition activity after subcutaneously transplanted tumor in ADJ-PC6 plasmacytoma cells,F,,Mus musculus,,80671
7182,7257,1,,980.0,,Intermediate,,ADJ/PC6,,10090.0,"Compound was tested for dose producing 90% reduction in tumor weight, in ADJ/PC6 mouse plasma cell tumor",F,,Mus musculus,,80671
7183,7257,1,,980.0,,Intermediate,,ADJ/PC6,,10090.0,Compound was tested for inhibition against ADJ/PC6 mouse plasma cell tumor at the dose of 320 mg/Kg,F,,Mus musculus,,80671
7184,7257,1,,980.0,,Intermediate,,ADJ/PC6,,10090.0,Compound was tested for dose required to kill 50 % of ADJ/PC6 mouse plasma cell tumor in a group,A,,Mus musculus,,80671
7185,8084,1,,980.0,,Intermediate,,ADJ/PC6,,10090.0,In vitro incorporation of the [3H]thymidine into the ADJ/PC6 Plasmacytoma cells,F,,Mus musculus,,80671
7186,14943,0,,,,Autocuration,,,,10090.0,Tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma,F,,Mus musculus,,22224
7187,14943,0,,,,Autocuration,,,,10090.0,The compound was tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma; Not determined,F,,Mus musculus,,22224
7188,14943,0,,,,Autocuration,,,,10090.0,Tested for cytotoxicity against ADJ/PC6 plasmacytoma,F,,Mus musculus,,22224
7189,10524,0,,,,Autocuration,,,,1423.0,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),A,In vivo,Bacillus subtilis,,22224
7190,3546,1,,,,Intermediate,1969.0,,Plasma,9615.0,AUC value in dog after IV administration at a dose of 5 mg/kg,A,,Canis lupus familiaris,,50588
7191,3546,1,,,,Intermediate,1969.0,,Plasma,9615.0,AUC value in dog after oral administration at a dose of 5 mg/kg,A,,Canis lupus familiaris,,50588
7192,3546,1,,,,Intermediate,,,,9615.0,Cmax value in dog after oral administration at a dose of 5 mg/kg,A,In vivo,Canis lupus familiaris,,50588
7193,3546,1,,,,Intermediate,,,,9615.0,Bioavailability in dog after oral administration at a dose of 5 mg/kg,A,In vivo,Canis lupus familiaris,,50588
7194,3546,1,,,,Intermediate,,,,9615.0,Tmax value in dog after oral administration at a dose of 5 mg/kg,A,In vivo,Canis lupus familiaris,,50588
7195,3184,1,,,,Intermediate,,,,9615.0,Compound was evaluated for its clearance when administered intravenously in dog,A,In vivo,Canis lupus familiaris,,50588
7196,16456,1,,,,Intermediate,,,,9615.0,Plasma clearance in Beagle dogs after intravenous administration at a dose of 10 mg/kg,A,In vivo,Canis lupus familiaris,,50588
7197,4809,1,,,,Intermediate,,,,9615.0,Plasma clearance was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),A,In vivo,Canis lupus familiaris,,50588
7198,4219,0,,,,Intermediate,,,,,Calculated partition coefficient (clogP),P,,,,22229
7199,3748,1,,,,Intermediate,,,,9615.0,Half life in dog,A,,Canis lupus familiaris,,50588
7200,3132,1,,,,Intermediate,,,,9615.0,Time taken for EC90 was determined when tested in dog,A,,Canis lupus familiaris,,50588
7201,4219,1,,,,Intermediate,,,,9615.0,Half life (iv) was determined,A,,Canis lupus familiaris,,50588
7202,16907,1,,,,Intermediate,2107.0,,Liver,9615.0,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,A,,Canis lupus familiaris,,50588
7203,6057,1,,,,Intermediate,,,,9615.0,Area under the curve was calculated in dog after iv administration,A,,Canis lupus familiaris,,50588
7204,6057,1,,,,Intermediate,,,,9615.0,Area under the curve was calculated in dog after peroral administration,A,,Canis lupus familiaris,,50588
7205,17853,1,,,,Intermediate,,,,9615.0,Dose-normalized area under curve in dog (p.o.) at 2.0 mpk,A,,Canis lupus familiaris,,50588
7206,3639,1,,,,Intermediate,,,,9615.0,pKa was evaluated in dog,A,,Canis lupus familiaris,,50588
7207,14541,1,,,,Intermediate,,,,9615.0,Compound was evaluated for pronounced GH response at 100 mg (n=6)(area under concentration curve was determined from 0-8 hr following morning and evening dosing with 25 mg of the compound,A,,Canis lupus familiaris,,50588
7208,16456,1,,,,Intermediate,,,,9615.0,Alpha-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,A,In vivo,Canis lupus familiaris,,50588
7209,16456,1,,,,Intermediate,,,,9615.0,Beta-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,A,In vivo,Canis lupus familiaris,,50588
7210,2652,1,,,,Intermediate,,,,9615.0,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,A,In vivo,Canis lupus familiaris,,50588
7211,3624,1,,,,Intermediate,,,,9615.0,Compound was evaluated for the half-life (t 1/2) in hours,A,,Canis lupus familiaris,,50588
7212,1337,1,,,,Intermediate,178.0,,Blood,9615.0,Half life to reach the blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,A,In vivo,Canis lupus familiaris,,50588
7213,1337,1,,,,Intermediate,178.0,,Blood,9615.0,Half life to reach the blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,A,In vivo,Canis lupus familiaris,,50588
7214,4709,1,,,,Intermediate,,,,9615.0,Half life after intravenous administration of 1 mg/kg in dog,A,In vivo,Canis lupus familiaris,,50588
7215,15660,1,,,,Intermediate,,,,9615.0,Half life was measured in dog,A,,Canis lupus familiaris,,50588
7216,5302,1,,,,Intermediate,,,,9615.0,Half life period in dog after 5 mg/kg dose,A,In vivo,Canis lupus familiaris,,50588
7217,17791,1,,,,Intermediate,,,,9615.0,Half life period was evaluated in dog; 4-4.8,A,,Canis lupus familiaris,,50588
7218,6348,1,,,,Intermediate,,,,9615.0,Half life was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,A,In vivo,Canis lupus familiaris,,50588
7219,4257,1,,,,Intermediate,,,,9615.0,Half-life was determined in dog after a3 mg/kg of iv dose,A,In vivo,Canis lupus familiaris,,50588
7220,3771,1,,,,Intermediate,,,,9615.0,Half-life was determined,A,,Canis lupus familiaris,,50588
7221,6305,1,,,,Intermediate,,,,9615.0,Half life in dogs,A,,Canis lupus familiaris,,50588
7222,13501,1,,,,Intermediate,1969.0,,Plasma,9615.0,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 2 mg/kg tp dog,A,In vivo,Canis lupus familiaris,,50588
7223,17594,1,,,,Intermediate,,,,9615.0,Apparent half-life after single intravenous bolus of 1 mg/kg in dogs,A,In vivo,Canis lupus familiaris,,50588
7224,3045,1,,,,Intermediate,,,,9615.0,Compound was evaluated for the half life period after iv administration in Beagle dog.,A,In vivo,Canis lupus familiaris,,50588
7225,3043,1,,,,Intermediate,,,,9615.0,Compound was evaluated for the half life period after oral administration in conscious dog.,A,In vivo,Canis lupus familiaris,,50588
7226,4839,1,,,,Intermediate,,,,9615.0,Compound was tested for half life in dog,A,,Canis lupus familiaris,,50588
7227,4839,1,,,,Intermediate,,,,9615.0,Compound was tested for its half life in dog,A,,Canis lupus familiaris,,50588
7228,5802,1,,,,Intermediate,,,,9615.0,Half life of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,A,In vivo,Canis lupus familiaris,,50588
7229,17839,1,,,,Intermediate,,,,9615.0,Half life of compound in dog was determined,A,,Canis lupus familiaris,,50588
7230,4219,1,,,,Intermediate,,,,9615.0,Half life (iv) was determined,A,In vivo,Canis lupus familiaris,,50588
7231,13966,1,,,,Intermediate,178.0,,Blood,9615.0,Half life following administration of 70 nM in canine whole blood (dose exceeding platelet binding capacity),A,,Canis lupus familiaris,,50588
7232,3994,1,,,,Intermediate,1969.0,,Plasma,9615.0,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,A,In vivo,Canis lupus familiaris,,50588
7233,3994,1,,,,Intermediate,1969.0,,Plasma,9615.0,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,F,In vivo,Canis lupus familiaris,,50588
7234,4453,1,,,,Intermediate,,,,9615.0,Half life in dog,A,,Canis lupus familiaris,,50588
7235,6535,1,,,,Intermediate,1969.0,,Plasma,9615.0,Half life in dog plasma,A,,Canis lupus familiaris,,50588
7236,6535,1,,,,Intermediate,1969.0,,Plasma,9615.0,Half life in dog plasma after administration of 0.25 mg/kg iv,A,In vivo,Canis lupus familiaris,,50588
7237,6535,1,,,,Intermediate,1969.0,,Plasma,9615.0,Half life in dog plasma after administration of 1 mg/kg iv,A,In vivo,Canis lupus familiaris,,50588
7238,3132,1,,,,Intermediate,1969.0,,Plasma,9615.0,Half life in dog plasma was determined at dose 10 mg/kg,A,In vivo,Canis lupus familiaris,,50588
7239,5374,1,,,,Intermediate,,,,9615.0,Half life in dog was determined,A,,Canis lupus familiaris,,50588
7240,5007,1,,,,Intermediate,,,,9615.0,Half life in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),A,In vivo,Canis lupus familiaris,,50588
7241,16907,1,,,,Intermediate,1969.0,,Plasma,9615.0,Half life upon exposure to human plasma,A,,Canis lupus familiaris,,50588
7242,6057,1,,,,Intermediate,,,,9615.0,Half life was calculated in dog,A,,Canis lupus familiaris,,50588
7243,5006,1,,,,Intermediate,,,,9615.0,Half life was determined,A,,Canis lupus familiaris,,50588
7244,5473,1,,,,Intermediate,,,,9615.0,Half life was determined,A,,Canis lupus familiaris,,50588
7245,4368,1,,,,Intermediate,,,,9615.0,Half life by intravenous administration of 1.2 mg/kg in dog,A,In vivo,Canis lupus familiaris,,50588
7246,6448,1,,,,Intermediate,,,,9615.0,Half life in dog,A,,Canis lupus familiaris,,50588
7247,4353,1,,,,Intermediate,,,,9615.0,Half life in dog after intra venous administration of the compound,A,,Canis lupus familiaris,,50588
7248,4353,1,,,,Intermediate,,,,9615.0,Half life in dog after intra venous administration of the compound; ND means Not determined,A,,Canis lupus familiaris,,50588
7249,4353,1,,,,Intermediate,,,,9615.0,Half life in dog after po administration of the compound,A,In vivo,Canis lupus familiaris,,50588
7250,4353,1,,,,Intermediate,,,,9615.0,Half life in dog after po administration of the compound; ND means Not determined,A,In vivo,Canis lupus familiaris,,50588
7251,6265,1,,,,Intermediate,,,,9615.0,Half life in dog at the single oral dose of 1 mg/kg,A,In vivo,Canis lupus familiaris,,50588
7252,5006,1,,,,Intermediate,,,,9615.0,Half life in dogs,A,,Canis lupus familiaris,,50588
7253,5356,1,,,,Intermediate,,,,9615.0,Half life in dogs at 1 mg/kg oral dosing; 35-100 min,A,In vivo,Canis lupus familiaris,,50588
7254,405,1,,,,Intermediate,,,,9615.0,Half life in rat,A,,Canis lupus familiaris,,50588
7255,6642,1,,,,Intermediate,,,,9615.0,Half life in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),A,In vivo,Canis lupus familiaris,,50588
7256,10107,1,,,,Intermediate,10000001.0,,Bone,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,Mus musculus,,50594
7257,10107,1,,,,Intermediate,10000001.0,,Bone,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,Mus musculus,,50594
7258,10107,1,,,,Intermediate,10000001.0,,Bone,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,Mus musculus,,50594
7259,10107,1,,,,Intermediate,10000001.0,,Bone,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,Mus musculus,,50594
7260,10107,1,,,,Intermediate,10000001.0,,Bone,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,Mus musculus,,50594
7261,10107,1,,,,Intermediate,10000004.0,,Gut,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,Mus musculus,,50594
7262,10107,1,,,,Intermediate,10000004.0,,Gut,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,In vivo,Mus musculus,,50594
7263,10107,1,,,,Intermediate,10000004.0,,Gut,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,Mus musculus,,50594
7264,10107,1,,,,Intermediate,10000004.0,,Gut,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,Mus musculus,,50594
7265,10107,1,,,,Intermediate,10000004.0,,Gut,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,Mus musculus,,50594
7266,10107,1,,,,Intermediate,10000004.0,,Gut,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,Mus musculus,,50594
7267,10107,1,,,,Intermediate,10000004.0,,Gut,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,Mus musculus,,50594
7268,10107,1,,,,Intermediate,948.0,,Heart,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,Mus musculus,,50594
7269,10107,1,,,,Intermediate,948.0,,Heart,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,In vivo,Mus musculus,,50594
7270,10107,1,,,,Intermediate,948.0,,Heart,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,Mus musculus,,50594
7271,10107,1,,,,Intermediate,948.0,,Heart,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,Mus musculus,,50594
7272,10107,1,,,,Intermediate,948.0,,Heart,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,Mus musculus,,50594
7273,10107,1,,,,Intermediate,948.0,,Heart,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,Mus musculus,,50594
7274,10107,1,,,,Intermediate,948.0,,Heart,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,Mus musculus,,50594
7275,10107,1,,,,Intermediate,2113.0,,Kidney,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,Mus musculus,,50594
7276,10107,1,,,,Intermediate,2113.0,,Kidney,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,A,In vivo,Mus musculus,,50594
7277,10107,1,,,,Intermediate,2113.0,,Kidney,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,Mus musculus,,50594
7278,10107,1,,,,Intermediate,2113.0,,Kidney,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,Mus musculus,,50594
7279,10107,1,,,,Intermediate,2113.0,,Kidney,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,Mus musculus,,50594
7280,10107,1,,,,Intermediate,2113.0,,Kidney,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,Mus musculus,,50594
7281,10107,1,,,,Intermediate,2113.0,,Kidney,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,Mus musculus,,50594
7282,10107,1,,,,Intermediate,2107.0,,Liver,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,Mus musculus,,50594
7283,10107,1,,,,Intermediate,2107.0,,Liver,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,In vivo,Mus musculus,,50594
7284,10107,1,,,,Intermediate,2107.0,,Liver,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,Mus musculus,,50594
7285,10107,1,,,,Intermediate,2107.0,,Liver,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,Mus musculus,,50594
7286,10107,1,,,,Intermediate,2107.0,,Liver,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,Mus musculus,,50594
7287,10107,1,,,,Intermediate,2107.0,,Liver,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,Mus musculus,,50594
7288,10107,1,,,,Intermediate,2107.0,,Liver,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,Mus musculus,,50594
7289,10107,1,,,,Intermediate,2048.0,,Lung,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,Mus musculus,,50594
7290,5895,1,,478.0,,Intermediate,,A2780,,9606.0,In vitro cytotoxicity against A2780 (human ovarian cancer),F,,Homo sapiens,,81034
7291,6338,1,,478.0,,Intermediate,,A2780,,9606.0,In vitro cytotoxicity against the paclitaxel sensitive human breast carcinoma cell line A2780,F,,Homo sapiens,,81034
7292,15163,1,,478.0,,Intermediate,,A2780,,9606.0,In vitro cytotoxicity against. ovarian carcinoma cell line A2780.,F,,Homo sapiens,,81034
7293,15163,1,,478.0,,Intermediate,,A2780,,9606.0,In vitro cytotoxicity against. ovarian carcinoma cell line A2780cisR (cisplatin resistant counter part of A2780).,F,,Homo sapiens,,81034
7294,15000,1,,478.0,,Expert,,A2780,,9606.0,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cell line,F,,Homo sapiens,,81034
7295,15000,1,,478.0,,Expert,,A2780,,9606.0,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cisplatin resistant cell line,F,,Homo sapiens,,81034
7296,14729,1,,478.0,,Expert,,A2780,,9606.0,In vitro cytotoxicity against A2780 ovarian cells using the sulforhodamine B(SRB) assay.,F,,Homo sapiens,,81034
7297,17270,1,,478.0,,Intermediate,,A2780,,9606.0,In vitro cytotoxicity against A2780 cell line,F,,Homo sapiens,,81034
7298,5685,1,,478.0,,Intermediate,,A2780,,9606.0,In vitro growth inhibitory activity against A2780 human ovarium carcinoma cell line was determined,F,,Homo sapiens,,81034
7299,3563,1,,478.0,,Intermediate,,A2780,,9606.0,In vitro inhibitory activity against human ovarian cancer A2780 cell line,F,,Homo sapiens,,81034
7300,17753,1,,478.0,,Intermediate,,A2780,,9606.0,In vivo cytotoxic concentration of compound against A2780 cell line after 72 hr exposure,F,,Homo sapiens,,81034
7301,16317,1,,478.0,,Intermediate,,A2780,,9606.0,"Inhibition of cell growth in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant)using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay",F,,Homo sapiens,,81034
7302,16936,1,,478.0,,Intermediate,,A2780,,9606.0,Inhibition of tubulin polymerization in analogy of ca.,F,,Homo sapiens,,81034
7303,3801,1,,478.0,,Intermediate,,A2780,,9606.0,Inhibitory activity against ovarian tumor cell line A2780 after 72 hr continuous exposure to compound,F,,Homo sapiens,,81034
7304,6181,1,,478.0,,Expert,,A2780,,9606.0,Cytotoxic effect in ovarian cancer cell line (A2780),F,,Homo sapiens,,81034
7305,5318,1,,478.0,,Intermediate,,A2780,,9606.0,Tested for cytotoxicity against Ovarian carcinoma parental type A2780 cell line expressing MDR-1 (-) gene,F,,Homo sapiens,,81034
7306,4840,1,,478.0,,Intermediate,,A2780,,9606.0,Tested for the cytotoxicity in A2780 ovarian cell line,F,,Homo sapiens,,81034
7307,15748,1,,478.0,,Intermediate,,A2780,,9606.0,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),F,,Homo sapiens,,81034
7308,15748,1,,478.0,,Intermediate,,A2780,,9606.0,The compound was tested for cytotoxic activity against A2780/Cs cell line(human ovarian carcinoma,F,,Homo sapiens,,81034
7309,15748,1,,481.0,,Intermediate,,A2780cisR,,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma,F,,,,80017
7310,15748,1,,481.0,,Intermediate,,A2780cisR,,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),F,,,,80017
7311,15748,1,,481.0,,Intermediate,,A2780cisR,,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ); ND means no data,F,,,,80017
7312,15748,1,,481.0,,Intermediate,,A2780cisR,,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma),F,,,,80017
7313,17753,1,,478.0,,Intermediate,,A2780,,9606.0,In vivo log of cells killed after administration of compound in A2780 cell line,F,,Homo sapiens,,81034
7314,17753,1,,478.0,,Intermediate,,A2780,,9606.0,Compound was tested in vivo for maximum tolerated dose after i.v. administration twice a day for 5 days in A2780 cell line,F,In vivo,Homo sapiens,,81034
7315,16936,1,,478.0,,Intermediate,,A2780,,9606.0,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.;NA means not active,F,,Homo sapiens,,81034
7316,16936,1,,478.0,,Intermediate,,A2780,,9606.0,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines (at 5 uM );NA means not active,F,,Homo sapiens,,81034
7317,16936,1,,478.0,,Intermediate,,A2780,,9606.0,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines; ND means no data,F,,Homo sapiens,,81034
7318,16936,1,,478.0,,Intermediate,,A2780,,9606.0,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines. (at 5 uM ); ND means no data,F,,Homo sapiens,,81034
7319,17528,1,,478.0,,Intermediate,,A2780,,9606.0,Optimal dose required to inhibit human ovarian A2780 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q4dX2),F,,Homo sapiens,,81034
7320,6633,1,,478.0,,Intermediate,,A2780,,9606.0,Resistance factor was determined as IC50 cisplatin-resistant/parent for human A2780 ovarian cell line,F,,Homo sapiens,,81034
7321,15000,1,,478.0,,Expert,,A2780,,9606.0,Resistance index is IC50 ratio of A2780 cell line and A2780cisR cell line,F,,Homo sapiens,,81034
7322,17528,1,,478.0,,Expert,,A2780,,9606.0,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,F,,Homo sapiens,,81034
7323,16936,1,,478.0,,Intermediate,,A2780,,9606.0,Compound was tested for Tubulin polymerization inhibition by using human ovarian cancer cell lines.,F,,Homo sapiens,,81034
7324,16936,1,,478.0,,Intermediate,,A2780,,9606.0,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.,F,,Homo sapiens,,81034
7325,16936,1,,478.0,,Intermediate,,A2780,,9606.0,Percent of Tubulin polymerization inhibition by using human ovarian cancer cell lines at a concentration of 5 uM,F,,Homo sapiens,,81034
7326,16936,1,,478.0,,Intermediate,,A2780,,9606.0,"Colchicine Binding Inhibition ( CBI ) by using human ovarian cancer cell lines at 5 uM, (values are mean of 9 over 4 concentrations +/- SD)",F,,Homo sapiens,,81034
7327,16936,1,,478.0,,Intermediate,,A2780,,9606.0,Compound tested for colchicine Binding Inhibition by using human ovarian cancer cell line (at 5 uM ),F,,Homo sapiens,,81034
7328,16936,1,,478.0,,Expert,,A2780,,9606.0,"Tested for colchicine binding inhibition, using human ovarian cancer cell lines (at 5 uM )",F,,Homo sapiens,,81034
7329,16936,1,,478.0,,Intermediate,,A2780,,9606.0,Compound tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),F,,Homo sapiens,,81034
7330,16936,1,,478.0,,Intermediate,,A2780,,9606.0,Compound was tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),F,,Homo sapiens,,81034
7331,16936,1,,478.0,,Intermediate,,A2780,,9606.0,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell line (at 5 uM ),F,,Homo sapiens,,81034
7332,17737,1,,478.0,,Intermediate,,A2780,,10090.0,In vitro antiproliferative activity against A2780 cell line,F,,Mus musculus,,81034
7333,17764,1,,478.0,,Expert,,A2780,,10090.0,Maximum tolerated dose in A2780 tumor in mice after intraperitoneal administration daily for 8 days,F,,Mus musculus,,81034
7334,3830,1,,478.0,,Intermediate,,A2780,,9606.0,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C after 96 hr,F,,Homo sapiens,,81034
7335,3829,1,,478.0,,Intermediate,,A2780,,9606.0,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C for 96 hr,F,,Homo sapiens,,81034
7336,3546,1,,,,Intermediate,,,,9615.0,Vc value in dog after IV administration at a dose of 5 mg/kg,A,,Canis lupus familiaris,,50588
7337,3546,1,,,,Intermediate,,,,9615.0,Half life period in dog after IV administration at a dose of 5 mg/kg,A,In vivo,Canis lupus familiaris,,50588
7338,5668,0,,,,Autocuration,,,,9527.0,Area under curve was determine after peroral administration at 10 mpk in Rhesus,A,,Cercopithecidae,,22224
7339,3443,0,,,,Autocuration,1969.0,,Plasma,9527.0,AUC (area under curve) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,,Cercopithecidae,,22224
7340,3443,0,,,,Autocuration,1969.0,,Plasma,9527.0,AUC (area under curve) compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,,Cercopithecidae,,22224
7341,4256,0,,,,Autocuration,,,,9541.0,Area under curve determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey,A,In vivo,Macaca fascicularis,,22224
7342,4256,0,,,,Autocuration,,,,9541.0,Area under curve determined after peroral administration at a dose of 10 mg/kg in cynomolgus monkey,A,In vivo,Macaca fascicularis,,22224
7343,4256,0,,,,Autocuration,,,,9541.0,Area under curve determined after peroral administration at a dose of 3 mg/kg in cynomolgus monkey,A,In vivo,Macaca fascicularis,,22224
7344,4256,0,,,,Autocuration,,,,10116.0,Oral Bioavailability in rat,A,In vivo,Rattus norvegicus,,22224
7345,1916,0,,,,Autocuration,,,,9527.0,Area under curve was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,A,,Cercopithecidae,,22224
7346,5302,0,,,,Autocuration,,,,9527.0,Area under curve value in monkey at a dose of 5 mg/kg,A,,Cercopithecidae,,22224
7347,4257,0,,,,Autocuration,,,,9527.0,Area under curve was determined in monkey after a 3 mg/kg of oral dose,A,,Cercopithecidae,,22224
7348,5355,0,,,,Autocuration,,,,9527.0,Area under curve was determined using trapezoidal rule after intravenous administration in cynomolgus monkeys,A,,Cercopithecidae,,22224
7349,5355,0,,,,Autocuration,,,,9527.0,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys,A,,Cercopithecidae,,22224
7350,5355,0,,,,Autocuration,,,,9527.0,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys; ND means Not determined,A,,Cercopithecidae,,22224
7351,6078,0,,,,Autocuration,,,,9527.0,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in monkey,A,,Cercopithecidae,,22224
7352,6078,0,,,,Autocuration,,,,9527.0,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in monkey,A,,Cercopithecidae,,22224
7353,6062,0,,,,Autocuration,,,,9527.0,Area under the curve was measured in monkey after an iv dose of 1 mg/kg,A,,Cercopithecidae,,22224
7354,2661,0,,,,Autocuration,,,,9527.0,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female cynomolgus monkey,A,,Cercopithecidae,,22224
7355,2661,0,,,,Autocuration,,,,9527.0,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female cynomolgus monkey,A,,Cercopithecidae,,22224
7356,5394,0,,,,Autocuration,,,,9527.0,Pharmacokinetic parameter Cmax was measured after administration into monkey at 3 mg/kg,A,,Cercopithecidae,,22224
7357,4397,0,,,,Autocuration,,,,9527.0,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in cynomolgus monkeys (0 to 24 hr) p.o.,A,,Cercopithecidae,,22224
7358,17509,0,,,,Autocuration,,,,9527.0,Area under curve value 24 hr after 2 mg/kg iv administration in monkeys,A,,Cercopithecidae,,22224
7359,17509,0,,,,Autocuration,,,,9527.0,Area under curve value 24 hr after 2 mg/kg oral administration in monkeys,A,,Cercopithecidae,,22224
7360,6641,0,,,,Autocuration,,,,9527.0,Oral AUCN in monkey (dosed at 0.5 mpk iv ),A,In vivo,Cercopithecidae,,22224
7361,5355,0,,,,Autocuration,,,,9527.0,Bioavailability was reported in cynomolgus monkeys (ratio of AUC in oral administration to that of intravenous administration),A,,Cercopithecidae,,22224
7362,3443,0,,,,Autocuration,,,,9527.0,Half life compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,In vivo,Cercopithecidae,,22224
7363,3443,0,,,,Autocuration,,,,9527.0,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,In vivo,Cercopithecidae,,22224
7364,17409,0,,,,Autocuration,,,,9527.0,Binding towards monkey plasma protein at 10 uM,A,,Cercopithecidae,,22224
7365,17409,0,,,,Autocuration,,,,9527.0,Binding towards monkey plasma protein at 100 uM,A,,Cercopithecidae,,22224
7366,1052,0,,,,Autocuration,,,,9527.0,Apparent bioavailability in squirrel monkey was determined,A,In vivo,Cercopithecidae,,22224
7367,13501,0,,,,Autocuration,,,,9527.0,Bioavailability was determined after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,A,In vivo,Cercopithecidae,,22224
7368,17509,0,,,,Autocuration,,,,9443.0,Bioavailability in monkey (dose 2 mg/kg),A,In vivo,monkey,,22224
7369,5394,0,,,,Autocuration,,,,9527.0,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for bioavailability after administration into monkey at 3 mg/kg,A,In vivo,Cercopithecidae,,22224
7370,2661,0,,,,Autocuration,,,,9527.0,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female cynomolgus monkey,A,In vivo,Cercopithecidae,,22224
7371,11219,0,,,,Autocuration,,,,9443.0,Bioavailability in monkey (i.d. dosing),A,In vivo,monkey,,22224
7372,3045,0,,,,Autocuration,,,,9527.0,Oral bioavailability after 5 mg/kg in cynomolgus monkey was determined,A,In vivo,Cercopithecidae,,22224
7373,17796,0,,,,Autocuration,,,,9527.0,Clearance of the drug was measured in cynomolgus,A,,Cercopithecidae,,22224
7374,1399,0,,,,Autocuration,,,,9527.0,Clearance was estimated in two squirrel monkeys after iv administration at 5 mg/kg,A,In vivo,Cercopithecidae,,22224
7375,2661,0,,,,Autocuration,,,,9527.0,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female cynomolgus monkey,A,In vivo,Cercopithecidae,,22224
7376,5005,0,,,,Autocuration,1969.0,,Plasma,9544.0,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,A,In vivo,Macaca mulatta,,22224
7377,17267,0,,,,Autocuration,,,,9527.0,Plasma clearance in rhesus monkey was determined,A,In vivo,Cercopithecidae,,22224
7378,6535,0,,,,Autocuration,,,,9527.0,Plasma clearance in monkey after administration of 1 mg/kg iv,A,In vivo,Cercopithecidae,,22224
7379,5922,0,,,,Autocuration,,,,9527.0,Plasma clearance in cynomolgus monkey,A,In vivo,Cercopithecidae,,22224
7380,6221,0,,,,Autocuration,,,,9527.0,Plasma clearance after oral administration (2.5 mg/kg) in monkey was determined,A,In vivo,Cercopithecidae,,22224
7381,5668,0,,,,Autocuration,,,,9527.0,Plasma clearance after peroral administration at 10 mpk in Rhesus,A,In vivo,Cercopithecidae,,22224
7382,5355,0,,,,Autocuration,,,,9527.0,The total clearance was determined after intravenous administration in cynomolgus monkeys,A,In vivo,Cercopithecidae,,22224
7383,5355,0,,,,Autocuration,,,,9527.0,The total clearance was determined after oral administration in cynomolgus monkeys; NA means Not applicable,A,In vivo,Cercopithecidae,,22224
7384,5355,0,,,,Autocuration,,,,9527.0,The total clearance was determined after oral administration in cynomolgus monkeys; NA means not applicable,A,In vivo,Cercopithecidae,,22224
7385,4578,0,,,,Autocuration,,,,9527.0,Tested for Clearance upon iv administration to african green monkey,A,In vivo,Cercopithecidae,,22224
7386,17592,0,,,,Autocuration,,,,9527.0,Clearance in monkey,A,In vivo,Cercopithecidae,,22224
7387,6641,1,,,,Intermediate,,,,9615.0,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),A,In vivo,Canis lupus familiaris,,50588
7388,6642,1,,,,Intermediate,,,,9615.0,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),A,In vivo,Canis lupus familiaris,,50588
7389,16367,1,,,,Intermediate,,,,9615.0,Half life was evaluated after intravenous administration to dogs,A,In vivo,Canis lupus familiaris,,50588
7390,5472,1,,,,Intermediate,,,,9615.0,Half life was evaluated in dog,A,,Canis lupus familiaris,,50588
7391,5474,1,,,,Intermediate,,,,9615.0,Half life was evaluated in dog,A,,Canis lupus familiaris,,50588
7392,5654,1,,,,Intermediate,,,,9615.0,Half life period (t1/2) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,A,In vivo,Canis lupus familiaris,,50588
7393,6227,1,,,,Intermediate,,,,9615.0,Half life period after intravenous administration (1 mg/kg) was determined in dog (in vivo),A,In vivo,Canis lupus familiaris,,50588
7394,6227,1,,,,Intermediate,,,,9615.0,Half life period after intravenous administration in dog,A,In vivo,Canis lupus familiaris,,50588
7395,6221,1,,,,Intermediate,,,,9615.0,Half life period after oral administration (2.5 mg/kg) in dog was determined,A,In vivo,Canis lupus familiaris,,50588
7396,4527,1,,,,Intermediate,,,,9615.0,Half life period at a dose of 1 uM/kg in dog was determined,A,,Canis lupus familiaris,,50588
7397,5668,1,,,,Intermediate,,,,9615.0,Half life period was determine after peroral administration at 10 mpk in dog,A,In vivo,Canis lupus familiaris,,50588
7398,5668,1,,,,Intermediate,,,,9615.0,Half life period was determine after peroral administration at 5 mpk in dog,A,In vivo,Canis lupus familiaris,,50588
7399,3854,1,,,,Intermediate,,,,9615.0,Half life period was determined,A,,Canis lupus familiaris,,50588
7400,5505,1,,,,Intermediate,,,,9615.0,Half life period was determined,A,,Canis lupus familiaris,,50588
7401,6251,1,,,,Intermediate,,,,9615.0,Half life period by iv administration in dog at a dose of 6 mg/kg,A,In vivo,Canis lupus familiaris,,50588
7402,1918,1,,,,Intermediate,,,,9615.0,Half life period was evaluated in dog,A,,Canis lupus familiaris,,50588
7403,5546,1,,,,Intermediate,,,,9615.0,Half life period was determined in Beagle dog at a dose of 1 mg/kg by iv administration,A,In vivo,Canis lupus familiaris,,50588
7404,4809,1,,,,Intermediate,,,,9615.0,Half life period was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),A,In vivo,Canis lupus familiaris,,50588
7405,6215,1,,,,Intermediate,,,,9615.0,Half life time after intravenous administration (0.5 mg/kg) was determined in dog,A,In vivo,Canis lupus familiaris,,50588
7406,4527,1,,,,Intermediate,,,,9615.0,Half-life period by oral administration at a dose of 10 uM/kg in dog was determined,A,In vivo,Canis lupus familiaris,,50588
7407,17594,1,,,,Intermediate,,,,9615.0,Half-life after oral dose of compound at 3 mg/kg in dogs,A,In vivo,Canis lupus familiaris,,50588
7408,17839,1,,,,Intermediate,,,,9615.0,Half-life of compound in dog following p.o. administration of 0.5 mg/kg,A,In vivo,Canis lupus familiaris,,50588
7409,17839,1,,,,Intermediate,,,,9615.0,Half-life of compound in dog following p.o. administration of 0.9 mg/kg,A,In vivo,Canis lupus familiaris,,50588
7410,17839,1,,,,Intermediate,,,,9615.0,Half-life of compound in dog following p.o. administration of 0.95 mg/kg,A,In vivo,Canis lupus familiaris,,50588
7411,17839,1,,,,Intermediate,,,,9615.0,Half-life of compound in dog following p.o. administration of 1 mg/kg,A,In vivo,Canis lupus familiaris,,50588
7412,5210,1,,,,Intermediate,1969.0,,Plasma,9615.0,Half-life of compound in plasma of dog was determined,A,,Canis lupus familiaris,,50588
7413,5210,1,,,,Intermediate,,,,9615.0,Half-life of compound was determined in dogs,A,,Canis lupus familiaris,,50588
7414,2959,1,,,,Intermediate,,,,9615.0,Half-life after administration of 4 mg/Kg oral dose in dog,A,In vivo,Canis lupus familiaris,,50588
7415,4137,1,,,,Intermediate,,,,9615.0,Half-life after intravenous administration of 1 mg/kg/h in dog,A,In vivo,Canis lupus familiaris,,50588
7416,5064,1,,,,Intermediate,,,,9615.0,Half-life in Dog,A,,Canis lupus familiaris,,50588
7417,5147,1,,,,Intermediate,,,,9615.0,Half-life in Dog,A,,Canis lupus familiaris,,50588
7418,5145,1,,,,Intermediate,,,,9615.0,Half-life in dog,A,,Canis lupus familiaris,,50588
7419,6123,1,,,,Intermediate,,,,9615.0,Half-life in dog after oral administration at 1 mg/kg,A,In vivo,Canis lupus familiaris,,50588
7420,6123,1,,,,Intermediate,,,,9615.0,Half-life in dog after oral administration at 1 mg/kg; nd is not determined,A,In vivo,Canis lupus familiaris,,50588
7421,4333,1,,,,Intermediate,,,,9615.0,Half-life in dogs,A,,Canis lupus familiaris,,50588
7422,4333,1,,,,Intermediate,,,,9615.0,Half-life in dogs; ND indicates not determined,A,,Canis lupus familiaris,,50588
7423,12500,1,,,,Intermediate,1969.0,,Plasma,9615.0,Half-life in plasma of dog,A,,Canis lupus familiaris,,50588
7424,12500,1,,,,Intermediate,1969.0,,Plasma,9615.0,Half-life in plasma of dog at dose of 3-10 mgkg,A,,Canis lupus familiaris,,50588
7425,6005,1,,,,Intermediate,,,,9615.0,Half-life was evaluated after i.v. administration in dog at a dose of 1 mg/kg,A,In vivo,Canis lupus familiaris,,50588
7426,6062,1,,,,Intermediate,,,,9615.0,Half-life was measured in dog after an iv dose of 1 mg/kg,A,In vivo,Canis lupus familiaris,,50588
7427,17650,1,,,,Intermediate,,,,9615.0,Half-life was measured in dogs after an oral dose of 10 uM/kg,A,In vivo,Canis lupus familiaris,,50588
7428,5530,1,,,,Intermediate,,,,9615.0,Half-life in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,A,In vivo,Canis lupus familiaris,,50588
7429,5530,1,,,,Intermediate,,,,9615.0,Half-life in vivo in dog by intravenous administration at a dose of 1 mg/kg,A,In vivo,Canis lupus familiaris,,50588
7430,5600,1,,,,Intermediate,,,,9615.0,Half-life of the compound after 0.3 mg/kg po administration in dog,A,In vivo,Canis lupus familiaris,,50588
7431,6039,1,,,,Intermediate,,,,9615.0,Half-life period after intravenous administration of 0.5 mg/kg in dog was determined,A,In vivo,Canis lupus familiaris,,50588
7432,6039,1,,,,Intermediate,,,,9615.0,Half-life period after intravenous administration of 1.0 mg/kg in dog was determined,A,In vivo,Canis lupus familiaris,,50588
7433,6039,1,,,,Intermediate,,,,9615.0,Half-life period after peroral administration of 0.2 mg/kg in dog was determined,A,In vivo,Canis lupus familiaris,,50588
7434,6227,1,,,,Intermediate,,,,9615.0,t1/2 in dog,A,,Canis lupus familiaris,,50588
7435,14541,1,,,,Intermediate,,,,9615.0,Half-life period measured in dogs,A,,Canis lupus familiaris,,50588
7436,4521,1,,,,Intermediate,,,,9615.0,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,A,In vivo,Canis lupus familiaris,,50588
7437,4521,1,,,,Intermediate,,,,9615.0,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,A,In vivo,Canis lupus familiaris,,50588
7438,6679,1,,,,Intermediate,,,,9615.0,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,A,In vivo,Canis lupus familiaris,,50588
7439,1116,1,,,,Intermediate,1969.0,,Plasma,9615.0,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in dog plasma",A,In vitro,Canis lupus familiaris,,50588
7440,5444,1,,,,Intermediate,,,,9615.0,In vivo half life period was calculated at 1 mg/kg in dog,A,In vivo,Canis lupus familiaris,,50588
7441,5444,1,,,,Intermediate,,,,9615.0,In vivo half life period was calculated at 1 mg/kg in dog; ND=Not determined,A,In vivo,Canis lupus familiaris,,50588
7442,17853,1,,,,Intermediate,,,,9615.0,Longer half-life in dog (i.v.) at 0.5 mpk,A,In vivo,Canis lupus familiaris,,50588
7443,4353,1,,,,Intermediate,,,,9615.0,Oral bioavailability in dog (dose 5 uM/kg),A,In vivo,Canis lupus familiaris,,50588
7444,16452,1,,,,Intermediate,,,,9615.0,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,A,In vivo,Canis lupus familiaris,,50588
7445,16452,1,,,,Intermediate,,,,9615.0,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,A,In vivo,Canis lupus familiaris,,50588
7446,16452,1,,,,Intermediate,,,,9615.0,Bioavailability in dog (dose 1 mg/kg i.v.),A,In vivo,Canis lupus familiaris,,50588
7447,10107,1,,,,Intermediate,2048.0,,Lung,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,A,In vivo,Mus musculus,,50594
7448,10107,1,,,,Intermediate,2048.0,,Lung,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,Mus musculus,,50594
7449,10107,1,,,,Intermediate,2048.0,,Lung,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,Mus musculus,,50594
7450,10107,1,,,,Intermediate,2048.0,,Lung,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,Mus musculus,,50594
7451,10107,1,,,,Intermediate,2048.0,,Lung,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,Mus musculus,,50594
7452,10107,1,,,,Intermediate,2048.0,,Lung,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,Mus musculus,,50594
7453,10107,1,,,,Intermediate,2385.0,,Muscle tissue,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,Mus musculus,,50594
7454,10107,1,,,,Intermediate,2385.0,,Muscle tissue,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,A,In vivo,Mus musculus,,50594
7455,10107,1,,,,Intermediate,2385.0,,Muscle tissue,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,Mus musculus,,50594
7456,10107,1,,,,Intermediate,2385.0,,Muscle tissue,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,Mus musculus,,50594
7457,10107,1,,,,Intermediate,2385.0,,Muscle tissue,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,Mus musculus,,50594
7458,10107,1,,,,Intermediate,2385.0,,Muscle tissue,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,Mus musculus,,50594
7459,10107,1,,,,Intermediate,2385.0,,Muscle tissue,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,Mus musculus,,50594
7460,10107,1,,,,Intermediate,14.0,,Zone of skin,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,Mus musculus,,50594
7461,10107,1,,,,Intermediate,14.0,,Zone of skin,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,In vivo,Mus musculus,,50594
7462,10107,1,,,,Intermediate,14.0,,Zone of skin,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,Mus musculus,,50594
7463,10107,1,,,,Intermediate,14.0,,Zone of skin,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,Mus musculus,,50594
7464,10107,1,,,,Intermediate,14.0,,Zone of skin,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,Mus musculus,,50594
7465,10107,1,,,,Intermediate,14.0,,Zone of skin,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,Mus musculus,,50594
7466,10107,1,,,,Intermediate,14.0,,Zone of skin,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,Mus musculus,,50594
7467,10107,1,,,,Intermediate,2106.0,,Spleen,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,Mus musculus,,50594
7468,10107,1,,,,Intermediate,2106.0,,Spleen,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,In vivo,Mus musculus,,50594
7469,10107,1,,,,Intermediate,2106.0,,Spleen,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,Mus musculus,,50594
7470,10107,1,,,,Intermediate,2106.0,,Spleen,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,Mus musculus,,50594
7471,10107,1,,,,Intermediate,2106.0,,Spleen,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,Mus musculus,,50594
7472,10107,1,,,,Intermediate,2106.0,,Spleen,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,Mus musculus,,50594
7473,10107,1,,,,Intermediate,2106.0,,Spleen,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,Mus musculus,,50594
7474,10107,1,,,,Intermediate,945.0,,Stomach,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,Mus musculus,,50594
7475,10107,1,,,,Intermediate,945.0,,Stomach,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,In vivo,Mus musculus,,50594
7476,10107,1,,,,Intermediate,945.0,,Stomach,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,Mus musculus,,50594
7477,10107,1,,,,Intermediate,945.0,,Stomach,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,Mus musculus,,50594
7478,10107,1,,,,Intermediate,945.0,,Stomach,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,Mus musculus,,50594
7479,10107,1,,,,Intermediate,945.0,,Stomach,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,Mus musculus,,50594
7480,10107,1,,,,Intermediate,945.0,,Stomach,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,Mus musculus,,50594
7481,4689,1,,,,Intermediate,,,,10116.0,Oral bioavailability in rat,A,In vivo,Rattus norvegicus,,50597
7482,4950,1,,,,Intermediate,,,,10116.0,Tested for the bioavailability in rat,A,In vivo,Rattus norvegicus,,50597
7483,5328,1,,,,Intermediate,,,,10116.0,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),A,In vivo,Rattus norvegicus,,50597
7484,406,1,,,,Intermediate,,,,10116.0,Bioavailability in rat,A,In vivo,Rattus norvegicus,,50597
7485,12500,1,,,,Intermediate,,,,10116.0,Bioavailability in rat,A,In vivo,Rattus norvegicus,,50597
7486,12500,1,,,,Intermediate,,,,10116.0,Bioavailability in rat (dose 3-10 mg/kg),A,In vivo,Rattus norvegicus,,50597
7487,5247,1,,,,Intermediate,,,,10116.0,Bioavailability in rat,A,In vivo,Rattus norvegicus,,50597
7488,4186,1,,,,Intermediate,1969.0,,Plasma,10116.0,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,A,In vivo,Rattus norvegicus,,50597
7489,4186,1,,,,Intermediate,1969.0,,Plasma,10116.0,Apparent terminal elimination half-life in rat plasma after administration of 50 mg/kg dose through subcutaneous route,A,In vivo,Rattus norvegicus,,50597
7490,6647,1,,,,Intermediate,,,,10116.0,Half life after oral administration was determined in rats at 6 mg/kg,A,In vivo,Rattus norvegicus,,50597
7491,6484,1,,,,Intermediate,,,,10116.0,Half life was determined,A,,Rattus norvegicus,,50597
7492,3249,1,,,,Intermediate,,,,10116.0,Half life the of compound was determined by ''Cr'' assay in rat at a dose of 10 mg/kg,A,In vivo,Rattus norvegicus,,50597
7493,6281,1,,,,Intermediate,1969.0,,Plasma,10116.0,Plasma half life in rat at oral dose 2.8 mg/mk body weight,A,In vivo,Rattus norvegicus,,50597
7494,3307,1,,,,Intermediate,,,,10116.0,Half life in rats,A,,Rattus norvegicus,,50597
7495,12058,1,,,,Intermediate,178.0,,Blood,10116.0,Half-lives were estimated from the elimination phase of the blood conc-time curve after oral administration,A,In vivo,Rattus norvegicus,,50597
7496,8833,1,,,,Intermediate,,,,10116.0,Hill coefficient of the compound,A,,Rattus norvegicus,,50597
7497,3193,1,,,,Intermediate,178.0,,Blood,10116.0,Compound was tested for percent hydrolysis in whole blood after a time interval of 0.5 min,A,,Rattus norvegicus,,50597
7498,3193,1,,,,Intermediate,178.0,,Blood,10116.0,Compound was tested for percent hydrolysis in whole blood after a time interval of 180.0 min,A,,Rattus norvegicus,,50597
7499,3193,1,,,,Intermediate,178.0,,Blood,10116.0,Compound was tested for percent hydrolysis in whole blood after a time interval of 2.0 min,A,,Rattus norvegicus,,50597
7500,3193,1,,,,Intermediate,178.0,,Blood,10116.0,Compound was tested for percent hydrolysis in whole blood after a time interval of 5.0 min,A,,Rattus norvegicus,,50597
7501,3193,1,,,,Intermediate,178.0,,Blood,10116.0,Compound was tested for percent hydrolysis in whole blood after a time interval of 60.0 min,A,,Rattus norvegicus,,50597
7502,3193,1,,,,Intermediate,178.0,,Blood,10116.0,Compound was tested for percent hydrolysis in whole blood after a time interval of 7.0 min,A,,Rattus norvegicus,,50597
7503,3193,1,,,,Intermediate,178.0,,Blood,10116.0,"Compound was tested for percent hydrolysis in whole blood, after a time interval of 15.0 min",A,,Rattus norvegicus,,50597
7504,5960,1,,,,Intermediate,,,,10116.0,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS,A,,Rattus norvegicus,,50597
7505,13950,1,,,,Intermediate,955.0,,Brain,10116.0,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/organ,A,In vivo,Rattus norvegicus,,50597
7506,13950,1,,,,Intermediate,955.0,,Brain,10116.0,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/organ,A,In vivo,Rattus norvegicus,,50597
7507,13950,1,,,,Intermediate,955.0,,Brain,10116.0,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/organ,A,In vivo,Rattus norvegicus,,50597
7508,13950,1,,,,Intermediate,955.0,,Brain,10116.0,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/organ,A,In vivo,Rattus norvegicus,,50597
7509,13950,1,,,,Intermediate,955.0,,Brain,10116.0,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/organ,A,In vivo,Rattus norvegicus,,50597
7510,13950,1,,,,Intermediate,2046.0,,Thyroid gland,10116.0,Biodistribution of [123I]-label in rat thyroid was reported at 0.33 hr post injection. Value shown is %ID/organ,A,In vivo,Rattus norvegicus,,50597
7511,13950,1,,,,Intermediate,2046.0,,Thyroid gland,10116.0,Biodistribution of [123I]-label in rat thyroid was reported at 1 hr post injection. Value shown is %ID/organ,A,In vivo,Rattus norvegicus,,50597
7512,13950,1,,,,Intermediate,2046.0,,Thyroid gland,10116.0,Biodistribution of [123I]-label in rat thyroid was reported at 2 hr post injection. Value shown is %ID/organ,A,In vivo,Rattus norvegicus,,50597
7513,13950,1,,,,Intermediate,2046.0,,Thyroid gland,10116.0,Biodistribution of [123I]-label in rat thyroid was reported at 24 hr post injection. Value shown is %ID/organ,A,In vivo,Rattus norvegicus,,50597
7514,13950,1,,,,Intermediate,2046.0,,Thyroid gland,10116.0,Biodistribution of [123I]-label in rat thyroid was reported at 4 hr post injection. Value shown is %ID/organ,A,In vivo,Rattus norvegicus,,50597
7515,9866,1,,,,Intermediate,178.0,,Blood,10116.0,Biodistribution in normal rat blood in the presence of 0.005 M Gd/0.01 M lig at 2 hr,A,In vivo,Rattus norvegicus,,50597
7516,9866,1,,,,Intermediate,178.0,,Blood,10116.0,Biodistribution in normal rat blood in the presence of 0.01 M Gd/0.05 M lig,A,In vivo,Rattus norvegicus,,50597
7517,9866,1,,,,Intermediate,178.0,,Blood,10116.0,Biodistribution in normal rat blood in the presence of NAC Gd 0.01 M lig at 2 hr,A,In vivo,Rattus norvegicus,,50597
7518,9866,1,,,,Intermediate,10000001.0,,Bone,10116.0,Biodistribution in normal rat bone in the presence of 0.005 M Gd/0.01 M lig at 2 hr,A,In vivo,Rattus norvegicus,,50597
7519,9866,1,,,,Intermediate,10000001.0,,Bone,10116.0,Biodistribution in normal rat bone in the presence of 0.01 M Gd/0.05 M lig,A,In vivo,Rattus norvegicus,,50597
7520,9866,1,,,,Intermediate,10000001.0,,Bone,10116.0,Biodistribution in normal rat bone in the presence of NAC Gd 0.01 M lig at 2 hr,A,In vivo,Rattus norvegicus,,50597
7521,9866,1,,,,Intermediate,948.0,,Heart,10116.0,Biodistribution in normal rat heart in the presence of 0.005 M Gd/0.01 M lig at 2 hr,A,In vivo,Rattus norvegicus,,50597
7522,9866,1,,,,Intermediate,948.0,,Heart,10116.0,Biodistribution in normal rat heart in the presence of 0.01 M Gd/0.05 M lig,A,In vivo,Rattus norvegicus,,50597
7523,9866,1,,,,Intermediate,948.0,,Heart,10116.0,Biodistribution in normal rat heart in the presence of NAC Gd 0.01 M lig at 2 hr,A,In vivo,Rattus norvegicus,,50597
